<SEC-DOCUMENT>0001104659-12-076010.txt : 20121108
<SEC-HEADER>0001104659-12-076010.hdr.sgml : 20121108
<ACCEPTANCE-DATETIME>20121108162151
ACCESSION NUMBER:		0001104659-12-076010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20120930
FILED AS OF DATE:		20121108
DATE AS OF CHANGE:		20121108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOSANTE PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001023024
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				582301143
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31812
		FILM NUMBER:		121190343

	BUSINESS ADDRESS:	
		STREET 1:		111 BARCLAY BLVD
		CITY:			LINCOLNSHIRE
		STATE:			IL
		ZIP:			60069
		BUSINESS PHONE:		8474780500

	MAIL ADDRESS:	
		STREET 1:		111 BARCLAY BLVD
		CITY:			LINCOLNSHIRE
		STATE:			IL
		ZIP:			60069

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEN ABRAHAM TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19991027
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>a12-19123_110q.htm
<DESCRIPTION>10-Q
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Mark one)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">x</font></b></p>    </td>
<td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">QUARTERLY   REPORT UNDER SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF   1934</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="100%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the   quarterly period ended September&nbsp;30, 2012</font></b></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">o</font></b></p>    </td>
<td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">TRANSITION   REPORT UNDER SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF   1934</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 20.15pt;text-indent:-20.15pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission File Number: 001-31812</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">BIOSANTE PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">58-2301143</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction of</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">incorporation or organization)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S. Employer</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">111 Barclay Boulevard</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Lincolnshire,&nbsp;Illinois&#160; 60069</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices) (Zip Code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(847) 478-0500</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number including area code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days. YES&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&#160; NO&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&#160; NO&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Large accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-accelerated filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Smaller reporting company </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Do not check if smaller reporting company)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;text-indent:36.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act). YES&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;NO&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
<p style="margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of November&nbsp;7, 2012, 24,422,240 shares of common stock and 65,211 shares of class C special stock of the registrant were outstanding.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-indent:.5in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105933\12-19123-1\task5644577\19123-1-ba-01.htm',USER='105933',CD='Nov  4 17:29 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIOSANTE PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SEPTEMBER 30, 2012</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b><a name="TableOfContents"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="91%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:91.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="6%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:6.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Page</font></b></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PART&nbsp;I.</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">FINANCIAL   INFORMATION</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ITEM   1.</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial   Statements</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedBalanceSheets_224443" title="Click to goto ">Condensed   Balance Sheets as of September&nbsp;30, 2012 and December&nbsp;31, 2011   (unaudited)</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedStatementsOfOperations_224453" title="Click to goto ">Condensed Statements of Operations for the three and   nine months ended September&nbsp;30, 2012 and 2011 (unaudited)</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedStatementsOfCashFlows_224503" title="Click to goto ">Condensed Statements of Cash Flows for the nine months   ended September&nbsp;30, 2012 and 2011 (unaudited)</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#NotesToTheCondensedFinancialState_224311" title="Click to goto ">Notes to the Condensed Financial Statements</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6-16</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_Managements_224142">ITEM 2.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_Managements_224142">Management&#146;s Discussion and   Analysis of Financial Condition and Results of Operations</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3__224740">ITEM 3.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3__224740">Quantitative and Qualitative   Disclosures About Market Risk</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4__225037">ITEM 4.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4__225037">Controls and Procedures</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PartIi__225236">PART&nbsp;II.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PartIi__225236">OTHER INFORMATION</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1__225238">ITEM 1.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1__225238">Legal Proceedings</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a__225241">ITEM 1A.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a__225241">Risk Factors</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2__225355">ITEM 2.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2__225355">Unregistered Sales of Equity   Securities and Use of Proceeds</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3__225357">ITEM 3.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3__225357">Defaults Upon Senior Securities</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4__225357">ITEM 4.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4__225357">Mine Safety Disclosures</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item5__225358">ITEM 5.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item5__225358">Other Information</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6__225401">ITEM 6.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6__225401">Exhibits</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40</font></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Signatures_235006" title="Click to goto ">SIGNATURE PAGE</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="91%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:91.16%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#ExhibitIndex_000327" title="Click to goto ">Exhibit&nbsp;Index</a></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">As used in this report, references to &#147;BioSante,&#148; the &#147;company,&#148; &#147;we,&#148; &#147;our&#148; or</font></i><font size="2" style="font-size:10.0pt;">  <i>&#147;us,&#148; unless the context otherwise requires, refer to BioSante Pharmaceuticals,&nbsp;Inc.</i></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">We own or have the rights to use various trademarks, trade names or service</font></i><font size="2" style="font-size:10.0pt;">  <i>marks, including BioSante</i></font><i><font size="1" style="font-size:6.5pt;font-style:italic;position:relative;top:-3.0pt;">&#174;</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">, LibiGel</font></i><i><font size="1" style="font-size:6.5pt;font-style:italic;position:relative;top:-3.0pt;">&#174;</font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">, GVAX&#153;,&#160; The Pill-Plus&#153; and Elestrin&#153;. &nbsp;This report also contains trademarks, trade names and</font></i><font size="2" style="font-size:10.0pt;">  <i>service marks that are owned by other persons or entities.</i></font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">All share and per share amounts have been adjusted to reflect the one-for-six reverse split of BioSante&#146;s outstanding common stock and class C special stock effective June&nbsp;1, 2012.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105933\12-19123-1\task5644577\19123-1-ba-01.htm',USER='105933',CD='Nov  4 17:29 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt .75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt .75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIOSANTE PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt .75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Balance Sheets<a name="CondensedBalanceSheets_224443"></a></font></b></p>
<p style="margin:0in 0in .0001pt .75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Septbember 30, 2012 and December&nbsp;31, 2011 (Unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ASSETS</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CURRENT ASSETS</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">38,049,095</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">57,225,234</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">534,037</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">801,147</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">38,583,132</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">58,026,381</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PROPERTY AND EQUIPMENT, NET </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1,184,764</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">861,364</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OTHER ASSETS</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investments</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3,413,762</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3,405,807</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deposits</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">30,088</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">86,203</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">43,211,746</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">62,379,755</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#146;   EQUITY</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CURRENT LIABILITIES</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2,004,814</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3,150,677</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued compensation</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">463,942</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1,597,329</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other accrued expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">860,094</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2,479,697</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of convertible senior notes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7,593,216</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10,922,066</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7,227,703</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term convertible senior notes</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17,336,760</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TOTAL LIABILITIES</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10,922,066</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">24,564,463</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">STOCKHOLDERS&#146; EQUITY </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Capital stock</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issued and outstanding</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2012 - 65,211; 2011 - 65,214 Class&nbsp;C special   stock</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">65</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">65</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2012 - 24,422,240; 2011 - 18,269,755 Common stock</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">273,259,171</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">255,054,375</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">273,259,236</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">255,054,440</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accumulated deficit</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(240,969,556</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(217,239,148</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TOTAL STOCKHOLDERS&#146; EQUITY </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">32,289,680</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">37,815,292</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">43,211,746</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">62,379,755</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See accompanying notes to the condensed financial statements.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_220147_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-03.htm',USER='bekuehe',CD='Nov  7 12:35 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIOSANTE PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt .75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Statements of Operations<a name="CondensedStatementsOfOperations_224453"></a></font></b></p>
<p style="margin:0in 0in .0001pt .75pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Three and Nine Months Ended September&nbsp;30, 2012 and 2011 (Unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt .75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">REVENUE</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="41%" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Licensing revenue </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">100,000</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">100,000</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Royalty revenue</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">110,383</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">82,784</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">333,163</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">220,787</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">110,383</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">182,784</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">333,163</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">320,787</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXPENSES</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3,872,736</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11,500,053</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14,454,258</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">37,480,873</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administration</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1,546,864</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1,675,268</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5,327,711</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5,257,853</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Depreciation and amortization</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">25,749</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">35,670</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">87,548</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">118,132</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5,445,349</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13,210,991</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">19,869,517</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">42,856,858</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OTHER</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible note fair value adjustment</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(843,412</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">463,000</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(4,037,797</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(1,929,000</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expense</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(67,105</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(172,000</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(283,348</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(516,000</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>   </tr>
<tr>
<td width="41%" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2,000</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15,000</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1,877</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1,516</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5,300</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6,472</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LOSS BEFORE INCOME TAX BENEFIT</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(6,243,606</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(12,733,691</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(23,852,199</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(44,959,599</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Income tax benefit</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">121,791</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">121,791</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NET LOSS</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(6,121,815</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(12,733,691</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(23,730,408</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(44,959,599</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BASIC AND DILUTED NET LOSS PER SHARE</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(0.27</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(0.73</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(1.14</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(2.86</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>   </tr>
<tr>
<td width="41%" valign="bottom" style="padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="41%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:41.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">22,921,176</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17,406,536</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">20,841,417</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15,744,738</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt .75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See accompanying notes to the condensed financial statements.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_220354_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-03.htm',USER='bekuehe',CD='Nov  7 12:35 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIOSANTE PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Statements of Cash Flows</font></b><a name="CondensedStatementsOfCashFlows_224503"></a></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Nine Months Ended September&nbsp;30, 2012 and 2011 (Unaudited)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CASH FLOWS (USED IN) OPERATING ACTIVITIES</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net   loss</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(23,730,408</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(44,959,599</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustments   to reconcile net loss to net cash (used in) operations</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Depreciation   and amortization</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">87,548</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">118,132</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss   on disposal of fixed assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">117,794</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">367,274</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Employee&nbsp;&amp;   director stock-based compensation </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">852,468</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">886,564</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock   warrant expense - noncash</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">180,759</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 40.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible   note fair value adjustment </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4,037,797</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1,929,000</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes   in other assets and liabilities affecting cash flows from operations</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt .7in;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid   expenses, deposits and other assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">323,225</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1,539,903</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 50.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts   payable and accrued liabilities</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(3,807,074</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2,993,059</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net cash (used in) operating activities</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(22,118,650</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(36,944,908</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CASH FLOWS (USED IN) INVESTING ACTIVITIES</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase   of investment</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(7,955</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase   of fixed assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(528,742</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(645,603</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net cash (used in) investing activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(536,697</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(645,603</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CASH FLOWS PROVIDED BY FINANCING ACTIVITIES</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fractional   share payout</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(658</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds   from common stock option exercises</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">32,442</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds   from warrants exercised</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">211,068</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">24,063</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds   from issuance of common stock by underwritten public offering</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">45,102,584</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds   from issuance of common stock by registered direct offerings</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3,268,798</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">23,876,370</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net cash provided by financing activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3,479,208</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">69,035,459</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NET (DECREASE) INCREASE IN CASH   AND CASH EQUIVALENTS</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(19,176,139</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">)</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">31,444,948</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">57,225,234</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">38,155,251</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CASH AND CASH EQUIVALENTS AT END OF PERIOD</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">38,049,095</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">69,600,199</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest   paid</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">184,094</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">344,000</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Noncash investing and financing activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt .7in;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shares   issued for convertible senior notes and accrued interest</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13,881,052</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt .7in;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unpaid   costs associated with registered direct offering</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7,933</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt .7in;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unpaid   costs associated with underwritten public offering</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">141,447</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt .7in;text-indent:-10.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase   of fixed assets on account, non-cash investing activity</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#151;</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">$</font></b></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">59,016</font></b></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See accompanying notes to the condensed financial statements.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_220422_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-03.htm',USER='bekuehe',CD='Nov  7 12:35 2012' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIOSANTE PHARMACEUTICALS,&nbsp;INC.<br> FORM&nbsp;10-Q<br> SEPTEMBER 30, 2012</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)</font></b><a name="NotesToTheCondensedFinancialState_224311"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">DESCRIPTION OF BUSINESS</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BioSante Pharmaceuticals,&nbsp;Inc.&#146;s (the Company) corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and the Company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company&#146;s products, either approved or in clinical development, include: (1)&nbsp;LibiGel, once daily transdermal testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD); (2)&nbsp;a once daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of hypogonadism, or testosterone deficiency in men, and licensed to Teva Pharmaceuticals USA,&nbsp;Inc. (Teva); (3)&nbsp;GVAX cancer vaccines, a portfolio of cancer vaccines, four of which have been granted FDA orphan drug designation, and which are currently in 17 Phase I and Phase II clinical trials for the treatment of various cancers; (4)&nbsp;The Pill-Plus (triple component contraceptive), once daily use of various combinations of estrogens, progestogens and androgens in Phase II development; and (5)&nbsp;Elestrin, once daily transdermal estradiol (estrogen) gel approved by the FDA indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S. by Meda Pharmaceuticals Inc. (Meda), the Company&#146;s licensee.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">BASIS OF PRESENTATION</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the opinion of management, the accompanying unaudited condensed financial statements contain all necessary adjustments, which are of a normal recurring nature, to present fairly the financial position of the Company as of September&nbsp;30, 2012 and December&nbsp;31, 2011, the results of operations for the three and nine months ended September&nbsp;30, 2012 and 2011, and the cash flows for the nine months ended September&nbsp;30, 2012 and 2011, in conformity with accounting principles generally accepted in the United States of America (GAAP).&#160; Operating results for the three and nine month periods ended September&nbsp;30, 2012 are not necessarily indicative of the results that may be expected for the full year ending December&nbsp;31, 2012.&#160; The Company does not have items of other comprehensive income for either of the three or nine month periods ended September&nbsp;30, 2012 or 2011; and therefore, has not presented comprehensive income.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">These unaudited interim condensed financial statements should be read in conjunction with the financial statements and related notes contained in the Company&#146;s Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2011.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On June&nbsp;1, 2012, the Company effected a one-for-six reverse split of its outstanding common stock and class C special stock.&#160; These unaudited interim condensed financial statements give retroactive effect to the reverse stock split.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">LIQUIDITY AND CAPITAL RESOURCES</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Substantially all of the Company&#146;s revenue to date has been derived from upfront, milestone and royalty payments earned on licensing transactions and from subcontracts.&#160; The Company&#146;s business </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_221110_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-05.htm',USER='bekuehe',CD='Nov  7 12:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">operations to date have consisted mostly of licensing and research and development activities.&#160; The Company itself has not introduced commercially any products.&#160; To date, the Company has used primarily equity financings, and to a lesser extent, licensing income, interest income and the cash received from its 2009 merger with Cell Genesys,&nbsp;Inc. (Cell Genesys), to fund its ongoing business operations and short-term liquidity needs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2012, the Company had $38,049,095 of cash and cash equivalents.&#160; As of September&nbsp;30, 2012, the Company had outstanding $8,277,850 in aggregate principal amount of its 3.125% convertible senior notes due May&nbsp;1, 2013.&#160; In August&nbsp;2012, the Company completed an offering of an aggregate of 2,359,932 shares of the Company&#146;s common stock and warrants to purchase an aggregate of 1,179,966 shares of the Company&#146;s common stock, resulting in net proceeds of $3,268,798, after deducting placement agent fees and other offering expenses. See Note 7, &#147;Stockholders&#146; Equity,&#148; for additional discussion regarding the August&nbsp;2012 registered direct offering.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Absent the receipt of any additional licensing income or financing, the Company expects its cash and cash equivalents balance to decrease as the Company continues to use cash to fund its operations.&#160; Assuming the Company&#146;s pending merger with ANIP Acquisition Company d/b/a ANI Pharmaceuticals,&nbsp;Inc. (ANI) is completed during the first quarter of 2013 (see Note 10, &#147;Subsequent Events&#148;), the Company expects its cash and cash equivalents as of September&nbsp;30, 2012 to meet the Company&#146;s liquidity requirements through at least the Company&#146;s anticipated closing of the merger, including the requirement under our merger agreement to have at least $17 million of net cash (as defined in the merger agreement) available upon the closing of the merger.&nbsp;&nbsp; If the Company&#146;s pending merger with ANI is not completed, the Company will need to reevaluate its strategic alternatives, which may include a sale of the company, liquidation of the company or other strategic transaction.&nbsp; The Company&#146;s liquidity position will be dependent upon the strategic alternative selected; however, assuming the Company does not enter into another strategic transaction, and assuming the Company decides not to commence the two new efficacy trials for LibiGel, the Company expects its cash and cash equivalents as of September&nbsp;30, 2012 will be sufficient to meet the Company&#146;s liquidity requirements for at least the next 3-5 years.&nbsp; Additional financing would be required should the Company decide to commence the two new efficacy trials for LibiGel.&nbsp; These estimates may prove incorrect or the Company, nonetheless, may choose to raise additional financing earlier.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company does not have any existing credit facilities under which the Company could borrow funds.&#160; In the event that the Company would require additional working capital to fund future operations, the Company could seek to acquire such funds through additional equity or debt financing arrangements. If the Company raises additional funds by issuing equity securities, the Company&#146;s stockholders may experience dilution.&#160; Debt financing, if available, may involve covenants restricting the Company&#146;s operations or the Company&#146;s ability to incur additional debt.&#160; There is no assurance that any financing transaction will be available on terms acceptable to the Company, or at all.&#160; As an alternative to raising additional financing, the Company may choose to attempt to license one or more of its products or technologies to a third party who may finance a portion or all of the continued development and, if approved, commercialization of that licensed product, sell certain assets or rights under the Company&#146;s existing license agreements.&#160; In addition, from time to time, the Company may purchase, exchange or restructure its outstanding convertible senior notes through cash purchases and/or exchanges for other equity securities of the Company, in open market purchases, privately negotiated transactions and/or a tender offer.&#160; Such purchases, exchanges or restructurings, if any, will depend on prevailing market conditions, the Company&#146;s available cash and cash equivalents, the Company&#146;s liquidity requirements, contractual restrictions and other factors.&#160; Such purchases, exchanges or restructurings could dilute the percentage ownership of the Company&#146;s stockholders, result in the issuance of securities at a discount to market price or that may have rights, preferences or privileges senior to those of the Company&#146;s existing stockholders and/or decrease the Company&#146;s cash </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_221145_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-05.htm',USER='bekuehe',CD='Nov  7 12:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">balance.&#160; A significant decrease in the Company&#146;s cash balance, together with an inability to raise additional financing when needed, may impair the Company&#146;s ability to complete its proposed merger with ANI, execute other strategic alternatives or leave the Company without sufficient cash remaining for operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company can provide no assurance that additional financing, if needed, will be available on terms favorable to the Company, or at all.&#160; This is particularly true if investors are not confident in the Company&#146;s business and future prospects, the future value of the Company and/or economic and market conditions deteriorate.&#160; In addition, the Company&#146;s ability to raise additional financing is limited by the terms of its agreement and plan of merger with ANI.&#160; See Note 10, &#147;Subsequent Events.&#148;&#160; If adequate funds are not available or are not available on acceptable terms when the Company needs them, the Company may need to reduce its operating costs or the Company may be forced to complete other strategic alternatives, such as winding down its operations and liquidating the Company.&#160; In such case, the Company&#146;s stockholders could lose some or all of their investment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">BASIC AND DILUTED NET LOSS PER SHARE</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The basic and diluted net loss per share is computed based on the weighted average number of shares of common stock and class C special stock outstanding, all being considered as equivalent of one another.&#160; Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding for the reporting period.&#160; Diluted net loss per share is intended to reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock.&#160; Because the Company has incurred net losses from operations in each of the periods presented, the Company&#146;s outstanding options, warrants and convertible debt are antidilutive; accordingly, such securities are excluded from the computation of diluted net loss per share and there is no difference between basic and diluted net loss per share amounts.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 37.05pt;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">CONVERTIBLE SENIOR NOTES</font></b></p>
<p style="margin:0in 0in .0001pt 37.05pt;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has outstanding 3.125% convertible senior notes due May&nbsp;1, 2013 (the 2013 Notes).&#160; The aggregate principal amount of the 2013 Notes outstanding at September&nbsp;30, 2012 and December&nbsp;31, 2011 was $8,277,850 and $20,782,000, respectively.&#160; In February&nbsp;2012, the Company issued 1,868,055 shares of its common stock to one of the holders of the 2013 Notes in exchange for the cancellation of $9,000,000 in aggregate principal amount of such notes and the related accrued and unpaid interest of $79,024.&#160; In July&nbsp;2012, the Company issued an aggregate of 1,784,070 shares of its common stock to two of the holders of the 2013 Notes in exchange for the cancellation of $3,504,150 in aggregate principal amount of such notes and accrued and unpaid interest of $20,686. Non-cash fair value adjustments of $(2,545,530) and $(611,621) were recorded during the first and third quarters of 2012 as a result of the cancellation of such notes. The fair value adjustment recorded upon the cancellation of the 2013 Notes is primarily attributable to the time value effect of settling these obligations at a date prior to the stated maturity of the 2013 Notes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The remaining $8,277,850 aggregate principal amount of the 2013 Notes are exchangeable at the option of the holder or upon certain specified events into an aggregate of approximately 370,871 shares of the Company&#146;s common stock at a conversion price of $22.32 per share.&#160; The 2013 Notes are general, unsecured obligations of the Company and are described in Note 7 to the Company&#146;s financial statements for the year ended December&nbsp;31, 2011.&#160; As of September&nbsp;30, 2012, the 2013 Notes were not eligible for redemption. The indenture governing the 2013 Notes, as supplemented by the supplemental indenture, does not contain any financial covenants and does not restrict the Company from paying dividends, incurring additional debt or issuing or repurchasing the Company&#146;s other securities.&#160; In addition, the indenture, as supplemented by the supplemental indenture, does not protect the holders of the 2013 Notes </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_221159_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-05.htm',USER='bekuehe',CD='Nov  7 12:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">in the event of a highly leveraged transaction or a fundamental change of the Company except in certain circumstances specified in the indenture.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:35.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As described in Note 3, &#147;Liquidity and Capital Resources,&#148; from time to time, the Company may purchase, exchange or restructure its outstanding 2013 Notes through cash purchases and/or exchanges for other equity securities of the Company, in open market purchases, privately negotiated transactions and/or a tender offer.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:35.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:35.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has elected to record the 2013 Notes at fair value in order to simplify the accounting for the convertible debt, inclusive of the redemption, repurchase and conversion adjustment features which otherwise would require specialized valuation, bifurcation and recognition.&#160; Accordingly, the Company has adjusted the carrying value of the 2013 Notes to their fair value as of September&nbsp;30, 2012, with changes in the fair value of the 2013 Notes occurring since December&nbsp;31, 2011, reflected in fair value adjustment in the unaudited condensed statements of operations.&#160; As described in Note 9, &#147;Fair Value Measurements,&#148; the fair value of the 2013 Notes is based on Level 2 inputs.&#160; The recorded fair value of the 2013 Notes of an aggregate of $7,593,216 as of September&nbsp;30, 2012 differs from their total stated aggregate principal amount of $8,277,850 as of such date by $684,634.&#160; The recorded fair value of the 2013 Notes of an aggregate of $17,336,760 as of December&nbsp;31, 2011 differed from their total stated aggregate principal amount of $20,782,000 as of such date by $3,445,240.&#160; During the three and nine months ended September&nbsp;30, 2012, the Company recorded a fair value adjustment of $(843,412) and $(4,037,797) related to the 2013 Notes that were converted to common stock during 2012 or that remained outstanding as of September&nbsp;30, 2012, that for the three months and nine months ended September&nbsp;30, 2012 increased the recorded liability and corresponding expense.&#160; For the three and nine months ended September&nbsp;30, 2011, the Company recorded a fair value adjustment of $463,000 and $(1,929,000) that decreased and increased the recorded liability and corresponding expense, respectively.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:35.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the nine months ended September&nbsp;30, 2012 and 2011, approximately $(41,000) and $230,000, respectively, of the fair value adjustment was attributable to the change in instrument specific credit risk.&#160; The change in the aggregate fair value of the 2013 Notes due to instrument specific credit risk for the nine months ended September&nbsp;30, 2012 was estimated by calculating the difference between the September&nbsp;30, 2012 fair value of the 2013 Notes as recorded and what the fair value of the 2013 Notes would have been on September&nbsp;30, 2012 if the December&nbsp;31, 2011 discount rate continued to be used in the calculation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The instrument specific credit risk for both periods has increased the fair value of the 2013 Notes as market borrowing rates have decreased for similarly rated companies and are estimated to have decreased for the Company as well, indicating a lower credit spread assuming no significant changes in the risk-free borrowing rate.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company establishes the value of the 2013 Notes based upon contractual terms of the 2013 Notes, as well as certain key assumptions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The assumptions as of September&nbsp;30, 2012 were:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="60%" style="border-collapse:collapse;margin-left:1.0in;width:60.0%;">
<tr>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.18%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Average risk-free rate</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.14</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.18%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Volatility of BioSante common stock</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">90.0</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.18%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Discount rate for principal payments in cash</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19.6</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The assumptions as of December&nbsp;31, 2011 were:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="60%" style="border-collapse:collapse;margin-left:1.0in;width:60.0%;">
<tr>
<td width="74%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.18%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Average&nbsp;risk-free&nbsp;rate</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.19</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" style="padding:0in 0in 0in 0in;width:74.18%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Volatility of BioSante common stock</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" style="padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">77.4</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="74%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:74.18%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Discount rate for principal payments in cash</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:20.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18.5</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_221336_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-05.htm',USER='bekuehe',CD='Nov  7 12:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.55pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The discount rate is based on observed yields as of the measurement date for debt securities of entities having a Ca and Caa3 rating for long-term corporate obligations as assigned by Moody&#146;s Investors Service.&#160; Volatility is based on the historical fluctuations in the Company&#146;s stock price for a period of time equal to the remaining time until the debt maturity.&#160; The risk-free rate is based on observed yields as of the measurement date of six month and one-year U.S. Treasury Bonds.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.55pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">STOCK-BASED COMPENSATION</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company typically grants options to purchase shares of the Company&#146;s common stock to existing employees and non-employee directors on an annual basis during the first quarter of each year and to new employees and non-employee directors throughout the year on or around the date their employment or service with the Company commences.&#160; All options are granted under the BioSante Pharmaceuticals,&nbsp;Inc. Amended and Restated 2008 Stock Incentive Plan (the 2008 Plan).&#160; As of September&nbsp;30, 2012, approximately 981,272 shares of the Company&#146;s common stock remain available for issuance under the 2008 Plan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the nine months ended September&nbsp;30, 2012, the Company granted options under the 2008 Plan to purchase an aggregate of 358,582 shares of the Company&#146;s common stock to certain employees of the Company and the Company&#146;s non-employee directors with a weighted average exercise price of $4.08 per share.&#160; Options to purchase an aggregate of 105,781 shares of the Company&#146;s common stock expired and were cancelled during the nine months ended September&nbsp;30, 2012.&#160; Options are granted at an exercise price equal to the closing price of the Company&#146;s common stock on the date of the grant.&#160; No options were exercised during the nine months ended September&nbsp;30, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No warrants were granted during the nine months ended September&nbsp;30, 2012, other than the warrants issued in conjunction with the Company&#146;s August&nbsp;2012 offering described in Note 7, &#147;Stockholders&#146; Equity&#148;.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 37.05pt;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">STOCKHOLDERS&#146; EQUITY</font></b></p>
<p style="margin:0in 0in .0001pt 37.05pt;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the nine months ended September&nbsp;30, 2012, the Company issued an aggregate of 3,652,125 shares of its common stock to holders of the 2013 Notes in exchange for the cancellation of $12,504,150 in aggregate principal amount of such notes and accrued and unpaid interest of $99,710. See Note 5, &#147;Convertible Senior Notes&#148; for information regarding the 2013 Notes.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In August&nbsp;2012, the Company completed an offering of 2,359,932 shares of its common stock and warrants to purchase an aggregate of 1,179,966 shares of its common stock at a purchase price of $1.4725 per share to one institutional investor for gross proceeds of $3,475,000.&#160; The offering resulted in net proceeds to the Company of $3,268,798, after deducting placement agent fees and offering expenses. The warrants are exercisable immediately and continue for a period of 5 years, at an exercise price of $1.50 per share.&#160; The number of shares issuable upon exercise of the warrants and the exercise price of the warrants are adjustable in the event of stock splits, combinations and reclassifications, but not in the event of the issuance of additional securities.&#160; On September&nbsp;20, 2012, warrants from the August&nbsp;2012 offering to purchase an aggregate of 140,712 shares of common stock were exercised resulting in proceeds of $211,068 to the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;30, 2012, the Company&#146;s stockholders approved an amendment to the Company&#146;s Restated Certificate of Incorporation to effect a reverse split of the Company&#146;s outstanding shares of common stock and class C special stock in the discretion of the Company&#146;s Board of Directors at an exchange ratio of not less than one-for-two and not more than one-for-ten.&#160; On June&nbsp;1, 2012, the Board of </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_221403_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-05.htm',USER='bekuehe',CD='Nov  7 12:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Directors of the Company effected a one-for-six reverse split of the Company&#146;s outstanding shares of common stock and class C special stock.&#160; No fractional shares were issued as a result of the reverse stock split, and stockholders who otherwise would have been entitled to a fractional share received, in lieu thereof, a cash payment based on the closing sale price of BioSante&#146;s common stock on June 1, 2012.&#160; The total cash payment for fractional shares was $658.&#160; The reverse stock split did not change the number of authorized shares of the Company&#146;s common stock or class C special stock or the par value of the Company&#146;s common stock or class C special stock, but because the number of authorized shares of the Company&#146;s common stock and class C special stock was not affected, the effect of the reverse stock split was to increase the number of authorized but unissued shares of the Company&#146;s common stock and class C special stock.&#160; The primary purpose of the reverse stock split was to increase the Company&#146;s ability to maintain the listing of its common stock on The NASDAQ Global Market.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 37.05pt;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></b></p>
<p style="margin:0in 0in .0001pt 37.05pt;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Aptar Pharma &#151; Gel Packaging Machine</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has a commitment with Aptar Pharma to purchase a gel packaging machine for $844,740. As of September&nbsp;30, 2012, the Company had paid Aptar $804,132.&#160; The remaining obligation of $40,608 is due upon the shipment, assembly and calibration of the machine at a location designated by the Company.&#160; In light of the Company&#146;s pending merger with ANI (see Note 10, &#147;Subsequent Events&#148;), the Company is evaluating the future plans for this gel packaging machine.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Pending Litigation</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On February&nbsp;3, 2012, a purported class action lawsuit was filed in the United States District Court for the Northern District of Illinois under the caption <i>Thomas Lauria, on behalf of himself and all others similarly situated v. BioSante Pharmaceuticals,&nbsp;Inc. and Stephen M. Simes</i> naming the Company and the Company&#146;s President and Chief Executive Officer, Stephen M. Simes, as defendants.&#160; The complaint alleges that certain of the Company&#146;s disclosures relating to the efficacy of LibiGel and its commercial potential were false and/or misleading and that such false and/or misleading statements had the effect of artificially inflating the price of the Company&#146;s securities resulting in violations of Section&nbsp;10(b)&nbsp;of the Securities Exchange Act of 1934, as amended (Exchange Act), Rule&nbsp;10b-5 and Section&nbsp;20(a)&nbsp;of the Exchange Act.&#160; Although a substantially similar complaint was filed in the same court on February&nbsp;21, 2012, such complaint was voluntarily dismissed by the plaintiff in April&nbsp;2012.&#160; The plaintiff seeks to represent a class of persons who purchased the Company&#146;s securities between February&nbsp;10, 2010 and December&nbsp;15, 2011, and seeks unspecified compensatory damages, equitable and/or injunctive relief, and reasonable costs, expert fees and attorneys&#146; fees on behalf of such purchasers.&#160; The Company believes the action is without merit and intends to defend the action vigorously.&#160; On October&nbsp;10, 2012, the District Court entered an order setting the dates on which the plaintiff&#146;s consolidated amended complaint is due and establishing a briefing schedule on the defendants&#146; anticipated motion to dismiss.&#160; On November&nbsp;6, 2012, plaintiff filed a consolidated amended complaint; the Company and Mr. Simes intend to file motions to dismiss the consolidated amended complaint on or before December&nbsp;21, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;7, 2012, Jerome W. Weinstein, a purported stockholder of the Company filed a shareholder derivative action in the United States District Court for the Northern District of Illinois under the caption <i>Weinstein v. BioSante Pharmaceuticals,&nbsp;Inc. et al.</i>, naming the Company&#146;s directors as defendants and the Company as a nominal defendant.&#160; A substantially similar complaint was filed in the same court on May&nbsp;22, 2012 and another substantially similar complaint was filed in the Circuit Court for Cook County, Illinois, County Department, Chancery Division, on June&nbsp;27, 2012.&#160; The suits generally related to the same events that are the subject of the class action litigation described above.&#160; The complaints allege breaches of fiduciary duty, abuse of control, gross mismanagement and unjust enrichment as causes of action occurring from at least February&nbsp;2010 through December&nbsp;2011.&#160; The complaints seek unspecified damages, punitive damages, costs and disbursements and unspecified reform and improvements in the Company&#146;s corporate governance and internal control procedures.&#160; On September&nbsp;24, 2012, the District Court consolidated the two cases before it and entered a stipulation and order setting the dates on which the plaintiff&#146;s consolidated amended complaint is due and establishing a </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_221431_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-05.htm',USER='bekuehe',CD='Nov  7 12:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">briefing schedule on defendants&#146; anticipated motions to dismiss. The Company expects a similar scheduling order to be entered in the action pending in Illinois state court.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The lawsuits are in their early stages; and, therefore, the Company is unable to predict the outcome of the lawsuits and the possible loss or range of loss, if any, associated with their resolution or any potential effect the lawsuits may have on the Company&#146;s operations.&#160; Depending on the outcome or resolution of these lawsuits, they could have a material effect on the Company&#146;s operations, including its financial condition, results of operations, or cash flows.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company is not involved in any other legal actions, however, from time to time may be subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business.&#160; Such matters are subject to many uncertainties and to outcomes that are not predictable with reasonable assurance and that may not be known for extended periods of time.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 37.05pt;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">FAIR VALUE MEASUREMENTS</font></b></p>
<p style="margin:0in 0in .0001pt 37.05pt;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company accounts for its convertible debt and U.S. Treasury money market fund at fair value.&#160; Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Level 1:&#160; Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.&#160; The fair value hierarchy gives the highest priority to Level 1 inputs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Level 2:&#160; Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Level 3:&#160; Unobservable inputs are used when little or no market data is available.&#160; The fair value hierarchy gives the lowest priority to Level 3 inputs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial assets and liabilities recorded at fair value on a recurring basis as of September&nbsp;30, 2012 and December&nbsp;31, 2011 are classified in the tables below in one of the three categories described above:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.5in;width:93.34%;">
<tr>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,<br>   2012&nbsp;Balance</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Quoted&nbsp;Prices&nbsp;in<br>   Active&nbsp;Markets<br>   for&nbsp;Identical<br>   Assets&nbsp;(Level&nbsp;1)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant<br>   Other<br>   Observable<br>   Inputs&nbsp;(Level&nbsp;2)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant<br>   Unobservable<br>   Inputs&nbsp;(Level&nbsp;3)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assets:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.94%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Money market fund</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36,957,469</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36,957,469</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36,957,469</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36,957,469</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Liabilities:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.94%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2013 Notes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.94%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,593,216</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,593,216</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,593,216</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,593,216</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_221624_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-05.htm',USER='bekuehe',CD='Nov  7 12:38 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.5in;width:93.34%;">
<tr>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2011&nbsp;Balance</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Quoted&nbsp;Prices&nbsp;in<br>   Active&nbsp;Markets<br>   for&nbsp;Identical<br>   Assets&nbsp;(Level&nbsp;1)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant<br>   &nbsp;Other<br>   &nbsp;Observable<br>   &nbsp;Inputs&nbsp;(Level&nbsp;2)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Significant<br>   Unobservable<br>   Inputs&nbsp;(Level&nbsp;3)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Assets:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.94%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Money market fund</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55,465,507</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55,465,507</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total assets</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55,465,507</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55,465,507</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Liabilities:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.94%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2013 Notes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.94%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,336,760</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,336,760</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.64%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,336,760</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.62%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,336,760</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.92%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company made an election to record the values of the 2013 Notes at fair value with gains and losses related to fluctuations in the value of these financial liabilities recorded in earnings immediately.&#160; The fair values of the 2013 Notes are estimated based on the risk-free borrowing rate, the volatility of the Company&#146;s stock, and the current borrowing rates for similar companies.&#160; See Note 6, &#147;Convertible Senior Notes&#148; for more information and disclosures regarding key assumptions used in this fair value determination.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">SUBSEQUENT EVENTS</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Agreement and Plan of Merger</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On October&nbsp;3, 2012, the Company entered into an agreement and plan of merger (the Merger Agreement) with ANIP Acquisition Company d/b/a ANI Pharmaceuticals,&nbsp;Inc.&#160; The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, ANI will merge with and into the Company, with the Company continuing as the surviving company (the Merger).&#160; At the effective time of the Merger, each outstanding share of capital stock of ANI will be converted into the right to receive a number of shares of the Company&#146;s common stock, if any, as determined pursuant to the exchange ratios described in the Merger Agreement and the provisions of ANI&#146;s certificate of incorporation.&#160; All options, warrants or other rights to purchase shares of capital stock of ANI, will be canceled at the effective time of the Merger without any consideration in exchange, except for certain warrants which although not cancelled will not represent the right to acquire any equity or other interest in the combined company after the Merger.&#160; No fractional shares of the Company&#146;s common stock will be issued in connection with the Merger, and holders of ANI capital stock will be entitled to receive cash in lieu thereof.&#160; Following the consummation of the transactions contemplated by the Merger Agreement, the current stockholders of ANI are expected to own approximately 53 percent of the outstanding shares of common stock of the combined company, and current stockholders of the Company are expected to own approximately 47 percent of the outstanding shares of common stock of the combined company.&#160; The exchange ratios are subject to potential adjustment as described in the Merger Agreement depending upon the amount of the Company&#146;s &#147;net cash&#148;, as defined in the Merger Agreement and generally consisting of the Company&#146;s cash and cash equivalents less certain expenses and liabilities, as of a determination date prior to the closing date of the Merger, but in no event will the current ANI stockholders own less than 50.1 percent (or the current Company stockholders own more than 49.9 percent) of the outstanding shares of common stock of the combined company.&#160; The Merger is intended to qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)&nbsp;of the Internal Revenue Code of 1986, as amended.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Merger Agreement provides that, immediately following the effective time of the Merger, the board of directors of the combined company will consist of five former directors of ANI and two former directors of the Company, and ANI&#146;s current executive officers are expected to serve as executive officers</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_223342_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-05.htm',USER='bekuehe',CD='Nov  7 12:38 2012' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of the combined company.&#160; In connection with the Merger, the Company will seek to amend its certificate of incorporation to: (i)&nbsp;effect a reverse split of its common stock at a ratio between the range of one-for-two and one-for-five, as determined by the Company and ANI, which is intended to ensure that the listing requirements of The NASDAQ Global Market or The NASDAQ Capital Market are satisfied; and (ii)&nbsp;change the name of the Company to &#147;ANI Pharmaceuticals,&nbsp;Inc.&#148; or another name as designated by ANI (together, the Charter Amendments).&#160; No fractional shares of the Company&#146;s common stock will be issued in connection with the reverse split and holders of the Company&#146;s common stock will be entitled to receive cash in lieu thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consummation of the Merger is subject to a number of conditions, including, but not limited to (i)&nbsp;the adoption and approval of the Merger Agreement and the transactions contemplated thereby by both the Company&#146;s and ANI&#146;s stockholders and the approval of the Charter Amendments by the Company&#146;s stockholders; (ii)&nbsp;the effectiveness of a Form&nbsp;S-4 registration statement to be filed by the Company with the Securities and Exchange Commission to register the shares of the Company&#146;s common stock to be issued in connection with the Merger, which will contain a joint proxy statement/prospectus; (iii)&nbsp;approval for the listing of shares of the Company&#146;s common stock to be issued in the Merger on The NASDAQ Global Market or The NASDAQ Capital Market; (iv)&nbsp;written opinions of counsel that the Merger will qualify as a reorganization within the meaning of Section&nbsp;368(a)&nbsp;of the Code; and (v)&nbsp;other customary closing conditions.&#160; In addition, the obligation of ANI to effect the Merger is subject to a condition that the Company&#146;s net cash, as calculated pursuant to the terms of the Merger Agreement, be no less than $17.0 million immediately prior to the effective time of the Merger.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each of the Company and ANI have made customary representations, warranties and covenants in the Merger Agreement, including among others, covenants that (i)&nbsp;each party will conduct its business in the ordinary course consistent with past practice during the interim period between the execution of the Merger Agreement and the consummation of the Merger; (ii)&nbsp;each party will not engage in certain kinds of transactions or take certain actions during such period; (iii)&nbsp;ANI will convene and hold a meeting of its stockholders for the purpose of considering the adoption and approval of the Merger Agreement and the transactions contemplated thereby and the board of directors of ANI will recommend that its stockholders adopt and approve the Merger Agreement, subject to certain exceptions; and (iv)&nbsp;the Company will convene and hold a meeting of its stockholders for the purpose of considering the adoption and approval of the Merger Agreement and the transactions contemplated thereby and the approval of the Charter Amendments and the Company&#146;s board of directors will recommend that the Company&#146;s stockholders adopt and approve the Merger Agreement and approve the charter amendments, subject to certain exceptions.&#160; Each of the Company and ANI also has agreed not to solicit proposals relating to alternative business combination transactions or enter into discussions or an agreement concerning any proposals for alternative business combination transactions, subject to exceptions for the Company in the event of the Company&#146;s receipt of a &#147;superior proposal.&#148;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Merger Agreement contains certain termination rights in favor of each of ANI and the Company in certain circumstances. If the Merger Agreement is terminated due to certain triggering events specified in the Merger Agreement, the Company will be required to pay ANI a termination fee of up to $1.0 million or ANI will be required to pay the Company a termination fee of up to $750,000. The Merger Agreement also provides that under specified circumstances, the Company may be required to reimburse ANI up to $500,000 for ANI&#146;s expenses in connection with the transaction. Any expenses paid by the Company will be credited against the $1.0 million termination fee if the termination fee subsequently becomes payable by the Company.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_223858_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\105735\12-19123-1\task5643966\19123-1-ba-07.htm',USER='105735',CD='Nov  4 00:09 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Voting Agreements</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Concurrently and in connection with the execution of the Merger Agreement, certain of ANI&#146;s stockholders, who collectively hold approximately 90 percent of the outstanding shares of ANI capital stock as of the close of business on October&nbsp;3, 2012,&#160; entered into voting agreements with the Company, pursuant to which each stockholder agreed to vote its shares of ANI capital stock in favor of the Merger, the Merger Agreement and the transactions contemplated by the Merger Agreement and against certain transactions or certain actions that would delay, prevent or nullify the Merger or the transaction contemplated by the Merger Agreement.&#160; In addition, one of the stockholders of ANI, who holds approximately 57 percent of the outstanding shares of ANI capital stock as of the close of business on October&nbsp;3, 2012, has agreed to vote in favor of the election of the two directors designated by the Company at the first annual meeting of stockholders following the completion of the Merger.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, certain of the Company&#146;s stockholders, directors and officers, who collectively hold approximately two percent of the outstanding shares of the Company&#146;s capital stock as of the close of business on October&nbsp;3, 2012, entered into voting agreements with ANI, pursuant to which each stockholder agreed to vote its shares of the Company&#146;s capital stock in favor of the Merger, the Merger Agreement and the transactions contemplated by the Merger Agreement and the charter amendments, and against certain transactions or certain actions that would delay, prevent or nullify the Merger or the transaction contemplated by the Merger Agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Lock-Up Agreements</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Concurrently and in connection with the execution of the Merger Agreement, ANI&#146;s chief executive officer and chief financial officer and certain stockholders of ANI, who collectively hold approximately 85 percent of the outstanding shares of ANI capital stock as of the close of business on October&nbsp;3, 2012, entered into lock-up agreements with the Company, pursuant to which each stockholder will be subject to a six-month lock-up on the sale of shares of the Company&#146;s common stock received in the Merger.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Contingent Value Rights Agreement</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company has the right in its sole discretion to issue contingent value rights (each, a CVR and collectively, the CVRs) to its existing stockholders immediately prior to the completion of the Merger.&#160; The Company expects that one CVR will be issued for each share of the Company&#146;s common stock outstanding as of the record date to be set at a date prior to the completion of the Merger.&#160; However, the CVRs will not be certificated and will not be attached to the shares of the Company&#146;s common stock.&#160; Each CVR will be a non-transferable (subject to certain limited exceptions) right to potentially receive certain cash payments in the event the Company receives net cash payments during the ten-year period after the distribution of the rights as a result of the sale, transfer, license or similar transaction relating to the Company&#146;s LibiGel program,&#160; upon the terms and subject to the conditions set forth in a contingent value rights agreement to be entered into between the Company and an as of yet unidentified third party, as rights agent.&#160; The aggregate cash payments to be distributed to the holders of the CVRs, if any, will be equal to 66 percent of the net cash payments received by the combined company as a result of the sale, transfer, license or similar transaction relating to the Company&#146;s LibiGel program, as determined pursuant to the CVR agreement, and will not exceed $40 million in the aggregate.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Employee Reduction Implications</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a result of the conclusion of the Company&#146;s LibiGel Phase III cardiovascular events and breast cancer safety study, as announced by the Company in September&nbsp;2012, and considering the Company&#146;s </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_223858_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\105735\12-19123-1\task5643966\19123-1-ba-07.htm',USER='105735',CD='Nov  4 00:09 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">October&nbsp;4, 2012 announcement of its potential merger with ANI, the Company plans to reduce its workforce during the fourth quarter of 2012.&#160; In connection with the announced reduction, the Company will pay approximately $300,000 in aggregate severance costs during the remainder of 2012. The termination of employment of these employees will result in the cessation of any further vesting in certain stock options held by these employees and a reversal of previously recognized non-cash stock-based compensation expense related to such options in a similar amount, thereby offsetting the employee reduction severance costs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Third Amendment To License Agreement with Teva</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In October&nbsp;2012, the Company entered into an amendment to its development and license agreement with Teva pursuant to which Teva made a $1.0 million payment to the Company upon the signing of the amendment and agreed to make the following milestone-based payments to the Company:&#160; (1)&nbsp;$500,000 if the FDA authorizes marketing of the licensed </font><font size="2" style="font-size:10.0pt;">male testosterone gel as an &#147;AB-rated&#148; equivalent to AndroGel</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">; (2)&nbsp;$750,000 upon the earlier to occur of (a)&nbsp;December&nbsp;31, 2012 and (b)&nbsp;five business days after Teva&#146;s submission to the FDA of a final report regarding a &#147;washing&#148; clinical study required by the FDA; and (3)&nbsp;$500,000 upon the earlier to occur of (a)&nbsp;December&nbsp;31, 2013 and (b)&nbsp;five business days after Teva&#146;s commencement of commercial manufacture of the licensed product for sale in the United States.&#160; In addition, Teva has agreed to pay the Company $4.0 million in the event Teva is the sole marketer in the United States of a generic 1% testosterone gel AB-rated to AndroGel</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;for at least 180 days immediately following the launch date of the licensed product in the United States.&#160; The royalty rate to be paid by Teva to the Company under the agreement is five percent of net sales; provided, however, that during the period of time that Teva markets the licensed product and is the sole marketer of a generic 1% testosterone gel that is AB-rated to AndroGel</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;in the United States, the royalty rate will be seven and one half percent of net sales.&#160; Additionally, pursuant to the terms of the October&nbsp;2012 amendment, the parties agreed to release each other from certain liabilities.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="PB_16_223858_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\105735\12-19123-1\task5643966\19123-1-ba-07.htm',USER='105735',CD='Nov  4 00:09 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 71.25pt;text-indent:-71.25pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 2.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">MANAGEMENT&#146;S<a name="Item2_Managements_224142"></a> DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></b></p>
<p style="margin:0in 0in .0001pt 71.25pt;text-indent:-71.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Management&#146;s Discussion and Analysis provides material historical and prospective disclosures intended to enable investors and other users to assess our financial condition and results of operations.&#160; Statements that are not historical are forward-looking and involve risks and uncertainties discussed under the heading &#147;Forward-Looking Statements&#148; below.&#160; The following discussion of our results of operations and financial condition should be read in conjunction with our financial statements and the related notes thereto included elsewhere in this report.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Business Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a specialty pharmaceutical company focused on developing products for female sexual health and oncology.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our products, either approved or in clinical development, include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">LibiGel &#151; once daily transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD).</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Male testosterone gel &#151; once daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of hypogonadism, or testosterone deficiency in men, and licensed to Teva Pharmaceuticals USA,&nbsp;Inc. (Teva).</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">GVAX cancer vaccines &#151; a portfolio of cancer vaccines, four of which have been granted FDA orphan drug designation, currently in 17 Phase I and Phase II clinical trials for the treatment of various cancers.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Pill-Plus (triple component contraceptive) &#151; once daily use of various combinations of estrogens, progestogens and androgens in Phase II development.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Elestrin &#151; once daily transdermal estradiol (estrogen) gel approved by the FDA indicated for the treatment of hot flashes associated with menopause and marketed in the U.S. by Meda Pharmaceuticals,&nbsp;Inc. (Meda), our licensee.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our corporate strategy is to develop high value medically-needed pharmaceutical products.&#160; As a part of our corporate strategy, we seek to implement strategic alternatives with respect to our products and our company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies.&#160; Therefore, as a matter of course, from time to time, we may engage in discussions with third parties regarding the licensure, sale or acquisition of our products and technologies or a merger or sale of our company, with the goal of maximizing stockholder value.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent Development</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Agreement and Plan of Merger</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On October&nbsp;3, 2012, we entered into an agreement and plan of merger with ANIP Acquisition Company d/b/a ANI Pharmaceuticals,&nbsp;Inc. (ANI).&#160; The merger agreement provides that, subject to the terms and conditions set forth in the merger agreement, ANI will merge with and into BioSante, with BioSante continuing as the surviving company.&#160; At the effective time of the merger, each outstanding </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="PB_17_223858_9497"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\105735\12-19123-1\task5643966\19123-1-ba-07.htm',USER='105735',CD='Nov  4 00:09 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">share of capital stock of ANI will be converted into the right to receive a number of shares of our common stock, if any, as determined pursuant to the exchange ratios described in the merger agreement and the provisions of ANI&#146;s certificate of incorporation.&#160; All options, warrants or other rights to purchase shares of capital stock of ANI, will be canceled at the effective time of the merger without any consideration in exchange, except for certain warrants which although not cancelled will not represent the right to acquire any equity or other interest in the combined company after the merger.&#160; No fractional shares of our common stock will be issued in connection with the merger, and holders of ANI capital stock will be entitled to receive cash in lieu thereof.&#160; Following the consummation of the transactions contemplated by the merger agreement, the current stockholders of ANI are expected to own approximately 53 percent of the outstanding shares of common stock of the combined company, and current stockholders of BioSante are expected to own approximately 47 percent of the outstanding shares of common stock of the combined company.&#160; The exchange ratios are subject to potential adjustment as described in the merger agreement depending upon the amount of&#160; our &#147;net cash,&#148; as defined in the merger agreement and generally consisting of our cash and cash equivalents less certain expenses and liabilities, as of a determination date prior to the closing date of the merger, but in no event will the current ANI stockholders own less than 50.1 percent (or the current BioSante stockholders own more than 49.9 percent) of the outstanding shares of common stock of the combined company.&#160; The merger is intended to qualify as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)&nbsp;of the Internal Revenue Code of 1986, as amended.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The merger agreement provides that, immediately following the effective time of the merger, the board of directors of the combined company will consist of five former directors of ANI and two former directors of BioSante, and ANI&#146;s current executive officers are expected to serve as executive officers of the combined company.&#160; In connection with the merger, we will seek to amend our certificate of incorporation to: (i)&nbsp;effect a reverse split of our common stock at a ratio between the range of one-for-two and one-for-five, as determined by us and ANI, which is intended to ensure that the listing requirements of The NASDAQ Global Market or The NASDAQ Capital Market are satisfied; and (ii)&nbsp;change the name of our company to &#147;ANI Pharmaceuticals,&nbsp;Inc.&#148; or another name as designated by ANI (together, the &#147;charter amendments&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consummation of the merger is subject to a number of conditions, including, but not limited to (i)&nbsp;the adoption and approval of the merger agreement and the transactions contemplated thereby by both our and ANI&#146;s stockholders and the approval of the charter amendments by our stockholders; (ii)&nbsp;the effectiveness of a Form&nbsp;S-4 registration statement to be filed by us with the Securities and Exchange Commission to register the shares of our common stock to be issued in connection with the merger, which will contain a joint proxy statement/prospectus; (iii)&nbsp;approval for the listing of shares of our common stock to be issued in the merger on The NASDAQ Global Market or The NASDAQ Capital Market; (iv)&nbsp;written opinions of counsel that the merger will qualify as a reorganization within the meaning of Section&nbsp;368(a)&nbsp;of the Code; and (v)&nbsp;other customary closing conditions.&#160; In addition, the obligation of ANI to effect the merger is subject to a condition that our net cash, after deducting all remaining liabilities, as calculated pursuant to the terms of the merger agreement, be no less than $17.0 million immediately prior to the effective time of the merger. No fractional shares of our common stock will be issued in connection with the reverse split and holders of our common stock will be entitled to receive cash in lieu thereof.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each of BioSante and ANI have made customary representations, warranties and covenants in the merger agreement, including among others, covenants that (i)&nbsp;each party will conduct its business in the ordinary course consistent with past practice during the interim period between the execution of the merger agreement and the consummation of the merger; (ii)&nbsp;each party will not engage in certain kinds of transactions or take certain actions during such period; (iii)&nbsp;ANI will convene and hold a meeting of its stockholders for the purpose of considering the adoption and approval of the merger agreement and the transactions contemplated thereby and the board of directors of ANI will recommend that its stockholders </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18<a name="PB_18_223858_3641"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\105735\12-19123-1\task5643966\19123-1-ba-07.htm',USER='105735',CD='Nov  4 00:09 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">adopt and approve the merger agreement, subject to certain exceptions; and (iv)&nbsp;we will convene and hold a meeting of our stockholders for the purpose of considering the adoption and approval of the merger agreement and the transactions contemplated thereby and the approval of the charter amendments and our board of directors will recommend that our stockholders adopt and approve the merger agreement and approve the charter amendments, subject to certain exceptions.&#160; Each of BioSante and ANI also has agreed not to solicit proposals relating to alternative business combination transactions or enter into discussions or an agreement concerning any proposals for alternative business combination transactions, subject to exceptions for us in the event of our receipt of a &#147;superior proposal.&#148;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The merger agreement contains certain termination rights in favor of each of ANI and us in certain circumstances. If the merger agreement is terminated due to certain triggering events specified in the merger agreement, we will be required to pay ANI a termination fee of up to $1.0 million or ANI will be required to pay us a termination fee of up to $750,000. The merger agreement also provides that under specified circumstances, we may be required to reimburse ANI up to $500,000 for ANI&#146;s expenses in connection with the transaction. Any expenses paid by us will be credited against the $1.0 million termination fee if the termination fee subsequently becomes payable by us.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Voting Agreements</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Concurrently and in connection with the execution of the merger agreement, certain of ANI&#146;s stockholders, who collectively hold approximately 90 percent of the outstanding shares of ANI capital stock as of the close of business on October&nbsp;3, 2012,&#160; entered into voting agreements with us, pursuant to which each stockholder agreed to vote its shares of ANI capital stock in favor of the merger, the merger agreement and the transactions contemplated by the merger agreement and against certain transactions or certain actions that would delay, prevent or nullify the merger or the transaction contemplated by the merger agreement.&#160; In addition, one of the stockholders of ANI, who holds approximately 57 percent of the outstanding shares of ANI capital stock as of the close of business on October&nbsp;3, 2012, has agreed to vote in favor of the election of the two directors designated by us at the first annual meeting of stockholders following the completion of the merger.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, certain of our stockholders, directors and officers, who collectively hold approximately two percent of the outstanding shares of our capital stock as of the close of business on October&nbsp;3, 2012, entered into voting agreements with ANI, pursuant to which each stockholder agreed to vote its shares of our capital stock in favor of the merger, the merger agreement and the transactions contemplated by the merger agreement and the charter amendments, and against certain transactions or certain actions that would delay, prevent or nullify the merger or the transaction contemplated by the merger agreement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Lock-Up Agreements</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Concurrently and in connection with the execution of the merger agreement, ANI&#146;s chief executive officer and chief financial officer and certain stockholders of ANI, who collectively hold approximately 85 percent of the outstanding shares of ANI capital stock as of the close of business on October&nbsp;3, 2012, entered into lock-up agreements with us, pursuant to which each stockholder will be subject to a six-month lock-up on the sale of shares of our common stock received in the merger.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Contingent Value Rights Agreement</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have the right in our sole discretion to issue contingent value rights (each, a CVR and collectively, the CVRs) to our existing stockholders immediately prior to the completion of the merger.&#160; We expect that one CVR will be issued for each share of our common stock outstanding as of the record </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19<a name="PB_19_223922_5250"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\105735\12-19123-1\task5643966\19123-1-ba-07.htm',USER='105735',CD='Nov  4 00:09 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">date to be set at a date prior to the completion of the merger.&#160; However, the CVRs will not be certificated and will not be attached to the shares of our common stock.&#160; Each CVR will be a non-transferable (subject to certain limited exceptions) right to potentially receive certain cash payments in the event we receive net cash payments during the ten-year period after the distribution of the rights as a result of the sale, transfer, license or similar transaction relating to our LibiGel program,&#160; upon the terms and subject to the conditions set forth in a contingent value rights agreement to be entered into between us and an as of yet unidentified third party, as rights agent.&#160; The aggregate cash payments to be distributed to the holders of the CVRs, if any, will be equal to 66 percent of the net cash payments received by the combined company as a result of the sale, transfer, license or similar transaction relating to our LibiGel program, as determined pursuant to the CVR agreement, and will not exceed $40 million in the aggregate.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Additional Business Developments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our lead product in development is LibiGel for the treatment of FSD, specifically HSDD, in postmenopausal women, for which there is no FDA-approved pharmaceutical product.&#160; For the past several years, we focused our efforts on two Phase III LibiGel efficacy trials and our LibiGel Phase III cardiovascular and breast cancer safety study.&#160; In December&nbsp;2011, we announced results from our two Phase III LibiGel efficacy trials, which showed that the trials did not meet the co-primary or secondary endpoints.&#160; Although LibiGel performed as predicted, increasing satisfying sexual events and sexual desire and decreasing distress associated with low desire, the placebo response in the two efficacy trials was greater than expected, and LibiGel&#146;s results were not shown to be statistically different from the placebo.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Beginning in December&nbsp;2011, we analyzed the data from our Phase III LibiGel efficacy trials, consulted with key opinion leaders in female sexual dysfunction, testosterone therapy and placebo effects, and met with representatives of the FDA.&#160; As a result of this process, in June&nbsp;2012 we announced a plan to initiate two new LibiGel Phase III efficacy trials.&#160; We subsequently began the process of developing a protocol for the two new efficacy trials and applying for an FDA Special Protocol Assessment (SPA) agreement covering aspects of the two new efficacy trials.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In September&nbsp;2012, we announced that the independent Data Monitoring Committee (DMC) completed its ninth unblinded review of the LibiGel Phase III cardiovascular events and breast cancer safety study and recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. At the time of the DMC review, there were 53 adjudicated CV events, with a lower than anticipated event rate of approximately 0.72 percent. In the same population of subjects, there were 27 breast cancers reported, a rate of approximately 0.37 percent, which is in line with the expected rate based on the ages of the subjects enrolled in the study. Given this latest review during which no specific or general safety issues were raised, and after extensive consideration, we also announced in September&nbsp;2012 the conclusion of the LibiGel Phase III safety study effective immediately. Prior to the initiation of the LibiGel safety study in 2008, the FDA advised us that subjects in the cardiovascular event and breast cancer safety study were required to have a minimum average exposure in the safety study of 12 months prior to submitting a LibiGel new drug application (NDA), and prior to a potential FDA approval of LibiGel. As of the date of the conclusion of the safety study, subjects had been in the study for an average time of 24.5 months; more than 3,200 subjects had been in the study for more than one year and over 1,700 subjects had been enrolled for more than two years. With this ninth positive unblinded review of the study by the DMC, and over 7,400 women-years of exposure, we believe that adequate safety data of LibiGel use in menopausal women has been obtained.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are continuing to develop a protocol for the two new LibiGel efficacy trials and will seek an FDA SPA agreement covering aspects of the two new efficacy trials.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20<a name="PB_20_223936_7672"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\105735\12-19123-1\task5643966\19123-1-ba-07.htm',USER='105735',CD='Nov  4 00:09 2012' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Elestrin was our first FDA approved product and now is one of our two FDA approved products.&#160; Meda Pharmaceuticals,&nbsp;Inc. (which acquired Jazz Pharmaceuticals,&nbsp;Inc.&#146;s women&#146;s health business and which in turn had acquired Azur Pharma International II Limited (Azur), our prior licensee), is marketing Elestrin in the U.S.&#160; In December&nbsp;2009, we entered into an amendment to our original licensing agreement with Azur pursuant to which we received $3.16 million in non-refundable payments in exchange for the elimination of all remaining future royalty payments and certain milestone payments that could have been paid to us related to sales of Elestrin.&#160; We maintain the right to receive up to $140 million in sales-based milestone payments from Meda if Elestrin reaches certain predefined sales per calendar year; although, based on current sales levels, we believe our receipt of such payments unlikely in the near term, if at all.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our male testosterone gel is our second FDA approved product.&#160; This product initially was developed by us, and then licensed by us to Teva for late stage clinical development.&#160; Teva submitted an NDA to the FDA in the beginning of 2011, which was approved by the FDA in February&nbsp;2012.&#160; Subsequent to Teva submitting the NDA, in April&nbsp;2011, a subsidiary of Abbott Laboratories, a marketer of a testosterone gel for men, filed a complaint against Teva alleging patent infringement.&#160; This litigation was settled in December&nbsp;2011; however, the terms of the settlement agreement are confidential and have not been disclosed publicly.&#160; No launch date for this product has been announced by Teva.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under our development and license agreement with Teva, Teva has agreed to market our male testosterone gel for the U.S. market and is responsible for any and all manufacturing and marketing associated with the product.&#160; The financial terms of the development and license agreement included a $1.5 million upfront payment by Teva, which was paid to us in December&nbsp;2002, and an obligation by Teva to pay us certain milestones and royalties on sales of the product in exchange for rights to develop and market the product, as described in more detail below. Teva is entitled to deduct the amount of any legal expenses incurred by Teva in connection with associated patent litigation against Teva from the net sales of the product.&#160; The term of the development and license agreement will expire 10 years from the date on which Teva makes its first commercial sale of the male testosterone gel to an unrelated third party in an arms-length transaction in the United States.&#160; The parties may terminate the development and license agreement upon the occurrence of certain events, including a material breach of the agreement by the other party.&#160; We may terminate the agreement if Teva files a petition in bankruptcy, enters into an arrangement with its creditors or makes an assignment for the benefit of creditors or a receiver or trustee is appointed or if Teva suffers or permits the entry of an order adjudicating it to be bankrupt or insolvent.&#160; Teva may terminate the agreement if Teva determines that the continued development and/or marketing of the male testosterone gel is no longer commercially viable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In October&nbsp;2012, we entered into an amendment to our agreement with Teva pursuant to which Teva made a $1.0 million payment to us upon the signing of the amendment and agreed to make the following milestone based payments to us:&#160; (1)&nbsp;$500,000 if the FDA authorizes marketing of the licensed </font><font size="2" style="font-size:10.0pt;">male testosterone gel as an &#147;AB-rated&#148; equivalent to AndroGel&#174;; (2)&nbsp;$750,000 upon the earlier to occur of (a)&nbsp;December&nbsp;31, 2012 and (b)&nbsp;five business days after Teva&#146;s submission to the FDA of a final report regarding a &#147;washing&#148; clinical study required by the FDA; and (3)&nbsp;$500,000 upon the earlier to occur of (a)&nbsp;December&nbsp;31, 2013 and (b)&nbsp;five business days after Teva&#146;s commencement of commercial manufacture of the licensed product for sale in the United States.&#160; In addition, Teva has agreed to pay us $4.0 million in the event Teva is the sole marketer in the United States of a generic 1% testosterone gel AB-rated to AndroGel&#174; for at least 180 days immediately following the launch date of the licensed product in the United States.&#160; The royalty rate to be paid by Teva to us under the agreement is five percent of net sales; provided, however, that during the period of time that Teva markets the licensed product and is the sole marketer of a generic 1% testosterone gel that is AB-rated to AndroGel&#174; in the United States, the royalty rate will be seven and one half percent of net sales.&#160; Additionally, pursuant to the terms of the October&nbsp;2012 amendment, the parties agreed to release each other from certain liabilities.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21<a name="PB_21_214122_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-09.htm',USER='bekuehe',CD='Nov  7 12:41 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We license the technology underlying certain of our gel products, including LibiGel and Elestrin, but not our male testosterone gel, from Antares Pharma,&nbsp;Inc.&#160; The patents covering the formulations used in the gel products covered under the license agreement are expected to expire in 2022, although with respect to LibiGel, a new U.S. patent covering the &#147;method of use&#148; of LibiGel for treating FSD and HSDD was issued, which will expire in December&nbsp;2028.&#160; Our license agreement with Antares requires us to pay Antares certain development and regulatory milestone payments and royalties based on net sales of any products we or our licensees sell incorporating the licensed technology.&#160; Specifically, we are obligated to pay Antares 25 percent of all upfront and milestone payments related to a license and a 4.5 percent royalty on net sales of product by us or a licensee.&#160; Since entering into the agreement and through September&nbsp;30, 2012, we have paid Antares an upfront payment of $1.0 million, an aggregate of $5.1 million in milestone payments and an aggregate of $100,000 in royalties.&#160; Aggregate potential milestone payments to be paid by us to Antares under the agreement include 25 percent of the potential $140 million in sales-based milestone payments, or $35 million from Meda if Elestrin reaches certain predefined sales per calendar year; although, based on current sales levels, we believe our receipt of such payments unlikely in the near term, if at all.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The term of our license agreement with Antares will expire on a country-by-country and product-by-product basis when the royalties expire (at patent expiration), at which time we will have a fully paid-up exclusive license regarding the applicable product in such country.&#160; We and Antares may terminate the license agreement upon the occurrence of certain events, including a material breach of the agreement by the other party or if the other party goes into liquidation or bankruptcy or makes an assignment for the benefit of creditors or a receiver is appointed.&#160; Antares may terminate the agreement with respect to certain products or territories if we do not continue development, seeking regulatory approval or marketing of such products in the covered territories.&#160; We may terminate the agreement with respect to certain products or territories if, for technical, scientific or regulatory reasons, it is not likely that the product will gain required regulatory approvals in a territory, if regulatory approvals in a territory are not obtained or if we determine that it is not economically viable to continue development or marketing of a product in a territory.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We license the technology underlying The Pill Plus from Wake Forest University Health Sciences and Cedars-Sinai Medical Center.&#160; The financial terms of this license include regulatory milestone payments, maintenance payments and royalty payments by us if a product incorporating the licensed technology gets approved and subsequently is marketed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our GVAX cancer vaccines, which are designed to stimulate a patient&#146;s immune system to fight effectively the patient&#146;s own cancer, are in development for the treatment of several different types of cancer including melanoma, leukemia, pancreatic, breast and prostate cancer.&#160; Four of these vaccines &#151; to treat pancreatic cancer, acute myeloid leukemia, chronic myeloid leukemia and melanoma &#151; have been granted FDA orphan drug designation.&#160; Currently, there are 17 Phase I and Phase II clinical studies involving our GVAX cancer vaccines ongoing.&#160; The studies are being funded by various sources, including certain foundations and our licensees. Our objective with respect to our GVAX cancer vaccines is to help facilitate further studies and commercialization in order to bring important cancer therapies to patients in need and to maximize the value of our GVAX cancer vaccine portfolio to our stockholders.&#160; This objective includes monetizing the entire portfolio or seeking additional licensees to fund, develop and eventually commercialize the cancer vaccines.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financial Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Substantially all of our revenue to date has been derived from upfront, milestone and royalty payments earned on licensing and sublicensing transactions and from subcontracts.&#160; Our business operations to date have consisted primarily of licensing and research and development activities and if we </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22<a name="PB_22_214148_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-09.htm',USER='bekuehe',CD='Nov  7 12:41 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">do not complete our proposed merger with ANI, we would expect this to continue for the immediate future.&#160; To date, we have used primarily equity financings, and to a lesser extent, licensing income, interest income and the cash received from our 2009 merger with Cell Genesys,&nbsp;Inc., to fund our ongoing business operations and short-term liquidity needs.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2012, we had $38.0 million of cash and cash equivalents and had outstanding $8.3 million in aggregate principal amount of our 3.125% convertible senior notes due May&nbsp;1, 2013.&#160; Absent the receipt of any additional licensing income or financing, we expect our cash and cash equivalents balance to decrease as we continue to use cash to fund our operations.&#160; Assuming our pending merger with ANI is completed, we expect our cash and cash equivalents as of September&nbsp;30, 2012 to meet our liquidity requirements through at least our anticipated closing of the merger, including the requirement under our merger agreement to have at least $17 million of net cash (as defined in the merger agreement) available upon the closing of the merger.&nbsp;&nbsp; If the Company&#146;s pending merger with ANI is not completed, the Company will need to reevaluate its strategic alternatives, which may include a sale of the company, liquidation of the company or other strategic transaction.&nbsp; The Company&#146;s liquidity position will be dependent upon the strategic alternative selected; however, assuming the Company does not enter into another strategic transaction, and assuming the Company decides not to commence the two new efficacy trials for LibiGel, the Company expects its cash and cash equivalents as of September&nbsp;30, 2012 will be sufficient to meet the Company&#146;s liquidity requirements for at least the next 3-5 years.&nbsp; Additional financing would be required should the Company decide to commence the two new efficacy trials for LibiGel.&nbsp; These estimates may prove incorrect or the Company, nonetheless, may choose to raise additional financing earlier.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We incurred expenses of $14.5 million on research and development activities during the nine months ended September&nbsp;30, 2012, which is a 61 percent decrease compared to the same period in 2011, primarily as a result of the conclusion of our two LibiGel Phase III efficacy trials at the end of 2011.&#160; We anticipate that our research and development expenses for the remainder of 2012 will consist primarily of expenses associated with the conclusion of the safety study and continuing to develop a protocol for the two new LibiGel Phase III efficacy trials.&#160; We currently expect to spend approximately $1.1 million per month on research and development activities during the remainder of 2012, which is based on the assumption that we do not in-license additional products and technologies requiring additional development.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our general and administrative expenses for the nine months ended September&nbsp;30, 2012 increased 1.3 percent compared to the same period in 2011 due primarily to an increase in professional fees and other administrative expenses.&#160; Our general and administrative expenses generally fluctuate from year-to-year and quarter-to-quarter depending upon the amount of non-cash, stock-based compensation expense and the amount of legal, public and investor relations, accounting, corporate governance and other general and administrative fees and expenses incurred.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We recognized an income tax benefit based on the receipt of an income tax credit for the three and nine months ended September&nbsp;30, 2012 of $121,791 compared to the recognition of no income tax benefit for the three and nine months ended September&nbsp;30, 2011.&#160; The income tax benefit was a result of an election to accelerate research and development credits in lieu of receiving bonus depreciation on certain property under Sec. 168(k)(4)&nbsp;of the Internal Revenue Code of 1986, as amended.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23<a name="PB_23_214204_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-09.htm',USER='bekuehe',CD='Nov  7 12:41 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We recognized a net loss for the three and nine months ended September&nbsp;30, 2012 of $6.1 million and $23.7 million, respectively, compared to a net loss of $12.7 million and $45.0 million for the three and nine months ended September&nbsp;30, 2011, respectively.&#160; These decreases were primarily a result of the conclusion of our prior two LibiGel Phase III efficacy trials at the end of 2011 and in September&nbsp;2012 the conclusion of the LibiGel Phase III safety study, and were offset, in part, by an increase in the non-cash fair value adjustment relating to the cancellation of $12.5 million in aggregate principal amount of our convertible senior notes.&#160; We recognized a net loss per share for the three and nine months ended September&nbsp;30, 2012 of $0.27 and $1.14, respectively, compared to a net loss per share of $0.73 and $2.86 for the three and nine months ended September&nbsp;30, 2011, respectively.&#160; These decreases in net loss per share were the result of the significantly higher weighted average number of shares outstanding, partially offset by the lower net loss described above.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Results of Operations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Three Months Ended September&nbsp;30, 2012 Compared to Three Months Ended September&nbsp;30, 2011</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth our results of operations for the three months ended September&nbsp;30, 2012 and 2011.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="97%" style="border-collapse:collapse;margin-left:.2in;width:97.34%;">
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="27%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$&nbsp;Change</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%&nbsp;Change</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenue</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">110,383</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">182,784</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(72,401</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(39.6</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,872,736</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11,500,053</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7,627,317</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(66.3</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,546,864</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,675,268</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(128,404</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7.7</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other expense &#150; Convertible note fair value   adjustment</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(843,412</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">463,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,306,412</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">282.2</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other expense &#150; Interest expense</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(67,105</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(172,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(104,895</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(61.0</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income - Interest income</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,877</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,516</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">361</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.8</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Income tax benefit</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">121,791</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">121,791</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100.0</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,121,815</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(12,733,691</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,611,876</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(51.9</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss per common share (basic and diluted)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.27</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.73</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.46</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(63.0</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted average number of common shares and   common equivalent shares outstanding</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22,921,176</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,406,536</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,514,640</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.7</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The only revenue recognized during the three months ended September&nbsp;30, 2012 consisted of royalty revenue from Jazz Pharmaceuticals for Elestrin sales, which royalty revenue is offset by our corresponding obligation to pay Antares royalties representing the same amount.&#160; Our corresponding obligation to pay Antares a portion of the royalties received, which equaled $110,383 during the three months ended September&nbsp;30, 2012 and $82,784 during the three months ended September&nbsp;30, 2011, is recorded within general and administrative expenses in our condensed statements of operations.&#160; In addition, during the three months ended September&nbsp;30, 2011, we recognized an additional $100,000 in revenue from our receipt of an upfront non-refundable licensing fee from The John P. Hussman Foundation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses for the three months ended September&nbsp;30, 2012 decreased 66 percent compared to the three months ended September&nbsp;30, 2011 primarily as a result of the </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24<a name="PB_24_215340_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-09.htm',USER='bekuehe',CD='Nov  7 12:41 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">completion of our two LibiGel Phase III efficacy trials at the end of 2011, and the conclusion of the LibiGel Phase III safety study as announced in September&nbsp;2012.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses for the three months ended September&nbsp;30, 2012 decreased 8 percent compared to the three months ended September&nbsp;30, 2011 primarily as a result of a decrease in personnel-related costs, professional fees and other administrative expenses.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The convertible note fair value adjustment to increase the recorded liability and corresponding expense was $843,412 for the three months ended September&nbsp;30, 2012 compared to a fair value adjustment to decrease the recorded liability and corresponding expense of $463,000 for the three months ended September&nbsp;30, 2011.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expense was $67,105 and $172,000 for the three months ended September&nbsp;30, 2012 and 2011, respectively, as a result of our convertible senior notes.&#160; Interest expense decreased during the most recent current year period as a result of the repayment of our 3.125% convertible senior notes due November&nbsp;1, 2011 during the fourth quarter of 2011 and the cancellation of $12.5 million in aggregate principal amount of our 3.125% convertible senior notes due May&nbsp;1, 2013, including accrued and unpaid interest, during the first and third quarter of 2012 in exchange for the issuance of 3,652,125 shares of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income increased $361 for the three months ended September&nbsp;30, 2012 compared to the three months ended September&nbsp;30, 2011 as a result of higher average cash balances during the three months ended September&nbsp;30, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We recognized an income tax benefit based on the receipt of an income tax credit for the three months ended September&nbsp;30, 2012 of $121,791 compared to the recognition of no income tax benefit for the three months ended September&nbsp;30, 2011.&#160; The income tax benefit was a result of an election to accelerate research and development credits in lieu of receiving bonus depreciation on certain property under Sec. 168(k)(4)&nbsp;of the Internal Revenue Code of 1986, as amended.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Nine Months Ended September&nbsp;30, 2012 Compared to Nine Months Ended September&nbsp;30, 2011</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table sets forth our results of operations for the nine months ended September&nbsp;30, 2012 and 2011.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="97%" style="border-collapse:collapse;margin-left:.2in;width:97.34%;">
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="27%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$&nbsp;Change</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%&nbsp;Change</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenue</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">333,163</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">320,787</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12,376</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.9</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expenses</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14,454,258</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37,480,873</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(23,026,615</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(61.4</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,327,711</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,257,853</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">69,858</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other expense &#150; Convertible note fair value   adjustment</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4,037,797</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,929,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,108,797</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">109.3</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other expense &#150; Interest expense</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(283,348</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(516,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(232,652</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(45.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income - Interest income</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,300</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,472</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,172</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(18.1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Income tax benefit</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">121,791</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">121,791</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100.0</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(23,730,408</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(44,959,682</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(21,229,274</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(47.2</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss per common share (basic and diluted)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1.14</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2.86</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="11%" valign="bottom" style="padding:0in 0in 0in 0in;width:11.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.72</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(60.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)%</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25<a name="PB_25_224111_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-09.htm',USER='bekuehe',CD='Nov  7 12:41 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="97%" style="border-collapse:collapse;margin-left:.2in;width:97.34%;">
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="27%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:27.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Nine&nbsp;Months&nbsp;Ended</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="bottom" style="padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.36%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.34%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">$&nbsp;Change</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">%&nbsp;Change</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.56%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="37%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:37.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted average number of common shares and   common equivalent shares outstanding</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.36%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,841,417</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15,744,738</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.34%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5,096,679</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.32%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.4</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.56%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The only revenue recognized during the nine months ended September&nbsp;30, 2012 consisted of royalty revenue from Jazz Pharmaceuticals for Elestrin sales, which royalty revenue is offset by our corresponding obligation to pay Antares royalties representing the same amount.&#160; Our corresponding obligation to pay Antares a portion of the royalties received, which equaled $333,163 during the nine months ended September&nbsp;30, 2012 and $220,787 during the nine months ended September&nbsp;30, 2011, is recorded within general and administrative expenses in our condensed statements of operations.&#160; In addition, during the nine months ended September&nbsp;30, 2011, we recognized an additional $100,000 in revenue from our receipt of an upfront non-refundable licensing fee from The John P. Hussman Foundation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses for the nine months ended September&nbsp;30, 2012 decreased 61 percent compared to the nine months ended September&nbsp;30, 2011 primarily as a result of the completion of our two LibiGel Phase III efficacy trials at the end of 2011 and the conclusion of the safety study in September&nbsp;2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses for the nine months ended September&nbsp;30, 2012 increased 1.3 percent compared to the nine months ended September&nbsp;30, 2011 primarily as a result of an increase in professional fees and other administrative expenses.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The fair value adjustment on our convertible senior notes for the nine months ended September&nbsp;30, 2012 was $4.0 million compared to $1.9 million for the nine months ended September&nbsp;30, 2011.&#160; The increase in the expense for the nine months ended September&nbsp;30, 2012 was primarily as a result of $3,157,151 non-cash fair value adjustment (expense) recorded upon cancellation of $12.5 million in aggregate principal amount of our convertible senior notes in February&nbsp;and July&nbsp;2012. The convertible fair value adjustment for the nine months ended September&nbsp;30, 2011 increased the recorded liability and corresponding expense by $1,929,000 and included the 2011 and 2013 Notes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expense was $283,348 and $516,000 for the nine months ended September&nbsp;30, 2012 and 2011, respectively, as a result of our convertible senior notes.&#160; Interest expense decreased during the most recent current year period as a result of the repayment of our 3.125% convertible senior notes due November&nbsp;1, 2011 during the fourth quarter of 2011 and the cancellation of $12.5 million in aggregate principal amount of our 3.125% convertible senior notes due May&nbsp;1, 2013, including accrued and unpaid interest, during the first and third quarter of 2012 in exchange for the issuance of 3,652,125 shares of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income decreased $1,172 for the nine months ended September&nbsp;30, 2012 compared to the nine months ended September&nbsp;30, 2011 as a result of lower cash balances and lower average interest rates during the nine months ended September&nbsp;30, 2012.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We recognized an income tax benefit based on the receipt of an income tax credit for the nine months ended September&nbsp;30, 2012 of $121,791 compared to the recognition of no income tax benefit for the nine months ended September&nbsp;30, 2011.&#160; The income tax benefit was a result of an election to accelerate research and development credits in lieu of receiving bonus depreciation on certain property under Sec. 168(k)(4)&nbsp;of the Internal Revenue Code of 1986, as amended.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26<a name="PB_26_224207_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-09.htm',USER='bekuehe',CD='Nov  7 12:41 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liquidity and Capital Resources</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table highlights several items from our condensed balance sheets:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;width:93.34%;">
<tr>
<td width="61%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:61.42%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Balance&nbsp;Sheet&nbsp;Data</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">September&nbsp;30,&nbsp;2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,&nbsp;2011</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:61.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash   and cash equivalents</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.78%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38,049,095</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.78%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">57,225,234</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total   current assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38,583,132</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">58,026,381</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investments</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,413,762</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,405,807</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total   assets</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43,211,746</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">62,379,755</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible   senior notes due 2013</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,593,216</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,336,760</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total   liabilities</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10,922,066</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24,564,463</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total   stockholders&#146; equity</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32,289,680</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.08%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37,815,292</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="429" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="9" style="border:none;"></td>
<td width="103" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="9" style="border:none;"></td>
<td width="103" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Liquidity</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Since our inception, we have incurred significant operating losses resulting in an accumulated deficit of $241.0 million as of September&nbsp;30, 2012.&#160; To date, we have used primarily equity financings, and to a lesser extent, licensing income, interest income and the cash received from our 2009 merger with Cell Genesys, to fund our ongoing business operations and short-term liquidity needs.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of September&nbsp;30, 2012, we had $38.0 million of cash and cash equivalents and $8,277,850 in aggregate principal amount of our 3.125% convertible senior notes due May&nbsp;1, 2013 (2013 Notes) outstanding.&#160; Absent the receipt of any additional licensing income or financing, we expect our cash and cash equivalents balance to decrease as we continue to use cash to fund our operations.&#160; Assuming our pending merger with ANI is completed during the first quarter of 2013, we expect our cash and cash equivalents as of September&nbsp;30, 2012 to meet our liquidity requirements through at least the anticipated closing of our merger with ANI, including the requirement under our merger agreement to have at least $17 million of net cash (as defined in the merger agreement) available upon the closing of the merger.&nbsp;&nbsp; If the Company&#146;s pending merger with ANI is not completed, the Company will need to reevaluate its strategic alternatives, which may include a sale of the company, liquidation of the company or other strategic transaction.&nbsp; The Company&#146;s liquidity position will be dependent upon the strategic alternative selected; however, assuming the Company does not enter into another strategic transaction, and assuming the Company decides not to commence the two new efficacy trials for LibiGel, the Company expects its cash and cash equivalents as of September&nbsp;30, 2012 will be sufficient to meet the Company&#146;s liquidity requirements for at least the next 3-5 years.&nbsp; Additional financing would be required should the Company decide to commence the two new efficacy trials for LibiGel.&nbsp; These estimates may prove incorrect or the Company, nonetheless, may choose to raise additional financing earlier.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our future capital requirements will depend upon numerous factors, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing, cost and successful completion of our proposed merger with ANI;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the progress, timing, cost and results of our clinical development programs, including in particular the conclusion of the LibiGel Phase III safety study, and if we have not completed our proposed merger with ANI, beginning in mid-2013, the two new LibiGel Phase III efficacy trials if we decide to commence such trials, and if we in-license additional new products that require further development;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the cost, timing and outcome of regulatory actions with respect to our products;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27<a name="PB_27_224306_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\bekue\12-19123-1\task5654088\19123-1-ba-09.htm',USER='bekuehe',CD='Nov  7 12:41 2012' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the success, progress, timing and costs of our business development efforts to implement business collaborations, licenses and other business combinations or transactions, and our efforts to evaluate various strategic alternatives available with respect to our products and our company.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to obtain value from our current products and technologies and our ability to out-license our products and technologies to third parties for development and commercialization and the terms of such out-licenses;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to acquire or in-license additional new products and technologies and the costs and expenses of such acquisitions or licenses;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing and amount of any royalties, milestone or other payments we may receive from or be obligated to pay to current and potential licensors, licensees and other third parties;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the costs of preparing, filing, prosecuting, maintaining and enforcing patent claims and other intellectual property rights;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the emergence of competing products and technologies, and other adverse market developments;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the perceived, potential and actual commercial success of our products;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the outstanding principal amount of our 3.125% convertible senior notes due May&nbsp;1, 2013 (convertible senior notes) that are scheduled to mature and become due and payable on May&nbsp;1, 2013 and our ability to avoid a &#147;fundamental change&#148; or an &#147;event of default&#148; under the indenture governing such notes, which may cause such notes to become due and payable prior to their maturity date on May&nbsp;1, 2013;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our operating expenses; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the resolution of our pending purported class action and shareholder derivative litigation and any amount we may be required to pay in excess of our directors&#146; and officers&#146; liability insurance.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not have any existing credit facilities under which we could borrow funds.&#160; In the event that we would require additional working capital to fund future operations, we could seek to acquire such funds through additional equity or debt financing arrangements.&#160; If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt.&#160; There is no assurance that any financing transaction will be available on terms acceptable to us, or at all.&#160; As an alternative to raising additional financing, we may choose to license one or more of our products or technologies to a third party who may finance a portion or all of the continued development and, if approved, commercialization of that licensed product, or sell certain assets or rights under our existing license agreements.&#160; In addition, from time to time, we may purchase, exchange or restructure our outstanding convertible senior notes through cash purchases and/or exchanges for other equity securities of our company, in open market purchases, privately negotiated transactions and/or a tender offer.&#160; In February&nbsp;2012, we issued an aggregate of 1,868,055 shares of our common stock to one of the holders of our 2013 Notes in exchange for the cancellation of $9,000,000 in aggregate principal amount of such notes, including accrued and unpaid interest of $79,024, and in July&nbsp;2012, we issued an aggregate of 1,784,070 shares of our common stock to two of the holders of our 2013 Notes in exchange for the cancellation of $3,504,150 in aggregate </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28<a name="PB_28_224445_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\105938\12-19123-1\task5643833\19123-1-ba-11.htm',USER='105938',CD='Nov  4 00:17 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">principal amount of such notes and accrued and unpaid interest of $20,686.&#160; Such additional purchases, exchanges or restructurings, if any, will depend on prevailing market conditions, the trading price and volume of our common stock, the willingness of the note holders to sell, exchange or restructure their notes, our available cash and cash equivalents, our liquidity requirements, regulatory limitations, contractual restrictions and other factors.&#160; Such future purchases, exchanges or restructurings could dilute the percentage ownership of our stockholders, result in the issuance of securities at a discount to market price or that may have rights, preferences or privileges senior to those of our existing stockholders and/or decrease our cash balance.&#160; A significant decrease in our cash balance, together with an inability to raise additional financing when needed, may impair our ability to execute strategic alternatives or leave us without sufficient cash remaining for operations.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are subject to pending purported class action and shareholder derivative litigation, which litigation is described in more detail in Note 8, &#147;Commitments and Contingencies&#148; to our unaudited condensed financial statements included in this report.&#160; Such litigation could divert management&#146;s attention, harm our business and/or reputation and result in significant liabilities, as well as harm our ability to raise additional financing and execute certain strategic alternatives.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We can provide no assurance that additional financing, if needed, will be available on terms favorable to us, or at all.&#160; This is particularly true if investors are not confident in the success of our proposed merger with ANI, our LibiGel clinical development program, the future value of our company and/or economic and market conditions deteriorate.&#160; If we do not complete our proposed merger with ANI and if adequate funds are not available or are not available on acceptable terms when we need them, we may need to reduce our operating costs further or we may be forced to explore other strategic alternatives, such as other business combination transactions or winding down our operations and liquidating our company.&#160; In such case, our stockholders could lose some or all of their investment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Uses of Cash and Cash Flow</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in operating activities was $22.1 million for the nine months ended September&nbsp;30, 2012 compared to net cash used in operating activities of $36.9 million for the nine months ended September&nbsp;30, 2011.&#160; Net cash used in operating activities for the nine months ended September&nbsp;30, 2012 was primarily the result of the net loss for that period which was lower compared to the prior year period due to lower clinical trial related expenses primarily as a result of the completion of our two LibiGel Phase III efficacy trials at the end of 2011 and the conclusion of the safety study in September&nbsp;2012.&#160; Net cash used in operating activities for the nine months ended September&nbsp;30, 2011 was primarily the result of the net loss for that period.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in investing activities was $536,697 for the nine months ended September&nbsp;30, 2012 compared to net cash used in investing activities of $645,603 for the nine months ended September&nbsp;30, 2011.&#160; Net cash used in investing activities for each of the nine months ended September&nbsp;30, 2012 and 2011 was due primarily to the purchase of fixed assets.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by financing activities was $3.5 million for the nine months ended September&nbsp;30, 2012 compared to net cash provided by financing activities of $69 million for the nine months ended September&nbsp;30, 2011.&#160; Net cash provided by financing activities for the nine months ended September&nbsp;30, 2012 was the result of our August&nbsp;2012 registered direct offering, which resulted in net proceeds of $3.3 million, after deduction of placement agent fees and offering expenses.&#160; Net cash provided by financing activities for the nine months ended September&nbsp;30, 2011 was the result of our August&nbsp;2011 underwritten public offering and March&nbsp;2011 registered direct offering, which resulted in net proceeds of $45.1 million and $23.9 million, respectively, after deduction of underwriting discounts and commissions or placement agent fees and offering expenses.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29<a name="PB_29_224501_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\105938\12-19123-1\task5643833\19123-1-ba-11.htm',USER='105938',CD='Nov  4 00:17 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Commitments and Contractual Obligations</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We did not have any material commitments for capital expenditures as of September&nbsp;30, 2012.&#160; We have a purchase obligation relating to a gel packaging machine of $40,608.&#160; This obligation is due upon the shipment, assembly and calibration of the machine at a location designated by us.&#160; In light of our pending merger with ANI, we are evaluating our future plans for this gel packaging machine.&#160; We also have several financial commitments, including our 2013 Notes, product development milestone payments to the licensors of certain of our products, payments under our license agreements with Johns Hopkins University and Wake Forest University Health Sciences, as well as minimum annual lease payments.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes the timing of these future contractual obligations and commitments as of September&nbsp;30, 2012:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="60%" colspan="14" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:60.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Payments&nbsp;Due&nbsp;by&nbsp;Period</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Less&nbsp;than</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">1&nbsp;Year</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">1-3&nbsp;Years</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">3-5&nbsp;Years</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">More&nbsp;than</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">5&nbsp;Years</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Convertible senior notes</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,277,850</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,277,850</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest payment obligations related to   convertible senior notes</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">150,898</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">150,898</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating lease</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">350,413</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">246,119</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">104,295</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commitments under license agreements with Johns   Hopkins University</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">320,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">135,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">90,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50,000</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commitments under license agreement with   Massachusetts Institute of Technology</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">50,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commitments under license agreement with   University of California</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">300,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">60,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">180,000</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commitments under license agreement with Wake   Forest</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">360,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">80,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">200,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">80,000</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="36%" valign="bottom" style="padding:0in 0in 0in 0in;width:36.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total contractual cash obligations</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9,859,162</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,869,867</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">549,295</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">210,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">230,000</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Off-Balance Sheet Arrangements</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not have any off-balance sheet arrangements that have or reasonably are likely to have a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.&#160; As a result, we are not exposed materially to any financing, liquidity, market or credit risk that could arise if we had engaged in these arrangements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Critical Accounting Policies</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The discussion and analysis of our unaudited condensed financial statements and results of operations are based upon our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.&#160; The preparation of these condensed financial statements requires management to make estimates and judgments that affect the reported amount of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities.&#160; The Securities and Exchange Commission has defined a company&#146;s most critical accounting policies as those that are most important to the portrayal of its financial condition and results of operations, and which requires the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain.&#160; Based on this definition, we have identified certain of our accounting policies as critical accounting policies.&#160; Our critical accounting policies are described in &#147;Item 7. Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2011.&#160; There have been no changes to the critical accounting policies described in our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2011.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30<a name="PB_30_224607_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\105938\12-19123-1\task5643833\19123-1-ba-11.htm',USER='105938',CD='Nov  4 00:17 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recently Issued Accounting Pronouncements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not expect the adoption of any recent accounting pronouncements to have a material effect on our financial position, results of operations or cash flows.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This quarterly report on Form&nbsp;10-Q contains not only historical information, but also forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections.&#160; In addition, we or others on our behalf may make forward-looking statements from time to time in oral presentations, including telephone conferences and/or web casts open to the public, in news releases or reports, on our Internet web site or otherwise.&#160; All statements other than statements of historical facts included in this report that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our plans, objectives, strategies and prospects regarding, among other things, our financial condition, results of operations and business.&#160; We have identified some of these forward-looking statements with words like &#147;believe,&#148; &#147;may,&#148; &#147;could,&#148; &#147;would,&#148; &#147;might,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;project,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;approximate,&#148; &#147;contemplate&#148; or &#147;continue,&#148; the negative of these words, other words and terms of similar meaning and the use of future dates.&#160; These forward-looking statements may be contained in the notes to our condensed financial statements and elsewhere in this report, including under the heading &#147;Part&nbsp;I. Item 2.&#160; Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148;&#160; Our forward-looking statements generally relate to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the status and timing of our proposed merger with ANI;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the status and conduct of our LibiGel Phase III clinical development program and the timing of certain events related thereto;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our future operating expenses, anticipated burn rate and whether and how long our existing cash and cash equivalents will be sufficient to fund our operations;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our efforts to explore and evaluate various strategic alternatives with respect to our products and the possible effect such strategic alternatives may have on our business, including in particular our LibiGel Phase III clinical development program;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the market size and market acceptance of our approved products and products in development;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the effect of new accounting pronouncements and future health care, tax and other legislation;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our need, ability and expected timing of any actions to raise additional capital through future equity and other financings; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our substantial and continuing losses.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Forward-looking statements are based on current expectations about future events affecting us and are subject to uncertainties and factors that affect all businesses operating in a global market as well as matters specific to us.&#160; These uncertainties and factors are difficult to predict and many of them are beyond our control.&#160; The following are some of the uncertainties and factors known to us that could cause </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31<a name="PB_31_224643_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\105938\12-19123-1\task5643833\19123-1-ba-11.htm',USER='105938',CD='Nov  4 00:17 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">our actual results to differ materially from what we have anticipated in our forward-looking statements or otherwise could materially adversely affect our business, financial condition or operating results:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">risk relating to our proposed merger with ANI, as described in more detail later in this report under the heading &#147;Part&nbsp;II &#151; Item 1A. Risk Factors&#148;;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the future and success of our LibiGel Phase III clinical development program;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to generate significant revenues and obtain profitability;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to obtain additional capital when needed or on acceptable terms and the effect of any future equity or debt financings or debt restructurings on our stockholders;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our substantial indebtedness and our ability to repay such debt when it becomes due and payable and the effect of such debt on our ability to operate our business;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the resolution of our pending purported class action and shareholder derivative litigation and the effect of such resolution on our business, operating results and financial condition;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to maintain the listing of our common stock on The NASDAQ Global Market;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to implement strategic alternatives with respect to our products and our company, including licenses, business collaborations, and other business combinations or transactions with other pharmaceutical and biotechnology companies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to acquire or invest in new businesses, products and technologies by way of a license, acquisition or merger transaction and the effect of such a transaction on our stockholders, business, operating results and financial condition;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our success in developing new products and technologies, obtaining any required regulatory approvals for such products and technologies and obtaining market acceptance and commercial success with respect to such new products and technologies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">results of our clinical studies and the actions of certain regulatory bodies, including the FDA;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to submit and receive an FDA SPA agreement and other applications for and obtain and maintain required regulatory approvals on a timely basis or at all;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the timing of when, if ever, our products will be approved and introduced commercially;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the size of the market and the level of market acceptance of our products if and when they are commercialized;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our dependence upon the maintenance of our license with Antares Pharma IPL AG and, to a lesser extent, other licensors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our dependence upon our licensees for the development, marketing and sale of certain of our products, including in particular Teva Pharmaceuticals USA Inc. with respect to our male testosterone gel and the uncertainty involved in when or if Teva will launch commercially our male testosterone gel and the commercial success of such product and the amount of revenues we may receive, if any, from such product;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32<a name="PB_32_224706_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\105938\12-19123-1\task5643833\19123-1-ba-11.htm',USER='105938',CD='Nov  4 00:17 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our dependence upon certain third parties who assist us in certain aspects of our clinical studies and certain manufacturers who produce our products;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to achieve projected goals and objectives within the time periods that we anticipate or announce publicly;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">uncertainties associated with the impact of published studies regarding the adverse health effects of certain forms of hormone therapy;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to protect our proprietary technology and to operate our business without infringing the proprietary rights of third parties;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to compete in a competitive industry;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our dependence upon key employees;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the risk of product liability lawsuits against us or our licensees;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to maintain effective internal control over financial reporting;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes in applicable laws or regulations and our failure to comply with applicable laws and regulations;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">changes in generally accepted accounting principles and the effect of new accounting pronouncements; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">conditions and changes in the biopharmaceutical industry or in general economic or business conditions.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For more information regarding these and other uncertainties and factors that could cause our actual results to differ materially from what we have anticipated in our forward-looking statements or otherwise could materially adversely affect our business, financial condition or operating results, see the risk factors described later in this report under the heading &#147;Part&nbsp;II &#151; Item 1A.&#160; Risk Factors.&#148;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All forward-looking statements included in this report are expressly qualified in their entirety by the foregoing cautionary statements.&#160; We wish to caution readers not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated.&#160; Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the uncertainties and factors described above and later in this report under the heading &#147;Part&nbsp;II &#151; Item 1A.&#160; Risk Factors&#148; as well as others that we may consider immaterial or do not anticipate at this time.&#160; Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. Our expectations reflected in our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown uncertainties and factors, including those described above and later in this report under the heading &#147;Part&nbsp;II &#151; Item 1A.&#160; Risk Factors.&#148;&#160; The risks and uncertainties described above and later in this report are not exclusive and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition, may emerge from time to time.&#160; We assume no obligation to update, amend or clarify forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements.&#160; We advise you, however, to consult any further disclosures we make on related subjects in our annual reports on Form&nbsp;10-K, quarterly reports </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33<a name="PB_33_224730_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\105938\12-19123-1\task5643833\19123-1-ba-11.htm',USER='105938',CD='Nov  4 00:17 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">on Form&nbsp;10-Q and current reports on Form&nbsp;8-K we file with or furnish to the Securities and Exchange Commission.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .8in;text-indent:-.8in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 3.</font></b><a name="Item3__224740"></a><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></b></p>
<p style="margin:0in 0in .0001pt .8in;text-indent:-.8in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are exposed to interest rate sensitivity on our cash equivalents in money market funds and our outstanding fixed rate debt.&#160; The objective of our investment activities is to preserve principal, while at the same time maximizing yields without significantly increasing risk.&#160; To achieve this objective, we invest in highly liquid U.S. Treasury money market funds.&#160; Our investments in U.S. Treasury money market funds are subject to interest rate risk.&#160; To minimize the exposure due to an adverse shift in interest rates, we invest in short-term securities and our goal is to maintain an average maturity of less than one year.&#160; As of the date of this report, all of our cash equivalents are only invested in a U.S. Treasury money market fund and a certificate of deposit.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table provides information about our financial instruments that are sensitive to changes in interest rates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:37.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Interest Rate Sensitivity</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Principal Amount by Expected Maturity and Average Interest Rate</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As&nbsp;of&nbsp;September&nbsp;30,&nbsp;2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Fair&nbsp;Value</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">September<br>   30,&nbsp;2012</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total Cash Equivalents</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36,957,469</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36,957,469</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Average Interest Rate</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.04</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fixed Interest Rate 2013   Convertible</font><font size="2" style="font-size:10.0pt;"> Senior   Notes</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,277,850</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8,277,850</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,593,216</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Average Interest Rate</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.125</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.125</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.125</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.125</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="243" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="65" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="65" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="75" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="65" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="95" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="32%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2011</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2012</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2013</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Total</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Fair&nbsp;Value</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">December<br>   31,&nbsp;2011</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total Cash Equivalents</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55,465,507</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">55,465,507</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Average Interest Rate</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.02</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fixed Interest Rate 2013   Convertible</font><font size="2" style="font-size:10.0pt;"> Senior   Notes</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,782,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,782,000</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" style="padding:0in 0in 0in 0in;width:12.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17,336,760</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:32.5%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Average Interest Rate</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.125</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.125</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.125</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="10%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.125</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="243" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="65" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="65" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="75" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="65" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="10" style="border:none;"></td>
<td width="95" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 4.</font></b><a name="Item4__225037"></a><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">CONTROLS AND PROCEDURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We maintain disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Securities Exchange Act of 1934, as amended) that are designed to provide reasonable assurance that the information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#146;s rules&nbsp;and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.&#160; In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34<a name="PB_34_225120_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\105938\12-19123-1\task5643833\19123-1-ba-11.htm',USER='105938',CD='Nov  4 00:17 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">can provide only reasonable assurance of achieving the desired control objectives, and we are required to apply our judgment in evaluating the cost-benefit relationship of possible internal controls.&#160; Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this quarterly report on Form&nbsp;10-Q.&#160; Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of such period to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC&#146;s rules&nbsp;and forms, and that material information relating to our company is made known to management, including our Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Changes in Internal Control Over Financial Reporting</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There was no change in our internal control over financial reporting that occurred during the three months ended September&nbsp;30, 2012 that has materially affected, or is reasonably likely to materially affect our internal control over financial reporting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35<a name="PB_35_225131_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\105938\12-19123-1\task5643833\19123-1-ba-11.htm',USER='105938',CD='Nov  4 00:17 2012' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART II.</font></b><a name="PartIi__225236"></a><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">OTHER INFORMATION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 1.</font></b><a name="Item1__225238"></a><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">LEGAL PROCEEDINGS</font></b></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A description of our legal proceedings in Note 8, &#147;Commitments and Contingencies&#148; to our unaudited condensed financial statements included in this report is incorporated herein by reference.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 1A.</font></b><a name="Item1a__225241"></a><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">RISK FACTORS</font></b></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are affected by risks specific to us as well as factors that affect all businesses.&#160; In addition to the other information set forth in this report, careful consideration should be taken of the factors described in our quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2012 under the heading &#147;Part II &#151; Item 1A. Risk Factors,&#148; which could materially adversely affect our business, financial condition or operating results.&#160; There has been no material change to those risk factors, except as described below:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The announcement and pendency of the merger could have an adverse effect on BioSante&#146;s stock price and/or the business, financial condition, results of operations or business prospects for BioSante.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The announcement and pendency of the merger could have an adverse effect on BioSante&#146;s stock price and/or the business, financial condition, results of operations or business prospects of BioSante.&#160; For example, third parties may seek to terminate and/or renegotiate their relationships with BioSante as a result of the merger, whether pursuant to the terms of their existing agreements with BioSante or otherwise.&#160; In addition, the attention of BioSante management may be directed toward the completion of the merger and related matters and may be diverted from the day-to-day business operations, including from other opportunities that otherwise might be beneficial to BioSante.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Failure to complete the merger could impact negatively BioSante&#146;s business, financial condition or results of operations or BioSante&#146;s stock price.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The completion of the merger is subject to a number of conditions and there can be no assurance that the conditions to the completion of the merger will be satisfied. If the merger is not completed, BioSante will be subject to several risks, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the current trading price of BioSante common stock may reflect a market assumption that the merger will occur, meaning that a failure to complete the merger could result in a decline in the price of BioSante common stock;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">certain executive officers and/or directors of BioSante may seek other employment opportunities, and the departure of any of BioSante&#146;s executive officers and the possibility that the company would be unable to recruit and hire an executive could impact negatively BioSante&#146;s business and operating results;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the BioSante board of directors will need to reevaluate BioSante&#146;s strategic alternatives, which alternatives may include a sale of the company, liquidation of the company or other strategic transaction;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante may be required to reimburse ANI for expenses of up to $500,000 or pay a termination fee of $1 million to ANI if the merger agreement is terminated by ANI or BioSante under certain circumstances;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36<a name="PB_36_235256_2983"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-ba-13.htm',USER='107310',CD='Nov  8 12:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante is expected to incur substantial transaction costs in connection with the merger whether or not the merger is completed;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante would not realize any of the anticipated benefits of having completed the merger; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">under the merger agreement, BioSante is subject to certain restrictions on the conduct of its business prior to the completion of the merger, which restrictions could adversely affect its ability to realize its business strategies or take advantage of certain business opportunities.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the merger is not completed, these risks may materialize and affect materially and adversely BioSante&#146;s business, financial condition, results of operations or stock price.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The issuance of shares of BioSante common stock to ANI stockholders in connection with the merger will dilute substantially the voting power of current BioSante stockholders.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the terms of the merger agreement, it is anticipated that BioSante will issue shares of BioSante common stock to ANI stockholders representing approximately 53 percent of the outstanding shares of common stock of the combined company as of immediately following the completion of the merger. After such issuance, the shares of BioSante common stock outstanding immediately prior to the completion of the merger will represent approximately 47 percent of the outstanding shares of common stock of the combined company as of immediately following the completion of the merger. These ownership percentages may change depending upon the amount of BioSante&#146;s net cash as of a determination date prior to the completion of the merger.&#160; Accordingly, the issuance of shares of BioSante common stock to ANI stockholders in connection with the merger will reduce significantly the relative voting power of each share of BioSante common stock held by current BioSante stockholders. Consequently, the BioSante stockholders as a group will have significantly less influence over the management and policies of the combined company after the merger than prior to the merger.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The exchange ratios in the merger agreement are subject to adjustment based on BioSante&#146;s net cash as of a determination date prior to the completion of the merger, which could dilute further the ownership of the BioSante stockholders in the combined company.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subject to the terms and conditions of the merger agreement, at the effective time of and as a result of the merger, each share of capital stock of ANI issued and outstanding immediately prior to the effective time of the merger will be converted into the right to receive a number of shares of BioSante common stock, if any, as determined pursuant to the exchange ratios described in the merger agreement and the provisions of ANI&#146;s certificate of incorporation.&#160; The exchange ratios are subject to potential adjustment as described in the merger agreement depending upon the amount of &#147;net cash&#148; of BioSante, as defined in the merger agreement and generally consisting of BioSante&#146;s cash and cash equivalents less certain expenses and liabilities, as of a determination date prior to the closing date of the merger. If BioSante has more than $18.0 million of net cash as of the determination date, then the percentage ownership of the current BioSante stockholders will be increased on a pro rata basis by 0.6 percent for each $1 million of net cash excess, which would dilute further the ownership of the current ANI stockholders in the combined company.&#160; If BioSante has less than $18.0 million of net cash as of the determination date, then the percentage ownership of current BioSante stockholders will be decreased on a pro rata basis by 0.6 percent for each $1 million of net cash shortfall, which would dilute further the ownership of the current BioSante stockholders in the combined company.&#160; In no event, however, will the current ANI stockholders own less than 50.1 percent (or the current BioSante stockholders own more than 49.9 percent) of the outstanding shares of common stock of the combined company.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37<a name="PB_37_235256_6228"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-ba-13.htm',USER='107310',CD='Nov  8 12:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The exchange ratios are not adjustable based on the market price of BioSante common stock and if the market price of BioSante common stock fluctuates, the market value of the shares of BioSante common stock to be received by the ANI stockholders in connection with the merger is subject to change prior to the completion of the merger.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The aggregate number of shares of BioSante common stock to be issued to ANI stockholders is expected to represent approximately 53 percent of the outstanding shares of common stock of the combined company as of immediately following the completion of the merger. The exchange ratios, as such ratios are calculated pursuant to the formulas set forth in the merger agreement, are based on the number of shares of BioSante common stock and ANI capital stock outstanding as of immediately prior to the completion of the merger, and in the case of BioSante, a certain percentage of the number of certain warrants to purchase shares of BioSante common stock outstanding as of such date, and will not be determined until that time.&#160; The exchange ratios will be adjusted upward or downward only as a result of changes to the outstanding capital stock of either or both of BioSante and ANI as of immediately prior to the completion of the merger and changes to BioSante&#146;s net cash as of a determination date prior to the completion of the merger. No adjustments to the exchange ratios will be made based on changes in the trading price of BioSante common stock or the value of ANI capital stock prior to the completion of the merger. Changes in the trading price of BioSante common stock or the value of ANI capital stock may result from a variety of factors, including, among others, general market and economic conditions, changes in BioSante&#146;s or ANI&#146;s respective businesses, operations and prospects, market assessment of the likelihood that the merger will be completed as anticipated or at all, and regulatory considerations. Many of these factors are beyond BioSante&#146;s or ANI&#146;s control. As a result, the value of the shares of BioSante common stock issued to ANI stockholders in connection with the merger could be substantially less or substantially more than the current market value of BioSante common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The exchange ratios are not adjustable based on issuances by BioSante of additional shares of BioSante common stock either upon the exercise of options or warrants or the conversion of convertible securities or otherwise, which issuances would result in additional dilution to the BioSante stockholders.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of November 1, 2012, BioSante had outstanding options to purchase an aggregate of&#160; approximately 1.2 million shares of BioSante common stock, warrants to purchase an aggregate of approximately 4.7 million shares of BioSante common stock, an aggregate of 65,211 shares of BioSante class C special stock that are convertible into 65,211 shares of BioSante common stock and an aggregate of $8.3 million in aggregate principal amount of 3.125% convertible senior notes due May 1, 2013 that are convertible into an aggregate of 370,871 shares of BioSante common stock.&#160; BioSante is not prohibited under the terms of the merger agreement from issuing additional equity securities under certain circumstances, including securities issued pursuant to the exercise of outstanding options or warrants or the conversion or exchange of outstanding convertible notes.&#160; It is possible that prior to the completion of the merger BioSante may issue additional equity securities.&#160; The exchange ratios in the merger agreement, which are designed to result in the issuance by BioSante of shares of BioSante common stock to ANI stockholders representing approximately 53 percent of the outstanding shares of common stock of the combined company as of immediately following the completion of the merger, are not adjustable based on issuances by BioSante of additional shares of BioSante common stock.&#160; Therefore, any such issuances by BioSante would result in additional dilution to the BioSante stockholders.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">BioSante has incurred and will continue to incur significant transaction costs in connection with the merger, some of which will be required to be paid even if the merger is not completed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BioSante has incurred and will continue to incur significant transaction costs in connection with the merger.&#160; These costs are primarily associated with the fees of attorneys and accountants and </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38<a name="PB_38_235256_6479"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-ba-13.htm',USER='107310',CD='Nov  8 12:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BioSante&#146;s financial advisor.&#160; Most of these costs will be paid even if the merger is not completed.&#160; In addition, if the merger agreement is terminated due to certain triggering events specified in the merger agreement, BioSante may be required to pay ANI a termination fee of $1.0 million.&#160; The merger agreement also provides that under specified circumstances, BioSante may be required to reimburse ANI up to $500,000 for its expenses in connection with the transaction.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The merger agreement and the voting agreements contain provisions that could discourage or make it difficult for a third party to acquire BioSante prior to the completion of the merger.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The merger agreement contains provisions that make it difficult for BioSante to entertain a third-party proposal for an acquisition of BioSante. These provisions include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the general prohibition on BioSante&#146;s soliciting or engaging in discussions or negotiations regarding any alternative acquisition proposal;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the requirement that BioSante reimburse ANI for expenses of up to $500,000 or pay a termination fee of $1 million to ANI if the merger agreement is terminated by ANI or BioSante under certain circumstances; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the requirement that BioSante submit the merger-related proposals to a vote of the BioSante stockholders even if the BioSante board of directors changes its recommendation with respect to such proposals, as applicable.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.55pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the voting agreements entered into between ANI and the directors, executive officers and certain stockholders of BioSante, each such director, executive officer and applicable stockholder has agreed not to take any actions that BioSante is prohibited from taking pursuant to the no-solicitation restrictions contained in the merger agreement. In addition, holders of shares representing approximately two percent of the outstanding capital stock of BioSante as of October 3, 2012 are subject to a voting agreement, pursuant to which the holders of such shares have agreed to vote in favor of the approval and adoption of the merger agreement and the transactions contemplated thereby, including the merger and the issuance of the shares of BioSante common stock, and the approval of the BioSante charter amendments, and BioSante is required under the terms of the merger agreement to convene and hold the BioSante special meeting regardless of any change in the recommendation of the BioSante board of directors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.55pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">These provisions might discourage an otherwise interested third party from considering or proposing an acquisition of BioSante, even one that may be deemed of greater value than the merger to BioSante stockholders. Furthermore, even if a third party elects to propose an acquisition, the concept of a termination fee or payment of the other party&#146;s expenses may result in that third party offering a lower value to BioSante stockholders than such third party might otherwise have offered.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Because the lack of a public market for ANI&#146;s outstanding shares makes it difficult to evaluate the fairness of the merger, ANI stockholders may receive consideration in the merger that is greater than the fair market value of the ANI shares.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ANI is privately held and its outstanding capital stock is not traded in any public market. The lack of a public market makes it extremely difficult to determine the fair market value of ANI or its shares of capital stock. Since the percentage of BioSante&#146;s equity to be issued to the ANI stockholders was determined based on negotiations between the parties, it is possible that the value of the BioSante common stock to be issued in connection with the merger will be greater than the fair market value of ANI.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39<a name="PB_39_235256_2639"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-ba-13.htm',USER='107310',CD='Nov  8 12:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">BioSante may not issue CVRs and, even if issued, the CVRs will not be certificated or transferable and may not result in any cash payments to holders of CVRs.</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although BioSante currently plans to enter into the contingent value rights agreement and issue CVRs to BioSante stockholders, there is no assurance that the CVRs will be issued. BioSante currently has not entered into the contingent value rights agreement and the BioSante board of directors may determine in its sole discretion not to issue the CVRs based on, among other things, the anticipated tax impact of the distribution and issuance of the CVRs to the BioSante stockholders.&#160; Furthermore, if BioSante and ANI agree, the terms of the contingent value rights agreement as currently contemplated may be changed prior to BioSante entering into the contingent value rights agreement.&#160; Even if CVRs are issued, they will not be certificated or transferable and may not result in any cash payments to holders of CVRs. Under the contingent value rights agreement, the combined company will not have any obligation, other than an obligation to act in good faith to pursue, engage in, negotiate, enter into or consummate an actual or potential LibiGel transaction (as such term is defined in the contingent value rights agreement).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:34.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 2.</font></b><a name="Item2__225355"></a><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></b></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent Sales of Unregistered Equity Securities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the three months ended September 30, 2012, we did not issue or sell any shares of our common stock or other equity securities of ours that were not registered under the Securities Act of 1933, as amended, other than the issuance of an aggregate of 1,784,070 shares of our common stock to two of the holders of our convertible senior notes in exchange for cancellation of $3,504,150 in aggregate principal amount of such notes and accrued and unpaid interest of $20,686, which shares were issued in a transaction exempt from the registration requirements of the Securities Act by virtue of the exemption provided for in Section 3(a)(9) of the Securities Act for securities exchanged by the issuer with an existing security holder. No commission or other remuneration was paid or given directly or indirectly for soliciting such exchange.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Issuer Purchases of Equity Securities</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We did not purchase any shares of our common stock or other equity securities of ours during the three months ended September 30, 2012.&#160; Our Board of Directors has not authorized any repurchase plan or program for purchase of our shares of common stock or other equity securities on the open market or otherwise, other than in connection with the cashless exercise of outstanding warrants and stock options.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 3.</font></b><a name="Item3__225357"></a><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">DEFAULTS UPON SENIOR SECURITIES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Not applicable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 4.</font></b><a name="Item4__225357"></a><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">MINE SAFETY DISCLOSURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Not applicable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 5.</font></b><a name="Item5__225358"></a><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">OTHER INFORMATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On October 16, 2012, we entered into an amendment to our development and license agreement with Teva Pharmaceuticals USA, Inc. pursuant to which Teva made a $1.0 million payment to us upon the signing of the amendment and agreed to make the following milestone-based payments to us:&#160; (1) $500,000 if the FDA authorizes marketing of the licensed male testosterone gel as an &#147;AB-rated&#148; equivalent to AndroGel&#174;; (2) $750,000 upon the earlier to occur of (a) December 31, 2012 and (b) five business days after Teva&#146;s submission to the FDA of a final report regarding a &#147;washing&#148; clinical study required by the FDA; and (3) $500,000 upon the earlier to occur of (a) December 31, 2013 and (b) five business days after Teva&#146;s commencement of commercial manufacture of the licensed product for sale in the United States.&#160; In addition, Teva has agreed to pay us $4.0 million in the event Teva is the sole marketer in the United States of a generic 1% testosterone gel AB-rated to AndroGel&#174; for at least 180 days immediately following the launch date of the licensed product in the United States.&#160; The royalty rate to be paid by Teva to us under the agreement is five percent of net sales; provided, however, that during the period of time that Teva markets the licensed product and is the sole marketer of a generic 1% testosterone gel that is AB-rated to AndroGel&#174; in the United States, the royalty rate will be seven and one half percent of net sales.&#160; Additionally, pursuant to the terms of the October 2012 amendment, the parties agreed to release each other from certain liabilities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 6.</font></b><a name="Item6__225401"></a><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">EXHIBITS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following exhibits are being filed or furnished with this quarterly report on Form 10-Q:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40<a name="PB_40_235256_2794"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-ba-13.htm',USER='107310',CD='Nov  8 12:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="88%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:88.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="bottom" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="88%" valign="bottom" style="padding:0in 0in 0in 0in;width:88.58%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Placement Agent Agreement dated August 16, 2012   between BioSante Pharmaceuticals, Inc. and Rodman &amp; Renshaw, LLC   (Incorporated by reference to Exhibit 1.1 to BioSante&#146;s current report on   Form 8-K as filed with the Securities and Exchange Commission on August 17,   2012 (File No. 001-31812))</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form of Common Stock Purchase Warrant issued by   BioSante Pharmaceuticals, Inc. to the investor in the August 2012 registered   direct offering (Incorporated by reference to Exhibit 4.1 to BioSante&#146;s   current report on Form 8-K as filed with the Securities and Exchange   Commission on August 17, 2012 (File No. 001-31812))</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form of Securities Purchase Agreement dated August   16, 2012 between BioSante Pharmaceuticals, Inc. and the investor in the   August 2012 registered direct offering (Incorporated by reference to Exhibit   10.1 to BioSante&#146;s current report on Form 8-K as filed with the Securities   and Exchange Commission on August 17, 2012 (File No. 001-31812))</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Development and License Agreement dated December   27, 2002 between Teva Pharmaceuticals USA, Inc. and BioSante Pharmaceuticals,   Inc. (Filed herewith)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.3</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">First Amendment to Development and License Agreement   dated March 13, 2003 between Teva Pharmaceuticals USA, Inc. and BioSante   Pharmaceuticals, Inc. (Filed herewith)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.4</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Letter Amendment dated June 4, 2007 between Teva   Pharmaceuticals USA, Inc. and BioSante Pharmaceuticals, Inc. (Filed herewith)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.5</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third Amendment to Development and License   Agreement dated as of October 16, 2012 between Teva Pharmaceuticals USA, Inc.   and BioSante Pharmaceuticals, Inc. (Filed herewith)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act   of 2002 and SEC Rule 13a-14(a) (Filed herewith)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act   of 2002 and SEC Rule 13a-14(a) (Filed herewith)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted   Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished   herewith)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted   Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished   herewith)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The   following materials from BioSante Pharmaceuticals, Inc.&#146;s Quarterly Report on   Form 10-Q for the quarter ended September 30, 2012, formatted in XBRL   (Extensible Business Reporting Language): (i) the unaudited Condensed Balance   Sheets, (ii) the unaudited Condensed Statements of Operations, (iii) the   unaudited Condensed Statements of Cash Flows, and (iv) Notes to Condensed   Financial Statements.*</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt 36.7pt;text-indent:-36.7pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pursuant to Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this quarterly report on Form 10-Q shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be deemed part of a registration statement, prospectus or other document filed under Section 11 or 12 of the Securities Act of 1933, as amended, or otherwise subject to the liability of those sections, except as shall be expressly set forth by specific reference in such filings.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">41<a name="PB_41_235256_8299"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='41',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-ba-13.htm',USER='107310',CD='Nov  8 12:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b><a name="Signatures_235006"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">November 8, 2012</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIOSANTE   PHARMACEUTICALS, INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Stephen M. Simes</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stephen   M. Simes</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice   Chairman, President and Chief</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive   Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(principal   executive officer)</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Phillip B. Donenberg</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phillip   B. Donenberg</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior   Vice President of Finance, Chief</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial   Officer and Secretary</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(principal   financial and accounting officer)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42<a name="PB_42_235256_8247"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='42',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-ba-13.htm',USER='107310',CD='Nov  8 12:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIOSANTE PHARMACEUTICALS, INC.<br> QUARTERLY REPORT ON FORM 10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT INDEX</font></b><a name="ExhibitIndex_000327"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.62%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="47%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="40%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Method&nbsp;of</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">Filing</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Placement Agent Agreement dated August 16, 2012   between BioSante Pharmaceuticals, Inc. and Rodman &amp; Renshaw, LLC </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit 1.1 to   BioSante&#146;s current report on Form 8-K as filed with the Securities and   Exchange Commission on August 17, 2012</font><font size="2" style="font-size:10.0pt;"> (File No. 001-31812)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form of Common Stock Purchase Warrant issued by   BioSante Pharmaceuticals, Inc. to the investor in the August 2012 registered   direct offering </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit 4.1 to   BioSante&#146;s current report on Form 8-K as filed with the Securities and   Exchange Commission on August 17, 2012</font><font size="2" style="font-size:10.0pt;"> (File No. 001-31812)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form of Securities Purchase Agreement dated August   16, 2012 between BioSante Pharmaceuticals, Inc. and the investor in the   August 2012 registered direct offering </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Incorporated by reference to Exhibit 10.1   to BioSante&#146;s current report on Form 8-K as filed with the Securities and   Exchange Commission on August 17, 2012</font><font size="2" style="font-size:10.0pt;"> (File No. 001-31812)</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Development and License Agreement dated December   27, 2002 between Teva Pharmaceuticals USA, Inc. and BioSante Pharmaceuticals,   Inc.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.3</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">First Amendment to Development and License   Agreement dated March 13, 2003 between Teva Pharmaceuticals USA, Inc. and BioSante   Pharmaceuticals, Inc.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.4</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Letter Amendment dated June 4, 2007 between Teva   Pharmaceuticals USA, Inc. and BioSante Pharmaceuticals, Inc.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.5</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Third Amendment to Development and License   Agreement dated as of October 16, 2012 between Teva Pharmaceuticals USA, Inc.   and BioSante Pharmaceuticals, Inc.</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act   of 2002 and SEC Rule 13a-14(a)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act   of 2002 and SEC Rule 13a-14(a)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed herewith</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted   Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furnished herewith</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43<a name="PB_43_235256_5893"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='43',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-ba-13.htm',USER='107310',CD='Nov  8 12:50 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.62%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="47%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:47.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="40%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Method&nbsp;of</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">Filing</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted   Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furnished herewith</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.62%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" valign="top" style="padding:0in 0in 0in 0in;width:47.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The   following materials from BioSante Pharmaceuticals, Inc.&#146;s Quarterly Report on   Form 10-Q for the quarter ended September 30, 2012, formatted in XBRL   (Extensible Business Reporting Language): (i) the unaudited Condensed Balance   Sheets, (ii) the unaudited Condensed Statements of Operations, (iii) the unaudited   Condensed Statements of Cash Flows, and (iv) Notes to Condensed Financial   Statements.*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Furnished herewith</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pursuant to Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this quarterly report on Form 10-Q shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be deemed part of a registration statement, prospectus or other document filed under Section 11 or 12 of the Securities Act of 1933, as amended, or otherwise subject to the liability of those sections, except as shall be expressly set forth by specific reference in such filings.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44<a name="PB_44_235256_9862"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='44',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-ba-13.htm',USER='107310',CD='Nov  8 12:50 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>a12-19123_1ex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.2</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DEVELOPMENT AND LICENSE AGREEMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">between</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TEVA PHARMACEUTICALS USA,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1090 Horsham Road, North Wales, PA 19454</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(&#147;Teva&#148;)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIOSANTE PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">111 Barclay Boulevard, Lincolnshire,&nbsp;IL 60069</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(&#147;BioSante&#148;)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, BioSante is engaged in the development of pharmaceutical products and has in development the pharmaceutical product listed in <b>Annex A</b> hereto (the &#147;Product&#148; as defined further below);</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, Teva, together with its Affiliates (as defined below), is engaged in the development, manufacture, sale, marketing and distribution of pharmaceutical products;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, BioSante desires to grant to Teva an exclusive license to the Product Know-How (as defined below) so that Teva may register, obtain Approval for, manufacture, market, sell and distribute the Product in the United States, all in accordance with and subject to the conditions set forth in this Agreement;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW THEREFORE, intending to be legally bound hereby and in consideration of the mutual representations, warranties and covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,&nbsp;IT IS HEREBY AGREED BY THE PARTIES AS FOLLOWS:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">INTERPRETATION AND DEFINITIONS</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The preamble to this Agreement forms an integral part hereof.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Section&nbsp;headings in this Agreement are intended solely for convenience of reference and should be given no effect in the interpretation of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All annexes to this Agreement, signed by both Parties, whether attached at the time of signature hereof or at any time thereafter, should be construed as an integral part of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">For the purposes of this Agreement, the following words and phrases shall bear the respective meanings assigned to them below (and cognate expressions shall bear corresponding meanings):</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_111832_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-01.htm',USER='107604',CD='Nov  7 11:22 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Affiliates</b>&#148; &#151; shall mean with respect to either Party, any Person that is controlled by, controls, or is under common control with that Party. For this purpose, &#147;control&#148; of a corporation or other business entity shall mean direct or indirect beneficial ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) in the equity of, or the right to appoint more than fifty percent (50%) of the directors or management of such corporation or other business entity.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>ANDA</b>&#148; &#151; shall mean an Abbreviated New Drug Application filed with the FDA pursuant to its rules&nbsp;and regulations.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Applicable Law</b>&#148; &#151; shall mean the applicable laws, rules, regulations, guidelines and requirements related to the development, registration, manufacture, importation and Marketing of the Product in the Territory.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Approval(s)</b>&#148; &#151; shall mean any and all approvals, licenses, registrations or authorizations of the applicable Regulatory Authority necessary for the Marketing of the Product and reimbursement, if applicable, in the Territory.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Calendar Quarter</b>&#148; &#151; shall mean a three (3)&nbsp;consecutive month period ending on March&nbsp;31, June&nbsp;30, September&nbsp;30 or December&nbsp;31.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Competing Product</b>&#148; &#151; shall mean any finished pharmaceutical product for sale in the prescription drug marketplace that contains the same active ingredient in the same dosage form and strength as the Product.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Confidential Information</b>&#148; &#151; shall mean all information, data and/or know-how disclosed by either Party and/or its Affiliates to the other Party and/or its Affiliates in writing (or if disclosed orally, visually and/or in another non-written form, identified as confidential at the time of disclosure, and summarized in reasonable detail in writing as to its general content within thirty (30) days after original disclosure) concerning the Product or concerning the technology, marketing strategies or business of the disclosing Party (whether disclosed prior to or subsequent to the Effective Date). Confidential Information shall not include information, data or know-how that the receiving Party can show:</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">was in the public domain at the time of the disclosure by the disclosing Party, or thereafter becomes part of the public domain without any fault of the receiving Party;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">rightfully was in its possession prior to the disclosure by the disclosing Party;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">was lawfully obtained from a third party, who had the right to make such disclosures as evidenced by written records; or</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_111900_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-01.htm',USER='107604',CD='Nov  7 11:22 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">was developed by it independently of such disclosure as evidenced by written records.</font></p>
<p style="margin:0in 0in .0001pt 2.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.8</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Effective Date</b>&#148; &#151; shall mean the date on which this Agreement is signed by the latter of the Parties to sign this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.9</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>FDA</b>&#148; &#151; shall mean the United States Food and Drug Administration and all agencies under its direct control or any successor organization.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.10</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Force Majeure Events</b>&#148; &#151; shall have the meaning set forth in Section&nbsp;16.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.11</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Launch Date</b>&#148; &#151; shall mean the date on which Teva makes its first commercial sale of the Product to an unrelated third party in an arms-length transaction in the Territory.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.12</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Market</b>&#148; &#151; shall mean to promote, distribute, market, advertise and/or sell.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.13</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Marketing Term</b>&#148; &#151; shall mean a period of ten (10)&nbsp;years from the Launch Date of the Product in the Territory, unless terminated prior to such date as expressly provided for in this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.14</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Net Sales</b>&#148; &#151; shall mean the gross amount invoiced for the Product by Teva or Teva&#146;s Affiliates sold on an arms-length basis in the Territory, less the sum of: (a)&nbsp;trade, quantity and/or cash discounts, allowances, rebates, retroactive price adjustments, free goods, bad debts, cash incentive payments (e.g. slotting allowance), and chargebacks; (b)&nbsp;credits or refunds for rejected, outdated or returned Product; (c)&nbsp;any tax, duty or other government charge upon or related to the sale, delivery or use of that Product; (d)&nbsp;cost of short dated Product, which is destroyed by Teva or its Affiliates; and (e)&nbsp;other specifically identifiable amounts included in the Product&#146;s gross sales that will have been or ultimately will be credited and are substantially similar to those listed above; in each case determined in accordance with U.S. GAAP.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.15</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Party</b>&#148;, &#147;<b>Parties</b>&#148; &#151; shall mean Teva and/or BioSante, as applicable.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.16</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Person</b>&#148; &#151; shall mean any individual, partnership, association, corporation, limited liability company, trust, or other legal person or entity.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.17</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Product</b>&#148; &#151; shall mean the finished pharmaceutical product listed in Annex A developed by BioSante.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.18</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Product Know-How</b>&#148; &#151; shall mean the Regulatory Documentation, Technical Package and any and all other proprietary methods, devices, technology, trade secrets, inventions, patent applications, patents,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_111934_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-01.htm',USER='107604',CD='Nov  7 11:22 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">compositions, designs, formulae, know-how, show-how, technical and training manuals and documentation and other information, including processes and analytical methodologies used in development, testing, analysis and manufacture, and medical, clinical testing as well as other scientific testing, related to or used in connection with the Product or any ingredient thereof, and/or the formulation, development, registration, manufacture, use or sale thereof, in BioSante&#146;s (or its Affiliates&#146;) possession or under its control whether now known or hereafter developed or otherwise acquired, directly or indirectly.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.19</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Regulatory Authority</b>&#148; &#151; shall mean any and all governmental bodies, organizations and agencies whose approval is necessary to develop, manufacture, import, use, and/or Market the Product in the Territory.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.20</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Regulatory Documentation</b>&#148; &#151; shall mean all submissions to Regulatory Authorities, including clinical studies, tests, and biostudies relating to the Product, including, without limitation, all ANDAs, 505(b)(2)&nbsp;applications, and DMFs, as well as all correspondence with Regulatory Authorities (registration and licenses, regulatory drug lists, advertising and promotion documents), adverse event files, complaint files, manufacturing records and inspection reports.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.21</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Regulatory Expenses</b>&#148; &#151; shall mean all reasonable out-of-pocket direct costs and expenses in connection with preparing, submitting, obtaining and maintaining Approvals of the Product.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.22</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Royalties</b>&#148; &#151; shall mean an amount equal to seven and one half percent (7.5%) of Net Sales; provided, however, that during the period of time that Teva is the sole marketer of a generic 1% testosterone gel AB-rated to AndroGel&#174; in the Territory such amount shall be equal to ten percent (10%) of Net Sales.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.23</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Technical Package</b>&#148; &#151; shall have the meaning set forth in Section&nbsp;2.4.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.24</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Term</b>&#148; &#151; shall mean the duration of this Agreement starting on the Effective Date and continuing until the end of the Marketing Term, unless terminated prior to such date pursuant to Section&nbsp;12.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.25</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>Territory</b>&#148; &#151; shall mean the U.S.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.26</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>U.S.</b>&#148; &#151; shall mean the United States of America and its territories, districts and possessions.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.4.27</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">&#147;<b>U.S. GAAP</b>&#148; &#151; shall mean generally accepted accounting principles in the U.S., consistently applied.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_111956_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-01.htm',USER='107604',CD='Nov  7 11:22 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">GRANT OF RIGHTS</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante, for itself and its Affiliates, grants to Teva and its Affiliates in accordance with the terms and conditions of this Agreement, the exclusive right (even as to BioSante and its Affiliates), under all of the existing or future Product Know-How owned or controlled by BioSante or its Affiliates, to register, make or have made, develop, import/export or have imported/exported, use or have used, Market, offer for sale or have sold, and otherwise exploit the Product on a sole and exclusive basis (even as to BioSante and its Affiliates) in or for the Territory.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Neither BioSante nor its Affiliates shall, directly or indirectly, during the Term, Market the Product or cause or permit the Product to be Marketed in or for the Territory, except as otherwise may be specifically permitted by the terms of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante and its Affiliates shall not, directly or indirectly, during the Term, disclose to any third party any Product Know-How, if such third party may or has the ability to use such Product Know-How to directly or indirectly Market a Competing Product in or for the Territory.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante shall provide to Teva by no later than the Effective Date (a)&nbsp;all Regulatory Documentation in BioSante&#146;s (or its Affiliates&#146;) possession or under its control; and (b)&nbsp;all technical information, data and know-how in BioSante&#146;s (or its Affiliates&#146;) possession or under its control with respect to the Product, including, without limitation, any and all raw material, work in process and samples related to the Product, useful or necessary for Teva or its nominee to continue the development of the Product and to set up a facility for the commercial manufacture of the Product (the &#147;<b>Technical Package</b>&#148;). BioSante shall promptly forward to Teva any such Regulatory Documentation and/or Technical Package materials that should later become available to BioSante during the Term of this Agreement.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva shall have the right to subcontract, in whole or in part, the manufacturing of the Product to a third party.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">REGULATORY APPROVAL</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva shall prepare the necessary Approval applications for the Product to obtain Approval of the Product in the Territory from the applicable Regulatory Authorities.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva shall use its commercially reasonable efforts customarily employed by Teva with respect to other generic drug products to conduct all tests and studies reasonably required to enable Teva to apply for, obtain and maintain Approval for the Product in the Territory.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva shall be responsible for all communications with the Regulatory Authorities relating to the Approval for the Product in the Territory. Teva shall provide to</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_112015_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-01.htm',USER='107604',CD='Nov  7 11:22 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BioSante copies of all Regulatory Documentation submitted to the Regulatory Authorities with respect to obtaining Approval for the Product.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Upon the request of BioSante, Teva shall provide BioSante with periodic updates (no more often than once per Calendar Quarter) concerning the development of the Product.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Approval applications shall be filed in Teva&#146;s name and Teva shall be the sole and exclusive owner of such Approval applications and all Regulatory Documentation in connection therewith.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante shall grant Teva reasonable and unrestricted access, without any charges, costs or expense, to any and all relevant documentation, data, information, tests, studies or know-how related to the Product, in its possession or under its control, and provide free of charge any and all assistance that Teva may reasonably request in order for Teva to obtain Approval for the Product in the Territory, and as necessary in connection with the manufacture and Marketing of the Product in or for the Territory.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva or its Affiliates shall be responsible for filing the Product, and thereafter processing such filing, with appropriate federal, state or private formularies in the Territory.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.8</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Each Party shall perform, or cause to be performed, its activities in furtherance of the provisions of this Section&nbsp;3 in a good scientific manner, in compliance in all material respects with all requirements of Applicable Law, and in an efficient and expeditious manner.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.9</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva agrees that it will use its commercially reasonable efforts customarily used by Teva with respect to other generic drug products to Market the Product in the Territory.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.10</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva has the sole and exclusive right to determine all terms and conditions for the sale of the Product in the Territory, including the determination of timing of launch of the Product in the Territory, which timing of launch shall be consistent with that customarily used by Teva for other generic products.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.11</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject to pre-approval by Teva, Teva shall bear all Regulatory Expenses incurred by BioSante after July&nbsp;1, 2002. Payments with respect to Regulatory Expenses shall be made by Teva within thirty (30) days following the end of each month and upon receipt of an invoice and all supporting documentation from BioSante.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.12</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Upon the request of BioSante, the Parties will discuss in good faith how Teva may provide assistance to BioSante in manufacturing the Product for sale outside the Territory.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_112032_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-01.htm',USER='107604',CD='Nov  7 11:22 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">TRADE MARK(S)</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva and its Affiliates shall have the right, in their respective sole discretion and at their expense, to select and to register any of their trademarks, as they wish to employ in connection with the Marketing of the Product in the Territory and to Market Product using such trademarks. Teva or its Affiliates shall own all right, title and interest in and to all such trademarks, and BioSante hereby agrees it shall have no right, title or interest in same.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">ROYALTIES</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Commencing on the Launch Date for the Product in the Territory, Teva shall pay to BioSante the Royalties as set forth in Section&nbsp;5.2 below.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">No later than thirty (30) days after the end of each Calendar Quarter, Teva shall report to BioSante the Net Sales for the Product sold by Teva and/or its Affiliates in the Territory and the Royalties due to BioSante for such period. The payment of Royalties by Teva to BioSante shall be made within thirty (30) days after the end of each Calendar Quarter.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">AUDITS</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva and its Affiliates shall permit an independent certified public accounting firm selected by BioSante, and reasonably acceptable to Teva, to have access, during normal business hours and upon reasonable prior notice (not more often than once in any calendar year), to those books and records maintained by Teva necessary for BioSante to verify the accuracy of Teva&#146;s calculation of any Net Sales and Royalties hereunder for any period ending not more than two (2)&nbsp;years prior to the date of such request. All such information shall be retained on a confidential basis by the accounting firm, and such accounting firm&#146;s use of such information shall be limited to the aforementioned verification.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante and its Affiliates shall permit an independent certified public accounting firm selected by Teva, and reasonably acceptable to BioSante, to have access, during normal business hours and upon reasonable prior notice (not more often than once in any calendar year), to those books and records maintained by BioSante necessary for Teva to verify the accuracy of BioSante&#146;s calculation of any Regulatory Expenses hereunder for any period ending not more than two (2)&nbsp;years prior to the date of such request. All such information shall be retained on a confidential basis by the accounting firm, and such accounting firm&#146;s use of such information shall be limited to the aforementioned verification.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva shall calculate and record Net Sales and Royalties in accordance with U.S. GAAP, and shall maintain all books and records related thereto in accordance with standard cost accounting policies and practices, in accordance with U.S. GAAP for the Term plus an additional three (3)&nbsp;years thereafter.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Each Party shall promptly supply the other Party with a copy of any notices or reports received from any Regulatory Authority related to an audit or other</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_112049_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-01.htm',USER='107604',CD='Nov  7 11:22 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">investigation by the Regulatory Authority with respect to the Product. Each Party shall use its commercially reasonable best efforts to provide such Regulatory Authority with a prompt, accurate and complete response to any deficiencies noted, and to promptly address, and if necessary correct, any and all such deficiencies to the satisfaction of the Regulatory Authority.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">MILESTONE PAYMENTS</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In partial consideration of the rights granted herein and subject to the terms and conditions set forth in this Agreement, Teva shall be obligated to BioSante for the following milestone payments:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">One Million Five Hundred Thousand U.S. Dollars (U.S. $1,500,000) upon the Effective Date;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">One Million U.S. Dollars (U.S. $1,000,000) within thirty (30) days following acceptance by the FDA of the ANDA for the Product;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">One Million U.S. Dollars (U.S. $1,000,000) within thirty (30) days following final Approval by the FDA for the Product; and</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">provided that Teva is the sole marketer in the Territory of a generic 1% testosterone gel AB-rated to AndroGel&#174; for at least one hundred and eighty (180) days immediately following the Launch Date in the Territory, then, in such event, Teva shall pay to BioSante, within thirty (30) days following such one hundred and eighty (180) day period, an amount equal to Four Million U.S. Dollars (U.S. $4,000,000).</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">ADDITIONAL REPRESENTATIONS, WARRANTIES AND COVENANTS OF BIOSANTE</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante hereby represents and/or warrants and/or undertakes to Teva that:</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">it has the corporate authority to enter into this Agreement and to perform its obligations hereunder;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">neither the execution and delivery of this Agreement by BioSante nor its performance hereunder conflicts with or results in any violation or breach of, or constitutes (with or without due notice or lapse of time or both) a default under any of the terms or conditions of any note, bond, mortgage, indenture, license, agreement or other instrument or obligation to which it or any of its Affiliates is a party or by which it or any of its Affiliates or any of their respective properties or assets may be bound, or to its best knowledge, violate any statute, law, rule, regulation, writ, injunction, judgment, order or decree of any court, administrative agency or governmental authority binding on it or any of its Affiliates or any of their respective properties or assets, excluding any such breaches or defaults that, individually and in the aggregate, would not have a material adverse effect on its business or financial condition;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_112110_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-01.htm',USER='107604',CD='Nov  7 11:22 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">this Agreement is a legal, valid and binding agreement of BioSante enforceable in accordance with its terms;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">neither it nor any of its Affiliates have or will, directly or indirectly, enter into any contract or any other transaction with any third party or Affiliate that conflicts or derogates from its undertakings hereunder;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">neither the Product nor the process for making the Product violates, infringes, or otherwise conflicts or interferes with the intellectual property rights of any third party in the Territory;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante has furnished Teva with a complete copy of the Regulatory Documentation and Technical Package for the Product, and BioSante is and was, at all times prior to the Effective Date, the lawful holder of all rights under the Product Know-How; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1.7</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante has the right, power and authority to grant the rights to Teva hereunder.</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">ADDITIONAL REPRESENTATIONS, WARRANTIES AND COVENANTS OF TEVA</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva hereby represents and/or warrants and/or undertakes to BioSante that:</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">it has the corporate authority to enter into this Agreement and to perform its obligations hereunder;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">neither the execution and delivery of this Agreement by Teva nor its performance hereunder conflicts with or results in any violation or breach of, or constitutes (with or without due notice or lapse of time or both) a default under any of the terms or conditions of any note, bond, mortgage, indenture, license, agreement or other instrument or obligation to which it is a party or by which it or any of its properties or assets may be bound, or to its best knowledge, violate any statute, law, rule, regulation, writ, injunction, judgment, order or decree of any court, administrative agency or governmental authority binding on it or any of its properties or assets, excluding any such breaches or defaults that, individually and in the aggregate, would not have a material adverse effect on its business or financial condition;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">this Agreement is a legal, valid and binding agreement of Teva, enforceable in accordance with its terms; and</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">it has not and will not, directly or indirectly, enter into any contract or any other transaction with any third party or Affiliate that conflicts or derogates from its undertakings hereunder.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_112128_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-01.htm',USER='107604',CD='Nov  7 11:22 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">INDEMNIFICATIONS AND LIABILITY</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">BioSante shall indemnify, defend and hold Teva, its Affiliates, and their respective officers, directors, employees, and representatives harmless from and against any and all losses, liabilities, damages, costs and expenses, including reasonable attorney&#146;s fees and disbursements, (collectively, &#147;<b>Damages</b>&#148;) in connection with any and all suits, investigations, claims or demands by third parties resulting from or arising out of: (a)&nbsp;any breach or alleged breach by BioSante (or its Affiliates) of any representation, warranty, undertaking or covenant in this Agreement ; or (b)&nbsp;any negligence or willful misconduct by BioSante (or its Affiliates).</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva shall indemnify, defend and hold BioSante, its Affiliates, and their respective officers, directors, employees, and representatives harmless from and against any and all Damages as defined above in connection with any and all suits, investigations, claims or demands by third parties resulting from or arising out of: (a)&nbsp;any breach or alleged breach by Teva (or its Affiliates) of any representation, warranty, undertaking or covenant in this Agreement; (b)&nbsp;any negligence or willful misconduct by Teva (or its Affiliates); or (c)&nbsp;any claims of strict product liability, whether based on allegations of design defect or unreasonable dangerousness, if allegedly arising out of Teva&#146;s or its designees&#146; actions related to the Product, including but not limited to the manufacturing or Marketing of the Product.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event that in determining the respective obligation of indemnification under this Section&nbsp;10, it is found that the fault of BioSante, Teva or their respective Affiliates, contributes to any Damages relating to the Product supplied and/or distributed or sold hereunder, then each of BioSante and Teva shall be responsible for that portion of the Damages to which its fault contributed.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">As soon as a Party becomes aware of the possibility of a claim involving indemnification under this Section&nbsp;10, the indemnified Party shall give the indemnifying Party prompt written notice in writing and shall permit the indemnifying Party to have control over the defense of such claim or suit. The indemnified Party agrees to provide all reasonable information and assistance to the indemnifying Party in such defense. No such claims shall be settled other than by the Party defending the same, and then only with the consent of the other Party, which shall not be unreasonably withheld or delayed; provided, however, that the indemnified Party shall have no obligation to consent to any settlement of any such claim which imposes on the indemnified Party any liability or obligation which cannot be assumed and performed in full by the indemnifying Party.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Except in the event of and to the extent of Damages awarded to a third party in connection with the indemnification provisions set forth in Sections 10.1 and 10.2, above, neither Teva nor BioSante shall be liable to the other for special, indirect, incidental or consequential damages, whether in contract, warranty, negligence, tort, strict liability or otherwise.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_112148_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-01.htm',USER='107604',CD='Nov  7 11:22 2012' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIALITY</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Each of the Parties agrees that: (a)&nbsp;it will not disclose any Confidential Information of the other to any third party at any time during the Term without the prior written consent of the disclosing Party; (b)&nbsp;it will not make use of any Confidential Information of the other Party for any purpose other than for the purposes set forth in, or in furtherance of the transactions contemplated by this Agreement; and/or (c)&nbsp;it will use all reasonable efforts to prevent unauthorized publication or disclosure by any person of such Confidential Information including requiring its employees, consultants or agents to enter into confidentiality agreements that require them to maintain Confidential Information in confidence to the same degree as its own confidential information.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Notwithstanding the foregoing, either Party may upon reasonable prior written notice to the other Party disclose Confidential Information as required by law or court order, except that upon receipt of any such request or requirement of law or court order, each Party agrees to promptly notify the other in order to give the other a reasonable opportunity to seek a protective order in the appropriate forum.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All Confidential Information in any form must be returned to the Party who disclosed the Confidential Information within thirty (30) days of the termination or expiration of this Agreement, save for the retention of one (1)&nbsp;copy of the Confidential Information by the receiving Party as a record of the receiving Party&#146;s ongoing confidentiality obligations under this Agreement.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Each of the Parties agrees that all Confidential Information that it receives from the other Party and/or its Affiliates in connection with the Product is the sole property of the disclosing Party and shall be used by it only in accordance with the terms and provisions of this Agreement.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">This Section&nbsp;11 shall be in effect during the Term and for a period of five (5)&nbsp;years following the termination or expiration thereof.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Parties acknowledge that it is their intention to limit the disclosure of Confidential Information hereunder to the Product and matters directly related thereto.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">TERM AND TERMINATION</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Upon expiration of the Term, BioSante shall grant to Teva and its Affiliates a perpetual, fully paid, royalty free, exclusive license to manufacture and Market the Product in or for the Territory and to use any Product Know-How existing as of the date of such expiration necessary to enable Teva and/or its Affiliates to manufacture and/or Market the Product in or for the Territory.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">This Agreement may be terminated by either Party by written notice provided to the other Party at any time during the Term if the other Party (the &#147;<b>Breaching Party</b>&#148;) is in material breach or default of any of its obligations hereunder</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_112319_4141"></a></font></p>
<div style="margin:0pt 0pt .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-03.htm',USER='107604',CD='Nov  7 12:49 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(including, without limitation, any payment obligations) or any of its representations or warranties hereunder were untrue in a material respect when made, as follows: (i)&nbsp;the terminating Party shall send written notice of the material breach or material default to the Breaching Party, and (ii)&nbsp;the termination shall become effective sixty (60) days after written notice thereof was provided to the Breaching Party, unless the Breaching Party has cured any such material breach or default prior to the expiration of the sixty (60) day period or if such material breach or material default is not capable of being cured within such sixty (60) day period, and the Breaching Party has commenced activities reasonably expected to cure such material breach or material default within such sixty (60) day period and thereafter uses diligent efforts to complete the cure as soon as practicable, but in no event shall such period exceed ninety (90) days.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject to the provisions of Section&nbsp;13.3 hereof, BioSante may terminate this Agreement effective upon issuance of written notice if, at any time, Teva files a petition in bankruptcy, or enters into an arrangement with its creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or suffers or permits the entry of an order adjudicating it to be bankrupt or insolvent.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">CONSEQUENCES OF TERMINATION</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Termination of this Agreement for whatever reason shall not affect the liabilities or obligations of the Parties hereunder in respect of matters accrued at the time of such termination, and shall be without prejudice to any other right or remedies available at law or in equity.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event of early termination of this Agreement by BioSante pursuant to Section&nbsp;12.2 and without derogating from any other rights or remedies available to BioSante, all rights, Approvals and data shall be promptly returned to BioSante without charge, and Teva agrees to execute without delay all documentation necessary to effectuate this purpose.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All rights and licenses granted pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n)&nbsp;of 11 U.S.C. &#167;101 et seq. (the &#147;<b>Bankruptcy Code</b>&#148;), licenses of rights to &#147;intellectual property&#148; as defined under Section&nbsp;101(35A) of the Bankruptcy Code. The Parties agree that Teva, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights (including, without limitation, any right to enforce any exclusivity provision of this Agreement (including any embodiment of such &#147;intellectual property&#148;)), remedies and elections under the Bankruptcy Code. To the fullest extent permitted by Applicable Law, the Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against BioSante under the Bankruptcy Code, Teva shall be entitled to all applicable rights under Section&nbsp;365 of the Bankruptcy Code, including but not limited to, a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_112348_8627"></a></font></p>
<div style="margin:0pt 0pt .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-03.htm',USER='107604',CD='Nov  7 12:49 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">embodiments of such intellectual property upon written request therefore by Teva, and such, if not already in its possession, shall be promptly delivered to Teva.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">INDEPENDENT CONTRACTORS</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The status of the Parties under this Agreement shall be that of independent contractors. Nothing is this Agreement shall be construed as establishing a partnership or joint venture relationship between the Parties hereto. No Party shall have the right to enter into any agreements on behalf of the other Party, nor shall it represent to any person that it has any such right or authority. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">SUCCESSORS AND ASSIGNS</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The terms and provisions hereof shall inure to the benefit of, and be binding upon, Teva, BioSante and their respective successors and permitted assigns. Neither Party shall assign this Agreement or any part of it to any third party without the prior written consent of the other Party, such consent not to be unreasonably withheld; provided, however, that either party may, without obtaining the consent of the other Party but upon written notice to the other Party, assign this Agreement or delegate any of its rights or obligations hereunder to any of its Affiliates.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">FORCE MAJEURE</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Neither Party shall be liable for non-performance or delay in the fulfillment of its obligations when any such non-performance or delay shall be occasioned by any unforeseeable cause beyond the reasonable control of Teva or BioSante, as the case may be, including without limitation, acts of God, fire, flood, earthquakes, explosions, sabotage, strikes, or labor disturbances (regardless of the reasonableness of the demands of the labor force), civil commotion, riots, military invasions, wars, failure of utilities, failure of carriers, or any acts, restraints, requisitions, regulations, or directives issued by a competent government authority not engendered by any act or omission of the Party (&#147;<b>Force Majeure Events</b>&#148;).</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event that either Party is prevented from discharging its obligations under this Agreement on account of a Force Majeure Event, such Party shall notify the other forthwith, and shall nevertheless make every endeavor, in the utmost good faith, to discharge its said obligations, even if in a partial or compromised manner.</font></p>
<p style="margin:0pt 0pt .0001pt 72.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">CURRENCY</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All payments under this Agreement shall be made in U.S. Dollars and, as applicable, the calculation of exchange rates shall be based upon the average over a twenty (20) business day period preceding the date that payment is due of the applicable rate of exchange as published in the Wall Street Journal.</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_112410_7906"></a></font></p>
<div style="margin:0pt 0pt .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-03.htm',USER='107604',CD='Nov  7 12:49 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">PUBLICITY AND DISCLOSURE OF AGREEMENT</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Concurrently with the execution of this Agreement, the Parties shall agree in good faith on a form of press release that BioSante may release.&#160; The Parties agree that no future press releases or other public announcements concerning the transactions contemplated hereby shall be issued without the advance written consent of the other Party, which consent shall not be unreasonably withheld, to the extent such release or announcement includes statements concerning terms of this Agreement and/or explicitly includes the Product or either Parties&#146; name(s), except to the extent such release or announcement may be required by Applicable Law.&#160; For releases or announcements required by law, the Party making the release or announcement shall, before making any such release or announcement, afford the other Party a reasonable opportunity to review and comment.&#160; Any copy of this Agreement to be filed with the Securities and Exchange Commission or any other Regulatory Authority shall be redacted to the fullest extent permitted by Applicable Law and to the reasonable satisfaction of both Parties; provided, however, in the event that the Securities and Exchange Commission or Regulatory Authority, as applicable, objects to the redaction of any portion of the Agreement after the initial submission, the filing Party shall inform the other Party of the objections and shall in good faith respond to the objections in an effort to limit the disclosure required by the Securities and Exchange Commission or Regulatory Authority, as applicable.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">19.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">SEVERABILITY</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Should any part or provision of this Agreement be held unenforceable or in conflict with Applicable Law, the invalid or unenforceable part or provision shall, provided that it does not go to the essence of this Agreement, be replaced with a revision which accomplishes, to the extent possible, the original commercial purpose of such part or provision in a valid and enforceable manner, and the balance of this Agreement shall remain in full force and effect and binding upon the Parties hereto.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">20.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">ENTIRE AGREEMENT</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement (including its Annexes) constitutes the entire agreement between the Parties with respect to its subject matter and supersedes all prior agreements, arrangements, dealings or writings between the Parties.&#160; This Agreement may not be amended or modified except in writing executed by the duly authorized representatives of both Parties.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">21.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">WAIVER</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No waiver of a breach or default hereunder shall be considered valid unless in writing and signed by the Party giving such waiver, and no such waiver shall be deemed a waiver of any subsequent breach or default of the same or similar nature.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">22.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">GOVERNING LAW</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement shall be governed, interpreted and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to principles of conflicts of law.&#160; To the extent that it may otherwise be applicable, the Parties hereby expressly agree to exclude from the operation of this Agreement the United Nations Convention on Contracts for the International</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_112432_3736"></a></font></p>
<div style="margin:0pt 0pt .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-03.htm',USER='107604',CD='Nov  7 12:49 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sale of Goods, concluded at Vienna, on 11 April&nbsp;1980, as amended and as may be amended further from time to time.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">23.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">NOTICES</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notices provided for under this Agreement shall be given in writing, in English, by facsimile; by first-class mail, federal express or similar service to the mailing address or facsimile numbers set out below:</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If   to Teva</font></p>    </td>
<td width="79%" colspan="2" valign="bottom" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TEVA   PHARMACEUTICALS USA,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1090   Horsham Road</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">North   Wales, PA 19454</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:   President</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">215-591-3000</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile:</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">215-591-8846</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With   a copy to:</font></p>    </td>
<td width="79%" colspan="2" valign="bottom" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TEVA   NORTH AMERICA</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1090   Horsham Road</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">North   Wales, Pennsylvania 19454</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice   President and General Counsel</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:10.58%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.76%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva   North America</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(215)   591-3000</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile:</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(215)   591-8813</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If   to BioSante</font></p>    </td>
<td width="79%" colspan="2" valign="bottom" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIOSANTE   PHARMACEUTICALS,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stephen   Simes</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">111   Barclay Boulevard</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lincolnshire,&nbsp;IL   60069</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">847   478-0500, ext 100</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile:</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">847   478-9260</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">With   a copy to:</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">GARY   I. LEVENSTEIN</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ungaretti&nbsp;&amp;   Harris</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3500   Three First National Plaza</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="79%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:79.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chicago,&nbsp;Illinois   60602-4283</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Telephone:</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">312   977-4400</font></p>    </td>   </tr>
<tr>
<td width="20%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:20.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="10%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:10.6%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Facsimile:</font></p>    </td>
<td width="68%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:68.74%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">312   977-4405</font></p>    </td>   </tr>  </table>
<p style="margin:0pt 0pt .0001pt 108.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">or to such other addresses or facsimile numbers as a Party shall designate by notice, similarly given, to the other Party. Notices shall be deemed to have been sufficiently given and served the day transmitted by facsimile (with confirmed transmission) or a date five (5)&nbsp;business days after the date of express mail or by mail courier.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">24.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">RESOLUTION OF DISAGREEMENTS</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If disagreements should arise under this Agreement, both BioSante and Teva agree to make good faith efforts to resolve the disagreements by discussion and negotiation. Any disagreements in</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_112540_9621"></a></font></p>
<div style="margin:0pt 0pt .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-03.htm',USER='107604',CD='Nov  7 12:49 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">connection with this Agreement or a Party&#146;s alleged breach of this Agreement that either Party believes has not been satisfactorily resolved through discussion and negotiation shall be resolved upon the written notice of either Party to the other requesting final and binding arbitration. If initially requested by Teva, the arbitration shall be held in Chicago,&nbsp;Illinois. If initially requested by BioSante, the arbitration shall be held in a location of Teva&#146;s selection within the Commonwealth of Pennsylvania. Such arbitration shall be before three (3)&nbsp;arbitrators, where each Party shall select one (1)&nbsp;arbitrator and the two (2)&nbsp;selected shall choose the third, and conducted under the Commercial Arbitration Rules&nbsp;of the American Arbitration Association. The prevailing Party in any such arbitration shall be entitled to recover only reasonable out-of-pocket costs of the arbitration (not attorney&#146;s fees) in addition to any award determined by the arbitrators. Any award rendered in such arbitration may be entered and enforced by either Party in any court having jurisdiction.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">25.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">STEERING COMMITTEE</font></u></b></p>
<p style="margin:0pt 0pt .0001pt 36.0pt;text-indent:-36.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Parties agree that a Steering Committee, comprised of two (2)&nbsp;representatives of each Party, shall be formed within thirty (30) days of the Effective Date and shall work cooperatively, and meet from time to time as it shall deem desirable, with the goals of effectuating smooth and prompt implementation of the Parties&#146; obligations under this Agreement and avoidance and resolution of disagreements between the Parties; and to provide updates of information as provided for in this Agreement.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, each of the Parties has executed this Agreement and Annexes as of the date below.</font></p>
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" colspan="3" valign="top" style="padding:0pt 0pt 0pt 0pt;width:48.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TEVA   PHARMACEUTICALS USA,&nbsp;INC.</font></p>    </td>
<td width="4%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:4.0%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" colspan="3" valign="top" style="padding:0pt 0pt 0pt 0pt;width:47.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIOSANTE   PHARMACEUTICALS,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="3" valign="top" style="padding:0pt 0pt 0pt 0pt;width:48.34%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:4.0%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" colspan="3" valign="top" style="padding:0pt 0pt 0pt 0pt;width:47.66%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:8.76%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature:</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt 0pt 0pt 0pt;width:39.58%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   George S. Barrett</font></p>    </td>
<td width="4%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:4.0%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:8.9%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature:</font></p>    </td>
<td width="38%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt 0pt 0pt 0pt;width:38.76%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Stephen M. Simes</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:8.76%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="border:none;padding:0pt 0pt 0pt 0pt;width:39.58%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:4.0%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="top" style="padding:0pt 0pt 0pt 0pt;width:8.9%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" style="border:none;padding:0pt 0pt 0pt 0pt;width:38.76%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:6.26%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt 0pt 0pt 0pt;width:42.08%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">George   S. Barrett</font></p>    </td>
<td width="4%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:4.0%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:6.24%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="41%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt 0pt 0pt 0pt;width:41.42%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stephen   M. Simes</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:6.26%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" colspan="2" valign="top" style="border:none;padding:0pt 0pt 0pt 0pt;width:42.08%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:4.0%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:6.24%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" colspan="2" valign="top" style="border:none;padding:0pt 0pt 0pt 0pt;width:41.42%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:6.26%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt 0pt 0pt 0pt;width:42.08%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President&nbsp;&amp;   CEO</font></p>    </td>
<td width="4%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:4.0%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:6.24%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="41%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt 0pt 0pt 0pt;width:41.42%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President&nbsp;&amp;   CEO</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:6.26%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" colspan="2" valign="top" style="border:none;padding:0pt 0pt 0pt 0pt;width:42.08%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:4.0%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:6.24%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" colspan="2" valign="top" style="border:none;padding:0pt 0pt 0pt 0pt;width:41.42%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:6.26%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="42%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt 0pt 0pt 0pt;width:42.08%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">December&nbsp;23,   2002</font></p>    </td>
<td width="4%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:4.0%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0pt 0pt 0pt 0pt;width:6.24%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="41%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt 0pt 0pt 0pt;width:41.42%;">
<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12/27/02</font></p>    </td>   </tr>
<tr height="0">
<td width="47" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="296" style="border:none;"></td>
<td width="30" style="border:none;"></td>
<td width="47" style="border:none;"></td>
<td width="20" style="border:none;"></td>
<td width="290" style="border:none;"></td>   </tr> </table>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="PB_16_113111_8715"></a></font></p>
<div style="margin:0pt 0pt .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-03.htm',USER='107604',CD='Nov  7 12:49 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ANNEX A</font></b></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Product</font></u></b></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1% testosterone gel AB-rated to AndroGel&#174;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="PB_17_113135_563"></a></font></p>
<div style="margin:0pt 0pt .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kg-03.htm',USER='107604',CD='Nov  7 12:49 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>a12-19123_1ex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.3</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT<br> (&#147;First Amendment&#148;)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">between</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TEVA PHARMACEUTICALS USA,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1090 Horsham Road, North Wales, PA 19454</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(&#147;Teva&#148;)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIOSANTE PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">111 Barclay Boulevard, Lincolnshire,&nbsp;IL 60069</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(&#147;BioSante&#148;)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, Teva and BioSante entered into a Development and License Agreement with an effective date of December&nbsp;27, 2002 (&#147;<b>the Agreement</b>&#148;);</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, subsequent to signature of the Agreement, the Parties have concluded that additional regulatory and legal work may be required;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, Teva and BioSante desire to amend the Agreement as their sole remedy for the changed circumstances of which they are both now aware, and in order to continue working together;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, in consideration of the mutual covenants set forth herein and for other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, BioSante and Teva agree to amend certain provisions of the Agreement pursuant to this First Amendment;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">WHEREAS, any defined terms used in this First Amendment shall have the same meaning as set out in the Agreement;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NOW THEREFORE, Teva and BioSante agree to amend the Agreement as set forth below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The definition of &#147;<b>Product</b>&#148; in Section&nbsp;1.4.17 of the Agreement shall be deleted in its entirety and replaced with the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Product</b>&#148; &#151; shall mean the finished pharmaceutical product listed in <b>Annex A</b> developed in whole or in part by BioSante.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The definition of &#147;<b>Royalties</b>&#148; in Section&nbsp;1.4.22 of the Agreement shall be deleted in its entirety and replaced with the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Royalties</b>&#148; &#151; shall mean the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-ki.htm',USER='107604',CD='Nov  7 12:54 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event that Teva launches the Product using a formulation developed solely by BioSante, an amount equal to seven and one half percent (7.5%) of Net Sales; provided, however, that during the period of time that Teva Markets such formulation and is the sole marketer of a generic 1% testosterone gel AB-rated to AndroGel&#174; in the Territory such amount shall be equal to ten percent (10%) of Net Sales.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event that Teva launches the Product using a formulation that was not developed solely by BioSante, an amount equal to five percent (5%) of Net Sales; provided, however, that during the period of time that Teva Markets such formulation and is the sole marketer of a generic 1% testosterone gel AB-rated to AndroGel&#174; in the Territory such amount shall be equal to seven and one half percent (7.5%) of Net Sales.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The following shall be added as Section&nbsp;2.6:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All data, information and know-how developed by Teva and/or its Affiliates with or without the assistance of BioSante in connection with the Product shall be owned solely and exclusively by Teva.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Section&nbsp;3.11 shall be deleted in its entirety and replaced with the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.11</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subject to pre-approval by Teva, Teva shall reimburse BioSante for all Regulatory Expenses incurred by BioSante after July&nbsp;1, 2002; provided, however, that Teva shall have no obligation to reimburse BioSante for any Regulatory Expenses related to a formulation for the Product based in whole or in part on information, data or expertise not contained in the Technical Package provided to Teva by BioSante on or before the Effective Date.&#160; Payment with respect to Regulatory Expenses recoverable by BioSante under this Section&nbsp;3.11 shall be made by Teva within thirty (30) days following receipt of an invoice and all supporting documentation from BioSante.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Section&nbsp;3.12 shall be renumbered to Section&nbsp;3.13 and the following shall be added as Section&nbsp;3.12:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.12</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva shall bear its own Regulatory Expenses; provided, however, that following launch of the Product in the Territory, Teva shall reduce the Royalties payable to BioSante hereunder by an amount equal to any and all Regulatory Expenses incurred by Teva and/or its Affiliates related to developing a formulation for the Product based in whole or in part on information, data or expertise not contained in the Technical Package provided to Teva by BioSante on or before the Effective Date.&#160; For the sake of clarification, the foregoing reduction shall apply only in the event that such formulation is used for the Product.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Section&nbsp;5.2 shall be renumbered to Section&nbsp;5.3 and the following shall be added as Section&nbsp;5.2:</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-ki.htm',USER='107604',CD='Nov  7 12:54 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">If a third party institutes a patent infringement suit or similar proceeding against Teva, its Affiliates and/or its subcontractors during the Term of this Agreement, which suit alleges that the filing of the ANDA for the Product and/or the manufacturing, Marketing, use, sale or offers for sale of the Product in the Territory infringes one or more patents owned by or licensed to such third party (&#147;<b>Patent Suit</b>&#148;), then Teva shall assume direction, control and disposition of the defense of claims arising therefrom. BioSante shall provide, at its sole cost and expense, any and all assistance that Teva may reasonably request relating to such Patent Suit. Teva shall advance all legal fees, expenses and reasonable settlement payments incurred by Teva and/or its Affiliates in connection with such Patent Suit (&#147;<b>Legal Expenses</b>&#148;).&#160; Following launch of the Product in the Territory, Teva shall be entitled prior to any payment to BioSante either under Section&nbsp;5 (Royalties) or Section&nbsp;7(d)&nbsp;(Milestone Payments), to recoup all reasonable Legal Expenses and shall reduce any such payments due until it is fully reimbursed such Legal Expenses.&#160; Nothing contained in this Section&nbsp;5.2 is meant to derogate from BioSante&#146;s representations and warranties and covenants as contained in Section&nbsp;8 or its indemnification obligations as contained in Section&nbsp;10.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Subsections. (b)&nbsp;and (c)&nbsp;of Section&nbsp;7 relating to milestone payments shall be deleted in their entirety and replaced with the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">provided that a Patent Suit has not been instituted against Teva and/or its Affiliates and/or its subcontractors, One Million U.S. Dollars (U.S. $1,000,000) within thirty (30) days following the Launch Date;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">provided that a Patent Suit has not been instituted against Teva and/or its Affiliates and/or its subcontractors, One Million U.S. Dollars (U.S. $1,000,000) one hundred and twenty (120) days following the Launch Date; and</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The following shall be added to the end of Section&nbsp;7:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">; provided, however, that in the event that a Patent Suit is instituted against Teva and/or its Affiliates and/or its subcontractors following payment by Teva of the milestone payments set forth in subsections (b)&nbsp;or (c), above, BioSante shall reimburse to Teva the applicable milestone payment within thirty (30) days following written request by Teva.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Parties agree that the following shall be added as Section&nbsp;26 of the Agreement:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><u><font size="2" style="font-size:10.0pt;font-weight:bold;">PERIODIC REPORTS/RIGHT TO AUDIT</font></u></b></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva shall provide quarterly reports to BioSante of any Regulatory Expenses and/or Legal Expenses incurred by Teva, which BioSante must reimburse to Teva pursuant to Sections 3.12 and/or 5.2 herein. Teva shall permit an independent certified auditor selected by BioSante and reasonably acceptable to Teva to have access, during normal business hours and upon reasonable prior notice, to those books and records maintained by Teva reasonably necessary for BioSante to verify the accuracy of any such Regulatory Expenses and/or Legal Expenses; provided, however, that BioSante agrees to preserve the confidentiality of all</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-ki.htm',USER='107604',CD='Nov  7 12:54 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">privileged or confidential information. Any such independent audit shall be performed at BioSante&#146;s sole cost and expense.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The Parties agree that save as expressly provided for herein all terms and conditions of the Agreement shall remain in full force and effect and that this First Amendment shall form an integral part of the Agreement.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, each of the Parties has executed this First Amendment as of the date below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the date below.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:48.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TEVA PHARMACEUTICALS USA,&nbsp;INC.</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="47%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:47.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIOSANTE   PHARMACEUTICALS,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="48%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:48.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="47%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:47.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:8.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature:</font></p>    </td>
<td width="39%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:39.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Richard Egosi</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:8.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature:</font></p>    </td>
<td width="38%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:38.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Stephen M. Simes</font></p>    </td>   </tr>
<tr>
<td width="8%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:8.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="39%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:39.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="8%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:8.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="38%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:38.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Richard   Egosi</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="41%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stephen   M. Simes</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:41.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">V.P.   General Counsel</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="41%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President&nbsp;&amp;   CEO</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="41%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:41.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="42%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">March&nbsp;11,   2003</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="41%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3/13/03</font></p>    </td>   </tr>
<tr height="0">
<td width="47" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="296" style="border:none;"></td>
<td width="30" style="border:none;"></td>
<td width="47" style="border:none;"></td>
<td width="20" style="border:none;"></td>
<td width="290" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-ki.htm',USER='107604',CD='Nov  7 12:54 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>a12-19123_1ex10d4.htm
<DESCRIPTION>EX-10.4
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.4</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TEVA</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Administrative Offices;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">TEVA PHARMACEUTICALS USA</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1090 Horsham Road, PO Box 1090</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">North Wales, PA&#160; 19454-1090</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phone:&#160; (215) 591-3000</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Toll Free:&#160; 888 TEVA USA</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mr.&nbsp;Stephen Simes</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President&nbsp;&amp; CEO</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BioSante Pharmaceuticals,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">111 Barclay Boulevard</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lincolnshire,&nbsp;IL&#160; 60069</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Re:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Development and License Agreement between Teva Pharmaceuticals USA,&nbsp;Inc. (&#147;Teva&#148;) and BioSante Pharmaceuticals,&nbsp;Inc. (&#147;BioSante&#148;) effective December&nbsp;27, 2002, as amended (the &#147;Agreement&#148;).</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Mr.&nbsp;Simes:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This letter will confirm that effective as of the date of your countersignature below (&#147;<b>Reactivation Date</b>&#148;), Teva and BioSante have mutually agreed that they will reactivate the Agreement and reactivate the development of a generic 1% testosterone gel product under the terms and conditions of the Agreement, as further amended as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The following shall be added as a new definition to Section&nbsp;1.4:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<b>Commercially Reasonable Efforts</b>&#148; &#151; shall mean with respect to the efforts to be expended by a Party with respect to any objective under this Agreement, reasonable, diligent, good-faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances exercising reasonable business judgment, it being understood and agreed that, with respect to the development, manufacture and commercialization of the Product, such efforts shall be substantially equivalent to those efforts and resources commonly used by such Party for a product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential as the Product, taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the Product, the likelihood of regulatory approval given the regulatory structure involved, the profitability, and other relevant factors commonly considered in similar circumstances.&#160; It is anticipated that the level of effort may change over time, reflecting changes in the status of the Product.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The term &#147;commercially reasonable efforts&#148; as used throughout the Agreement shall be deleted in its entirety and replaced with &#147;Commercially Reasonable Efforts.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kk.htm',USER='107604',CD='Nov  7 11:51 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Section&nbsp;3.9 of the Agreement shall be deleted in its entirety and replaced with the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva shall use Commercially Reasonable Efforts to file an ANDA for the Product. Following the Launch Date, Teva shall use Commercially Reasonable Efforts to Market the Product in the Territory.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Section&nbsp;3.11 shall be deleted in its entirety and replaced with &#147;[intentionally left blank].&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Section&nbsp;3.12 of the Agreement shall be deleted in its entirety and replaced with the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Each Party shall bear its own Regulatory Expenses.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Section&nbsp;5.2 of the Agreement shall be deleted in its entirety and replaced with the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If a third party institutes a patent infringement suit or similar proceeding against Teva, its Affiliates and/or its subcontractors during the Term of this Agreement, which suit alleges that the filing of the ANDA for the Product and/or the manufacturing, Marketing, importation, use, sale or offers for sale of the Product in the Territory infringes one or more patents owned by or licensed to such third party (&#147;<b>Patent Suit</b>&#148;), then Teva shall assume direction, control and disposition of the defense of claims arising therefrom. BioSante shall provide, at its sole cost and expense, any and all assistance that Teva may reasonably request relating to such Patent Suit. Teva shall initially bear all legal fees, expenses and reasonable settlement payments incurred by Teva and/or its Affiliates in connection with such Patent Suit (&#147;<b>Legal Expenses</b>&#148;); provided, however, that following the launch of the Product in the Territory, Teva shall be entitled prior to any payment to BioSante under Section&nbsp;5 (Royalties) to deduct the amount of any and all such Legal Expenses from Net Sales. Teva shall permit an independent certified auditor selected by BioSante and reasonably acceptable to Teva to have access, during normal business hours and upon reasonable prior notice, to those books and records maintained by Teva reasonably necessary for BioSante to verify, on a one time basis, the accuracy of any such Legal Expenses; provided, however, that BioSante agrees to preserve the confidentiality of all privileged or confidential information.&#160; Any such independent audit shall be performed at BioSante&#146;s sole cost and expense.&#160; Nothing contained in this Section&nbsp;5.2 is meant to derogate from BioSante&#146;s representations and warranties and covenants as contained in Section&nbsp;8 or its indemnification obligations as contained in Section&nbsp;10.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_114602_3641"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kk.htm',USER='107604',CD='Nov  7 11:51 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The following sentence shall be added to the end of Section&nbsp;7 of the Agreement:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the foregoing, following the launch of the Product in the Territory, and provided BioSante has not previously reimbursed Teva for the milestone payments as a result of a Patent Suit, Teva shall be entitled prior to any payment to BioSante under Section&nbsp;5 (Royalties) to deduct the amount of any and all milestone payments paid by Teva to BioSante under subsections (b)&nbsp;and (c), above, from Net Sales.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(8)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The following Sections 12.4, 12.5 and 12.6 shall be added to the Agreement:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva shall have the right, at its sole option, to terminate this Agreement immediately upon written notice to BioSante in the event that any pilot or pivotal bioequivalence study for the Product, completed subsequent to the Reactivation Date, fails to demonstrate bioequivalence of the Product to the branded product AndroGel</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;to the reasonable satisfaction of Teva consistent with FDA bioequivalence standards and prevailing standards of statistical methods. In such event, subject to the provisions of Section&nbsp;12.6, Teva shall grant to BioSante a perpetual, worldwide, semi-exclusive license to all data, information and know-how developed by Teva, as referenced in Section&nbsp;2.6, including but not limited to biostudy reports and other clinical data related to the Product (the &#147;<b>Teva License</b>&#148;) to be used by BioSante to Market the Product.&#160; For purposes of the definition of &#147;Teva License&#148;, &#147;semi-exclusive&#148; shall mean that Teva and/or its Affiliates (or a third party on their behalf) shall have the right to use such Teva data, information and know-how for any purpose whatsoever.&#160; For the avoidance of doubt, Teva acknowledges and agrees that following the termination of this Agreement for any reason, except as expressly set forth in this Agreement, Teva shall not be permitted to use for any purpose BioSante&#146;s Confidential Information contained in the Technical Package provided to Teva by BioSante on or before the Effective Date.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Teva shall have the right to terminate this Agreement, upon ninety (90) days prior written notice to BioSante, in the event that Teva determines, in its sole discretion, that the continued development and/or Marketing of the Product is no longer commercially viable.&#160; In the event that Teva exercises such termination right, subject to the provisions of Section&nbsp;12.6, Teva shall grant to BioSante the Teva License to Market the Product.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">In the event that Teva grants to BioSante the Teva License under Sections 12.4 or 12.5, then if BioSante, its Affiliate or a third party pursuant to an arrangement with BioSante subsequently launches or sells a generic 1% testosterone gel product AB Rated to AndroGel</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;in the Territory, BioSante shall pay to Teva, on a quarterly basis, five percent (5%) of all consideration received by BioSante or its Affiliates as a result of the commercial sale of such product until such time that</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_114626_5250"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kk.htm',USER='107604',CD='Nov  7 11:51 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Teva has been paid either (a)&nbsp;Three Million Five Hundred Thousand U.S. Dollars (U.S. $3,500,000) if (i)&nbsp;Teva did not file an ANDA for the Product, or (ii)&nbsp;Teva filed an ANDA for the Product and a Patent Suit was not instituted against Teva and/or its Affiliates and/or its subcontractors, or (b)&nbsp;Five Million U.S. Dollars (U.S. $5,000,000) if Teva filed an ANDA for the Product and a Patent Suit was instituted against Teva and/or its Affiliates and/or its subcontractors. For purposes of this Section&nbsp;12.6, &#147;consideration&#148; shall mean, by way of example and not limitation, net sales (calculated in the same manner as Net Sales hereunder), and all royalties, milestone payments, and other payments, but shall not include reimbursement of costs and expenses or payments for the costs of goods and/or services.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Section&nbsp;26 of the Agreement shall be deleted in its entirety.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(10)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Upon the Reactivation Date, both the notice of termination provided by Teva by letter of February&nbsp;9, 2005 to BioSante and Section&nbsp;4 of the letter of July&nbsp;27, 2005 provided by Teva to BioSante shall be considered null and void.&#160; However, BioSante and Teva each fully and forever releases, acquits and discharges the other Party and its predecessors, successors, assigns, Affiliates, officers and directors from any and all claims, demands, obligations, losses, damages, promises, costs, expenses, liabilities and causes of action of any nature whatsoever, whether in law or in equity, whether direct or indirect, whether known or unknown, whether fixed or contingent, whether suspected or unsuspected, relating to or arising out of (a)&nbsp;the contents and the disclosure to BioSante of the Teva Data (as defined in the July&nbsp;27, 2005 letter) and (b)&nbsp;the performance or non-performance by either party under the Agreement prior to the Reactivation Date.&#160; Notwithstanding the foregoing, BioSante shall continue to be bound by its obligations of confidentiality with respect to the Teva Data and shall be responsible for the breach of any such obligations by itself or any third party to whom BioSante provided the Teva Data under Section&nbsp;2 of the July&nbsp;27, 2005 letter.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_114648_7672"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kk.htm',USER='107604',CD='Nov  7 11:51 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Please sign below as your confirmation of the foregoing, and return a signed copy of this letter to me via facsimile at (215) 591-8811.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Best   regards,</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   John C. James</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">John   C. James</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice   President, Alliance Management</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   not legible</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Its:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Acknowledged and Agreed</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">this 4</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font><font size="2" style="font-size:10.0pt;">&#160;day of June, 2007</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BioSante Pharmaceuticals,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Stephen M. Simes</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Phillip B Donenberg</font></p>    </td>   </tr>
<tr>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Its:</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President&nbsp;&amp;   CEO</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:49.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CFO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6/4/07</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_115044_536"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-kk.htm',USER='107604',CD='Nov  7 11:51 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>a12-19123_1ex10d5.htm
<DESCRIPTION>EX-10.5
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;10.5</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIS AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT</font></b><font size="2" style="font-size:10.0pt;"> (&#147;<u>Third Amendment</u>&#148;), is entered into as of the Third Amendment Effective Date (as defined below), by and between Teva Pharmaceuticals USA,&nbsp;Inc.&#160; (&#147;<u>Teva</u>&#148;) and BioSante Pharmaceuticals,&nbsp;Inc.&#160; (&#147;<u>BioSante</u>&#148;), and amends certain terms of the Agreement (as defined below).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BACKGROUND</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS</font></b><font size="2" style="font-size:10.0pt;">, Teva and BioSante entered into a Development and License Agreement on December&nbsp;27, 2002 (as amended by the First Amendment and the 2007 Letter Agreement (each as defined below), the &#147;<u>Agreement</u>&#148;);</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS</font></b><font size="2" style="font-size:10.0pt;">, Teva and BioSante amended certain terms of the Agreement pursuant to the First Amendment to Development and License Agreement (dated March&nbsp;13, 2003) (the &#147;<u>First Amendment</u>&#148;), and further amended certain terms of the Agreement pursuant to the letter agreement dated June&nbsp;4, 2007 (the &#147;<u>2007 Letter Agreement</u>&#148;); and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS</font></b><font size="2" style="font-size:10.0pt;">, Teva and BioSante desire to amend certain terms of the Agreement as set forth in this Third Amendment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOW THEREFORE</font></b><font size="2" style="font-size:10.0pt;">, for good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged, Teva and BioSante agree as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Definitions</font></u><font size="2" style="font-size:10.0pt;">.&#160; All terms used and not otherwise defined in this Third Amendment shall have the same meanings ascribed to them in the Agreement.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Payment</font></u><b><font size="2" style="font-size:10.0pt;font-weight:bold;">. </font></b><font size="2" style="font-size:10.0pt;">In full and complete consideration for the agreements set forth in this Third Amendment, within five (5)&nbsp;business days following the date the later of the two parties signs and delivers to the other party this Third Amendment (the &#147;<u>Third Amendment Effective Date</u>&#148;), Teva shall make a one-time payment to BioSante of One Million Dollars (US$1,000,000).</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Amendment</font></u><font size="2" style="font-size:10.0pt;">. The Agreement is hereby amended as follows:</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Sections 7(b)&nbsp;and (c)&nbsp;(as amended by the First Amendment) are hereby deleted in their entirety, Section&nbsp;7(d)&nbsp;is hereby re-lettered as Section&nbsp;7(e), and the following new Sections 7(b), (c)&nbsp;and (d)&nbsp;shall be added to the Agreement:</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 94.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;(b)&nbsp;Five Hundred Thousand U.S. Dollars (US$500,000) if the FDA authorizes marketing of the Product as an &#147;AB-rated&#148; equivalent to AndroGel&#174;;</font></p>
<p style="margin:0in 0in .0001pt 94.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 94.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)&nbsp;Seven Hundred Fifty Thousand U.S. Dollars (US$750,000) upon the earlier to occur of (i)&nbsp;December&nbsp;31, 2012 and (ii)&nbsp;five (5)&nbsp;business days after Teva&#146;s submission to the FDA of a final report regarding the clinical study required by the FDA and titled &#147;A Clinical Study to Evaluate the Effects of Washing the Application Site on Residual Concentrations of Testosterone Following Single Topical Applications of 5 grams of 1% Testosterone Gel (Teva) in Healthy Male Subjects&#148;; and</font></p>
<p style="margin:0in 0in .0001pt 94.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 94.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Five Hundred Thousand U.S. Dollars (US$500,000) upon the earlier to occur of (i)&nbsp;December&nbsp;31, 2013 and (ii)&nbsp;five (5)&nbsp;business days after Teva&#146;s</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-km.htm',USER='107604',CD='Nov  7 13:09 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 94.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commencement of Commercial Manufacture of Product for sale in the Territory.&#160; For purposes hereof, &#147;<b>Commencement of Commercial Manufacture</b>&#148; shall mean commencement of the manufacturing of the first batch of Product after successful completion of the validation process.</font></p>
<p style="margin:0in 0in .0001pt 94.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The final sentence of Section&nbsp;7 of the Agreement (as added by Paragraph (7)&nbsp;of the 2007 Letter Agreement) is hereby deleted in its entirety.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">C.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The definition of &#147;Royalties&#148; in Section&nbsp;1.4.22 (as amended by the First Amendment) is hereby deleted in its entirety and is replaced with the following:</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 94.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;&#147;Royalties&#148; - shall mean an amount equal to five percent (5%) of Net Sales; provided, however, that during the period of time that Teva Markets Product and is the sole marketer of a generic 1% testosterone gel that is AB-rated to AndroGel&#174; in the Territory, such amount shall be equal to seven and one half percent (7.5%) of Net Sales.&#148;</font></p>
<p style="margin:0in 0in .0001pt 94.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Acknowledgement</font></u><font size="2" style="font-size:10.0pt;">.&#160; Notwithstanding anything contained in this Third Amendment or the Agreement to the contrary, BioSante hereby acknowledges and agrees that the success of the development and/or commercialization of the Product is not guaranteed and that Teva has not yet secured a source for commercial manufacture of the Product.&nbsp; Accordingly, BioSante further acknowledges and agrees, subject to Teva&#146;s obligations under Sections 3.2 and 3.9 to use commercially reasonable efforts to (i)&nbsp;apply for, obtain and maintain Approval for the Product and (ii)&nbsp;Market the Product, in each case in the Territory, that the milestone payments contained in Section&nbsp;7(b)&nbsp;and 7(e)&nbsp;of the Agreement and the royalty contained in the Agreement are contingent in nature, due solely upon the occurrence of the certain events that are expressly set forth herein.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Release of Teva by BioSante</font></u><font size="2" style="font-size:10.0pt;">.&#160; In consideration of its execution of this Third Amendment and its agreement to be legally bound by the terms hereof, including, without limitation, its rights to receive the milestone payments in accordance with this Third Amendment, and subject to the remainder of this Paragraph 5 and Paragraph 7, BioSante, with the intention of binding itself and its Affiliates, and its and their respective predecessors, successors, heirs and assigns, directors, officers, employees and representatives, hereby fully, finally and irrevocably releases and discharges Teva and its Affiliates, and its and their respective predecessors, successors, heirs and assigns, directors, officers, employees and representatives, from any and all actions, causes of action, suits, debts, dues, sums of money, accounts, reckonings, bonds, bills, specialties, covenants, contracts, liabilities, controversies, agreements, promises, variances, trespasses, damages, judgments, extents, executions, claims, counterclaims, demands, costs, expenses, losses, liens and obligations (collectively, &#147;<u>Liabilities</u>&#148;), whatsoever, in law or equity, whether known or unknown, and waive any and all defenses, occurring before or as of the Third Amendment Effective Date related to the performance or non-performance by Teva under the Agreement prior to the Third Amendment Effective Date.&#160; In connection with this Agreement, BioSante, on behalf of itself and its Affiliates, expressly waives and relinquishes all rights and benefits afforded in any jurisdiction similar to those afforded in Section&nbsp;1542 of the California Civil Code, which provides as follows:</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN TO HIM OR</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_115306_5926"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-km.htm',USER='107604',CD='Nov  7 13:09 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Release of BioSante by Teva</font></u><font size="2" style="font-size:10.0pt;">.&#160; In consideration of its execution of this Third Amendment and its agreement to be legally bound by the terms hereof, and subject to the remainder of this Paragraph 6 and Paragraph 7, Teva, with the intention of binding itself and its Affiliates, and its and their respective predecessors, successors, heirs and assigns, directors, officers, employees and representatives, hereby fully, finally and irrevocably releases and discharges BioSante and its Affiliates, and its and their respective predecessors, successors, heirs and assigns, directors, officers, employees and representatives, from any and all Liabilities whatsoever, in law or equity, whether known or unknown, and waive any and all defenses, occurring before or as of the Third Amendment Effective Date related to the performance or non-performance by BioSante under the Agreement prior to the Third Amendment Effective Date.&#160; In connection with this Agreement, Teva, on behalf of itself and its Affiliates, expressly waives and relinquishes all rights and benefits afforded in any jurisdiction similar to those afforded in Section&nbsp;1542 of the California Civil Code, which provides as follows:</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN TO HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.</font></p>
<p style="margin:0in 0in .0001pt .75in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Unreleased Liabilities</font></u><font size="2" style="font-size:10.0pt;">.&#160; Notwithstanding anything in Paragraphs 5 and 6 to the contrary, nothing herein shall release or discharge either Party from, or prevent or impair the right of either Party to bring a claim or action regarding, any Unreleased Liabilities.&#160; For the purposes of this Third Amendment, &#147;<u>Unreleased Liabilities</u>&#148; means any liabilities arising out of (i)&nbsp;a breach by a Party of its obligations of confidentiality set forth in in Sections 11 or 18 of the Agreement, (ii)&nbsp; a breach by BioSante of the warranties and representations in Sections 8.1.1, 8.1.3, 8.1.5 or 8.1.6 of the Agreement, (iii)&nbsp;a breach by Teva of the warranties and representations in Sections 9.1.1 or 9.1.3 of the Agreement or (iv)&nbsp;a Party&#146;s indemnification obligations under Section&nbsp;10 of the Agreement, but only with respect to suits, investigations, claims or demands brought or asserted by Third Parties after the Third Amendment Effective Date.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">General Terms</font></u><font size="2" style="font-size:10.0pt;">.&#160; This Third Amendment will act to amend the Agreement strictly as stated in Paragraph 2 above.&#160; All other terms and conditions of the Agreement shall remain in full force and effect, without modification.&#160; For the avoidance of doubt, the Parties acknowledge and agree that the terms of this Third Amendment and the negotiations of the Parties pertaining to them, shall be maintained in confidence by the Parties in accordance with Sections 11 or 18 of the Agreement.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Counterparts</font></u><font size="2" style="font-size:10.0pt;">.&#160; This Third Amendment may be signed in any number of counterparts with the same effect as if the signatures to each counterpart were upon a single instrument, and all such counterparts together shall be deemed an original of this Third Amendment.</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-35.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u><font size="2" style="font-size:10.0pt;">Governing Law</font></u><font size="2" style="font-size:10.0pt;">. This Third Amendment shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania without regard to any conflict of laws provisions thereof.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_115324_4688"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-km.htm',USER='107604',CD='Nov  7 13:09 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[<b><i style="font-weight:bold;">Remainder of page&nbsp;intentionally left blank</i></b>]</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_115336_2983"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-km.htm',USER='107604',CD='Nov  7 13:09 2012' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF,</font></b><font size="2" style="font-size:10.0pt;"> BioSante and Teva each has caused this Third Amendment to be executed by its duly authorized representative.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.6%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TEVA   PHARMACEUTICALS USA,&nbsp;INC.</font></b></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIOSANTE   PHARMACEUTICALS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.6%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Jamie Bertansko</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Stephen M. Simes</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Jamie Bertansko</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stephen M. Simes</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">VP of Finance and Controller</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and CEO</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10/12/2012</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.06%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10/9/2012</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Timothy C. Crew</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Timothy C. Crew</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SVP, Teva Pharmaceuticals</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="42%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:</font></p>    </td>
<td width="42%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:42.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10/12/2012</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107604\12-19123-1\task5652134\19123-1-km.htm',USER='107604',CD='Nov  7 13:09 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>a12-19123_1ex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 31.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION OF CEO PURSUANT TO SECTION 302 OF THE<br> SARBANES OXLEY ACT OF 2002 AND SEC RULE 13a-14(a)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Stephen M. Simes, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">I have reviewed this quarterly report on Form 10-Q of BioSante Pharmaceuticals, Inc.;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   November 8, 2012</font></p>    </td>
<td width="49%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Stephen M. Simes</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stephen   M. Simes </font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice   Chairman, President and Chief Executive Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(principal   executive officer)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_235439_9111"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-ma.htm',USER='107310',CD='Nov  8 12:51 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>a12-19123_1ex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.2</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION OF CFO PURSUANT TO SECTION&nbsp;302 OF THE<br> SARBANES OXLEY ACT OF 2002 AND SEC RULE 13a-14(a)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Phillip B. Donenberg, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">I have reviewed this quarterly report on Form&nbsp;10-Q of BioSante Pharmaceuticals,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   November&nbsp;8, 2012</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Phillip B. Donenberg</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phillip   B. Donenberg</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior   Vice President of Finance, Chief Financial Officer and Secretary</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(principal   financial officer)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1<a name="PB_1_235847_2270"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='1',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-mc.htm',USER='107310',CD='Nov  8 12:51 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>a12-19123_1ex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. SECTION&nbsp;1350, AS ADOPTED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PURSUANT TO SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the Quarterly Report of BioSante Pharmaceuticals,&nbsp;Inc. (the &#147;Company&#148;) on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;),&nbsp;I, Stephen M. Simes, Vice Chairman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Stephen M. Simes</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stephen   M. Simes</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice   Chairman, President and Chief Executive Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">November&nbsp;8,   2012</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-me.htm',USER='107310',CD='Nov  8 12:52 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>a12-19123_1ex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.2</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. SECTION&nbsp;1350, AS ADOPTED </font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PURSUANT TO SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the Quarterly Report of BioSante Pharmaceuticals,&nbsp;Inc. (the &#147;Company&#148;) on Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;),&nbsp;I, Phillip B. Donenberg, Senior Vice President of Finance, Chief Financial Officer and Secretary of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Phillip B. Donenberg</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Phillip   B. Donenberg</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior   Vice President of Finance, Chief Financial Officer and Secretary</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">November&nbsp;8,   2012</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107310\12-19123-1\task5656554\19123-1-mg.htm',USER='107310',CD='Nov  8 12:53 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>bpax-20120930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<!--Generated by IRIS Proton Version 4.0.2.0-->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:bpax="http://www.biosantepharma.com/20120930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:schemaRef xlink:type="simple" xlink:href="bpax-20120930.xsd" />
  <xbrli:context id="I2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3SO_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-11-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_StockOptionsMember_SB">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_MoneyMarketFundsMember_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_EstimateOfFairValueFairValueDisclosureMember_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_FairValueInputsLevel2Member_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_MoneyMarketFundsMember_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_EstimateOfFairValueFairValueDisclosureMember_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011_FairValueInputsLevel2Member_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_M02_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-02-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M06">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-06-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2011Q3YTD_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M05_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-05-01</xbrli:startDate>
      <xbrli:endDate>2012-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q2_M05_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-05-01</xbrli:startDate>
      <xbrli:endDate>2012-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_CapitalAdditionsMember_AptarPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:AptarPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_CapitalAdditionsMember_AptarPharmaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:AptarPharmaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_MergerAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_MinimumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_MergerAgreementMember_MinimumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_MaximumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:MergerAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-02</xbrli:startDate>
      <xbrli:endDate>2012-10-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:VotingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:VotingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-02</xbrli:startDate>
      <xbrli:endDate>2012-10-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_LockUpAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:LockUpAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1003_ANIPharmaceuticalsIncMember_LockUpAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:LockUpAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-02</xbrli:startDate>
      <xbrli:endDate>2012-10-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-02</xbrli:startDate>
      <xbrli:endDate>2012-10-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_MaximumMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M07_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0731_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1_M0229_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1_ConvertibleNotesPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3SO_CommonClassCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-11-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M08_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:WarrantIssuedToInstitutionalInvestorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>
      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M08_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>
      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0831_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_M0831_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bpax:WarrantIssuedToInstitutionalInvestorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M0920_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-09-19</xbrli:startDate>
      <xbrli:endDate>2012-09-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012_ANIPharmaceuticalsIncMember_EmployeeSeveranceMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:ANIPharmaceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3_M0924_ShareholderDerivativeActionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">bpax:ShareholderDerivativeActionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-09-23</xbrli:startDate>
      <xbrli:endDate>2012-09-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q3_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q3YTD_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M10_MinimumMember_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis">bpax:ThirdAmendmentToLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bpax:TevaPharmaceuticalsUSAIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">bpax:PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Vaccine">
    <xbrli:measure>bpax:vaccine</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Holder">
    <xbrli:measure>bpax:holder</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Item">
    <xbrli:measure>bpax:item</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag1" decimals="0" contextRef="I2011" unitRef="USD">57225234</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag2" decimals="0" contextRef="I2011" unitRef="USD">801147</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag3" decimals="0" contextRef="I2011" unitRef="USD">58026381</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag4" decimals="0" contextRef="I2011" unitRef="USD">861364</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:LongTermInvestments id="Tag5" decimals="0" contextRef="I2011" unitRef="USD">3405807</us-gaap:LongTermInvestments>
  <us-gaap:DepositsAssetsNoncurrent id="Tag6" decimals="0" contextRef="I2011" unitRef="USD">86203</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:Assets id="Tag7" decimals="0" contextRef="I2011" unitRef="USD">62379755</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="Tag8" decimals="0" contextRef="I2011" unitRef="USD">3150677</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Tag9" decimals="0" contextRef="I2011" unitRef="USD">1597329</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Tag10" decimals="0" contextRef="I2011" unitRef="USD">2479697</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag11" decimals="0" contextRef="I2011" unitRef="USD">7227703</us-gaap:LiabilitiesCurrent>
  <us-gaap:ConvertibleLongTermNotesPayable id="Tag12" decimals="0" contextRef="I2011" unitRef="USD">17336760</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:Liabilities id="Tag13" decimals="0" contextRef="I2011" unitRef="USD">24564463</us-gaap:Liabilities>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag14" decimals="0" contextRef="I2011" unitRef="USD">-217239148</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="Tag15" decimals="0" contextRef="I2011" unitRef="USD">37815292</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag16" decimals="0" contextRef="I2011" unitRef="USD">62379755</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag17" decimals="0" contextRef="I2012Q3" unitRef="USD">-240969556</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="Tag18" decimals="0" contextRef="I2012Q3" unitRef="USD">32289680</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag19" decimals="0" contextRef="I2012Q3" unitRef="USD">43211746</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockValueOutstanding id="Tag20" decimals="0" contextRef="I2011_CommonClassCMember" unitRef="USD">65</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding id="Tag21" decimals="0" contextRef="I2011_CommonStockMember" unitRef="USD">255054375</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding id="Tag22" decimals="0" contextRef="I2012Q3_CommonStockMember" unitRef="USD">273259171</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding id="Tag23" decimals="0" contextRef="I2012Q3_CommonClassCMember" unitRef="USD">65</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding id="Tag24" decimals="0" contextRef="I2011" unitRef="USD">255054440</us-gaap:CommonStockValueOutstanding>
  <us-gaap:CommonStockSharesIssued id="Tag25" decimals="INF" contextRef="I2012Q3_CommonClassCMember" unitRef="Shares">65211</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="Tag26" decimals="INF" contextRef="I2012Q3_CommonStockMember" unitRef="Shares">24422240</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="Tag27" decimals="INF" contextRef="I2011_CommonClassCMember" unitRef="Shares">65214</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="Tag28" decimals="INF" contextRef="I2011_CommonStockMember" unitRef="Shares">18269755</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Tag29" decimals="INF" contextRef="I2011_CommonStockMember" unitRef="Shares">18269755</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="Tag30" decimals="INF" contextRef="I2012Q3_CommonClassCMember" unitRef="Shares">65211</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="Tag31" decimals="INF" contextRef="I2011_CommonClassCMember" unitRef="Shares">65214</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="Tag32" decimals="INF" contextRef="I2012Q3_CommonStockMember" unitRef="Shares">24422240</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RoyaltyRevenue id="Tag33" decimals="0" contextRef="D2011Q3" unitRef="USD">82784</us-gaap:RoyaltyRevenue>
  <us-gaap:Revenues id="Tag34" decimals="0" contextRef="D2011Q3" unitRef="USD">182784</us-gaap:Revenues>
  <us-gaap:RoyaltyRevenue id="Tag35" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">220787</us-gaap:RoyaltyRevenue>
  <us-gaap:Revenues id="Tag36" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">320787</us-gaap:Revenues>
  <us-gaap:Revenues id="Tag37" decimals="0" contextRef="D2012Q3" unitRef="USD">110383</us-gaap:Revenues>
  <us-gaap:Revenues id="Tag38" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">333163</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag39" decimals="0" contextRef="D2011Q3" unitRef="USD">11500053</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag40" decimals="0" contextRef="D2011Q3" unitRef="USD">1675268</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag41" decimals="0" contextRef="D2011Q3" unitRef="USD">35670</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:CostsAndExpenses id="Tag42" decimals="0" contextRef="D2011Q3" unitRef="USD">13210991</us-gaap:CostsAndExpenses>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag43" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">37480873</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag44" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">5257853</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag45" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">118132</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Tag46" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-367274</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:CostsAndExpenses id="Tag47" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">42856858</us-gaap:CostsAndExpenses>
  <us-gaap:InterestExpense id="Tag48" decimals="0" contextRef="D2011Q3" unitRef="USD">172000</us-gaap:InterestExpense>
  <us-gaap:OtherNonoperatingIncome id="Tag49" decimals="0" contextRef="D2011Q3" unitRef="USD">2000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:InterestExpense id="Tag50" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">516000</us-gaap:InterestExpense>
  <us-gaap:OtherNonoperatingIncome id="Tag51" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">15000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag52" decimals="0" contextRef="D2011Q3" unitRef="USD">-12733691</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag53" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-44959599</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag54" decimals="2" contextRef="D2011Q3" unitRef="USDPerShare">-0.73</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag55" decimals="2" contextRef="D2011Q3YTD" unitRef="USDPerShare">-2.86</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag56" decimals="0" contextRef="D2011Q3" unitRef="Shares">17406536</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Tag57" decimals="0" contextRef="D2011Q3" unitRef="Shares">17406536</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag58" decimals="0" contextRef="D2011Q3YTD" unitRef="Shares">15744738</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Tag59" decimals="0" contextRef="D2011Q3YTD" unitRef="Shares">15744738</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ShareBasedCompensation id="Tag60" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">886564</us-gaap:ShareBasedCompensation>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="Tag61" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">180759</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag62" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-1539903</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag63" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">2993059</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag64" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-36944908</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag65" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">645603</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag66" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-645603</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag67" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-536697</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromStockOptionsExercised id="Tag68" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">32442</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag69" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">23876370</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag70" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">69035459</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:InterestPaid id="Tag71" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">344000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid id="Tag72" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">184094</us-gaap:InterestPaid>
  <us-gaap:ProceedsFromWarrantExercises id="Tag73" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">24063</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag74" decimals="0" contextRef="I2012Q3" unitRef="USD">38049095</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag75" decimals="0" contextRef="I2010" unitRef="USD">38155251</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag76" decimals="0" contextRef="I2011Q3" unitRef="USD">69600199</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag77" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">3479208</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NatureOfOperations id="Tag78" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;1.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;DESCRIPTION OF BUSINESS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;BioSante Pharmaceuticals,&amp;#160;Inc.&amp;#8217;s (the Company) corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and the Company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company&amp;#8217;s products, either approved or in clinical development, include: (1)&amp;#160;LibiGel, once daily transdermal testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD); (2)&amp;#160;a once daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of hypogonadism, or testosterone deficiency in men, and licensed to Teva Pharmaceuticals USA,&amp;#160;Inc. (Teva); (3)&amp;#160;GVAX cancer vaccines, a portfolio of cancer vaccines, four of which have been granted FDA orphan drug designation, and which are currently in 17 Phase I and Phase II clinical trials for the treatment of various cancers; (4)&amp;#160;The Pill-Plus (triple component contraceptive), once daily use of various combinations of estrogens, progestogens and androgens in Phase II development; and (5)&amp;#160;Elestrin, once daily transdermal estradiol (estrogen) gel approved by the FDA indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S. by Meda Pharmaceuticals Inc. (Meda), the Company&amp;#8217;s licensee.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:NatureOfOperations>
  <us-gaap:BasisOfAccounting id="Tag79" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;BASIS OF PRESENTATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In the opinion of management, the accompanying unaudited condensed financial statements contain all necessary adjustments, which are of a normal recurring nature, to present fairly the financial position of the Company as of September&amp;#160;30, 2012 and December&amp;#160;31, 2011, the results of operations for the three and nine months ended September&amp;#160;30, 2012 and 2011, and the cash flows for the nine months ended September&amp;#160;30, 2012 and 2011, in conformity with accounting principles generally accepted in the United States of America (GAAP).&amp;#160; Operating results for the three and nine month periods ended September&amp;#160;30, 2012 are not necessarily indicative of the results that may be expected for the full year ending December&amp;#160;31, 2012.&amp;#160; The Company does not have items of other comprehensive income for either of the three or nine month periods ended September&amp;#160;30, 2012 or 2011; and therefore, has not presented comprehensive income.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;These unaudited interim condensed financial statements should be read in conjunction with the financial statements and related notes contained in the Company&amp;#8217;s Annual Report on Form&amp;#160;10-K for the year ended December&amp;#160;31, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On June&amp;#160;1, 2012, the Company effected a one-for-six reverse split of its outstanding common stock and class C special stock.&amp;#160; These unaudited interim condensed financial statements give retroactive effect to the reverse stock split.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:BasisOfAccounting>
  <bpax:LiquidityAndCapitalResourcesTextBlock id="Tag80" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;3.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;LIQUIDITY AND CAPITAL RESOURCES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Substantially all of the Company&amp;#8217;s revenue to date has been derived from upfront, milestone and royalty payments earned on licensing transactions and from subcontracts.&amp;#160; The Company&amp;#8217;s business operations to date have consisted mostly of licensing and research and development activities.&amp;#160; The Company itself has not introduced commercially any products.&amp;#160; To date, the Company has used primarily equity financings, and to a lesser extent, licensing income, interest income and the cash received from its 2009 merger with Cell Genesys,&amp;#160;Inc. (Cell Genesys), to fund its ongoing business operations and short-term liquidity needs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;As of September&amp;#160;30, 2012, the Company had $38,049,095 of cash and cash equivalents.&amp;#160; As of September&amp;#160;30, 2012, the Company had outstanding $8,277,850 in aggregate principal amount of its 3.125% convertible senior notes due May&amp;#160;1, 2013.&amp;#160; In August&amp;#160;2012, the Company completed an offering of an aggregate of 2,359,932 shares of the Company&amp;#8217;s common stock and warrants to purchase an aggregate of 1,179,966 shares of the Company&amp;#8217;s common stock, resulting in net proceeds of $3,268,798, after deducting placement agent fees and other offering expenses. See Note 7, &amp;#8220;Stockholders&amp;#8217; Equity,&amp;#8221; for additional discussion regarding the August&amp;#160;2012 registered direct offering.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Absent the receipt of any additional licensing income or financing, the Company expects its cash and cash equivalents balance to decrease as the Company continues to use cash to fund its operations.&amp;#160; Assuming the Company&amp;#8217;s pending merger with ANIP Acquisition Company d/b/a ANI Pharmaceuticals,&amp;#160;Inc. (ANI) is completed during the first quarter of 2013 (see Note 10, &amp;#8220;Subsequent Events&amp;#8221;), the Company expects its cash and cash equivalents as of September&amp;#160;30, 2012 to meet the Company&amp;#8217;s liquidity requirements through at least the Company&amp;#8217;s anticipated closing of the merger, including the requirement under our merger agreement to have at least $17 million of net cash (as defined in the merger agreement) available upon the closing of the merger.&amp;#160;&amp;#160; If the Company&amp;#8217;s pending merger with ANI is not completed, the Company will need to reevaluate its strategic alternatives, which may include a sale of the company, liquidation of the company or other strategic transaction.&amp;#160; The Company&amp;#8217;s liquidity position will be dependent upon the strategic alternative selected; however, assuming the Company does not enter into another strategic transaction, and assuming the Company decides not to commence the two new efficacy trials for LibiGel, the Company expects its cash and cash equivalents as of September&amp;#160;30, 2012 will be sufficient to meet the Company&amp;#8217;s liquidity requirements for at least the next 3-5 years.&amp;#160; Additional financing would be required should the Company decide to commence the two new efficacy trials for LibiGel.&amp;#160; These estimates may prove incorrect or the Company, nonetheless, may choose to raise additional financing earlier.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company does not have any existing credit facilities under which the Company could borrow funds.&amp;#160; In the event that the Company would require additional working capital to fund future operations, the Company could seek to acquire such funds through additional equity or debt financing arrangements. If the Company raises additional funds by issuing equity securities, the Company&amp;#8217;s stockholders may experience dilution.&amp;#160; Debt financing, if available, may involve covenants restricting the Company&amp;#8217;s operations or the Company&amp;#8217;s ability to incur additional debt.&amp;#160; There is no assurance that any financing transaction will be available on terms acceptable to the Company, or at all.&amp;#160; As an alternative to raising additional financing, the Company may choose to attempt to license one or more of its products or technologies to a third party who may finance a portion or all of the continued development and, if approved, commercialization of that licensed product, sell certain assets or rights under the Company&amp;#8217;s existing license agreements.&amp;#160; In addition, from time to time, the Company may purchase, exchange or restructure its outstanding convertible senior notes through cash purchases and/or exchanges for other equity securities of the Company, in open market purchases, privately negotiated transactions and/or a tender offer.&amp;#160; Such purchases, exchanges or restructurings, if any, will depend on prevailing market conditions, the Company&amp;#8217;s available cash and cash equivalents, the Company&amp;#8217;s liquidity requirements, contractual restrictions and other factors.&amp;#160; Such purchases, exchanges or restructurings could dilute the percentage ownership of the Company&amp;#8217;s stockholders, result in the issuance of securities at a discount to market price or that may have rights, preferences or privileges senior to those of the Company&amp;#8217;s existing stockholders and/or decrease the Company&amp;#8217;s cash balance.&amp;#160; A significant decrease in the Company&amp;#8217;s cash balance, together with an inability to raise additional financing when needed, may impair the Company&amp;#8217;s ability to complete its proposed merger with ANI, execute other strategic alternatives or leave the Company without sufficient cash remaining for operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company can provide no assurance that additional financing, if needed, will be available on terms favorable to the Company, or at all.&amp;#160; This is particularly true if investors are not confident in the Company&amp;#8217;s business and future prospects, the future value of the Company and/or economic and market conditions deteriorate.&amp;#160; In addition, the Company&amp;#8217;s ability to raise additional financing is limited by the terms of its agreement and plan of merger with ANI.&amp;#160; See Note 10, &amp;#8220;Subsequent Events.&amp;#8221;&amp;#160; If adequate funds are not available or are not available on acceptable terms when the Company needs them, the Company may need to reduce its operating costs or the Company may be forced to complete other strategic alternatives, such as winding down its operations and liquidating the Company.&amp;#160; In such case, the Company&amp;#8217;s stockholders could lose some or all of their investment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</bpax:LiquidityAndCapitalResourcesTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="Tag81" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;4.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;BASIC AND DILUTED NET LOSS PER SHARE&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The basic and diluted net loss per share is computed based on the weighted average number of shares of common stock and class C special stock outstanding, all being considered as equivalent of one another.&amp;#160; Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding for the reporting period.&amp;#160; Diluted net loss per share is intended to reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock.&amp;#160; Because the Company has incurred net losses from operations in each of the periods presented, the Company&amp;#8217;s outstanding options, warrants and convertible debt are antidilutive; accordingly, such securities are excluded from the computation of diluted net loss per share and there is no difference between basic and diluted net loss per share amounts.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="Tag82" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;5.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;CONVERTIBLE SENIOR NOTES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has outstanding 3.125% convertible senior notes due May&amp;#160;1, 2013 (the 2013 Notes).&amp;#160; The aggregate principal amount of the 2013 Notes outstanding at September&amp;#160;30, 2012 and December&amp;#160;31, 2011 was $8,277,850 and $20,782,000, respectively.&amp;#160; In February&amp;#160;2012, the Company issued 1,868,055 shares of its common stock to one of the holders of the 2013 Notes in exchange for the cancellation of $9,000,000 in aggregate principal amount of such notes and the related accrued and unpaid interest of $79,024.&amp;#160; In July&amp;#160;2012, the Company issued an aggregate of 1,784,070 shares of its common stock to two of the holders of the 2013 Notes in exchange for the cancellation of $3,504,150 in aggregate principal amount of such notes and accrued and unpaid interest of $20,686. Non-cash fair value adjustments of $(2,545,530) and $(611,621) were recorded during the first and third quarters of 2012 as a result of the cancellation of such notes. The fair value adjustment recorded upon the cancellation of the 2013 Notes is primarily attributable to the time value effect of settling these obligations at a date prior to the stated maturity of the 2013 Notes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The remaining $8,277,850 aggregate principal amount of the 2013 Notes are exchangeable at the option of the holder or upon certain specified events into an aggregate of approximately 370,871 shares of the Company&amp;#8217;s common stock at a conversion price of $22.32 per share.&amp;#160; The 2013 Notes are general, unsecured obligations of the Company and are described in Note 7 to the Company&amp;#8217;s financial statements for the year ended December&amp;#160;31, 2011.&amp;#160; As of September&amp;#160;30, 2012, the 2013 Notes were not eligible for redemption. The indenture governing the 2013 Notes, as supplemented by the supplemental indenture, does not contain any financial covenants and does not restrict the Company from paying dividends, incurring additional debt or issuing or repurchasing the Company&amp;#8217;s other securities.&amp;#160; In addition, the indenture, as supplemented by the supplemental indenture, does not protect the holders of the 2013 Notes in the event of a highly leveraged transaction or a fundamental change of the Company except in certain circumstances specified in the indenture.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.1pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;As described in Note 3, &amp;#8220;Liquidity and Capital Resources,&amp;#8221; from time to time, the Company may purchase, exchange or restructure its outstanding 2013 Notes through cash purchases and/or exchanges for other equity securities of the Company, in open market purchases, privately negotiated transactions and/or a tender offer.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.1pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.1pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has elected to record the 2013 Notes at fair value in order to simplify the accounting for the convertible debt, inclusive of the redemption, repurchase and conversion adjustment features which otherwise would require specialized valuation, bifurcation and recognition.&amp;#160; Accordingly, the Company has adjusted the carrying value of the 2013 Notes to their fair value as of September&amp;#160;30, 2012, with changes in the fair value of the 2013 Notes occurring since December&amp;#160;31, 2011, reflected in fair value adjustment in the unaudited condensed statements of operations.&amp;#160; As described in Note 9, &amp;#8220;Fair Value Measurements,&amp;#8221; the fair value of the 2013 Notes is based on Level 2 inputs.&amp;#160; The recorded fair value of the 2013 Notes of an aggregate of $7,593,216 as of September&amp;#160;30, 2012 differs from their total stated aggregate principal amount of $8,277,850 as of such date by $684,634.&amp;#160; The recorded fair value of the 2013 Notes of an aggregate of $17,336,760 as of December&amp;#160;31, 2011 differed from their total stated aggregate principal amount of $20,782,000 as of such date by $3,445,240.&amp;#160; During the three and nine months ended September&amp;#160;30, 2012, the Company recorded a fair value adjustment of $(843,412) and $(4,037,797) related to the 2013 Notes that were converted to common stock during 2012 or that remained outstanding as of September&amp;#160;30, 2012, that for the three months and nine months ended September&amp;#160;30, 2012 increased the recorded liability and corresponding expense.&amp;#160; For the three and nine months ended September&amp;#160;30, 2011, the Company recorded a fair value adjustment of $463,000 and $(1,929,000) that decreased and increased the recorded liability and corresponding expense, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.1pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;For the nine months ended September&amp;#160;30, 2012 and 2011, approximately $(41,000) and $230,000, respectively, of the fair value adjustment was attributable to the change in instrument specific credit risk.&amp;#160; The change in the aggregate fair value of the 2013 Notes due to instrument specific credit risk for the nine months ended September&amp;#160;30, 2012 was estimated by calculating the difference between the September&amp;#160;30, 2012 fair value of the 2013 Notes as recorded and what the fair value of the 2013 Notes would have been on September&amp;#160;30, 2012 if the December&amp;#160;31, 2011 discount rate continued to be used in the calculation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The instrument specific credit risk for both periods has increased the fair value of the 2013 Notes as market borrowing rates have decreased for similarly rated companies and are estimated to have decreased for the Company as well, indicating a lower credit spread assuming no significant changes in the risk-free borrowing rate.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company establishes the value of the 2013 Notes based upon contractual terms of the 2013 Notes, as well as certain key assumptions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The assumptions as of September&amp;#160;30, 2012 were:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="60%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Average risk-free rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.14&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Volatility of BioSante common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;90.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Discount rate for principal payments in cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;19.6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The assumptions as of December&amp;#160;31, 2011 were:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="60%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="bottom" width="74%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Average&amp;#160;risk-free&amp;#160;rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.19&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Volatility of BioSante common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;77.4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Discount rate for principal payments in cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;18.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 34.55pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The discount rate is based on observed yields as of the measurement date for debt securities of entities having a Ca and Caa3 rating for long-term corporate obligations as assigned by Moody&amp;#8217;s Investors Service.&amp;#160; Volatility is based on the historical fluctuations in the Company&amp;#8217;s stock price for a period of time equal to the remaining time until the debt maturity.&amp;#160; The risk-free rate is based on observed yields as of the measurement date of six month and one-year U.S. Treasury Bonds.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 34.55pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Tag83" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;6.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company typically grants options to purchase shares of the Company&amp;#8217;s common stock to existing employees and non-employee directors on an annual basis during the first quarter of each year and to new employees and non-employee directors throughout the year on or around the date their employment or service with the Company commences.&amp;#160; All options are granted under the BioSante Pharmaceuticals,&amp;#160;Inc. Amended and Restated 2008 Stock Incentive Plan (the 2008 Plan).&amp;#160; As of September&amp;#160;30, 2012, approximately 981,272 shares of the Company&amp;#8217;s common stock remain available for issuance under the 2008 Plan.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;During the nine months ended September&amp;#160;30, 2012, the Company granted options under the 2008 Plan to purchase an aggregate of 358,582 shares of the Company&amp;#8217;s common stock to certain employees of the Company and the Company&amp;#8217;s non-employee directors with a weighted average exercise price of $4.08 per share.&amp;#160; Options to purchase an aggregate of 105,781 shares of the Company&amp;#8217;s common stock expired and were cancelled during the nine months ended September&amp;#160;30, 2012.&amp;#160; Options are granted at an exercise price equal to the closing price of the Company&amp;#8217;s common stock on the date of the grant.&amp;#160; No options were exercised during the nine months ended September&amp;#160;30, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;No warrants were granted during the nine months ended September&amp;#160;30, 2012, other than the warrants issued in conjunction with the Company&amp;#8217;s August&amp;#160;2012 offering described in Note 7, &amp;#8220;Stockholders&amp;#8217; Equity&amp;#8221;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Tag84" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;STOCKHOLDERS&amp;#8217; EQUITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;During the nine months ended September&amp;#160;30, 2012, the Company issued an aggregate of 3,652,125 shares of its common stock to holders of the 2013 Notes in exchange for the cancellation of $12,504,150 in aggregate principal amount of such notes and accrued and unpaid interest of $99,710. See Note 5, &amp;#8220;Convertible Senior Notes&amp;#8221; for information regarding the 2013 Notes.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 36.7pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In August&amp;#160;2012, the Company completed an offering of 2,359,932 shares of its common stock and warrants to purchase an aggregate of 1,179,966 shares of its common stock at a purchase price of $1.4725 per share to one institutional investor for gross proceeds of $3,475,000.&amp;#160; The offering resulted in net proceeds to the Company of $3,268,798, after deducting placement agent fees and offering expenses. The warrants are exercisable immediately and continue for a period of 5 years, at an exercise price of $1.50 per share.&amp;#160; The number of shares issuable upon exercise of the warrants and the exercise price of the warrants are adjustable in the event of stock splits, combinations and reclassifications, but not in the event of the issuance of additional securities.&amp;#160; On September&amp;#160;20, 2012, warrants from the August&amp;#160;2012 offering to purchase an aggregate of 140,712 shares of common stock were exercised resulting in proceeds of $211,068 to the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 36.7pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 36.7pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On May&amp;#160;30, 2012, the Company&amp;#8217;s stockholders approved an amendment to the Company&amp;#8217;s Restated Certificate of Incorporation to effect a reverse split of the Company&amp;#8217;s outstanding shares of common stock and class C special stock in the discretion of the Company&amp;#8217;s Board of Directors at an exchange ratio of not less than one-for-two and not more than one-for-ten.&amp;#160; On June&amp;#160;1, 2012, the Board of Directors of the Company effected a one-for-six reverse split of the Company&amp;#8217;s outstanding shares of common stock and class C special stock.&amp;#160; No fractional shares were issued as a result of the reverse stock split, and stockholders who otherwise would have been entitled to a fractional share received, in lieu thereof, a cash payment based on the closing sale price of BioSante&amp;#8217;s common stock on June 1, 2012.&amp;#160; The total cash payment for fractional shares was $658.&amp;#160; The reverse stock split did not change the number of authorized shares of the Company&amp;#8217;s common stock or class C special stock or the par value of the Company&amp;#8217;s common stock or class C special stock, but because the number of authorized shares of the Company&amp;#8217;s common stock and class C special stock was not affected, the effect of the reverse stock split was to increase the number of authorized but unissued shares of the Company&amp;#8217;s common stock and class C special stock.&amp;#160; The primary purpose of the reverse stock split was to increase the Company&amp;#8217;s ability to maintain the listing of its common stock on The NASDAQ Global Market.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="Tag85" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;9.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company accounts for its convertible debt and U.S. Treasury money market fund at fair value.&amp;#160; Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Level 1:&amp;#160; Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.&amp;#160; The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Level 2:&amp;#160; Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Level 3:&amp;#160; Unobservable inputs are used when little or no market data is available.&amp;#160; The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Financial assets and liabilities recorded at fair value on a recurring basis as of September&amp;#160;30, 2012 and December&amp;#160;31, 2011 are classified in the tables below in one of the three categories described above:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Description&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;September&amp;#160;30,&lt;br /&gt;
2012&amp;#160;Balance&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;br /&gt;
Active&amp;#160;Markets&lt;br /&gt;
for&amp;#160;Identical&lt;br /&gt;
Assets&amp;#160;(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;br /&gt;
Other&lt;br /&gt;
Observable&lt;br /&gt;
Inputs&amp;#160;(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs&amp;#160;(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Money market fund&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;36,957,469&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;36,957,469&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;36,957,469&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;36,957,469&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2013 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,593,216&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,593,216&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,593,216&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,593,216&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Description&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;December&amp;#160;31,&lt;br /&gt;
2011&amp;#160;Balance&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;br /&gt;
Active&amp;#160;Markets&lt;br /&gt;
for&amp;#160;Identical&lt;br /&gt;
Assets&amp;#160;(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;br /&gt;
&amp;#160;Other&lt;br /&gt;
&amp;#160;Observable&lt;br /&gt;
&amp;#160;Inputs&amp;#160;(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs&amp;#160;(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Money market fund&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;55,465,507&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;55,465,507&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;55,465,507&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;55,465,507&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2013 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,336,760&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,336,760&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,336,760&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,336,760&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company made an election to record the values of the 2013 Notes at fair value with gains and losses related to fluctuations in the value of these financial liabilities recorded in earnings immediately.&amp;#160; The fair values of the 2013 Notes are estimated based on the risk-free borrowing rate, the volatility of the Company&amp;#8217;s stock, and the current borrowing rates for similar companies. &amp;#160;See Note 6, &amp;#8220;Convertible Senior Notes&amp;#8221; for more information and disclosures regarding key assumptions used in this fair value determination.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:FairValueDisclosuresTextBlock>
  <dei:EntityRegistrantName id="Tag86" contextRef="D2012Q3YTD">BIOSANTE PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="Tag87" contextRef="D2012Q3YTD">0001023024</dei:EntityCentralIndexKey>
  <dei:DocumentType id="Tag88" contextRef="D2012Q3YTD">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="Tag89" contextRef="D2012Q3YTD">2012-09-30</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag id="Tag90" contextRef="D2012Q3YTD">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag91" contextRef="D2012Q3YTD">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus id="Tag92" contextRef="D2012Q3YTD">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="Tag93" contextRef="D2012Q3YTD">Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus id="Tag94" contextRef="D2012Q3YTD">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="Tag95" contextRef="D2012Q3YTD">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:EntityCommonStockSharesOutstanding id="Tag96" decimals="INF" contextRef="I2012Q3SO_CommonStockMember" unitRef="Shares">24422240</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:LiabilitiesCurrent id="Tag97" decimals="0" contextRef="I2012Q3" unitRef="USD">10922066</us-gaap:LiabilitiesCurrent>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 id="Tag98" decimals="0" contextRef="D2011Q3" unitRef="USD">463000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 id="Tag99" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-1929000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:CostsAndExpenses id="Tag100" decimals="0" contextRef="D2012Q3" unitRef="USD">5445349</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="Tag101" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">19869517</us-gaap:CostsAndExpenses>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag102" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">31444948</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <bpax:NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation id="Tag103" decimals="INF" contextRef="D2012Q3YTD" unitRef="Vaccine">4</bpax:NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="Tag104" decimals="INF" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="Shares">3652125</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="Tag105" decimals="INF" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="Pure">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <bpax:ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering id="Tag106" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">45102584</bpax:ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering>
  <bpax:ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock id="Tag107" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The assumptions as of September&amp;#160;30, 2012 were:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="60%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Average risk-free rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.14&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Volatility of BioSante common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;90.0&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Discount rate for principal payments in cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;19.6&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The assumptions as of December&amp;#160;31, 2011 were:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="60%" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="bottom" width="74%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Average&amp;#160;risk-free&amp;#160;rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;0.19&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Volatility of BioSante common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;77.4&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Discount rate for principal payments in cash&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;18.5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</bpax:ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 id="Tag108" decimals="2" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="USDPerShare">22.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:LongTermDebtFairValue id="Tag109" decimals="0" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="USD">7593216</us-gaap:LongTermDebtFairValue>
  <us-gaap:DebtInstrumentFaceAmount id="Tag110" decimals="0" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="USD">8277850</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments id="Tag111" decimals="0" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="USD">684634</us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments>
  <us-gaap:LongTermDebtFairValue id="Tag112" decimals="0" contextRef="I2011_ConvertibleNotesPayableMember" unitRef="USD">17336760</us-gaap:LongTermDebtFairValue>
  <us-gaap:DebtInstrumentFaceAmount id="Tag113" decimals="0" contextRef="I2011_ConvertibleNotesPayableMember" unitRef="USD">20782000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments id="Tag114" decimals="0" contextRef="I2011_ConvertibleNotesPayableMember" unitRef="USD">3445240</us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="Tag115" decimals="4" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="Pure">0.0014</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="Tag116" decimals="3" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="Pure">0.900</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <bpax:FairValueAssumptionsDiscountRate id="Tag117" decimals="3" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="Pure">0.196</bpax:FairValueAssumptionsDiscountRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate id="Tag118" decimals="4" contextRef="D2011_ConvertibleNotesPayableMember" unitRef="Pure">0.0019</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="Tag119" decimals="3" contextRef="D2011_ConvertibleNotesPayableMember" unitRef="Pure">0.774</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <bpax:FairValueAssumptionsDiscountRate id="Tag120" decimals="3" contextRef="D2011_ConvertibleNotesPayableMember" unitRef="Pure">0.185</bpax:FairValueAssumptionsDiscountRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Tag121" decimals="0" contextRef="I2012Q3" unitRef="Shares">981272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Tag122" decimals="INF" contextRef="D2012Q3YTD_StockOptionsMember_SB" unitRef="Shares">358582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Tag123" decimals="2" contextRef="D2012Q3YTD_StockOptionsMember_SB" unitRef="USDPerShare">4.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="Tag124" decimals="INF" contextRef="D2012Q3YTD_StockOptionsMember_SB" unitRef="Shares">105781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="Tag125" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 788px; BORDER-COLLAPSE: collapse; HEIGHT: 149px" cellspacing="0" cellpadding="0" width="788" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Description&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;September&amp;#160;30,&lt;br /&gt;
2012&amp;#160;Balance&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;br /&gt;
Active&amp;#160;Markets&lt;br /&gt;
for&amp;#160;Identical&lt;br /&gt;
Assets&amp;#160;(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;br /&gt;
Other&lt;br /&gt;
Observable&lt;br /&gt;
Inputs&amp;#160;(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs&amp;#160;(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Money market fund&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;36,957,469&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;36,957,469&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;36,957,469&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;36,957,469&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2013 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,593,216&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,593,216&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,593,216&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;7,593,216&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-LEFT: 0.5in; WIDTH: 783px; BORDER-COLLAPSE: collapse; HEIGHT: 149px" cellspacing="0" cellpadding="0" width="783" border="0"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Description&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;December&amp;#160;31,&lt;br /&gt;
2011&amp;#160;Balance&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;br /&gt;
Active&amp;#160;Markets&lt;br /&gt;
for&amp;#160;Identical&lt;br /&gt;
Assets&amp;#160;(Level&amp;#160;1)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;br /&gt;
&amp;#160;Other&lt;br /&gt;
&amp;#160;Observable&lt;br /&gt;
&amp;#160;Inputs&amp;#160;(Level&amp;#160;2)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1"&gt;Significant&lt;br /&gt;
Unobservable&lt;br /&gt;
Inputs&amp;#160;(Level&amp;#160;3)&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Money market fund&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;55,465,507&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;55,465,507&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;55,465,507&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;55,465,507&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;2013 Notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,336,760&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,336,760&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,336,760&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;17,336,760&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:AssetsFairValueDisclosure id="Tag126" decimals="0" contextRef="I2012Q3_MoneyMarketFundsMember_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">36957469</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag127" decimals="0" contextRef="I2012Q3_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">36957469</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag128" decimals="0" contextRef="I2012Q3_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">36957469</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag129" decimals="0" contextRef="I2012Q3_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">36957469</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ConvertibleDebtFairValueDisclosures id="Tag130" decimals="0" contextRef="I2012Q3_EstimateOfFairValueFairValueDisclosureMember_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember" unitRef="USD">7593216</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtFairValueDisclosures id="Tag131" decimals="0" contextRef="I2012Q3_FairValueInputsLevel2Member_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember" unitRef="USD">7593216</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:LiabilitiesFairValueDisclosure id="Tag132" decimals="0" contextRef="I2012Q3_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">7593216</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="Tag133" decimals="0" contextRef="I2012Q3_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">7593216</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag134" decimals="0" contextRef="I2011_MoneyMarketFundsMember_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">55465507</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag135" decimals="0" contextRef="I2011_MoneyMarketFundsMember_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">55465507</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag136" decimals="0" contextRef="I2011_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">55465507</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="Tag137" decimals="0" contextRef="I2011_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">55465507</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ConvertibleDebtFairValueDisclosures id="Tag138" decimals="0" contextRef="I2011_EstimateOfFairValueFairValueDisclosureMember_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember" unitRef="USD">17336760</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtFairValueDisclosures id="Tag139" decimals="0" contextRef="I2011_FairValueInputsLevel2Member_ConvertibleNotesPayableMember_FairValueMeasurementsRecurringMember" unitRef="USD">17336760</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:LiabilitiesFairValueDisclosure id="Tag140" decimals="0" contextRef="I2011_EstimateOfFairValueFairValueDisclosureMember_FairValueMeasurementsRecurringMember" unitRef="USD">17336760</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="Tag141" decimals="0" contextRef="I2011_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD">17336760</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments id="Tag142" decimals="INF" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="Shares">370871</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:InvestmentIncomeInterest id="Tag143" decimals="0" contextRef="D2011Q3" unitRef="USD">1516</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="Tag144" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">6472</us-gaap:InvestmentIncomeInterest>
  <us-gaap:StockIssued1 id="Tag145" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">13881052</us-gaap:StockIssued1>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="Tag146" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">59016</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CommitmentsDisclosureTextBlock id="Tag147" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;8.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Aptar Pharma &amp;#8212; Gel Packaging Machine&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has a commitment with Aptar Pharma to purchase a gel packaging machine for $844,740. As of September&amp;#160;30, 2012, the Company had paid Aptar $804,132.&amp;#160; The remaining obligation of $40,608 is due upon the shipment, assembly and calibration of the machine at a location designated by the Company.&amp;#160; In light of the Company&amp;#8217;s pending merger with ANI (see Note 10, &amp;#8220;Subsequent Events&amp;#8221;), the Company is evaluating the future plans for this gel packaging machine.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Pending Litigation&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On February&amp;#160;3, 2012, a purported class action lawsuit was filed in the United States District Court for the Northern District of Illinois under the caption &lt;i&gt;Thomas Lauria, on behalf of himself and all others similarly situated v. BioSante Pharmaceuticals,&amp;#160;Inc. and Stephen M. Simes&lt;/i&gt; naming the Company and the Company&amp;#8217;s President and Chief Executive Officer, Stephen M. Simes, as defendants.&amp;#160; The complaint alleges that certain of the Company&amp;#8217;s disclosures relating to the efficacy of LibiGel and its commercial potential were false and/or misleading and that such false and/or misleading statements had the effect of artificially inflating the price of the Company&amp;#8217;s securities resulting in violations of Section&amp;#160;10(b)&amp;#160;of the Securities Exchange Act of 1934, as amended (Exchange Act), Rule&amp;#160;10b-5 and Section&amp;#160;20(a)&amp;#160;of the Exchange Act.&amp;#160; Although a substantially similar complaint was filed in the same court on February&amp;#160;21, 2012, such complaint was voluntarily dismissed by the plaintiff in April&amp;#160;2012.&amp;#160; The plaintiff seeks to represent a class of persons who purchased the Company&amp;#8217;s securities between February&amp;#160;10, 2010 and December&amp;#160;15, 2011, and seeks unspecified compensatory damages, equitable and/or injunctive relief, and reasonable costs, expert fees and attorneys&amp;#8217; fees on behalf of such purchasers.&amp;#160; The Company believes the action is without merit and intends to defend the action vigorously.&amp;#160; On October&amp;#160;10, 2012, the District Court entered an order setting the dates on which the plaintiff&amp;#8217;s consolidated amended complaint is due and establishing a briefing schedule on the defendants&amp;#8217; anticipated motion to dismiss.&amp;#160; On November&amp;#160;6, 2012, plaintiff filed a consolidated amended complaint; the Company and Mr. Simes intend to file motions to dismiss the consolidated amended complaint on or before December&amp;#160;21, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On May&amp;#160;7, 2012, Jerome W. Weinstein, a purported stockholder of the Company filed a shareholder derivative action in the United States District Court for the Northern District of Illinois under the caption &lt;i&gt;Weinstein v. BioSante Pharmaceuticals,&amp;#160;Inc. et al.&lt;/i&gt;, naming the Company&amp;#8217;s directors as defendants and the Company as a nominal defendant.&amp;#160; A substantially similar complaint was filed in the same court on May&amp;#160;22, 2012 and another substantially similar complaint was filed in the Circuit Court for Cook County, Illinois, County Department, Chancery Division, on June&amp;#160;27, 2012.&amp;#160; The suits generally related to the same events that are the subject of the class action litigation described above.&amp;#160; The complaints allege breaches of fiduciary duty, abuse of control, gross mismanagement and unjust enrichment as causes of action occurring from at least February&amp;#160;2010 through December&amp;#160;2011.&amp;#160; The complaints seek unspecified damages, punitive damages, costs and disbursements and unspecified reform and improvements in the Company&amp;#8217;s corporate governance and internal control procedures.&amp;#160; On September&amp;#160;24, 2012, the District Court consolidated the two cases before it and entered a stipulation and order setting the dates on which the plaintiff&amp;#8217;s consolidated amended complaint is due and establishing a briefing schedule on defendants&amp;#8217; anticipated motions to dismiss. The Company expects a similar scheduling order to be entered in the action pending in Illinois state court.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The lawsuits are in their early stages; and, therefore, the Company is unable to predict the outcome of the lawsuits and the possible loss or range of loss, if any, associated with their resolution or any potential effect the lawsuits may have on the Company&amp;#8217;s operations.&amp;#160; Depending on the outcome or resolution of these lawsuits, they could have a material effect on the Company&amp;#8217;s operations, including its financial condition, results of operations, or cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company is not involved in any other legal actions, however, from time to time may be subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business.&amp;#160; Such matters are subject to many uncertainties and to outcomes that are not predictable with reasonable assurance and that may not be known for extended periods of time.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag148" decimals="0" contextRef="D2012Q3" unitRef="Shares">22921176</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Tag149" decimals="0" contextRef="D2012Q3" unitRef="Shares">22921176</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag150" decimals="0" contextRef="D2012Q3YTD" unitRef="Shares">20841417</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Tag151" decimals="0" contextRef="D2012Q3YTD" unitRef="Shares">20841417</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 id="Tag152" decimals="0" contextRef="D2012Q3" unitRef="USD">-843412</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:FairValueOptionChangesInFairValueGainLoss1 id="Tag153" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-4037797</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag154" decimals="2" contextRef="D2012Q3" unitRef="USDPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag155" decimals="2" contextRef="D2012Q3YTD" unitRef="USDPerShare">-1.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag156" decimals="0" contextRef="I2012Q3" unitRef="USD">1184764</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets id="Tag157" decimals="0" contextRef="I2012Q3" unitRef="USD">43211746</us-gaap:Assets>
  <us-gaap:SeniorNotesCurrent id="Tag158" decimals="0" contextRef="I2012Q3" unitRef="USD">7593216</us-gaap:SeniorNotesCurrent>
  <us-gaap:Liabilities id="Tag159" decimals="0" contextRef="I2012Q3" unitRef="USD">10922066</us-gaap:Liabilities>
  <us-gaap:CommonStockValueOutstanding id="Tag160" decimals="0" contextRef="I2012Q3" unitRef="USD">273259236</us-gaap:CommonStockValueOutstanding>
  <us-gaap:PaymentsToAcquireInvestments id="Tag161" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">7955</us-gaap:PaymentsToAcquireInvestments>
  <bpax:PaymentsToFractionalSharePayout id="Tag162" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">658</bpax:PaymentsToFractionalSharePayout>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag163" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-19176139</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="Tag164" decimals="INF" contextRef="D2012Q1_M02_ConvertibleNotesPayableMember" unitRef="Shares">1868055</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <bpax:StockholdersEquityReverseStockSplitConversionRatio id="Tag165" decimals="4" contextRef="D2012Q2_M06" unitRef="Pure">0.1667</bpax:StockholdersEquityReverseStockSplitConversionRatio>
  <us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities id="Tag166" decimals="0" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="USD">-41000</us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities>
  <us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities id="Tag167" decimals="0" contextRef="D2011Q3YTD_ConvertibleNotesPayableMember" unitRef="USD">230000</us-gaap:FairValueOptionCreditRiskGainsLossesOnLiabilities>
  <bpax:StockholdersEquityReverseStockSplitConversionRatio id="Tag168" decimals="1" contextRef="D2012Q2_M05_MinimumMember" unitRef="Pure">0.5</bpax:StockholdersEquityReverseStockSplitConversionRatio>
  <bpax:StockholdersEquityReverseStockSplitConversionRatio id="Tag169" decimals="1" contextRef="D2012Q2_M05_MaximumMember" unitRef="Pure">0.1</bpax:StockholdersEquityReverseStockSplitConversionRatio>
  <us-gaap:LongTermPurchaseCommitmentAmount id="Tag170" decimals="0" contextRef="D2012Q3YTD_CapitalAdditionsMember_AptarPharmaMember" unitRef="USD">844740</us-gaap:LongTermPurchaseCommitmentAmount>
  <bpax:PurchaseCommitmentCumulativePaymentsToAcquireMachinery id="Tag171" decimals="0" contextRef="I2012Q3_CapitalAdditionsMember_AptarPharmaMember" unitRef="USD">804132</bpax:PurchaseCommitmentCumulativePaymentsToAcquireMachinery>
  <us-gaap:PurchaseObligation id="Tag172" decimals="0" contextRef="I2012Q3_CapitalAdditionsMember_AptarPharmaMember" unitRef="USD">40608</us-gaap:PurchaseObligation>
  <bpax:UnpaidCostsAssociatedWithUnderWrittenPublicOffering id="Tag173" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">141447</bpax:UnpaidCostsAssociatedWithUnderWrittenPublicOffering>
  <bpax:NumberOfDebtInstrumentHoldersToWhomSharesAreIssued id="Tag174" decimals="INF" contextRef="D2012Q1_M02_ConvertibleNotesPayableMember" unitRef="Holder">1</bpax:NumberOfDebtInstrumentHoldersToWhomSharesAreIssued>
  <bpax:NumberOfPhaseIAndPhaseIIClinicalTrials id="Tag175" decimals="INF" contextRef="D2012Q3YTD" unitRef="Item">17</bpax:NumberOfPhaseIAndPhaseIIClinicalTrials>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="Tag176" decimals="0" contextRef="D2012Q1_M02_ConvertibleNotesPayableMember" unitRef="USD">9000000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="Tag177" decimals="0" contextRef="D2012Q3YTD_ConvertibleNotesPayableMember" unitRef="USD">12504150</us-gaap:DebtConversionOriginalDebtAmount1>
  <bpax:FairValueOptionChangesInFairValueNonCashAdjustment id="Tag178" decimals="0" contextRef="D2012Q3_ConvertibleNotesPayableMember" unitRef="USD">-611621</bpax:FairValueOptionChangesInFairValueNonCashAdjustment>
  <us-gaap:SubsequentEventsTextBlock id="Tag179" contextRef="D2012Q3YTD">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;10.&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2"&gt;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Agreement and Plan of Merger&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;On October&amp;#160;3, 2012, the Company entered into an agreement and plan of merger (the Merger Agreement) with ANIP Acquisition Company d/b/a ANI Pharmaceuticals,&amp;#160;Inc.&amp;#160; The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, ANI will merge with and into the Company, with the Company continuing as the surviving company (the Merger).&amp;#160; At the effective time of the Merger, each outstanding share of capital stock of ANI will be converted into the right to receive a number of shares of the Company&amp;#8217;s common stock, if any, as determined pursuant to the exchange ratios described in the Merger Agreement and the provisions of ANI&amp;#8217;s certificate of incorporation.&amp;#160; All options, warrants or other rights to purchase shares of capital stock of ANI, will be canceled at the effective time of the Merger without any consideration in exchange, except for certain warrants which although not cancelled will not represent the right to acquire any equity or other interest in the combined company after the Merger.&amp;#160; No fractional shares of the Company&amp;#8217;s common stock will be issued in connection with the Merger, and holders of ANI capital stock will be entitled to receive cash in lieu thereof.&amp;#160; Following the consummation of the transactions contemplated by the Merger Agreement, the current stockholders of ANI are expected to own approximately 53 percent of the outstanding shares of common stock of the combined company, and current stockholders of the Company are expected to own approximately 47 percent of the outstanding shares of common stock of the combined company.&amp;#160; The exchange ratios are subject to potential adjustment as described in the Merger Agreement depending upon the amount of the Company&amp;#8217;s &amp;#8220;net cash&amp;#8221;, as defined in the Merger Agreement and generally consisting of the Company&amp;#8217;s cash and cash equivalents less certain expenses and liabilities, as of a determination date prior to the closing date of the Merger, but in no event will the current ANI stockholders own less than 50.1 percent (or the current Company stockholders own more than 49.9 percent) of the outstanding shares of common stock of the combined company.&amp;#160; The Merger is intended to qualify as a &amp;#8220;reorganization&amp;#8221; within the meaning of Section&amp;#160;368(a)&amp;#160;of the Internal Revenue Code of 1986, as amended.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Merger Agreement provides that, immediately following the effective time of the Merger, the board of directors of the combined company will consist of five former directors of ANI and two former directors of the Company, and ANI&amp;#8217;s current executive officers are expected to serve as executive officers of the combined company.&amp;#160; In connection with the Merger, the Company will seek to amend its certificate of incorporation to: (i)&amp;#160;effect a reverse split of its common stock at a ratio between the range of one-for-two and one-for-five, as determined by the Company and ANI, which is intended to ensure that the listing requirements of The NASDAQ Global Market or The NASDAQ Capital Market are satisfied; and (ii)&amp;#160;change the name of the Company to &amp;#8220;ANI Pharmaceuticals,&amp;#160;Inc.&amp;#8221; or another name as designated by ANI (together, the Charter Amendments).&amp;#160; No fractional shares of the Company&amp;#8217;s common stock will be issued in connection with the reverse split and holders of the Company&amp;#8217;s common stock will be entitled to receive cash in lieu thereof.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Consummation of the Merger is subject to a number of conditions, including, but not limited to (i)&amp;#160;the adoption and approval of the Merger Agreement and the transactions contemplated thereby by both the Company&amp;#8217;s and ANI&amp;#8217;s stockholders and the approval of the Charter Amendments by the Company&amp;#8217;s stockholders; (ii)&amp;#160;the effectiveness of a Form&amp;#160;S-4 registration statement to be filed by the Company with the Securities and Exchange Commission to register the shares of the Company&amp;#8217;s common stock to be issued in connection with the Merger, which will contain a joint proxy statement/prospectus; (iii)&amp;#160;approval for the listing of shares of the Company&amp;#8217;s common stock to be issued in the Merger on The NASDAQ Global Market or The NASDAQ Capital Market; (iv)&amp;#160;written opinions of counsel that the Merger will qualify as a reorganization within the meaning of Section&amp;#160;368(a)&amp;#160;of the Code; and (v)&amp;#160;other customary closing conditions.&amp;#160; In addition, the obligation of ANI to effect the Merger is subject to a condition that the Company&amp;#8217;s net cash, as calculated pursuant to the terms of the Merger Agreement, be no less than $17.0 million immediately prior to the effective time of the Merger.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Each of the Company and ANI have made customary representations, warranties and covenants in the Merger Agreement, including among others, covenants that (i)&amp;#160;each party will conduct its business in the ordinary course consistent with past practice during the interim period between the execution of the Merger Agreement and the consummation of the Merger; (ii)&amp;#160;each party will not engage in certain kinds of transactions or take certain actions during such period; (iii)&amp;#160;ANI will convene and hold a meeting of its stockholders for the purpose of considering the adoption and approval of the Merger Agreement and the transactions contemplated thereby and the board of directors of ANI will recommend that its stockholders adopt and approve the Merger Agreement, subject to certain exceptions; and (iv)&amp;#160;the Company will convene and hold a meeting of its stockholders for the purpose of considering the adoption and approval of the Merger Agreement and the transactions contemplated thereby and the approval of the Charter Amendments and the Company&amp;#8217;s board of directors will recommend that the Company&amp;#8217;s stockholders adopt and approve the Merger Agreement and approve the charter amendments, subject to certain exceptions.&amp;#160; Each of the Company and ANI also has agreed not to solicit proposals relating to alternative business combination transactions or enter into discussions or an agreement concerning any proposals for alternative business combination transactions, subject to exceptions for the Company in the event of the Company&amp;#8217;s receipt of a &amp;#8220;superior proposal.&amp;#8221;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Merger Agreement contains certain termination rights in favor of each of ANI and the Company in certain circumstances. If the Merger Agreement is terminated due to certain triggering events specified in the Merger Agreement, the Company will be required to pay ANI a termination fee of up to $1.0 million or ANI will be required to pay the Company a termination fee of up to $750,000. The Merger Agreement also provides that under specified circumstances, the Company may be required to reimburse ANI up to $500,000 for ANI&amp;#8217;s expenses in connection with the transaction. Any expenses paid by the Company will be credited against the $1.0 million termination fee if the termination fee subsequently becomes payable by the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Voting Agreements&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Concurrently and in connection with the execution of the Merger Agreement, certain of ANI&amp;#8217;s stockholders, who collectively hold approximately 90 percent of the outstanding shares of ANI capital stock as of the close of business on October&amp;#160;3, 2012,&amp;#160; entered into voting agreements with the Company, pursuant to which each stockholder agreed to vote its shares of ANI capital stock in favor of the Merger, the Merger Agreement and the transactions contemplated by the Merger Agreement and against certain transactions or certain actions that would delay, prevent or nullify the Merger or the transaction contemplated by the Merger Agreement.&amp;#160; In addition, one of the stockholders of ANI, who holds approximately 57 percent of the outstanding shares of ANI capital stock as of the close of business on October&amp;#160;3, 2012, has agreed to vote in favor of the election of the two directors designated by the Company at the first annual meeting of stockholders following the completion of the Merger.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In addition, certain of the Company&amp;#8217;s stockholders, directors and officers, who collectively hold approximately two percent of the outstanding shares of the Company&amp;#8217;s capital stock as of the close of business on October&amp;#160;3, 2012, entered into voting agreements with ANI, pursuant to which each stockholder agreed to vote its shares of the Company&amp;#8217;s capital stock in favor of the Merger, the Merger Agreement and the transactions contemplated by the Merger Agreement and the charter amendments, and against certain transactions or certain actions that would delay, prevent or nullify the Merger or the transaction contemplated by the Merger Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Lock-Up Agreements&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;Concurrently and in connection with the execution of the Merger Agreement, ANI&amp;#8217;s chief executive officer and chief financial officer and certain stockholders of ANI, who collectively hold approximately 85 percent of the outstanding shares of ANI capital stock as of the close of business on October&amp;#160;3, 2012, entered into lock-up agreements with the Company, pursuant to which each stockholder will be subject to a six-month lock-up on the sale of shares of the Company&amp;#8217;s common stock received in the Merger.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Contingent Value Rights Agreement&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;The Company has the right in its sole discretion to issue contingent value rights (each, a CVR and collectively, the CVRs) to its existing stockholders immediately prior to the completion of the Merger.&amp;#160; The Company expects that one CVR will be issued for each share of the Company&amp;#8217;s common stock outstanding as of the record date to be set at a date prior to the completion of the Merger.&amp;#160; However, the CVRs will not be certificated and will not be attached to the shares of the Company&amp;#8217;s common stock.&amp;#160; Each CVR will be a non-transferable (subject to certain limited exceptions) right to potentially receive certain cash payments in the event the Company receives net cash payments during the ten-year period after the distribution of the rights as a result of the sale, transfer, license or similar transaction relating to the Company&amp;#8217;s LibiGel program,&amp;#160; upon the terms and subject to the conditions set forth in a contingent value rights agreement to be entered into between the Company and an as of yet unidentified third party, as rights agent.&amp;#160; The aggregate cash payments to be distributed to the holders of the CVRs, if any, will be equal to 66 percent of the net cash payments received by the combined company as a result of the sale, transfer, license or similar transaction relating to the Company&amp;#8217;s LibiGel program, as determined pursuant to the CVR agreement, and will not exceed $40 million in the aggregate.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Employee Reduction Implications&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;As a result of the conclusion of the Company&amp;#8217;s LibiGel Phase III cardiovascular events and breast cancer safety study, as announced by the Company in September&amp;#160;2012, and considering the Company&amp;#8217;s October&amp;#160;4, 2012 announcement of its potential merger with ANI, the Company plans to reduce its workforce during the fourth quarter of 2012.&amp;#160; In connection with the announced reduction, the Company will pay approximately $300,000 in aggregate severance costs during the remainder of 2012. The termination of employment of these employees will result in the cessation of any further vesting in certain stock options held by these employees and a reversal of previously recognized non-cash stock-based compensation expense related to such options in a similar amount, thereby offsetting the employee reduction severance costs.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2"&gt;Third Amendment To License Agreement with Teva&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;In October&amp;#160;2012, the Company entered into an amendment to its development and license agreement with Teva pursuant to which Teva made a $1.0 million payment to the Company upon the signing of the amendment and agreed to make the following milestone-based payments to the Company:&amp;#160; (1)&amp;#160;$500,000 if the FDA authorizes marketing of the licensed &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;male testosterone gel as an &amp;#8220;AB-rated&amp;#8221; equivalent to AndroGel&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;; (2)&amp;#160;$750,000 upon the earlier to occur of (a)&amp;#160;December&amp;#160;31, 2012 and (b)&amp;#160;five business days after Teva&amp;#8217;s submission to the FDA of a final report regarding a &amp;#8220;washing&amp;#8221; clinical study required by the FDA; and (3)&amp;#160;$500,000 upon the earlier to occur of (a)&amp;#160;December&amp;#160;31, 2013 and (b)&amp;#160;five business days after Teva&amp;#8217;s commencement of commercial manufacture of the licensed product for sale in the United States.&amp;#160; In addition, Teva has agreed to pay the Company $4.0 million in the event Teva is the sole marketer in the United States of a generic 1% testosterone gel AB-rated to AndroGel&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;for at least 180 days immediately following the launch date of the licensed product in the United States.&amp;#160; The royalty rate to be paid by Teva to the Company under the agreement is five percent of net sales; provided, however, that during the period of time that Teva markets the licensed product and is the sole marketer of a generic 1% testosterone gel that is AB-rated to AndroGel&lt;/font&gt;&lt;font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1"&gt;&amp;#174;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;&amp;#160;in the United States, the royalty rate will be seven and one half percent of net sales.&amp;#160; Additionally, pursuant to the terms of the October&amp;#160;2012 amendment, the parties agreed to release each other from certain liabilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"&gt;&lt;font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="Tag180" decimals="0" contextRef="I2012Q3_ConvertibleNotesPayableMember" unitRef="USD">99710</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:LicensesRevenue id="Tag181" decimals="0" contextRef="D2011Q3" unitRef="USD">100000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue id="Tag182" decimals="0" contextRef="D2011Q3YTD" unitRef="USD">100000</us-gaap:LicensesRevenue>
  <bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders id="Tag183" decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_SubsequentEventMember" unitRef="Pure">0.53</bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders>
  <bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders id="Tag184" decimals="2" contextRef="I2012Q4_M1003_MergerAgreementMember_SubsequentEventMember" unitRef="Pure">0.47</bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders>
  <bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders id="Tag185" decimals="3" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_MinimumMember_SubsequentEventMember" unitRef="Pure">0.501</bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders>
  <bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders id="Tag186" decimals="3" contextRef="I2012Q4_M1003_MergerAgreementMember_MinimumMember_SubsequentEventMember" unitRef="Pure">0.499</bpax:OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders>
  <bpax:NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany id="Tag187" decimals="INF" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_SubsequentEventMember" unitRef="Item">5</bpax:NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany>
  <bpax:NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany id="Tag188" decimals="INF" contextRef="I2012Q4_M1003_MergerAgreementMember_SubsequentEventMember" unitRef="Item">2</bpax:NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany>
  <bpax:ReverseStockSplitConversionRatio id="Tag189" decimals="1" contextRef="I2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember" unitRef="Pure">0.5</bpax:ReverseStockSplitConversionRatio>
  <bpax:NetCashRequiredToObligateEntityToEffectMerger id="Tag190" decimals="-5" contextRef="I2012Q4_M1003_MergerAgreementMember_MinimumMember_SubsequentEventMember" unitRef="USD">17000000</bpax:NetCashRequiredToObligateEntityToEffectMerger>
  <bpax:BusinessMergerTerminationFeePayable id="Tag191" decimals="-5" contextRef="I2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember" unitRef="USD">1000000</bpax:BusinessMergerTerminationFeePayable>
  <bpax:BusinessMergerTerminationFeePayable id="Tag192" decimals="0" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_MergerAgreementMember_MaximumMember_SubsequentEventMember" unitRef="USD">750000</bpax:BusinessMergerTerminationFeePayable>
  <bpax:BusinessMergerReimbursementOfExpenses id="Tag193" decimals="0" contextRef="D2012Q4_M1003_MergerAgreementMember_MaximumMember_SubsequentEventMember" unitRef="USD">500000</bpax:BusinessMergerReimbursementOfExpenses>
  <bpax:PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders id="Tag194" decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember" unitRef="Pure">0.90</bpax:PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders>
  <bpax:NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock id="Tag195" decimals="INF" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember" unitRef="Item">1</bpax:NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock>
  <bpax:PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors id="Tag196" decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember" unitRef="Pure">0.57</bpax:PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors>
  <bpax:NumberOfDirectorsDesignatedByEntity id="Tag197" decimals="INF" contextRef="D2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember" unitRef="Item">2</bpax:NumberOfDirectorsDesignatedByEntity>
  <bpax:PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements id="Tag198" decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_VotingAgreementMember_SubsequentEventMember" unitRef="Pure">0.02</bpax:PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements>
  <bpax:PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements id="Tag199" decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_LockUpAgreementMember_SubsequentEventMember" unitRef="Pure">0.85</bpax:PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements>
  <bpax:LockingPeriodOnSaleOfSharesPostMerger id="Tag200" contextRef="D2012Q4_M1003_ANIPharmaceuticalsIncMember_LockUpAgreementMember_SubsequentEventMember">P6M</bpax:LockingPeriodOnSaleOfSharesPostMerger>
  <bpax:NumberOfContingentValueRightsIssuedInExchangeForOneShare id="Tag201" decimals="INF" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_SubsequentEventMember" unitRef="Shares">1</bpax:NumberOfContingentValueRightsIssuedInExchangeForOneShare>
  <bpax:PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights id="Tag202" contextRef="D2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_SubsequentEventMember">P10Y</bpax:PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights>
  <bpax:NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived id="Tag203" decimals="2" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_SubsequentEventMember" unitRef="Pure">0.66</bpax:NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived>
  <bpax:AggregateNetCashPaymentsToBeDistributedToHolders id="Tag204" decimals="-6" contextRef="I2012Q4_M1003_ANIPharmaceuticalsIncMember_ContingentValueRightsAgreementMember_MaximumMember_SubsequentEventMember" unitRef="USD">40000000</bpax:AggregateNetCashPaymentsToBeDistributedToHolders>
  <bpax:ReverseStockSplitConversionRatio id="Tag205" decimals="1" contextRef="I2012Q4_M1003_MergerAgreementMember_MinimumMember_SubsequentEventMember" unitRef="Pure">0.2</bpax:ReverseStockSplitConversionRatio>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="Tag206" decimals="INF" contextRef="D2012Q3_M07_ConvertibleNotesPayableMember" unitRef="Shares">1784070</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="Tag207" decimals="0" contextRef="I2012Q3_M0731_ConvertibleNotesPayableMember" unitRef="USD">20686</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:InterestPayableCurrentAndNoncurrent id="Tag208" decimals="0" contextRef="I2012Q1_M0229_ConvertibleNotesPayableMember" unitRef="USD">79024</us-gaap:InterestPayableCurrentAndNoncurrent>
  <bpax:NumberOfDebtInstrumentHoldersToWhomSharesAreIssued id="Tag209" decimals="INF" contextRef="D2012Q3_M07_ConvertibleNotesPayableMember" unitRef="Holder">2</bpax:NumberOfDebtInstrumentHoldersToWhomSharesAreIssued>
  <us-gaap:DebtConversionOriginalDebtAmount1 id="Tag210" decimals="0" contextRef="D2012Q3_M07_ConvertibleNotesPayableMember" unitRef="USD">3504150</us-gaap:DebtConversionOriginalDebtAmount1>
  <bpax:FairValueOptionChangesInFairValueNonCashAdjustment id="Tag211" decimals="0" contextRef="D2012Q1_ConvertibleNotesPayableMember" unitRef="USD">-2545530</bpax:FairValueOptionChangesInFairValueNonCashAdjustment>
  <bpax:NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing id="Tag212" decimals="INF" contextRef="D2012Q3YTD_MinimumMember" unitRef="Item">1</bpax:NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing>
  <dei:EntityCommonStockSharesOutstanding id="Tag213" decimals="INF" contextRef="I2012Q3SO_CommonClassCMember" unitRef="Shares">65211</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Tag214" decimals="0" contextRef="D2012Q3_M08_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember" unitRef="Shares">1179966</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Tag215" decimals="0" contextRef="D2012Q3_M08_CommonStockMember" unitRef="Shares">2359932</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="Tag216" decimals="0" contextRef="D2012Q3_M08_CommonStockMember" unitRef="USD">3268798</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:SharePrice id="Tag217" decimals="4" contextRef="I2012Q3_M0831_CommonStockMember" unitRef="USDPerShare">1.4725</us-gaap:SharePrice>
  <bpax:ProceedsFromIssuanceOfCommonStockGross id="Tag218" decimals="0" contextRef="D2012Q3_M08_CommonStockMember" unitRef="USD">3475000</bpax:ProceedsFromIssuanceOfCommonStockGross>
  <bpax:NumberOfInstitutionalInvestorsToWhomOfferingMade id="Tag219" decimals="0" contextRef="I2012Q3_M0831_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember" unitRef="Item">1</bpax:NumberOfInstitutionalInvestorsToWhomOfferingMade>
  <bpax:ClassOfWarrantOrRightTermOfWarrants id="Tag220" contextRef="D2012Q3_M08_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember">P5Y</bpax:ClassOfWarrantOrRightTermOfWarrants>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights id="Tag221" decimals="2" contextRef="I2012Q3_M0831_WarrantIssuedToInstitutionalInvestorsMember_CommonStockMember" unitRef="USDPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag222" decimals="0" contextRef="I2012Q3" unitRef="USD">534037</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag223" decimals="0" contextRef="I2012Q3" unitRef="USD">38583132</us-gaap:AssetsCurrent>
  <us-gaap:LongTermInvestments id="Tag224" decimals="0" contextRef="I2012Q3" unitRef="USD">3413762</us-gaap:LongTermInvestments>
  <us-gaap:DepositsAssetsNoncurrent id="Tag225" decimals="0" contextRef="I2012Q3" unitRef="USD">30088</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:AccountsPayableCurrent id="Tag226" decimals="0" contextRef="I2012Q3" unitRef="USD">2004814</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="Tag227" decimals="0" contextRef="I2012Q3" unitRef="USD">463942</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="Tag228" decimals="0" contextRef="I2012Q3" unitRef="USD">860094</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:RoyaltyRevenue id="Tag229" decimals="0" contextRef="D2012Q3" unitRef="USD">110383</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue id="Tag230" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">333163</us-gaap:RoyaltyRevenue>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag231" decimals="0" contextRef="D2012Q3" unitRef="USD">25749</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag232" decimals="0" contextRef="D2012Q3" unitRef="USD">1546864</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag233" decimals="0" contextRef="D2012Q3" unitRef="USD">3872736</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag234" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">14454258</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag235" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">5327711</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag236" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">87548</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:InterestExpense id="Tag237" decimals="0" contextRef="D2012Q3" unitRef="USD">67105</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest id="Tag239" decimals="0" contextRef="D2012Q3" unitRef="USD">1877</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InterestExpense id="Tag240" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">283348</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest id="Tag242" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">5300</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag243" decimals="0" contextRef="D2012Q3" unitRef="USD">-6121815</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="Tag244" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-23730408</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Tag245" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-117794</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:ShareBasedCompensation id="Tag246" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">852468</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag247" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-323225</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Tag248" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-3807074</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag249" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-22118650</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag250" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">528742</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromWarrantExercises id="Tag251" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">211068</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag252" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">3268798</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Tag253" decimals="0" contextRef="D2012Q3_M0920_CommonStockMember" unitRef="Shares">140712</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <bpax:ProceedsFromIssuanceOfCommonStockGross id="Tag254" decimals="0" contextRef="D2012Q3_M0920_CommonStockMember" unitRef="USD">211068</bpax:ProceedsFromIssuanceOfCommonStockGross>
  <us-gaap:SeveranceCosts id="Tag255" decimals="0" contextRef="D2012_ANIPharmaceuticalsIncMember_EmployeeSeveranceMember_SubsequentEventMember" unitRef="USD">300000</us-gaap:SeveranceCosts>
  <bpax:UnpaidCostsAssociatedWithRegisteredDirectOffering id="Tag256" decimals="0" contextRef="D2012Q3YTD" unitRef="USD">7933</bpax:UnpaidCostsAssociatedWithRegisteredDirectOffering>
  <bpax:NumberOfCasesConsolidated id="Tag257" decimals="INF" contextRef="D2012Q3_M0924_ShareholderDerivativeActionMember" unitRef="Item">2</bpax:NumberOfCasesConsolidated>
  <bpax:NetCashRequiredToObligateEntityToEffectMerger id="Tag258" decimals="-6" contextRef="I2012Q3_MinimumMember" unitRef="USD">17000000</bpax:NetCashRequiredToObligateEntityToEffectMerger>
  <bpax:PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements id="Tag259" contextRef="D2012Q3YTD_MinimumMember">P3Y</bpax:PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements>
  <bpax:PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements id="Tag260" contextRef="D2012Q3YTD_MaximumMember">P5Y</bpax:PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements>
  <us-gaap:ProceedsFromCollaborators id="Tag261" decimals="-5" contextRef="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember" unitRef="USD">1000000</us-gaap:ProceedsFromCollaborators>
  <bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable id="Tag262" decimals="0" contextRef="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember_ScenarioForecastMember" unitRef="USD">500000</bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable>
  <bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable id="Tag263" decimals="0" contextRef="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_ScenarioForecastMember" unitRef="USD">750000</bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable>
  <bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable id="Tag264" decimals="0" contextRef="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_ScenarioForecastMember" unitRef="USD">500000</bpax:CollaborativeArrangementPotentialMilestonePaymentsReceivable>
  <bpax:NumberOfBusinessDaysConsideredInMilestonePayments id="Tag265" decimals="INF" contextRef="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_ScenarioForecastMember" unitRef="Item">5</bpax:NumberOfBusinessDaysConsideredInMilestonePayments>
  <bpax:CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight id="Tag266" decimals="-5" contextRef="I2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember" unitRef="USD">4000000</bpax:CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight>
  <bpax:NumberOfBusinessDaysConsideredInMilestonePayments id="Tag267" decimals="INF" contextRef="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_ScenarioForecastMember" unitRef="Item">5</bpax:NumberOfBusinessDaysConsideredInMilestonePayments>
  <bpax:NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment id="Tag268" decimals="INF" contextRef="D2012Q4_M10_MinimumMember_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember" unitRef="Item">180</bpax:NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment>
  <bpax:CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales id="Tag269" decimals="2" contextRef="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember" unitRef="Pure">0.05</bpax:CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales>
  <bpax:CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales id="Tag270" decimals="4" contextRef="D2012Q4_M10_ThirdAmendmentToLicenseAgreementMember_TevaPharmaceuticalsUSAIncMember_SubsequentEventMember_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_ScenarioForecastMember" unitRef="Pure">0.0750</bpax:CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals="0" contextRef="D2012Q3" unitRef="USD">-6243606</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals="0" contextRef="D2011Q3" unitRef="USD">-12733691</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-23852199</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals="0" contextRef="D2011Q3YTD" unitRef="USD">-44959599</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit decimals="0" contextRef="D2012Q3" unitRef="USD">-121791</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit decimals="0" contextRef="D2012Q3YTD" unitRef="USD">-121791</us-gaap:IncomeTaxExpenseBenefit>
  <bpax:PaymentsToFractionalSharePayout decimals="0" contextRef="D2012Q2_M06" unitRef="USD">658</bpax:PaymentsToFractionalSharePayout>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>bpax-20120930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<!--Generated by IRIS XBRL Generation Engine-->
<xsd:schema targetNamespace="http://www.biosantepharma.com/20120930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:bpax="http://www.biosantepharma.com/20120930" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ref="http://www.xbrl.org/2004/ref" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="bpax-20120930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="bpax-20120930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="bpax-20120930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="bpax-20120930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.biosantepharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/BalanceSheet" id="BalanceSheet">
        <link:definition>0010 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/BalanceSheetParenthetical" id="BalanceSheetParenthetical">
        <link:definition>0015 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/StatementOfIncome" id="StatementOfIncome">
        <link:definition>0020 - Statement - Condensed Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/CashFlows" id="CashFlows">
        <link:definition>0030 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>1010 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>1020 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureLiquidityAndCapitalResources" id="DisclosureLiquidityAndCapitalResources">
        <link:definition>1030 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureBasicAndDilutedNetLossPerShare" id="DisclosureBasicAndDilutedNetLossPerShare">
        <link:definition>1040 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotes" id="DisclosureConvertibleSeniorNotes">
        <link:definition>1050 - Disclosure - CONVERTIBLE SENIOR NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>1060 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>1070 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>1080 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>1090 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>1100 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesTables" id="DisclosureConvertibleSeniorNotesTables">
        <link:definition>3050 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>3090 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureDescriptionOfBusinessDetails" id="DisclosureDescriptionOfBusinessDetails">
        <link:definition>4010 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureBasisOfPresentationDetails" id="DisclosureBasisOfPresentationDetails">
        <link:definition>4020 - Disclosure - BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureLiquidityAndCapitalResourcesDetails" id="DisclosureLiquidityAndCapitalResourcesDetails">
        <link:definition>4030 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesDetails" id="DisclosureConvertibleSeniorNotesDetails">
        <link:definition>4050 - Disclosure - CONVERTIBLE SENIOR NOTES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>4060 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>4070 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>4080 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails2" id="DisclosureCommitmentsAndContingenciesDetails2">
        <link:definition>4081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>4090 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>4100 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/StatementOfStockholdersEquity" id="StatementOfStockholdersEquity">
        <link:definition>8000 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>8010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureAcquisitionOfNetAssetsOfCellGenesys" id="DisclosureAcquisitionOfNetAssetsOfCellGenesys">
        <link:definition>8020 - Disclosure - ACQUISITION OF NET ASSETS OF CELL GENESYS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureLicenseAgreements" id="DisclosureLicenseAgreements">
        <link:definition>8030 - Disclosure - LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>8040 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>8050 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureRetirementPlan" id="DisclosureRetirementPlan">
        <link:definition>8060 - Disclosure - RETIREMENT PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureLeaseArrangements" id="DisclosureLeaseArrangements">
        <link:definition>8070 - Disclosure - LEASE ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureRecentlyIssuedAccountingPronouncements" id="DisclosureRecentlyIssuedAccountingPronouncements">
        <link:definition>8080 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureSelectedQuarterlyFinancialData" id="DisclosureSelectedQuarterlyFinancialData">
        <link:definition>8090 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:definition>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureInvestments" id="DisclosureInvestments">
        <link:definition>8100 - Disclosure - INVESTMENTS</link:definition>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureInvestmentsDetails" id="DisclosureInvestmentsDetails">
        <link:definition>8110 - Disclosure - INVESTMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.biosantepharma.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails" id="DisclosureBasicAndDilutedNetLossPerShareDetails">
        <link:definition>8120 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:element name="ThirdAmendmentToLicenseAgreementMember" id="bpax_ThirdAmendmentToLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" id="bpax_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" id="bpax_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" id="bpax_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" id="bpax_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementPotentialMilestonePaymentsReceivable" id="bpax_CollaborativeArrangementPotentialMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfBusinessDaysConsideredInMilestonePayments" id="bpax_NumberOfBusinessDaysConsideredInMilestonePayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" id="bpax_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" id="bpax_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" id="bpax_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" id="bpax_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" id="bpax_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="AggregateNetCashPaymentsToBeDistributedToHolders" id="bpax_AggregateNetCashPaymentsToBeDistributedToHolders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NetCashRequiredToObligateEntityToEffectMerger" id="bpax_NetCashRequiredToObligateEntityToEffectMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="UnpaidCostsAssociatedWithRegisteredDirectOffering" id="bpax_UnpaidCostsAssociatedWithRegisteredDirectOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" id="bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareholderDerivativeActionMember" id="bpax_ShareholderDerivativeActionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfCasesConsolidated" id="bpax_NumberOfCasesConsolidated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReverseStockSplitConversionRatio" id="bpax_ReverseStockSplitConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="BusinessMergerTerminationFeePayable" id="bpax_BusinessMergerTerminationFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="BusinessMergerReimbursementOfExpenses" id="bpax_BusinessMergerReimbursementOfExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" id="bpax_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" id="bpax_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" id="bpax_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfDirectorsDesignatedByEntity" id="bpax_NumberOfDirectorsDesignatedByEntity" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" id="bpax_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="LockingPeriodOnSaleOfSharesPostMerger" id="bpax_LockingPeriodOnSaleOfSharesPostMerger" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfContingentValueRightsIssuedInExchangeForOneShare" id="bpax_NumberOfContingentValueRightsIssuedInExchangeForOneShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="CapitalStockAbstract" id="bpax_CapitalStockAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" id="bpax_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPhaseIAndPhaseIIClinicalTrials" id="bpax_NumberOfPhaseIAndPhaseIIClinicalTrials" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" id="bpax_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfNewLibiGelPhaseIIIEfficacyTrials" id="bpax_NumberOfNewLibiGelPhaseIIIEfficacyTrials" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" id="bpax_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfSeriesOfConvertibleNotesAssumed" id="bpax_NumberOfSeriesOfConvertibleNotesAssumed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DescriptionOfBusinessDisclosureAbstract" id="bpax_DescriptionOfBusinessDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LiquidityAndCapitalResourcesDisclosureAbstract" id="bpax_LiquidityAndCapitalResourcesDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LiquidityAndCapitalResourcesLineItems" id="bpax_LiquidityAndCapitalResourcesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementsDisclosureAbstract" id="bpax_LicenseAgreementsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementsDisclosureTextBlock" id="bpax_LicenseAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" id="bpax_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="bpax_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" id="bpax_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExcessConsiderationPaidOverFairValue" id="bpax_ExcessConsiderationPaidOverFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfCommonSharesAbstract" id="bpax_IssuanceOfCommonSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueCommonSharesAndWarrants" id="bpax_StockIssuedDuringPeriodValueCommonSharesAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" id="bpax_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodCommonSharesAndWarrants" id="bpax_StockIssuedDuringPeriodCommonSharesAndWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="bpax_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" id="bpax_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="bpax_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NoncashInvestment" id="bpax_NoncashInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" id="bpax_ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" id="bpax_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RepaymentsOfShortTermConvertibleDebt" id="bpax_RepaymentsOfShortTermConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="LiquidityAndCapitalResourcesTextBlock" id="bpax_LiquidityAndCapitalResourcesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfLiquidityAndCapitalResourcesTable" id="bpax_ScheduleOfLiquidityAndCapitalResourcesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleSeniorNotes3.125PercentDue2013Member" id="bpax_ConvertibleSeniorNotes3.125PercentDue2013Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" id="bpax_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" id="bpax_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleSeniorNotes3.125PercentDue2011Member" id="bpax_ConvertibleSeniorNotes3.125PercentDue2011Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" id="bpax_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" id="bpax_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FairValueAssumptionsDiscountRate" id="bpax_FairValueAssumptionsDiscountRate" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" id="bpax_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" id="bpax_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" id="bpax_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" id="bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" id="bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" id="bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfStockholdersEquityTable" id="bpax_ScheduleOfStockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantIssuedToInstitutionalInvestorsMember" id="bpax_WarrantIssuedToInstitutionalInvestorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityLineItems" id="bpax_StockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantIssuedToPlacementAgentsMember" id="bpax_WarrantIssuedToPlacementAgentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockGross" id="bpax_ProceedsFromIssuanceOfCommonStockGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightTermOfWarrants" id="bpax_ClassOfWarrantOrRightTermOfWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PaymentsToFractionalSharePayout" id="bpax_PaymentsToFractionalSharePayout" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityReverseStockSplitConversionRatio" id="bpax_StockholdersEquityReverseStockSplitConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" id="bpax_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AptarPharmaMember" id="bpax_AptarPharmaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FairValueOptionChangesInFairValueNonCashAdjustment" id="bpax_FairValueOptionChangesInFairValueNonCashAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NumberOfNewLibiGelEfficacyTrials" id="bpax_NumberOfNewLibiGelEfficacyTrials" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" id="bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfInstitutionalInvestorsToWhomOfferingMade" id="bpax_NumberOfInstitutionalInvestorsToWhomOfferingMade" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ANIPharmaceuticalsIncMember" id="bpax_ANIPharmaceuticalsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MergerAgreementMember" id="bpax_MergerAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VotingAgreementMember" id="bpax_VotingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LockUpAgreementMember" id="bpax_LockUpAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContingentValueRightsAgreementMember" id="bpax_ContingentValueRightsAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" id="bpax_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="TevaPharmaceuticalsUSAIncMember" id="bpax_TevaPharmaceuticalsUSAIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" id="bpax_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>bpax-20120930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.biosantepharma.com/role/StatementOfIncome" xlink:type="simple" xlink:href="bpax-20120930.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/CashFlows" xlink:type="simple" xlink:href="bpax-20120930.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/BalanceSheet" xlink:type="simple" xlink:href="bpax-20120930.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureConvertibleSeniorNotesDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="Revenues" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to Revenues" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Revenues" xlink:to="LicensesRevenue" xlink:title="calculation: Revenues to LicensesRevenue" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Revenues" xlink:to="RoyaltyRevenue" xlink:title="calculation: Revenues to RoyaltyRevenue" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="CostsAndExpenses" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to CostsAndExpenses" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: CostsAndExpenses to ResearchAndDevelopmentExpense" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: CostsAndExpenses to GeneralAndAdministrativeExpense" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: CostsAndExpenses to DepreciationDepletionAndAmortization" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="FairValueOptionChangesInFairValueGainLoss1" xlink:title="FairValueOptionChangesInFairValueGainLoss1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="FairValueOptionChangesInFairValueGainLoss1" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to FairValueOptionChangesInFairValueGainLoss1" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="InterestExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to InterestExpense" use="optional" order="4.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OtherNonoperatingIncome" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OtherNonoperatingIncome" use="optional" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to InvestmentIncomeInterest" order="6.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to IncomeTaxExpenseBenefit" order="1.0" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to DepreciationDepletionAndAmortization" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="3.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to ShareBasedCompensation" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" order="5.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="FairValueOptionChangesInFairValueGainLoss1" xlink:title="FairValueOptionChangesInFairValueGainLoss1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="FairValueOptionChangesInFairValueGainLoss1" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to FairValueOptionChangesInFairValueGainLoss1" use="optional" order="6.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="7.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="8.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="PaymentsToAcquireInvestments" xlink:title="PaymentsToAcquireInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsToAcquireInvestments" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsToAcquireInvestments" use="optional" order="1.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="2.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="calculation: NetCashProvidedByUsedInContinuingOperations to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PaymentsToFractionalSharePayout" xlink:label="PaymentsToFractionalSharePayout" xlink:title="PaymentsToFractionalSharePayout" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="PaymentsToFractionalSharePayout" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to PaymentsToFractionalSharePayout" use="optional" order="1.0" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromStockOptionsExercised" use="optional" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromWarrantExercises" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromWarrantExercises" use="optional" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:label="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:title="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to ProceedsFromIssuanceOfCommonStock" use="optional" order="5.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="LongTermInvestments" xlink:title="LongTermInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="LongTermInvestments" xlink:title="calculation: Assets to LongTermInvestments" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="DepositsAssetsNoncurrent" xlink:title="calculation: Assets to DepositsAssetsNoncurrent" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to EmployeeRelatedLiabilitiesCurrent" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to OtherAccruedLiabilitiesCurrent" order="3.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeniorNotesCurrent" xlink:label="SeniorNotesCurrent" xlink:title="SeniorNotesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="SeniorNotesCurrent" xlink:title="calculation: LiabilitiesCurrent to SeniorNotesCurrent" use="optional" order="4.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="ConvertibleLongTermNotesPayable" xlink:title="ConvertibleLongTermNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="ConvertibleLongTermNotesPayable" xlink:title="calculation: Liabilities to ConvertibleLongTermNotesPayable" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="2.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="CommonStockValueOutstanding" xlink:title="CommonStockValueOutstanding" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValueOutstanding" xlink:title="calculation: StockholdersEquity to CommonStockValueOutstanding" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" use="optional" order="2.0" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="calculation: LongTermDebt to LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" use="optional" order="1.0" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebt" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="calculation: LongTermDebt to LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" order="2.0" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>bpax-20120930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureSubsequentEventsDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureConvertibleSeniorNotesDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureLiquidityAndCapitalResourcesDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureLiquidityAndCapitalResourcesDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureStockholdersEquityDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureStockholdersEquityDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureStockBasedCompensationDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureFairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureCommitmentsAndContingenciesDetails2" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="bpax-20120930.xsd#DocumentAndEntityInformation" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/CashFlows" xlink:type="simple" xlink:href="bpax-20120930.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/StatementOfIncome" xlink:type="simple" xlink:href="bpax-20120930.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/BalanceSheet" xlink:type="simple" xlink:href="bpax-20120930.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/BalanceSheetParenthetical" xlink:type="simple" xlink:href="bpax-20120930.xsd#BalanceSheetParenthetical" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/StatementOfStockholdersEquity" xlink:type="simple" xlink:href="bpax-20120930.xsd#StatementOfStockholdersEquity" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureBasicAndDilutedNetLossPerShareDetails" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureSubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="LegalEntityAxis" xlink:title="definition: SubsequentEventTable to LegalEntityAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ANIPharmaceuticalsIncMember" xlink:label="ANIPharmaceuticalsIncMember" xlink:title="ANIPharmaceuticalsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="ANIPharmaceuticalsIncMember" xlink:title="definition: EntityDomain to ANIPharmaceuticalsIncMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_TevaPharmaceuticalsUSAIncMember" xlink:label="TevaPharmaceuticalsUSAIncMember" xlink:title="TevaPharmaceuticalsUSAIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="TevaPharmaceuticalsUSAIncMember" xlink:title="definition: EntityDomain to TevaPharmaceuticalsUSAIncMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InstrumentAxis" xlink:label="InstrumentAxis" xlink:title="InstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="InstrumentAxis" xlink:title="definition: SubsequentEventTable to InstrumentAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InstrumentTypeMember" xlink:label="InstrumentTypeMember" xlink:title="InstrumentTypeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="InstrumentAxis" xlink:to="InstrumentTypeMember" xlink:title="definition: InstrumentAxis to InstrumentTypeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InstrumentTypeMember" xlink:label="InstrumentTypeMember_2" xlink:title="InstrumentTypeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InstrumentAxis" xlink:to="InstrumentTypeMember_2" xlink:title="definition: InstrumentAxis to InstrumentTypeMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MergerAgreementMember" xlink:label="MergerAgreementMember" xlink:title="MergerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InstrumentTypeMember" xlink:to="MergerAgreementMember" xlink:title="definition: InstrumentTypeMember to MergerAgreementMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_VotingAgreementMember" xlink:label="VotingAgreementMember" xlink:title="VotingAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InstrumentTypeMember" xlink:to="VotingAgreementMember" xlink:title="definition: InstrumentTypeMember to VotingAgreementMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LockUpAgreementMember" xlink:label="LockUpAgreementMember" xlink:title="LockUpAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InstrumentTypeMember" xlink:to="LockUpAgreementMember" xlink:title="definition: InstrumentTypeMember to LockUpAgreementMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ContingentValueRightsAgreementMember" xlink:label="ContingentValueRightsAgreementMember" xlink:title="ContingentValueRightsAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InstrumentTypeMember" xlink:to="ContingentValueRightsAgreementMember" xlink:title="definition: InstrumentTypeMember to ContingentValueRightsAgreementMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ThirdAmendmentToLicenseAgreementMember" xlink:label="ThirdAmendmentToLicenseAgreementMember" xlink:title="ThirdAmendmentToLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InstrumentTypeMember" xlink:to="ThirdAmendmentToLicenseAgreementMember" xlink:title="definition: InstrumentTypeMember to ThirdAmendmentToLicenseAgreementMember" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="definition: SubsequentEventTable to RestructuringCostAndReserveAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain_2" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain_2" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="definition: TypeOfRestructuringDomain to EmployeeSeveranceMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="RangeAxis" xlink:title="definition: SubsequentEventTable to RangeAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:title="definition: SubsequentEventTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_2" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_2" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:label="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:title="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember to MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:label="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:title="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember to MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:label="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:title="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember to MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:label="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:title="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember to PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="StatementScenarioAxis" xlink:title="definition: SubsequentEventTable to StatementScenarioAxis" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="definition: ScenarioUnspecifiedDomain to ScenarioForecastMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:label="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:title="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:title="definition: SubsequentEventLineItems to OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:label="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:title="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:title="definition: SubsequentEventLineItems to NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ReverseStockSplitConversionRatio" xlink:label="ReverseStockSplitConversionRatio" xlink:title="ReverseStockSplitConversionRatio" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ReverseStockSplitConversionRatio" xlink:title="definition: SubsequentEventLineItems to ReverseStockSplitConversionRatio" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NetCashRequiredToObligateEntityToEffectMerger" xlink:label="NetCashRequiredToObligateEntityToEffectMerger" xlink:title="NetCashRequiredToObligateEntityToEffectMerger" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NetCashRequiredToObligateEntityToEffectMerger" xlink:title="definition: SubsequentEventLineItems to NetCashRequiredToObligateEntityToEffectMerger" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_BusinessMergerTerminationFeePayable" xlink:label="BusinessMergerTerminationFeePayable" xlink:title="BusinessMergerTerminationFeePayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="BusinessMergerTerminationFeePayable" xlink:title="definition: SubsequentEventLineItems to BusinessMergerTerminationFeePayable" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_BusinessMergerReimbursementOfExpenses" xlink:label="BusinessMergerReimbursementOfExpenses" xlink:title="BusinessMergerReimbursementOfExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="BusinessMergerReimbursementOfExpenses" xlink:title="definition: SubsequentEventLineItems to BusinessMergerReimbursementOfExpenses" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:label="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:title="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:title="definition: SubsequentEventLineItems to PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:label="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:title="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:title="definition: SubsequentEventLineItems to NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" use="optional" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:label="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:title="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:title="definition: SubsequentEventLineItems to PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDirectorsDesignatedByEntity" xlink:label="NumberOfDirectorsDesignatedByEntity" xlink:title="NumberOfDirectorsDesignatedByEntity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfDirectorsDesignatedByEntity" xlink:title="definition: SubsequentEventLineItems to NumberOfDirectorsDesignatedByEntity" use="optional" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:label="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:title="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:title="definition: SubsequentEventLineItems to PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" use="optional" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LockingPeriodOnSaleOfSharesPostMerger" xlink:label="LockingPeriodOnSaleOfSharesPostMerger" xlink:title="LockingPeriodOnSaleOfSharesPostMerger" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LockingPeriodOnSaleOfSharesPostMerger" xlink:title="definition: SubsequentEventLineItems to LockingPeriodOnSaleOfSharesPostMerger" use="optional" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:label="NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:title="NumberOfContingentValueRightsIssuedInExchangeForOneShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:title="definition: SubsequentEventLineItems to NumberOfContingentValueRightsIssuedInExchangeForOneShare" use="optional" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:label="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:title="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:title="definition: SubsequentEventLineItems to PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" use="optional" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:label="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:title="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:title="definition: SubsequentEventLineItems to NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" use="optional" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AggregateNetCashPaymentsToBeDistributedToHolders" xlink:label="AggregateNetCashPaymentsToBeDistributedToHolders" xlink:title="AggregateNetCashPaymentsToBeDistributedToHolders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="AggregateNetCashPaymentsToBeDistributedToHolders" xlink:title="definition: SubsequentEventLineItems to AggregateNetCashPaymentsToBeDistributedToHolders" use="optional" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeveranceCosts" xlink:label="SeveranceCosts" xlink:title="SeveranceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SeveranceCosts" xlink:title="definition: SubsequentEventLineItems to SeveranceCosts" use="optional" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="ProceedsFromCollaborators" xlink:title="ProceedsFromCollaborators" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsFromCollaborators" xlink:title="definition: SubsequentEventLineItems to ProceedsFromCollaborators" use="optional" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:label="CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:title="CollaborativeArrangementPotentialMilestonePaymentsReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:title="definition: SubsequentEventLineItems to CollaborativeArrangementPotentialMilestonePaymentsReceivable" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfBusinessDaysConsideredInMilestonePayments" xlink:label="NumberOfBusinessDaysConsideredInMilestonePayments" xlink:title="NumberOfBusinessDaysConsideredInMilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfBusinessDaysConsideredInMilestonePayments" xlink:title="definition: SubsequentEventLineItems to NumberOfBusinessDaysConsideredInMilestonePayments" use="optional" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:label="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:title="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:title="definition: SubsequentEventLineItems to CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" use="optional" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:label="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:title="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:title="definition: SubsequentEventLineItems to NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" use="optional" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:label="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:title="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:title="definition: SubsequentEventLineItems to CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" use="optional" order="24.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: DebtInstrumentTable to LongtermDebtTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="definition: LongtermDebtTypeDomain to ConvertibleNotesPayableMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:label="ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:title="ConvertibleSeniorNotes3.125PercentDue2011Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:title="definition: LongtermDebtTypeDomain to ConvertibleSeniorNotes3.125PercentDue2011Member" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:label="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:title="ConvertibleSeniorNotes3.125PercentDue2013Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:title="definition: LongtermDebtTypeDomain to ConvertibleSeniorNotes3.125PercentDue2013Member" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="definition: DebtInstrumentLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:label="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:title="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:title="definition: DebtInstrumentLineItems to NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtConversionOriginalDebtAmount1" xlink:title="definition: DebtInstrumentLineItems to DebtConversionOriginalDebtAmount1" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestPayableCurrentAndNoncurrent" xlink:title="definition: DebtInstrumentLineItems to InterestPayableCurrentAndNoncurrent" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_FairValueOptionChangesInFairValueNonCashAdjustment" xlink:label="FairValueOptionChangesInFairValueNonCashAdjustment" xlink:title="FairValueOptionChangesInFairValueNonCashAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueOptionChangesInFairValueNonCashAdjustment" xlink:title="definition: DebtInstrumentLineItems to FairValueOptionChangesInFairValueNonCashAdjustment" use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConvertibleNumberOfEquityInstruments" use="optional" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConvertibleConversionPrice1" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtFairValue" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtFairValue" use="optional" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:label="FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:title="FairValueOptionAggregateDifferencesLongTermDebtInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:title="definition: DebtInstrumentLineItems to FairValueOptionAggregateDifferencesLongTermDebtInstruments" use="optional" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="FairValueOptionChangesInFairValueGainLoss1" xlink:title="FairValueOptionChangesInFairValueGainLoss1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueOptionChangesInFairValueGainLoss1" xlink:title="definition: DebtInstrumentLineItems to FairValueOptionChangesInFairValueGainLoss1" use="optional" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:label="FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:title="FairValueOptionCreditRiskGainsLossesOnLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:title="definition: DebtInstrumentLineItems to FairValueOptionCreditRiskGainsLossesOnLiabilities" use="optional" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="definition: DebtInstrumentLineItems to FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsRiskFreeInterestRate" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsExpectedVolatilityRate" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_FairValueAssumptionsDiscountRate" xlink:label="FairValueAssumptionsDiscountRate" xlink:title="FairValueAssumptionsDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsDiscountRate" xlink:title="definition: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsDiscountRate" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfSeriesOfConvertibleNotesAssumed" xlink:label="NumberOfSeriesOfConvertibleNotesAssumed" xlink:title="NumberOfSeriesOfConvertibleNotesAssumed" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfSeriesOfConvertibleNotesAssumed" xlink:title="definition: DebtInstrumentLineItems to NumberOfSeriesOfConvertibleNotesAssumed" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:label="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:title="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:label="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:title="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" use="optional" order="8002.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:title="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" use="optional" order="8003.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:title="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" use="optional" order="8004.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:label="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:title="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" use="optional" order="8005.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="LongTermDebtByMaturityAbstract" xlink:title="LongTermDebtByMaturityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtByMaturityAbstract" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtByMaturityAbstract" use="optional" order="8006.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="definition: LongTermDebtByMaturityAbstract to LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="definition: LongTermDebtByMaturityAbstract to LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="LongTermDebt" xlink:title="definition: LongTermDebtByMaturityAbstract to LongTermDebt" use="optional" order="8002.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureLiquidityAndCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain_2" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain_2" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="definition: LongtermDebtTypeDomain to ConvertibleNotesPayableMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:label="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:title="ConvertibleSeniorNotes3.125PercentDue2013Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:title="definition: LongtermDebtTypeDomain to ConvertibleSeniorNotes3.125PercentDue2013Member" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LiquidityAndCapitalResourcesLineItems" xlink:label="LiquidityAndCapitalResourcesLineItems" xlink:title="LiquidityAndCapitalResourcesLineItems" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ScheduleOfLiquidityAndCapitalResourcesTable" xlink:label="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:title="ScheduleOfLiquidityAndCapitalResourcesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to ScheduleOfLiquidityAndCapitalResourcesTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: ScheduleOfLiquidityAndCapitalResourcesTable to LongtermDebtTypeAxis" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfLiquidityAndCapitalResourcesTable to RangeAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfLiquidityAndCapitalResourcesTable to StatementEquityComponentsAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ScheduleOfLiquidityAndCapitalResourcesTable to ClassOfWarrantOrRightAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_WarrantIssuedToInstitutionalInvestorsMember" xlink:label="WarrantIssuedToInstitutionalInvestorsMember" xlink:title="WarrantIssuedToInstitutionalInvestorsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantIssuedToInstitutionalInvestorsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantIssuedToInstitutionalInvestorsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_WarrantIssuedToPlacementAgentsMember" xlink:label="WarrantIssuedToPlacementAgentsMember" xlink:title="WarrantIssuedToPlacementAgentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantIssuedToPlacementAgentsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantIssuedToPlacementAgentsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to CashAndCashEquivalentsAtCarryingValue" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to DebtInstrumentFaceAmount" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to DebtInstrumentInterestRateStatedPercentage" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to StockIssuedDuringPeriodSharesNewIssues" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to ProceedsFromIssuanceOrSaleOfEquity" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NetCashRequiredToObligateEntityToEffectMerger" xlink:label="NetCashRequiredToObligateEntityToEffectMerger" xlink:title="NetCashRequiredToObligateEntityToEffectMerger" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="NetCashRequiredToObligateEntityToEffectMerger" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to NetCashRequiredToObligateEntityToEffectMerger" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:label="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:title="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:label="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:title="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" use="optional" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:label="NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:title="NumberOfNewLibiGelPhaseIIIEfficacyTrials" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to NumberOfNewLibiGelPhaseIIIEfficacyTrials" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfNewLibiGelEfficacyTrials" xlink:label="NumberOfNewLibiGelEfficacyTrials" xlink:title="NumberOfNewLibiGelEfficacyTrials" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="NumberOfNewLibiGelEfficacyTrials" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to NumberOfNewLibiGelEfficacyTrials" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:label="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:title="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" use="optional" order="8003.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureStockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="definition: LongtermDebtTypeDomain to ConvertibleNotesPayableMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_WarrantIssuedToInstitutionalInvestorsMember" xlink:label="WarrantIssuedToInstitutionalInvestorsMember" xlink:title="WarrantIssuedToInstitutionalInvestorsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantIssuedToInstitutionalInvestorsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantIssuedToInstitutionalInvestorsMember" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_WarrantIssuedToPlacementAgentsMember" xlink:label="WarrantIssuedToPlacementAgentsMember" xlink:title="WarrantIssuedToPlacementAgentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantIssuedToPlacementAgentsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantIssuedToPlacementAgentsMember" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockholdersEquityLineItems" xlink:label="StockholdersEquityLineItems" xlink:title="StockholdersEquityLineItems" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ScheduleOfStockholdersEquityTable" xlink:label="ScheduleOfStockholdersEquityTable" xlink:title="ScheduleOfStockholdersEquityTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StockholdersEquityLineItems" xlink:to="ScheduleOfStockholdersEquityTable" xlink:title="definition: StockholdersEquityLineItems to ScheduleOfStockholdersEquityTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="LongtermDebtTypeAxis" xlink:title="definition: ScheduleOfStockholdersEquityTable to LongtermDebtTypeAxis" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfStockholdersEquityTable to RangeAxis" use="optional" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ScheduleOfStockholdersEquityTable to ClassOfWarrantOrRightAxis" use="optional" order="3.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfStockholdersEquityTable to StatementEquityComponentsAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="definition: StockholdersEquityLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="DebtConversionOriginalDebtAmount1" xlink:title="definition: StockholdersEquityLineItems to DebtConversionOriginalDebtAmount1" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="InterestPayableCurrentAndNoncurrent" xlink:title="definition: StockholdersEquityLineItems to InterestPayableCurrentAndNoncurrent" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StockholdersEquityLineItems to StockIssuedDuringPeriodSharesNewIssues" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="SharePrice" xlink:title="definition: StockholdersEquityLineItems to SharePrice" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:label="NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:title="NumberOfInstitutionalInvestorsToWhomOfferingMade" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:title="definition: StockholdersEquityLineItems to NumberOfInstitutionalInvestorsToWhomOfferingMade" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ProceedsFromIssuanceOfCommonStockGross" xlink:label="ProceedsFromIssuanceOfCommonStockGross" xlink:title="ProceedsFromIssuanceOfCommonStockGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="ProceedsFromIssuanceOfCommonStockGross" xlink:title="definition: StockholdersEquityLineItems to ProceedsFromIssuanceOfCommonStockGross" use="optional" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="definition: StockholdersEquityLineItems to ProceedsFromIssuanceOrSaleOfEquity" use="optional" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ClassOfWarrantOrRightTermOfWarrants" xlink:label="ClassOfWarrantOrRightTermOfWarrants" xlink:title="ClassOfWarrantOrRightTermOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="ClassOfWarrantOrRightTermOfWarrants" xlink:title="definition: StockholdersEquityLineItems to ClassOfWarrantOrRightTermOfWarrants" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="definition: StockholdersEquityLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" use="optional" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockholdersEquityReverseStockSplitConversionRatio" xlink:label="StockholdersEquityReverseStockSplitConversionRatio" xlink:title="StockholdersEquityReverseStockSplitConversionRatio" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="StockholdersEquityReverseStockSplitConversionRatio" xlink:title="definition: StockholdersEquityLineItems to StockholdersEquityReverseStockSplitConversionRatio" use="optional" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: StockholdersEquityLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PaymentsToFractionalSharePayout" xlink:label="PaymentsToFractionalSharePayout" xlink:title="PaymentsToFractionalSharePayout" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityLineItems" xlink:to="PaymentsToFractionalSharePayout" xlink:title="definition: StockholdersEquityLineItems to PaymentsToFractionalSharePayout" use="optional" order="13.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="StockOptionsMember" xlink:title="StockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="StockOptionsMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to StockOptionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="WarrantMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to WarrantMember" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" use="optional" order="8002.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" use="optional" order="8003.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="EstimateOfFairValueFairValueDisclosureMember" xlink:title="EstimateOfFairValueFairValueDisclosureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="EstimateOfFairValueFairValueDisclosureMember" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to EstimateOfFairValueFairValueDisclosureMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByAssetClassAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByAssetClassAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="MoneyMarketFundsMember" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to MoneyMarketFundsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByLiabilityClassAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByLiabilityClassAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to ConvertibleNotesPayableMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="AssetsFairValueDisclosureAbstract" xlink:title="AssetsFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosureAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosureAbstract" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsFairValueDisclosureAbstract" xlink:to="AssetsFairValueDisclosure" xlink:title="definition: AssetsFairValueDisclosureAbstract to AssetsFairValueDisclosure" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosureAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosureAbstract" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="ConvertibleDebtFairValueDisclosures" xlink:title="ConvertibleDebtFairValueDisclosures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="ConvertibleDebtFairValueDisclosures" xlink:title="definition: LiabilitiesFairValueDisclosureAbstract to ConvertibleDebtFairValueDisclosures" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="definition: LiabilitiesFairValueDisclosureAbstract to LiabilitiesFairValueDisclosure" use="optional" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AptarPharmaMember" xlink:label="AptarPharmaMember" xlink:title="AptarPharmaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="AptarPharmaMember" xlink:title="definition: EntityDomain to AptarPharmaMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="LongTermPurchaseCommitmentLineItems" xlink:title="LongTermPurchaseCommitmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="LongTermPurchaseCommitmentTable" xlink:title="LongTermPurchaseCommitmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="LongTermPurchaseCommitmentTable" xlink:title="definition: LongTermPurchaseCommitmentLineItems to LongTermPurchaseCommitmentTable" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="definition: LongTermPurchaseCommitmentTable to LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="definition: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis to LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2" xlink:title="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2" xlink:title="definition: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis to LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalAdditionsMember" xlink:label="CapitalAdditionsMember" xlink:title="CapitalAdditionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="CapitalAdditionsMember" xlink:title="definition: LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain to CapitalAdditionsMember" use="optional" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="LegalEntityAxis" xlink:title="definition: LongTermPurchaseCommitmentTable to LegalEntityAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="LongTermPurchaseCommitmentAmount" xlink:title="LongTermPurchaseCommitmentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="LongTermPurchaseCommitmentAmount" xlink:title="definition: LongTermPurchaseCommitmentLineItems to LongTermPurchaseCommitmentAmount" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:label="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:title="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:title="definition: LongTermPurchaseCommitmentLineItems to PurchaseCommitmentCumulativePaymentsToAcquireMachinery" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="PurchaseObligation" xlink:title="PurchaseObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="PurchaseObligation" xlink:title="definition: LongTermPurchaseCommitmentLineItems to PurchaseObligation" use="optional" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" use="optional" order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="LitigationCaseAxis" xlink:title="LitigationCaseAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="LitigationCaseAxis" xlink:title="definition: LossContingenciesTable to LitigationCaseAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="LitigationCaseTypeDomain" xlink:title="LitigationCaseTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LitigationCaseAxis" xlink:to="LitigationCaseTypeDomain" xlink:title="definition: LitigationCaseAxis to LitigationCaseTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="LitigationCaseTypeDomain_2" xlink:title="LitigationCaseTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LitigationCaseAxis" xlink:to="LitigationCaseTypeDomain_2" xlink:title="definition: LitigationCaseAxis to LitigationCaseTypeDomain" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareholderDerivativeActionMember" xlink:label="ShareholderDerivativeActionMember" xlink:title="ShareholderDerivativeActionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LitigationCaseTypeDomain" xlink:to="ShareholderDerivativeActionMember" xlink:title="definition: LitigationCaseTypeDomain to ShareholderDerivativeActionMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfCasesConsolidated" xlink:label="NumberOfCasesConsolidated" xlink:title="NumberOfCasesConsolidated" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfCasesConsolidated" xlink:title="definition: LossContingenciesLineItems to NumberOfCasesConsolidated" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" use="optional" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="definition: ClassOfStockDomain to CommonClassCMember" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EntityRegistrantName" xlink:title="definition: StatementLineItems to EntityRegistrantName" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EntityCentralIndexKey" xlink:title="definition: StatementLineItems to EntityCentralIndexKey" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DocumentType" xlink:title="definition: StatementLineItems to DocumentType" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="definition: StatementLineItems to DocumentPeriodEndDate" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AmendmentFlag" xlink:title="definition: StatementLineItems to AmendmentFlag" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AmendmentDescription" xlink:title="definition: StatementLineItems to AmendmentDescription" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CurrentFiscalYearEndDate" xlink:title="definition: StatementLineItems to CurrentFiscalYearEndDate" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="definition: StatementLineItems to EntityWellKnownSeasonedIssuer" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EntityVoluntaryFilers" xlink:title="definition: StatementLineItems to EntityVoluntaryFilers" use="optional" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EntityCurrentReportingStatus" xlink:title="definition: StatementLineItems to EntityCurrentReportingStatus" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EntityFilerCategory" xlink:title="definition: StatementLineItems to EntityFilerCategory" use="optional" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EntityPublicFloat" xlink:title="definition: StatementLineItems to EntityPublicFloat" use="optional" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="definition: StatementLineItems to EntityCommonStockSharesOutstanding" use="optional" order="140.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="definition: StatementLineItems to DocumentFiscalYearFocus" use="optional" order="150.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="definition: StatementLineItems to DocumentFiscalPeriodFocus" use="optional" order="160.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" use="optional" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="definition: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="definition: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="definition: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="definition: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="definition: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="FairValueOptionChangesInFairValueGainLoss1" xlink:title="FairValueOptionChangesInFairValueGainLoss1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FairValueOptionChangesInFairValueGainLoss1" xlink:title="definition: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FairValueOptionChangesInFairValueGainLoss1" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="BusinessCombinationAcquisitionRelatedCosts" xlink:title="BusinessCombinationAcquisitionRelatedCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="BusinessCombinationAcquisitionRelatedCosts" xlink:title="definition: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to BusinessCombinationAcquisitionRelatedCosts" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ResearchAndDevelopmentInProcess" xlink:title="definition: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ResearchAndDevelopmentInProcess" use="optional" order="8010.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ExcessConsiderationPaidOverFairValue" xlink:label="ExcessConsiderationPaidOverFairValue" xlink:title="ExcessConsiderationPaidOverFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ExcessConsiderationPaidOverFairValue" xlink:title="definition: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ExcessConsiderationPaidOverFairValue" use="optional" order="8020.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:label="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:title="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:title="definition: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" use="optional" order="8030.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="OtherNoncashIncomeExpense" xlink:title="OtherNoncashIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OtherNoncashIncomeExpense" xlink:title="definition: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OtherNoncashIncomeExpense" use="optional" order="8040.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to IncreaseDecreaseInOperatingCapitalAbstract" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="IncreaseDecreaseInRoyaltiesPayable" xlink:title="IncreaseDecreaseInRoyaltiesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInRoyaltiesPayable" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInRoyaltiesPayable" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="definition: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" use="optional" order="8010.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="definition: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="PaymentsToAcquireInvestments" xlink:title="PaymentsToAcquireInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireInvestments" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireInvestments" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="PaymentsToAcquireShortTermInvestments" xlink:title="PaymentsToAcquireShortTermInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireShortTermInvestments" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireShortTermInvestments" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireProductiveAssets" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireProductiveAssets" use="optional" order="8010.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="ProceedsFromSaleOfShortTermInvestments" xlink:title="ProceedsFromSaleOfShortTermInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfShortTermInvestments" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfShortTermInvestments" use="optional" order="8020.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfProductiveAssets" xlink:title="definition: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfProductiveAssets" use="optional" order="8030.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PaymentsToFractionalSharePayout" xlink:label="PaymentsToFractionalSharePayout" xlink:title="PaymentsToFractionalSharePayout" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToFractionalSharePayout" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to PaymentsToFractionalSharePayout" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromStockOptionsExercised" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromWarrantExercises" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromWarrantExercises" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:label="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:title="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStock" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="ProceedsFromPaymentsForOtherFinancingActivities" xlink:title="ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromPaymentsForOtherFinancingActivities" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromPaymentsForOtherFinancingActivities" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="CashAcquiredFromAcquisition" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to CashAcquiredFromAcquisition" use="optional" order="8010.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_RepaymentsOfShortTermConvertibleDebt" xlink:label="RepaymentsOfShortTermConvertibleDebt" xlink:title="RepaymentsOfShortTermConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfShortTermConvertibleDebt" xlink:title="definition: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfShortTermConvertibleDebt" use="optional" order="8020.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInContinuingOperations" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInContinuingOperations" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="definition: StatementLineItems to SupplementalCashFlowInformationAbstract" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaid" xlink:title="definition: SupplementalCashFlowInformationAbstract to InterestPaid" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:title="OtherNoncashInvestingAndFinancingItemsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:title="definition: SupplementalCashFlowInformationAbstract to OtherNoncashInvestingAndFinancingItemsAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="StockIssued1" xlink:title="definition: OtherNoncashInvestingAndFinancingItemsAbstract to StockIssued1" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:label="UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:title="UnpaidCostsAssociatedWithRegisteredDirectOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:title="definition: OtherNoncashInvestingAndFinancingItemsAbstract to UnpaidCostsAssociatedWithRegisteredDirectOffering" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:label="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:title="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:title="definition: OtherNoncashInvestingAndFinancingItemsAbstract to UnpaidCostsAssociatedWithUnderWrittenPublicOffering" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="CapitalExpendituresIncurredButNotYetPaid" xlink:title="CapitalExpendituresIncurredButNotYetPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="CapitalExpendituresIncurredButNotYetPaid" xlink:title="definition: OtherNoncashInvestingAndFinancingItemsAbstract to CapitalExpendituresIncurredButNotYetPaid" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="definition: OtherNoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NoncashInvestment" xlink:label="NoncashInvestment" xlink:title="NoncashInvestment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashInvestment" xlink:title="definition: OtherNoncashInvestingAndFinancingItemsAbstract to NoncashInvestment" use="optional" order="8010.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:title="definition: OtherNoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" use="optional" order="8020.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:label="NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:title="NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:title="definition: OtherNoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" use="optional" order="8030.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:label="NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:title="NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:title="definition: OtherNoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" use="optional" order="8040.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="definition: StatementTable to StatementScenarioAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RevenuesAbstract" xlink:title="definition: StatementLineItems to RevenuesAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesAbstract" xlink:to="LicensesRevenue" xlink:title="definition: RevenuesAbstract to LicensesRevenue" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesAbstract" xlink:to="RoyaltyRevenue" xlink:title="definition: RevenuesAbstract to RoyaltyRevenue" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesAbstract" xlink:to="Revenues" xlink:title="definition: RevenuesAbstract to Revenues" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="OtherSalesRevenueNet" xlink:title="OtherSalesRevenueNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesAbstract" xlink:to="OtherSalesRevenueNet" xlink:title="definition: RevenuesAbstract to OtherSalesRevenueNet" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesAbstract" xlink:to="RevenueFromGrants" xlink:title="definition: RevenuesAbstract to RevenueFromGrants" use="optional" order="8010.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CostsAndExpensesAbstract" xlink:title="definition: StatementLineItems to CostsAndExpensesAbstract" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="definition: CostsAndExpensesAbstract to GeneralAndAdministrativeExpense" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="definition: CostsAndExpensesAbstract to DepreciationDepletionAndAmortization" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="CostsAndExpenses" xlink:title="definition: CostsAndExpensesAbstract to CostsAndExpenses" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="BusinessCombinationAcquisitionRelatedCosts" xlink:title="BusinessCombinationAcquisitionRelatedCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="BusinessCombinationAcquisitionRelatedCosts" xlink:title="definition: CostsAndExpensesAbstract to BusinessCombinationAcquisitionRelatedCosts" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentInProcess" xlink:title="definition: CostsAndExpensesAbstract to ResearchAndDevelopmentInProcess" order="8010.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ExcessConsiderationPaidOverFairValue" xlink:label="ExcessConsiderationPaidOverFairValue" xlink:title="ExcessConsiderationPaidOverFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="ExcessConsiderationPaidOverFairValue" xlink:title="definition: CostsAndExpensesAbstract to ExcessConsiderationPaidOverFairValue" use="optional" order="8020.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseCosts" xlink:label="LicenseCosts" xlink:title="LicenseCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CostsAndExpensesAbstract" xlink:to="LicenseCosts" xlink:title="definition: CostsAndExpensesAbstract to LicenseCosts" use="optional" order="8030.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="definition: StatementLineItems to NonoperatingIncomeExpenseAbstract" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="FairValueOptionChangesInFairValueGainLoss1" xlink:title="FairValueOptionChangesInFairValueGainLoss1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="FairValueOptionChangesInFairValueGainLoss1" xlink:title="definition: NonoperatingIncomeExpenseAbstract to FairValueOptionChangesInFairValueGainLoss1" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpense" xlink:title="definition: NonoperatingIncomeExpenseAbstract to InterestExpense" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncome" xlink:title="definition: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncome" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="definition: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:label="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:title="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:title="definition: NonoperatingIncomeExpenseAbstract to OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="definition: StatementLineItems to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="definition: StatementLineItems to EarningsPerShareBasicAndDiluted" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfSharesOutstandingAbstract" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="definition: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareAbstract" xlink:title="definition: StatementLineItems to EarningsPerShareAbstract" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="definition: EarningsPerShareAbstract to EarningsPerShareBasic" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="definition: EarningsPerShareAbstract to EarningsPerShareDiluted" use="optional" order="8010.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="definition: StatementLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="51.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="definition: StatementLineItems to IncomeTaxExpenseBenefit" order="52.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="definition: ClassOfStockDomain to CommonClassCMember" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="definition: StatementLineItems to AssetsAbstract" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="definition: AssetsAbstract to AssetsCurrentAbstract" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="definition: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="definition: AssetsCurrentAbstract to AssetsCurrent" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="OtherReceivablesGrossCurrent" xlink:title="OtherReceivablesGrossCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsCurrentAbstract" xlink:to="OtherReceivablesGrossCurrent" xlink:title="definition: AssetsCurrentAbstract to OtherReceivablesGrossCurrent" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: AssetsAbstract to PropertyPlantAndEquipmentNet" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="OtherAssetsNoncurrentAbstract" xlink:title="OtherAssetsNoncurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrentAbstract" xlink:title="definition: AssetsAbstract to OtherAssetsNoncurrentAbstract" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="LongTermInvestments" xlink:title="LongTermInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherAssetsNoncurrentAbstract" xlink:to="LongTermInvestments" xlink:title="definition: OtherAssetsNoncurrentAbstract to LongTermInvestments" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherAssetsNoncurrentAbstract" xlink:to="DepositsAssetsNoncurrent" xlink:title="definition: OtherAssetsNoncurrentAbstract to DepositsAssetsNoncurrent" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="definition: AssetsAbstract to Assets" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to EmployeeRelatedLiabilitiesCurrent" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to OtherAccruedLiabilitiesCurrent" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeniorNotesCurrent" xlink:label="SeniorNotesCurrent" xlink:title="SeniorNotesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="SeniorNotesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to SeniorNotesCurrent" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="AccruedRoyaltiesCurrent" xlink:title="AccruedRoyaltiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedRoyaltiesCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to AccruedRoyaltiesCurrent" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ConvertibleNotesPayableCurrent" xlink:title="definition: LiabilitiesCurrentAbstract to ConvertibleNotesPayableCurrent" order="8010.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="ConvertibleLongTermNotesPayable" xlink:title="ConvertibleLongTermNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="ConvertibleLongTermNotesPayable" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to ConvertibleLongTermNotesPayable" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CapitalStockAbstract" xlink:label="CapitalStockAbstract" xlink:title="CapitalStockAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="CapitalStockAbstract" xlink:title="definition: StockholdersEquityAbstract to CapitalStockAbstract" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="CommonStockValueOutstanding" xlink:title="CommonStockValueOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CapitalStockAbstract" xlink:to="CommonStockValueOutstanding" xlink:title="definition: CapitalStockAbstract to CommonStockValueOutstanding" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="definition: StockholdersEquityAbstract to StockholdersEquity" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="definition: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="50.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/BalanceSheetParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="definition: ClassOfStockDomain to CommonClassCMember" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: StatementLineItems to CommonStockSharesIssued" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: StatementLineItems to CommonStockSharesOutstanding" use="optional" order="30.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/StatementOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="10.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="definition: ClassOfStockDomain to CommonClassCMember" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" use="optional" order="20.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_IssuanceOfCommonSharesAbstract" xlink:label="IssuanceOfCommonSharesAbstract" xlink:title="IssuanceOfCommonSharesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="IssuanceOfCommonSharesAbstract" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to IssuanceOfCommonSharesAbstract" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IssuanceOfCommonSharesAbstract" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: IssuanceOfCommonSharesAbstract to StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IssuanceOfCommonSharesAbstract" xlink:to="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="definition: IssuanceOfCommonSharesAbstract to StockIssuedDuringPeriodValueWarrantsExercised" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="definition: StockIssuedDuringPeriodValueWarrantsExercised to StockIssuedDuringPeriodSharesWarrantsExercised" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:label="StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:title="StockIssuedDuringPeriodValueCommonSharesAndWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueCommonSharesAndWarrants" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:label="StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:title="StockIssuedDuringPeriodCommonSharesAndWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:to="StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:title="definition: StockIssuedDuringPeriodValueCommonSharesAndWarrants to StockIssuedDuringPeriodCommonSharesAndWarrants" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAcquisitions" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: StockIssuedDuringPeriodValueAcquisitions to StockIssuedDuringPeriodSharesAcquisitions" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:label="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:title="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityPeriodIncreaseDecrease" xlink:title="definition: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityPeriodIncreaseDecrease" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="definition: StockholdersEquityPeriodIncreaseDecrease to StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" use="optional" order="10.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="8000.0" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="StockOptionsMember" xlink:title="StockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockOptionsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to StockOptionsMember" use="optional" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="ConvertibleDebtSecuritiesMember" xlink:title="ConvertibleDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertibleDebtSecuritiesMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to ConvertibleDebtSecuritiesMember" use="optional" order="8002.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to RangeAxis" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" use="optional" order="8002.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>bpax-20120930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:label="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:title="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xml:lang="en-US" id="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany">Number of Directors of Entity in Board of Directors of Combined Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:to="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:title="label: NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany to label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xml:lang="en-US" id="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany_2">Number of directors of the entity in board of directors of the combined company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:to="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany_2" xlink:title="label: NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany to label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xml:lang="en-US" id="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany_3">Represents the number of directors of the entity in board of directors of the combined company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:to="label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany_3" xlink:title="label: NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany to label_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:label="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:title="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" />
    <link:label xlink:type="resource" xlink:label="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xml:lang="en-US" id="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights">Period During which Net Cash Payments can be Received after Distribution of Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:to="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:title="label: PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights to label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xml:lang="en-US" id="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights_2">Period during which net cash payments can be received after distribution of rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:to="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights_2" xlink:title="label: PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights to label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xml:lang="en-US" id="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights_3">Represents the period during which net cash payments can be received after distribution of rights from contingent value rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:to="label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights_3" xlink:title="label: PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights to label_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:label="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:title="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" />
    <link:label xlink:type="resource" xlink:label="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xml:lang="en-US" id="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived">Net Cash Payments to be Distributed to Holders Expressed as Percentage of Net Cash Payments Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:to="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:title="label: NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived to label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xml:lang="en-US" id="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived_2">Net cash payments to be distributed to holders of the CVRs expressed as percentage of net cash payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:to="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived_2" xlink:title="label: NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived to label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xml:lang="en-US" id="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived_3">Represents the net cash payments to be distributed to holders of the contingent value rights expressed as percentage of net cash payments received by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:to="label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived_3" xlink:title="label: NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived to label_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AggregateNetCashPaymentsToBeDistributedToHolders" xlink:label="AggregateNetCashPaymentsToBeDistributedToHolders" xlink:title="AggregateNetCashPaymentsToBeDistributedToHolders" />
    <link:label xlink:type="resource" xlink:label="label_AggregateNetCashPaymentsToBeDistributedToHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AggregateNetCashPaymentsToBeDistributedToHolders" xml:lang="en-US" id="label_AggregateNetCashPaymentsToBeDistributedToHolders">Aggregate Net Cash Payments to be Distributed to Holders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateNetCashPaymentsToBeDistributedToHolders" xlink:to="label_AggregateNetCashPaymentsToBeDistributedToHolders" xlink:title="label: AggregateNetCashPaymentsToBeDistributedToHolders to label_AggregateNetCashPaymentsToBeDistributedToHolders" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AggregateNetCashPaymentsToBeDistributedToHolders_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AggregateNetCashPaymentsToBeDistributedToHolders" xml:lang="en-US" id="label_AggregateNetCashPaymentsToBeDistributedToHolders_2">Aggregate net cash payments to be distributed to holders of CVRs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateNetCashPaymentsToBeDistributedToHolders" xlink:to="label_AggregateNetCashPaymentsToBeDistributedToHolders_2" xlink:title="label: AggregateNetCashPaymentsToBeDistributedToHolders to label_AggregateNetCashPaymentsToBeDistributedToHolders" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AggregateNetCashPaymentsToBeDistributedToHolders_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AggregateNetCashPaymentsToBeDistributedToHolders" xml:lang="en-US" id="label_AggregateNetCashPaymentsToBeDistributedToHolders_3">Represents the aggregate net cash payments to be distributed to holders of the contingent value rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateNetCashPaymentsToBeDistributedToHolders" xlink:to="label_AggregateNetCashPaymentsToBeDistributedToHolders_3" xlink:title="label: AggregateNetCashPaymentsToBeDistributedToHolders to label_AggregateNetCashPaymentsToBeDistributedToHolders" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NetCashRequiredToObligateEntityToEffectMerger" xlink:label="NetCashRequiredToObligateEntityToEffectMerger" xlink:title="NetCashRequiredToObligateEntityToEffectMerger" />
    <link:label xlink:type="resource" xlink:label="label_NetCashRequiredToObligateEntityToEffectMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashRequiredToObligateEntityToEffectMerger" xml:lang="en-US" id="label_NetCashRequiredToObligateEntityToEffectMerger">Net Cash Required to Obligate Entity to Effect Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashRequiredToObligateEntityToEffectMerger" xlink:to="label_NetCashRequiredToObligateEntityToEffectMerger" xlink:title="label: NetCashRequiredToObligateEntityToEffectMerger to label_NetCashRequiredToObligateEntityToEffectMerger" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashRequiredToObligateEntityToEffectMerger_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashRequiredToObligateEntityToEffectMerger" xml:lang="en-US" id="label_NetCashRequiredToObligateEntityToEffectMerger_2">Net cash required to obligate the entity to effect merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashRequiredToObligateEntityToEffectMerger" xlink:to="label_NetCashRequiredToObligateEntityToEffectMerger_2" xlink:title="label: NetCashRequiredToObligateEntityToEffectMerger to label_NetCashRequiredToObligateEntityToEffectMerger" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashRequiredToObligateEntityToEffectMerger_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NetCashRequiredToObligateEntityToEffectMerger" xml:lang="en-US" id="label_NetCashRequiredToObligateEntityToEffectMerger_3">Represents the amount of net cash required to obligate the entity to effect merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashRequiredToObligateEntityToEffectMerger" xlink:to="label_NetCashRequiredToObligateEntityToEffectMerger_3" xlink:title="label: NetCashRequiredToObligateEntityToEffectMerger to label_NetCashRequiredToObligateEntityToEffectMerger" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:label="UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:title="UnpaidCostsAssociatedWithRegisteredDirectOffering" />
    <link:label xlink:type="resource" xlink:label="label_UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UnpaidCostsAssociatedWithRegisteredDirectOffering" xml:lang="en-US" id="label_UnpaidCostsAssociatedWithRegisteredDirectOffering">Unpaid Costs Associated With Registered Direct Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:to="label_UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:title="label: UnpaidCostsAssociatedWithRegisteredDirectOffering to label_UnpaidCostsAssociatedWithRegisteredDirectOffering" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_UnpaidCostsAssociatedWithRegisteredDirectOffering_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_UnpaidCostsAssociatedWithRegisteredDirectOffering" xml:lang="en-US" id="label_UnpaidCostsAssociatedWithRegisteredDirectOffering_2">Unpaid costs associated with registered direct offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:to="label_UnpaidCostsAssociatedWithRegisteredDirectOffering_2" xlink:title="label: UnpaidCostsAssociatedWithRegisteredDirectOffering to label_UnpaidCostsAssociatedWithRegisteredDirectOffering" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_UnpaidCostsAssociatedWithRegisteredDirectOffering_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_UnpaidCostsAssociatedWithRegisteredDirectOffering" xml:lang="en-US" id="label_UnpaidCostsAssociatedWithRegisteredDirectOffering_3">Represents the amount of unpaid costs associated with registered direct offering in a noncash or partial noncash transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:to="label_UnpaidCostsAssociatedWithRegisteredDirectOffering_3" xlink:title="label: UnpaidCostsAssociatedWithRegisteredDirectOffering to label_UnpaidCostsAssociatedWithRegisteredDirectOffering" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AwardTypeAxis" xml:lang="en-US" id="label_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="label_AwardTypeAxis" xlink:title="label: AwardTypeAxis to label_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:label="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:title="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" />
    <link:label xlink:type="resource" xlink:label="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xml:lang="en-US" id="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted">Period for Which Cash and Cash Equivalents Will Meet Liquidity Requirements if Pending MergerIs Not Completed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:to="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:title="label: PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted to label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xml:lang="en-US" id="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted_2">Period for which cash and cash equivalents will meet liquidity requirements, if the pending merger is not completed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:to="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted_2" xlink:title="label: PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted to label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xml:lang="en-US" id="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted_3">Represents the period for which cash and cash equivalents will meet liquidity requirements, if the entity's pending merger is not completed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:to="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted_3" xlink:title="label: PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted to label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareholderDerivativeActionMember" xlink:label="ShareholderDerivativeActionMember" xlink:title="ShareholderDerivativeActionMember" />
    <link:label xlink:type="resource" xlink:label="label_ShareholderDerivativeActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareholderDerivativeActionMember" xml:lang="en-US" id="label_ShareholderDerivativeActionMember">Shareholder derivative action</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareholderDerivativeActionMember" xlink:to="label_ShareholderDerivativeActionMember" xlink:title="label: ShareholderDerivativeActionMember to label_ShareholderDerivativeActionMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareholderDerivativeActionMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareholderDerivativeActionMember" xml:lang="en-US" id="label_ShareholderDerivativeActionMember_2">Represents information pertaining to the shareholder derivative action filed against the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareholderDerivativeActionMember" xlink:to="label_ShareholderDerivativeActionMember_2" xlink:title="label: ShareholderDerivativeActionMember to label_ShareholderDerivativeActionMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareholderDerivativeActionMember_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareholderDerivativeActionMember" xml:lang="en-US" id="label_ShareholderDerivativeActionMember_3">Shareholder Derivative Action [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareholderDerivativeActionMember" xlink:to="label_ShareholderDerivativeActionMember_3" xlink:title="label: ShareholderDerivativeActionMember to label_ShareholderDerivativeActionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfCasesConsolidated" xlink:label="NumberOfCasesConsolidated" xlink:title="NumberOfCasesConsolidated" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfCasesConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfCasesConsolidated" xml:lang="en-US" id="label_NumberOfCasesConsolidated">Number of Cases Consolidated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCasesConsolidated" xlink:to="label_NumberOfCasesConsolidated" xlink:title="label: NumberOfCasesConsolidated to label_NumberOfCasesConsolidated" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfCasesConsolidated_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfCasesConsolidated" xml:lang="en-US" id="label_NumberOfCasesConsolidated_2">Number of cases consolidated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCasesConsolidated" xlink:to="label_NumberOfCasesConsolidated_2" xlink:title="label: NumberOfCasesConsolidated to label_NumberOfCasesConsolidated" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfCasesConsolidated_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfCasesConsolidated" xml:lang="en-US" id="label_NumberOfCasesConsolidated_3">Represents the number of cases that were consolidated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCasesConsolidated" xlink:to="label_NumberOfCasesConsolidated_3" xlink:title="label: NumberOfCasesConsolidated to label_NumberOfCasesConsolidated" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ReverseStockSplitConversionRatio" xlink:label="ReverseStockSplitConversionRatio" xlink:title="ReverseStockSplitConversionRatio" />
    <link:label xlink:type="resource" xlink:label="label_ReverseStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ReverseStockSplitConversionRatio" xml:lang="en-US" id="label_ReverseStockSplitConversionRatio">Reverse Stock Split Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitConversionRatio" xlink:to="label_ReverseStockSplitConversionRatio" xlink:title="label: ReverseStockSplitConversionRatio to label_ReverseStockSplitConversionRatio" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ReverseStockSplitConversionRatio_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ReverseStockSplitConversionRatio" xml:lang="en-US" id="label_ReverseStockSplitConversionRatio_2">Reverse split ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitConversionRatio" xlink:to="label_ReverseStockSplitConversionRatio_2" xlink:title="label: ReverseStockSplitConversionRatio to label_ReverseStockSplitConversionRatio" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ReverseStockSplitConversionRatio_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ReverseStockSplitConversionRatio" xml:lang="en-US" id="label_ReverseStockSplitConversionRatio_3">Represents the conversion ratio used in the calculation of a reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitConversionRatio" xlink:to="label_ReverseStockSplitConversionRatio_3" xlink:title="label: ReverseStockSplitConversionRatio to label_ReverseStockSplitConversionRatio" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentDescription" xml:lang="en-US" id="label_AmendmentDescription">Amendment Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentDescription" xlink:to="label_AmendmentDescription" xlink:title="label: AmendmentDescription to label_AmendmentDescription" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_BusinessMergerTerminationFeePayable" xlink:label="BusinessMergerTerminationFeePayable" xlink:title="BusinessMergerTerminationFeePayable" />
    <link:label xlink:type="resource" xlink:label="label_BusinessMergerTerminationFeePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessMergerTerminationFeePayable" xml:lang="en-US" id="label_BusinessMergerTerminationFeePayable">Business Merger Termination Fee Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessMergerTerminationFeePayable" xlink:to="label_BusinessMergerTerminationFeePayable" xlink:title="label: BusinessMergerTerminationFeePayable to label_BusinessMergerTerminationFeePayable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BusinessMergerTerminationFeePayable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessMergerTerminationFeePayable" xml:lang="en-US" id="label_BusinessMergerTerminationFeePayable_2">Termination fee payable under specified circumstances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessMergerTerminationFeePayable" xlink:to="label_BusinessMergerTerminationFeePayable_2" xlink:title="label: BusinessMergerTerminationFeePayable to label_BusinessMergerTerminationFeePayable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BusinessMergerTerminationFeePayable_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BusinessMergerTerminationFeePayable" xml:lang="en-US" id="label_BusinessMergerTerminationFeePayable_3">Represents the amount of a termination fee that may be payable on meeting of certain triggering events specified in the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessMergerTerminationFeePayable" xlink:to="label_BusinessMergerTerminationFeePayable_3" xlink:title="label: BusinessMergerTerminationFeePayable to label_BusinessMergerTerminationFeePayable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentFlag" xml:lang="en-US" id="label_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="label_AmendmentFlag" xlink:title="label: AmendmentFlag to label_AmendmentFlag" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_BusinessMergerReimbursementOfExpenses" xlink:label="BusinessMergerReimbursementOfExpenses" xlink:title="BusinessMergerReimbursementOfExpenses" />
    <link:label xlink:type="resource" xlink:label="label_BusinessMergerReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessMergerReimbursementOfExpenses" xml:lang="en-US" id="label_BusinessMergerReimbursementOfExpenses">Business Merger Reimbursement of Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessMergerReimbursementOfExpenses" xlink:to="label_BusinessMergerReimbursementOfExpenses" xlink:title="label: BusinessMergerReimbursementOfExpenses to label_BusinessMergerReimbursementOfExpenses" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BusinessMergerReimbursementOfExpenses_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessMergerReimbursementOfExpenses" xml:lang="en-US" id="label_BusinessMergerReimbursementOfExpenses_2">Reimbursement of expenses in connection with merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessMergerReimbursementOfExpenses" xlink:to="label_BusinessMergerReimbursementOfExpenses_2" xlink:title="label: BusinessMergerReimbursementOfExpenses to label_BusinessMergerReimbursementOfExpenses" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BusinessMergerReimbursementOfExpenses_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_BusinessMergerReimbursementOfExpenses" xml:lang="en-US" id="label_BusinessMergerReimbursementOfExpenses_3">Represents the amount of reimbursement of expenses in connection with merger on meeting certain specified circumstances as specified in the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessMergerReimbursementOfExpenses" xlink:to="label_BusinessMergerReimbursementOfExpenses_3" xlink:title="label: BusinessMergerReimbursementOfExpenses to label_BusinessMergerReimbursementOfExpenses" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:label="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:title="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xml:lang="en-US" id="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders">Percentage of Outstanding Shares of Capital Stock Held by Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:to="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:title="label: PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders to label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xml:lang="en-US" id="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders_2">Percentage of outstanding shares of capital stock held by stockholders as of the close of business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:to="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders_2" xlink:title="label: PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders to label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xml:lang="en-US" id="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders_3">Represents the percentage of outstanding shares of capital stock held by stockholders as of the close of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:to="label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders_3" xlink:title="label: PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders to label_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:label="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:title="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xml:lang="en-US" id="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock">Number of Stockholders Holding Specified Percentage of Outstanding Shares of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:to="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:title="label: NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock to label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xml:lang="en-US" id="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock_2">Number of stockholders holding 57 percent of outstanding shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:to="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock_2" xlink:title="label: NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock to label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xml:lang="en-US" id="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock_3">Represents the number of stockholders holding specified percentage of outstanding shares of common stock as of the close of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:to="label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock_3" xlink:title="label: NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock to label_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:label="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:title="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xml:lang="en-US" id="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors">Percentage of Outstanding Shares of Common Stock Held by Stockholders Who Agreed to Vote in Favor of Election of Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:to="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:title="label: PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors to label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xml:lang="en-US" id="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors_2">Percentage of outstanding shares of common stock held by stockholders who agreed to vote in favor of election of directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:to="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors_2" xlink:title="label: PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors to label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xml:lang="en-US" id="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors_3">Represents the percentage of outstanding shares of common stock held by stockholders as of the close of business, who agreed to vote in favor of election of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:to="label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors_3" xlink:title="label: PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors to label_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDirectorsDesignatedByEntity" xlink:label="NumberOfDirectorsDesignatedByEntity" xlink:title="NumberOfDirectorsDesignatedByEntity" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDirectorsDesignatedByEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfDirectorsDesignatedByEntity" xml:lang="en-US" id="label_NumberOfDirectorsDesignatedByEntity">Number of Directors Designated by Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsDesignatedByEntity" xlink:to="label_NumberOfDirectorsDesignatedByEntity" xlink:title="label: NumberOfDirectorsDesignatedByEntity to label_NumberOfDirectorsDesignatedByEntity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDirectorsDesignatedByEntity_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfDirectorsDesignatedByEntity" xml:lang="en-US" id="label_NumberOfDirectorsDesignatedByEntity_2">Number of directors designated by the entity at the first annual meeting of stockholders following the completion of the Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsDesignatedByEntity" xlink:to="label_NumberOfDirectorsDesignatedByEntity_2" xlink:title="label: NumberOfDirectorsDesignatedByEntity to label_NumberOfDirectorsDesignatedByEntity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDirectorsDesignatedByEntity_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfDirectorsDesignatedByEntity" xml:lang="en-US" id="label_NumberOfDirectorsDesignatedByEntity_3">Represents the number of directors designated by the entity at the first annual meeting of stockholders following the completion of the merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsDesignatedByEntity" xlink:to="label_NumberOfDirectorsDesignatedByEntity_3" xlink:title="label: NumberOfDirectorsDesignatedByEntity to label_NumberOfDirectorsDesignatedByEntity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:label="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:title="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xml:lang="en-US" id="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements">Percentage of Outstanding Shares of Common Stock Held by Specified Personnel Who Entered Into Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:to="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:title="label: PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements to label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xml:lang="en-US" id="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements_2">Percentage of outstanding shares of common stock held collectively by specified personnel who entered into voting agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:to="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements_2" xlink:title="label: PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements to label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xml:lang="en-US" id="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements_3">Represents the percentage of outstanding shares of common stock held by specified personnel as of the close of business, who entered into agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:to="label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements_3" xlink:title="label: PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements to label_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LockingPeriodOnSaleOfSharesPostMerger" xlink:label="LockingPeriodOnSaleOfSharesPostMerger" xlink:title="LockingPeriodOnSaleOfSharesPostMerger" />
    <link:label xlink:type="resource" xlink:label="label_LockingPeriodOnSaleOfSharesPostMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LockingPeriodOnSaleOfSharesPostMerger" xml:lang="en-US" id="label_LockingPeriodOnSaleOfSharesPostMerger">Locking Period on Sale of Shares Post Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockingPeriodOnSaleOfSharesPostMerger" xlink:to="label_LockingPeriodOnSaleOfSharesPostMerger" xlink:title="label: LockingPeriodOnSaleOfSharesPostMerger to label_LockingPeriodOnSaleOfSharesPostMerger" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LockingPeriodOnSaleOfSharesPostMerger_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LockingPeriodOnSaleOfSharesPostMerger" xml:lang="en-US" id="label_LockingPeriodOnSaleOfSharesPostMerger_2">Locking period on the sale of shares of the Company's common stock received in the Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockingPeriodOnSaleOfSharesPostMerger" xlink:to="label_LockingPeriodOnSaleOfSharesPostMerger_2" xlink:title="label: LockingPeriodOnSaleOfSharesPostMerger to label_LockingPeriodOnSaleOfSharesPostMerger" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LockingPeriodOnSaleOfSharesPostMerger_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LockingPeriodOnSaleOfSharesPostMerger" xml:lang="en-US" id="label_LockingPeriodOnSaleOfSharesPostMerger_3">Represents the locking period on the sale of shares of the entity's common stock received in the merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockingPeriodOnSaleOfSharesPostMerger" xlink:to="label_LockingPeriodOnSaleOfSharesPostMerger_3" xlink:title="label: LockingPeriodOnSaleOfSharesPostMerger to label_LockingPeriodOnSaleOfSharesPostMerger" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:label="NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:title="NumberOfContingentValueRightsIssuedInExchangeForOneShare" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare" xml:lang="en-US" id="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare">Represents the number of contingent value rights issued in exchange for one share of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:to="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:title="label: NumberOfContingentValueRightsIssuedInExchangeForOneShare to label_NumberOfContingentValueRightsIssuedInExchangeForOneShare" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare" xml:lang="en-US" id="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare_2">Number of Contingent Value Rights Issued in Exchange for One Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:to="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare_2" xlink:title="label: NumberOfContingentValueRightsIssuedInExchangeForOneShare to label_NumberOfContingentValueRightsIssuedInExchangeForOneShare" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare" xml:lang="en-US" id="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare_3">Number of contingent value rights issued in exchange for one share of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:to="label_NumberOfContingentValueRightsIssuedInExchangeForOneShare_3" xlink:title="label: NumberOfContingentValueRightsIssuedInExchangeForOneShare to label_NumberOfContingentValueRightsIssuedInExchangeForOneShare" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CapitalStockAbstract" xlink:label="CapitalStockAbstract" xlink:title="CapitalStockAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CapitalStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CapitalStockAbstract" xml:lang="en-US" id="label_CapitalStockAbstract">Capital Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalStockAbstract" xlink:to="label_CapitalStockAbstract" xlink:title="label: CapitalStockAbstract to label_CapitalStockAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CapitalStockAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CapitalStockAbstract" xml:lang="en-US" id="label_CapitalStockAbstract_2">Capital stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalStockAbstract" xlink:to="label_CapitalStockAbstract_2" xlink:title="label: CapitalStockAbstract to label_CapitalStockAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xlink:label="NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xlink:title="NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xml:lang="en-US" id="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation">Represents the number of cancer vaccines developed by the entity which have been granted FDA orphan drug designation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xlink:to="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xlink:title="label: NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation to label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xml:lang="en-US" id="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation_2">Number of Vaccines Granted with FDA Orphan Drug Designation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xlink:to="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation_2" xlink:title="label: NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation to label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xml:lang="en-US" id="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation_3">Number of cancer vaccines that have been granted FDA orphan drug designation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xlink:to="label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation_3" xlink:title="label: NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation to label_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfPhaseIAndPhaseIIClinicalTrials" xlink:label="NumberOfPhaseIAndPhaseIIClinicalTrials" xlink:title="NumberOfPhaseIAndPhaseIIClinicalTrials" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfPhaseIAndPhaseIIClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfPhaseIAndPhaseIIClinicalTrials" xml:lang="en-US" id="label_NumberOfPhaseIAndPhaseIIClinicalTrials">Number of Phase I and Phase II Clinical Trials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPhaseIAndPhaseIIClinicalTrials" xlink:to="label_NumberOfPhaseIAndPhaseIIClinicalTrials" xlink:title="label: NumberOfPhaseIAndPhaseIIClinicalTrials to label_NumberOfPhaseIAndPhaseIIClinicalTrials" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfPhaseIAndPhaseIIClinicalTrials_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfPhaseIAndPhaseIIClinicalTrials" xml:lang="en-US" id="label_NumberOfPhaseIAndPhaseIIClinicalTrials_2">Number of Phase I and Phase II clinical trials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPhaseIAndPhaseIIClinicalTrials" xlink:to="label_NumberOfPhaseIAndPhaseIIClinicalTrials_2" xlink:title="label: NumberOfPhaseIAndPhaseIIClinicalTrials to label_NumberOfPhaseIAndPhaseIIClinicalTrials" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfPhaseIAndPhaseIIClinicalTrials_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfPhaseIAndPhaseIIClinicalTrials" xml:lang="en-US" id="label_NumberOfPhaseIAndPhaseIIClinicalTrials_3">Represents the number of Phase I and Phase II clinical trials for the treatment of various cancers in which the entity is participating.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPhaseIAndPhaseIIClinicalTrials" xlink:to="label_NumberOfPhaseIAndPhaseIIClinicalTrials_3" xlink:title="label: NumberOfPhaseIAndPhaseIIClinicalTrials to label_NumberOfPhaseIAndPhaseIIClinicalTrials" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:label="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:title="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xml:lang="en-US" id="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued">Number of Debt Instrument, Holders to Whom Shares are Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:to="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:title="label: NumberOfDebtInstrumentHoldersToWhomSharesAreIssued to label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xml:lang="en-US" id="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued_2">Number of holders of debt instrument to whom shares are issued by the entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:to="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued_2" xlink:title="label: NumberOfDebtInstrumentHoldersToWhomSharesAreIssued to label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xml:lang="en-US" id="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued_3">Represents the number of holders of debt instrument to whom shares are issued by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:to="label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued_3" xlink:title="label: NumberOfDebtInstrumentHoldersToWhomSharesAreIssued to label_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:label="NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:title="NumberOfNewLibiGelPhaseIIIEfficacyTrials" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials" xml:lang="en-US" id="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials">Number of New LibiGel Phase III Efficacy Trials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:to="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:title="label: NumberOfNewLibiGelPhaseIIIEfficacyTrials to label_NumberOfNewLibiGelPhaseIIIEfficacyTrials" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials" xml:lang="en-US" id="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials_2">Number of new LibiGel Phase III efficacy trials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:to="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials_2" xlink:title="label: NumberOfNewLibiGelPhaseIIIEfficacyTrials to label_NumberOfNewLibiGelPhaseIIIEfficacyTrials" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials" xml:lang="en-US" id="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials_3">Represents the number of new LibiGel Phase III efficacy trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:to="label_NumberOfNewLibiGelPhaseIIIEfficacyTrials_3" xlink:title="label: NumberOfNewLibiGelPhaseIIIEfficacyTrials to label_NumberOfNewLibiGelPhaseIIIEfficacyTrials" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xlink:label="RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xlink:title="RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" />
    <link:label xlink:type="resource" xlink:label="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xml:lang="en-US" id="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers">Right of Entity to Designate Members on Board of Investee Number of Members</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xlink:to="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xlink:title="label: RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers to label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xml:lang="en-US" id="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers_2">Number of members that the entity can designate on board of directors of Ceregene, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xlink:to="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers_2" xlink:title="label: RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers to label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xml:lang="en-US" id="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers_3">Represents the number of members that can be designated on board of directors of the investee by virtue of their stock ownership in that entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xlink:to="label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers_3" xlink:title="label: RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers to label_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfSeriesOfConvertibleNotesAssumed" xlink:label="NumberOfSeriesOfConvertibleNotesAssumed" xlink:title="NumberOfSeriesOfConvertibleNotesAssumed" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfSeriesOfConvertibleNotesAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfSeriesOfConvertibleNotesAssumed" xml:lang="en-US" id="label_NumberOfSeriesOfConvertibleNotesAssumed">Number of series of convertible notes assumed in merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSeriesOfConvertibleNotesAssumed" xlink:to="label_NumberOfSeriesOfConvertibleNotesAssumed" xlink:title="label: NumberOfSeriesOfConvertibleNotesAssumed to label_NumberOfSeriesOfConvertibleNotesAssumed" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfSeriesOfConvertibleNotesAssumed_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfSeriesOfConvertibleNotesAssumed" xml:lang="en-US" id="label_NumberOfSeriesOfConvertibleNotesAssumed_2">Represents the number of series of convertible notes assumed by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSeriesOfConvertibleNotesAssumed" xlink:to="label_NumberOfSeriesOfConvertibleNotesAssumed_2" xlink:title="label: NumberOfSeriesOfConvertibleNotesAssumed to label_NumberOfSeriesOfConvertibleNotesAssumed" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfSeriesOfConvertibleNotesAssumed_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfSeriesOfConvertibleNotesAssumed" xml:lang="en-US" id="label_NumberOfSeriesOfConvertibleNotesAssumed_3">Number of Series of Convertible Notes Assumed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSeriesOfConvertibleNotesAssumed" xlink:to="label_NumberOfSeriesOfConvertibleNotesAssumed_3" xlink:title="label: NumberOfSeriesOfConvertibleNotesAssumed to label_NumberOfSeriesOfConvertibleNotesAssumed" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DescriptionOfBusinessDisclosureAbstract" xlink:label="DescriptionOfBusinessDisclosureAbstract" xlink:title="DescriptionOfBusinessDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DescriptionOfBusinessDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DescriptionOfBusinessDisclosureAbstract" xml:lang="en-US" id="label_DescriptionOfBusinessDisclosureAbstract">DESCRIPTION OF BUSINESS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfBusinessDisclosureAbstract" xlink:to="label_DescriptionOfBusinessDisclosureAbstract" xlink:title="label: DescriptionOfBusinessDisclosureAbstract to label_DescriptionOfBusinessDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="label_CurrentFiscalYearEndDate" xlink:title="label: CurrentFiscalYearEndDate to label_CurrentFiscalYearEndDate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LiquidityAndCapitalResourcesDisclosureAbstract" xlink:label="LiquidityAndCapitalResourcesDisclosureAbstract" xlink:title="LiquidityAndCapitalResourcesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiquidityAndCapitalResourcesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiquidityAndCapitalResourcesDisclosureAbstract" xml:lang="en-US" id="label_LiquidityAndCapitalResourcesDisclosureAbstract">LIQUIDITY AND CAPITAL RESOURCES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesDisclosureAbstract" xlink:to="label_LiquidityAndCapitalResourcesDisclosureAbstract" xlink:title="label: LiquidityAndCapitalResourcesDisclosureAbstract to label_LiquidityAndCapitalResourcesDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LiquidityAndCapitalResourcesLineItems" xlink:label="LiquidityAndCapitalResourcesLineItems" xlink:title="LiquidityAndCapitalResourcesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_LiquidityAndCapitalResourcesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiquidityAndCapitalResourcesLineItems" xml:lang="en-US" id="label_LiquidityAndCapitalResourcesLineItems">Liquidity and Capital Resources [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="label_LiquidityAndCapitalResourcesLineItems" xlink:title="label: LiquidityAndCapitalResourcesLineItems to label_LiquidityAndCapitalResourcesLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiquidityAndCapitalResourcesLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiquidityAndCapitalResourcesLineItems" xml:lang="en-US" id="label_LiquidityAndCapitalResourcesLineItems_2">Liquidity and capital resources</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="label_LiquidityAndCapitalResourcesLineItems_2" xlink:title="label: LiquidityAndCapitalResourcesLineItems to label_LiquidityAndCapitalResourcesLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LicenseAgreementsDisclosureAbstract" xlink:label="LicenseAgreementsDisclosureAbstract" xlink:title="LicenseAgreementsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LicenseAgreementsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LicenseAgreementsDisclosureAbstract" xml:lang="en-US" id="label_LicenseAgreementsDisclosureAbstract">LICENSE AGREEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAgreementsDisclosureAbstract" xlink:to="label_LicenseAgreementsDisclosureAbstract" xlink:title="label: LicenseAgreementsDisclosureAbstract to label_LicenseAgreementsDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LicenseAgreementsDisclosureTextBlock" xlink:label="LicenseAgreementsDisclosureTextBlock" xlink:title="LicenseAgreementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_LicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LicenseAgreementsDisclosureTextBlock" xml:lang="en-US" id="label_LicenseAgreementsDisclosureTextBlock">LICENSE AGREEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAgreementsDisclosureTextBlock" xlink:to="label_LicenseAgreementsDisclosureTextBlock" xlink:title="label: LicenseAgreementsDisclosureTextBlock to label_LicenseAgreementsDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LicenseAgreementsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LicenseAgreementsDisclosureTextBlock" xml:lang="en-US" id="label_LicenseAgreementsDisclosureTextBlock_2">License Agreements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAgreementsDisclosureTextBlock" xlink:to="label_LicenseAgreementsDisclosureTextBlock_2" xlink:title="label: LicenseAgreementsDisclosureTextBlock to label_LicenseAgreementsDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LicenseAgreementsDisclosureTextBlock_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LicenseAgreementsDisclosureTextBlock" xml:lang="en-US" id="label_LicenseAgreementsDisclosureTextBlock_3">The entire disclosure for all or part of the information related to license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAgreementsDisclosureTextBlock" xlink:to="label_LicenseAgreementsDisclosureTextBlock_3" xlink:title="label: LicenseAgreementsDisclosureTextBlock to label_LicenseAgreementsDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:label="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:title="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" />
    <link:label xlink:type="resource" xlink:label="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xml:lang="en-US" id="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering">Unpaid Costs Associated with Under Written Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:to="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:title="label: UnpaidCostsAssociatedWithUnderWrittenPublicOffering to label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xml:lang="en-US" id="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering_2">Unpaid costs associated with underwritten public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:to="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering_2" xlink:title="label: UnpaidCostsAssociatedWithUnderWrittenPublicOffering to label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xml:lang="en-US" id="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering_3">Represents the amount of unpaid costs associated with underwritten public offering in a noncash or partial noncash transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:to="label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering_3" xlink:title="label: UnpaidCostsAssociatedWithUnderWrittenPublicOffering to label_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_DocumentAndEntityInformationAbstract">Document and Entity Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="label_DocumentAndEntityInformationAbstract" xlink:title="label: DocumentAndEntityInformationAbstract to label_DocumentAndEntityInformationAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:label="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:title="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering">Proceeds from Issuance of Common Stock by Underwritten Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:to="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:title="label: ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering to label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering_2">Represents the proceeds, net of underwriters' discounts, commissions and offering expenses, from the issuance of stock through an underwritten public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:to="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering_2" xlink:title="label: ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering to label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering_3">Net proceeds from issuance of shares through an underwritten public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:to="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering_3" xlink:title="label: ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering to label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering_4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering_4">Proceeds from issuance of common stock by underwritten public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:to="label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering_4" xlink:title="label: ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering to label_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ExcessConsiderationPaidOverFairValue" xlink:label="ExcessConsiderationPaidOverFairValue" xlink:title="ExcessConsiderationPaidOverFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ExcessConsiderationPaidOverFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ExcessConsiderationPaidOverFairValue" xml:lang="en-US" id="label_ExcessConsiderationPaidOverFairValue">Excess Consideration Paid over Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExcessConsiderationPaidOverFairValue" xlink:to="label_ExcessConsiderationPaidOverFairValue" xlink:title="label: ExcessConsiderationPaidOverFairValue to label_ExcessConsiderationPaidOverFairValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ExcessConsiderationPaidOverFairValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ExcessConsiderationPaidOverFairValue" xml:lang="en-US" id="label_ExcessConsiderationPaidOverFairValue_2">Excess consideration paid over fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExcessConsiderationPaidOverFairValue" xlink:to="label_ExcessConsiderationPaidOverFairValue_2" xlink:title="label: ExcessConsiderationPaidOverFairValue to label_ExcessConsiderationPaidOverFairValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ExcessConsiderationPaidOverFairValue_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ExcessConsiderationPaidOverFairValue" xml:lang="en-US" id="label_ExcessConsiderationPaidOverFairValue_3">Amount of expenses charged against earnings during the period related to business combination, which is the excess of the cost of the acquired entity over the fair value assigned to assets acquired and liabilities assumed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExcessConsiderationPaidOverFairValue" xlink:to="label_ExcessConsiderationPaidOverFairValue_3" xlink:title="label: ExcessConsiderationPaidOverFairValue to label_ExcessConsiderationPaidOverFairValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_IssuanceOfCommonSharesAbstract" xlink:label="IssuanceOfCommonSharesAbstract" xlink:title="IssuanceOfCommonSharesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfCommonSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IssuanceOfCommonSharesAbstract" xml:lang="en-US" id="label_IssuanceOfCommonSharesAbstract">Issuance of Common Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonSharesAbstract" xlink:to="label_IssuanceOfCommonSharesAbstract" xlink:title="label: IssuanceOfCommonSharesAbstract to label_IssuanceOfCommonSharesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfCommonSharesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IssuanceOfCommonSharesAbstract" xml:lang="en-US" id="label_IssuanceOfCommonSharesAbstract_2">Issuance of common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonSharesAbstract" xlink:to="label_IssuanceOfCommonSharesAbstract_2" xlink:title="label: IssuanceOfCommonSharesAbstract to label_IssuanceOfCommonSharesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:label="StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:title="StockIssuedDuringPeriodValueCommonSharesAndWarrants" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants">Stock Issued During Period Value, Common Shares and Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:to="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:title="label: StockIssuedDuringPeriodValueCommonSharesAndWarrants to label_StockIssuedDuringPeriodValueCommonSharesAndWarrants" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants_2">Registered direct offerings of common shares and warrants, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:to="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants_2" xlink:title="label: StockIssuedDuringPeriodValueCommonSharesAndWarrants to label_StockIssuedDuringPeriodValueCommonSharesAndWarrants" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants_3">Value of common stock and warrants issued during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:to="label_StockIssuedDuringPeriodValueCommonSharesAndWarrants_3" xlink:title="label: StockIssuedDuringPeriodValueCommonSharesAndWarrants to label_StockIssuedDuringPeriodValueCommonSharesAndWarrants" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:label="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:title="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility">Adjustments to Additional Paid in Capital Credit Equity Financing Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility to label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility_2">Credit equity financing facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility to label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility_3">Increase in Additional Paid-in-Capital pursuant to credit equity financing facility under which entity could borrow funds. Further, convertible notes are subject to repurchase by entity at each holder's option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility_3" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility to label_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentPeriodEndDate" xml:lang="en-US" id="label_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="label_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to label_DocumentPeriodEndDate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:label="StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:title="StockIssuedDuringPeriodCommonSharesAndWarrants" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodCommonSharesAndWarrants" xml:lang="en-US" id="label_StockIssuedDuringPeriodCommonSharesAndWarrants">Stock Issued During Period, Common Shares and Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:to="label_StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:title="label: StockIssuedDuringPeriodCommonSharesAndWarrants to label_StockIssuedDuringPeriodCommonSharesAndWarrants" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodCommonSharesAndWarrants_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodCommonSharesAndWarrants" xml:lang="en-US" id="label_StockIssuedDuringPeriodCommonSharesAndWarrants_2">Registered direct offerings of common shares and warrants, net (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:to="label_StockIssuedDuringPeriodCommonSharesAndWarrants_2" xlink:title="label: StockIssuedDuringPeriodCommonSharesAndWarrants to label_StockIssuedDuringPeriodCommonSharesAndWarrants" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodCommonSharesAndWarrants_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodCommonSharesAndWarrants" xml:lang="en-US" id="label_StockIssuedDuringPeriodCommonSharesAndWarrants_3">Number of common shares and warrants issued during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:to="label_StockIssuedDuringPeriodCommonSharesAndWarrants_3" xlink:title="label: StockIssuedDuringPeriodCommonSharesAndWarrants to label_StockIssuedDuringPeriodCommonSharesAndWarrants" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueWarrantsExercised">Stock Issued During Period Value, Warrants Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to label_StockIssuedDuringPeriodValueWarrantsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueWarrantsExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueWarrantsExercised_2">Warrant exercises - various</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodValueWarrantsExercised_2" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to label_StockIssuedDuringPeriodValueWarrantsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueWarrantsExercised_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueWarrantsExercised_3">Value stock issued during the period as a result of the exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodValueWarrantsExercised_3" xlink:title="label: StockIssuedDuringPeriodValueWarrantsExercised to label_StockIssuedDuringPeriodValueWarrantsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:label="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:title="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" />
    <link:label xlink:type="resource" xlink:label="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xml:lang="en-US" id="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery">Purchase Commitment Cumulative Payments to Acquire Machinery</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:to="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:title="label: PurchaseCommitmentCumulativePaymentsToAcquireMachinery to label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xml:lang="en-US" id="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery_2">Amount paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:to="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery_2" xlink:title="label: PurchaseCommitmentCumulativePaymentsToAcquireMachinery to label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xml:lang="en-US" id="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery_3">Represents the cumulative amount paid by the entity for purchase of machinery.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:to="label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery_3" xlink:title="label: PurchaseCommitmentCumulativePaymentsToAcquireMachinery to label_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesWarrantsExercised">Stock Issued During Period Shares, Warrants Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="label: StockIssuedDuringPeriodSharesWarrantsExercised to label_StockIssuedDuringPeriodSharesWarrantsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesWarrantsExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesWarrantsExercised_2">Warrant exercises - various (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodSharesWarrantsExercised_2" xlink:title="label: StockIssuedDuringPeriodSharesWarrantsExercised to label_StockIssuedDuringPeriodSharesWarrantsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesWarrantsExercised_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesWarrantsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesWarrantsExercised_3">Number of shares of stock issued during the period as a result of the exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="label_StockIssuedDuringPeriodSharesWarrantsExercised_3" xlink:title="label: StockIssuedDuringPeriodSharesWarrantsExercised to label_StockIssuedDuringPeriodSharesWarrantsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NoncashInvestment" xlink:label="NoncashInvestment" xlink:title="NoncashInvestment" />
    <link:label xlink:type="resource" xlink:label="label_NoncashInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashInvestment" xml:lang="en-US" id="label_NoncashInvestment">Noncash Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestment" xlink:to="label_NoncashInvestment" xlink:title="label: NoncashInvestment to label_NoncashInvestment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NoncashInvestment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashInvestment" xml:lang="en-US" id="label_NoncashInvestment_2">Investment - non-cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestment" xlink:to="label_NoncashInvestment_2" xlink:title="label: NoncashInvestment to label_NoncashInvestment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NoncashInvestment_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NoncashInvestment" xml:lang="en-US" id="label_NoncashInvestment_3">The value of investments in noncash investing or financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestment" xlink:to="label_NoncashInvestment_3" xlink:title="label: NoncashInvestment to label_NoncashInvestment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" xlink:label="ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" xlink:title="ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" xml:lang="en-US" id="label_ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" xlink:to="label_ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" xlink:title="label: ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract to label_ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xlink:label="ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xlink:title="ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xml:lang="en-US" id="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xlink:to="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xlink:title="label: ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock to label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xml:lang="en-US" id="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock_2">Consolidation Basis of Presentation and Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xlink:to="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock_2" xlink:title="label: ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock to label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xml:lang="en-US" id="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock_3">The entire disclosure for consolidation, basis of presentation and accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xlink:to="label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock_3" xlink:title="label: ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock to label_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_RepaymentsOfShortTermConvertibleDebt" xlink:label="RepaymentsOfShortTermConvertibleDebt" xlink:title="RepaymentsOfShortTermConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfShortTermConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RepaymentsOfShortTermConvertibleDebt" xml:lang="en-US" id="label_RepaymentsOfShortTermConvertibleDebt">Repayments of Short Term Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfShortTermConvertibleDebt" xlink:to="label_RepaymentsOfShortTermConvertibleDebt" xlink:title="label: RepaymentsOfShortTermConvertibleDebt to label_RepaymentsOfShortTermConvertibleDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfShortTermConvertibleDebt_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_RepaymentsOfShortTermConvertibleDebt" xml:lang="en-US" id="label_RepaymentsOfShortTermConvertibleDebt_2">Cash paid for convertible note repayment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfShortTermConvertibleDebt" xlink:to="label_RepaymentsOfShortTermConvertibleDebt_2" xlink:title="label: RepaymentsOfShortTermConvertibleDebt to label_RepaymentsOfShortTermConvertibleDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RepaymentsOfShortTermConvertibleDebt_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_RepaymentsOfShortTermConvertibleDebt" xml:lang="en-US" id="label_RepaymentsOfShortTermConvertibleDebt_3">The cash outflow from the conversion at maturity of a short-term debt instrument which was exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfShortTermConvertibleDebt" xlink:to="label_RepaymentsOfShortTermConvertibleDebt_3" xlink:title="label: RepaymentsOfShortTermConvertibleDebt to label_RepaymentsOfShortTermConvertibleDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LiquidityAndCapitalResourcesTextBlock" xlink:label="LiquidityAndCapitalResourcesTextBlock" xlink:title="LiquidityAndCapitalResourcesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_LiquidityAndCapitalResourcesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiquidityAndCapitalResourcesTextBlock" xml:lang="en-US" id="label_LiquidityAndCapitalResourcesTextBlock">Liquidity and Capital Resources [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="label_LiquidityAndCapitalResourcesTextBlock" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to label_LiquidityAndCapitalResourcesTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiquidityAndCapitalResourcesTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiquidityAndCapitalResourcesTextBlock" xml:lang="en-US" id="label_LiquidityAndCapitalResourcesTextBlock_2">LIQUIDITY AND CAPITAL RESOURCES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="label_LiquidityAndCapitalResourcesTextBlock_2" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to label_LiquidityAndCapitalResourcesTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiquidityAndCapitalResourcesTextBlock_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LiquidityAndCapitalResourcesTextBlock" xml:lang="en-US" id="label_LiquidityAndCapitalResourcesTextBlock_3">This element may be used for the entire disclosure related to entity's liquidity and capital resources, which includes description of entity's revenue, stockholders' equity, including other comprehensive income, and cash and cash equivalents disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="label_LiquidityAndCapitalResourcesTextBlock_3" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to label_LiquidityAndCapitalResourcesTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:label xlink:type="resource" xlink:label="label_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityDomain" xml:lang="en-US" id="label_EntityDomain">Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityDomain" xlink:to="label_EntityDomain" xlink:title="label: EntityDomain to label_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ScheduleOfLiquidityAndCapitalResourcesTable" xlink:label="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:title="ScheduleOfLiquidityAndCapitalResourcesTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfLiquidityAndCapitalResourcesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfLiquidityAndCapitalResourcesTable" xml:lang="en-US" id="label_ScheduleOfLiquidityAndCapitalResourcesTable">Schedule of Liquidity and Capital Resources [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="label_ScheduleOfLiquidityAndCapitalResourcesTable" xlink:title="label: ScheduleOfLiquidityAndCapitalResourcesTable to label_ScheduleOfLiquidityAndCapitalResourcesTable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfLiquidityAndCapitalResourcesTable_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ScheduleOfLiquidityAndCapitalResourcesTable" xml:lang="en-US" id="label_ScheduleOfLiquidityAndCapitalResourcesTable_2">Represents details pertaining to liquidity position and availability of capital resources to the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="label_ScheduleOfLiquidityAndCapitalResourcesTable_2" xlink:title="label: ScheduleOfLiquidityAndCapitalResourcesTable to label_ScheduleOfLiquidityAndCapitalResourcesTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:label="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:title="ConvertibleSeniorNotes3.125PercentDue2013Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleSeniorNotes3.125PercentDue2013Member" xml:lang="en-US" id="label_ConvertibleSeniorNotes3.125PercentDue2013Member">Convertible Senior Notes 3.125 Percent Due 2013 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:to="label_ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:title="label: ConvertibleSeniorNotes3.125PercentDue2013Member to label_ConvertibleSeniorNotes3.125PercentDue2013Member" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSeniorNotes3.125PercentDue2013Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleSeniorNotes3.125PercentDue2013Member" xml:lang="en-US" id="label_ConvertibleSeniorNotes3.125PercentDue2013Member_2">2013 Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:to="label_ConvertibleSeniorNotes3.125PercentDue2013Member_2" xlink:title="label: ConvertibleSeniorNotes3.125PercentDue2013Member to label_ConvertibleSeniorNotes3.125PercentDue2013Member" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSeniorNotes3.125PercentDue2013Member_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleSeniorNotes3.125PercentDue2013Member" xml:lang="en-US" id="label_ConvertibleSeniorNotes3.125PercentDue2013Member_3">Represents convertible senior notes bearing an interest of 3.125 percent which mature in 2013.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:to="label_ConvertibleSeniorNotes3.125PercentDue2013Member_3" xlink:title="label: ConvertibleSeniorNotes3.125PercentDue2013Member to label_ConvertibleSeniorNotes3.125PercentDue2013Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities">Antidilutive Securities Excluded from Computation of Earnings Per Share, Exercise Price of Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities_2">Exercise price of securities (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities_2" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities_3">Represents the exercise price of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future, that were not included in the computation of diluted EPS or EPU as it would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities_3" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xlink:label="ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xlink:title="ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xml:lang="en-US" id="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock">Tabular disclosure of the significant assumptions used during the period to estimate the fair value of debt instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xlink:to="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xlink:title="label: ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock to label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xml:lang="en-US" id="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock_2">Schedule of Fair Value Assumptions Used for Debt Instruments [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xlink:to="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock_2" xlink:title="label: ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock to label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xml:lang="en-US" id="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock_3">Schedule of key assumptions used to establish the value of the 2013 Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xlink:to="label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock_3" xlink:title="label: ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock to label_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:label="ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:title="ConvertibleSeniorNotes3.125PercentDue2011Member" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleSeniorNotes3.125PercentDue2011Member" xml:lang="en-US" id="label_ConvertibleSeniorNotes3.125PercentDue2011Member">Convertible Senior Notes 3.125 Percent Due 2011 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:to="label_ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:title="label: ConvertibleSeniorNotes3.125PercentDue2011Member to label_ConvertibleSeniorNotes3.125PercentDue2011Member" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSeniorNotes3.125PercentDue2011Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleSeniorNotes3.125PercentDue2011Member" xml:lang="en-US" id="label_ConvertibleSeniorNotes3.125PercentDue2011Member_2">2011 Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:to="label_ConvertibleSeniorNotes3.125PercentDue2011Member_2" xlink:title="label: ConvertibleSeniorNotes3.125PercentDue2011Member to label_ConvertibleSeniorNotes3.125PercentDue2011Member" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleSeniorNotes3.125PercentDue2011Member_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConvertibleSeniorNotes3.125PercentDue2011Member" xml:lang="en-US" id="label_ConvertibleSeniorNotes3.125PercentDue2011Member_3">Represents convertible senior notes bearing an interest of 3.125 percent which mature in 2011.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:to="label_ConvertibleSeniorNotes3.125PercentDue2011Member_3" xlink:title="label: ConvertibleSeniorNotes3.125PercentDue2011Member to label_ConvertibleSeniorNotes3.125PercentDue2011Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:label="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:title="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xml:lang="en-US" id="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder">Long Term Debt, Redemption Price as Percentage of Principal Amount, Option to Holder</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:to="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:title="label: LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder to label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xml:lang="en-US" id="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder_2">Percentage of principal amount at which the holder may require the entity to repurchase notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:to="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder_2" xlink:title="label: LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder to label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xml:lang="en-US" id="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder_3">Represents the percentage of principal amount used in the computation of the redemption price at which the holders may require the entity to repurchase the debt instruments on or after specified dates in case a fundamental change (as defined in the indenture) occurs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:to="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder_3" xlink:title="label: LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder to label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:label="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:title="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xml:lang="en-US" id="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount">Percentage of principal amount at which the entity may redeem notes in whole or in part</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:to="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:title="label: LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount to label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xml:lang="en-US" id="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount_2">Represents the percentage of principal amount used in the computation of the redemption price at which the entity may redeem some or all of the debt instruments on or after specified dates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:to="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount_2" xlink:title="label: LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount to label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xml:lang="en-US" id="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount_3">Long Term Debt, Redemption Price as Percentage of Principal Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:to="label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount_3" xlink:title="label: LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount to label_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_FairValueAssumptionsDiscountRate" xlink:label="FairValueAssumptionsDiscountRate" xlink:title="FairValueAssumptionsDiscountRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_FairValueAssumptionsDiscountRate" xml:lang="en-US" id="label_FairValueAssumptionsDiscountRate">Represents discount rate for principal payments in cash, an assumption used in valuation of an instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsDiscountRate" xlink:to="label_FairValueAssumptionsDiscountRate" xlink:title="label: FairValueAssumptionsDiscountRate to label_FairValueAssumptionsDiscountRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsDiscountRate_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsDiscountRate" xml:lang="en-US" id="label_FairValueAssumptionsDiscountRate_2">Fair Value Assumptions Discount Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsDiscountRate" xlink:to="label_FairValueAssumptionsDiscountRate_2" xlink:title="label: FairValueAssumptionsDiscountRate to label_FairValueAssumptionsDiscountRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsDiscountRate_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsDiscountRate" xml:lang="en-US" id="label_FairValueAssumptionsDiscountRate_3">Discount rate for principal payments in cash (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsDiscountRate" xlink:to="label_FairValueAssumptionsDiscountRate_3" xlink:title="label: FairValueAssumptionsDiscountRate to label_FairValueAssumptionsDiscountRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:title="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xml:lang="en-US" id="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice">Debt Instrument Conversion Obligation Common Stock Closing Sales Price as Percentage of Conversion Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:to="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:title="label: DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice to label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xml:lang="en-US" id="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_2">Percentage of the closing sales price of the entity's common stock that the conversion price must exceed in order for the notes to be convertible</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:to="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_2" xlink:title="label: DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice to label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xml:lang="en-US" id="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_3">Represents the percentage of the closing sales price of the entity's common stock for at least 20 days within 30 consecutive trading days that the closing sales price of the entity's common stock must exceed the conversion price in order for the debt instruments to be convertible.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:to="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_3" xlink:title="label: DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice to label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:title="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xml:lang="en-US" id="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays">Debt Instrument Conversion Obligation Common Stock Closing Sales Price Number of Trading Days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:to="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:title="label: DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays to label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xml:lang="en-US" id="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_2">Number of days within 30 consecutive trading days in which the closing price of the entity's common stock must exceed the conversion price for the notes to be redeemable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:to="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_2" xlink:title="label: DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays to label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xml:lang="en-US" id="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_3">Represents the number of trading days within a period of 30 consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:to="label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_3" xlink:title="label: DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays to label_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:label="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:title="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xml:lang="en-US" id="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays">Debt Instrument Conversion Obligation Number of Consecutive Trading Days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:to="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:title="label: DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays to label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xml:lang="en-US" id="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_2">Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be redeemable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:to="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_2" xlink:title="label: DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays to label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xml:lang="en-US" id="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_3">Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:to="label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays_3" xlink:title="label: DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays to label_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment">Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Authorized before Amendment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment_2">Number of shares of the entity's common stock authorized for issuance under the plan before amendment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment_3">The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), before amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment_3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod">Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_2">Warrants expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_3">Represents the decrease in the number of shares that could be issued, attributable to the lapse of rights to exercise previously issued awards other than stock options under the terms of the award agreements under the plan during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod_3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice">Share Based Compensation Arrangement by Share Based Payment Award Other than Options Expired in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_2">Weighted average exercise price of warrants expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_3">Represents the weighted average price at which grantees could have exercised the awards that were terminated during the reporting period due to noncompliance with plan terms during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice_3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ScheduleOfStockholdersEquityTable" xlink:label="ScheduleOfStockholdersEquityTable" xlink:title="ScheduleOfStockholdersEquityTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfStockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfStockholdersEquityTable" xml:lang="en-US" id="label_ScheduleOfStockholdersEquityTable">Schedule of Stockholders Equity [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="label_ScheduleOfStockholdersEquityTable" xlink:title="label: ScheduleOfStockholdersEquityTable to label_ScheduleOfStockholdersEquityTable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfStockholdersEquityTable_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ScheduleOfStockholdersEquityTable" xml:lang="en-US" id="label_ScheduleOfStockholdersEquityTable_2">Represents information pertaining to changes in stockholder's equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="label_ScheduleOfStockholdersEquityTable_2" xlink:title="label: ScheduleOfStockholdersEquityTable to label_ScheduleOfStockholdersEquityTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_WarrantIssuedToInstitutionalInvestorsMember" xlink:label="WarrantIssuedToInstitutionalInvestorsMember" xlink:title="WarrantIssuedToInstitutionalInvestorsMember" />
    <link:label xlink:type="resource" xlink:label="label_WarrantIssuedToInstitutionalInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantIssuedToInstitutionalInvestorsMember" xml:lang="en-US" id="label_WarrantIssuedToInstitutionalInvestorsMember">Represents details pertaining to warrants, which are issued to institutional investors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssuedToInstitutionalInvestorsMember" xlink:to="label_WarrantIssuedToInstitutionalInvestorsMember" xlink:title="label: WarrantIssuedToInstitutionalInvestorsMember to label_WarrantIssuedToInstitutionalInvestorsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WarrantIssuedToInstitutionalInvestorsMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantIssuedToInstitutionalInvestorsMember" xml:lang="en-US" id="label_WarrantIssuedToInstitutionalInvestorsMember_2">Warrant Issued to Institutional Investors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssuedToInstitutionalInvestorsMember" xlink:to="label_WarrantIssuedToInstitutionalInvestorsMember_2" xlink:title="label: WarrantIssuedToInstitutionalInvestorsMember to label_WarrantIssuedToInstitutionalInvestorsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WarrantIssuedToInstitutionalInvestorsMember_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantIssuedToInstitutionalInvestorsMember" xml:lang="en-US" id="label_WarrantIssuedToInstitutionalInvestorsMember_3">Warrants issued to institutional investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssuedToInstitutionalInvestorsMember" xlink:to="label_WarrantIssuedToInstitutionalInvestorsMember_3" xlink:title="label: WarrantIssuedToInstitutionalInvestorsMember to label_WarrantIssuedToInstitutionalInvestorsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockholdersEquityLineItems" xlink:label="StockholdersEquityLineItems" xlink:title="StockholdersEquityLineItems" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityLineItems" xml:lang="en-US" id="label_StockholdersEquityLineItems">Stockholder's equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityLineItems" xlink:to="label_StockholdersEquityLineItems" xlink:title="label: StockholdersEquityLineItems to label_StockholdersEquityLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityLineItems_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockholdersEquityLineItems" xml:lang="en-US" id="label_StockholdersEquityLineItems_2">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityLineItems" xlink:to="label_StockholdersEquityLineItems_2" xlink:title="label: StockholdersEquityLineItems to label_StockholdersEquityLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityLineItems_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityLineItems" xml:lang="en-US" id="label_StockholdersEquityLineItems_3">Stockholders Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityLineItems" xlink:to="label_StockholdersEquityLineItems_3" xlink:title="label: StockholdersEquityLineItems to label_StockholdersEquityLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_WarrantIssuedToPlacementAgentsMember" xlink:label="WarrantIssuedToPlacementAgentsMember" xlink:title="WarrantIssuedToPlacementAgentsMember" />
    <link:label xlink:type="resource" xlink:label="label_WarrantIssuedToPlacementAgentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantIssuedToPlacementAgentsMember" xml:lang="en-US" id="label_WarrantIssuedToPlacementAgentsMember">Warrant Issued to Placement Agents [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssuedToPlacementAgentsMember" xlink:to="label_WarrantIssuedToPlacementAgentsMember" xlink:title="label: WarrantIssuedToPlacementAgentsMember to label_WarrantIssuedToPlacementAgentsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WarrantIssuedToPlacementAgentsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantIssuedToPlacementAgentsMember" xml:lang="en-US" id="label_WarrantIssuedToPlacementAgentsMember_2">Placement agent warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssuedToPlacementAgentsMember" xlink:to="label_WarrantIssuedToPlacementAgentsMember_2" xlink:title="label: WarrantIssuedToPlacementAgentsMember to label_WarrantIssuedToPlacementAgentsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WarrantIssuedToPlacementAgentsMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WarrantIssuedToPlacementAgentsMember" xml:lang="en-US" id="label_WarrantIssuedToPlacementAgentsMember_3">Represents details pertaining to warrants, which are issued to placement agents.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantIssuedToPlacementAgentsMember" xlink:to="label_WarrantIssuedToPlacementAgentsMember_3" xlink:title="label: WarrantIssuedToPlacementAgentsMember to label_WarrantIssuedToPlacementAgentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ProceedsFromIssuanceOfCommonStockGross" xlink:label="ProceedsFromIssuanceOfCommonStockGross" xlink:title="ProceedsFromIssuanceOfCommonStockGross" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfCommonStockGross" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStockGross">Proceeds from Issuance of Common Stock, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockGross" xlink:to="label_ProceedsFromIssuanceOfCommonStockGross" xlink:title="label: ProceedsFromIssuanceOfCommonStockGross to label_ProceedsFromIssuanceOfCommonStockGross" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStockGross_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfCommonStockGross" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStockGross_2">Gross proceeds from issuance of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockGross" xlink:to="label_ProceedsFromIssuanceOfCommonStockGross_2" xlink:title="label: ProceedsFromIssuanceOfCommonStockGross to label_ProceedsFromIssuanceOfCommonStockGross" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStockGross_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ProceedsFromIssuanceOfCommonStockGross" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStockGross_3">Represents the gross amount of cash inflow from the additional capital contribution to the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStockGross" xlink:to="label_ProceedsFromIssuanceOfCommonStockGross_3" xlink:title="label: ProceedsFromIssuanceOfCommonStockGross to label_ProceedsFromIssuanceOfCommonStockGross" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ClassOfWarrantOrRightTermOfWarrants" xlink:label="ClassOfWarrantOrRightTermOfWarrants" xlink:title="ClassOfWarrantOrRightTermOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightTermOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightTermOfWarrants" xml:lang="en-US" id="label_ClassOfWarrantOrRightTermOfWarrants">Class of Warrant or Right Term of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTermOfWarrants" xlink:to="label_ClassOfWarrantOrRightTermOfWarrants" xlink:title="label: ClassOfWarrantOrRightTermOfWarrants to label_ClassOfWarrantOrRightTermOfWarrants" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightTermOfWarrants_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightTermOfWarrants" xml:lang="en-US" id="label_ClassOfWarrantOrRightTermOfWarrants_2">Term of warrants (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTermOfWarrants" xlink:to="label_ClassOfWarrantOrRightTermOfWarrants_2" xlink:title="label: ClassOfWarrantOrRightTermOfWarrants to label_ClassOfWarrantOrRightTermOfWarrants" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightTermOfWarrants_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ClassOfWarrantOrRightTermOfWarrants" xml:lang="en-US" id="label_ClassOfWarrantOrRightTermOfWarrants_3">Represents the term over which the warrants expire.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTermOfWarrants" xlink:to="label_ClassOfWarrantOrRightTermOfWarrants_3" xlink:title="label: ClassOfWarrantOrRightTermOfWarrants to label_ClassOfWarrantOrRightTermOfWarrants" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PaymentsToFractionalSharePayout" xlink:label="PaymentsToFractionalSharePayout" xlink:title="PaymentsToFractionalSharePayout" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToFractionalSharePayout" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToFractionalSharePayout" xml:lang="en-US" id="label_PaymentsToFractionalSharePayout">Payments to Fractional Share Payout</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToFractionalSharePayout" xlink:to="label_PaymentsToFractionalSharePayout" xlink:title="label: PaymentsToFractionalSharePayout to label_PaymentsToFractionalSharePayout" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToFractionalSharePayout_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToFractionalSharePayout" xml:lang="en-US" id="label_PaymentsToFractionalSharePayout_2">Fractional share payout</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToFractionalSharePayout" xlink:to="label_PaymentsToFractionalSharePayout_2" xlink:title="label: PaymentsToFractionalSharePayout to label_PaymentsToFractionalSharePayout" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToFractionalSharePayout_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PaymentsToFractionalSharePayout" xml:lang="en-US" id="label_PaymentsToFractionalSharePayout_3">Represents payments of fractional shares as a result of reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToFractionalSharePayout" xlink:to="label_PaymentsToFractionalSharePayout_3" xlink:title="label: PaymentsToFractionalSharePayout to label_PaymentsToFractionalSharePayout" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToFractionalSharePayout_4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaymentsToFractionalSharePayout" xml:lang="en-US" id="label_PaymentsToFractionalSharePayout_4">Fractional share payout</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToFractionalSharePayout" xlink:to="label_PaymentsToFractionalSharePayout_4" xlink:title="label: PaymentsToFractionalSharePayout to label_PaymentsToFractionalSharePayout" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockholdersEquityReverseStockSplitConversionRatio" xlink:label="StockholdersEquityReverseStockSplitConversionRatio" xlink:title="StockholdersEquityReverseStockSplitConversionRatio" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityReverseStockSplitConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityReverseStockSplitConversionRatio" xml:lang="en-US" id="label_StockholdersEquityReverseStockSplitConversionRatio">Stockholders Equity Reverse, Stock Split Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityReverseStockSplitConversionRatio" xlink:to="label_StockholdersEquityReverseStockSplitConversionRatio" xlink:title="label: StockholdersEquityReverseStockSplitConversionRatio to label_StockholdersEquityReverseStockSplitConversionRatio" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityReverseStockSplitConversionRatio_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityReverseStockSplitConversionRatio" xml:lang="en-US" id="label_StockholdersEquityReverseStockSplitConversionRatio_2">Reverse stock split conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityReverseStockSplitConversionRatio" xlink:to="label_StockholdersEquityReverseStockSplitConversionRatio_2" xlink:title="label: StockholdersEquityReverseStockSplitConversionRatio to label_StockholdersEquityReverseStockSplitConversionRatio" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityReverseStockSplitConversionRatio_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockholdersEquityReverseStockSplitConversionRatio" xml:lang="en-US" id="label_StockholdersEquityReverseStockSplitConversionRatio_3">Represents the conversion ratio used in the calculation of reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityReverseStockSplitConversionRatio" xlink:to="label_StockholdersEquityReverseStockSplitConversionRatio_3" xlink:title="label: StockholdersEquityReverseStockSplitConversionRatio to label_StockholdersEquityReverseStockSplitConversionRatio" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:label="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:title="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xml:lang="en-US" id="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing">Number of Products or Technologies Licensed by Entity as Alternative to Raising Additional Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:to="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:title="label: NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing to label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xml:lang="en-US" id="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing_2">Number of products or technologies licensed by the entity as an alternative to raising additional financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:to="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing_2" xlink:title="label: NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing to label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xml:lang="en-US" id="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing_3">Represents the number of products or technologies licensed by the entity as an alternative to raising additional financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:to="label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing_3" xlink:title="label: NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing to label_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AptarPharmaMember" xlink:label="AptarPharmaMember" xlink:title="AptarPharmaMember" />
    <link:label xlink:type="resource" xlink:label="label_AptarPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AptarPharmaMember" xml:lang="en-US" id="label_AptarPharmaMember">Aptar Pharma [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AptarPharmaMember" xlink:to="label_AptarPharmaMember" xlink:title="label: AptarPharmaMember to label_AptarPharmaMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AptarPharmaMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AptarPharmaMember" xml:lang="en-US" id="label_AptarPharmaMember_2">Aptar Pharma</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AptarPharmaMember" xlink:to="label_AptarPharmaMember_2" xlink:title="label: AptarPharmaMember to label_AptarPharmaMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AptarPharmaMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AptarPharmaMember" xml:lang="en-US" id="label_AptarPharmaMember_3">Represents the details pertaining to Aptar Pharma.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AptarPharmaMember" xlink:to="label_AptarPharmaMember_3" xlink:title="label: AptarPharmaMember to label_AptarPharmaMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_FairValueOptionChangesInFairValueNonCashAdjustment" xlink:label="FairValueOptionChangesInFairValueNonCashAdjustment" xlink:title="FairValueOptionChangesInFairValueNonCashAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionChangesInFairValueNonCashAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueOptionChangesInFairValueNonCashAdjustment" xml:lang="en-US" id="label_FairValueOptionChangesInFairValueNonCashAdjustment">Fair Value Option Changes in Fair Value Non Cash Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionChangesInFairValueNonCashAdjustment" xlink:to="label_FairValueOptionChangesInFairValueNonCashAdjustment" xlink:title="label: FairValueOptionChangesInFairValueNonCashAdjustment to label_FairValueOptionChangesInFairValueNonCashAdjustment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionChangesInFairValueNonCashAdjustment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueOptionChangesInFairValueNonCashAdjustment" xml:lang="en-US" id="label_FairValueOptionChangesInFairValueNonCashAdjustment_2">Additional non-cash fair value adjustment attributable to conversion of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionChangesInFairValueNonCashAdjustment" xlink:to="label_FairValueOptionChangesInFairValueNonCashAdjustment_2" xlink:title="label: FairValueOptionChangesInFairValueNonCashAdjustment to label_FairValueOptionChangesInFairValueNonCashAdjustment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionChangesInFairValueNonCashAdjustment_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_FairValueOptionChangesInFairValueNonCashAdjustment" xml:lang="en-US" id="label_FairValueOptionChangesInFairValueNonCashAdjustment_3">For each line item in the statement of financial position, the non-cash increase (decrease) in fair value resulting from transactions during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionChangesInFairValueNonCashAdjustment" xlink:to="label_FairValueOptionChangesInFairValueNonCashAdjustment_3" xlink:title="label: FairValueOptionChangesInFairValueNonCashAdjustment to label_FairValueOptionChangesInFairValueNonCashAdjustment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfNewLibiGelEfficacyTrials" xlink:label="NumberOfNewLibiGelEfficacyTrials" xlink:title="NumberOfNewLibiGelEfficacyTrials" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfNewLibiGelEfficacyTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfNewLibiGelEfficacyTrials" xml:lang="en-US" id="label_NumberOfNewLibiGelEfficacyTrials">Number of New LibiGel Efficacy Trials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewLibiGelEfficacyTrials" xlink:to="label_NumberOfNewLibiGelEfficacyTrials" xlink:title="label: NumberOfNewLibiGelEfficacyTrials to label_NumberOfNewLibiGelEfficacyTrials" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfNewLibiGelEfficacyTrials_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfNewLibiGelEfficacyTrials" xml:lang="en-US" id="label_NumberOfNewLibiGelEfficacyTrials_2">Number of new LibiGel efficacy trials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewLibiGelEfficacyTrials" xlink:to="label_NumberOfNewLibiGelEfficacyTrials_2" xlink:title="label: NumberOfNewLibiGelEfficacyTrials to label_NumberOfNewLibiGelEfficacyTrials" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfNewLibiGelEfficacyTrials_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfNewLibiGelEfficacyTrials" xml:lang="en-US" id="label_NumberOfNewLibiGelEfficacyTrials_3">Represents the number of new LibiGel efficacy trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewLibiGelEfficacyTrials" xlink:to="label_NumberOfNewLibiGelEfficacyTrials_3" xlink:title="label: NumberOfNewLibiGelEfficacyTrials to label_NumberOfNewLibiGelEfficacyTrials" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:label="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:title="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" />
    <link:label xlink:type="resource" xlink:label="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xml:lang="en-US" id="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements">Period for which Cash and Cash Equivalents will Meet Liquidity Requirements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:to="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:title="label: PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements to label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xml:lang="en-US" id="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements_2">Period for which cash and cash equivalents will meet liquidity requirements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:to="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements_2" xlink:title="label: PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements to label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xml:lang="en-US" id="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements_3">Represents the period for which cash and cash equivalents will meet liquidity requirements of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:to="label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements_3" xlink:title="label: PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements to label_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:label="NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:title="NumberOfInstitutionalInvestorsToWhomOfferingMade" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfInstitutionalInvestorsToWhomOfferingMade" xml:lang="en-US" id="label_NumberOfInstitutionalInvestorsToWhomOfferingMade">Number of Institutional Investors to Whom Offering Made</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:to="label_NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:title="label: NumberOfInstitutionalInvestorsToWhomOfferingMade to label_NumberOfInstitutionalInvestorsToWhomOfferingMade" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfInstitutionalInvestorsToWhomOfferingMade_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfInstitutionalInvestorsToWhomOfferingMade" xml:lang="en-US" id="label_NumberOfInstitutionalInvestorsToWhomOfferingMade_2">Number of institutional investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:to="label_NumberOfInstitutionalInvestorsToWhomOfferingMade_2" xlink:title="label: NumberOfInstitutionalInvestorsToWhomOfferingMade to label_NumberOfInstitutionalInvestorsToWhomOfferingMade" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfInstitutionalInvestorsToWhomOfferingMade_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfInstitutionalInvestorsToWhomOfferingMade" xml:lang="en-US" id="label_NumberOfInstitutionalInvestorsToWhomOfferingMade_3">Represents the number of institutional investors to whom offerings were made to raise funds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:to="label_NumberOfInstitutionalInvestorsToWhomOfferingMade_3" xlink:title="label: NumberOfInstitutionalInvestorsToWhomOfferingMade to label_NumberOfInstitutionalInvestorsToWhomOfferingMade" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ANIPharmaceuticalsIncMember" xlink:label="ANIPharmaceuticalsIncMember" xlink:title="ANIPharmaceuticalsIncMember" />
    <link:label xlink:type="resource" xlink:label="label_ANIPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ANIPharmaceuticalsIncMember" xml:lang="en-US" id="label_ANIPharmaceuticalsIncMember">ANI Pharmaceuticals Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ANIPharmaceuticalsIncMember" xlink:to="label_ANIPharmaceuticalsIncMember" xlink:title="label: ANIPharmaceuticalsIncMember to label_ANIPharmaceuticalsIncMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ANIPharmaceuticalsIncMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ANIPharmaceuticalsIncMember" xml:lang="en-US" id="label_ANIPharmaceuticalsIncMember_2">ANI Pharmaceuticals, Inc</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ANIPharmaceuticalsIncMember" xlink:to="label_ANIPharmaceuticalsIncMember_2" xlink:title="label: ANIPharmaceuticalsIncMember to label_ANIPharmaceuticalsIncMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ANIPharmaceuticalsIncMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ANIPharmaceuticalsIncMember" xml:lang="en-US" id="label_ANIPharmaceuticalsIncMember_3">Represents the details pertaining to ANI Pharmaceuticals, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ANIPharmaceuticalsIncMember" xlink:to="label_ANIPharmaceuticalsIncMember_3" xlink:title="label: ANIPharmaceuticalsIncMember to label_ANIPharmaceuticalsIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MergerAgreementMember" xlink:label="MergerAgreementMember" xlink:title="MergerAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_MergerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MergerAgreementMember" xml:lang="en-US" id="label_MergerAgreementMember">Merger Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementMember" xlink:to="label_MergerAgreementMember" xlink:title="label: MergerAgreementMember to label_MergerAgreementMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_MergerAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MergerAgreementMember" xml:lang="en-US" id="label_MergerAgreementMember_2">Agreement and Plan of Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementMember" xlink:to="label_MergerAgreementMember_2" xlink:title="label: MergerAgreementMember to label_MergerAgreementMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_MergerAgreementMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_MergerAgreementMember" xml:lang="en-US" id="label_MergerAgreementMember_3">Represents the details pertaining to merger agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementMember" xlink:to="label_MergerAgreementMember_3" xlink:title="label: MergerAgreementMember to label_MergerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_VotingAgreementMember" xlink:label="VotingAgreementMember" xlink:title="VotingAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_VotingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VotingAgreementMember" xml:lang="en-US" id="label_VotingAgreementMember">Voting Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VotingAgreementMember" xlink:to="label_VotingAgreementMember" xlink:title="label: VotingAgreementMember to label_VotingAgreementMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_VotingAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_VotingAgreementMember" xml:lang="en-US" id="label_VotingAgreementMember_2">Voting Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VotingAgreementMember" xlink:to="label_VotingAgreementMember_2" xlink:title="label: VotingAgreementMember to label_VotingAgreementMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_VotingAgreementMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_VotingAgreementMember" xml:lang="en-US" id="label_VotingAgreementMember_3">Represents the details pertaining to voting agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VotingAgreementMember" xlink:to="label_VotingAgreementMember_3" xlink:title="label: VotingAgreementMember to label_VotingAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LockUpAgreementMember" xlink:label="LockUpAgreementMember" xlink:title="LockUpAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_LockUpAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LockUpAgreementMember" xml:lang="en-US" id="label_LockUpAgreementMember">Lock Up Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockUpAgreementMember" xlink:to="label_LockUpAgreementMember" xlink:title="label: LockUpAgreementMember to label_LockUpAgreementMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LockUpAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LockUpAgreementMember" xml:lang="en-US" id="label_LockUpAgreementMember_2">Lock-Up Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockUpAgreementMember" xlink:to="label_LockUpAgreementMember_2" xlink:title="label: LockUpAgreementMember to label_LockUpAgreementMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LockUpAgreementMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LockUpAgreementMember" xml:lang="en-US" id="label_LockUpAgreementMember_3">Represents the details pertaining to lock-up agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockUpAgreementMember" xlink:to="label_LockUpAgreementMember_3" xlink:title="label: LockUpAgreementMember to label_LockUpAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ContingentValueRightsAgreementMember" xlink:label="ContingentValueRightsAgreementMember" xlink:title="ContingentValueRightsAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_ContingentValueRightsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ContingentValueRightsAgreementMember" xml:lang="en-US" id="label_ContingentValueRightsAgreementMember">Contingent Value Rights Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsAgreementMember" xlink:to="label_ContingentValueRightsAgreementMember" xlink:title="label: ContingentValueRightsAgreementMember to label_ContingentValueRightsAgreementMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ContingentValueRightsAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ContingentValueRightsAgreementMember" xml:lang="en-US" id="label_ContingentValueRightsAgreementMember_2">Contingent Value Rights Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsAgreementMember" xlink:to="label_ContingentValueRightsAgreementMember_2" xlink:title="label: ContingentValueRightsAgreementMember to label_ContingentValueRightsAgreementMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ContingentValueRightsAgreementMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ContingentValueRightsAgreementMember" xml:lang="en-US" id="label_ContingentValueRightsAgreementMember_3">Represents the details pertaining to contingent value rights agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsAgreementMember" xlink:to="label_ContingentValueRightsAgreementMember_3" xlink:title="label: ContingentValueRightsAgreementMember to label_ContingentValueRightsAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:label="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:title="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" />
    <link:label xlink:type="resource" xlink:label="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xml:lang="en-US" id="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders">Ownership Percentage of Outstanding Shares of Common Stock of Combined Company by Current Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:to="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:title="label: OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders to label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xml:lang="en-US" id="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders_2">Percentage of outstanding shares of common stock of combined company owned by current stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:to="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders_2" xlink:title="label: OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders to label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xml:lang="en-US" id="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders_3">Represents the percentage of outstanding shares of common stock of combined company owned by current stockholders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:to="label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders_3" xlink:title="label: OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders to label_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_TevaPharmaceuticalsUSAIncMember" xlink:label="TevaPharmaceuticalsUSAIncMember" xlink:title="TevaPharmaceuticalsUSAIncMember" />
    <link:label xlink:type="resource" xlink:label="label_TevaPharmaceuticalsUSAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TevaPharmaceuticalsUSAIncMember" xml:lang="en-US" id="label_TevaPharmaceuticalsUSAIncMember">Teva Pharmaceuticals USA Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TevaPharmaceuticalsUSAIncMember" xlink:to="label_TevaPharmaceuticalsUSAIncMember" xlink:title="label: TevaPharmaceuticalsUSAIncMember to label_TevaPharmaceuticalsUSAIncMember" />
    <link:label xlink:type="resource" xlink:label="label_TevaPharmaceuticalsUSAIncMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TevaPharmaceuticalsUSAIncMember" xml:lang="en-US" id="label_TevaPharmaceuticalsUSAIncMember_2">Teva</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TevaPharmaceuticalsUSAIncMember" xlink:to="label_TevaPharmaceuticalsUSAIncMember_2" xlink:title="label: TevaPharmaceuticalsUSAIncMember to label_TevaPharmaceuticalsUSAIncMember" />
    <link:label xlink:type="resource" xlink:label="label_TevaPharmaceuticalsUSAIncMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TevaPharmaceuticalsUSAIncMember" xml:lang="en-US" id="label_TevaPharmaceuticalsUSAIncMember_3">Represents the details pertaining to Teva Pharmaceuticals USA, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TevaPharmaceuticalsUSAIncMember" xlink:to="label_TevaPharmaceuticalsUSAIncMember_3" xlink:title="label: TevaPharmaceuticalsUSAIncMember to label_TevaPharmaceuticalsUSAIncMember" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ThirdAmendmentToLicenseAgreementMember" xlink:label="ThirdAmendmentToLicenseAgreementMember" xlink:title="ThirdAmendmentToLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_ThirdAmendmentToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ThirdAmendmentToLicenseAgreementMember" xml:lang="en-US" id="label_ThirdAmendmentToLicenseAgreementMember">Third Amendment to License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdAmendmentToLicenseAgreementMember" xlink:to="label_ThirdAmendmentToLicenseAgreementMember" xlink:title="label: ThirdAmendmentToLicenseAgreementMember to label_ThirdAmendmentToLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_ThirdAmendmentToLicenseAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ThirdAmendmentToLicenseAgreementMember" xml:lang="en-US" id="label_ThirdAmendmentToLicenseAgreementMember_2">Third Amendment To License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdAmendmentToLicenseAgreementMember" xlink:to="label_ThirdAmendmentToLicenseAgreementMember_2" xlink:title="label: ThirdAmendmentToLicenseAgreementMember to label_ThirdAmendmentToLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_ThirdAmendmentToLicenseAgreementMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ThirdAmendmentToLicenseAgreementMember" xml:lang="en-US" id="label_ThirdAmendmentToLicenseAgreementMember_3">Represents information pertaining to the third amendment to license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThirdAmendmentToLicenseAgreementMember" xlink:to="label_ThirdAmendmentToLicenseAgreementMember_3" xlink:title="label: ThirdAmendmentToLicenseAgreementMember to label_ThirdAmendmentToLicenseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:label="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:title="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xml:lang="en-US" id="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember">Milestone Payment Upon FDA Authorization of Marketing of Licensed Male Testosterone Gel [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:to="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:title="label: MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember to label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xml:lang="en-US" id="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember_2">Milestone payment upon FDA authorization of marketing of licensed male testosterone gel</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:to="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember_2" xlink:title="label: MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember to label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xml:lang="en-US" id="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember_3">Represents the milestone payment upon FDA authorization of marketing of licensed male testosterone gel.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:to="label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember_3" xlink:title="label: MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember to label_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:label="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:title="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xml:lang="en-US" id="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember">Milestone Payment Upon Earlier of 31 December 2012 and Five Business Days After Submission to FDA of Final Report on Washing Clinical Study [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:to="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:title="label: MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember to label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xml:lang="en-US" id="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_2">Milestone payment upon earlier of December 31, 2012 and five business days after submission to FDA of final report on washing clinical study</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:to="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_2" xlink:title="label: MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember to label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xml:lang="en-US" id="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_3">Represents the milestone payment upon earlier of December 31, 2012 and five business days after submission to FDA of final report on washing clinical study.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:to="label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember_3" xlink:title="label: MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember to label_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:label="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:title="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xml:lang="en-US" id="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember">Milestone Payment Upon Earlier of 31 December 2013 and Five Business Days After Commencement of Commercial Manufacture of Licensed Product [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:to="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:title="label: MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember to label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xml:lang="en-US" id="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_2">Milestone payment upon earlier of December 31, 2013 and five business days after commencement of commercial manufacture of licensed product for sale in the United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:to="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_2" xlink:title="label: MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember to label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xml:lang="en-US" id="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_3">Represents the milestone payment upon earlier of December 31, 2013 and five business days after commencement of commercial manufacture of licensed product for sale in the United States.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:to="label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember_3" xlink:title="label: MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember to label_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:label="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:title="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" />
    <link:label xlink:type="resource" xlink:label="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xml:lang="en-US" id="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember">Payment for Being Sole Marketer in US of 1 Percent Testosterone Gel for Atleast 180 Days Immediately Following Launch in US [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:to="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:title="label: PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember to label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" />
    <link:label xlink:type="resource" xlink:label="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xml:lang="en-US" id="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_2">Payment for being the sole marketer in the United States of a generic 1% testosterone gel AB-rated to AndroGel for at least 180 days immediately following the launch date of the licensed product in the United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:to="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_2" xlink:title="label: PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember to label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" />
    <link:label xlink:type="resource" xlink:label="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xml:lang="en-US" id="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_3">Represents the payment for being the sole marketer in the United States of a generic 1 percent testosterone gel AB-rated to AndroGel for at least 180 days immediately following the launch date of the licensed product in the United States.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:to="label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember_3" xlink:title="label: PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember to label_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:label="CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:title="CollaborativeArrangementPotentialMilestonePaymentsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable" xml:lang="en-US" id="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable">Collaborative Arrangement Potential Milestone Payments Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:to="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:title="label: CollaborativeArrangementPotentialMilestonePaymentsReceivable to label_CollaborativeArrangementPotentialMilestonePaymentsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable" xml:lang="en-US" id="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable_2">Aggregate amount receivable, if regulatory milestones are successfully achieved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:to="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable_2" xlink:title="label: CollaborativeArrangementPotentialMilestonePaymentsReceivable to label_CollaborativeArrangementPotentialMilestonePaymentsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable" xml:lang="en-US" id="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable_3">Represents the total amount that could be received based on certain regulatory or commercial events achieved by members to the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:to="label_CollaborativeArrangementPotentialMilestonePaymentsReceivable_3" xlink:title="label: CollaborativeArrangementPotentialMilestonePaymentsReceivable to label_CollaborativeArrangementPotentialMilestonePaymentsReceivable" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfBusinessDaysConsideredInMilestonePayments" xlink:label="NumberOfBusinessDaysConsideredInMilestonePayments" xlink:title="NumberOfBusinessDaysConsideredInMilestonePayments" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfBusinessDaysConsideredInMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfBusinessDaysConsideredInMilestonePayments" xml:lang="en-US" id="label_NumberOfBusinessDaysConsideredInMilestonePayments">Number of Business Days Considered in Milestone Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysConsideredInMilestonePayments" xlink:to="label_NumberOfBusinessDaysConsideredInMilestonePayments" xlink:title="label: NumberOfBusinessDaysConsideredInMilestonePayments to label_NumberOfBusinessDaysConsideredInMilestonePayments" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfBusinessDaysConsideredInMilestonePayments_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfBusinessDaysConsideredInMilestonePayments" xml:lang="en-US" id="label_NumberOfBusinessDaysConsideredInMilestonePayments_2">Number of business days considered in milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysConsideredInMilestonePayments" xlink:to="label_NumberOfBusinessDaysConsideredInMilestonePayments_2" xlink:title="label: NumberOfBusinessDaysConsideredInMilestonePayments to label_NumberOfBusinessDaysConsideredInMilestonePayments" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfBusinessDaysConsideredInMilestonePayments_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfBusinessDaysConsideredInMilestonePayments" xml:lang="en-US" id="label_NumberOfBusinessDaysConsideredInMilestonePayments_3">Represents the number of business days considered in milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysConsideredInMilestonePayments" xlink:to="label_NumberOfBusinessDaysConsideredInMilestonePayments_3" xlink:title="label: NumberOfBusinessDaysConsideredInMilestonePayments to label_NumberOfBusinessDaysConsideredInMilestonePayments" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:label="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:title="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xml:lang="en-US" id="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment">Number of Days from Launch of Product for Which Sole Marketer Right is Given for Additional Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:to="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:title="label: NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment to label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xml:lang="en-US" id="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment_2">Number of days from the launch of the licensed product in the United States for which sole marketer right is given for additional payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:to="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment_2" xlink:title="label: NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment to label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xml:lang="en-US" id="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment_3">Represents the number of days from the launch of the licensed product in the United States for which sole marketer right is given for additional payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:to="label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment_3" xlink:title="label: NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment to label_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:label="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:title="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xml:lang="en-US" id="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales">Royalty rate as a percentage of net sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:to="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:title="label: CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales to label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xml:lang="en-US" id="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales_2">Represents the royalty rate as a percentage of net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:to="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales_2" xlink:title="label: CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales to label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xml:lang="en-US" id="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales_3">Collaborative Arrangement Royalty Rate as Percentage of Net Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:to="label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales_3" xlink:title="label: CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales to label_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountingPoliciesAbstract" xml:lang="en-US" id="label_AccountingPoliciesAbstract">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="label_AccountingPoliciesAbstract" xlink:title="label: AccountingPoliciesAbstract to label_AccountingPoliciesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:label="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:title="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xml:lang="en-US" id="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight">Collaborative Arrangement Potential Payments Receivable for Giving Sole Marketer Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:to="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:title="label: CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight to label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xml:lang="en-US" id="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight_2">Payments receivable, if sole marketer rights are given</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:to="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight_2" xlink:title="label: CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight to label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight_3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xml:lang="en-US" id="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight_3">Represents the payments receivable, if sole marketer rights are given by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:to="label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight_3" xlink:title="label: CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight to label_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="label_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="label_EntityWellKnownSeasonedIssuer">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="label_EntityWellKnownSeasonedIssuer" xlink:title="label: EntityWellKnownSeasonedIssuer to label_EntityWellKnownSeasonedIssuer" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="label_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityVoluntaryFilers" xml:lang="en-US" id="label_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="label_EntityVoluntaryFilers" xlink:title="label: EntityVoluntaryFilers to label_EntityVoluntaryFilers" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="label_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCurrentReportingStatus" xml:lang="en-US" id="label_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="label_EntityCurrentReportingStatus" xlink:title="label: EntityCurrentReportingStatus to label_EntityCurrentReportingStatus" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityFilerCategory" xml:lang="en-US" id="label_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="label_EntityFilerCategory" xlink:title="label: EntityFilerCategory to label_EntityFilerCategory" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="label_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityPublicFloat" xml:lang="en-US" id="label_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="label_EntityPublicFloat" xlink:title="label: EntityPublicFloat to label_EntityPublicFloat" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityRegistrantName" xml:lang="en-US" id="label_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="label_EntityRegistrantName" xlink:title="label: EntityRegistrantName to label_EntityRegistrantName" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCentralIndexKey" xml:lang="en-US" id="label_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="label_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to label_EntityCentralIndexKey" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="label_EntityCommonStockSharesOutstanding" xlink:title="label: EntityCommonStockSharesOutstanding to label_EntityCommonStockSharesOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalYearFocus" xml:lang="en-US" id="label_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="label_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to label_DocumentFiscalYearFocus" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="label_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to label_DocumentFiscalPeriodFocus" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:label xlink:type="resource" xlink:label="label_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LegalEntityAxis" xml:lang="en-US" id="label_LegalEntityAxis">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalEntityAxis" xlink:to="label_LegalEntityAxis" xlink:title="label: LegalEntityAxis to label_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentType" xml:lang="en-US" id="label_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="label_DocumentType" xlink:title="label: DocumentType to label_DocumentType" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableCurrent" xml:lang="en-US" id="label_AccountsPayableCurrent">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent" xlink:title="label: AccountsPayableCurrent to label_AccountsPayableCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableCurrent" xml:lang="en-US" id="label_AccountsPayableCurrent_2">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="label_AccountsPayableCurrent_2" xlink:title="label: AccountsPayableCurrent to label_AccountsPayableCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="AccruedRoyaltiesCurrent" xlink:title="AccruedRoyaltiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccruedRoyaltiesCurrent" xml:lang="en-US" id="label_AccruedRoyaltiesCurrent">Accrued Royalties, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRoyaltiesCurrent" xlink:to="label_AccruedRoyaltiesCurrent" xlink:title="label: AccruedRoyaltiesCurrent to label_AccruedRoyaltiesCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AccruedRoyaltiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccruedRoyaltiesCurrent" xml:lang="en-US" id="label_AccruedRoyaltiesCurrent_2">Due to licensor - Antares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRoyaltiesCurrent" xlink:to="label_AccruedRoyaltiesCurrent_2" xlink:title="label: AccruedRoyaltiesCurrent to label_AccruedRoyaltiesCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2">Stock option expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2">Adjustments to reconcile net loss to net cash (used in) operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:title="label: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2">Stock warrant expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to label_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2">Number of shares excluded from computation of EPS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2">Securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="label_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="label_AntidilutiveSecuritiesNameDomain" xlink:title="label: AntidilutiveSecuritiesNameDomain to label_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to label_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsFairValueDisclosure" xml:lang="en-US" id="label_AssetsFairValueDisclosure">Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="label_AssetsFairValueDisclosure" xlink:title="label: AssetsFairValueDisclosure to label_AssetsFairValueDisclosure" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsFairValueDisclosure_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsFairValueDisclosure" xml:lang="en-US" id="label_AssetsFairValueDisclosure_2">Total Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="label_AssetsFairValueDisclosure_2" xlink:title="label: AssetsFairValueDisclosure to label_AssetsFairValueDisclosure" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to label_AssetsCurrentAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract_2">CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract_2" xlink:title="label: AssetsCurrentAbstract to label_AssetsCurrentAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract" xlink:title="label: AssetsAbstract to label_AssetsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract_2">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract_2" xlink:title="label: AssetsAbstract to label_AssetsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent" xlink:title="label: AssetsCurrent to label_AssetsCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent_2">TOTAL CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent_2" xlink:title="label: AssetsCurrent to label_AssetsCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets" xlink:title="label: Assets to label_Assets" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_Assets_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets_2">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets_2" xlink:title="label: Assets to label_Assets" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="AssetsFairValueDisclosureAbstract" xlink:title="AssetsFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsFairValueDisclosureAbstract" xml:lang="en-US" id="label_AssetsFairValueDisclosureAbstract">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosureAbstract" xlink:to="label_AssetsFairValueDisclosureAbstract" xlink:title="label: AssetsFairValueDisclosureAbstract to label_AssetsFairValueDisclosureAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_AssetsFairValueDisclosureAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsFairValueDisclosureAbstract" xml:lang="en-US" id="label_AssetsFairValueDisclosureAbstract_2">Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosureAbstract" xlink:to="label_AssetsFairValueDisclosureAbstract_2" xlink:title="label: AssetsFairValueDisclosureAbstract to label_AssetsFairValueDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="BasisOfAccounting" xlink:title="BasisOfAccounting" />
    <link:label xlink:type="resource" xlink:label="label_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BasisOfAccounting" xml:lang="en-US" id="label_BasisOfAccounting">Basis of Accounting [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccounting" xlink:to="label_BasisOfAccounting" xlink:title="label: BasisOfAccounting to label_BasisOfAccounting" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BasisOfAccounting_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BasisOfAccounting" xml:lang="en-US" id="label_BasisOfAccounting_2">BASIS OF PRESENTATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccounting" xlink:to="label_BasisOfAccounting_2" xlink:title="label: BasisOfAccounting to label_BasisOfAccounting" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionAxis" xml:lang="en-US" id="label_BusinessAcquisitionAxis">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAxis" xlink:to="label_BusinessAcquisitionAxis" xlink:title="label: BusinessAcquisitionAxis to label_BusinessAcquisitionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:label xlink:type="resource" xlink:label="label_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessAcquisitionAcquireeDomain" xml:lang="en-US" id="label_BusinessAcquisitionAcquireeDomain">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="label_BusinessAcquisitionAcquireeDomain" xlink:title="label: BusinessAcquisitionAcquireeDomain to label_BusinessAcquisitionAcquireeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessCombinationsAbstract" xml:lang="en-US" id="label_BusinessCombinationsAbstract">ACQUISITION OF NET ASSETS OF CELL GENESYS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationsAbstract" xlink:to="label_BusinessCombinationsAbstract" xlink:title="label: BusinessCombinationsAbstract to label_BusinessCombinationsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="BusinessCombinationDisclosureTextBlock" xlink:title="BusinessCombinationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessCombinationDisclosureTextBlock" xml:lang="en-US" id="label_BusinessCombinationDisclosureTextBlock">Business Combination Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDisclosureTextBlock" xlink:to="label_BusinessCombinationDisclosureTextBlock" xlink:title="label: BusinessCombinationDisclosureTextBlock to label_BusinessCombinationDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessCombinationDisclosureTextBlock" xml:lang="en-US" id="label_BusinessCombinationDisclosureTextBlock_2">ACQUISITION OF NET ASSETS OF CELL GENESYS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDisclosureTextBlock" xlink:to="label_BusinessCombinationDisclosureTextBlock_2" xlink:title="label: BusinessCombinationDisclosureTextBlock to label_BusinessCombinationDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="BusinessCombinationAcquisitionRelatedCosts" xlink:title="BusinessCombinationAcquisitionRelatedCosts" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessCombinationAcquisitionRelatedCosts" xml:lang="en-US" id="label_BusinessCombinationAcquisitionRelatedCosts">Business Combination, Acquisition Related Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationAcquisitionRelatedCosts" xlink:to="label_BusinessCombinationAcquisitionRelatedCosts" xlink:title="label: BusinessCombinationAcquisitionRelatedCosts to label_BusinessCombinationAcquisitionRelatedCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationAcquisitionRelatedCosts_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessCombinationAcquisitionRelatedCosts" xml:lang="en-US" id="label_BusinessCombinationAcquisitionRelatedCosts_2">Acquired in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationAcquisitionRelatedCosts" xlink:to="label_BusinessCombinationAcquisitionRelatedCosts_2" xlink:title="label: BusinessCombinationAcquisitionRelatedCosts to label_BusinessCombinationAcquisitionRelatedCosts" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalAdditionsMember" xlink:label="CapitalAdditionsMember" xlink:title="CapitalAdditionsMember" />
    <link:label xlink:type="resource" xlink:label="label_CapitalAdditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CapitalAdditionsMember" xml:lang="en-US" id="label_CapitalAdditionsMember">Capital Addition Purchase Commitments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalAdditionsMember" xlink:to="label_CapitalAdditionsMember" xlink:title="label: CapitalAdditionsMember to label_CapitalAdditionsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CapitalAdditionsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CapitalAdditionsMember" xml:lang="en-US" id="label_CapitalAdditionsMember_2">Gel Packaging Machine</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalAdditionsMember" xlink:to="label_CapitalAdditionsMember_2" xlink:title="label: CapitalAdditionsMember to label_CapitalAdditionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="CapitalExpendituresIncurredButNotYetPaid" xlink:title="CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xlink:type="resource" xlink:label="label_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US" id="label_CapitalExpendituresIncurredButNotYetPaid">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalExpendituresIncurredButNotYetPaid" xlink:to="label_CapitalExpendituresIncurredButNotYetPaid" xlink:title="label: CapitalExpendituresIncurredButNotYetPaid to label_CapitalExpendituresIncurredButNotYetPaid" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CapitalExpendituresIncurredButNotYetPaid_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US" id="label_CapitalExpendituresIncurredButNotYetPaid_2">Purchase of fixed assets on account, non-cash investing activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalExpendituresIncurredButNotYetPaid" xlink:to="label_CapitalExpendituresIncurredButNotYetPaid_2" xlink:title="label: CapitalExpendituresIncurredButNotYetPaid to label_CapitalExpendituresIncurredButNotYetPaid" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_2">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_3">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_4">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_4" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:label xlink:type="resource" xlink:label="label_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAcquiredFromAcquisition" xml:lang="en-US" id="label_CashAcquiredFromAcquisition">Cash received in transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAcquiredFromAcquisition" xlink:to="label_CashAcquiredFromAcquisition" xlink:title="label: CashAcquiredFromAcquisition to label_CashAcquiredFromAcquisition" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CashAcquiredFromAcquisition_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAcquiredFromAcquisition" xml:lang="en-US" id="label_CashAcquiredFromAcquisition_2">Cash Acquired from Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAcquiredFromAcquisition" xlink:to="label_CashAcquiredFromAcquisition_2" xlink:title="label: CashAcquiredFromAcquisition to label_CashAcquiredFromAcquisition" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightDomain" xml:lang="en-US" id="label_ClassOfWarrantOrRightDomain">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="label_ClassOfWarrantOrRightDomain" xlink:title="label: ClassOfWarrantOrRightDomain to label_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightAxis" xml:lang="en-US" id="label_ClassOfWarrantOrRightAxis">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="label_ClassOfWarrantOrRightAxis" xlink:title="label: ClassOfWarrantOrRightAxis to label_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xml:lang="en-US" id="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights to label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xml:lang="en-US" id="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_2">Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_2" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights to label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfStockDomain" xml:lang="en-US" id="label_ClassOfStockDomain">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="label_ClassOfStockDomain" xlink:title="label: ClassOfStockDomain to label_ClassOfStockDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2">Warrants issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xml:lang="en-US" id="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember to label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xml:lang="en-US" id="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis to label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="CommitmentsDisclosureTextBlock" xlink:title="CommitmentsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommitmentsDisclosureTextBlock" xml:lang="en-US" id="label_CommitmentsDisclosureTextBlock">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsDisclosureTextBlock" xlink:to="label_CommitmentsDisclosureTextBlock" xlink:title="label: CommitmentsDisclosureTextBlock to label_CommitmentsDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsDisclosureTextBlock" xml:lang="en-US" id="label_CommitmentsDisclosureTextBlock_2">Commitments Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsDisclosureTextBlock" xlink:to="label_CommitmentsDisclosureTextBlock_2" xlink:title="label: CommitmentsDisclosureTextBlock to label_CommitmentsDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureAbstract">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="label_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to label_CommitmentsAndContingenciesDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember" xlink:title="label: CommonStockMember to label_CommonStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember_2">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember_2" xlink:title="label: CommonStockMember to label_CommonStockMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember_3">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember_3" xlink:title="label: CommonStockMember to label_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to label_CommonStockSharesOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding_2">Capital stock, outstanding shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding_2" xlink:title="label: CommonStockSharesOutstanding to label_CommonStockSharesOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to label_CommonStockSharesIssued" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued_2">Capital stock, issued shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued_2" xlink:title="label: CommonStockSharesIssued to label_CommonStockSharesIssued" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="CommonStockValueOutstanding" xlink:title="CommonStockValueOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockValueOutstanding" xml:lang="en-US" id="label_CommonStockValueOutstanding">Common Stock, Value, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValueOutstanding" xlink:to="label_CommonStockValueOutstanding" xlink:title="label: CommonStockValueOutstanding to label_CommonStockValueOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValueOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockValueOutstanding" xml:lang="en-US" id="label_CommonStockValueOutstanding_2">Capital stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValueOutstanding" xlink:to="label_CommonStockValueOutstanding_2" xlink:title="label: CommonStockValueOutstanding to label_CommonStockValueOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonClassCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonClassCMember" xml:lang="en-US" id="label_CommonClassCMember">Class C special stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassCMember" xlink:to="label_CommonClassCMember" xlink:title="label: CommonClassCMember to label_CommonClassCMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CommonClassCMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonClassCMember" xml:lang="en-US" id="label_CommonClassCMember_2">Common Class C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassCMember" xlink:to="label_CommonClassCMember_2" xlink:title="label: CommonClassCMember to label_CommonClassCMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US" id="label_CompensationAndRetirementDisclosureAbstract">RETIREMENT PLAN</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="label_CompensationAndRetirementDisclosureAbstract" xlink:title="label: CompensationAndRetirementDisclosureAbstract to label_CompensationAndRetirementDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="ConvertibleDebtSecuritiesMember" xlink:title="ConvertibleDebtSecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleDebtSecuritiesMember" xml:lang="en-US" id="label_ConvertibleDebtSecuritiesMember">Convertible Debt Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtSecuritiesMember" xlink:to="label_ConvertibleDebtSecuritiesMember" xlink:title="label: ConvertibleDebtSecuritiesMember to label_ConvertibleDebtSecuritiesMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleDebtSecuritiesMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleDebtSecuritiesMember" xml:lang="en-US" id="label_ConvertibleDebtSecuritiesMember_2">Convertible debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtSecuritiesMember" xlink:to="label_ConvertibleDebtSecuritiesMember_2" xlink:title="label: ConvertibleDebtSecuritiesMember to label_ConvertibleDebtSecuritiesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotesPayableCurrent" xml:lang="en-US" id="label_ConvertibleNotesPayableCurrent">Convertible Notes Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableCurrent" xlink:to="label_ConvertibleNotesPayableCurrent" xlink:title="label: ConvertibleNotesPayableCurrent to label_ConvertibleNotesPayableCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayableCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleNotesPayableCurrent" xml:lang="en-US" id="label_ConvertibleNotesPayableCurrent_2">Current portion of Convertible Senior Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableCurrent" xlink:to="label_ConvertibleNotesPayableCurrent_2" xlink:title="label: ConvertibleNotesPayableCurrent to label_ConvertibleNotesPayableCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="ConvertibleLongTermNotesPayable" xlink:title="ConvertibleLongTermNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleLongTermNotesPayable" xml:lang="en-US" id="label_ConvertibleLongTermNotesPayable">Convertible Notes Payable, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleLongTermNotesPayable" xlink:to="label_ConvertibleLongTermNotesPayable" xlink:title="label: ConvertibleLongTermNotesPayable to label_ConvertibleLongTermNotesPayable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleLongTermNotesPayable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleLongTermNotesPayable" xml:lang="en-US" id="label_ConvertibleLongTermNotesPayable_2">Long-term convertible senior notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleLongTermNotesPayable" xlink:to="label_ConvertibleLongTermNotesPayable_2" xlink:title="label: ConvertibleLongTermNotesPayable to label_ConvertibleLongTermNotesPayable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleNotesPayableMember" xml:lang="en-US" id="label_ConvertibleNotesPayableMember">Convertible Notes Payable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableMember" xlink:to="label_ConvertibleNotesPayableMember" xlink:title="label: ConvertibleNotesPayableMember to label_ConvertibleNotesPayableMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleNotesPayableMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleNotesPayableMember" xml:lang="en-US" id="label_ConvertibleNotesPayableMember_2">2013 Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleNotesPayableMember" xlink:to="label_ConvertibleNotesPayableMember_2" xlink:title="label: ConvertibleNotesPayableMember to label_ConvertibleNotesPayableMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="ConvertibleDebtFairValueDisclosures" xlink:title="ConvertibleDebtFairValueDisclosures" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleDebtFairValueDisclosures" xml:lang="en-US" id="label_ConvertibleDebtFairValueDisclosures">Convertible Debt, Fair Value Disclosures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtFairValueDisclosures" xlink:to="label_ConvertibleDebtFairValueDisclosures" xlink:title="label: ConvertibleDebtFairValueDisclosures to label_ConvertibleDebtFairValueDisclosures" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleDebtFairValueDisclosures_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertibleDebtFairValueDisclosures" xml:lang="en-US" id="label_ConvertibleDebtFairValueDisclosures_2">Fair value of convertible debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtFairValueDisclosures" xlink:to="label_ConvertibleDebtFairValueDisclosures_2" xlink:title="label: ConvertibleDebtFairValueDisclosures to label_ConvertibleDebtFairValueDisclosures" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:label="CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:title="CostAndEquityMethodInvestmentsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CostAndEquityMethodInvestmentsDisclosureTextBlock" xml:lang="en-US" id="label_CostAndEquityMethodInvestmentsDisclosureTextBlock">Cost and Equity Method Investments Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:to="label_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:title="label: CostAndEquityMethodInvestmentsDisclosureTextBlock to label_CostAndEquityMethodInvestmentsDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CostAndEquityMethodInvestmentsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CostAndEquityMethodInvestmentsDisclosureTextBlock" xml:lang="en-US" id="label_CostAndEquityMethodInvestmentsDisclosureTextBlock_2">INVESTMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:to="label_CostAndEquityMethodInvestmentsDisclosureTextBlock_2" xlink:title="label: CostAndEquityMethodInvestmentsDisclosureTextBlock to label_CostAndEquityMethodInvestmentsDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CostsAndExpensesAbstract" xml:lang="en-US" id="label_CostsAndExpensesAbstract">Costs and Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="label_CostsAndExpensesAbstract" xlink:title="label: CostsAndExpensesAbstract to label_CostsAndExpensesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpensesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CostsAndExpensesAbstract" xml:lang="en-US" id="label_CostsAndExpensesAbstract_2">EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="label_CostsAndExpensesAbstract_2" xlink:title="label: CostsAndExpensesAbstract to label_CostsAndExpensesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CostsAndExpenses" xml:lang="en-US" id="label_CostsAndExpenses">Costs and Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="label_CostsAndExpenses" xlink:title="label: CostsAndExpenses to label_CostsAndExpenses" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_CostsAndExpenses_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_CostsAndExpenses" xml:lang="en-US" id="label_CostsAndExpenses_2">Total expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="label_CostsAndExpenses_2" xlink:title="label: CostsAndExpenses to label_CostsAndExpenses" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentLineItems" xml:lang="en-US" id="label_DebtInstrumentLineItems">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="label_DebtInstrumentLineItems" xlink:title="label: DebtInstrumentLineItems to label_DebtInstrumentLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentLineItems" xml:lang="en-US" id="label_DebtInstrumentLineItems_2">Convertible senior notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="label_DebtInstrumentLineItems_2" xlink:title="label: DebtInstrumentLineItems to label_DebtInstrumentLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentTable" xml:lang="en-US" id="label_DebtInstrumentTable">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="label_DebtInstrumentTable" xlink:title="label: DebtInstrumentTable to label_DebtInstrumentTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtConversionOriginalDebtAmount1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1">Debt Conversion, Original Debt, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1" xlink:title="label: DebtConversionOriginalDebtAmount1 to label_DebtConversionOriginalDebtAmount1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtConversionOriginalDebtAmount1_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtConversionOriginalDebtAmount1" xml:lang="en-US" id="label_DebtConversionOriginalDebtAmount1_2">Principal amount of debt cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtConversionOriginalDebtAmount1" xlink:to="label_DebtConversionOriginalDebtAmount1_2" xlink:title="label: DebtConversionOriginalDebtAmount1 to label_DebtConversionOriginalDebtAmount1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtDisclosureTextBlock" xml:lang="en-US" id="label_DebtDisclosureTextBlock">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="label_DebtDisclosureTextBlock" xlink:title="label: DebtDisclosureTextBlock to label_DebtDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtDisclosureTextBlock" xml:lang="en-US" id="label_DebtDisclosureTextBlock_2">CONVERTIBLE SENIOR NOTES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="label_DebtDisclosureTextBlock_2" xlink:title="label: DebtDisclosureTextBlock to label_DebtDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtDisclosureAbstract" xml:lang="en-US" id="label_DebtDisclosureAbstract">CONVERTIBLE SENIOR NOTES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="label_DebtDisclosureAbstract" xlink:title="label: DebtDisclosureAbstract to label_DebtDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US" id="label_DebtInstrumentConvertibleConversionPrice1">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPrice1" xlink:to="label_DebtInstrumentConvertibleConversionPrice1" xlink:title="label: DebtInstrumentConvertibleConversionPrice1 to label_DebtInstrumentConvertibleConversionPrice1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleConversionPrice1_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US" id="label_DebtInstrumentConvertibleConversionPrice1_2">Conversion price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPrice1" xlink:to="label_DebtInstrumentConvertibleConversionPrice1_2" xlink:title="label: DebtInstrumentConvertibleConversionPrice1 to label_DebtInstrumentConvertibleConversionPrice1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentConvertibleNumberOfEquityInstruments" xml:lang="en-US" id="label_DebtInstrumentConvertibleNumberOfEquityInstruments">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="label_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="label: DebtInstrumentConvertibleNumberOfEquityInstruments to label_DebtInstrumentConvertibleNumberOfEquityInstruments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentConvertibleNumberOfEquityInstruments_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentConvertibleNumberOfEquityInstruments" xml:lang="en-US" id="label_DebtInstrumentConvertibleNumberOfEquityInstruments_2">Number of shares of common stock receivable upon conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="label_DebtInstrumentConvertibleNumberOfEquityInstruments_2" xlink:title="label: DebtInstrumentConvertibleNumberOfEquityInstruments to label_DebtInstrumentConvertibleNumberOfEquityInstruments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentFaceAmount" xml:lang="en-US" id="label_DebtInstrumentFaceAmount">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount" xlink:title="label: DebtInstrumentFaceAmount to label_DebtInstrumentFaceAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentFaceAmount" xml:lang="en-US" id="label_DebtInstrumentFaceAmount_2">Principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount_2" xlink:title="label: DebtInstrumentFaceAmount to label_DebtInstrumentFaceAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_DebtInstrumentInterestRateStatedPercentage">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="label_DebtInstrumentInterestRateStatedPercentage" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to label_DebtInstrumentInterestRateStatedPercentage" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateStatedPercentage_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_DebtInstrumentInterestRateStatedPercentage_2">Interest rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="label_DebtInstrumentInterestRateStatedPercentage_2" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to label_DebtInstrumentInterestRateStatedPercentage" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DepositsAssetsNoncurrent" xml:lang="en-US" id="label_DepositsAssetsNoncurrent">Deposits Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAssetsNoncurrent" xlink:to="label_DepositsAssetsNoncurrent" xlink:title="label: DepositsAssetsNoncurrent to label_DepositsAssetsNoncurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DepositsAssetsNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DepositsAssetsNoncurrent" xml:lang="en-US" id="label_DepositsAssetsNoncurrent_2">Deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAssetsNoncurrent" xlink:to="label_DepositsAssetsNoncurrent_2" xlink:title="label: DepositsAssetsNoncurrent to label_DepositsAssetsNoncurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_DepreciationDepletionAndAmortization">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="label_DepreciationDepletionAndAmortization" xlink:title="label: DepreciationDepletionAndAmortization to label_DepreciationDepletionAndAmortization" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationDepletionAndAmortization_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_DepreciationDepletionAndAmortization_2">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="label_DepreciationDepletionAndAmortization_2" xlink:title="label: DepreciationDepletionAndAmortization to label_DepreciationDepletionAndAmortization" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:label="DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:title="DescriptionOfNewAccountingPronouncementsNotYetAdopted" />
    <link:label xlink:type="resource" xlink:label="label_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xml:lang="en-US" id="label_DescriptionOfNewAccountingPronouncementsNotYetAdopted">Description of New Accounting Pronouncements Not yet Adopted [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:to="label_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:title="label: DescriptionOfNewAccountingPronouncementsNotYetAdopted to label_DescriptionOfNewAccountingPronouncementsNotYetAdopted" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DescriptionOfNewAccountingPronouncementsNotYetAdopted_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xml:lang="en-US" id="label_DescriptionOfNewAccountingPronouncementsNotYetAdopted_2">RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:to="label_DescriptionOfNewAccountingPronouncementsNotYetAdopted_2" xlink:title="label: DescriptionOfNewAccountingPronouncementsNotYetAdopted to label_DescriptionOfNewAccountingPronouncementsNotYetAdopted" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2">STOCK-BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">STOCK-BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareDiluted" xml:lang="en-US" id="label_EarningsPerShareDiluted">Earnings Per Share, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="label_EarningsPerShareDiluted" xlink:title="label: EarningsPerShareDiluted to label_EarningsPerShareDiluted" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareDiluted_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareDiluted" xml:lang="en-US" id="label_EarningsPerShareDiluted_2">Diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="label_EarningsPerShareDiluted_2" xlink:title="label: EarningsPerShareDiluted to label_EarningsPerShareDiluted" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasic" xml:lang="en-US" id="label_EarningsPerShareBasic">Earnings Per Share, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="label_EarningsPerShareBasic" xlink:title="label: EarningsPerShareBasic to label_EarningsPerShareBasic" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasic_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareBasic" xml:lang="en-US" id="label_EarningsPerShareBasic_2">Basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="label_EarningsPerShareBasic_2" xlink:title="label: EarningsPerShareBasic to label_EarningsPerShareBasic" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted">BASIC AND DILUTED NET LOSS PER SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted" xlink:title="label: EarningsPerShareBasicAndDiluted to label_EarningsPerShareBasicAndDiluted" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasicAndDiluted_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_EarningsPerShareBasicAndDiluted_2">Earnings Per Share, Basic and Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAndDiluted" xlink:to="label_EarningsPerShareBasicAndDiluted_2" xlink:title="label: EarningsPerShareBasicAndDiluted to label_EarningsPerShareBasicAndDiluted" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareTextBlock" xml:lang="en-US" id="label_EarningsPerShareTextBlock">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="label_EarningsPerShareTextBlock" xlink:title="label: EarningsPerShareTextBlock to label_EarningsPerShareTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareTextBlock" xml:lang="en-US" id="label_EarningsPerShareTextBlock_2">BASIC AND DILUTED NET LOSS PER SHARE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="label_EarningsPerShareTextBlock_2" xlink:title="label: EarningsPerShareTextBlock to label_EarningsPerShareTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareAbstract" xml:lang="en-US" id="label_EarningsPerShareAbstract">BASIC AND DILUTED NET LOSS PER SHARE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="label_EarningsPerShareAbstract" xlink:title="label: EarningsPerShareAbstract to label_EarningsPerShareAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareAbstract" xml:lang="en-US" id="label_EarningsPerShareAbstract_2">NET LOSS PER SHARE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="label_EarningsPerShareAbstract_2" xlink:title="label: EarningsPerShareAbstract to label_EarningsPerShareAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US" id="label_EmployeeRelatedLiabilitiesCurrent">Employee-related Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="label_EmployeeRelatedLiabilitiesCurrent" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to label_EmployeeRelatedLiabilitiesCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeRelatedLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US" id="label_EmployeeRelatedLiabilitiesCurrent_2">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="label_EmployeeRelatedLiabilitiesCurrent_2" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to label_EmployeeRelatedLiabilitiesCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeSeveranceMember" xml:lang="en-US" id="label_EmployeeSeveranceMember">Employee Severance [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeSeveranceMember" xlink:to="label_EmployeeSeveranceMember" xlink:title="label: EmployeeSeveranceMember to label_EmployeeSeveranceMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeSeveranceMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeSeveranceMember" xml:lang="en-US" id="label_EmployeeSeveranceMember_2">Employee Reduction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeSeveranceMember" xlink:to="label_EmployeeSeveranceMember_2" xlink:title="label: EmployeeSeveranceMember to label_EmployeeSeveranceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityComponentDomain" xml:lang="en-US" id="label_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="label_EquityComponentDomain" xlink:title="label: EquityComponentDomain to label_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="EstimateOfFairValueFairValueDisclosureMember" xlink:title="EstimateOfFairValueFairValueDisclosureMember" />
    <link:label xlink:type="resource" xlink:label="label_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember" xml:lang="en-US" id="label_EstimateOfFairValueFairValueDisclosureMember">Estimate of Fair Value, Fair Value Disclosure [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimateOfFairValueFairValueDisclosureMember" xlink:to="label_EstimateOfFairValueFairValueDisclosureMember" xlink:title="label: EstimateOfFairValueFairValueDisclosureMember to label_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_EstimateOfFairValueFairValueDisclosureMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EstimateOfFairValueFairValueDisclosureMember" xml:lang="en-US" id="label_EstimateOfFairValueFairValueDisclosureMember_2">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimateOfFairValueFairValueDisclosureMember" xlink:to="label_EstimateOfFairValueFairValueDisclosureMember_2" xlink:title="label: EstimateOfFairValueFairValueDisclosureMember to label_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByMeasurementFrequencyAxis" xml:lang="en-US" id="label_FairValueByMeasurementFrequencyAxis">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="label_FairValueByMeasurementFrequencyAxis" xlink:title="label: FairValueByMeasurementFrequencyAxis to label_FairValueByMeasurementFrequencyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US" id="label_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain">Fair Value by Asset Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="label_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to label_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_FairValueAssumptionsExpectedVolatilityRate">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedVolatilityRate" xlink:to="label_FairValueAssumptionsExpectedVolatilityRate" xlink:title="label: FairValueAssumptionsExpectedVolatilityRate to label_FairValueAssumptionsExpectedVolatilityRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsExpectedVolatilityRate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_FairValueAssumptionsExpectedVolatilityRate_2">Volatility of BioSante common stock (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedVolatilityRate" xlink:to="label_FairValueAssumptionsExpectedVolatilityRate_2" xlink:title="label: FairValueAssumptionsExpectedVolatilityRate to label_FairValueAssumptionsExpectedVolatilityRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="FairValueOptionChangesInFairValueGainLoss1" xlink:title="FairValueOptionChangesInFairValueGainLoss1" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US" id="label_FairValueOptionChangesInFairValueGainLoss1">Convertible note fair value adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionChangesInFairValueGainLoss1" xlink:to="label_FairValueOptionChangesInFairValueGainLoss1" xlink:title="label: FairValueOptionChangesInFairValueGainLoss1 to label_FairValueOptionChangesInFairValueGainLoss1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionChangesInFairValueGainLoss1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US" id="label_FairValueOptionChangesInFairValueGainLoss1_2">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionChangesInFairValueGainLoss1" xlink:to="label_FairValueOptionChangesInFairValueGainLoss1_2" xlink:title="label: FairValueOptionChangesInFairValueGainLoss1 to label_FairValueOptionChangesInFairValueGainLoss1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionChangesInFairValueGainLoss1_3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US" id="label_FairValueOptionChangesInFairValueGainLoss1_3">Convertible note fair value adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionChangesInFairValueGainLoss1" xlink:to="label_FairValueOptionChangesInFairValueGainLoss1_3" xlink:title="label: FairValueOptionChangesInFairValueGainLoss1 to label_FairValueOptionChangesInFairValueGainLoss1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionChangesInFairValueGainLoss1_4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US" id="label_FairValueOptionChangesInFairValueGainLoss1_4">Fair value adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionChangesInFairValueGainLoss1" xlink:to="label_FairValueOptionChangesInFairValueGainLoss1_4" xlink:title="label: FairValueOptionChangesInFairValueGainLoss1 to label_FairValueOptionChangesInFairValueGainLoss1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="label_FairValueByFairValueHierarchyLevelAxis">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="label_FairValueByFairValueHierarchyLevelAxis" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to label_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByLiabilityClassAxis" xml:lang="en-US" id="label_FairValueByLiabilityClassAxis">Liability Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByLiabilityClassAxis" xlink:to="label_FairValueByLiabilityClassAxis" xlink:title="label: FairValueByLiabilityClassAxis to label_FairValueByLiabilityClassAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember" xlink:title="label: FairValueMeasurementsRecurringMember to label_FairValueMeasurementsRecurringMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember_2">Recurring basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember_2" xlink:title="label: FairValueMeasurementsRecurringMember to label_FairValueMeasurementsRecurringMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementFrequencyDomain" xml:lang="en-US" id="label_FairValueMeasurementFrequencyDomain">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="label_FairValueMeasurementFrequencyDomain" xlink:title="label: FairValueMeasurementFrequencyDomain to label_FairValueMeasurementFrequencyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_FairValueAssumptionsRiskFreeInterestRate">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsRiskFreeInterestRate" xlink:to="label_FairValueAssumptionsRiskFreeInterestRate" xlink:title="label: FairValueAssumptionsRiskFreeInterestRate to label_FairValueAssumptionsRiskFreeInterestRate" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsRiskFreeInterestRate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_FairValueAssumptionsRiskFreeInterestRate_2">Average risk-free rate (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsRiskFreeInterestRate" xlink:to="label_FairValueAssumptionsRiskFreeInterestRate_2" xlink:title="label: FairValueAssumptionsRiskFreeInterestRate to label_FairValueAssumptionsRiskFreeInterestRate" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByAssetClassAxis" xml:lang="en-US" id="label_FairValueByAssetClassAxis">Asset Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByAssetClassAxis" xlink:to="label_FairValueByAssetClassAxis" xlink:title="label: FairValueByAssetClassAxis to label_FairValueByAssetClassAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="label_FairValueMeasurementsFairValueHierarchyDomain">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to label_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xml:lang="en-US" id="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="label: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xml:lang="en-US" id="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_2">Assumptions to establish the value of the Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract_2" xlink:title="label: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to label_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2">Fair value of assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresAbstract" xml:lang="en-US" id="label_FairValueDisclosuresAbstract">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="label_FairValueDisclosuresAbstract" xlink:title="label: FairValueDisclosuresAbstract to label_FairValueDisclosuresAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock" xlink:title="label: FairValueDisclosuresTextBlock to label_FairValueDisclosuresTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueDisclosuresTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_FairValueDisclosuresTextBlock_2">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="label_FairValueDisclosuresTextBlock_2" xlink:title="label: FairValueDisclosuresTextBlock to label_FairValueDisclosuresTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel3Member" xml:lang="en-US" id="label_FairValueInputsLevel3Member">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member" xlink:title="label: FairValueInputsLevel3Member to label_FairValueInputsLevel3Member" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel3Member" xml:lang="en-US" id="label_FairValueInputsLevel3Member_2">Significant Other Unobservable Inputs (Level 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member_2" xlink:title="label: FairValueInputsLevel3Member to label_FairValueInputsLevel3Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel1Member" xml:lang="en-US" id="label_FairValueInputsLevel1Member">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member" xlink:title="label: FairValueInputsLevel1Member to label_FairValueInputsLevel1Member" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel1Member" xml:lang="en-US" id="label_FairValueInputsLevel1Member_2">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member_2" xlink:title="label: FairValueInputsLevel1Member to label_FairValueInputsLevel1Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel2Member" xml:lang="en-US" id="label_FairValueInputsLevel2Member">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="label_FairValueInputsLevel2Member" xlink:title="label: FairValueInputsLevel2Member to label_FairValueInputsLevel2Member" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel2Member_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel2Member" xml:lang="en-US" id="label_FairValueInputsLevel2Member_2">Significant Other Observable Inputs (Level 2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="label_FairValueInputsLevel2Member_2" xlink:title="label: FairValueInputsLevel2Member to label_FairValueInputsLevel2Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:label="FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:title="FairValueOptionAggregateDifferencesLongTermDebtInstruments" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueOptionAggregateDifferencesLongTermDebtInstruments" xml:lang="en-US" id="label_FairValueOptionAggregateDifferencesLongTermDebtInstruments">Fair Value, Option, Aggregate Differences, Long-term Debt Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:to="label_FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:title="label: FairValueOptionAggregateDifferencesLongTermDebtInstruments to label_FairValueOptionAggregateDifferencesLongTermDebtInstruments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionAggregateDifferencesLongTermDebtInstruments_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueOptionAggregateDifferencesLongTermDebtInstruments" xml:lang="en-US" id="label_FairValueOptionAggregateDifferencesLongTermDebtInstruments_2">Amount of difference between aggregate recorded fair value of the notes and their total stated principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:to="label_FairValueOptionAggregateDifferencesLongTermDebtInstruments_2" xlink:title="label: FairValueOptionAggregateDifferencesLongTermDebtInstruments to label_FairValueOptionAggregateDifferencesLongTermDebtInstruments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:label="FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:title="FairValueOptionCreditRiskGainsLossesOnLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueOptionCreditRiskGainsLossesOnLiabilities" xml:lang="en-US" id="label_FairValueOptionCreditRiskGainsLossesOnLiabilities">Fair Value, Option, Credit Risk, Gains (Losses) on Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:to="label_FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:title="label: FairValueOptionCreditRiskGainsLossesOnLiabilities to label_FairValueOptionCreditRiskGainsLossesOnLiabilities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOptionCreditRiskGainsLossesOnLiabilities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueOptionCreditRiskGainsLossesOnLiabilities" xml:lang="en-US" id="label_FairValueOptionCreditRiskGainsLossesOnLiabilities_2">Fair value adjustment attributable to the change in instrument specific credit risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:to="label_FairValueOptionCreditRiskGainsLossesOnLiabilities_2" xlink:title="label: FairValueOptionCreditRiskGainsLossesOnLiabilities to label_FairValueOptionCreditRiskGainsLossesOnLiabilities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US" id="label_GainLossOnSaleOfPropertyPlantEquipment">Gain (Loss) on Sale of Property Plant Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="label: GainLossOnSaleOfPropertyPlantEquipment to label_GainLossOnSaleOfPropertyPlantEquipment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GainLossOnSaleOfPropertyPlantEquipment_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US" id="label_GainLossOnSaleOfPropertyPlantEquipment_2">Loss on disposal of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_GainLossOnSaleOfPropertyPlantEquipment_2" xlink:title="label: GainLossOnSaleOfPropertyPlantEquipment to label_GainLossOnSaleOfPropertyPlantEquipment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense" xlink:title="label: GeneralAndAdministrativeExpense to label_GeneralAndAdministrativeExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense_2">General and administration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense_2" xlink:title="label: GeneralAndAdministrativeExpense to label_GeneralAndAdministrativeExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InstrumentTypeMember" xlink:label="InstrumentTypeMember" xlink:title="InstrumentTypeMember" />
    <link:label xlink:type="resource" xlink:label="label_InstrumentTypeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InstrumentTypeMember" xml:lang="en-US" id="label_InstrumentTypeMember">Instrument Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InstrumentTypeMember" xlink:to="label_InstrumentTypeMember" xlink:title="label: InstrumentTypeMember to label_InstrumentTypeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InstrumentAxis" xlink:label="InstrumentAxis" xlink:title="InstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="label_InstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InstrumentAxis" xml:lang="en-US" id="label_InstrumentAxis">Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InstrumentAxis" xlink:to="label_InstrumentAxis" xlink:title="label: InstrumentAxis to label_InstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementAbstract" xml:lang="en-US" id="label_IncomeStatementAbstract">Condensed Statements of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="label_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to label_IncomeStatementAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock" xlink:title="label: IncomeTaxDisclosureTextBlock to label_IncomeTaxDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock_2">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock_2" xlink:title="label: IncomeTaxDisclosureTextBlock to label_IncomeTaxDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="label_IncomeTaxDisclosureAbstract">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="label_IncomeTaxDisclosureAbstract" xlink:title="label: IncomeTaxDisclosureAbstract to label_IncomeTaxDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsReceivable">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="label_IncreaseDecreaseInAccountsReceivable" xlink:title="label: IncreaseDecreaseInAccountsReceivable to label_IncreaseDecreaseInAccountsReceivable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsReceivable_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsReceivable_2">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="label_IncreaseDecreaseInAccountsReceivable_2" xlink:title="label: IncreaseDecreaseInAccountsReceivable to label_IncreaseDecreaseInAccountsReceivable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to label_IncreaseDecreaseInOperatingCapitalAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract_2">Changes in other assets and liabilities affecting cash flows from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract_2" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to label_IncreaseDecreaseInOperatingCapitalAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="IncreaseDecreaseInOtherReceivables" xlink:title="IncreaseDecreaseInOtherReceivables" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOtherReceivables" xml:lang="en-US" id="label_IncreaseDecreaseInOtherReceivables">Increase (Decrease) in Other Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherReceivables" xlink:to="label_IncreaseDecreaseInOtherReceivables" xlink:title="label: IncreaseDecreaseInOtherReceivables to label_IncreaseDecreaseInOtherReceivables" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2">Prepaid expenses, deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="IncreaseDecreaseInRoyaltiesPayable" xlink:title="IncreaseDecreaseInRoyaltiesPayable" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInRoyaltiesPayable" xml:lang="en-US" id="label_IncreaseDecreaseInRoyaltiesPayable">Increase (Decrease) in Royalties Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInRoyaltiesPayable" xlink:to="label_IncreaseDecreaseInRoyaltiesPayable" xlink:title="label: IncreaseDecreaseInRoyaltiesPayable to label_IncreaseDecreaseInRoyaltiesPayable" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInRoyaltiesPayable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInRoyaltiesPayable" xml:lang="en-US" id="label_IncreaseDecreaseInRoyaltiesPayable_2">Due to licensor - Antares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInRoyaltiesPayable" xlink:to="label_IncreaseDecreaseInRoyaltiesPayable_2" xlink:title="label: IncreaseDecreaseInRoyaltiesPayable to label_IncreaseDecreaseInRoyaltiesPayable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="label_IncreaseDecreaseInStockholdersEquityRollForward">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="label_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to label_IncreaseDecreaseInStockholdersEquityRollForward" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInStockholdersEquityRollForward_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="label_IncreaseDecreaseInStockholdersEquityRollForward_2">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="label_IncreaseDecreaseInStockholdersEquityRollForward_2" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to label_IncreaseDecreaseInStockholdersEquityRollForward" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestPayableCurrentAndNoncurrent" xml:lang="en-US" id="label_InterestPayableCurrentAndNoncurrent">Accrued and unpaid interest payable on cancellation of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrentAndNoncurrent" xlink:to="label_InterestPayableCurrentAndNoncurrent" xlink:title="label: InterestPayableCurrentAndNoncurrent to label_InterestPayableCurrentAndNoncurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InterestPayableCurrentAndNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPayableCurrentAndNoncurrent" xml:lang="en-US" id="label_InterestPayableCurrentAndNoncurrent_2">Interest Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrentAndNoncurrent" xlink:to="label_InterestPayableCurrentAndNoncurrent_2" xlink:title="label: InterestPayableCurrentAndNoncurrent to label_InterestPayableCurrentAndNoncurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestExpense" xml:lang="en-US" id="label_InterestExpense">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense" xlink:title="label: InterestExpense to label_InterestExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpense_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_InterestExpense" xml:lang="en-US" id="label_InterestExpense_2">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="label_InterestExpense_2" xlink:title="label: InterestExpense to label_InterestExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestPaid" xml:lang="en-US" id="label_InterestPaid">Interest Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="label_InterestPaid" xlink:title="label: InterestPaid to label_InterestPaid" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InterestPaid_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InterestPaid" xml:lang="en-US" id="label_InterestPaid_2">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaid" xlink:to="label_InterestPaid_2" xlink:title="label: InterestPaid to label_InterestPaid" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InvestmentIncomeInterest" xml:lang="en-US" id="label_InvestmentIncomeInterest">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="label_InvestmentIncomeInterest" xlink:title="label: InvestmentIncomeInterest to label_InvestmentIncomeInterest" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentIncomeInterest_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InvestmentIncomeInterest" xml:lang="en-US" id="label_InvestmentIncomeInterest_2">Investment Income, Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="label_InvestmentIncomeInterest_2" xlink:title="label: InvestmentIncomeInterest to label_InvestmentIncomeInterest" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="InvestmentIncomeNet" xlink:title="InvestmentIncomeNet" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InvestmentIncomeNet" xml:lang="en-US" id="label_InvestmentIncomeNet">Investment Income, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeNet" xlink:to="label_InvestmentIncomeNet" xlink:title="label: InvestmentIncomeNet to label_InvestmentIncomeNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentIncomeNet_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InvestmentIncomeNet" xml:lang="en-US" id="label_InvestmentIncomeNet_2">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeNet" xlink:to="label_InvestmentIncomeNet_2" xlink:title="label: InvestmentIncomeNet to label_InvestmentIncomeNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="InvestmentsDebtAndEquitySecuritiesAbstract" xlink:title="InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US" id="label_InvestmentsDebtAndEquitySecuritiesAbstract">INVESTMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="label_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:title="label: InvestmentsDebtAndEquitySecuritiesAbstract to label_InvestmentsDebtAndEquitySecuritiesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US" id="label_IssuanceOfStockAndWarrantsForServicesOrClaims">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="label_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="label: IssuanceOfStockAndWarrantsForServicesOrClaims to label_IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfStockAndWarrantsForServicesOrClaims_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US" id="label_IssuanceOfStockAndWarrantsForServicesOrClaims_2">Stock warrant expense - noncash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="label_IssuanceOfStockAndWarrantsForServicesOrClaims_2" xlink:title="label: IssuanceOfStockAndWarrantsForServicesOrClaims to label_IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongtermDebtTypeDomain" xml:lang="en-US" id="label_LongtermDebtTypeDomain">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeDomain" xlink:to="label_LongtermDebtTypeDomain" xlink:title="label: LongtermDebtTypeDomain to label_LongtermDebtTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongtermDebtTypeAxis" xml:lang="en-US" id="label_LongtermDebtTypeAxis">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtTypeAxis" xlink:to="label_LongtermDebtTypeAxis" xlink:title="label: LongtermDebtTypeAxis to label_LongtermDebtTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LeasesAbstract" xml:lang="en-US" id="label_LeasesAbstract">LEASE ARRANGEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="label_LeasesAbstract" xlink:title="label: LeasesAbstract to label_LeasesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="LeasesOfLesseeDisclosureTextBlock" xlink:title="LeasesOfLesseeDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_LeasesOfLesseeDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US" id="label_LeasesOfLesseeDisclosureTextBlock">Leases of Lessee Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesOfLesseeDisclosureTextBlock" xlink:to="label_LeasesOfLesseeDisclosureTextBlock" xlink:title="label: LeasesOfLesseeDisclosureTextBlock to label_LeasesOfLesseeDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LeasesOfLesseeDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US" id="label_LeasesOfLesseeDisclosureTextBlock_2">LEASE ARRANGEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesOfLesseeDisclosureTextBlock" xlink:to="label_LeasesOfLesseeDisclosureTextBlock_2" xlink:title="label: LeasesOfLesseeDisclosureTextBlock to label_LeasesOfLesseeDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to label_LiabilitiesCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent_2">TOTAL CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent_2" xlink:title="label: LiabilitiesCurrent to label_LiabilitiesCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesFairValueDisclosure" xml:lang="en-US" id="label_LiabilitiesFairValueDisclosure">Liabilities, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="label_LiabilitiesFairValueDisclosure" xlink:title="label: LiabilitiesFairValueDisclosure to label_LiabilitiesFairValueDisclosure" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesFairValueDisclosure_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesFairValueDisclosure" xml:lang="en-US" id="label_LiabilitiesFairValueDisclosure_2">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="label_LiabilitiesFairValueDisclosure_2" xlink:title="label: LiabilitiesFairValueDisclosure to label_LiabilitiesFairValueDisclosure" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to label_LiabilitiesCurrentAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract_2">CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract_2" xlink:title="label: LiabilitiesCurrentAbstract to label_LiabilitiesCurrentAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Liabilities" xml:lang="en-US" id="label_Liabilities">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="label_Liabilities" xlink:title="label: Liabilities to label_Liabilities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_Liabilities_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Liabilities" xml:lang="en-US" id="label_Liabilities_2">TOTAL LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="label_Liabilities_2" xlink:title="label: Liabilities to label_Liabilities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to label_LiabilitiesAndStockholdersEquityAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract_2">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract_2" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to label_LiabilitiesAndStockholdersEquityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US" id="label_LiabilitiesFairValueDisclosureAbstract">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="label_LiabilitiesFairValueDisclosureAbstract" xlink:title="label: LiabilitiesFairValueDisclosureAbstract to label_LiabilitiesFairValueDisclosureAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesFairValueDisclosureAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US" id="label_LiabilitiesFairValueDisclosureAbstract_2">Liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="label_LiabilitiesFairValueDisclosureAbstract_2" xlink:title="label: LiabilitiesFairValueDisclosureAbstract to label_LiabilitiesFairValueDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to label_LiabilitiesAndStockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity_2">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity_2" xlink:title="label: LiabilitiesAndStockholdersEquity to label_LiabilitiesAndStockholdersEquity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseCosts" xlink:label="LicenseCosts" xlink:title="LicenseCosts" />
    <link:label xlink:type="resource" xlink:label="label_LicenseCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LicenseCosts" xml:lang="en-US" id="label_LicenseCosts">License Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseCosts" xlink:to="label_LicenseCosts" xlink:title="label: LicenseCosts to label_LicenseCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LicenseCosts_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LicenseCosts" xml:lang="en-US" id="label_LicenseCosts_2">Licensing expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseCosts" xlink:to="label_LicenseCosts_2" xlink:title="label: LicenseCosts to label_LicenseCosts" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:label xlink:type="resource" xlink:label="label_LicensesRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LicensesRevenue" xml:lang="en-US" id="label_LicensesRevenue">Licenses Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensesRevenue" xlink:to="label_LicensesRevenue" xlink:title="label: LicensesRevenue to label_LicensesRevenue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LicensesRevenue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LicensesRevenue" xml:lang="en-US" id="label_LicensesRevenue_2">Licensing revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensesRevenue" xlink:to="label_LicensesRevenue_2" xlink:title="label: LicensesRevenue to label_LicensesRevenue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="LitigationCaseTypeDomain" xlink:title="LitigationCaseTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LitigationCaseTypeDomain" xml:lang="en-US" id="label_LitigationCaseTypeDomain">Litigation Case Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LitigationCaseTypeDomain" xlink:to="label_LitigationCaseTypeDomain" xlink:title="label: LitigationCaseTypeDomain to label_LitigationCaseTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="LitigationCaseAxis" xlink:title="LitigationCaseAxis" />
    <link:label xlink:type="resource" xlink:label="label_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LitigationCaseAxis" xml:lang="en-US" id="label_LitigationCaseAxis">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LitigationCaseAxis" xlink:to="label_LitigationCaseAxis" xlink:title="label: LitigationCaseAxis to label_LitigationCaseAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebt" xml:lang="en-US" id="label_LongTermDebt">Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="label_LongTermDebt" xlink:title="label: LongTermDebt to label_LongTermDebt" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebt_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LongTermDebt" xml:lang="en-US" id="label_LongTermDebt_2">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="label_LongTermDebt_2" xlink:title="label: LongTermDebt to label_LongTermDebt" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtFairValue" xml:lang="en-US" id="label_LongTermDebtFairValue">Long-term Debt, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtFairValue" xlink:to="label_LongTermDebtFairValue" xlink:title="label: LongTermDebtFairValue to label_LongTermDebtFairValue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtFairValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtFairValue" xml:lang="en-US" id="label_LongTermDebtFairValue_2">Recorded fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtFairValue" xlink:to="label_LongTermDebtFairValue_2" xlink:title="label: LongTermDebtFairValue to label_LongTermDebtFairValue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear to label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2">2012</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear to label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="LongTermDebtByMaturityAbstract" xlink:title="LongTermDebtByMaturityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtByMaturityAbstract" xml:lang="en-US" id="label_LongTermDebtByMaturityAbstract">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="label_LongTermDebtByMaturityAbstract" xlink:title="label: LongTermDebtByMaturityAbstract to label_LongTermDebtByMaturityAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtByMaturityAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtByMaturityAbstract" xml:lang="en-US" id="label_LongTermDebtByMaturityAbstract_2">Maturities of required principal payments by year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="label_LongTermDebtByMaturityAbstract_2" xlink:title="label: LongTermDebtByMaturityAbstract to label_LongTermDebtByMaturityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="LongTermPurchaseCommitmentTable" xlink:title="LongTermPurchaseCommitmentTable" />
    <link:label xlink:type="resource" xlink:label="label_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermPurchaseCommitmentTable" xml:lang="en-US" id="label_LongTermPurchaseCommitmentTable">Long-term Purchase Commitment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="label_LongTermPurchaseCommitmentTable" xlink:title="label: LongTermPurchaseCommitmentTable to label_LongTermPurchaseCommitmentTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="LongTermPurchaseCommitmentLineItems" xlink:title="LongTermPurchaseCommitmentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermPurchaseCommitmentLineItems" xml:lang="en-US" id="label_LongTermPurchaseCommitmentLineItems">Long-term Purchase Commitment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="label_LongTermPurchaseCommitmentLineItems" xlink:title="label: LongTermPurchaseCommitmentLineItems to label_LongTermPurchaseCommitmentLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermPurchaseCommitmentLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermPurchaseCommitmentLineItems" xml:lang="en-US" id="label_LongTermPurchaseCommitmentLineItems_2">Commitment and contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="label_LongTermPurchaseCommitmentLineItems_2" xlink:title="label: LongTermPurchaseCommitmentLineItems to label_LongTermPurchaseCommitmentLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo to label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2">2013</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2" xlink:title="label: LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo to label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="LongTermInvestments" xlink:title="LongTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermInvestments" xml:lang="en-US" id="label_LongTermInvestments">Long-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermInvestments" xlink:to="label_LongTermInvestments" xlink:title="label: LongTermInvestments to label_LongTermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermInvestments_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermInvestments" xml:lang="en-US" id="label_LongTermInvestments_2">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermInvestments" xlink:to="label_LongTermInvestments_2" xlink:title="label: LongTermInvestments to label_LongTermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermInvestments_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_LongTermInvestments" xml:lang="en-US" id="label_LongTermInvestments_3">Investment in Ceregene, Inc. accounted under cost method</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermInvestments" xlink:to="label_LongTermInvestments_3" xlink:title="label: LongTermInvestments to label_LongTermInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:label xlink:type="resource" xlink:label="label_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US" id="label_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">Category of Item Purchased [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="label_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="label: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis to label_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:label xlink:type="resource" xlink:label="label_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US" id="label_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain">Long-term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="label_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="label: LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain to label_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="LongTermPurchaseCommitmentAmount" xlink:title="LongTermPurchaseCommitmentAmount" />
    <link:label xlink:type="resource" xlink:label="label_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermPurchaseCommitmentAmount" xml:lang="en-US" id="label_LongTermPurchaseCommitmentAmount">Long-term Purchase Commitment, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentAmount" xlink:to="label_LongTermPurchaseCommitmentAmount" xlink:title="label: LongTermPurchaseCommitmentAmount to label_LongTermPurchaseCommitmentAmount" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LongTermPurchaseCommitmentAmount_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermPurchaseCommitmentAmount" xml:lang="en-US" id="label_LongTermPurchaseCommitmentAmount_2">Amount of commitment to purchase machinery</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermPurchaseCommitmentAmount" xlink:to="label_LongTermPurchaseCommitmentAmount_2" xlink:title="label: LongTermPurchaseCommitmentAmount to label_LongTermPurchaseCommitmentAmount" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="label_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LossContingenciesTable" xml:lang="en-US" id="label_LossContingenciesTable">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesTable" xlink:to="label_LossContingenciesTable" xlink:title="label: LossContingenciesTable to label_LossContingenciesTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LossContingenciesLineItems" xml:lang="en-US" id="label_LossContingenciesLineItems">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesLineItems" xlink:to="label_LossContingenciesLineItems" xlink:title="label: LossContingenciesLineItems to label_LossContingenciesLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_LossContingenciesLineItems_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LossContingenciesLineItems" xml:lang="en-US" id="label_LossContingenciesLineItems_2">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesLineItems" xlink:to="label_LossContingenciesLineItems_2" xlink:title="label: LossContingenciesLineItems to label_LossContingenciesLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MaximumMember" xml:lang="en-US" id="label_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember" xlink:title="label: MaximumMember to label_MaximumMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_MaximumMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MaximumMember" xml:lang="en-US" id="label_MaximumMember_2">High end of range</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember_2" xlink:title="label: MaximumMember to label_MaximumMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_MaximumMember_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_MaximumMember" xml:lang="en-US" id="label_MaximumMember_3">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember_3" xlink:title="label: MaximumMember to label_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MinimumMember" xml:lang="en-US" id="label_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember" xlink:title="label: MinimumMember to label_MinimumMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_MinimumMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MinimumMember" xml:lang="en-US" id="label_MinimumMember_2">Low end of range</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember_2" xlink:title="label: MinimumMember to label_MinimumMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_MinimumMember_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_MinimumMember" xml:lang="en-US" id="label_MinimumMember_3">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember_3" xlink:title="label: MinimumMember to label_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:label xlink:type="resource" xlink:label="label_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MoneyMarketFundsMember" xml:lang="en-US" id="label_MoneyMarketFundsMember">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MoneyMarketFundsMember" xlink:to="label_MoneyMarketFundsMember" xlink:title="label: MoneyMarketFundsMember to label_MoneyMarketFundsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_MoneyMarketFundsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MoneyMarketFundsMember" xml:lang="en-US" id="label_MoneyMarketFundsMember_2">Money market fund</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MoneyMarketFundsMember" xlink:to="label_MoneyMarketFundsMember_2" xlink:title="label: MoneyMarketFundsMember to label_MoneyMarketFundsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:label xlink:type="resource" xlink:label="label_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NatureOfOperations" xml:lang="en-US" id="label_NatureOfOperations">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="label_NatureOfOperations" xlink:title="label: NatureOfOperations to label_NatureOfOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NatureOfOperations_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NatureOfOperations" xml:lang="en-US" id="label_NatureOfOperations_2">DESCRIPTION OF BUSINESS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="label_NatureOfOperations_2" xlink:title="label: NatureOfOperations to label_NatureOfOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2">CASH FLOWS PROVIDED BY FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2">Net cash (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2">CASH FLOWS (USED IN) OPERATING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInContinuingOperations">Net Cash Provided by (Used in) Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="label_NetCashProvidedByUsedInContinuingOperations" xlink:title="label: NetCashProvidedByUsedInContinuingOperations to label_NetCashProvidedByUsedInContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInContinuingOperations_2">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInContinuingOperations" xlink:to="label_NetCashProvidedByUsedInContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInContinuingOperations to label_NetCashProvidedByUsedInContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2">Net cash (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to label_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic_2">NET LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic_2" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to label_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic_3">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic_3" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to label_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2">CASH FLOWS (USED IN) INVESTING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_2" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to label_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:title="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xml:lang="en-US" id="label_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="label_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:title="label: NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract to label_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:label="NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:title="NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1">Other assets acquired in Cell Genesys transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:to="label_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:title="label: NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1 to label_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_2">Noncash or Part Noncash Acquisition, Other Assets Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:to="label_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_2" xlink:title="label: NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1 to label_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:label="NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:title="NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1">Investment acquired through Cell Genesys transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:to="label_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:title="label: NoncashOrPartNoncashAcquisitionInvestmentsAcquired1 to label_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_2">Noncash or Part Noncash Acquisition, Investments Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:to="label_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1_2" xlink:title="label: NoncashOrPartNoncashAcquisitionInvestmentsAcquired1 to label_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="label: NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 to label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_2">Accrued liabilities for deferred acquisition costs, noncash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_2" xlink:title="label: NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 to label_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">Liabilities acquired through Cell Genesys transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="label_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:title="label: NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 to label_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_2">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="label_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_2" xlink:title="label: NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 to label_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="label_NonoperatingIncomeExpenseAbstract">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="label_NonoperatingIncomeExpenseAbstract" xlink:title="label: NonoperatingIncomeExpenseAbstract to label_NonoperatingIncomeExpenseAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_NonoperatingIncomeExpenseAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="label_NonoperatingIncomeExpenseAbstract_2">OTHER</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="label_NonoperatingIncomeExpenseAbstract_2" xlink:title="label: NonoperatingIncomeExpenseAbstract to label_NonoperatingIncomeExpenseAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">BASIS OF PRESENTATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US" id="label_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="label_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="label: OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock to label_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="OtherNoncashIncomeExpense" xlink:title="OtherNoncashIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNoncashIncomeExpense" xml:lang="en-US" id="label_OtherNoncashIncomeExpense">Other Noncash Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashIncomeExpense" xlink:to="label_OtherNoncashIncomeExpense" xlink:title="label: OtherNoncashIncomeExpense to label_OtherNoncashIncomeExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherNoncashIncomeExpense_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_OtherNoncashIncomeExpense" xml:lang="en-US" id="label_OtherNoncashIncomeExpense_2">Other non-cash items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashIncomeExpense" xlink:to="label_OtherNoncashIncomeExpense_2" xlink:title="label: OtherNoncashIncomeExpense to label_OtherNoncashIncomeExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="OtherReceivablesGrossCurrent" xlink:title="OtherReceivablesGrossCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherReceivablesGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherReceivablesGrossCurrent" xml:lang="en-US" id="label_OtherReceivablesGrossCurrent">Other Receivables, Gross, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherReceivablesGrossCurrent" xlink:to="label_OtherReceivablesGrossCurrent" xlink:title="label: OtherReceivablesGrossCurrent to label_OtherReceivablesGrossCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherReceivablesGrossCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherReceivablesGrossCurrent" xml:lang="en-US" id="label_OtherReceivablesGrossCurrent_2">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherReceivablesGrossCurrent" xlink:to="label_OtherReceivablesGrossCurrent_2" xlink:title="label: OtherReceivablesGrossCurrent to label_OtherReceivablesGrossCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:label="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:title="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:label xlink:type="resource" xlink:label="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xml:lang="en-US" id="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet">Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:to="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:title="label: OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet to label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xml:lang="en-US" id="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_2">Investment impairment charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:to="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_2" xlink:title="label: OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet to label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xml:lang="en-US" id="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_3">Investment impairment charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:to="label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_3" xlink:title="label: OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet to label_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="OtherAssetsNoncurrentAbstract" xlink:title="OtherAssetsNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAssetsNoncurrentAbstract" xml:lang="en-US" id="label_OtherAssetsNoncurrentAbstract">Other Assets, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrentAbstract" xlink:to="label_OtherAssetsNoncurrentAbstract" xlink:title="label: OtherAssetsNoncurrentAbstract to label_OtherAssetsNoncurrentAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrentAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAssetsNoncurrentAbstract" xml:lang="en-US" id="label_OtherAssetsNoncurrentAbstract_2">OTHER ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrentAbstract" xlink:to="label_OtherAssetsNoncurrentAbstract_2" xlink:title="label: OtherAssetsNoncurrentAbstract to label_OtherAssetsNoncurrentAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNonoperatingIncome" xml:lang="en-US" id="label_OtherNonoperatingIncome">Other Nonoperating Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncome" xlink:to="label_OtherNonoperatingIncome" xlink:title="label: OtherNonoperatingIncome to label_OtherNonoperatingIncome" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncome_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherNonoperatingIncome" xml:lang="en-US" id="label_OtherNonoperatingIncome_2">Other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncome" xlink:to="label_OtherNonoperatingIncome_2" xlink:title="label: OtherNonoperatingIncome to label_OtherNonoperatingIncome" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:title="OtherNoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US" id="label_OtherNoncashInvestingAndFinancingItemsAbstract">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="label_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:title="label: OtherNoncashInvestingAndFinancingItemsAbstract to label_OtherNoncashInvestingAndFinancingItemsAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherNoncashInvestingAndFinancingItemsAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherNoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US" id="label_OtherNoncashInvestingAndFinancingItemsAbstract_2">Noncash investing and financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="label_OtherNoncashInvestingAndFinancingItemsAbstract_2" xlink:title="label: OtherNoncashInvestingAndFinancingItemsAbstract to label_OtherNoncashInvestingAndFinancingItemsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="OtherSalesRevenueNet" xlink:title="OtherSalesRevenueNet" />
    <link:label xlink:type="resource" xlink:label="label_OtherSalesRevenueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherSalesRevenueNet" xml:lang="en-US" id="label_OtherSalesRevenueNet">Other Revenue, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherSalesRevenueNet" xlink:to="label_OtherSalesRevenueNet" xlink:title="label: OtherSalesRevenueNet to label_OtherSalesRevenueNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherSalesRevenueNet_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherSalesRevenueNet" xml:lang="en-US" id="label_OtherSalesRevenueNet_2">Other revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherSalesRevenueNet" xlink:to="label_OtherSalesRevenueNet_2" xlink:title="label: OtherSalesRevenueNet to label_OtherSalesRevenueNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAccruedLiabilitiesCurrent" xml:lang="en-US" id="label_OtherAccruedLiabilitiesCurrent">Other Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="label_OtherAccruedLiabilitiesCurrent" xlink:title="label: OtherAccruedLiabilitiesCurrent to label_OtherAccruedLiabilitiesCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_OtherAccruedLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAccruedLiabilitiesCurrent" xml:lang="en-US" id="label_OtherAccruedLiabilitiesCurrent_2">Other accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="label_OtherAccruedLiabilitiesCurrent_2" xlink:title="label: OtherAccruedLiabilitiesCurrent to label_OtherAccruedLiabilitiesCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment">Purchase of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to label_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment_2">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment_2" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to label_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="PaymentsToAcquireInvestments" xlink:title="PaymentsToAcquireInvestments" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquireInvestments" xml:lang="en-US" id="label_PaymentsToAcquireInvestments">Payments to Acquire Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireInvestments" xlink:to="label_PaymentsToAcquireInvestments" xlink:title="label: PaymentsToAcquireInvestments to label_PaymentsToAcquireInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireInvestments_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquireInvestments" xml:lang="en-US" id="label_PaymentsToAcquireInvestments_2">Purchase of investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireInvestments" xlink:to="label_PaymentsToAcquireInvestments_2" xlink:title="label: PaymentsToAcquireInvestments to label_PaymentsToAcquireInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquireProductiveAssets" xml:lang="en-US" id="label_PaymentsToAcquireProductiveAssets">Payments to Acquire Productive Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssets" xlink:to="label_PaymentsToAcquireProductiveAssets" xlink:title="label: PaymentsToAcquireProductiveAssets to label_PaymentsToAcquireProductiveAssets" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireProductiveAssets_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquireProductiveAssets" xml:lang="en-US" id="label_PaymentsToAcquireProductiveAssets_2">Purchase of capital assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssets" xlink:to="label_PaymentsToAcquireProductiveAssets_2" xlink:title="label: PaymentsToAcquireProductiveAssets to label_PaymentsToAcquireProductiveAssets" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="PaymentsToAcquireShortTermInvestments" xlink:title="PaymentsToAcquireShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquireShortTermInvestments" xml:lang="en-US" id="label_PaymentsToAcquireShortTermInvestments">Payments to Acquire Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireShortTermInvestments" xlink:to="label_PaymentsToAcquireShortTermInvestments" xlink:title="label: PaymentsToAcquireShortTermInvestments to label_PaymentsToAcquireShortTermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireShortTermInvestments_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquireShortTermInvestments" xml:lang="en-US" id="label_PaymentsToAcquireShortTermInvestments_2">Purchase of short term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireShortTermInvestments" xlink:to="label_PaymentsToAcquireShortTermInvestments_2" xlink:title="label: PaymentsToAcquireShortTermInvestments to label_PaymentsToAcquireShortTermInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2">RETIREMENT PLAN</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to label_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to label_PrepaidExpenseAndOtherAssetsCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent_2">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent_2" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to label_PrepaidExpenseAndOtherAssetsCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromWarrantExercises" xml:lang="en-US" id="label_ProceedsFromWarrantExercises">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="label_ProceedsFromWarrantExercises" xlink:title="label: ProceedsFromWarrantExercises to label_ProceedsFromWarrantExercises" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromWarrantExercises_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromWarrantExercises" xml:lang="en-US" id="label_ProceedsFromWarrantExercises_2">Proceeds from warrants exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="label_ProceedsFromWarrantExercises_2" xlink:title="label: ProceedsFromWarrantExercises to label_ProceedsFromWarrantExercises" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="ProceedsFromPaymentsForOtherFinancingActivities" xlink:title="ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US" id="label_ProceedsFromPaymentsForOtherFinancingActivities">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="label_ProceedsFromPaymentsForOtherFinancingActivities" xlink:title="label: ProceedsFromPaymentsForOtherFinancingActivities to label_ProceedsFromPaymentsForOtherFinancingActivities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromPaymentsForOtherFinancingActivities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromPaymentsForOtherFinancingActivities" xml:lang="en-US" id="label_ProceedsFromPaymentsForOtherFinancingActivities_2">Cash paid for transaction related costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="label_ProceedsFromPaymentsForOtherFinancingActivities_2" xlink:title="label: ProceedsFromPaymentsForOtherFinancingActivities to label_ProceedsFromPaymentsForOtherFinancingActivities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="ProceedsFromCollaborators" xlink:title="ProceedsFromCollaborators" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromCollaborators" xml:lang="en-US" id="label_ProceedsFromCollaborators">Proceeds from Collaborators</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromCollaborators" xlink:to="label_ProceedsFromCollaborators" xlink:title="label: ProceedsFromCollaborators to label_ProceedsFromCollaborators" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromCollaborators_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromCollaborators" xml:lang="en-US" id="label_ProceedsFromCollaborators_2">Payments received from agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromCollaborators" xlink:to="label_ProceedsFromCollaborators_2" xlink:title="label: ProceedsFromCollaborators to label_ProceedsFromCollaborators" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStock">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="label_ProceedsFromIssuanceOfCommonStock" xlink:title="label: ProceedsFromIssuanceOfCommonStock to label_ProceedsFromIssuanceOfCommonStock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfCommonStock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_ProceedsFromIssuanceOfCommonStock_2">Proceeds from issuance of common stock by registered direct offerings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="label_ProceedsFromIssuanceOfCommonStock_2" xlink:title="label: ProceedsFromIssuanceOfCommonStock to label_ProceedsFromIssuanceOfCommonStock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US" id="label_ProceedsFromIssuanceOrSaleOfEquity">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquity" xlink:to="label_ProceedsFromIssuanceOrSaleOfEquity" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquity to label_ProceedsFromIssuanceOrSaleOfEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOrSaleOfEquity_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US" id="label_ProceedsFromIssuanceOrSaleOfEquity_2">Net proceeds from issuance of shares and warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquity" xlink:to="label_ProceedsFromIssuanceOrSaleOfEquity_2" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquity to label_ProceedsFromIssuanceOrSaleOfEquity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromSaleOfProductiveAssets" xml:lang="en-US" id="label_ProceedsFromSaleOfProductiveAssets">Proceeds from Sale of Productive Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfProductiveAssets" xlink:to="label_ProceedsFromSaleOfProductiveAssets" xlink:title="label: ProceedsFromSaleOfProductiveAssets to label_ProceedsFromSaleOfProductiveAssets" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfProductiveAssets_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromSaleOfProductiveAssets" xml:lang="en-US" id="label_ProceedsFromSaleOfProductiveAssets_2">Proceeds from sale of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfProductiveAssets" xlink:to="label_ProceedsFromSaleOfProductiveAssets_2" xlink:title="label: ProceedsFromSaleOfProductiveAssets to label_ProceedsFromSaleOfProductiveAssets" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="ProceedsFromSaleOfShortTermInvestments" xlink:title="ProceedsFromSaleOfShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromSaleOfShortTermInvestments" xml:lang="en-US" id="label_ProceedsFromSaleOfShortTermInvestments">Proceeds from Sale of Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfShortTermInvestments" xlink:to="label_ProceedsFromSaleOfShortTermInvestments" xlink:title="label: ProceedsFromSaleOfShortTermInvestments to label_ProceedsFromSaleOfShortTermInvestments" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromSaleOfShortTermInvestments_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromSaleOfShortTermInvestments" xml:lang="en-US" id="label_ProceedsFromSaleOfShortTermInvestments_2">Redemption of short term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfShortTermInvestments" xlink:to="label_ProceedsFromSaleOfShortTermInvestments_2" xlink:title="label: ProceedsFromSaleOfShortTermInvestments to label_ProceedsFromSaleOfShortTermInvestments" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="label_ProceedsFromStockOptionsExercised">Proceeds from common stock option exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="label_ProceedsFromStockOptionsExercised" xlink:title="label: ProceedsFromStockOptionsExercised to label_ProceedsFromStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="label_ProceedsFromStockOptionsExercised_2">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="label_ProceedsFromStockOptionsExercised_2" xlink:title="label: ProceedsFromStockOptionsExercised to label_ProceedsFromStockOptionsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="label_PropertyPlantAndEquipmentAbstract">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="label_PropertyPlantAndEquipmentAbstract" xlink:title="label: PropertyPlantAndEquipmentAbstract to label_PropertyPlantAndEquipmentAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet_2">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet_2" xlink:title="label: PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to label_PropertyPlantAndEquipmentDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock_2">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock_2" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to label_PropertyPlantAndEquipmentDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="PurchaseObligation" xlink:title="PurchaseObligation" />
    <link:label xlink:type="resource" xlink:label="label_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PurchaseObligation" xml:lang="en-US" id="label_PurchaseObligation">Purchase Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseObligation" xlink:to="label_PurchaseObligation" xlink:title="label: PurchaseObligation to label_PurchaseObligation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_PurchaseObligation_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PurchaseObligation" xml:lang="en-US" id="label_PurchaseObligation_2">Remaining obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseObligation" xlink:to="label_PurchaseObligation_2" xlink:title="label: PurchaseObligation to label_PurchaseObligation" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="QuarterlyFinancialInformationTextBlock" xlink:title="QuarterlyFinancialInformationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_QuarterlyFinancialInformationTextBlock" xml:lang="en-US" id="label_QuarterlyFinancialInformationTextBlock">Quarterly Financial Information [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationTextBlock" xlink:to="label_QuarterlyFinancialInformationTextBlock" xlink:title="label: QuarterlyFinancialInformationTextBlock to label_QuarterlyFinancialInformationTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_QuarterlyFinancialInformationTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_QuarterlyFinancialInformationTextBlock" xml:lang="en-US" id="label_QuarterlyFinancialInformationTextBlock_2">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationTextBlock" xlink:to="label_QuarterlyFinancialInformationTextBlock_2" xlink:title="label: QuarterlyFinancialInformationTextBlock to label_QuarterlyFinancialInformationTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_QuarterlyFinancialInformationDisclosureAbstract" xml:lang="en-US" id="label_QuarterlyFinancialInformationDisclosureAbstract">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="label_QuarterlyFinancialInformationDisclosureAbstract" xlink:title="label: QuarterlyFinancialInformationDisclosureAbstract to label_QuarterlyFinancialInformationDisclosureAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeAxis" xml:lang="en-US" id="label_RangeAxis">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="label_RangeAxis" xlink:title="label: RangeAxis to label_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeMember" xml:lang="en-US" id="label_RangeMember">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="label_RangeMember" xlink:title="label: RangeMember to label_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense_2">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense_2" xlink:title="label: ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentInProcess" xml:lang="en-US" id="label_ResearchAndDevelopmentInProcess">Acquired in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcess" xlink:to="label_ResearchAndDevelopmentInProcess" xlink:title="label: ResearchAndDevelopmentInProcess to label_ResearchAndDevelopmentInProcess" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentInProcess_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentInProcess" xml:lang="en-US" id="label_ResearchAndDevelopmentInProcess_2">Research and Development in Process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcess" xlink:to="label_ResearchAndDevelopmentInProcess_2" xlink:title="label: ResearchAndDevelopmentInProcess to label_ResearchAndDevelopmentInProcess" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:label xlink:type="resource" xlink:label="label_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestructuringCostAndReserveAxis" xml:lang="en-US" id="label_RestructuringCostAndReserveAxis">Restructuring Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringCostAndReserveAxis" xlink:to="label_RestructuringCostAndReserveAxis" xlink:title="label: RestructuringCostAndReserveAxis to label_RestructuringCostAndReserveAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit" xlink:title="label: RetainedEarningsAccumulatedDeficit to label_RetainedEarningsAccumulatedDeficit" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit_2">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit_2" xlink:title="label: RetainedEarningsAccumulatedDeficit to label_RetainedEarningsAccumulatedDeficit" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsMember" xml:lang="en-US" id="label_RetainedEarningsMember">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="label_RetainedEarningsMember" xlink:title="label: RetainedEarningsMember to label_RetainedEarningsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsMember" xml:lang="en-US" id="label_RetainedEarningsMember_2">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="label_RetainedEarningsMember_2" xlink:title="label: RetainedEarningsMember to label_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueFromGrants" xml:lang="en-US" id="label_RevenueFromGrants">Revenue from Grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromGrants" xlink:to="label_RevenueFromGrants" xlink:title="label: RevenueFromGrants to label_RevenueFromGrants" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromGrants_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueFromGrants" xml:lang="en-US" id="label_RevenueFromGrants_2">Grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromGrants" xlink:to="label_RevenueFromGrants_2" xlink:title="label: RevenueFromGrants to label_RevenueFromGrants" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:label xlink:type="resource" xlink:label="label_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Revenues" xml:lang="en-US" id="label_Revenues">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenues" xlink:to="label_Revenues" xlink:title="label: Revenues to label_Revenues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_Revenues_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Revenues" xml:lang="en-US" id="label_Revenues_2">Total revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenues" xlink:to="label_Revenues_2" xlink:title="label: Revenues to label_Revenues" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenuesAbstract" xml:lang="en-US" id="label_RevenuesAbstract">Revenues [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="label_RevenuesAbstract" xlink:title="label: RevenuesAbstract to label_RevenuesAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RevenuesAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenuesAbstract" xml:lang="en-US" id="label_RevenuesAbstract_2">REVENUE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="label_RevenuesAbstract_2" xlink:title="label: RevenuesAbstract to label_RevenuesAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RoyaltyRevenue" xml:lang="en-US" id="label_RoyaltyRevenue">Royalty Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRevenue" xlink:to="label_RoyaltyRevenue" xlink:title="label: RoyaltyRevenue to label_RoyaltyRevenue" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyRevenue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RoyaltyRevenue" xml:lang="en-US" id="label_RoyaltyRevenue_2">Royalty revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyRevenue" xlink:to="label_RoyaltyRevenue_2" xlink:title="label: RoyaltyRevenue to label_RoyaltyRevenue" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="label_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScenarioUnspecifiedDomain" xml:lang="en-US" id="label_ScenarioUnspecifiedDomain">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="label_ScenarioUnspecifiedDomain" xlink:title="label: ScenarioUnspecifiedDomain to label_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:label xlink:type="resource" xlink:label="label_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScenarioForecastMember" xml:lang="en-US" id="label_ScenarioForecastMember">Forecast</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioForecastMember" xlink:to="label_ScenarioForecastMember" xlink:title="label: ScenarioForecastMember to label_ScenarioForecastMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScenarioForecastMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScenarioForecastMember" xml:lang="en-US" id="label_ScenarioForecastMember_2">Scenario, Forecast [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioForecastMember" xlink:to="label_ScenarioForecastMember_2" xlink:title="label: ScenarioForecastMember to label_ScenarioForecastMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US" id="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="label: ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US" id="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2">Schedule of financial assets and liabilities recorded at fair value on a recurring basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2" xlink:title="label: ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to label_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US" id="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="label: ScheduleOfMaturitiesOfLongTermDebtTableTextBlock to label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US" id="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2">Schedule of maturities of required principal payments by year related to the convertible senior notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2" xlink:title="label: ScheduleOfMaturitiesOfLongTermDebtTableTextBlock to label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to label_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to label_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:label xlink:type="resource" xlink:label="label_SeniorLongTermNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeniorLongTermNotes" xml:lang="en-US" id="label_SeniorLongTermNotes">Long-term convertible senior notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorLongTermNotes" xlink:to="label_SeniorLongTermNotes" xlink:title="label: SeniorLongTermNotes to label_SeniorLongTermNotes" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SeniorLongTermNotes_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeniorLongTermNotes" xml:lang="en-US" id="label_SeniorLongTermNotes_2">Senior Notes, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorLongTermNotes" xlink:to="label_SeniorLongTermNotes_2" xlink:title="label: SeniorLongTermNotes to label_SeniorLongTermNotes" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeniorNotesCurrent" xlink:label="SeniorNotesCurrent" xlink:title="SeniorNotesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_SeniorNotesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeniorNotesCurrent" xml:lang="en-US" id="label_SeniorNotesCurrent">Senior Notes, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesCurrent" xlink:to="label_SeniorNotesCurrent" xlink:title="label: SeniorNotesCurrent to label_SeniorNotesCurrent" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SeniorNotesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeniorNotesCurrent" xml:lang="en-US" id="label_SeniorNotesCurrent_2">Current portion of convertible senior notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesCurrent" xlink:to="label_SeniorNotesCurrent_2" xlink:title="label: SeniorNotesCurrent to label_SeniorNotesCurrent" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeveranceCosts" xlink:label="SeveranceCosts" xlink:title="SeveranceCosts" />
    <link:label xlink:type="resource" xlink:label="label_SeveranceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeveranceCosts" xml:lang="en-US" id="label_SeveranceCosts">Severance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeveranceCosts" xlink:to="label_SeveranceCosts" xlink:title="label: SeveranceCosts to label_SeveranceCosts" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SeveranceCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeveranceCosts" xml:lang="en-US" id="label_SeveranceCosts_2">Severance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeveranceCosts" xlink:to="label_SeveranceCosts_2" xlink:title="label: SeveranceCosts to label_SeveranceCosts" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation">Share-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to label_ShareBasedCompensation" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensation_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensation" xml:lang="en-US" id="label_ShareBasedCompensation_2">Employee &amp; director stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="label_ShareBasedCompensation_2" xlink:title="label: ShareBasedCompensation to label_ShareBasedCompensation" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2">Options granted under the plan (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:label xlink:type="resource" xlink:label="label_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharePrice" xml:lang="en-US" id="label_SharePrice">Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="label_SharePrice" xlink:title="label: SharePrice to label_SharePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SharePrice_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharePrice" xml:lang="en-US" id="label_SharePrice_2">Purchase price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharePrice" xlink:to="label_SharePrice_2" xlink:title="label: SharePrice to label_SharePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2">Weighted average exercise price of options granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2">Weighted average exercise price of options exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2">Number of shares that remained available for issuance under the plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2">Number of shares of the entity's common stock authorized for issuance under the plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2">Options expired and cancelled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="label_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementTable" xml:lang="en-US" id="label_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="label_StatementTable" xlink:title="label: StatementTable to label_StatementTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementScenarioAxis" xml:lang="en-US" id="label_StatementScenarioAxis">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="label_StatementScenarioAxis" xlink:title="label: StatementScenarioAxis to label_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementLineItems" xml:lang="en-US" id="label_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems" xlink:title="label: StatementLineItems to label_StatementLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StatementLineItems" xml:lang="en-US" id="label_StatementLineItems_2">Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems_2" xlink:title="label: StatementLineItems to label_StatementLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="label_StatementOfStockholdersEquityAbstract">Statements of Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="label_StatementOfStockholdersEquityAbstract" xlink:title="label: StatementOfStockholdersEquityAbstract to label_StatementOfStockholdersEquityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_StatementOfCashFlowsAbstract">Condensed Statements of Cash Flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="label_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to label_StatementOfCashFlowsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementEquityComponentsAxis" xml:lang="en-US" id="label_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="label_StatementEquityComponentsAxis" xlink:title="label: StatementEquityComponentsAxis to label_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_StatementOfFinancialPositionAbstract">Condensed Balance Sheets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="label_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to label_StatementOfFinancialPositionAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementClassOfStockAxis" xml:lang="en-US" id="label_StatementClassOfStockAxis">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="label_StatementClassOfStockAxis" xlink:title="label: StatementClassOfStockAxis to label_StatementClassOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">Stock Issued During Period, Shares, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="label: StockIssuedDuringPeriodSharesPeriodIncreaseDecrease to label_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesAcquisitions">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="label_StockIssuedDuringPeriodSharesAcquisitions" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to label_StockIssuedDuringPeriodSharesAcquisitions" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesAcquisitions_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesAcquisitions_2">Issuance of common shares pursuant to Cell Genesys, Inc. transaction (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="label_StockIssuedDuringPeriodSharesAcquisitions_2" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to label_StockIssuedDuringPeriodSharesAcquisitions" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="StockOptionsMember" xlink:title="StockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_StockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockOptionsMember" xml:lang="en-US" id="label_StockOptionsMember">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsMember" xlink:to="label_StockOptionsMember" xlink:title="label: StockOptionsMember to label_StockOptionsMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockOptionsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockOptionsMember" xml:lang="en-US" id="label_StockOptionsMember_2">Stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsMember" xlink:to="label_StockOptionsMember_2" xlink:title="label: StockOptionsMember to label_StockOptionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueStockOptionsExercised">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to label_StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueStockOptionsExercised_2">Stock option exercise</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodValueStockOptionsExercised_2" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to label_StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueAcquisitions">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="label_StockIssuedDuringPeriodValueAcquisitions" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to label_StockIssuedDuringPeriodValueAcquisitions" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueAcquisitions_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueAcquisitions_2">Issuance of common shares pursuant to Cell Genesys, Inc. transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="label_StockIssuedDuringPeriodValueAcquisitions_2" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to label_StockIssuedDuringPeriodValueAcquisitions" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueNewIssues">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="label_StockIssuedDuringPeriodValueNewIssues" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to label_StockIssuedDuringPeriodValueNewIssues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueNewIssues_2">Underwritten offering of common shares, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="label_StockIssuedDuringPeriodValueNewIssues_2" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to label_StockIssuedDuringPeriodValueNewIssues" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssued1" xml:lang="en-US" id="label_StockIssued1">Stock Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="label_StockIssued1" xlink:title="label: StockIssued1 to label_StockIssued1" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssued1_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssued1" xml:lang="en-US" id="label_StockIssued1_2">Shares issued for convertible senior notes and accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="label_StockIssued1_2" xlink:title="label: StockIssued1 to label_StockIssued1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to label_StockIssuedDuringPeriodSharesNewIssues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues_2">Stock issued during period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues_2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to label_StockIssuedDuringPeriodSharesNewIssues" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues_3">Warrants issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues_3" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to label_StockIssuedDuringPeriodSharesNewIssues" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesStockOptionsExercised">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to label_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2">Options exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to label_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2">Number of shares issued in exchange for cancellation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to label_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US" id="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US" id="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_2" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract to label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US" id="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US" id="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2">TOTAL STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to label_StockholdersEquityAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract_2">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract_2" xlink:title="label: StockholdersEquityAbstract to label_StockholdersEquityAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity" xlink:title="label: StockholdersEquity to label_StockholdersEquity" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity_2">TOTAL STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_2" xlink:title="label: StockholdersEquity to label_StockholdersEquity" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_StockholdersEquityNoteAbstract">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="label_StockholdersEquityNoteAbstract" xlink:title="label: StockholdersEquityNoteAbstract to label_StockholdersEquityNoteAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to label_StockholdersEquityNoteDisclosureTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock_2">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock_2" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to label_StockholdersEquityNoteDisclosureTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityPeriodIncreaseDecrease" xml:lang="en-US" id="label_StockholdersEquityPeriodIncreaseDecrease">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="label_StockholdersEquityPeriodIncreaseDecrease" xlink:title="label: StockholdersEquityPeriodIncreaseDecrease to label_StockholdersEquityPeriodIncreaseDecrease" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsTextBlock" xml:lang="en-US" id="label_SubsequentEventsTextBlock">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock" xlink:title="label: SubsequentEventsTextBlock to label_SubsequentEventsTextBlock" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventsTextBlock" xml:lang="en-US" id="label_SubsequentEventsTextBlock_2">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock_2" xlink:title="label: SubsequentEventsTextBlock to label_SubsequentEventsTextBlock" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsAbstract" xml:lang="en-US" id="label_SubsequentEventsAbstract">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="label_SubsequentEventsAbstract" xlink:title="label: SubsequentEventsAbstract to label_SubsequentEventsAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTypeDomain" xml:lang="en-US" id="label_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="label_SubsequentEventTypeDomain" xlink:title="label: SubsequentEventTypeDomain to label_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventLineItems" xml:lang="en-US" id="label_SubsequentEventLineItems">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="label_SubsequentEventLineItems" xlink:title="label: SubsequentEventLineItems to label_SubsequentEventLineItems" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventLineItems" xml:lang="en-US" id="label_SubsequentEventLineItems_2">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="label_SubsequentEventLineItems_2" xlink:title="label: SubsequentEventLineItems to label_SubsequentEventLineItems" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTypeAxis" xml:lang="en-US" id="label_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="label_SubsequentEventTypeAxis" xlink:title="label: SubsequentEventTypeAxis to label_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTable" xml:lang="en-US" id="label_SubsequentEventTable">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="label_SubsequentEventTable" xlink:title="label: SubsequentEventTable to label_SubsequentEventTable" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventMember" xml:lang="en-US" id="label_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="label_SubsequentEventMember" xlink:title="label: SubsequentEventMember to label_SubsequentEventMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventMember" xml:lang="en-US" id="label_SubsequentEventMember_2">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="label_SubsequentEventMember_2" xlink:title="label: SubsequentEventMember to label_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_SupplementalCashFlowInformationAbstract">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="label_SupplementalCashFlowInformationAbstract" xlink:title="label: SupplementalCashFlowInformationAbstract to label_SupplementalCashFlowInformationAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_SupplementalCashFlowInformationAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_SupplementalCashFlowInformationAbstract_2">SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="label_SupplementalCashFlowInformationAbstract_2" xlink:title="label: SupplementalCashFlowInformationAbstract to label_SupplementalCashFlowInformationAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:label xlink:type="resource" xlink:label="label_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TypeOfRestructuringDomain" xml:lang="en-US" id="label_TypeOfRestructuringDomain">Type of Restructuring [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfRestructuringDomain" xlink:to="label_TypeOfRestructuringDomain" xlink:title="label: TypeOfRestructuringDomain to label_TypeOfRestructuringDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantMember" xml:lang="en-US" id="label_WarrantMember">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember" xlink:title="label: WarrantMember to label_WarrantMember" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantMember" xml:lang="en-US" id="label_WarrantMember_2">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember_2" xlink:title="label: WarrantMember to label_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingAbstract">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="label_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="label: WeightedAverageNumberOfSharesOutstandingAbstract to label_WeightedAverageNumberOfSharesOutstandingAbstract" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingAbstract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingAbstract_2">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="label_WeightedAverageNumberOfSharesOutstandingAbstract_2" xlink:title="label: WeightedAverageNumberOfSharesOutstandingAbstract to label_WeightedAverageNumberOfSharesOutstandingAbstract" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingBasic">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to label_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingBasic_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingBasic_2">Basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_WeightedAverageNumberOfSharesOutstandingBasic_2" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to label_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="label_WeightedAverageNumberOfDilutedSharesOutstanding">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to label_WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfDilutedSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="label_WeightedAverageNumberOfDilutedSharesOutstanding_2">Diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_WeightedAverageNumberOfDilutedSharesOutstanding_2" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to label_WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">LOSS BEFORE INCOME TAX BENEFIT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2">Income (Loss) From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit">Other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit" xlink:title="label: IncomeTaxExpenseBenefit to label_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit_2">Income tax expense benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit_2" xlink:title="label: IncomeTaxExpenseBenefit to label_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit_3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit_3">Income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit_3" xlink:title="label: IncomeTaxExpenseBenefit to label_IncomeTaxExpenseBenefit" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>bpax-20120930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<!--Generated by IRIS XBRL Generation Engine-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureLiquidityAndCapitalResourcesDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureLiquidityAndCapitalResourcesDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureSubsequentEventsDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureSubsequentEventsDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureDescriptionOfBusinessDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureDescriptionOfBusinessDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureConvertibleSeniorNotesTables" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureFairValueMeasurementsTables" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureBasisOfPresentationDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureBasisOfPresentationDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureInvestmentsDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureInvestmentsDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureCommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureStockholdersEquityDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureStockholdersEquityDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureConvertibleSeniorNotesDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureStockBasedCompensationDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureStockBasedCompensationDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureFairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureCommitmentsAndContingenciesDetails2" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureDescriptionOfBusiness" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureDescriptionOfBusiness" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureLiquidityAndCapitalResources" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureLiquidityAndCapitalResources" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotes" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureConvertibleSeniorNotes" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureStockBasedCompensation" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureStockBasedCompensation" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureStockholdersEquity" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureStockholdersEquity" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureFairValueMeasurements" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureFairValueMeasurements" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureCommitmentsAndContingencies" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="bpax-20120930.xsd#DocumentAndEntityInformation" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureBasisOfPresentation" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureBasisOfPresentation" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureSubsequentEvents" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureSubsequentEvents" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureBasicAndDilutedNetLossPerShare" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureBasicAndDilutedNetLossPerShare" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/StatementOfIncome" xlink:type="simple" xlink:href="bpax-20120930.xsd#StatementOfIncome" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/CashFlows" xlink:type="simple" xlink:href="bpax-20120930.xsd#CashFlows" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/BalanceSheet" xlink:type="simple" xlink:href="bpax-20120930.xsd#BalanceSheet" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/BalanceSheetParenthetical" xlink:type="simple" xlink:href="bpax-20120930.xsd#BalanceSheetParenthetical" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/StatementOfStockholdersEquity" xlink:type="simple" xlink:href="bpax-20120930.xsd#StatementOfStockholdersEquity" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureLicenseAgreements" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureLicenseAgreements" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosurePropertyAndEquipment" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosurePropertyAndEquipment" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureIncomeTaxes" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureIncomeTaxes" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureAcquisitionOfNetAssetsOfCellGenesys" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureAcquisitionOfNetAssetsOfCellGenesys" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureRetirementPlan" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureRetirementPlan" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureLeaseArrangements" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureLeaseArrangements" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureSelectedQuarterlyFinancialData" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureSelectedQuarterlyFinancialData" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureRecentlyIssuedAccountingPronouncements" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureRecentlyIssuedAccountingPronouncements" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureInvestments" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureInvestments" />
  <link:roleRef roleURI="http://www.biosantepharma.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="bpax-20120930.xsd#DisclosureBasicAndDilutedNetLossPerShareDetails" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureLiquidityAndCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LiquidityAndCapitalResourcesDisclosureAbstract" xlink:label="LiquidityAndCapitalResourcesDisclosureAbstract" xlink:title="LiquidityAndCapitalResourcesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ScheduleOfLiquidityAndCapitalResourcesTable" xlink:label="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:title="ScheduleOfLiquidityAndCapitalResourcesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesDisclosureAbstract" xlink:to="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:title="presentation: LiquidityAndCapitalResourcesDisclosureAbstract to ScheduleOfLiquidityAndCapitalResourcesTable" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: ScheduleOfLiquidityAndCapitalResourcesTable to LongtermDebtTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="presentation: LongtermDebtTypeDomain to ConvertibleNotesPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:label="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:title="ConvertibleSeniorNotes3.125PercentDue2013Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:title="presentation: LongtermDebtTypeDomain to ConvertibleSeniorNotes3.125PercentDue2013Member" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfLiquidityAndCapitalResourcesTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfLiquidityAndCapitalResourcesTable to StatementEquityComponentsAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ScheduleOfLiquidityAndCapitalResourcesTable to ClassOfWarrantOrRightAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_WarrantIssuedToInstitutionalInvestorsMember" xlink:label="WarrantIssuedToInstitutionalInvestorsMember" xlink:title="WarrantIssuedToInstitutionalInvestorsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantIssuedToInstitutionalInvestorsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to WarrantIssuedToInstitutionalInvestorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_WarrantIssuedToPlacementAgentsMember" xlink:label="WarrantIssuedToPlacementAgentsMember" xlink:title="WarrantIssuedToPlacementAgentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantIssuedToPlacementAgentsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to WarrantIssuedToPlacementAgentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LiquidityAndCapitalResourcesLineItems" xlink:label="LiquidityAndCapitalResourcesLineItems" xlink:title="LiquidityAndCapitalResourcesLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLiquidityAndCapitalResourcesTable" xlink:to="LiquidityAndCapitalResourcesLineItems" xlink:title="presentation: ScheduleOfLiquidityAndCapitalResourcesTable to LiquidityAndCapitalResourcesLineItems" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to CashAndCashEquivalentsAtCarryingValue" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to DebtInstrumentFaceAmount" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to DebtInstrumentInterestRateStatedPercentage" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to StockIssuedDuringPeriodSharesNewIssues" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to ProceedsFromIssuanceOrSaleOfEquity" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NetCashRequiredToObligateEntityToEffectMerger" xlink:label="NetCashRequiredToObligateEntityToEffectMerger" xlink:title="NetCashRequiredToObligateEntityToEffectMerger" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="NetCashRequiredToObligateEntityToEffectMerger" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to NetCashRequiredToObligateEntityToEffectMerger" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:label="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:title="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:label="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:title="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:label="NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:title="NumberOfNewLibiGelPhaseIIIEfficacyTrials" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="NumberOfNewLibiGelPhaseIIIEfficacyTrials" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to NumberOfNewLibiGelPhaseIIIEfficacyTrials" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfNewLibiGelEfficacyTrials" xlink:label="NumberOfNewLibiGelEfficacyTrials" xlink:title="NumberOfNewLibiGelEfficacyTrials" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="NumberOfNewLibiGelEfficacyTrials" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to NumberOfNewLibiGelEfficacyTrials" use="optional" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:label="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:title="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirementsIfPendingMergerIsNotCompleted" use="optional" order="8003.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureSubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="LegalEntityAxis" xlink:title="presentation: SubsequentEventTable to LegalEntityAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ANIPharmaceuticalsIncMember" xlink:label="ANIPharmaceuticalsIncMember" xlink:title="ANIPharmaceuticalsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="ANIPharmaceuticalsIncMember" xlink:title="presentation: EntityDomain to ANIPharmaceuticalsIncMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_TevaPharmaceuticalsUSAIncMember" xlink:label="TevaPharmaceuticalsUSAIncMember" xlink:title="TevaPharmaceuticalsUSAIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="TevaPharmaceuticalsUSAIncMember" xlink:title="presentation: EntityDomain to TevaPharmaceuticalsUSAIncMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InstrumentAxis" xlink:label="InstrumentAxis" xlink:title="InstrumentAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="InstrumentAxis" xlink:title="presentation: SubsequentEventTable to InstrumentAxis" use="optional" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InstrumentTypeMember" xlink:label="InstrumentTypeMember" xlink:title="InstrumentTypeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InstrumentAxis" xlink:to="InstrumentTypeMember" xlink:title="presentation: InstrumentAxis to InstrumentTypeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MergerAgreementMember" xlink:label="MergerAgreementMember" xlink:title="MergerAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InstrumentTypeMember" xlink:to="MergerAgreementMember" xlink:title="presentation: InstrumentTypeMember to MergerAgreementMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_VotingAgreementMember" xlink:label="VotingAgreementMember" xlink:title="VotingAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InstrumentTypeMember" xlink:to="VotingAgreementMember" xlink:title="presentation: InstrumentTypeMember to VotingAgreementMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LockUpAgreementMember" xlink:label="LockUpAgreementMember" xlink:title="LockUpAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InstrumentTypeMember" xlink:to="LockUpAgreementMember" xlink:title="presentation: InstrumentTypeMember to LockUpAgreementMember" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ContingentValueRightsAgreementMember" xlink:label="ContingentValueRightsAgreementMember" xlink:title="ContingentValueRightsAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InstrumentTypeMember" xlink:to="ContingentValueRightsAgreementMember" xlink:title="presentation: InstrumentTypeMember to ContingentValueRightsAgreementMember" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ThirdAmendmentToLicenseAgreementMember" xlink:label="ThirdAmendmentToLicenseAgreementMember" xlink:title="ThirdAmendmentToLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InstrumentTypeMember" xlink:to="ThirdAmendmentToLicenseAgreementMember" xlink:title="presentation: InstrumentTypeMember to ThirdAmendmentToLicenseAgreementMember" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="presentation: SubsequentEventTable to RestructuringCostAndReserveAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="presentation: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="presentation: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="RangeAxis" xlink:title="presentation: SubsequentEventTable to RangeAxis" use="optional" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:title="presentation: SubsequentEventTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" use="optional" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:label="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:title="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember to MilestonePaymentUponFDAAuthorizationOfMarketingOfLicensedMaleTestosteroneGelMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:label="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:title="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember to MilestonePaymentUponEarlierOf31December2012AndFiveBusinessDaysAfterSubmissionToFDAOfFinalReportOnWashingClinicalStudyMember" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:label="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:title="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember to MilestonePaymentUponEarlierOf31December2013AndFiveBusinessDaysAfterCommencementOfCommercialManufactureOfLicensedProductMember" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:label="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:title="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember to PaymentForBeingSoleMarketerInUSOf1PercentTestosteroneGelForAtleast180DaysImmediatelyFollowingLaunchInUSMember" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: SubsequentEventTable to StatementScenarioAxis" use="optional" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ScenarioForecastMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:label="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:title="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" xlink:title="presentation: SubsequentEventLineItems to OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:label="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:title="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" xlink:title="presentation: SubsequentEventLineItems to NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ReverseStockSplitConversionRatio" xlink:label="ReverseStockSplitConversionRatio" xlink:title="ReverseStockSplitConversionRatio" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ReverseStockSplitConversionRatio" xlink:title="presentation: SubsequentEventLineItems to ReverseStockSplitConversionRatio" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NetCashRequiredToObligateEntityToEffectMerger" xlink:label="NetCashRequiredToObligateEntityToEffectMerger" xlink:title="NetCashRequiredToObligateEntityToEffectMerger" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NetCashRequiredToObligateEntityToEffectMerger" xlink:title="presentation: SubsequentEventLineItems to NetCashRequiredToObligateEntityToEffectMerger" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_BusinessMergerTerminationFeePayable" xlink:label="BusinessMergerTerminationFeePayable" xlink:title="BusinessMergerTerminationFeePayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="BusinessMergerTerminationFeePayable" xlink:title="presentation: SubsequentEventLineItems to BusinessMergerTerminationFeePayable" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_BusinessMergerReimbursementOfExpenses" xlink:label="BusinessMergerReimbursementOfExpenses" xlink:title="BusinessMergerReimbursementOfExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="BusinessMergerReimbursementOfExpenses" xlink:title="presentation: SubsequentEventLineItems to BusinessMergerReimbursementOfExpenses" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:label="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:title="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" xlink:title="presentation: SubsequentEventLineItems to PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:label="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:title="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" xlink:title="presentation: SubsequentEventLineItems to NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:label="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:title="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" xlink:title="presentation: SubsequentEventLineItems to PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors" use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDirectorsDesignatedByEntity" xlink:label="NumberOfDirectorsDesignatedByEntity" xlink:title="NumberOfDirectorsDesignatedByEntity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfDirectorsDesignatedByEntity" xlink:title="presentation: SubsequentEventLineItems to NumberOfDirectorsDesignatedByEntity" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:label="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:title="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" xlink:title="presentation: SubsequentEventLineItems to PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements" use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LockingPeriodOnSaleOfSharesPostMerger" xlink:label="LockingPeriodOnSaleOfSharesPostMerger" xlink:title="LockingPeriodOnSaleOfSharesPostMerger" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="LockingPeriodOnSaleOfSharesPostMerger" xlink:title="presentation: SubsequentEventLineItems to LockingPeriodOnSaleOfSharesPostMerger" use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:label="NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:title="NumberOfContingentValueRightsIssuedInExchangeForOneShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfContingentValueRightsIssuedInExchangeForOneShare" xlink:title="presentation: SubsequentEventLineItems to NumberOfContingentValueRightsIssuedInExchangeForOneShare" use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:label="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:title="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" xlink:title="presentation: SubsequentEventLineItems to PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights" use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:label="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:title="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" xlink:title="presentation: SubsequentEventLineItems to NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived" use="optional" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AggregateNetCashPaymentsToBeDistributedToHolders" xlink:label="AggregateNetCashPaymentsToBeDistributedToHolders" xlink:title="AggregateNetCashPaymentsToBeDistributedToHolders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="AggregateNetCashPaymentsToBeDistributedToHolders" xlink:title="presentation: SubsequentEventLineItems to AggregateNetCashPaymentsToBeDistributedToHolders" use="optional" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeveranceCosts" xlink:label="SeveranceCosts" xlink:title="SeveranceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="SeveranceCosts" xlink:title="presentation: SubsequentEventLineItems to SeveranceCosts" use="optional" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="ProceedsFromCollaborators" xlink:title="ProceedsFromCollaborators" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="ProceedsFromCollaborators" xlink:title="presentation: SubsequentEventLineItems to ProceedsFromCollaborators" use="optional" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:label="CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:title="CollaborativeArrangementPotentialMilestonePaymentsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="CollaborativeArrangementPotentialMilestonePaymentsReceivable" xlink:title="presentation: SubsequentEventLineItems to CollaborativeArrangementPotentialMilestonePaymentsReceivable" use="optional" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfBusinessDaysConsideredInMilestonePayments" xlink:label="NumberOfBusinessDaysConsideredInMilestonePayments" xlink:title="NumberOfBusinessDaysConsideredInMilestonePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfBusinessDaysConsideredInMilestonePayments" xlink:title="presentation: SubsequentEventLineItems to NumberOfBusinessDaysConsideredInMilestonePayments" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:label="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:title="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" xlink:title="presentation: SubsequentEventLineItems to CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight" use="optional" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:label="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:title="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" xlink:title="presentation: SubsequentEventLineItems to NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment" use="optional" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:label="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:title="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" xlink:title="presentation: SubsequentEventLineItems to CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales" use="optional" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureDescriptionOfBusinessDetails">
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DescriptionOfBusinessDisclosureAbstract" xlink:label="DescriptionOfBusinessDisclosureAbstract" xlink:title="DescriptionOfBusinessDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xlink:label="NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xlink:title="NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionOfBusinessDisclosureAbstract" xlink:to="NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" xlink:title="presentation: DescriptionOfBusinessDisclosureAbstract to NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfPhaseIAndPhaseIIClinicalTrials" xlink:label="NumberOfPhaseIAndPhaseIIClinicalTrials" xlink:title="NumberOfPhaseIAndPhaseIIClinicalTrials" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionOfBusinessDisclosureAbstract" xlink:to="NumberOfPhaseIAndPhaseIIClinicalTrials" xlink:title="presentation: DescriptionOfBusinessDisclosureAbstract to NumberOfPhaseIAndPhaseIIClinicalTrials" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xlink:label="ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xlink:title="ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" xlink:title="presentation: DebtDisclosureAbstract to ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="presentation: DebtDisclosureAbstract to ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureBasisOfPresentationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockholdersEquityReverseStockSplitConversionRatio" xlink:label="StockholdersEquityReverseStockSplitConversionRatio" xlink:title="StockholdersEquityReverseStockSplitConversionRatio" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="StockholdersEquityReverseStockSplitConversionRatio" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to StockholdersEquityReverseStockSplitConversionRatio" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="InvestmentsDebtAndEquitySecuritiesAbstract" xlink:title="InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xlink:label="RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xlink:title="RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" xlink:title="presentation: InvestmentsDebtAndEquitySecuritiesAbstract to RightOfEntityToDesignateMembersOnBoardOfInvesteeNumberOfMembers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AptarPharmaMember" xlink:label="AptarPharmaMember" xlink:title="AptarPharmaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="AptarPharmaMember" xlink:title="presentation: EntityDomain to AptarPharmaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="LongTermPurchaseCommitmentTable" xlink:title="LongTermPurchaseCommitmentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LongTermPurchaseCommitmentTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LongTermPurchaseCommitmentTable" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:title="presentation: LongTermPurchaseCommitmentTable to LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:title="presentation: LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis to LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalAdditionsMember" xlink:label="CapitalAdditionsMember" xlink:title="CapitalAdditionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="CapitalAdditionsMember" xlink:title="presentation: LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain to CapitalAdditionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="LegalEntityAxis" xlink:title="presentation: LongTermPurchaseCommitmentTable to LegalEntityAxis" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="LongTermPurchaseCommitmentLineItems" xlink:title="LongTermPurchaseCommitmentLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentTable" xlink:to="LongTermPurchaseCommitmentLineItems" xlink:title="presentation: LongTermPurchaseCommitmentTable to LongTermPurchaseCommitmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="LongTermPurchaseCommitmentAmount" xlink:title="LongTermPurchaseCommitmentAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="LongTermPurchaseCommitmentAmount" xlink:title="presentation: LongTermPurchaseCommitmentLineItems to LongTermPurchaseCommitmentAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:label="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:title="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="PurchaseCommitmentCumulativePaymentsToAcquireMachinery" xlink:title="presentation: LongTermPurchaseCommitmentLineItems to PurchaseCommitmentCumulativePaymentsToAcquireMachinery" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="PurchaseObligation" xlink:title="PurchaseObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermPurchaseCommitmentLineItems" xlink:to="PurchaseObligation" xlink:title="presentation: LongTermPurchaseCommitmentLineItems to PurchaseObligation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureStockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="presentation: LongtermDebtTypeDomain to ConvertibleNotesPayableMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_WarrantIssuedToInstitutionalInvestorsMember" xlink:label="WarrantIssuedToInstitutionalInvestorsMember" xlink:title="WarrantIssuedToInstitutionalInvestorsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantIssuedToInstitutionalInvestorsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to WarrantIssuedToInstitutionalInvestorsMember" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_WarrantIssuedToPlacementAgentsMember" xlink:label="WarrantIssuedToPlacementAgentsMember" xlink:title="WarrantIssuedToPlacementAgentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantIssuedToPlacementAgentsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to WarrantIssuedToPlacementAgentsMember" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ScheduleOfStockholdersEquityTable" xlink:label="ScheduleOfStockholdersEquityTable" xlink:title="ScheduleOfStockholdersEquityTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfStockholdersEquityTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfStockholdersEquityTable" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: ScheduleOfStockholdersEquityTable to LongtermDebtTypeAxis" use="optional" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfStockholdersEquityTable to RangeAxis" use="optional" order="2.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ScheduleOfStockholdersEquityTable to ClassOfWarrantOrRightAxis" use="optional" order="3.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfStockholdersEquityTable to StatementEquityComponentsAxis" use="optional" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockholdersEquityLineItems" xlink:label="StockholdersEquityLineItems" xlink:title="StockholdersEquityLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockholdersEquityTable" xlink:to="StockholdersEquityLineItems" xlink:title="presentation: ScheduleOfStockholdersEquityTable to StockholdersEquityLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="presentation: StockholdersEquityLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="DebtConversionOriginalDebtAmount1" xlink:title="presentation: StockholdersEquityLineItems to DebtConversionOriginalDebtAmount1" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="InterestPayableCurrentAndNoncurrent" xlink:title="presentation: StockholdersEquityLineItems to InterestPayableCurrentAndNoncurrent" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: StockholdersEquityLineItems to StockIssuedDuringPeriodSharesNewIssues" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharePrice" xlink:label="SharePrice" xlink:title="SharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="SharePrice" xlink:title="presentation: StockholdersEquityLineItems to SharePrice" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:label="NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:title="NumberOfInstitutionalInvestorsToWhomOfferingMade" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="NumberOfInstitutionalInvestorsToWhomOfferingMade" xlink:title="presentation: StockholdersEquityLineItems to NumberOfInstitutionalInvestorsToWhomOfferingMade" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ProceedsFromIssuanceOfCommonStockGross" xlink:label="ProceedsFromIssuanceOfCommonStockGross" xlink:title="ProceedsFromIssuanceOfCommonStockGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="ProceedsFromIssuanceOfCommonStockGross" xlink:title="presentation: StockholdersEquityLineItems to ProceedsFromIssuanceOfCommonStockGross" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="presentation: StockholdersEquityLineItems to ProceedsFromIssuanceOrSaleOfEquity" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ClassOfWarrantOrRightTermOfWarrants" xlink:label="ClassOfWarrantOrRightTermOfWarrants" xlink:title="ClassOfWarrantOrRightTermOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="ClassOfWarrantOrRightTermOfWarrants" xlink:title="presentation: StockholdersEquityLineItems to ClassOfWarrantOrRightTermOfWarrants" use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:title="presentation: StockholdersEquityLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockholdersEquityReverseStockSplitConversionRatio" xlink:label="StockholdersEquityReverseStockSplitConversionRatio" xlink:title="StockholdersEquityReverseStockSplitConversionRatio" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="StockholdersEquityReverseStockSplitConversionRatio" xlink:title="presentation: StockholdersEquityLineItems to StockholdersEquityReverseStockSplitConversionRatio" use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: StockholdersEquityLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PaymentsToFractionalSharePayout" xlink:label="PaymentsToFractionalSharePayout" xlink:title="PaymentsToFractionalSharePayout" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityLineItems" xlink:to="PaymentsToFractionalSharePayout" xlink:title="presentation: StockholdersEquityLineItems to PaymentsToFractionalSharePayout" use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="presentation: LongtermDebtTypeAxis to LongtermDebtTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="presentation: LongtermDebtTypeDomain to ConvertibleNotesPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:label="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:title="ConvertibleSeniorNotes3.125PercentDue2013Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleSeniorNotes3.125PercentDue2013Member" xlink:title="presentation: LongtermDebtTypeDomain to ConvertibleSeniorNotes3.125PercentDue2013Member" use="optional" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:label="ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:title="ConvertibleSeniorNotes3.125PercentDue2011Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtTypeDomain" xlink:to="ConvertibleSeniorNotes3.125PercentDue2011Member" xlink:title="presentation: LongtermDebtTypeDomain to ConvertibleSeniorNotes3.125PercentDue2011Member" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="1.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="LongtermDebtTypeAxis" xlink:title="presentation: DebtInstrumentTable to LongtermDebtTypeAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentFaceAmount" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="presentation: DebtInstrumentLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" use="optional" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:label="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:title="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" xlink:title="presentation: DebtInstrumentLineItems to NumberOfDebtInstrumentHoldersToWhomSharesAreIssued" use="optional" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="DebtConversionOriginalDebtAmount1" xlink:title="DebtConversionOriginalDebtAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtConversionOriginalDebtAmount1" xlink:title="presentation: DebtInstrumentLineItems to DebtConversionOriginalDebtAmount1" use="optional" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="InterestPayableCurrentAndNoncurrent" xlink:title="presentation: DebtInstrumentLineItems to InterestPayableCurrentAndNoncurrent" use="optional" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_FairValueOptionChangesInFairValueNonCashAdjustment" xlink:label="FairValueOptionChangesInFairValueNonCashAdjustment" xlink:title="FairValueOptionChangesInFairValueNonCashAdjustment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueOptionChangesInFairValueNonCashAdjustment" xlink:title="presentation: DebtInstrumentLineItems to FairValueOptionChangesInFairValueNonCashAdjustment" use="optional" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentConvertibleNumberOfEquityInstruments" use="optional" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentConvertibleConversionPrice1" use="optional" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtFairValue" xlink:title="presentation: DebtInstrumentLineItems to LongTermDebtFairValue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:label="FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:title="FairValueOptionAggregateDifferencesLongTermDebtInstruments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueOptionAggregateDifferencesLongTermDebtInstruments" xlink:title="presentation: DebtInstrumentLineItems to FairValueOptionAggregateDifferencesLongTermDebtInstruments" use="optional" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="FairValueOptionChangesInFairValueGainLoss1" xlink:title="FairValueOptionChangesInFairValueGainLoss1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueOptionChangesInFairValueGainLoss1" xlink:title="presentation: DebtInstrumentLineItems to FairValueOptionChangesInFairValueGainLoss1" use="optional" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:label="FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:title="FairValueOptionCreditRiskGainsLossesOnLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueOptionCreditRiskGainsLossesOnLiabilities" xlink:title="presentation: DebtInstrumentLineItems to FairValueOptionCreditRiskGainsLossesOnLiabilities" use="optional" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:label="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:title="presentation: DebtInstrumentLineItems to FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" use="optional" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="FairValueAssumptionsRiskFreeInterestRate" xlink:title="FairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsRiskFreeInterestRate" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="FairValueAssumptionsExpectedVolatilityRate" xlink:title="FairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_FairValueAssumptionsDiscountRate" xlink:label="FairValueAssumptionsDiscountRate" xlink:title="FairValueAssumptionsDiscountRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract" xlink:to="FairValueAssumptionsDiscountRate" xlink:title="presentation: FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract to FairValueAssumptionsDiscountRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfSeriesOfConvertibleNotesAssumed" xlink:label="NumberOfSeriesOfConvertibleNotesAssumed" xlink:title="NumberOfSeriesOfConvertibleNotesAssumed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfSeriesOfConvertibleNotesAssumed" xlink:title="presentation: DebtInstrumentLineItems to NumberOfSeriesOfConvertibleNotesAssumed" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:label="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:title="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" xlink:title="presentation: DebtInstrumentLineItems to LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmountOptionToHolder" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:label="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:title="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" xlink:title="presentation: DebtInstrumentLineItems to LongTermDebtRedemptionPriceAsPercentageOfPrincipalAmount" order="8002.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:title="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" order="8003.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:title="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" order="8004.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:label="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:title="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentConversionObligationNumberOfConsecutiveTradingDays" order="8005.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="LongTermDebtByMaturityAbstract" xlink:title="LongTermDebtByMaturityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtByMaturityAbstract" xlink:title="presentation: DebtInstrumentLineItems to LongTermDebtByMaturityAbstract" order="8006.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="presentation: LongTermDebtByMaturityAbstract to LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="presentation: LongTermDebtByMaturityAbstract to LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="LongTermDebt" xlink:title="presentation: LongTermDebtByMaturityAbstract to LongTermDebt" order="8002.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="StockOptionsMember" xlink:title="StockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="StockOptionsMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to StockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="WarrantMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to WarrantMember" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod" use="optional" order="8002.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice" use="optional" order="8003.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedBeforeAmendment" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="EstimateOfFairValueFairValueDisclosureMember" xlink:title="EstimateOfFairValueFairValueDisclosureMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="EstimateOfFairValueFairValueDisclosureMember" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to EstimateOfFairValueFairValueDisclosureMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByAssetClassAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByAssetClassAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="presentation: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="MoneyMarketFundsMember" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByLiabilityClassAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByLiabilityClassAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="presentation: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="ConvertibleNotesPayableMember" xlink:title="ConvertibleNotesPayableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="ConvertibleNotesPayableMember" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to ConvertibleNotesPayableMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="AssetsFairValueDisclosureAbstract" xlink:title="AssetsFairValueDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosureAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosureAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsFairValueDisclosureAbstract" xlink:to="AssetsFairValueDisclosure" xlink:title="presentation: AssetsFairValueDisclosureAbstract to AssetsFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosureAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosureAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="ConvertibleDebtFairValueDisclosures" xlink:title="ConvertibleDebtFairValueDisclosures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="ConvertibleDebtFairValueDisclosures" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to ConvertibleDebtFairValueDisclosures" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to LiabilitiesFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails2">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="LitigationCaseAxis" xlink:title="LitigationCaseAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LitigationCaseAxis" xlink:title="presentation: LossContingenciesTable to LitigationCaseAxis" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="LitigationCaseTypeDomain" xlink:title="LitigationCaseTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LitigationCaseAxis" xlink:to="LitigationCaseTypeDomain" xlink:title="presentation: LitigationCaseAxis to LitigationCaseTypeDomain" use="optional" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ShareholderDerivativeActionMember" xlink:label="ShareholderDerivativeActionMember" xlink:title="ShareholderDerivativeActionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LitigationCaseTypeDomain" xlink:to="ShareholderDerivativeActionMember" xlink:title="presentation: LitigationCaseTypeDomain to ShareholderDerivativeActionMember" use="optional" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" use="optional" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NumberOfCasesConsolidated" xlink:label="NumberOfCasesConsolidated" xlink:title="NumberOfCasesConsolidated" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfCasesConsolidated" xlink:title="presentation: LossContingenciesLineItems to NumberOfCasesConsolidated" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureDescriptionOfBusiness">
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DescriptionOfBusinessDisclosureAbstract" xlink:label="DescriptionOfBusinessDisclosureAbstract" xlink:title="DescriptionOfBusinessDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DescriptionOfBusinessDisclosureAbstract" xlink:to="NatureOfOperations" xlink:title="presentation: DescriptionOfBusinessDisclosureAbstract to NatureOfOperations" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureLiquidityAndCapitalResources">
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LiquidityAndCapitalResourcesDisclosureAbstract" xlink:label="LiquidityAndCapitalResourcesDisclosureAbstract" xlink:title="LiquidityAndCapitalResourcesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LiquidityAndCapitalResourcesTextBlock" xlink:label="LiquidityAndCapitalResourcesTextBlock" xlink:title="LiquidityAndCapitalResourcesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesDisclosureAbstract" xlink:to="LiquidityAndCapitalResourcesTextBlock" xlink:title="presentation: LiquidityAndCapitalResourcesDisclosureAbstract to LiquidityAndCapitalResourcesTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtDisclosureTextBlock" xlink:title="presentation: DebtDisclosureAbstract to DebtDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureStockBasedCompensation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to StockholdersEquityNoteDisclosureTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureFairValueMeasurements">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="CommitmentsDisclosureTextBlock" xlink:title="CommitmentsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsDisclosureTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" xlink:title="DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="StatementTable" xlink:title="presentation: DocumentAndEntityInformationAbstract to StatementTable" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="presentation: ClassOfStockDomain to CommonClassCMember" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: StatementLineItems to EntityRegistrantName" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: StatementLineItems to EntityCentralIndexKey" use="optional" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DocumentType" xlink:title="presentation: StatementLineItems to DocumentType" use="optional" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: StatementLineItems to DocumentPeriodEndDate" use="optional" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: StatementLineItems to AmendmentFlag" use="optional" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentDescription" xlink:label="AmendmentDescription" xlink:title="AmendmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AmendmentDescription" xlink:title="presentation: StatementLineItems to AmendmentDescription" use="optional" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: StatementLineItems to CurrentFiscalYearEndDate" use="optional" order="70.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: StatementLineItems to EntityWellKnownSeasonedIssuer" use="optional" order="80.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: StatementLineItems to EntityVoluntaryFilers" use="optional" order="90.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: StatementLineItems to EntityCurrentReportingStatus" use="optional" order="100.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EntityFilerCategory" xlink:title="presentation: StatementLineItems to EntityFilerCategory" use="optional" order="110.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EntityPublicFloat" xlink:title="presentation: StatementLineItems to EntityPublicFloat" use="optional" order="120.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: StatementLineItems to EntityCommonStockSharesOutstanding" use="optional" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: StatementLineItems to DocumentFiscalYearFocus" use="optional" order="140.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: StatementLineItems to DocumentFiscalPeriodFocus" use="optional" order="150.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureBasisOfPresentation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="BasisOfAccounting" xlink:title="BasisOfAccounting" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="BasisOfAccounting" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to BasisOfAccounting" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureSubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureBasicAndDilutedNetLossPerShare">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareTextBlock" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/StatementOfIncome">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RevenuesAbstract" xlink:title="presentation: StatementLineItems to RevenuesAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="LicensesRevenue" xlink:title="LicensesRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="LicensesRevenue" xlink:title="presentation: RevenuesAbstract to LicensesRevenue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="RoyaltyRevenue" xlink:title="RoyaltyRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="RoyaltyRevenue" xlink:title="presentation: RevenuesAbstract to RoyaltyRevenue" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="Revenues" xlink:title="presentation: RevenuesAbstract to Revenues" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="OtherSalesRevenueNet" xlink:title="OtherSalesRevenueNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="OtherSalesRevenueNet" xlink:title="presentation: RevenuesAbstract to OtherSalesRevenueNet" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="RevenueFromGrants" xlink:title="RevenueFromGrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="RevenueFromGrants" xlink:title="presentation: RevenuesAbstract to RevenueFromGrants" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CostsAndExpensesAbstract" xlink:title="presentation: StatementLineItems to CostsAndExpensesAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: CostsAndExpensesAbstract to GeneralAndAdministrativeExpense" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: CostsAndExpensesAbstract to DepreciationDepletionAndAmortization" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="CostsAndExpenses" xlink:title="presentation: CostsAndExpensesAbstract to CostsAndExpenses" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="BusinessCombinationAcquisitionRelatedCosts" xlink:title="BusinessCombinationAcquisitionRelatedCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="BusinessCombinationAcquisitionRelatedCosts" xlink:title="presentation: CostsAndExpensesAbstract to BusinessCombinationAcquisitionRelatedCosts" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentInProcess" xlink:title="presentation: CostsAndExpensesAbstract to ResearchAndDevelopmentInProcess" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ExcessConsiderationPaidOverFairValue" xlink:label="ExcessConsiderationPaidOverFairValue" xlink:title="ExcessConsiderationPaidOverFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ExcessConsiderationPaidOverFairValue" xlink:title="presentation: CostsAndExpensesAbstract to ExcessConsiderationPaidOverFairValue" use="optional" order="8020.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicenseCosts" xlink:label="LicenseCosts" xlink:title="LicenseCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="LicenseCosts" xlink:title="presentation: CostsAndExpensesAbstract to LicenseCosts" use="optional" order="8030.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: StatementLineItems to NonoperatingIncomeExpenseAbstract" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="FairValueOptionChangesInFairValueGainLoss1" xlink:title="FairValueOptionChangesInFairValueGainLoss1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="FairValueOptionChangesInFairValueGainLoss1" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to FairValueOptionChangesInFairValueGainLoss1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpense" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="OtherNonoperatingIncome" xlink:title="OtherNonoperatingIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncome" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncome" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:label="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:title="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: StatementLineItems to NetIncomeLossAvailableToCommonStockholdersBasic" order="52.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="EarningsPerShareBasicAndDiluted" xlink:title="EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasicAndDiluted" xlink:title="presentation: StatementLineItems to EarningsPerShareBasicAndDiluted" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="presentation: StatementLineItems to WeightedAverageNumberOfSharesOutstandingAbstract" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: StatementLineItems to EarningsPerShareAbstract" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasic" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareDiluted" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: StatementLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: StatementLineItems to IncomeTaxExpenseBenefit" order="51.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="StatementTable" xlink:title="presentation: IncomeStatementAbstract to StatementTable" use="optional" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/CashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IssuanceOfStockAndWarrantsForServicesOrClaims" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="FairValueOptionChangesInFairValueGainLoss1" xlink:title="FairValueOptionChangesInFairValueGainLoss1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FairValueOptionChangesInFairValueGainLoss1" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FairValueOptionChangesInFairValueGainLoss1" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="BusinessCombinationAcquisitionRelatedCosts" xlink:title="BusinessCombinationAcquisitionRelatedCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="BusinessCombinationAcquisitionRelatedCosts" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to BusinessCombinationAcquisitionRelatedCosts" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ResearchAndDevelopmentInProcess" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ResearchAndDevelopmentInProcess" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ExcessConsiderationPaidOverFairValue" xlink:label="ExcessConsiderationPaidOverFairValue" xlink:title="ExcessConsiderationPaidOverFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ExcessConsiderationPaidOverFairValue" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ExcessConsiderationPaidOverFairValue" use="optional" order="8020.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:label="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:title="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" use="optional" order="8030.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="OtherNoncashIncomeExpense" xlink:title="OtherNoncashIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OtherNoncashIncomeExpense" xlink:title="presentation: AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OtherNoncashIncomeExpense" use="optional" order="8040.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to IncreaseDecreaseInOperatingCapitalAbstract" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="IncreaseDecreaseInRoyaltiesPayable" xlink:title="IncreaseDecreaseInRoyaltiesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInRoyaltiesPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInRoyaltiesPayable" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" order="8010.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="PaymentsToAcquireInvestments" xlink:title="PaymentsToAcquireInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireInvestments" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireInvestments" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="PaymentsToAcquireShortTermInvestments" xlink:title="PaymentsToAcquireShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireShortTermInvestments" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireShortTermInvestments" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToAcquireProductiveAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to PaymentsToAcquireProductiveAssets" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="ProceedsFromSaleOfShortTermInvestments" xlink:title="ProceedsFromSaleOfShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfShortTermInvestments" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfShortTermInvestments" use="optional" order="8020.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromSaleOfProductiveAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract to ProceedsFromSaleOfProductiveAssets" use="optional" order="8030.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_PaymentsToFractionalSharePayout" xlink:label="PaymentsToFractionalSharePayout" xlink:title="PaymentsToFractionalSharePayout" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="PaymentsToFractionalSharePayout" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to PaymentsToFractionalSharePayout" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromStockOptionsExercised" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromWarrantExercises" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromWarrantExercises" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:label="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:title="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromIssuanceOfCommonStock" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="ProceedsFromPaymentsForOtherFinancingActivities" xlink:title="ProceedsFromPaymentsForOtherFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="ProceedsFromPaymentsForOtherFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to ProceedsFromPaymentsForOtherFinancingActivities" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="CashAcquiredFromAcquisition" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to CashAcquiredFromAcquisition" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_RepaymentsOfShortTermConvertibleDebt" xlink:label="RepaymentsOfShortTermConvertibleDebt" xlink:title="RepaymentsOfShortTermConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="RepaymentsOfShortTermConvertibleDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract to RepaymentsOfShortTermConvertibleDebt" use="optional" order="8020.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInContinuingOperations" xlink:label="NetCashProvidedByUsedInContinuingOperations" xlink:title="NetCashProvidedByUsedInContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInContinuingOperations" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInContinuingOperations" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue_2" xlink:title="presentation: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" use="optional" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementLineItems to SupplementalCashFlowInformationAbstract" use="optional" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:label="InterestPaid" xlink:title="InterestPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaid" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaid" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:title="OtherNoncashInvestingAndFinancingItemsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:title="presentation: SupplementalCashFlowInformationAbstract to OtherNoncashInvestingAndFinancingItemsAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="StockIssued1" xlink:title="presentation: OtherNoncashInvestingAndFinancingItemsAbstract to StockIssued1" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:label="UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:title="UnpaidCostsAssociatedWithRegisteredDirectOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="UnpaidCostsAssociatedWithRegisteredDirectOffering" xlink:title="presentation: OtherNoncashInvestingAndFinancingItemsAbstract to UnpaidCostsAssociatedWithRegisteredDirectOffering" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:label="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:title="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="UnpaidCostsAssociatedWithUnderWrittenPublicOffering" xlink:title="presentation: OtherNoncashInvestingAndFinancingItemsAbstract to UnpaidCostsAssociatedWithUnderWrittenPublicOffering" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="CapitalExpendituresIncurredButNotYetPaid" xlink:title="CapitalExpendituresIncurredButNotYetPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="CapitalExpendituresIncurredButNotYetPaid" xlink:title="presentation: OtherNoncashInvestingAndFinancingItemsAbstract to CapitalExpendituresIncurredButNotYetPaid" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="presentation: OtherNoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_NoncashInvestment" xlink:label="NoncashInvestment" xlink:title="NoncashInvestment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashInvestment" xlink:title="presentation: OtherNoncashInvestingAndFinancingItemsAbstract to NoncashInvestment" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:title="presentation: OtherNoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" use="optional" order="8020.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:label="NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:title="NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" xlink:title="presentation: OtherNoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashAcquisitionInvestmentsAcquired1" use="optional" order="8030.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:label="NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:title="NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:title="presentation: OtherNoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" use="optional" order="8040.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: StatementTable to StatementScenarioAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfCashFlowsAbstract to StatementTable" use="optional" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/BalanceSheet">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="presentation: ClassOfStockDomain to CommonClassCMember" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="presentation: StatementLineItems to AssetsAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="OtherReceivablesGrossCurrent" xlink:title="OtherReceivablesGrossCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OtherReceivablesGrossCurrent" xlink:title="presentation: AssetsCurrentAbstract to OtherReceivablesGrossCurrent" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="OtherAssetsNoncurrentAbstract" xlink:title="OtherAssetsNoncurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrentAbstract" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrentAbstract" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="LongTermInvestments" xlink:title="LongTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAssetsNoncurrentAbstract" xlink:to="LongTermInvestments" xlink:title="presentation: OtherAssetsNoncurrentAbstract to LongTermInvestments" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="DepositsAssetsNoncurrent" xlink:title="DepositsAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAssetsNoncurrentAbstract" xlink:to="DepositsAssetsNoncurrent" xlink:title="presentation: OtherAssetsNoncurrentAbstract to DepositsAssetsNoncurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to EmployeeRelatedLiabilitiesCurrent" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OtherAccruedLiabilitiesCurrent" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SeniorNotesCurrent" xlink:label="SeniorNotesCurrent" xlink:title="SeniorNotesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="SeniorNotesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to SeniorNotesCurrent" use="optional" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="AccruedRoyaltiesCurrent" xlink:title="AccruedRoyaltiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedRoyaltiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedRoyaltiesCurrent" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="ConvertibleNotesPayableCurrent" xlink:title="ConvertibleNotesPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ConvertibleNotesPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ConvertibleNotesPayableCurrent" use="optional" order="8010.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="ConvertibleLongTermNotesPayable" xlink:title="ConvertibleLongTermNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="ConvertibleLongTermNotesPayable" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to ConvertibleLongTermNotesPayable" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" use="optional" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_CapitalStockAbstract" xlink:label="CapitalStockAbstract" xlink:title="CapitalStockAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CapitalStockAbstract" xlink:title="presentation: StockholdersEquityAbstract to CapitalStockAbstract" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="CommonStockValueOutstanding" xlink:title="CommonStockValueOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CapitalStockAbstract" xlink:to="CommonStockValueOutstanding" xlink:title="presentation: CapitalStockAbstract to CommonStockValueOutstanding" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" use="optional" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" use="optional" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/BalanceSheetParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="presentation: ClassOfStockDomain to CommonClassCMember" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StatementLineItems to CommonStockSharesIssued" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StatementLineItems to CommonStockSharesOutstanding" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" use="optional" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/StatementOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="presentation: EquityComponentDomain to RetainedEarningsMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="presentation: ClassOfStockDomain to CommonClassCMember" use="optional" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" use="optional" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_IssuanceOfCommonSharesAbstract" xlink:label="IssuanceOfCommonSharesAbstract" xlink:title="IssuanceOfCommonSharesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="IssuanceOfCommonSharesAbstract" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to IssuanceOfCommonSharesAbstract" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonSharesAbstract" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IssuanceOfCommonSharesAbstract to StockIssuedDuringPeriodValueStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="StockIssuedDuringPeriodValueWarrantsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfCommonSharesAbstract" xlink:to="StockIssuedDuringPeriodValueWarrantsExercised" xlink:title="presentation: IssuanceOfCommonSharesAbstract to StockIssuedDuringPeriodValueWarrantsExercised" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="StockIssuedDuringPeriodSharesWarrantsExercised" xlink:title="presentation: StockIssuedDuringPeriodValueWarrantsExercised to StockIssuedDuringPeriodSharesWarrantsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" order="60.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:label="StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:title="StockIssuedDuringPeriodValueCommonSharesAndWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueCommonSharesAndWarrants" order="70.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:label="StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:title="StockIssuedDuringPeriodCommonSharesAndWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueCommonSharesAndWarrants" xlink:to="StockIssuedDuringPeriodCommonSharesAndWarrants" xlink:title="presentation: StockIssuedDuringPeriodValueCommonSharesAndWarrants to StockIssuedDuringPeriodCommonSharesAndWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAcquisitions" order="80.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: StockIssuedDuringPeriodValueAcquisitions to StockIssuedDuringPeriodSharesAcquisitions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:label="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:title="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalCreditEquityFinancingFacility" order="90.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="StockholdersEquityPeriodIncreaseDecrease" xlink:title="StockholdersEquityPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityPeriodIncreaseDecrease" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityPeriodIncreaseDecrease" order="130.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityPeriodIncreaseDecrease" xlink:to="StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:title="presentation: StockholdersEquityPeriodIncreaseDecrease to StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" order="10.0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="10.0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureLicenseAgreements">
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LicenseAgreementsDisclosureAbstract" xlink:label="LicenseAgreementsDisclosureAbstract" xlink:title="LicenseAgreementsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_LicenseAgreementsDisclosureTextBlock" xlink:label="LicenseAgreementsDisclosureTextBlock" xlink:title="LicenseAgreementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAgreementsDisclosureAbstract" xlink:to="LicenseAgreementsDisclosureTextBlock" xlink:title="presentation: LicenseAgreementsDisclosureAbstract to LicenseAgreementsDisclosureTextBlock" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" xlink:label="ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" xlink:title="ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xlink:label="ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xlink:title="ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract" xlink:to="ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" xlink:title="presentation: ConsolidationBasisOfPresentationAndAccountingPoliciesAbstract to ConsolidationBasisOfPresentationAndAccountingPoliciesTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureIncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureAcquisitionOfNetAssetsOfCellGenesys">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="BusinessCombinationDisclosureTextBlock" xlink:title="BusinessCombinationDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="BusinessCombinationDisclosureTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to BusinessCombinationDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureRetirementPlan">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureLeaseArrangements">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="LeasesOfLesseeDisclosureTextBlock" xlink:title="LeasesOfLesseeDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LeasesOfLesseeDisclosureTextBlock" xlink:title="presentation: LeasesAbstract to LeasesOfLesseeDisclosureTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureSelectedQuarterlyFinancialData">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="QuarterlyFinancialInformationTextBlock" xlink:title="QuarterlyFinancialInformationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="QuarterlyFinancialInformationTextBlock" xlink:title="presentation: QuarterlyFinancialInformationDisclosureAbstract to QuarterlyFinancialInformationTextBlock" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureRecentlyIssuedAccountingPronouncements">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:title="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:label="DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:title="DescriptionOfNewAccountingPronouncementsNotYetAdopted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:title="presentation: NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract to DescriptionOfNewAccountingPronouncementsNotYetAdopted" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureInvestments">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="InvestmentsDebtAndEquitySecuritiesAbstract" xlink:title="InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:label="CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:title="CostAndEquityMethodInvestmentsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="CostAndEquityMethodInvestmentsDisclosureTextBlock" xlink:title="presentation: InvestmentsDebtAndEquitySecuritiesAbstract to CostAndEquityMethodInvestmentsDisclosureTextBlock" use="optional" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biosantepharma.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="8000.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockOptionsMember" xlink:label="StockOptionsMember" xlink:title="StockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockOptionsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to StockOptionsMember" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="ConvertibleDebtSecuritiesMember" xlink:title="ConvertibleDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertibleDebtSecuritiesMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to ConvertibleDebtSecuritiesMember" order="8002.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to RangeAxis" order="8001.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="8002.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="8000.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="bpax-20120930.xsd#bpax_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareExercisePriceOfSecurities" order="8001.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 2) (Shareholder derivative action)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 24, 2012

</div>
          <div>item</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Shareholder derivative action</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfCasesConsolidated', window );">Number of cases consolidated</a></td>
        <td class="nump">2<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfCasesConsolidated">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of cases that were consolidated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfCasesConsolidated</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LossContingenciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>BASIC AND DILUTED NET LOSS PER SHARE</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET LOSS PER SHARE</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">4.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">BASIC AND DILUTED NET LOSS PER SHARE</font></b></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The basic and diluted net loss per share is computed based on the weighted average number of shares of common stock and class C special stock outstanding, all being considered as equivalent of one another.&#160; Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding for the reporting period.&#160; Diluted net loss per share is intended to reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock.&#160; Because the Company has incurred net losses from operations in each of the periods presented, the Company&#8217;s outstanding options, warrants and convertible debt are antidilutive; accordingly, such securities are excluded from the computation of diluted net loss per share and there is no difference between basic and diluted net loss per share amounts.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16381557&amp;loc=d3e4984-109258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>19
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T)A
M;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0V]N9&5N<V5D7T)A;&%N8V5?4VAE971S7U!A<F5N/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7U-T871E
M;65N='-?;V9?3W!E<F%T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N9&5N<V5D7U-T871E;65N='-?;V9?0V%S:%]&/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1$530U))4%1)3TY?
M3T9?0E5324Y%4U,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y"05-)4U]/1E]04D5314Y4051)3TX\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#<N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y,25%5241)5%E?04Y$7T-!4$E404Q?4D53
M3U520T4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"
M05-)0U]!3D1?1$E,551%1%].151?3$]34U]015(\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#DN
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY615)424),15]314Y)3U)?3D]4
M15,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#
M2T)!4T5$7T-/35!%3E-!5$E/3CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-43T-+2$],1$524U]%455)5%D\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-251-14Y44U]!3D1?0T].
M5$E.1T5.0TE%4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9!25)?5D%,545?345!4U5214U%3E13/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$T+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4U5"4T51545.5%]%5D5.5%,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY615)424),15]3
M14Y)3U)?3D]415-?5&%B;&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y&04E27U9!3%5%7TU%05-54D5-14Y44U]486)L97,\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$15-#4DE05$E/
M3E]/1E]"55-)3D534U]$971A:6P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3@N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y"05-)4U]/1E]04D5314Y4051)3TY?1&5T86EL<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQ)455)1$E4
M65]!3D1?0T%0251!3%]215-/55)#13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C`N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y#3TY615)424),15]314Y)3U)?3D]415-?1&5T
M86D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#
M2T)!4T5$7T-/35!%3E-!5$E/3E]$971A:6P\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2TA/3$1%4E-?15%525197T1E=&%I
M;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-
M251-14Y44U]!3D1?0T].5$E.1T5.0TE%4U\\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C0N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-251-14Y44U]!3D1?0T].5$E.1T5.
M0TE%4U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M1D%)4E]604Q515]-14%355)%345.5%-?1&5T86EL/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U5"4T51545.5%]%5D5.5%-?1&5T
M86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE
M970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T
M:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C
M='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T
M5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7
M;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D
M>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC
M<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,V,T.3DR7S8T.3%?-#DX-5\X
M.68U7S`S.#DU-38S9#DU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\X,C-C-#DY,E\V-#DQ7S0Y.#5?.#EF-5\P,S@Y-34V,V0Y-3$O5V]R:W-H
M965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6DE!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`P-RP@,C`Q,CQB
M<CY#;&%S<R!#('-P96-I86P@<W1O8VL\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^3F]V+B`P-RP@,C`Q,CQB<CY#;VUM;VX@<W1O8VL\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I
M<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D))
M3U-!3E1%(%!(05)-04-%551)0T%,4R!)3D,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN
M9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,#`P,3`R
M,S`R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,3`M43QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1&]C=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y397`@,S`L#0H)"3(P,3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD
M;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS
M93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-U<G)E;G0@4F5P
M;W)T:6YG(%-T871U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/D%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V]M;6]N
M(%-T;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8U+#(Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(T+#0R,BPR-#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A
M;"!996%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR
M,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y1,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?.#(S8S0Y.3)?-C0Y,5\T.3@U7S@Y9C5?,#,X
M.34U-C-D.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,V,T
M.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU,2]7;W)K<VAE971S+U-H
M965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5/2D%'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R
M;VYG/D-O;F1E;G-E9"!"86QA;F-E(%-H965T<R`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#55)214Y4($%34T544SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,X+#`T.2PP.34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4W
M+#(R-2PR,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,T+#`S-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P,2PQ-#<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y43U1!3"!#55)214Y4($%34T544SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S@L-3@S+#$S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4X+#`R-BPS.#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!23U!%4E19($%.1"!%
M455)4$U%3E0L($Y%5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PQ.#0L-S8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#8Q+#,V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/5$A%4B!!4U-%5%,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV97-T;65N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#$S+#<V,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-#`U+#@P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5P;W-I=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,P+#`X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C@V+#(P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1/5$%,($%34T544SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#,L,C$Q+#<T-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R+#,W.2PW-34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0U524D5.5"!,24%"24Q)5$E%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P-"PX,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$U,"PV-S<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8W)U960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-C,L.30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU.3<L,S(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!A8V-R=65D(&5X<&5N<V5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-C`L,#DT/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT-SDL
M-CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#=7)R96YT('!O<G1I;VX@;V8@8V]N=F5R=&EB;&4@<V5N:6]R(&YO
M=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4Y,RPR,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y43U1!3"!#55)214Y4($Q)04))3$E42453/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,"PY,C(L,#8V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPR,C<L-S`S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@
M8V]N=F5R=&EB;&4@<V5N:6]R(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-RPS,S8L-S8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$]404P@3$E!0DE,251)15,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#DR,BPP-C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PU-C0L
M-#8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-A<&ET86P@<W1O8VL\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%P:71A;"!S=&]C:SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<S+#(U.2PR,S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-34L,#4T+#0T
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,C0P+#DV.2PU-38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C$W+#(S.2PQ-#@I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$]404P@4U1/
M0TM(3TQ$15)3)R!%455)5%D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,R+#(X.2PV.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-RPX,34L,CDR/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$]404P@3$E!0DE,251)15,@
M04Y$(%-43T-+2$],1$524R<@15%52519/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,RPR,3$L-S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C(L,S<Y+#<U-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQA<W,@0R!S<&5C
M:6%L('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0V%P:71A;"!S=&]C:SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L('-T;V-K/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87!I=&%L('-T;V-K
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<&ET86P@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,C<S+#(U.2PQ-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(U-2PP-30L,S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15E.04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS
M=')O;F<^0V]N9&5N<V5D($)A;&%N8V4@4VAE971S("A087)E;G1H971I8V%L
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-L87-S($,@<W!E8VEA;"!S=&]C:SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L('-T;V-K+"!I<W-U960@<VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-2PR,3$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-2PR,30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-A<&ET86P@<W1O8VLL(&]U='-T86YD:6YG('-H87)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C4L,C$Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C4L,C$T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%P:71A;"!S
M=&]C:RP@:7-S=65D('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C0L-#(R+#(T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$X+#(V.2PW-34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<&ET86P@<W1O8VLL(&]U
M='-T86YD:6YG('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C0L-#(R+#(T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$X+#(V.2PW-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S
M.#DU-38S9#DU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C-C
M-#DY,E\V-#DQ7S0Y.#5?.#EF-5\P,S@Y-34V,V0Y-3$O5V]R:W-H965T<R]3
M:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%4U)!1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#;VYD96YS960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)%5D5.544\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS:6YG(')E=F5N=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F]Y86QT>2!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,3`L,S@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#(L-S@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S,S+#$V,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R,"PW.#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R
M979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3`L,S@S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3@R+#<X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,S,RPQ-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,C`L-S@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D584$5.4T53/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H
M(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPX-S(L-S,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$L-3`P+#`U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#0U-"PR-3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-RPT.#`L.#<S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'
M96YE<F%L(&%N9"!A9&UI;FES=')A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU-#8L.#8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-S4L,C8X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS,C<L-S$Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PR-3<L
M.#4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L-S0Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4L-C<P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<L-30X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$X+#$S
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU+#0T-2PS-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,RPR,3`L.3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL.#8Y+#4Q-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R+#@U-BPX-3@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3U1(15(\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@;F]T92!F86ER('9A;'5E(&%D:G5S
M=&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@T,RPT,3(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#8S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#0L,#,W+#<Y-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q+#DR.2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V-RPQ,#4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<R+#`P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R.#,L,S0X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4Q-BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!I;F-O;64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O
M;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#<W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#,P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L-#<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,3U-3($)%1D]212!)3D-/344@5$%8($)%3D5&250\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L,C0S+#8P-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPW,S,L
M-CDQ*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(S+#@U,BPQ.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#0L.34Y+#4Y.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!T87@@8F5N969I
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Q+#<Y,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,2PW
M.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.150@3$]34SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@V+#$R,2PX,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@Q,BPW,S,L-CDQ*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C,L-S,P+#0P."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0T+#DU
M.2PU.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"05-)0R!!3D0@1$E,551%1"!.150@3$]34R!015(@4TA!4D4@
M*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@P+C(W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,"XW,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$N,30I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R+C@V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY714E'2%1%1"!!5D5204=%($Y534)%4B!/1B!32$%215,@3U544U1!3D1)
M3D<\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F%S:6,@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(R+#DR,2PQ-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-RPT,#8L-3,V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L.#0Q+#0Q-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#<T-"PW,S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1I;'5T960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(R+#DR,2PQ-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-RPT,#8L-3,V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L.#0Q+#0Q-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#<T-"PW
M,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R
M,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU,0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\X,C-C-#DY,E\V-#DQ7S0Y.#5?.#EF-5\P
M,S@Y-34V,V0Y-3$O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M-4U!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYD96YS960@4W1A=&5M
M96YT<R!O9B!#87-H($9L;W=S("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/5U,@*%53
M140@24XI($]015)!5$E.1R!!0U1)5DE42453/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#(S+#<S,"PT,#@I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T-"PY-3DL-3DY
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@
M=&\@;F5T(&-A<V@@*'5S960@:6XI(&]P97)A=&EO;G,\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N
M9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@W+#4T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q."PQ,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@9&ES<&]S86P@;V8@9FEX960@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3<L-SDT/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8W
M+#(W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16UP;&]Y964@)F%M<#L@9&ER96-T;W(@<W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-3(L
M-#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#@V+#4V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VL@=V%R<F%N="!E>'!E;G-E("T@;F]N8V%S:#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@P+#<U.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R
M=&EB;&4@;F]T92!F86ER('9A;'5E(&%D:G5S=&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0L,#,W+#<Y-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3(Y+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#:&%N9V5S(&EN(&]T:&5R(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@869F
M96-T:6YG(&-A<V@@9FQO=W,@9G)O;2!O<&5R871I;VYS/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS
M97,L(&1E<&]S:71S(&%N9"!O=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,R,RPR,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4S.2PY,#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A
M>6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,L.#`W+#`W-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DY,RPP-3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S
M:"`H=7-E9"!I;BD@;W!E<F%T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(R+#$Q."PV-3`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S8L.30T+#DP."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0T%32"!&3$]74R`H55-%1"!)3BD@24Y615-424Y'($%#5$E6251)
M15,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4'5R8VAA<V4@;V8@:6YV97-T;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-RPY-34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!F:7AE9"!A<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4R."PW-#(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C0U+#8P,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@8V%S:"`H=7-E9"!I;BD@:6YV97-T:6YG(&%C=&EV:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4S-BPV.3<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C0U+#8P,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0T%32"!&3$]74R!04D]6241%1"!"62!&24Y!3D-)3D<@04-4
M259)5$E%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&<F%C=&EO;F%L('-H87)E('!A>6]U=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-C4X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!C;VUM;VX@<W1O
M8VL@;W!T:6]N(&5X97)C:7-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S(L-#0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('=A<G)A;G1S(&5X97)C:7-E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$Q+#`V.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T+#`V
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@8GD@
M=6YD97)W<FET=&5N('!U8FQI8R!O9F9E<FEN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#4L,3`R+#4X-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U
M86YC92!O9B!C;VUM;VX@<W1O8VL@8GD@<F5G:7-T97)E9"!D:7)E8W0@;V9F
M97)I;F=S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(V."PW
M.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,RPX-S8L,S<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN86YC:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-#<Y+#(P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8Y+#`S-2PT-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.150@*$1%0U)%05-%*2!)3D-214%312!)
M3B!#05-(($%.1"!#05-(($5154E604Q%3E13/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q.2PQ-S8L,3,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#0T-"PY-#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-!4T@@04Y$
M($-!4T@@15%5259!3$5.5%,@050@0D5'24Y.24Y'($]&(%!%4DE/1#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L,C(U+#(S-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#$U-2PR
M-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-!4T@@04Y$($-!4T@@15%5259!3$5.5%,@050@14Y$($]&(%!%4DE/
M1#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L,#0Y+#`Y-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y
M+#8P,"PQ.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4U504$Q%345.5$%,(%-#2$5$54Q%($]&($-!
M4T@@1DQ/5R!)3D9/4DU!5$E/3CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!P86ED/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ.#0L,#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0T+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;VYC
M87-H(&EN=F5S=&EN9R!A;F0@9FEN86YC:6YG(&%C=&EV:71I97,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES
M<W5E9"!F;W(@8V]N=F5R=&EB;&4@<V5N:6]R(&YO=&5S(&%N9"!A8V-R=65D
M(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPX
M.#$L,#4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5;G!A:60@8V]S=',@87-S;V-I871E9"!W:71H(')E9VES=&5R
M960@9&ER96-T(&]F9F5R:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW+#DS,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^56YP86ED(&-O<W1S(&%S<V]C:6%T960@=VET:"!U;F1E
M<G=R:71T96X@<'5B;&EC(&]F9F5R:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-#$L-#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!F:7AE9"!A<W-E=',@
M;VX@86-C;W5N="P@;F]N+6-A<V@@:6YV97-T:6YG(&%C=&EV:71Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4Y+#`Q-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(S8S0Y.3)?-C0Y,5\T
M.3@U7S@Y9C5?,#,X.34U-C-D.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU,2]7
M;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY$15-#4DE05$E/3B!/1B!"55-)3D534SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1%4T-2
M25!424].($]&($)54TE.15-3/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1%4T-225!424].($]&($)54TE.15-3/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@<W1Y;&4],T0G9F]N
M="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG+'1I
M;65S+'-E<FEF.R<^#0H\='(^#0H\=&0^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T(#`N-6EN.R!415A4+4E.1$5.5#H@+3`N-6EN)SX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q
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M3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T)R!S:7IE/3-$,CY$
M15-#4DE05$E/3B!/1B!"55-)3D534SPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P+C5I;CL@5$585"U)3D1%3E0Z
M("TP+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
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M9WD@8V]M<&%N:65S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
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M('-E>'5A;"!D>7-F=6YC=&EO;B`H1E-$*2P@<W!E8VEF:6-A;&QY(&AY<&]A
M8W1I=F4@<V5X=6%L(&1E<VER92!D:7-O<F1E<B`H2%-$1"D[("@R*28C,38P
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M.TEN8RX@*%1E=F$I.R`H,RDF(S$V,#M'5D%8(&-A;F-E<B!V86-C:6YE<RP@
M82!P;W)T9F]L:6\@;V8@8V%N8V5R('9A8V-I;F5S+"!F;W5R(&]F('=H:6-H
M(&AA=F4@8F5E;B!G<F%N=&5D($9$02!O<G!H86X@9')U9R!D97-I9VYA=&EO
M;BP@86YD('=H:6-H(&%R92!C=7)R96YT;'D@:6X@,3<@4&AA<V4@22!A;F0@
M4&AA<V4@24D@8VQI;FEC86P@=')I86QS(&9O<B!T:&4@=')E871M96YT(&]F
M('9A<FEO=7,@8V%N8V5R<SL@*#0I)B,Q-C`[5&AE(%!I;&PM4&QU<R`H=')I
M<&QE(&-O;7!O;F5N="!C;VYT<F%C97!T:79E*2P@;VYC92!D86EL>2!U<V4@
M;V8@=F%R:6]U<R!C;VUB:6YA=&EO;G,@;V8@97-T<F]G96YS+"!P<F]G97-T
M;V=E;G,@86YD(&%N9')O9V5N<R!I;B!0:&%S92!)22!D979E;&]P;65N=#L@
M86YD("@U*28C,38P.T5L97-T<FEN+"!O;F-E(&1A:6QY('1R86YS9&5R;6%L
M(&5S=')A9&EO;"`H97-T<F]G96XI(&=E;"!A<'!R;W9E9"!B>2!T:&4@1D1!
M(&EN9&EC871E9"!F;W(@=&AE('1R96%T;65N="!O9B!M;V1E<F%T92UT;RUS
M979E<F4@=F%S;VUO=&]R('-Y;7!T;VUS("AH;W0@9FQA<VAE<RD@87-S;V-I
M871E9"!W:71H(&UE;F]P875S92!A;F0@;6%R:V5T960@:6X@=&AE(%4N4RX@
M8GD@365D82!0:&%R;6%C975T:6-A;',@26YC+B`H365D82DL('1H92!#;VUP
M86YY)B,X,C$W.W,@;&EC96YS964N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(S8S0Y.3)?
M-C0Y,5\T.3@U7S@Y9C5?,#,X.34U-C-D.34Q#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S
M9#DU,2]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY"05-)4R!/1B!04D5314Y4051)3TX\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"
M05-)4R!/1B!04D5314Y4051)3TX\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0D%325,@3T8@4%)%4T5.5$%424]./"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@<W1Y;&4],T0G9F]N
M="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG+'1I
M;65S+'-E<FEF.R<^#0H\='(^#0H\=&0^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T(#`N-6EN.R!415A4+4E.1$5.5#H@+3`N-6EN)SX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q
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M3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T)R!S:7IE/3-$,CY"
M05-)4R!/1B!04D5314Y4051)3TX\+V9O;G0^/"]B/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M
M,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
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M96UB97(F(S$V,#LS,"P@,C`Q,B!A;F0@1&5C96UB97(F(S$V,#LS,2P@,C`Q
M,2P@=&AE(')E<W5L=',@;V8@;W!E<F%T:6]N<R!F;W(@=&AE('1H<F5E(&%N
M9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,B!A
M;F0@,C`Q,2P@86YD('1H92!C87-H(&9L;W=S(&9O<B!T:&4@;FEN92!M;VYT
M:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(@86YD(#(P,3$L(&EN
M(&-O;F9O<FUI='D@=VET:"!A8V-O=6YT:6YG('!R:6YC:7!L97,@9V5N97)A
M;&QY(&%C8V5P=&5D(&EN('1H92!5;FET960@4W1A=&5S(&]F($%M97)I8V$@
M*$=!05`I+B8C,38P.R!/<&5R871I;F<@<F5S=6QT<R!F;W(@=&AE('1H<F5E
M(&%N9"!N:6YE(&UO;G1H('!E<FEO9',@96YD960@4V5P=&5M8F5R)B,Q-C`[
M,S`L(#(P,3(@87)E(&YO="!N96-E<W-A<FEL>2!I;F1I8V%T:79E(&]F('1H
M92!R97-U;'1S('1H870@;6%Y(&)E(&5X<&5C=&5D(&9O<B!T:&4@9G5L;"!Y
M96%R(&5N9&EN9R!$96-E;6)E<B8C,38P.S,Q+"`R,#$R+B8C,38P.R!4:&4@
M0V]M<&%N>2!D;V5S(&YO="!H879E(&ET96US(&]F(&]T:&5R(&-O;7!R96AE
M;G-I=F4@:6YC;VUE(&9O<B!E:71H97(@;V8@=&AE('1H<F5E(&]R(&YI;F4@
M;6]N=&@@<&5R:6]D<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,B!O
M<B`R,#$Q.R!A;F0@=&AE<F5F;W)E+"!H87,@;F]T('!R97-E;G1E9"!C;VUP
M<F5H96YS:79E(&EN8V]M92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG
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M9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$N/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/D]N($IU;F4F(S$V,#LQ+"`R,#$R+"!T:&4@0V]M<&%N>2!E9F9E
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M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^/"]T<CX\+W1A8FQE/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQ)
M455)1$E462!!3D0@0T%0251!3"!215-/55)#15,\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,25%5241)5%D@04Y$
M($-!4$E404P@4D533U520T53/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQ)455)1$E462!!3D0@0T%0251!3"!215-/55)#
M15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!S='EL
M93TS1"=F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI;'DZ)U1I;65S($YE=R!2
M;VUA;B<L=&EM97,L<V5R:68[)SX-"CQT<CX-"CQT9#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`M,"XU
M:6XG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/C,N/"]F;VYT/CPO8CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`S<'0G('-I>F4],T0Q/B8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]B/CQB/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0G('-I
M>F4],T0R/DQ)455)1$E462!!3D0@0T%0251!3"!215-/55)#15,\+V9O;G0^
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU
M:6X[(%1%6%0M24Y$14Y4.B`M,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
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M97,N)B,Q-C`[(%1H92!#;VUP86YY(&ET<V5L9B!H87,@;F]T(&EN=')O9'5C
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M;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/D%S(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R+"!T:&4@0V]M
M<&%N>2!H860@)#,X+#`T.2PP.34@;V8@8V%S:"!A;F0@8V%S:"!E<75I=F%L
M96YT<RXF(S$V,#L@07,@;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(L('1H
M92!#;VUP86YY(&AA9"!O=71S=&%N9&EN9R`D."PR-S<L.#4P(&EN(&%G9W)E
M9V%T92!P<FEN8VEP86P@86UO=6YT(&]F(&ET<R`S+C$R-24@8V]N=F5R=&EB
M;&4@<V5N:6]R(&YO=&5S(&1U92!-87DF(S$V,#LQ+"`R,#$S+B8C,38P.R!)
M;B!!=6=U<W0F(S$V,#LR,#$R+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@86X@
M;V9F97)I;F<@;V8@86X@86=G<F5G871E(&]F(#(L,S4Y+#DS,B!S:&%R97,@
M;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@86YD('=A<G)A
M;G1S('1O('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`Q+#$W.2PY-C8@<VAA
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M9&ER96-T(&]F9F5R:6YG+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
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M<F=E<B!W:71H($%.25`@06-Q=6ES:71I;VX@0V]M<&%N>2!D+V(O82!!3DD@
M4&AA<FUA8V5U=&EC86QS+"8C,38P.TEN8RX@*$%.22D@:7,@8V]M<&QE=&5D
M(&1U<FEN9R!T:&4@9FER<W0@<75A<G1E<B!O9B`R,#$S("AS964@3F]T92`Q
M,"P@)B,X,C(P.U-U8G-E<75E;G0@179E;G1S)B,X,C(Q.RDL('1H92!#;VUP
M86YY(&5X<&5C=',@:71S(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@87,@
M;V8@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(@=&\@;65E="!T:&4@0V]M<&%N
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M;6)E<B8C,38P.S,P+"`R,#$R('=I;&P@8F4@<W5F9FEC:65N="!T;R!M965T
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M;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL
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M)B,Q-C`[($1E8G0@9FEN86YC:6YG+"!I9B!A=F%I;&%B;&4L(&UA>2!I;G9O
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M+"!O<B!A="!A;&PN)B,Q-C`[($%S(&%N(&%L=&5R;F%T:79E('1O(')A:7-I
M;F<@861D:71I;VYA;"!F:6YA;F-I;F<L('1H92!#;VUP86YY(&UA>2!C:&]O
M<V4@=&\@871T96UP="!T;R!L:6-E;G-E(&]N92!O<B!M;W)E(&]F(&ET<R!P
M<F]D=6-T<R!O<B!T96-H;F]L;V=I97,@=&\@82!T:&ER9"!P87)T>2!W:&\@
M;6%Y(&9I;F%N8V4@82!P;W)T:6]N(&]R(&%L;"!O9B!T:&4@8V]N=&EN=65D
M(&1E=F5L;W!M96YT(&%N9"P@:68@87!P<F]V960L(&-O;6UE<F-I86QI>F%T
M:6]N(&]F('1H870@;&EC96YS960@<')O9'5C="P@<V5L;"!C97)T86EN(&%S
M<V5T<R!O<B!R:6=H=',@=6YD97(@=&AE($-O;7!A;GDF(S@R,3<[<R!E>&ES
M=&EN9R!L:6-E;G-E(&%G<F5E;65N=',N)B,Q-C`[($EN(&%D9&ET:6]N+"!F
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M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4
M.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
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M;F1I=&EO;G,@9&5T97)I;W)A=&4N)B,Q-C`[($EN(&%D9&ET:6]N+"!T:&4@
M0V]M<&%N>28C.#(Q-SMS(&%B:6QI='D@=&\@<F%I<V4@861D:71I;VYA;"!F
M:6YA;F-I;F<@:7,@;&EM:71E9"!B>2!T:&4@=&5R;7,@;V8@:71S(&%G<F5E
M;65N="!A;F0@<&QA;B!O9B!M97)G97(@=VET:"!!3DDN)B,Q-C`[(%-E92!.
M;W1E(#$P+"`F(S@R,C`[4W5B<V5Q=65N="!%=F5N=',N)B,X,C(Q.R8C,38P
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M;&EQ=6ED871I;F<@=&AE($-O;7!A;GDN)B,Q-C`[($EN('-U8V@@8V%S92P@
M=&AE($-O;7!A;GDF(S@R,3<[<R!S=&]C:VAO;&1E<G,@8V]U;&0@;&]S92!S
M;VUE(&]R(&%L;"!O9B!T:&5I<B!I;G9E<W1M96YT+CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@
M,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(S8S0Y.3)?-C0Y,5\T.3@U7S@Y9C5?
M,#,X.34U-C-D.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R
M,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU,2]7;W)K<VAE971S
M+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY"05-)0R!!3D0@1$E,551%1"!.150@3$]34R!015(@4TA!4D4\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"
M05-)0R!!3D0@1$E,551%1"!.150@3$]34R!015(@4TA!4D4\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0D%324,@04Y$($1)
M3%54140@3D54($Q/4U,@4$52(%-(05)%/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE.C$P<'0[(&9O
M;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG+'1I;65S+'-E<FEF.R<^#0H\
M='(^#0H\=&0^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N
M-6EN.R!415A4+4E.1$5.5#H@+3`N-6EN)SX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q,'!T)R!S:7IE/3-$,CY"05-)
M0R!!3D0@1$E,551%1"!.150@3$]34R!015(@4TA!4D4\+V9O;G0^/"]B/CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%
M6%0M24Y$14Y4.B`M,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY4:&4@8F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R('-H
M87)E(&ES(&-O;7!U=&5D(&)A<V5D(&]N('1H92!W96EG:'1E9"!A=F5R86=E
M(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%N9"!C;&%S<R!#
M('-P96-I86P@<W1O8VL@;W5T<W1A;F1I;F<L(&%L;"!B96EN9R!C;VYS:61E
M<F5D(&%S(&5Q=6EV86QE;G0@;V8@;VYE(&%N;W1H97(N)B,Q-C`[($)A<VEC
M(&YE="!L;W-S('!E<B!S:&%R92!I<R!C;VUP=71E9"!B>2!D:79I9&EN9R!T
M:&4@;F5T(&QO<W,@8GD@=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F
M('-H87)E<R!O=71S=&%N9&EN9R!F;W(@=&AE(')E<&]R=&EN9R!P97)I;V0N
M)B,Q-C`[($1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E(&ES(&EN=&5N9&5D
M('1O(')E9FQE8W0@=&AE('!O=&5N=&EA;"!D:6QU=&EO;B!T:&%T(&-O=6QD
M(&]C8W5R(&EF('-E8W5R:71I97,@;W(@;W1H97(@8V]N=')A8W1S('1O(&ES
M<W5E(&-O;6UO;B!S=&]C:R!W97)E(&5X97)C:7-E9"!O<B!C;VYV97)T960@
M:6YT;R!C;VUM;VX@<W1O8VLN)B,Q-C`[($)E8V%U<V4@=&AE($-O;7!A;GD@
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M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^
M/"]T<CX\+W1A8FQE/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3E9%
M4E1)0DQ%(%-%3DE/4B!.3U1%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-/3E9%4E1)0DQ%(%-%3DE/4B!.3U1%
M4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M3TY615)424),12!314Y)3U(@3D]415,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<L=&EM97,L<V5R:68[)SX-"CQT
M<CX-"CQT9#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,S<N
M,#5P=#L@5$585"U)3D1%3E0Z("TP+C5I;B<^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-2X\+V9O;G0^/"]B/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z
M(#-P="<@<VEZ93TS1#$^)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[(#PO9F]N=#X\+V(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P="<@<VEZ93TS1#(^0T].
M5D525$E"3$4@4T5.24]2($Y/5$53/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#,W+C`U<'0[(%1%6%0M24Y$14Y4
M.B`M,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4
M:&4@0V]M<&%N>2!H87,@;W5T<W1A;F1I;F<@,RXQ,C4E(&-O;G9E<G1I8FQE
M('-E;FEO<B!N;W1E<R!D=64@36%Y)B,Q-C`[,2P@,C`Q,R`H=&AE(#(P,3,@
M3F]T97,I+B8C,38P.R!4:&4@86=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0@
M;V8@=&AE(#(P,3,@3F]T97,@;W5T<W1A;F1I;F<@870@4V5P=&5M8F5R)B,Q
M-C`[,S`L(#(P,3(@86YD($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$@=V%S("0X
M+#(W-RPX-3`@86YD("0R,"PW.#(L,#`P+"!R97-P96-T:79E;'DN)B,Q-C`[
M($EN($9E8G)U87)Y)B,Q-C`[,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D(#$L
M.#8X+#`U-2!S:&%R97,@;V8@:71S(&-O;6UO;B!S=&]C:R!T;R!O;F4@;V8@
M=&AE(&AO;&1E<G,@;V8@=&AE(#(P,3,@3F]T97,@:6X@97AC:&%N9V4@9F]R
M('1H92!C86YC96QL871I;VX@;V8@)#DL,#`P+#`P,"!I;B!A9V=R96=A=&4@
M<')I;F-I<&%L(&%M;W5N="!O9B!S=6-H(&YO=&5S(&%N9"!T:&4@<F5L871E
M9"!A8V-R=65D(&%N9"!U;G!A:60@:6YT97)E<W0@;V8@)#<Y+#`R-"XF(S$V
M,#L@26X@2G5L>28C,38P.S(P,3(L('1H92!#;VUP86YY(&ES<W5E9"!A;B!A
M9V=R96=A=&4@;V8@,2PW.#0L,#<P('-H87)E<R!O9B!I=',@8V]M;6]N('-T
M;V-K('1O('1W;R!O9B!T:&4@:&]L9&5R<R!O9B!T:&4@,C`Q,R!.;W1E<R!I
M;B!E>&-H86YG92!F;W(@=&AE(&-A;F-E;&QA=&EO;B!O9B`D,RPU,#0L,34P
M(&EN(&%G9W)E9V%T92!P<FEN8VEP86P@86UO=6YT(&]F('-U8V@@;F]T97,@
M86YD(&%C8W)U960@86YD('5N<&%I9"!I;G1E<F5S="!O9B`D,C`L-C@V+B!.
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M9B!T:&4@,C`Q,R!.;W1E<R!I<R!P<FEM87)I;'D@871T<FEB=71A8FQE('1O
M('1H92!T:6UE('9A;'5E(&5F9F5C="!O9B!S971T;&EN9R!T:&5S92!O8FQI
M9V%T:6]N<R!A="!A(&1A=&4@<')I;W(@=&\@=&AE('-T871E9"!M871U<FET
M>2!O9B!T:&4@,C`Q,R!.;W1E<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU
M:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE(')E;6%I;FEN9R`D
M."PR-S<L.#4P(&%G9W)E9V%T92!P<FEN8VEP86P@86UO=6YT(&]F('1H92`R
M,#$S($YO=&5S(&%R92!E>&-H86YG96%B;&4@870@=&AE(&]P=&EO;B!O9B!T
M:&4@:&]L9&5R(&]R('5P;VX@8V5R=&%I;B!S<&5C:69I960@979E;G1S(&EN
M=&\@86X@86=G<F5G871E(&]F(&%P<')O>&EM871E;'D@,S<P+#@W,2!S:&%R
M97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@870@82!C
M;VYV97)S:6]N('!R:6-E(&]F("0R,BXS,B!P97(@<VAA<F4N)B,Q-C`[(%1H
M92`R,#$S($YO=&5S(&%R92!G96YE<F%L+"!U;G-E8W5R960@;V)L:6=A=&EO
M;G,@;V8@=&AE($-O;7!A;GD@86YD(&%R92!D97-C<FEB960@:6X@3F]T92`W
M('1O('1H92!#;VUP86YY)B,X,C$W.W,@9FEN86YC:6%L('-T871E;65N=',@
M9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R)B,Q-C`[,S$L(#(P,3$N)B,Q
M-C`[($%S(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R+"!T:&4@,C`Q,R!.
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M<')O=&5C="!T:&4@:&]L9&5R<R!O9B!T:&4@,C`Q,R!.;W1E<R!I;B!T:&4@
M979E;G0@;V8@82!H:6=H;'D@;&5V97)A9V5D('1R86YS86-T:6]N(&]R(&$@
M9G5N9&%M96YT86P@8VAA;F=E(&]F('1H92!#;VUP86YY(&5X8V5P="!I;B!C
M97)T86EN(&-I<F-U;7-T86YC97,@<W!E8VEF:65D(&EN('1H92!I;F1E;G1U
M<F4N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#,U+C%P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY!<R!D97-C<FEB960@:6X@3F]T92`S+"`F(S@R,C`[
M3&EQ=6ED:71Y(&%N9"!#87!I=&%L(%)E<V]U<F-E<RPF(S@R,C$[(&9R;VT@
M=&EM92!T;R!T:6UE+"!T:&4@0V]M<&%N>2!M87D@<'5R8VAA<V4L(&5X8VAA
M;F=E(&]R(')E<W1R=6-T=7)E(&ET<R!O=71S=&%N9&EN9R`R,#$S($YO=&5S
M('1H<F]U9V@@8V%S:"!P=7)C:&%S97,@86YD+V]R(&5X8VAA;F=E<R!F;W(@
M;W1H97(@97%U:71Y('-E8W5R:71I97,@;V8@=&AE($-O;7!A;GDL(&EN(&]P
M96X@;6%R:V5T('!U<F-H87-E<RP@<')I=F%T96QY(&YE9V]T:6%T960@=')A
M;G-A8W1I;VYS(&%N9"]O<B!A('1E;F1E<B!O9F9E<BX\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z
M(#,U+C%P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#,U+C%P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4
M:&4@0V]M<&%N>2!H87,@96QE8W1E9"!T;R!R96-O<F0@=&AE(#(P,3,@3F]T
M97,@870@9F%I<B!V86QU92!I;B!O<F1E<B!T;R!S:6UP;&EF>2!T:&4@86-C
M;W5N=&EN9R!F;W(@=&AE(&-O;G9E<G1I8FQE(&1E8G0L(&EN8VQU<VEV92!O
M9B!T:&4@<F5D96UP=&EO;BP@<F5P=7)C:&%S92!A;F0@8V]N=F5R<VEO;B!A
M9&IU<W1M96YT(&9E871U<F5S('=H:6-H(&]T:&5R=VES92!W;W5L9"!R97%U
M:7)E('-P96-I86QI>F5D('9A;'5A=&EO;BP@8FEF=7)C871I;VX@86YD(')E
M8V]G;FET:6]N+B8C,38P.R!!8V-O<F1I;F=L>2P@=&AE($-O;7!A;GD@:&%S
M(&%D:G5S=&5D('1H92!C87)R>6EN9R!V86QU92!O9B!T:&4@,C`Q,R!.;W1E
M<R!T;R!T:&5I<B!F86ER('9A;'5E(&%S(&]F(%-E<'1E;6)E<B8C,38P.S,P
M+"`R,#$R+"!W:71H(&-H86YG97,@:6X@=&AE(&9A:7(@=F%L=64@;V8@=&AE
M(#(P,3,@3F]T97,@;V-C=7)R:6YG('-I;F-E($1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,3$L(')E9FQE8W1E9"!I;B!F86ER('9A;'5E(&%D:G5S=&UE;G0@:6X@
M=&AE('5N875D:71E9"!C;VYD96YS960@<W1A=&5M96YT<R!O9B!O<&5R871I
M;VYS+B8C,38P.R!!<R!D97-C<FEB960@:6X@3F]T92`Y+"`F(S@R,C`[1F%I
M<B!686QU92!-96%S=7)E;65N=',L)B,X,C(Q.R!T:&4@9F%I<B!V86QU92!O
M9B!T:&4@,C`Q,R!.;W1E<R!I<R!B87-E9"!O;B!,979E;"`R(&EN<'5T<RXF
M(S$V,#L@5&AE(')E8V]R9&5D(&9A:7(@=F%L=64@;V8@=&AE(#(P,3,@3F]T
M97,@;V8@86X@86=G<F5G871E(&]F("0W+#4Y,RPR,38@87,@;V8@4V5P=&5M
M8F5R)B,Q-C`[,S`L(#(P,3(@9&EF9F5R<R!F<F]M('1H96ER('1O=&%L('-T
M871E9"!A9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N="!O9B`D."PR-S<L.#4P
M(&%S(&]F('-U8V@@9&%T92!B>2`D-C@T+#8S-"XF(S$V,#L@5&AE(')E8V]R
M9&5D(&9A:7(@=F%L=64@;V8@=&AE(#(P,3,@3F]T97,@;V8@86X@86=G<F5G
M871E(&]F("0Q-RPS,S8L-S8P(&%S(&]F($1E8V5M8F5R)B,Q-C`[,S$L(#(P
M,3$@9&EF9F5R960@9G)O;2!T:&5I<B!T;W1A;"!S=&%T960@86=G<F5G871E
M('!R:6YC:7!A;"!A;6]U;G0@;V8@)#(P+#<X,BPP,#`@87,@;V8@<W5C:"!D
M871E(&)Y("0S+#0T-2PR-#`N)B,Q-C`[($1U<FEN9R!T:&4@=&AR964@86YD
M(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R+"!T
M:&4@0V]M<&%N>2!R96-O<F1E9"!A(&9A:7(@=F%L=64@861J=7-T;65N="!O
M9B`D*#@T,RPT,3(I(&%N9"`D*#0L,#,W+#<Y-RD@<F5L871E9"!T;R!T:&4@
M,C`Q,R!.;W1E<R!T:&%T('=E<F4@8V]N=F5R=&5D('1O(&-O;6UO;B!S=&]C
M:R!D=7)I;F<@,C`Q,B!O<B!T:&%T(')E;6%I;F5D(&]U='-T86YD:6YG(&%S
M(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R+"!T:&%T(&9O<B!T:&4@=&AR
M964@;6]N=&AS(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V
M,#LS,"P@,C`Q,B!I;F-R96%S960@=&AE(')E8V]R9&5D(&QI86)I;&ET>2!A
M;F0@8V]R<F5S<&]N9&EN9R!E>'!E;G-E+B8C,38P.R!&;W(@=&AE('1H<F5E
M(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q
M,2P@=&AE($-O;7!A;GD@<F5C;W)D960@82!F86ER('9A;'5E(&%D:G5S=&UE
M;G0@;V8@)#0V,RPP,#`@86YD("0H,2PY,CDL,#`P*2!T:&%T(&1E8W)E87-E
M9"!A;F0@:6YC<F5A<V5D('1H92!R96-O<F1E9"!L:6%B:6QI='D@86YD(&-O
M<G)E<W!O;F1I;F<@97AP96YS92P@<F5S<&5C=&EV96QY+CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
M5#H@,S4N,7!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M1F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@
M,C`Q,B!A;F0@,C`Q,2P@87!P<F]X:6UA=&5L>2`D*#0Q+#`P,"D@86YD("0R
M,S`L,#`P+"!R97-P96-T:79E;'DL(&]F('1H92!F86ER('9A;'5E(&%D:G5S
M=&UE;G0@=V%S(&%T=')I8G5T86)L92!T;R!T:&4@8VAA;F=E(&EN(&EN<W1R
M=6UE;G0@<W!E8VEF:6,@8W)E9&ET(')I<VLN)B,Q-C`[(%1H92!C:&%N9V4@
M:6X@=&AE(&%G9W)E9V%T92!F86ER('9A;'5E(&]F('1H92`R,#$S($YO=&5S
M(&1U92!T;R!I;G-T<G5M96YT('-P96-I9FEC(&-R961I="!R:7-K(&9O<B!T
M:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P,3(@
M=V%S(&5S=&EM871E9"!B>2!C86QC=6QA=&EN9R!T:&4@9&EF9F5R96YC92!B
M971W965N('1H92!397!T96UB97(F(S$V,#LS,"P@,C`Q,B!F86ER('9A;'5E
M(&]F('1H92`R,#$S($YO=&5S(&%S(')E8V]R9&5D(&%N9"!W:&%T('1H92!F
M86ER('9A;'5E(&]F('1H92`R,#$S($YO=&5S('=O=6QD(&AA=F4@8F5E;B!O
M;B!397!T96UB97(F(S$V,#LS,"P@,C`Q,B!I9B!T:&4@1&5C96UB97(F(S$V
M,#LS,2P@,C`Q,2!D:7-C;W5N="!R871E(&-O;G1I;G5E9"!T;R!B92!U<V5D
M(&EN('1H92!C86QC=6QA=&EO;BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU
M:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE(&EN<W1R=6UE;G0@
M<W!E8VEF:6,@8W)E9&ET(')I<VL@9F]R(&)O=&@@<&5R:6]D<R!H87,@:6YC
M<F5A<V5D('1H92!F86ER('9A;'5E(&]F('1H92`R,#$S($YO=&5S(&%S(&UA
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M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^5&AE($-O;7!A;GD@97-T86)L:7-H97,@=&AE('9A;'5E(&]F
M('1H92`R,#$S($YO=&5S(&)A<V5D('5P;VX@8V]N=')A8W1U86P@=&5R;7,@
M;V8@=&AE(#(P,3,@3F]T97,L(&%S('=E;&P@87,@8V5R=&%I;B!K97D@87-S
M=6UP=&EO;G,N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/E1H92!A<W-U;7!T:6]N<R!A<R!O9B!397!T
M96UB97(F(S$V,#LS,"P@,C`Q,B!W97)E.CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%2
M1TE.+4Q%1E0Z(#%I;CL@5TE$5$@Z(#8P)3L@0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#8P)2!B;W)D97(],T0P/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`W-"XQ."4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#<T)2!B
M9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS
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M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#(P)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,C`E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXP+C$T/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C8V)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-S0N,3@E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0W-"4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$
M14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY6;VQA=&EL
M:71Y(&]F($)I;U-A;G1E(&-O;6UO;B!S=&]C:SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-"XQ-B4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,C`E.R!0041$24Y'+51/4#H@
M,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,"4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/CDP+C`\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$
M5$@Z(#$N-C8E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X\
M+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`W-"XQ."4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#<T)2!B9V-O;&]R/3-$(T-#145&
M1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$58
M5"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D1I
M<V-O=6YT(')A=&4@9F]R('!R:6YC:7!A;"!P87EM96YT<R!I;B!C87-H/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`T+C$V)3L@4$%$1$E.1RU43U`Z
M(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`R,"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(P)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3DN-CPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XV-B4[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE/"]F;VYT/CPO<#X\+W1D/CPO='(^
M/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/E1H92!A<W-U;7!T:6]N<R!A<R!O9B!$96-E;6)E<B8C,38P.S,Q
M+"`R,#$Q('=E<F4Z/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`Q:6X[(%=)1%1(.B`V,"4[($)/4D1%4BU#3TQ,
M05!313H@8V]L;&%P<V4G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0V,"4@8F]R9&5R/3-$,#X-"CQT<CX-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M-S0N,3@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0W-"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!=F5R86=E)B,Q-C`[<FES:RUF<F5E
M)B,Q-C`[<F%T93PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-"XQ-B4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,C`E.R!0041$24Y'+51/4#H@,&EN
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,"4@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
M24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/C`N,3D\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N-C8E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)3PO9F]N=#X\
M+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`W-"XQ."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#<T)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/E9O;&%T:6QI='D@;V8@0FEO4V%N=&4@8V]M;6]N('-T
M;V-K/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`T+C$V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`R,"4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(P)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^-S<N-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XV-B4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXE/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#<T
M+C$X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M-S0E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T
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M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(P)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E(&)G8V]L;W(]
M,T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXQ."XU/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`Q+C8V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4\
M+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS
M1&-E;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4E.1$5.5#H@,S0N-35P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
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M:6P@=&AE(&1E8G0@;6%T=7)I='DN)B,Q-C`[(%1H92!R:7-K+69R964@<F%T
M92!I<R!B87-E9"!O;B!O8G-E<G9E9"!Y:65L9',@87,@;V8@=&AE(&UE87-U
M<F5M96YT(&1A=&4@;V8@<VEX(&UO;G1H(&%N9"!O;F4M>65A<B!5+E,N(%1R
M96%S=7)Y($)O;F1S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,S0N-35P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX\
M+W1A8FQE/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-43T-++4)!4T5$
M($-/35!%3E-!5$E/3CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-43T-++4)!4T5$($-/35!%3E-!5$E/3CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y35$]#2RU"
M05-%1"!#3TU014Y3051)3TX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI
M;'DZ)U1I;65S($YE=R!2;VUA;B<L=&EM97,L<V5R:68[)SX-"CQT<CX-"CQT
M9#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[(%1%
M6%0M24Y$14Y4.B`M,"XU:6XG/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/C8N/"]F;VYT/CPO8CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`S<'0G('-I
M>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R`\+V9O;G0^/"]B/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/E-43T-++4)!4T5$
M($-/35!%3E-!5$E/3CPO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="`P+C5I;CL@5$585"U)3D1%3E0Z("TP+C5I;B<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z
M(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
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M(%!L86X@*'1H92`R,#`X(%!L86XI+B8C,38P.R!!<R!O9B!397!T96UB97(F
M(S$V,#LS,"P@,C`Q,BP@87!P<F]X:6UA=&5L>2`Y.#$L,C<R('-H87)E<R!O
M9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!R96UA:6X@879A
M:6QA8FQE(&9O<B!I<W-U86YC92!U;F1E<B!T:&4@,C`P."!0;&%N+CPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY$=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C
M,38P.S,P+"`R,#$R+"!T:&4@0V]M<&%N>2!G<F%N=&5D(&]P=&EO;G,@=6YD
M97(@=&AE(#(P,#@@4&QA;B!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@
M,S4X+#4X,B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@
M<W1O8VL@=&\@8V5R=&%I;B!E;7!L;WEE97,@;V8@=&AE($-O;7!A;GD@86YD
M('1H92!#;VUP86YY)B,X,C$W.W,@;F]N+65M<&QO>65E(&1I<F5C=&]R<R!W
M:71H(&$@=V5I9VAT960@879E<F%G92!E>&5R8VES92!P<FEC92!O9B`D-"XP
M."!P97(@<VAA<F4N)B,Q-C`[($]P=&EO;G,@=&\@<'5R8VAA<V4@86X@86=G
M<F5G871E(&]F(#$P-2PW.#$@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W
M.W,@8V]M;6]N('-T;V-K(&5X<&ER960@86YD('=E<F4@8V%N8V5L;&5D(&1U
M<FEN9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L
M(#(P,3(N)B,Q-C`[($]P=&EO;G,@87)E(&=R86YT960@870@86X@97AE<F-I
M<V4@<')I8V4@97%U86P@=&\@=&AE(&-L;W-I;F<@<')I8V4@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@;VX@=&AE(&1A=&4@;V8@=&AE
M(&=R86YT+B8C,38P.R!.;R!O<'1I;VYS('=E<F4@97AE<F-I<V5D(&1U<FEN
M9R!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B,Q-C`[,S`L(#(P
M,3(N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/DYO('=A<G)A;G1S('=E<F4@9W)A;G1E9"!D=7)I;F<@
M=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R
M+"!O=&AE<B!T:&%N('1H92!W87)R86YT<R!I<W-U960@:6X@8V]N:G5N8W1I
M;VX@=VET:"!T:&4@0V]M<&%N>28C.#(Q-SMS($%U9W5S="8C,38P.S(P,3(@
M;V9F97)I;F<@9&5S8W)I8F5D(&EN($YO=&4@-RP@)B,X,C(P.U-T;V-K:&]L
M9&5R<R8C.#(Q-SL@17%U:71Y)B,X,C(Q.RX\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X\+W1R/CPO=&%B;&4^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU
M-38S9#DU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C-C-#DY
M,E\V-#DQ7S0Y.#5?.#EF-5\P,S@Y-34V,V0Y-3$O5V]R:W-H965T<R]3:&5E
M=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4U1/0TM(3TQ$15)3)R!%455)5%D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY35$]#2TA/3$1%4E,G($5154E463PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y35$]#
M2TA/3$1%4E,G($5154E463PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3HG5&EM97,@3F5W(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R/@T*/'1D
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="`S-RXP-7!T.R!415A4+4E.1$5.5#H@
M+3`N-6EN)SX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
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M5"U325I%.B`Q,'!T)R!S:7IE/3-$,CY35$]#2TA/3$1%4E,F(S@R,3<[($51
M54E463PO9F]N=#X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="`S-RXP-7!T.R!415A4+4E.1$5.5#H@+3`N-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^1'5R:6YG('1H92!N:6YE(&UO
M;G1H<R!E;F1E9"!397!T96UB97(F(S$V,#LS,"P@,C`Q,BP@=&AE($-O;7!A
M;GD@:7-S=65D(&%N(&%G9W)E9V%T92!O9B`S+#8U,BPQ,C4@<VAA<F5S(&]F
M(&ET<R!C;VUM;VX@<W1O8VL@=&\@:&]L9&5R<R!O9B!T:&4@,C`Q,R!.;W1E
M<R!I;B!E>&-H86YG92!F;W(@=&AE(&-A;F-E;&QA=&EO;B!O9B`D,3(L-3`T
M+#$U,"!I;B!A9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N="!O9B!S=6-H(&YO
M=&5S(&%N9"!A8V-R=65D(&%N9"!U;G!A:60@:6YT97)E<W0@;V8@)#DY+#<Q
M,"X@4V5E($YO=&4@-2P@)B,X,C(P.T-O;G9E<G1I8FQE(%-E;FEO<B!.;W1E
M<R8C.#(R,3L@9F]R(&EN9F]R;6%T:6]N(')E9V%R9&EN9R!T:&4@,C`Q,R!.
M;W1E<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,S8N-W!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/DEN($%U9W5S="8C,38P.S(P,3(L('1H92!#;VUP
M86YY(&-O;7!L971E9"!A;B!O9F9E<FEN9R!O9B`R+#,U.2PY,S(@<VAA<F5S
M(&]F(&ET<R!C;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S('1O('!U<F-H87-E
M(&%N(&%G9W)E9V%T92!O9B`Q+#$W.2PY-C8@<VAA<F5S(&]F(&ET<R!C;VUM
M;VX@<W1O8VL@870@82!P=7)C:&%S92!P<FEC92!O9B`D,2XT-S(U('!E<B!S
M:&%R92!T;R!O;F4@:6YS=&ET=71I;VYA;"!I;G9E<W1O<B!F;W(@9W)O<W,@
M<')O8V5E9',@;V8@)#,L-#<U+#`P,"XF(S$V,#L@5&AE(&]F9F5R:6YG(')E
M<W5L=&5D(&EN(&YE="!P<F]C965D<R!T;R!T:&4@0V]M<&%N>2!O9B`D,RPR
M-C@L-SDX+"!A9G1E<B!D961U8W1I;F<@<&QA8V5M96YT(&%G96YT(&9E97,@
M86YD(&]F9F5R:6YG(&5X<&5N<V5S+B!4:&4@=V%R<F%N=',@87)E(&5X97)C
M:7-A8FQE(&EM;65D:6%T96QY(&%N9"!C;VYT:6YU92!F;W(@82!P97)I;V0@
M;V8@-2!Y96%R<RP@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#$N-3`@<&5R
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M96UB97(F(S$V,#LR,"P@,C`Q,BP@=V%R<F%N=',@9G)O;2!T:&4@075G=7-T
M)B,Q-C`[,C`Q,B!O9F9E<FEN9R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@
M;V8@,30P+#<Q,B!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=E<F4@97AE<F-I
M<V5D(')E<W5L=&EN9R!I;B!P<F]C965D<R!O9B`D,C$Q+#`V."!T;R!T:&4@
M0V]M<&%N>2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U)3D1%3E0Z(#,V+C=P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#,V+C=P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY/;B!-87DF(S$V,#LS,"P@,C`Q,BP@=&AE
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M96XN)B,Q-C`[($]N($IU;F4F(S$V,#LQ+"`R,#$R+"!T:&4@0F]A<F0@;V8@
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M<W1O8VL@;VX@2G5N92`Q+"`R,#$R+B8C,38P.R!4:&4@=&]T86P@8V%S:"!P
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M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^
M/"]T86)L93X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?.#(S8S0Y.3)?-C0Y,5\T.3@U7S@Y9C5?,#,X.34U-C-D.34Q#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,V,T.3DR7S8T.3%?-#DX
M-5\X.68U7S`S.#DU-38S9#DU,2]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TU-251-14Y4
M4R!!3D0@0T].5$E.1T5.0TE%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-/34U)5$U%3E13($%.1"!#3TY424Y'
M14Y#2453/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-/34U)5$U%3E13($%.1"!#3TY424Y'14Y#2453/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@<W1Y;&4],T0G9F]N="US:7IE
M.C$P<'0[(&9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG+'1I;65S+'-E
M<FEF.R<^#0H\='(^#0H\=&0^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#,W+C`U
M<'0[(%1%6%0M24Y$14Y4.B`M,"XU:6XG/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C@N/"]F;VYT/CPO8CX\8CX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`S
M<'0G('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R`\+V9O;G0^/"]B/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/D-/34U)
M5$U%3E13($%.1"!#3TY424Y'14Y#2453/"]F;VYT/CPO8CX\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#,W+C`U<'0[(%1%6%0M24Y$
M14Y4.B`M,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&D^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%P=&%R(%!H87)M82`F(S@R,3([
M($=E;"!086-K86=I;F<@36%C:&EN93PO9F]N=#X\+VD^/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
M5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A
M;GD@:&%S(&$@8V]M;6ET;65N="!W:71H($%P=&%R(%!H87)M82!T;R!P=7)C
M:&%S92!A(&=E;"!P86-K86=I;F<@;6%C:&EN92!F;W(@)#@T-"PW-#`N($%S
M(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R+"!T:&4@0V]M<&%N>2!H860@
M<&%I9"!!<'1A<B`D.#`T+#$S,BXF(S$V,#L@5&AE(')E;6%I;FEN9R!O8FQI
M9V%T:6]N(&]F("0T,"PV,#@@:7,@9'5E('5P;VX@=&AE('-H:7!M96YT+"!A
M<W-E;6)L>2!A;F0@8V%L:6)R871I;VX@;V8@=&AE(&UA8VAI;F4@870@82!L
M;V-A=&EO;B!D97-I9VYA=&5D(&)Y('1H92!#;VUP86YY+B8C,38P.R!);B!L
M:6=H="!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS('!E;F1I;F<@;65R9V5R('=I
M=&@@04Y)("AS964@3F]T92`Q,"P@)B,X,C(P.U-U8G-E<75E;G0@179E;G1S
M)B,X,C(Q.RDL('1H92!#;VUP86YY(&ES(&5V86QU871I;F<@=&AE(&9U='5R
M92!P;&%N<R!F;W(@=&AI<R!G96P@<&%C:V%G:6YG(&UA8VAI;F4N/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\:3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^4&5N9&EN9R!,:71I9V%T:6]N
M/"]F;VYT/CPO:3X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
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M:6-A;',L)B,Q-C`[26YC+B!A;F0@4W1E<&AE;B!-+B!3:6UE<SPO:3X@;F%M
M:6YG('1H92!#;VUP86YY(&%N9"!T:&4@0V]M<&%N>28C.#(Q-SMS(%!R97-I
M9&5N="!A;F0@0VAI968@17AE8W5T:79E($]F9FEC97(L(%-T97!H96X@32X@
M4VEM97,L(&%S(&1E9F5N9&%N=',N)B,Q-C`[(%1H92!C;VUP;&%I;G0@86QL
M96=E<R!T:&%T(&-E<G1A:6X@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!D:7-C
M;&]S=7)E<R!R96QA=&EN9R!T;R!T:&4@969F:6-A8WD@;V8@3&EB:4=E;"!A
M;F0@:71S(&-O;6UE<F-I86P@<&]T96YT:6%L('=E<F4@9F%L<V4@86YD+V]R
M(&UI<VQE861I;F<@86YD('1H870@<W5C:"!F86QS92!A;F0O;W(@;6ES;&5A
M9&EN9R!S=&%T96UE;G1S(&AA9"!T:&4@969F96-T(&]F(&%R=&EF:6-I86QL
M>2!I;F9L871I;F<@=&AE('!R:6-E(&]F('1H92!#;VUP86YY)B,X,C$W.W,@
M<V5C=7)I=&EE<R!R97-U;'1I;F<@:6X@=FEO;&%T:6]N<R!O9B!396-T:6]N
M)B,Q-C`[,3`H8BDF(S$V,#MO9B!T:&4@4V5C=7)I=&EE<R!%>&-H86YG92!!
M8W0@;V8@,3DS-"P@87,@86UE;F1E9"`H17AC:&%N9V4@06-T*2P@4G5L928C
M,38P.S$P8BTU(&%N9"!396-T:6]N)B,Q-C`[,C`H82DF(S$V,#MO9B!T:&4@
M17AC:&%N9V4@06-T+B8C,38P.R!!;'1H;W5G:"!A('-U8G-T86YT:6%L;'D@
M<VEM:6QA<B!C;VUP;&%I;G0@=V%S(&9I;&5D(&EN('1H92!S86UE(&-O=7)T
M(&]N($9E8G)U87)Y)B,Q-C`[,C$L(#(P,3(L('-U8V@@8V]M<&QA:6YT('=A
M<R!V;VQU;G1A<FEL>2!D:7-M:7-S960@8GD@=&AE('!L86EN=&EF9B!I;B!!
M<')I;"8C,38P.S(P,3(N)B,Q-C`[(%1H92!P;&%I;G1I9F8@<V5E:W,@=&\@
M<F5P<F5S96YT(&$@8VQA<W,@;V8@<&5R<V]N<R!W:&\@<'5R8VAA<V5D('1H
M92!#;VUP86YY)B,X,C$W.W,@<V5C=7)I=&EE<R!B971W965N($9E8G)U87)Y
M)B,Q-C`[,3`L(#(P,3`@86YD($1E8V5M8F5R)B,Q-C`[,34L(#(P,3$L(&%N
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M-C`[($]N($]C=&]B97(F(S$V,#LQ,"P@,C`Q,BP@=&AE($1I<W1R:6-T($-O
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M+"`R,#$R+"!P;&%I;G1I9F8@9FEL960@82!C;VYS;VQI9&%T960@86UE;F1E
M9"!C;VUP;&%I;G0[('1H92!#;VUP86YY(&%N9"!-<BX@4VEM97,@:6YT96YD
M('1O(&9I;&4@;6]T:6]N<R!T;R!D:7-M:7-S('1H92!C;VYS;VQI9&%T960@
M86UE;F1E9"!C;VUP;&%I;G0@;VX@;W(@8F5F;W)E($1E8V5M8F5R)B,Q-C`[
M,C$L(#(P,3(N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/D]N($UA>28C,38P.S<L(#(P,3(L($IE<F]M
M92!7+B!796EN<W1E:6XL(&$@<'5R<&]R=&5D('-T;V-K:&]L9&5R(&]F('1H
M92!#;VUP86YY(&9I;&5D(&$@<VAA<F5H;VQD97(@9&5R:79A=&EV92!A8W1I
M;VX@:6X@=&AE(%5N:71E9"!3=&%T97,@1&ES=')I8W0@0V]U<G0@9F]R('1H
M92!.;W)T:&5R;B!$:7-T<FEC="!O9B!);&QI;F]I<R!U;F1E<B!T:&4@8V%P
M=&EO;B`\:3Y796EN<W1E:6X@=BX@0FEO4V%N=&4@4&AA<FUA8V5U=&EC86QS
M+"8C,38P.TEN8RX@970@86PN/"]I/BP@;F%M:6YG('1H92!#;VUP86YY)B,X
M,C$W.W,@9&ER96-T;W)S(&%S(&1E9F5N9&%N=',@86YD('1H92!#;VUP86YY
M(&%S(&$@;F]M:6YA;"!D969E;F1A;G0N)B,Q-C`[($$@<W5B<W1A;G1I86QL
M>2!S:6UI;&%R(&-O;7!L86EN="!W87,@9FEL960@:6X@=&AE('-A;64@8V]U
M<G0@;VX@36%Y)B,Q-C`[,C(L(#(P,3(@86YD(&%N;W1H97(@<W5B<W1A;G1I
M86QL>2!S:6UI;&%R(&-O;7!L86EN="!W87,@9FEL960@:6X@=&AE($-I<F-U
M:70@0V]U<G0@9F]R($-O;VL@0V]U;G1Y+"!);&QI;F]I<RP@0V]U;G1Y($1E
M<&%R=&UE;G0L($-H86YC97)Y($1I=FES:6]N+"!O;B!*=6YE)B,Q-C`[,C<L
M(#(P,3(N)B,Q-C`[(%1H92!S=6ET<R!G96YE<F%L;'D@<F5L871E9"!T;R!T
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M<FEN9R!F<F]M(&%T(&QE87-T($9E8G)U87)Y)B,Q-C`[,C`Q,"!T:')O=6=H
M($1E8V5M8F5R)B,Q-C`[,C`Q,2XF(S$V,#L@5&AE(&-O;7!L86EN=',@<V5E
M:R!U;G-P96-I9FEE9"!D86UA9V5S+"!P=6YI=&EV92!D86UA9V5S+"!C;W-T
M<R!A;F0@9&ES8G5R<V5M96YT<R!A;F0@=6YS<&5C:69I960@<F5F;W)M(&%N
M9"!I;7!R;W9E;65N=',@:6X@=&AE($-O;7!A;GDF(S@R,3<[<R!C;W)P;W)A
M=&4@9V]V97)N86YC92!A;F0@:6YT97)N86P@8V]N=')O;"!P<F]C961U<F5S
M+B8C,38P.R!/;B!397!T96UB97(F(S$V,#LR-"P@,C`Q,BP@=&AE($1I<W1R
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M(&-O=7)T+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
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M;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL
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M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(S8S0Y.3)?-C0Y,5\T
M.3@U7S@Y9C5?,#,X.34U-C-D.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU,2]7
M;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY&04E2(%9!3%5%($U%05-54D5-14Y44SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9!25(@
M5D%,544@345!4U5214U%3E13/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9!25(@5D%,544@345!4U5214U%3E13/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@<W1Y;&4],T0G9F]N
M="US:7IE.C$P<'0[(&9O;G0M9F%M:6QY.B=4:6UE<R!.97<@4F]M86XG+'1I
M;65S+'-E<FEF.R<^#0H\='(^#0H\=&0^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T(#,W+C`U<'0[(%1%6%0M24Y$14Y4.B`M,"XU:6XG/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/CDN/"]F;VYT/CPO8CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`S<'0G('-I>F4],T0Q/B8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R`\+V9O;G0^/"]B/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P
M<'0G('-I>F4],T0R/D9!25(@5D%,544@345!4U5214U%3E13/"]F;VYT/CPO
M8CX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#,W+C`U
M<'0[(%1%6%0M24Y$14Y4.B`M,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
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M<V-R:6)E9"!B96QO=SH\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3&5V96P@,3HF(S$V,#L@475O=&5D
M('!R:6-E<R`H=6YA9&IU<W1E9"D@:6X@86-T:79E(&UA<FME=',@=&AA="!A
M<F4@86-C97-S:6)L92!A="!T:&4@;65A<W5R96UE;G0@9&%T92!F;W(@87-S
M971S(&]R(&QI86)I;&ET:65S+B8C,38P.R!4:&4@9F%I<B!V86QU92!H:65R
M87)C:'D@9VEV97,@=&AE(&AI9VAE<W0@<')I;W)I='D@=&\@3&5V96P@,2!I
M;G!U=',N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/DQE=F5L(#(Z)B,Q-C`[($]B<V5R=F%B;&4@<')I
M8V5S('1H870@87)E(&)A<V5D(&]N(&EN<'5T<R!N;W0@<75O=&5D(&]N(&%C
M=&EV92!M87)K971S+"!B=70@8V]R<F]B;W)A=&5D(&)Y(&UA<FME="!D871A
M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY,979E;"`S.B8C,38P.R!5;F]B<V5R=F%B;&4@:6YP=71S
M(&%R92!U<V5D('=H96X@;&ET=&QE(&]R(&YO(&UA<FME="!D871A(&ES(&%V
M86EL86)L92XF(S$V,#L@5&AE(&9A:7(@=F%L=64@:&EE<F%R8VAY(&=I=F5S
M('1H92!L;W=E<W0@<')I;W)I='D@=&\@3&5V96P@,R!I;G!U=',N/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
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M:7-K+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CY&:6YA;F-I86P@87-S971S(&%N9"!L:6%B:6QI=&EE
M<R!R96-O<F1E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES
M(&%S(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R(&%N9"!$96-E;6)E<B8C
M,38P.S,Q+"`R,#$Q(&%R92!C;&%S<VEF:65D(&EN('1H92!T86)L97,@8F5L
M;W<@:6X@;VYE(&]F('1H92!T:')E92!C871E9V]R:65S(&1E<V-R:6)E9"!A
M8F]V93H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU,1494.B`P+C5I;CL@5TE$
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M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`S,BXU)3L@4$%$
M1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,R)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^1&5S8W)I<'1I;VX\+V9O;G0^
M/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)
M1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@
M,3,N.30E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/E-E<'1E
M;6)E<B8C,38P.S,P+#QB<B`O/@T*,C`Q,B8C,38P.T)A;&%N8V4\+V9O;G0^
M/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)
M1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@
M,3,N.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'
M3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&
M3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/E%U;W1E9"8C,38P.U!R:6-E
M<R8C,38P.VEN/&)R("\^#0I!8W1I=F4F(S$V,#M-87)K971S/&)R("\^#0IF
M;W(F(S$V,#M)9&5N=&EC86P\8G(@+SX-"D%S<V5T<R8C,38P.RA,979E;"8C
M,38P.S$I/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E
M;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C
M96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/
M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,3Y3:6=N:69I8V%N=#QB<B`O/@T*3W1H97(\8G(@+SX-"D]B<V5R
M=F%B;&4\8G(@+SX-"DEN<'5T<R8C,38P.RA,979E;"8C,38P.S(I/"]F;VYT
M/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3Y3:6=N:69I8V%N=#QB<B`O
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M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT
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M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#,R
M+C4E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,S(E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R!4
M15A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M07-S971S.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G
M8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!724142#H@,3,N.30E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]4
M5$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N
M.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN.R!"
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3,E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG
M:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7
M24142#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-
M.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G
M8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,2XP."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`S,BXU)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,S(E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P
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M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$N,R4[(%!!1$1)
M3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@
M,3(N-C0E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD
M;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXS-BPY-3<L-#8Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU2
M24=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52
M+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(
M.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
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M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!724142#H@,3(N-C(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXS-BPY-3<L-#8Y/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
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M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,S(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#,R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P=#L@5$585"U)3D1%3E0Z("TQ
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/E1O=&%L(&%S<V5T<SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@
M,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
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M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,S8L.34W+#0V
M.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(]
M,T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0
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M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ
M(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@
M4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R
M+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O
M;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0
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M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,S8L.34W+#0V.3PO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'
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M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!724142#H@,2XP."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`S,BXU)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,S(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.
M5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3&EA8FEL:71I
M97,Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY-"4[(%!!
M1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H
M="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M
M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!
M1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R
M+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P
M:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R
M+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&
M5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P
M:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`X)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#,R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T
M;W`@=VED=&@],T0S,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXR,#$S($YO=&5S/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY
M-"4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8F=C
M;VQO<CTS1"-#0T5%1D8@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<L-3DS+#(Q-CPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N
M.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T
M97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G
M8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M
M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8F=C;VQO<CTS1"-#0T5%
M1D8@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/C<L-3DS+#(Q-CPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'
M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q
M+C`X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#,R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1T;W`@=VED=&@],T0S,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T(#(P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!L:6%B:6QI=&EE<SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I
M;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414
M2#H@,3(N-C0E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^-RPU.3,L,C$V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO
M;F4[(%=)1%1(.B`Q+C,E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]4
M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,BXV,B4[(%!!
M1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR
M-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG
M:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
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M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDR
M)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`R+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
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M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`P+C5I;CL@5TE$5$@Z(#DS+C,T)3L@0D]21$52+4-/3$Q!4%-%.B!C
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M1%1(.B`S,BXU)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^1&5S
M8W)I<'1I;VX\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$
M8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&
M3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!724142#H@,3,N.30E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS
M1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@
M1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0Q/D1E8V5M8F5R)B,Q-C`[,S$L/&)R("\^#0HR,#$Q)B,Q-C`[
M0F%L86YC93PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C
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M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^475O
M=&5D)B,Q-C`[4')I8V5S)B,Q-C`[:6X\8G(@+SX-"D%C=&EV928C,38P.TUA
M<FME=',\8G(@+SX-"F9O<B8C,38P.TED96YT:6-A;#QB<B`O/@T*07-S971S
M)B,Q-C`[*$QE=F5L)B,Q-C`[,2D\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT
M97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'+51/
M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0Q/E-I9VYI9FEC86YT/&)R("\^#0HF(S$V
M,#M/=&AE<CQB<B`O/@T*)B,Q-C`[3V)S97)V86)L93QB<B`O/@T*)B,Q-C`[
M26YP=71S)B,Q-C`[*$QE=F5L)B,Q-C`[,BD\+V9O;G0^/"]B/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@
M4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$
M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A
M;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0Q/E-I9VYI9FEC86YT/&)R("\^#0I5;F]B<V5R=F%B
M;&4\8G(@+SX-"DEN<'5T<R8C,38P.RA,979E;"8C,38P.S,I/"]F;VYT/CPO
M8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,2XP."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+V(^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"="
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,S(N-24[(%!!1$1)3D<M
M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE)R!V86QI9VX]
M,T1T;W`@=VED=&@],T0S,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M
M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY!<W-E=',Z/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY
M-"4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8F=C;VQO<CTS1"-#
M0T5%1D8@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M
M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H
M="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)
M1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8F=C
M;VQO<CTS1"-#0T5%1D8@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'
M2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[
M(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
M24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`X
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
M1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@5TE$5$@Z(#,R+C4E.R!0041$24Y'+51/4#H@,&EN)R!V86QI
M9VX],T1T;W`@=VED=&@],T0S,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CY-;VYE>2!M87)K970@9G5N9#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV
M."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,BXV-"4[(%!!1$1)
M3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI
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M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$
M1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.
M1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q
M,BXV,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
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M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
M1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,2XP."4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`S
M,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,S(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="`R,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^5&]T86P@87-S971S/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,
M1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-
M.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I
M;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q+C,E.R!0041$24Y'
M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,BXV
M-"4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E
M>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXU-2PT-C4L-3`W/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!
M1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR
M-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]2
M1$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q+C,E.R!0041$24Y'+51/4#H@
M,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z
M(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,BXV,B4[(%!!
M1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR
M-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXU-2PT-C4L-3`W/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M
M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O
M=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`Q+C`X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#,R+C4E.R!0041$24Y'+51/4#H@,&EN
M)R!V86QI9VX],T1T;W`@=VED=&@],T0S,B4^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY,:6%B:6QI=&EE<SH\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N
M-C@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDT)3L@4$%$1$E.1RU43U`Z(#!I
M;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I
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M,T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.
M1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I
M;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)2!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN
M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N
M93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/
M5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
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M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,S(N
M-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#,R
M)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL
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M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDT)3L@4$%$1$E.1RU4
M3U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&
M1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^,3<L,S,V+#<V,#PO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'
M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G8V]L;W(],T0C0T-%
M149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R
M+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4@8F=C;VQO<CTS1"-#0T5%1D8@8V]L<W!A;CTS
M1#(^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
M24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/C$W+#,S-BPW-C`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#(N-C@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X
M,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XP."4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`S,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,S(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="`R,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/
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M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$R+C8T)3L@
M4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R
M+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R
M:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/C$W+#,S-BPW-C`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S
M+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,
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M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$N,R4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O
M=W1E>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$R+C8R)3L@4$%$1$E.1RU43U`Z
M(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE
M)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C$W+#,S-BPW-C`\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M5TE$5$@Z(#(N-C@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.
M1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@
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M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/CPO=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@;6%D92!A;B!E;&5C
M=&EO;B!T;R!R96-O<F0@=&AE('9A;'5E<R!O9B!T:&4@,C`Q,R!.;W1E<R!A
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M;&%R(&-O;7!A;FEE<RX@)B,Q-C`[4V5E($YO=&4@-BP@)B,X,C(P.T-O;G9E
M<G1I8FQE(%-E;FEO<B!.;W1E<R8C.#(R,3L@9F]R(&UO<F4@:6YF;W)M871I
M;VX@86YD(&1I<V-L;W-U<F5S(')E9V%R9&EN9R!K97D@87-S=6UP=&EO;G,@
M=7-E9"!I;B!T:&ES(&9A:7(@=F%L=64@9&5T97)M:6YA=&EO;BX\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)
M3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,V,T.3DR7S8T.3%?-#DX
M-5\X.68U7S`S.#DU-38S9#DU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\X,C-C-#DY,E\V-#DQ7S0Y.#5?.#EF-5\P,S@Y-34V,V0Y-3$O5V]R
M:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4U5"4T51545.5"!%5D5.5%,\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY354)315%514Y4($56
M14Y44SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y354)315%514Y4($5614Y44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A
M;6EL>3HG5&EM97,@3F5W(%)O;6%N)RQT:6UE<RQS97)I9CLG/@T*/'1R/@T*
M/'1D/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`P+C5I;CL@
M5$585"U)3D1%3E0Z("TP+C5I;B<^/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3`N/"]F;VYT/CPO8CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`S<'0G
M('-I>F4],T0Q/B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R`\+V9O;G0^/"]B/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#$P<'0G('-I>F4],T0R/E-50E-%
M455%3E0@159%3E13/"]F;VYT/CPO8CX\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T(#`N-6EN.R!415A4+4E.1$5.5#H@+3`N-6EN)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@
M,"XU:6XG/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CY!9W)E96UE;G0@86YD(%!L86X@;V8@365R9V5R/"]F;VYT
M/CPO:3X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S
M:7IE/3-$,CY/;B!/8W1O8F5R)B,Q-C`[,RP@,C`Q,BP@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&%N(&%G<F5E;65N="!A;F0@<&QA;B!O9B!M97)G97(@
M*'1H92!-97)G97(@06=R965M96YT*2!W:71H($%.25`@06-Q=6ES:71I;VX@
M0V]M<&%N>2!D+V(O82!!3DD@4&AA<FUA8V5U=&EC86QS+"8C,38P.TEN8RXF
M(S$V,#L@5&AE($UE<F=E<B!!9W)E96UE;G0@<')O=FED97,@=&AA="P@=7!O
M;B!T:&4@=&5R;7,@86YD('-U8FIE8W0@=&\@=&AE(&-O;F1I=&EO;G,@<V5T
M(&9O<G1H(&EN('1H92!-97)G97(@06=R965M96YT+"!!3DD@=VEL;"!M97)G
M92!W:71H(&%N9"!I;G1O('1H92!#;VUP86YY+"!W:71H('1H92!#;VUP86YY
M(&-O;G1I;G5I;F<@87,@=&AE('-U<G9I=FEN9R!C;VUP86YY("AT:&4@365R
M9V5R*2XF(S$V,#L@070@=&AE(&5F9F5C=&EV92!T:6UE(&]F('1H92!-97)G
M97(L(&5A8V@@;W5T<W1A;F1I;F<@<VAA<F4@;V8@8V%P:71A;"!S=&]C:R!O
M9B!!3DD@=VEL;"!B92!C;VYV97)T960@:6YT;R!T:&4@<FEG:'0@=&\@<F5C
M96EV92!A(&YU;6)E<B!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[
M<R!C;VUM;VX@<W1O8VLL(&EF(&%N>2P@87,@9&5T97)M:6YE9"!P=7)S=6%N
M="!T;R!T:&4@97AC:&%N9V4@<F%T:6]S(&1E<V-R:6)E9"!I;B!T:&4@365R
M9V5R($%G<F5E;65N="!A;F0@=&AE('!R;W9I<VEO;G,@;V8@04Y))B,X,C$W
M.W,@8V5R=&EF:6-A=&4@;V8@:6YC;W)P;W)A=&EO;BXF(S$V,#L@06QL(&]P
M=&EO;G,L('=A<G)A;G1S(&]R(&]T:&5R(')I9VAT<R!T;R!P=7)C:&%S92!S
M:&%R97,@;V8@8V%P:71A;"!S=&]C:R!O9B!!3DDL('=I;&P@8F4@8V%N8V5L
M960@870@=&AE(&5F9F5C=&EV92!T:6UE(&]F('1H92!-97)G97(@=VET:&]U
M="!A;GD@8V]N<VED97)A=&EO;B!I;B!E>&-H86YG92P@97AC97!T(&9O<B!C
M97)T86EN('=A<G)A;G1S('=H:6-H(&%L=&AO=6=H(&YO="!C86YC96QL960@
M=VEL;"!N;W0@<F5P<F5S96YT('1H92!R:6=H="!T;R!A8W%U:7)E(&%N>2!E
M<75I='D@;W(@;W1H97(@:6YT97)E<W0@:6X@=&AE(&-O;6)I;F5D(&-O;7!A
M;GD@869T97(@=&AE($UE<F=E<BXF(S$V,#L@3F\@9G)A8W1I;VYA;"!S:&%R
M97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@=VEL;"!B
M92!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H('1H92!-97)G97(L(&%N9"!H
M;VQD97)S(&]F($%.22!C87!I=&%L('-T;V-K('=I;&P@8F4@96YT:71L960@
M=&\@<F5C96EV92!C87-H(&EN(&QI974@=&AE<F5O9BXF(S$V,#L@1F]L;&]W
M:6YG('1H92!C;VYS=6UM871I;VX@;V8@=&AE('1R86YS86-T:6]N<R!C;VYT
M96UP;&%T960@8GD@=&AE($UE<F=E<B!!9W)E96UE;G0L('1H92!C=7)R96YT
M('-T;V-K:&]L9&5R<R!O9B!!3DD@87)E(&5X<&5C=&5D('1O(&]W;B!A<'!R
M;WAI;6%T96QY(#4S('!E<F-E;G0@;V8@=&AE(&]U='-T86YD:6YG('-H87)E
M<R!O9B!C;VUM;VX@<W1O8VL@;V8@=&AE(&-O;6)I;F5D(&-O;7!A;GDL(&%N
M9"!C=7)R96YT('-T;V-K:&]L9&5R<R!O9B!T:&4@0V]M<&%N>2!A<F4@97AP
M96-T960@=&\@;W=N(&%P<')O>&EM871E;'D@-#<@<&5R8V5N="!O9B!T:&4@
M;W5T<W1A;F1I;F<@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!O9B!T:&4@8V]M
M8FEN960@8V]M<&%N>2XF(S$V,#L@5&AE(&5X8VAA;F=E(')A=&EO<R!A<F4@
M<W5B:F5C="!T;R!P;W1E;G1I86P@861J=7-T;65N="!A<R!D97-C<FEB960@
M:6X@=&AE($UE<F=E<B!!9W)E96UE;G0@9&5P96YD:6YG('5P;VX@=&AE(&%M
M;W5N="!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS("8C.#(R,#MN970@8V%S:"8C
M.#(R,3LL(&%S(&1E9FEN960@:6X@=&AE($UE<F=E<B!!9W)E96UE;G0@86YD
M(&=E;F5R86QL>2!C;VYS:7-T:6YG(&]F('1H92!#;VUP86YY)B,X,C$W.W,@
M8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!L97-S(&-E<G1A:6X@97AP96YS
M97,@86YD(&QI86)I;&ET:65S+"!A<R!O9B!A(&1E=&5R;6EN871I;VX@9&%T
M92!P<FEO<B!T;R!T:&4@8VQO<VEN9R!D871E(&]F('1H92!-97)G97(L(&)U
M="!I;B!N;R!E=F5N="!W:6QL('1H92!C=7)R96YT($%.22!S=&]C:VAO;&1E
M<G,@;W=N(&QE<W,@=&AA;B`U,"XQ('!E<F-E;G0@*&]R('1H92!C=7)R96YT
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M,3DX-BP@87,@86UE;F1E9"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG
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M;GDN)B,Q-C`[($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@365R9V5R+"!T:&4@
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M($-A<&ET86P@36%R:V5T(&%R92!S871I<V9I960[(&%N9"`H:6DI)B,Q-C`[
M8VAA;F=E('1H92!N86UE(&]F('1H92!#;VUP86YY('1O("8C.#(R,#M!3DD@
M4&AA<FUA8V5U=&EC86QS+"8C,38P.TEN8RXF(S@R,C$[(&]R(&%N;W1H97(@
M;F%M92!A<R!D97-I9VYA=&5D(&)Y($%.22`H=&]G971H97(L('1H92!#:&%R
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M96]F+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
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M92!#;VUP86YY)B,X,C$W.W,@<W1O8VMH;VQD97)S.R`H:6DI)B,Q-C`[=&AE
M(&5F9F5C=&EV96YE<W,@;V8@82!&;W)M)B,Q-C`[4RTT(')E9VES=')A=&EO
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M96YT+W!R;W-P96-T=7,[("AI:6DI)B,Q-C`[87!P<F]V86P@9F]R('1H92!L
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M;&]S:6YG(&-O;F1I=&EO;G,N)B,Q-C`[($EN(&%D9&ET:6]N+"!T:&4@;V)L
M:6=A=&EO;B!O9B!!3DD@=&\@969F96-T('1H92!-97)G97(@:7,@<W5B:F5C
M="!T;R!A(&-O;F1I=&EO;B!T:&%T('1H92!#;VUP86YY)B,X,C$W.W,@;F5T
M(&-A<V@L(&%S(&-A;&-U;&%T960@<'5R<W5A;G0@=&\@=&AE('1E<FUS(&]F
M('1H92!-97)G97(@06=R965M96YT+"!B92!N;R!L97-S('1H86X@)#$W+C`@
M;6EL;&EO;B!I;6UE9&EA=&5L>2!P<FEO<B!T;R!T:&4@969F96-T:79E('1I
M;64@;V8@=&AE($UE<F=E<BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG
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M97)I;V0[("AI:6DI)B,Q-C`[04Y)('=I;&P@8V]N=F5N92!A;F0@:&]L9"!A
M(&UE971I;F<@;V8@:71S('-T;V-K:&]L9&5R<R!F;W(@=&AE('!U<G!O<V4@
M;V8@8V]N<VED97)I;F<@=&AE(&%D;W!T:6]N(&%N9"!A<'!R;W9A;"!O9B!T
M:&4@365R9V5R($%G<F5E;65N="!A;F0@=&AE('1R86YS86-T:6]N<R!C;VYT
M96UP;&%T960@=&AE<F5B>2!A;F0@=&AE(&)O87)D(&]F(&1I<F5C=&]R<R!O
M9B!!3DD@=VEL;"!R96-O;6UE;F0@=&AA="!I=',@<W1O8VMH;VQD97)S(&%D
M;W!T(&%N9"!A<'!R;W9E('1H92!-97)G97(@06=R965M96YT+"!S=6)J96-T
M('1O(&-E<G1A:6X@97AC97!T:6]N<SL@86YD("AI=BDF(S$V,#MT:&4@0V]M
M<&%N>2!W:6QL(&-O;G9E;F4@86YD(&AO;&0@82!M965T:6YG(&]F(&ET<R!S
M=&]C:VAO;&1E<G,@9F]R('1H92!P=7)P;W-E(&]F(&-O;G-I9&5R:6YG('1H
M92!A9&]P=&EO;B!A;F0@87!P<F]V86P@;V8@=&AE($UE<F=E<B!!9W)E96UE
M;G0@86YD('1H92!T<F%N<V%C=&EO;G,@8V]N=&5M<&QA=&5D('1H97)E8GD@
M86YD('1H92!A<'!R;W9A;"!O9B!T:&4@0VAA<G1E<B!!;65N9&UE;G1S(&%N
M9"!T:&4@0V]M<&%N>28C.#(Q-SMS(&)O87)D(&]F(&1I<F5C=&]R<R!W:6QL
M(')E8V]M;65N9"!T:&%T('1H92!#;VUP86YY)B,X,C$W.W,@<W1O8VMH;VQD
M97)S(&%D;W!T(&%N9"!A<'!R;W9E('1H92!-97)G97(@06=R965M96YT(&%N
M9"!A<'!R;W9E('1H92!C:&%R=&5R(&%M96YD;65N=',L('-U8FIE8W0@=&\@
M8V5R=&%I;B!E>&-E<'1I;VYS+B8C,38P.R!%86-H(&]F('1H92!#;VUP86YY
M(&%N9"!!3DD@86QS;R!H87,@86=R965D(&YO="!T;R!S;VQI8VET('!R;W!O
M<V%L<R!R96QA=&EN9R!T;R!A;'1E<FYA=&EV92!B=7-I;F5S<R!C;VUB:6YA
M=&EO;B!T<F%N<V%C=&EO;G,@;W(@96YT97(@:6YT;R!D:7-C=7-S:6]N<R!O
M<B!A;B!A9W)E96UE;G0@8V]N8V5R;FEN9R!A;GD@<')O<&]S86QS(&9O<B!A
M;'1E<FYA=&EV92!B=7-I;F5S<R!C;VUB:6YA=&EO;B!T<F%N<V%C=&EO;G,L
M('-U8FIE8W0@=&\@97AC97!T:6]N<R!F;W(@=&AE($-O;7!A;GD@:6X@=&AE
M(&5V96YT(&]F('1H92!#;VUP86YY)B,X,C$W.W,@<F5C96EP="!O9B!A("8C
M.#(R,#MS=7!E<FEO<B!P<F]P;W-A;"XF(S@R,C$[/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P
M+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)
M3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
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M:6YA=&EO;B!F964@;V8@=7`@=&\@)#$N,"!M:6QL:6]N(&]R($%.22!W:6QL
M(&)E(')E<75I<F5D('1O('!A>2!T:&4@0V]M<&%N>2!A('1E<FUI;F%T:6]N
M(&9E92!O9B!U<"!T;R`D-S4P+#`P,"X@5&AE($UE<F=E<B!!9W)E96UE;G0@
M86QS;R!P<F]V:61E<R!T:&%T('5N9&5R('-P96-I9FEE9"!C:7)C=6US=&%N
M8V5S+"!T:&4@0V]M<&%N>2!M87D@8F4@<F5Q=6ER960@=&\@<F5I;6)U<G-E
M($%.22!U<"!T;R`D-3`P+#`P,"!F;W(@04Y))B,X,C$W.W,@97AP96YS97,@
M:6X@8V]N;F5C=&EO;B!W:71H('1H92!T<F%N<V%C=&EO;BX@06YY(&5X<&5N
M<V5S('!A:60@8GD@=&AE($-O;7!A;GD@=VEL;"!B92!C<F5D:71E9"!A9V%I
M;G-T('1H92`D,2XP(&UI;&QI;VX@=&5R;6EN871I;VX@9F5E(&EF('1H92!T
M97)M:6YA=&EO;B!F964@<W5B<V5Q=65N=&QY(&)E8V]M97,@<&%Y86)L92!B
M>2!T:&4@0V]M<&%N>2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E
M;G1E<CX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.
M1$5.5#H@,"XU:6XG/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CY6;W1I;F<@06=R965M96YT<SPO9F]N=#X\+VD^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)
M3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
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M;V8@8G5S:6YE<W,@;VX@3V-T;V)E<B8C,38P.S,L(#(P,3(L)B,Q-C`[(&5N
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M87!P<F]X:6UA=&5L>2`U-R!P97)C96YT(&]F('1H92!O=71S=&%N9&EN9R!S
M:&%R97,@;V8@04Y)(&-A<&ET86P@<W1O8VL@87,@;V8@=&AE(&-L;W-E(&]F
M(&)U<VEN97-S(&]N($]C=&]B97(F(S$V,#LS+"`R,#$R+"!H87,@86=R965D
M('1O('9O=&4@:6X@9F%V;W(@;V8@=&AE(&5L96-T:6]N(&]F('1H92!T=V\@
M9&ER96-T;W)S(&1E<VEG;F%T960@8GD@=&AE($-O;7!A;GD@870@=&AE(&9I
M<G-T(&%N;G5A;"!M965T:6YG(&]F('-T;V-K:&]L9&5R<R!F;VQL;W=I;F<@
M=&AE(&-O;7!L971I;VX@;V8@=&AE($UE<F=E<BX\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N
M-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.
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M)B,Q-C`[,RP@,C`Q,BP@96YT97)E9"!I;G1O('9O=&EN9R!A9W)E96UE;G1S
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M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M24Y$
M14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@
M5$585"U)3D1%3E0Z(#`N-6EN)SX\:3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M4U193$4Z(&ET86QI8SL@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^3&]C:RU5<"!!9W)E96UE;G1S/"]F
M;VYT/CPO:3X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
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M)B,Q-C`[,RP@,C`Q,BP@96YT97)E9"!I;G1O(&QO8VLM=7`@86=R965M96YT
M<R!W:71H('1H92!#;VUP86YY+"!P=7)S=6%N="!T;R!W:&EC:"!E86-H('-T
M;V-K:&]L9&5R('=I;&P@8F4@<W5B:F5C="!T;R!A('-I>"UM;VYT:"!L;V-K
M+75P(&]N('1H92!S86QE(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&-O;6UO;B!S=&]C:R!R96-E:79E9"!I;B!T:&4@365R9V5R+CPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&D^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5-464Q%.B!I=&%L:6,[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D-O;G1I;F=E;G0@5F%L=64@
M4FEG:'1S($%G<F5E;65N=#PO9F]N=#X\+VD^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU
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M<R!C;VUM;VX@<W1O8VLN)B,Q-C`[($5A8V@@0U92('=I;&P@8F4@82!N;VXM
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M:6X@=&AE(&%G9W)E9V%T92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG
M/CQI/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U35%E,
M13H@:71A;&EC.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CY%;7!L;WEE92!2961U8W1I;VX@26UP;&EC871I;VYS/"]F;VYT/CPO
M:3X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
M+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0[(%1%6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
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M)B,Q-C`[-"P@,C`Q,B!A;FYO=6YC96UE;G0@;V8@:71S('!O=&5N=&EA;"!M
M97)G97(@=VET:"!!3DDL('1H92!#;VUP86YY('!L86YS('1O(')E9'5C92!I
M=',@=V]R:V9O<F-E(&1U<FEN9R!T:&4@9F]U<G1H('%U87)T97(@;V8@,C`Q
M,BXF(S$V,#L@26X@8V]N;F5C=&EO;B!W:71H('1H92!A;FYO=6YC960@<F5D
M=6-T:6]N+"!T:&4@0V]M<&%N>2!W:6QL('!A>2!A<'!R;WAI;6%T96QY("0S
M,#`L,#`P(&EN(&%G9W)E9V%T92!S979E<F%N8V4@8V]S=',@9'5R:6YG('1H
M92!R96UA:6YD97(@;V8@,C`Q,BX@5&AE('1E<FUI;F%T:6]N(&]F(&5M<&QO
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M;G0^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$58
M5"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQI/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U35%E,13H@:71A;&EC.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4:&ER9"!!;65N9&UE;G0@
M5&\@3&EC96YS92!!9W)E96UE;G0@=VET:"!4979A/"]F;VYT/CPO:3X\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.
M5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%
M6%0M24Y$14Y4.B`P+C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY)
M;B!/8W1O8F5R)B,Q-C`[,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O
M(&%N(&%M96YD;65N="!T;R!I=',@9&5V96QO<&UE;G0@86YD(&QI8V5N<V4@
M86=R965M96YT('=I=&@@5&5V82!P=7)S=6%N="!T;R!W:&EC:"!4979A(&UA
M9&4@82`D,2XP(&UI;&QI;VX@<&%Y;65N="!T;R!T:&4@0V]M<&%N>2!U<&]N
M('1H92!S:6=N:6YG(&]F('1H92!A;65N9&UE;G0@86YD(&%G<F5E9"!T;R!M
M86ME('1H92!F;VQL;W=I;F<@;6EL97-T;VYE+6)A<V5D('!A>6UE;G1S('1O
M('1H92!#;VUP86YY.B8C,38P.R`H,2DF(S$V,#LD-3`P+#`P,"!I9B!T:&4@
M1D1!(&%U=&AO<FEZ97,@;6%R:V5T:6YG(&]F('1H92!L:6-E;G-E9"`\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)R!S:7IE/3-$,CYM
M86QE('1E<W1O<W1E<F]N92!G96P@87,@86X@)B,X,C(P.T%"+7)A=&5D)B,X
M,C(Q.R!E<75I=F%L96YT('1O($%N9')O1V5L/"]F;VYT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@-BXU<'0[(%!/4TE424]..B!R96QA=&EV93L@5$]0
M.B`M,W!T)R!S:7IE/3-$,3XF(S$W-#L\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T)R!S:7IE/3-$,CX[("@R*28C,38P.R0W-3`L,#`P
M('5P;VX@=&AE(&5A<FQI97(@=&\@;V-C=7(@;V8@*&$I)B,Q-C`[1&5C96UB
M97(F(S$V,#LS,2P@,C`Q,B!A;F0@*&(I)B,Q-C`[9FEV92!B=7-I;F5S<R!D
M87ES(&%F=&5R(%1E=F$F(S@R,3<[<R!S=6)M:7-S:6]N('1O('1H92!&1$$@
M;V8@82!F:6YA;"!R97!O<G0@<F5G87)D:6YG(&$@)B,X,C(P.W=A<VAI;F<F
M(S@R,C$[(&-L:6YI8V%L('-T=61Y(')E<75I<F5D(&)Y('1H92!&1$$[(&%N
M9"`H,RDF(S$V,#LD-3`P+#`P,"!U<&]N('1H92!E87)L:65R('1O(&]C8W5R
M(&]F("AA*28C,38P.T1E8V5M8F5R)B,Q-C`[,S$L(#(P,3,@86YD("AB*28C
M,38P.V9I=F4@8G5S:6YE<W,@9&%Y<R!A9G1E<B!4979A)B,X,C$W.W,@8V]M
M;65N8V5M96YT(&]F(&-O;6UE<F-I86P@;6%N=69A8W1U<F4@;V8@=&AE(&QI
M8V5N<V5D('!R;V1U8W0@9F]R('-A;&4@:6X@=&AE(%5N:71E9"!3=&%T97,N
M)B,Q-C`[($EN(&%D9&ET:6]N+"!4979A(&AA<R!A9W)E960@=&\@<&%Y('1H
M92!#;VUP86YY("0T+C`@;6EL;&EO;B!I;B!T:&4@979E;G0@5&5V82!I<R!T
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M)B,Q-C`[9F]R(&%T(&QE87-T(#$X,"!D87ES(&EM;65D:6%T96QY(&9O;&QO
M=VEN9R!T:&4@;&%U;F-H(&1A=&4@;V8@=&AE(&QI8V5N<V5D('!R;V1U8W0@
M:6X@=&AE(%5N:71E9"!3=&%T97,N)B,Q-C`[(%1H92!R;WEA;'1Y(')A=&4@
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M>6QE/3-$)T9/3E0M4TE:13H@,3!P="<@<VEZ93TS1#(^)B,Q-C`[:6X@=&AE
M(%5N:71E9"!3=&%T97,L('1H92!R;WEA;'1Y(')A=&4@=VEL;"!B92!S979E
M;B!A;F0@;VYE(&AA;&8@<&5R8V5N="!O9B!N970@<V%L97,N)B,Q-C`[($%D
M9&ET:6]N86QL>2P@<'5R<W5A;G0@=&\@=&AE('1E<FUS(&]F('1H92!/8W1O
M8F5R)B,Q-C`[,C`Q,B!A;65N9&UE;G0L('1H92!P87)T:65S(&%G<F5E9"!T
M;R!R96QE87-E(&5A8V@@;W1H97(@9G)O;2!C97)T86EN(&QI86)I;&ET:65S
M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^
M/"]T86)L93X-"CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?.#(S8S0Y.3)?-C0Y,5\T.3@U7S@Y9C5?,#,X.34U-C-D.34Q#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S@R,V,T.3DR7S8T.3%?-#DX
M-5\X.68U7S`S.#DU-38S9#DU,2]7;W)K<VAE971S+U-H965T,38N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY615)424),
M12!314Y)3U(@3D]415,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#3TY615)424),12!314Y)3U(@
M3D]415,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V-H961U;&4@;V8@:V5Y(&%S<W5M<'1I;VYS('5S960@=&\@97-T86)L
M:7-H('1H92!V86QU92!O9B!T:&4@,C`Q,R!.;W1E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$)V9O;G0M<VEZ93HQ
M,'!T.R!F;VYT+69A;6EL>3HG5&EM97,@3F5W(%)O;6%N)RQT:6UE<RQS97)I
M9CLG/@T*/'1R/@T*/'1D/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^5&AE(&%S<W5M<'1I;VYS(&%S
M(&]F(%-E<'1E;6)E<B8C,38P.S,P+"`R,#$R('=E<F4Z/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL
M93TS1"=-05)'24XM3$5&5#H@,6EN.R!724142#H@-C`E.R!"3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$-C`E(&)O<F1E<CTS1#`^#0H\='(^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z
M(#<T+C$X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$-S0E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^079E<F%G92!R:7-K+69R964@<F%T93PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@-"XQ-B4[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,C`E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R,"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C`N,30\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N-C8E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$
M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X\+W1R
M/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`W
M-"XQ."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#<T)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@
M5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/E9O;&%T:6QI='D@;V8@0FEO4V%N=&4@8V]M;6]N('-T;V-K/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`T
M+C$V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-"4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R,"4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I
M9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M.3`N,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@
M,&EN.R!724142#H@,2XV-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE/"]F;VYT/CPO
M<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#<T+C$X)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-S0E(&)G8V]L;W(]
M,T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q
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M;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#(P)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXQ.2XV/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C8V)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO
M=&0^/"]T<CX\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T.R!415A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^5&AE(&%S<W5M<'1I;VYS(&%S(&]F($1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,3$@=V5R93H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U)3D1%3E0Z(#`N-6EN)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B
M;&4@<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#%I;CL@5TE$5$@Z(#8P)3L@0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#8P)2!B;W)D97(],T0P/@T*/'1R/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`W-"XQ."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#<T)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/D%V97)A9V4F(S$V,#MR
M:7-K+69R964F(S$V,#MR871E/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`T+C$V)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'
M2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R,"4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)2!B9V-O;&]R
M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[
M(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^,"XQ.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,2XV-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXE
M/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#<T+C$X)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$-S0E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^5F]L871I;&ET>2!O9B!":6]386YT92!C
M;VUM;VX@<W1O8VL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#0N,38E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#(P)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,C`E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXW-RXT/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C8V)3L@4$%$1$E.
M1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B4\+V9O;G0^/"]P/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@-S0N,3@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@
M=VED=&@],T0W-"4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY$:7-C;W5N="!R871E(&9O<B!P
M<FEN8VEP86P@<&%Y;65N=',@:6X@8V%S:#PO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@-"XQ-B4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#0E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,C`E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R,"4@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
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M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)3PO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G
M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(S8S0Y.3)?-C0Y,5\T
M.3@U7S@Y9C5?,#,X.34U-C-D.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU,2]7
M;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY&04E2(%9!3%5%($U%05-54D5-14Y44R`H5&%B;&5S
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D9!25(@5D%,544@345!4U5214U%3E13/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(&9I;F%N8VEA
M;"!A<W-E=',@86YD(&QI86)I;&ET:65S(')E8V]R9&5D(&%T(&9A:7(@=F%L
M=64@;VX@82!R96-U<G)I;F<@8F%S:7,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQT86)L92!S='EL93TS1"=F;VYT+7-I>F4Z,3!P=#L@9F]N
M="UF86UI;'DZ)U1I;65S($YE=R!2;VUA;B<L=&EM97,L<V5R:68[)SX-"CQT
M<CX-"CQT9#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/B8C
M,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM3$5&5#H@,"XU:6X[
M(%=)1%1(.B`W.#AP>#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@2$5)
M1TA4.B`Q-#EP>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#<X."!B;W)D97(],T0P/@T*/'1R/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%=)1%1(.B`S,BXU)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/
M33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#,R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQB
M/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z
M(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^
M1&5S8W)I<'1I;VX\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!724142#H@,3,N.30E.R!0041$24Y'+51/4#H@,&EN.R!"
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9#L@1D].5"U325I%.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0Q/E-E<'1E;6)E<B8C,38P.S,P+#QB<B`O/@T*,C`Q,B8C
M,38P.T)A;&%N8V4\+V9O;G0^/"]B/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I
M;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N
M/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN.R!"
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\
M8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%
M.B`X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q
M/E%U;W1E9"8C,38P.U!R:6-E<R8C,38P.VEN/&)R("\^#0I!8W1I=F4F(S$V
M,#M-87)K971S/&)R("\^#0IF;W(F(S$V,#M)9&5N=&EC86P\8G(@+SX-"D%S
M<V5T<R8C,38P.RA,979E;"8C,38P.S$I/"]F;VYT/CPO8CX\+W`^/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&
M5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!
M1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@
M8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.
M1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!C;VQS<&%N/3-$,CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3Y3:6=N:69I8V%N=#QB<B`O/@T*
M3W1H97(\8G(@+SX-"D]B<V5R=F%B;&4\8G(@+SX-"DEN<'5T<R8C,38P.RA,
M979E;"8C,38P.S(I/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$
M24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P
M:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG
M;CTS1&-E;G1E<CX\8CX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9#L@1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^
M/&(^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:
M13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,3Y3:6=N:69I8V%N=#QB<B`O/@T*56YO8G-E<G9A8FQE/&)R("\^#0I);G!U
M=',F(S$V,#LH3&5V96PF(S$V,#LS*3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#$N,#@E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E
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M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@5TE$5$@Z(#,R+C4E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,S(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^07-S971S.CPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@
M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.30E.R!0041$24Y'+51/
M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3,E(&)G8V]L;W(],T0C0T-%149&(&-O;'-P86X]
M,T0R/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!
M3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV
M."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0
M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&)G8V]L;W(],T0C0T-%149&
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=2
M3U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'+51/4#H@
M,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3,E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XP."4[(%!!1$1)3D<M5$]0
M.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\
M+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`S,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,S(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T
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M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!
M1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@
M5TE$5$@Z(#$N,R4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!724142#H@,3(N-C0E.R!0041$24Y'+51/4#H@,&EN.R!"
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS-BPY-3<L-#8Y/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[
M($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\
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M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M5$]0.B`P:6X[($)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(N-C(E.R!0041$24Y'
M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXS-BPY-3<L-#8Y
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO
M;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"
M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)
M3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI
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M;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,S(N-24[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T:#TS1#,R)2!B9V-O;&]R/3-$
M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,C!P
M=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/E1O=&%L(&%S<V5T<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+
M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@
M,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@
M(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/
M4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#
M2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52
M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(N-C0E.R!0041$24Y'+51/
M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B
M;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-#
M145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^,S8L.34W+#0V.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"
M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN
M.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,X,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$
M.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@
M,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!724142#H@,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/
M5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.
M1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!724142#H@,3(N-C(E.R!0041$24Y'+51/4#H@,&EN
M.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!B9V-O;&]R/3-$(T-#145&1CX-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ
M(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,S8L.34W+#0V.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV
M."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
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M>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT
M)R!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X
M,C$R.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XP."4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`S,BXU)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,S(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="`Q,'!T.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@
M<VEZ93TS1#(^3&EA8FEL:71I97,Z/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%=)1%1(.B`Q,RXY-"4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U14
M3TTZ(&UE9&EU;2!N;VYE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@
M8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M.R!415A4+4%,24=..B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U14
M3TTZ(&UE9&EU;2!N;VYE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY
M,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/
M33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY
M,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N
M;VYE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)
M1%1(.B`Q+C`X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\
M+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@
M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#,R+C4E.R!0041$24Y'+51/
M4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0S,B4@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#$P<'0[
M(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXR,#$S($YO=&5S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D
M:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M
M(&YO;F4[(%=)1%1(.B`Q,RXY-"4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4@8F=C;VQO<CTS1"-#0T5%1D8@8V]L<W!A;CTS1#(^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
M.B!R:6=H="<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/C<L-3DS+#(Q-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV
M."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C
M965F9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU
M;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$
M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3,E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(
M.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4@8F=C;VQO<CTS1"-#0T5%1D8@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/C<L-3DS+#(Q
M-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L;W(]
M,T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.
M1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!72414
M2#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W
M:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3,E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]4
M5$]-.B`P:6X[(%=)1%1(.B`Q+C`X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\='(^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#,R+C4E.R!0
M041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0S,B4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[(%1%6%0M24Y$
M14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A;"!L
M:6%B:6QI=&EE<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS
M)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X
M="`R+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P
M:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!724142#H@,3(N-C0E.R!0041$24Y'+51/4#H@,&EN
M.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-RPU.3,L,C$V/"]F;VYT
M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@
M4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(
M.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!
M1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M
M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0
M.B`P:6X[($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L
M92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F
M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I
M;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)
M1%1(.B`R+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T
M)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$
M15(M3$5&5#H@;65D:75M(&YO;F4[(%=)1%1(.B`Q+C,E.R!0041$24Y'+51/
M4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B
M;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(
M5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/
M4#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%=)1%1(.B`Q,BXV,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U14
M3TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N)R!S:7IE/3-$,CXW+#4Y,RPR,38\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$
M24Y'+51/4#H@,&EN)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@
M,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P
M:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52
M+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
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M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^/"]T<CX\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE
M('-T>6QE/3-$)TU!4D=)3BU,1494.B`P+C5I;CL@5TE$5$@Z(#<X,W!X.R!"
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!(14E'2%0Z(#$T.7!X)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S@S(&)O<F1E
M<CTS1#`^#0H\='(^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#,R+C4E.R!0
M041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&(^/&9O;G0@<W1Y;&4],T0G
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M;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M.B`Q,RXY-"4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"3U143TTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^1&5C
M96UB97(F(S$V,#LS,2P\8G(@+SX-"C(P,3$F(S$V,#M"86QA;F-E/"]F;VYT
M/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@8V5N=&5R)R!A;&EG;CTS1&-E;G1E<CX\8CX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z
M(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@86QI9VX],T1C96YT97(^/&(^/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&)O;&0[($9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,3Y1=6]T960F(S$V,#M0<FEC
M97,F(S$V,#MI;CQB<B`O/@T*06-T:79E)B,Q-C`[36%R:V5T<SQB<B`O/@T*
M9F]R)B,Q-C`[261E;G1I8V%L/&)R("\^#0I!<W-E=',F(S$V,#LH3&5V96PF
M(S$V,#LQ*3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+51/4#H@,&EN)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI9VX],T1C
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M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%
M4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,R4@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$
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M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@86QI
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M;65D:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[
M($)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I
M;B`P:6X@,'!T.R!415A4+4%,24=..B!C96YT97(G(&%L:6=N/3-$8V5N=&5R
M/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!&3TY4+5-)
M6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#$^4VEG;FEF:6-A;G0\8G(@+SX-"E5N;V)S97)V86)L93QB<B`O/@T*26YP
M=71S)B,Q-C`[*$QE=F5L)B,Q-C`[,RD\+V9O;G0^/"]B/CPO<#X\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494
M.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`X)3L@4$%$
M1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!C
M96YT97(G(&%L:6=N/3-$8V5N=&5R/CQB/CQF;VYT('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD.R!&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO8CX\+W`^
M/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%=)1%1(.B`S,BXU)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2
M1$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#,R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/D%S<V5T<SH\+V9O;G0^/"]P/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+4Q%1E0Z
M(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$1$E.1RU"3U143TTZ(#!I
M;CL@5TE$5$@Z(#(N-C@E.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDT)3L@4$%$1$E.1RU4
M3U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N
M/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M
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M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2
M1$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I
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M"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(
M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494
M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P
M:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@
M4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&
M1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
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M)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$
M15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,
M1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z
M(#!I;CL@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$S)2!B9V-O;&]R/3-$(T-#145&1CX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A
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M(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO=&0^
M/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[
M(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!72414
M2#H@,S(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#,R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,3!P
M=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/DUO;F5Y(&UA<FME="!F=6YD/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@
M0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!0
M041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[
M(%=)1%1(.B`Q+C,E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU2
M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,
M1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@5TE$5$@Z(#$R+C8T)3L@4$%$1$E.1RU43U`Z(#!I;CL@
M0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN
M(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-34L-#8U+#4P-SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV
M."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z
M(&UE9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN
M.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.
M1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R+C8X
M)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,B4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU224=(5#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@;65D:75M(&YO;F4[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@
M;65D:75M(&YO;F4[(%=)1%1(.B`Q+C,E.R!0041$24Y'+51/4#H@,&EN.R!"
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P
M:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]P
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N
M93L@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/
M4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$R+C8R)3L@4$%$1$E.
M1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^-34L-#8U+#4P
M-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$
M24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%!!1$1)3D<M0D]45$]-.B`P:6X[
M(%=)1%1(.B`Q+C`X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@
M,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M<#X\+W1D/CPO='(^#0H\='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(
M5#H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F
M9CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#,R+C4E.R!0041$24Y'
M+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0S,B4@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#(P
M<'0[(%1%6%0M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
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M3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0
M.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z
M("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M
M961I=6T@;F]N93L@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M5$]0.B`P:6X[($)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"
M3U)$15(M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!
M0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%
M4BU,1494.B!M961I=6T@;F]N93L@5TE$5$@Z(#$R+C8T)3L@4$%$1$E.1RU4
M3U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U
M8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4
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M4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I
M;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
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M(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I
M=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E
M9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@
M;F]N93L@5TE$5$@Z(#$N,R4[(%!!1$1)3D<M5$]0.B`P:6X[($)/4D1%4BU"
M3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L92<@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))
M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M
M5$]0.B!M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]5
M3D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494
M.B!M961I=6T@;F]N93L@5TE$5$@Z(#$R+C8R)3L@4$%$1$E.1RU43U`Z(#!I
M;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,B4@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=.
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M,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]P/CPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C
M8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I
M=6T@;F]N93L@5TE$5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]2
M1$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,R4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H
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M;&]R/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P
M/CPO=&0^/"]T<CX-"CQT<CX-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,S(N-24[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#,R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P
M<'0@,3!P=#L@5$585"U)3D1%3E0Z("TQ,'!T)SX\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG
M('-I>F4],T0R/DQI86)I;&ET:65S.CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!724142#H@,3,N.30E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]4
M5$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M(&-O;'-P86X],T0R/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN
M.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M
M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[
M($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@
M4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE
M.R!724142#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]4
M5$]-.B!M961I=6T@;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N
M.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E(&-O;'-P86X],T0R
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/
M5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U14
M3TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N
M.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N92<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3,E/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,2XP."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X\+W1R/@T*/'1R/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z
M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[
M(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`S,BXU)3L@4$%$1$E.1RU4
M3U`Z(#!I;B<@=F%L:6=N/3-$=&]P('=I9'1H/3-$,S(E(&)G8V]L;W(],T0C
M0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="`Q,'!T
M.R!415A4+4E.1$5.5#H@+3$P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS
M1#(^,C`Q,R!.;W1E<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/
M54Y$.B`C8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV
M."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#(E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE
M9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE
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M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P=#L@5$585"U!3$E'
M3CH@<FEG:'0G(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE
M/3-$,CXQ-RPS,S8L-S8P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[($)!0TM'
M4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M0D]45$]-.B`P:6X[(%=)1%1(.B`R
M+C8X)3L@4$%$1$E.1RU43U`Z(#!I;B<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,B4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#%P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU224=(5#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M4DE'2%0Z(#!I;CL@0D]21$52+51/4#H@
M;65D:75M(&YO;F4[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C
M8V-E969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!"3U)$15(M3$5&5#H@;65D
M:75M(&YO;F4[(%=)1%1(.B`Q,RXY,B4[(%!!1$1)3D<M5$]0.B`P:6X[($)/
M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,R4@8F=C;VQO<CTS1"-#0T5%1D8^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!415A4+4%,24=..B!R:6=H="<@
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M/3-$(T-#145&1CX-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,7!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]P/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@
M4$%$1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)
M3D<M0D]45$]-.B`P:6X[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@5TE$
M5$@Z(#$S+CDR)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$S)2!B9V-O;&]R/3-$(T-#145&1B!C;VQS<&%N/3-$,CX-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3<L,S,V
M+#<V,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))
M1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E
M969F.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)
M3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E(&)G8V]L
M;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@0D%#2T=23U5.1#H@(V-C965F9CL@4$%$
M1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!7
M24142#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M0D]45$]-
M.B!W:6YD;W=T97AT(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3,E(&)G8V]L;W(],T0C0T-%149&/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P:6X@,&EN(#!P=#L@5$585"U!3$E'3CH@<FEG:'0G(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO
M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M4DE'2%0Z(#!I;CL@4$%$
M1$E.1RU,1494.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D<M
M0D]45$]-.B`P:6X[(%=)1%1(.B`Q+C`X)3L@4$%$1$E.1RU43U`Z(#!I;B<@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T)SX\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^#0H\
M='(^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'
M+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@5TE$5$@Z(#,R+C4E
M.R!0041$24Y'+51/4#H@,&EN)R!V86QI9VX],T1T;W`@=VED=&@],T0S,B4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#(P<'0[(%1%6%0M
M24Y$14Y4.B`M,3!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)R!S:7IE/3-$,CY4;W1A
M;"!L:6%B:6QI=&EE<SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'
M+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'
M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU4
M3U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"
M3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@
M,2XS)3L@4$%$1$E.1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W
M=&5X="`R+C(U<'0@9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4
M.B`P:6X[($)/4D1%4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!0041$
M24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%
M1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3(N-C0E.R!0041$24Y'+51/4#H@
M,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^,3<L,S,V+#<V,#PO
M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P
M:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!7
M24142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P
M="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE
M.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]2
M1$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'
M+51/4#H@,&EN.R!"3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D
M;W5B;&4G('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R
M.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4
M.B`P:6X[(%!!1$1)3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN
M.R!724142#H@,BXV."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#(E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN
M(#!P="<^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N
M;VYE.R!0041$24Y'+4Q%1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@
M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!724142#H@,2XS)3L@4$%$1$E.
M1RU43U`Z(#!I;CL@0D]21$52+4)/5%1/33H@=VEN9&]W=&5X="`R+C(U<'0@
M9&]U8FQE)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%
M4BU43U`Z('=I;F1O=W1E>'0@,7!T('-O;&ED.R!0041$24Y'+4Q%1E0Z(#!I
M;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE9&EU;2!N
M;VYE.R!724142#H@,3(N-C(E.R!0041$24Y'+51/4#H@,&EN.R!"3U)$15(M
M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$R)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,&EN(#!I
M;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;B<@<VEZ93TS1#(^,3<L,S,V+#<V,#PO9F]N=#X\+W`^/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D<M
M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,BXV."4[
M(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+5))
M1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4Q%
M1E0Z(#!I;CL@4$%$1$E.1RU"3U143TTZ(#!I;CL@0D]21$52+4Q%1E0Z(&UE
M9&EU;2!N;VYE.R!724142#H@,3,N.3(E.R!0041$24Y'+51/4#H@,&EN.R!"
M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4G('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$S)3X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,&EN(#!I;B`P<'0[(%1%6%0M04Q)1TXZ(')I9VAT)R!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^)B,X,C$R.SPO9F]N=#X\+W`^
M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)
M3D<M3$5&5#H@,&EN.R!0041$24Y'+4)/5%1/33H@,&EN.R!724142#H@,2XP
M."4[(%!!1$1)3D<M5$]0.B`P:6XG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*/'`@<W1Y;&4],T0G34%21TE..B`P:6X@,&EN(#!P="<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W`^/"]T9#X\+W1R
M/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R!4
M15A4+4E.1$5.5#H@,"XU:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO<#X\+W1D/CPO='(^/"]T86)L93X-"CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(S8S0Y.3)?-C0Y
M,5\T.3@U7S@Y9C5?,#,X.34U-C-D.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU
M,2]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$581SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY$15-#4DE05$E/3B!/1B!"55-)3D534R`H1&5T
M86EL<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,CQB<CYI=&5M/&)R/G9A8V-I;F4\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1$530U))4%1)3TX@3T8@0E53
M24Y%4U,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3G5M8F5R(&]F(&-A;F-E<B!V86-C:6YE<R!T:&%T(&AA=F4@8F5E;B!G
M<F%N=&5D($9$02!O<G!H86X@9')U9R!D97-I9VYA=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%!H87-E($D@86YD
M(%!H87-E($E)(&-L:6YI8V%L('1R:6%L<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU
M,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C-C-#DY,E\V-#DQ
M7S0Y.#5?.#EF-5\P,S@Y-34V,V0Y-3$O5V]R:W-H965T<R]3:&5E=#$Y+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%5T4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0D%325,@
M3T8@4%)%4T5.5$%424].("A$971A:6QS*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D)!4TE3($]&(%!215-%3E1!
M5$E/3CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y2979E<G-E('-T;V-K('-P;&ET(&-O;G9E<G-I;VX@<F%T:6\\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,38V-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?.#(S8S0Y.3)?-C0Y,5\T.3@U
M7S@Y9C5?,#,X.34U-C-D.34Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU,2]7;W)K
M<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$526D%'/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/DQ)455)1$E462!!3D0@0T%0251!3"!215-/55)#15,@
M*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#(P+"`R,#$R/&)R/D-O;6UO
M;B!S=&]C:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!=6<N
M(#,Q+"`R,#$R/&)R/D-O;6UO;B!S=&]C:SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!=6<N(#,Q+"`R,#$R/&)R/D-O;6UO;B!S=&]C:SQB
M<CY787)R86YT<R!I<W-U960@=&\@:6YS=&ET=71I;VYA;"!I;G9E<W1O<G,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CY-:6YI;75M/&)R/FET96T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY-87AI;75M/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^,C`Q,R!.
M;W1E<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$Q/&)R/C(P,3,@3F]T97,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3&EQ=6ED:71Y(&%N9"!C87!I=&%L(')E
M<V]U<F-E<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#,X+#`T.2PP.34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4W+#(R-2PR,S0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8Y
M+#8P,"PQ.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,X+#$U-2PR-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,C<W+#@U,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#<X,BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN=&5R97-T(')A=&4@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,N,3,E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!I<W-U960@9'5R:6YG('!E
M<FEO9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,30P+#<Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,S4Y+#DS,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,3<Y+#DV-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T('!R;V-E961S(&9R
M;VT@:7-S=6%N8V4@;V8@<VAA<F5S(&%N9"!W87)R86YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR-C@L-SDX/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!R97%U
M:7)E9"!T;R!O8FQI9V%T92!T:&4@96YT:71Y('1O(&5F9F5C="!M97)G97(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4&5R:6]D(&9O<B!W:&EC:"!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S('=I
M;&P@;65E="!L:7%U:61I='D@<F5Q=6ER96UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XS('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('!R
M;V1U8W1S(&]R('1E8VAN;VQO9VEE<R!L:6-E;G-E9"!B>2!T:&4@96YT:71Y
M(&%S(&%N(&%L=&5R;F%T:79E('1O(')A:7-I;F<@861D:71I;VYA;"!F:6YA
M;F-I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,V,T.3DR7S8T
M.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU,0T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\X,C-C-#DY,E\V-#DQ7S0Y.#5?.#EF-5\P,S@Y-34V,V0Y
M-3$O5V]R:W-H965T<R]3:&5E=#(Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%65I!23X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY615)424),12!314Y)3U(@3D]415,@
M*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3(\8G(^,C`Q
M,R!.;W1E<SQB<CYH;VQD97(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1F5B+B`R.2P@,C`Q,CQB<CXR,#$S($YO=&5S/&)R/FAO;&1E<CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/C(P,3,@3F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,CQB<CXR,#$S($YO=&5S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^,C`Q,R!.;W1E
M<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$Q/&)R/C(P,3,@3F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CXR,#$S($YO=&5S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;G9E<G1I8FQE
M('-E;FEO<B!N;W1E<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);G1E<F5S="!R871E("AA<R!A('!E<F-E;G0I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C$S)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,N,3,E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP
M86P@86UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L
M,C<W+#@U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@."PR-S<L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R,"PW.#(L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA
M<F5S(&ES<W5E9"!I;B!E>&-H86YG92!F;W(@8V%N8V5L;&%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<X-"PP-S`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@V."PP-34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#8U,BPQ,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYU;6)E<B!O9B!H;VQD97)S(&]F(&1E8G0@:6YS=')U;65N
M="!T;R!W:&]M('-H87)E<R!A<F4@:7-S=65D(&)Y('1H92!E;G1I='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP86P@86UO
M=6YT(&]F(&1E8G0@8V%N8V5L;&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#4P-"PQ-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPU,#0L,34P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D
M(&%N9"!U;G!A:60@:6YT97)E<W0@<&%Y86)L92!O;B!C86YC96QL871I;VX@
M;V8@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L-C@V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-SDL,#(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.3DL-S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.3DL-S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L(&YO;BUC87-H(&9A:7(@
M=F%L=64@861J=7-T;65N="!A='1R:6)U=&%B;&4@=&\@8V]N=F5R<VEO;B!O
M9B!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V,3$L-C(Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(L-30U+#4S,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M(')E8V5I=F%B;&4@=7!O;B!C;VYV97)S:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-S`L.#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N('!R:6-E("AI;B!D
M;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C(N,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(R+C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y296-O<F1E9"!F86ER('9A;'5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4Y,RPR,38\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4Y,RPR,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-RPS,S8L-S8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!;6]U;G0@;V8@9&EF9F5R96YC92!B971W965N(&%G9W)E
M9V%T92!R96-O<F1E9"!F86ER('9A;'5E(&]F('1H92!N;W1E<R!A;F0@=&AE
M:7(@=&]T86P@<W1A=&5D('!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8X-"PV,S0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.#0L-C,T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT-#4L,C0P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86ER('9A;'5E(&%D:G5S=&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#@T,RPT,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#8S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#0L,#,W+#<Y-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#DR.2PP,#`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86ER('9A;'5E(&%D:G5S=&UE;G0@871T<FEB=71A8FQE('1O('1H92!C:&%N
M9V4@:6X@:6YS=')U;65N="!S<&5C:69I8R!C<F5D:70@<FES:SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@T,2PP,#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,S`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D%S<W5M<'1I;VYS('1O(&5S=&%B;&ES:"!T:&4@=F%L=64@;V8@
M=&AE($YO=&5S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%V97)A9V4@<FES:RUF<F5E(')A=&4@*&%S(&$@<&5R8V5N="D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,30E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XQ.24\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9O
M;&%T:6QI='D@;V8@0FEO4V%N=&4@8V]M;6]N('-T;V-K("AA<R!A('!E<F-E
M;G0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,"XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-RXT
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1I<V-O=6YT(')A=&4@9F]R('!R:6YC:7!A;"!P87EM96YT<R!I;B!C
M87-H("AA<R!A('!E<F-E;G0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.2XV,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ."XU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U7S`S.#DU-38S
M9#DU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X,C-C-#DY,E\V
M-#DQ7S0Y.#5?.#EF-5\P,S@Y-34V,V0Y-3$O5V]R:W-H965T<R]3:&5E=#(R
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%4DI!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M5$]#2RU"05-%1"!#3TU014Y3051)3TX@*$1E=&%I;',I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M5$]#2RU"05-%1"!#3TU014Y3051)3TX\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!T:&%T(')E
M;6%I;F5D(&%V86EL86)L92!F;W(@:7-S=6%N8V4@=6YD97(@=&AE('!L86X\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDX,2PR-S(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=&]C:RUB87-E9"!C;VUP96YS871I;VX\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!G<F%N=&5D('5N
M9&5R('1H92!P;&%N("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-3@L-3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&5X97)C:7-E
M('!R:6-E(&]F(&]P=&EO;G,@9W)A;G1E9"`H:6X@9&]L;&%R<R!P97(@<VAA
M<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N,#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P
M=&EO;G,@97AP:7)E9"!A;F0@8V%N8V5L;&5D("AI;B!S:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#4L-S@Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14910D<^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!%455)5%D@*$1E=&%I;',I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#8^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`R,"P@,C`Q,CQB<CY#;VUM;VX@<W1O8VL\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^075G+B`S,2P@,C`Q,CQB<CY#;VUM;VX@<W1O
M8VL\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^075G+B`S,2P@
M,C`Q,CQB<CY787)R86YT<R!I<W-U960@=&\@:6YS=&ET=71I;VYA;"!I;G9E
M<W1O<G,\8G(^0V]M;6]N('-T;V-K/&)R/FET96T\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%Y(#,Q+"`R,#$R/&)R/DUI;FEM=6T\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#,Q+"`R,#$R/&)R
M/DUA>&EM=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L
M+B`S,2P@,C`Q,CQB<CXR,#$S($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D9E8BX@,CDL(#(P,3(\8G(^,C`Q,R!.;W1E<SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R
M/C(P,3,@3F]T97,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4W1O8VMH;VQD97(G<R!E<75I='D\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E
M<R!I<W-U960@:6X@97AC:&%N9V4@9F]R(&-A;F-E;&QA=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW.#0L,#<P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX-C@L,#4U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV
M-3(L,3(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<FEN8VEP86P@86UO=6YT(&]F(&1E8G0@8V%N8V5L;&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-3`T+#$U,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.2PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,BPU,#0L,34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&%N9"!U;G!A:60@:6YT97)E
M<W0@<&%Y86)L92!O;B!C86YC96QL871I;VX@;V8@9&5B=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L-C@V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SDL,#(T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3DL-S$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:R!I<W-U960@9'5R:6YG('!E<FEO9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,30P+#<Q,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S4Y+#DS,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3<Y+#DV
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4'5R8VAA<V4@<')I8V4@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C0W,C4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O
M9B!I;G-T:71U=&EO;F%L(&EN=F5S=&]R<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1W)O<W,@<')O8V5E9',@9G)O;2!I<W-U86YC92!O
M9B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q,2PP
M-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#0W-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!P<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F('-H
M87)E<R!A;F0@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,C8X+#<Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&5R;2!O9B!W87)R86YT<R`H:6X@>65A<G,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES
M92!P<FEC92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V97)S92!S=&]C:R!S<&QI="!C
M;VYV97)S:6]N(')A=&EO/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP+C$V-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9R86-T:6]N86P@<VAA<F4@<&%Y;W5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8U.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C4X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I%04,^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)
M15,@*$1E=&%I;',I("A'96P@4&%C:V%G:6YG($UA8VAI;F4L($%P=&%R(%!H
M87)M82P@55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D=E;"!086-K86=I;F<@36%C:&EN92!\($%P=&%R(%!H87)M83PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI
M=&UE;G0@86YD(&-O;G1I;F=E;F-I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06UO=6YT(&]F(&-O;6UI=&UE;G0@=&\@
M<'5R8VAA<V4@;6%C:&EN97)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#@T-"PW-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!P86ED/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX,#0L,3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296UA:6YI;F<@;V)L:6=A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,"PV,#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,V,T.3DR7S8T
M.3%?-#DX-5\X.68U7S`S.#DU-38S9#DU,0T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\X,C-C-#DY,E\V-#DQ7S0Y.#5?.#EF-5\P,S@Y-34V,V0Y
M-3$O5V]R:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5T)!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TU-251-14Y44R!!3D0@0T].5$E.1T5.
M0TE%4R`H1&5T86EL<R`R*2`H4VAA<F5H;VQD97(@9&5R:79A=&EV92!A8W1I
M;VXI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,C0L
M(#(P,3(\8G(^:71E;3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F5H;VQD97(@9&5R:79A=&EV92!A8W1I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#3TU-251-14Y44R!!
M3D0@0T].5$E.1T5.0TE%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@8V%S97,@8V]N<V]L:61A=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P145-04<^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0Q/CQS=')O;F<^1D%)4B!604Q512!-14%355)%345.5%,@*$1E=&%I;',I
M("A296-U<G)I;F<@8F%S:7,L(%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^07-S971S.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!!
M<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S8L.34W
M+#0V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-34L-#8U+#4P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI=&EE<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA
M8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-3DS
M+#(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$W+#,S-BPW-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L('P@,C`Q,R!.;W1E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI86)I;&ET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M('9A;'5E(&]F(&-O;G9E<G1I8FQE(&1E8G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<L-3DS+#(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#,S-BPW-C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('P@36]N
M97D@;6%R:V5T(&9U;F0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L($%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S8L.34W+#0V.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U+#0V-2PU,#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC
M86YT($]T:&5R($]B<V5R=F%B;&4@26YP=71S("A,979E;"`R*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-BPY-3<L
M-#8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-34L-#8U+#4P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-3DS+#(Q
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$W+#,S-BPW-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-I9VYI9FEC86YT($]T:&5R($]B<V5R=F%B;&4@26YP
M=71S("A,979E;"`R*2!\(#(P,3,@3F]T97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O
M9B!C;VYV97)T:6)L92!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW+#4Y,RPR,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-RPS,S8L-S8P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=N:69I8V%N="!/=&AE<B!/
M8G-E<G9A8FQE($EN<'5T<R`H3&5V96P@,BD@?"!-;VYE>2!M87)K970@9G5N
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%S
M<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,V+#DU-RPT-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#4U+#0V-2PU,#<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U
M7S`S.#DU-38S9#DU,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\X
M,C-C-#DY,E\V-#DQ7S0Y.#5?.#EF-5\P,S@Y-34V,V0Y-3$O5V]R:W-H965T
M<R]3:&5E=#(W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%6D1#2SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY354)315%514Y4($5614Y44R`H1&5T86EL<RD@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$R/&)R/DUI;FEM=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^3V-T+B`P,RP@,C`Q,CQB<CY3=6)S97%U96YT($5V96YT/&)R
M/D%G<F5E;65N="!A;F0@4&QA;B!O9B!-97)G97(\8G(^:71E;3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#`S+"`R,#$R/&)R/E-U
M8G-E<75E;G0@179E;G0\8G(^06=R965M96YT(&%N9"!0;&%N(&]F($UE<F=E
M<CQB<CY-:6YI;75M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D]C="X@,#,L(#(P,3(\8G(^4W5B<V5Q=65N="!%=F5N=#QB<CY!9W)E96UE
M;G0@86YD(%!L86X@;V8@365R9V5R/&)R/DUA>&EM=6T\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY3=6)S97%U
M96YT($5V96YT/&)R/D%.22!0:&%R;6%C975T:6-A;',L($EN8SQB<CY%;7!L
M;WEE92!2961U8W1I;VX\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^3V-T+B`P,RP@,C`Q,CQB<CY3=6)S97%U96YT($5V96YT/&)R/D%.22!0
M:&%R;6%C975T:6-A;',L($EN8SQB<CY!9W)E96UE;G0@86YD(%!L86X@;V8@
M365R9V5R/&)R/FET96T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^3V-T+B`P,RP@,C`Q,CQB<CY3=6)S97%U96YT($5V96YT/&)R/D%.22!0
M:&%R;6%C975T:6-A;',L($EN8SQB<CY!9W)E96UE;G0@86YD(%!L86X@;V8@
M365R9V5R/&)R/DUI;FEM=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^3V-T+B`P,RP@,C`Q,CQB<CY3=6)S97%U96YT($5V96YT/&)R/D%.
M22!0:&%R;6%C975T:6-A;',L($EN8SQB<CY!9W)E96UE;G0@86YD(%!L86X@
M;V8@365R9V5R/&)R/DUA>&EM=6T\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^3V-T+B`P,RP@,C`Q,CQB<CY3=6)S97%U96YT($5V96YT/&)R
M/D%.22!0:&%R;6%C975T:6-A;',L($EN8SQB<CY6;W1I;F<@06=R965M96YT
M<SQB<CYI=&5M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C
M="X@,#,L(#(P,3(\8G(^4W5B<V5Q=65N="!%=F5N=#QB<CY!3DD@4&AA<FUA
M8V5U=&EC86QS+"!);F,\8G(^3&]C:RU5<"!!9W)E96UE;G1S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,#,L(#(P,3(\8G(^4W5B
M<V5Q=65N="!%=F5N=#QB<CY!3DD@4&AA<FUA8V5U=&EC86QS+"!);F,\8G(^
M0V]N=&EN9V5N="!686QU92!2:6=H=',@06=R965M96YT/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,#,L(#(P,3(\8G(^4W5B<V5Q
M=65N="!%=F5N=#QB<CY!3DD@4&AA<FUA8V5U=&EC86QS+"!);F,\8G(^0V]N
M=&EN9V5N="!686QU92!2:6=H=',@06=R965M96YT/&)R/DUA>&EM=6T\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`Q,CQB
M<CY3=6)S97%U96YT($5V96YT/&)R/E1E=F$\8G(^5&AI<F0@06UE;F1M96YT
M(%1O($QI8V5N<V4@06=R965M96YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D]C="X@,S$L(#(P,3(\8G(^4W5B<V5Q=65N="!%=F5N=#QB
M<CY4979A/&)R/E1H:7)D($%M96YD;65N="!4;R!,:6-E;G-E($%G<F5E;65N
M=#QB<CY-:6QE<W1O;F4@<&%Y;65N="!U<&]N($9$02!A=71H;W)I>F%T:6]N
M(&]F(&UA<FME=&EN9R!O9B!L:6-E;G-E9"!M86QE('1E<W1O<W1E<F]N92!G
M96P\8G(^1F]R96-A<W0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^3V-T+B`S,2P@,C`Q,CQB<CY3=6)S97%U96YT($5V96YT/&)R/E1E=F$\
M8G(^5&AI<F0@06UE;F1M96YT(%1O($QI8V5N<V4@06=R965M96YT/&)R/DUI
M;&5S=&]N92!P87EM96YT('5P;VX@96%R;&EE<B!O9B!$96-E;6)E<B`S,2P@
M,C`Q,B!A;F0@9FEV92!B=7-I;F5S<R!D87ES(&%F=&5R('-U8FUI<W-I;VX@
M=&\@1D1!(&]F(&9I;F%L(')E<&]R="!O;B!W87-H:6YG(&-L:6YI8V%L('-T
M=61Y/&)R/D9O<F5C87-T/&)R/FET96T\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`Q,CQB<CY3=6)S97%U96YT($5V96YT
M/&)R/E1E=F$\8G(^5&AI<F0@06UE;F1M96YT(%1O($QI8V5N<V4@06=R965M
M96YT/&)R/DUI;&5S=&]N92!P87EM96YT('5P;VX@96%R;&EE<B!O9B!$96-E
M;6)E<B`S,2P@,C`Q,R!A;F0@9FEV92!B=7-I;F5S<R!D87ES(&%F=&5R(&-O
M;6UE;F-E;65N="!O9B!C;VUM97)C:6%L(&UA;G5F86-T=7)E(&]F(&QI8V5N
M<V5D('!R;V1U8W0@9F]R('-A;&4@:6X@=&AE(%5N:71E9"!3=&%T97,\8G(^
M1F]R96-A<W0\8G(^:71E;3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y/8W0N(#,Q+"`R,#$R/&)R/E-U8G-E<75E;G0@179E;G0\8G(^5&5V
M83QB<CY4:&ER9"!!;65N9&UE;G0@5&\@3&EC96YS92!!9W)E96UE;G0\8G(^
M4&%Y;65N="!F;W(@8F5I;F<@=&AE('-O;&4@;6%R:V5T97(@:6X@=&AE(%5N
M:71E9"!3=&%T97,@;V8@82!G96YE<FEC(#$E('1E<W1O<W1E<F]N92!G96P@
M04(M<F%T960@=&\@06YD<F]'96P@9F]R(&%T(&QE87-T(#$X,"!D87ES(&EM
M;65D:6%T96QY(&9O;&QO=VEN9R!T:&4@;&%U;F-H(&1A=&4@;V8@=&AE(&QI
M8V5N<V5D('!R;V1U8W0@:6X@=&AE(%5N:71E9"!3=&%T97,\8G(^1F]R96-A
M<W0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@
M,C`Q,CQB<CY3=6)S97%U96YT($5V96YT/&)R/E1E=F$\8G(^5&AI<F0@06UE
M;F1M96YT(%1O($QI8V5N<V4@06=R965M96YT/&)R/DUI;FEM=6T\8G(^4&%Y
M;65N="!F;W(@8F5I;F<@=&AE('-O;&4@;6%R:V5T97(@:6X@=&AE(%5N:71E
M9"!3=&%T97,@;V8@82!G96YE<FEC(#$E('1E<W1O<W1E<F]N92!G96P@04(M
M<F%T960@=&\@06YD<F]'96P@9F]R(&%T(&QE87-T(#$X,"!D87ES(&EM;65D
M:6%T96QY(&9O;&QO=VEN9R!T:&4@;&%U;F-H(&1A=&4@;V8@=&AE(&QI8V5N
M<V5D('!R;V1U8W0@:6X@=&AE(%5N:71E9"!3=&%T97,\8G(^1F]R96-A<W0\
M8G(^:71E;3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY354)315%514Y4($5614Y44SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&]U='-T86YD
M:6YG('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@;V8@8V]M8FEN960@8V]M<&%N
M>2!O=VYE9"!B>2!C=7)R96YT('-T;V-K:&]L9&5R<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#<N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DN.3`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`N,3`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@9&ER96-T;W)S(&]F('1H92!E;G1I='D@:6X@8F]A<F0@;V8@
M9&ER96-T;W)S(&]F('1H92!C;VUB:6YE9"!C;VUP86YY/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V97)S92!S<&QI="!R871I;SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XR/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XU/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S
M:"!R97%U:7)E9"!T;R!O8FQI9V%T92!T:&4@96YT:71Y('1O(&5F9F5C="!M
M97)G97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3<L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&5R;6EN871I;VX@9F5E('!A>6%B;&4@=6YD
M97(@<W!E8VEF:65D(&-I<F-U;7-T86YC97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<U,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E:6UB=7)S96UE;G0@
M;V8@97AP96YS97,@:6X@8V]N;F5C=&EO;B!W:71H(&UE<F=E<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O
M9B!O=71S=&%N9&EN9R!S:&%R97,@;V8@8V%P:71A;"!S=&]C:R!H96QD(&)Y
M('-T;V-K:&]L9&5R<R!A<R!O9B!T:&4@8VQO<V4@;V8@8G5S:6YE<W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M('-T;V-K:&]L9&5R<R!H;VQD:6YG(#4W('!E<F-E;G0@;V8@;W5T<W1A;F1I
M;F<@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!O=71S=&%N9&EN9R!S:&%R
M97,@;V8@8V]M;6]N('-T;V-K(&AE;&0@8GD@<W1O8VMH;VQD97)S('=H;R!A
M9W)E960@=&\@=F]T92!I;B!F879O<B!O9B!E;&5C=&EO;B!O9B!D:7)E8W1O
M<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M
M8F5R(&]F(&1I<F5C=&]R<R!D97-I9VYA=&5D(&)Y('1H92!E;G1I='D@870@
M=&AE(&9I<G-T(&%N;G5A;"!M965T:6YG(&]F('-T;V-K:&]L9&5R<R!F;VQL
M;W=I;F<@=&AE(&-O;7!L971I;VX@;V8@=&AE($UE<F=E<CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!O=71S=&%N
M9&EN9R!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&AE;&0@8V]L;&5C=&EV96QY
M(&)Y('-P96-I9FEE9"!P97)S;VYN96P@=VAO(&5N=&5R960@:6YT;R!V;W1I
M;F<@86=R965M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQO8VMI;F<@<&5R:6]D(&]N('1H92!S86QE(&]F('-H
M87)E<R!O9B!T:&4@0V]M<&%N>2=S(&-O;6UO;B!S=&]C:R!R96-E:79E9"!I
M;B!T:&4@365R9V5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV
M(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F(&-O;G1I;F=E;G0@=F%L=64@<FEG:'1S(&ES
M<W5E9"!I;B!E>&-H86YG92!F;W(@;VYE('-H87)E(&]F(&-O;6UO;B!S=&]C
M:R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4&5R:6]D(&1U<FEN9R!W:&EC:"!N970@8V%S:"!P87EM96YT<R!C86X@
M8F4@<F5C96EV960@869T97(@9&ES=')I8G5T:6]N(&]F(')I9VAT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`@>65A<G,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H
M('!A>6UE;G1S('1O(&)E(&1I<W1R:6)U=&5D('1O(&AO;&1E<G,@;V8@=&AE
M($-64G,@97AP<F5S<V5D(&%S('!E<F-E;G1A9V4@;V8@;F5T(&-A<V@@<&%Y
M;65N=',@<F5C96EV960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8V+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06=G<F5G871E(&YE="!C87-H('!A>6UE;G1S('1O(&)E(&1I
M<W1R:6)U=&5D('1O(&AO;&1E<G,@;V8@0U92<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5V97)A;F-E(&-O<W1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT
M<R!R96-E:79E9"!F<F]M(&%G<F5E;65N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E(&%M;W5N="!R96-E
M:79A8FQE+"!I9B!R96=U;&%T;W)Y(&UI;&5S=&]N97,@87)E('-U8V-E<W-F
M=6QL>2!A8VAI979E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@8G5S:6YE<W,@9&%Y
M<R!C;VYS:61E<F5D(&EN(&UI;&5S=&]N92!P87EM96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE;G1S(')E8V5I=F%B;&4L
M(&EF('-O;&4@;6%R:V5T97(@<FEG:'1S(&%R92!G:79E;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!D
M87ES(&9R;VT@=&AE(&QA=6YC:"!O9B!T:&4@;&EC96YS960@<')O9'5C="!I
M;B!T:&4@56YI=&5D(%-T871E<R!F;W(@=VAI8V@@<V]L92!M87)K971E<B!R
M:6=H="!I<R!G:79E;B!F;W(@861D:71I;VYA;"!P87EM96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@<F%T92!A<R!A
M('!E<F-E;G1A9V4@;V8@;F5T('-A;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C<N:'1M;"(O/@T*/"]X
M;6P^#0HM+2TM+2T]7TYE>'1087)T7S@R,V,T.3DR7S8T.3%?-#DX-5\X.68U
17S`S.#DU-38S9#DU,2TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LIQUIDITY AND CAPITAL RESOURCES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_LiquidityAndCapitalResourcesDisclosureAbstract', window );"><strong>LIQUIDITY AND CAPITAL RESOURCES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_LiquidityAndCapitalResourcesTextBlock', window );">LIQUIDITY AND CAPITAL RESOURCES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">3.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">LIQUIDITY AND CAPITAL RESOURCES</font></b></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Substantially all of the Company&#8217;s revenue to date has been derived from upfront, milestone and royalty payments earned on licensing transactions and from subcontracts.&#160; The Company&#8217;s business operations to date have consisted mostly of licensing and research and development activities.&#160; The Company itself has not introduced commercially any products.&#160; To date, the Company has used primarily equity financings, and to a lesser extent, licensing income, interest income and the cash received from its 2009 merger with Cell Genesys,&#160;Inc. (Cell Genesys), to fund its ongoing business operations and short-term liquidity needs.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">As of September&#160;30, 2012, the Company had $38,049,095 of cash and cash equivalents.&#160; As of September&#160;30, 2012, the Company had outstanding $8,277,850 in aggregate principal amount of its 3.125% convertible senior notes due May&#160;1, 2013.&#160; In August&#160;2012, the Company completed an offering of an aggregate of 2,359,932 shares of the Company&#8217;s common stock and warrants to purchase an aggregate of 1,179,966 shares of the Company&#8217;s common stock, resulting in net proceeds of $3,268,798, after deducting placement agent fees and other offering expenses. See Note 7, &#8220;Stockholders&#8217; Equity,&#8221; for additional discussion regarding the August&#160;2012 registered direct offering.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Absent the receipt of any additional licensing income or financing, the Company expects its cash and cash equivalents balance to decrease as the Company continues to use cash to fund its operations.&#160; Assuming the Company&#8217;s pending merger with ANIP Acquisition Company d/b/a ANI Pharmaceuticals,&#160;Inc. (ANI) is completed during the first quarter of 2013 (see Note 10, &#8220;Subsequent Events&#8221;), the Company expects its cash and cash equivalents as of September&#160;30, 2012 to meet the Company&#8217;s liquidity requirements through at least the Company&#8217;s anticipated closing of the merger, including the requirement under our merger agreement to have at least $17 million of net cash (as defined in the merger agreement) available upon the closing of the merger.&#160;&#160; If the Company&#8217;s pending merger with ANI is not completed, the Company will need to reevaluate its strategic alternatives, which may include a sale of the company, liquidation of the company or other strategic transaction.&#160; The Company&#8217;s liquidity position will be dependent upon the strategic alternative selected; however, assuming the Company does not enter into another strategic transaction, and assuming the Company decides not to commence the two new efficacy trials for LibiGel, the Company expects its cash and cash equivalents as of September&#160;30, 2012 will be sufficient to meet the Company&#8217;s liquidity requirements for at least the next 3-5 years.&#160; Additional financing would be required should the Company decide to commence the two new efficacy trials for LibiGel.&#160; These estimates may prove incorrect or the Company, nonetheless, may choose to raise additional financing earlier.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company does not have any existing credit facilities under which the Company could borrow funds.&#160; In the event that the Company would require additional working capital to fund future operations, the Company could seek to acquire such funds through additional equity or debt financing arrangements. If the Company raises additional funds by issuing equity securities, the Company&#8217;s stockholders may experience dilution.&#160; Debt financing, if available, may involve covenants restricting the Company&#8217;s operations or the Company&#8217;s ability to incur additional debt.&#160; There is no assurance that any financing transaction will be available on terms acceptable to the Company, or at all.&#160; As an alternative to raising additional financing, the Company may choose to attempt to license one or more of its products or technologies to a third party who may finance a portion or all of the continued development and, if approved, commercialization of that licensed product, sell certain assets or rights under the Company&#8217;s existing license agreements.&#160; In addition, from time to time, the Company may purchase, exchange or restructure its outstanding convertible senior notes through cash purchases and/or exchanges for other equity securities of the Company, in open market purchases, privately negotiated transactions and/or a tender offer.&#160; Such purchases, exchanges or restructurings, if any, will depend on prevailing market conditions, the Company&#8217;s available cash and cash equivalents, the Company&#8217;s liquidity requirements, contractual restrictions and other factors.&#160; Such purchases, exchanges or restructurings could dilute the percentage ownership of the Company&#8217;s stockholders, result in the issuance of securities at a discount to market price or that may have rights, preferences or privileges senior to those of the Company&#8217;s existing stockholders and/or decrease the Company&#8217;s cash balance.&#160; A significant decrease in the Company&#8217;s cash balance, together with an inability to raise additional financing when needed, may impair the Company&#8217;s ability to complete its proposed merger with ANI, execute other strategic alternatives or leave the Company without sufficient cash remaining for operations.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company can provide no assurance that additional financing, if needed, will be available on terms favorable to the Company, or at all.&#160; This is particularly true if investors are not confident in the Company&#8217;s business and future prospects, the future value of the Company and/or economic and market conditions deteriorate.&#160; In addition, the Company&#8217;s ability to raise additional financing is limited by the terms of its agreement and plan of merger with ANI.&#160; See Note 10, &#8220;Subsequent Events.&#8221;&#160; If adequate funds are not available or are not available on acceptable terms when the Company needs them, the Company may need to reduce its operating costs or the Company may be forced to complete other strategic alternatives, such as winding down its operations and liquidating the Company.&#160; In such case, the Company&#8217;s stockholders could lose some or all of their investment.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_LiquidityAndCapitalResourcesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_LiquidityAndCapitalResourcesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_LiquidityAndCapitalResourcesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element may be used for the entire disclosure related to entity's liquidity and capital resources, which includes description of entity's revenue, stockholders' equity, including other comprehensive income, and cash and cash equivalents disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_LiquidityAndCapitalResourcesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EOJAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 38,049,095<span></span></td>
        <td class="nump">$ 57,225,234<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
        <td class="nump">534,037<span></span></td>
        <td class="nump">801,147<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
        <td class="nump">38,583,132<span></span></td>
        <td class="nump">58,026,381<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
        <td class="nump">1,184,764<span></span></td>
        <td class="nump">861,364<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments</a></td>
        <td class="nump">3,413,762<span></span></td>
        <td class="nump">3,405,807<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
        <td class="nump">30,088<span></span></td>
        <td class="nump">86,203<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
        <td class="nump">43,211,746<span></span></td>
        <td class="nump">62,379,755<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">2,004,814<span></span></td>
        <td class="nump">3,150,677<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
        <td class="nump">463,942<span></span></td>
        <td class="nump">1,597,329<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
        <td class="nump">860,094<span></span></td>
        <td class="nump">2,479,697<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotesCurrent', window );">Current portion of convertible senior notes</a></td>
        <td class="nump">7,593,216<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
        <td class="nump">10,922,066<span></span></td>
        <td class="nump">7,227,703<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Long-term convertible senior notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,336,760<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
        <td class="nump">10,922,066<span></span></td>
        <td class="nump">24,564,463<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_CapitalStockAbstract', window );"><strong>Capital stock</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Capital stock</a></td>
        <td class="nump">273,259,236<span></span></td>
        <td class="nump">255,054,440<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(240,969,556)<span></span></td>
        <td class="num">(217,239,148)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
        <td class="nump">32,289,680<span></span></td>
        <td class="nump">37,815,292<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
        <td class="nump">43,211,746<span></span></td>
        <td class="nump">62,379,755<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Class C special stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_CapitalStockAbstract', window );"><strong>Capital stock</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Capital stock</a></td>
        <td class="nump">65<span></span></td>
        <td class="nump">65<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_CapitalStockAbstract', window );"><strong>Capital stock</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Capital stock</a></td>
        <td class="nump">$ 273,259,171<span></span></td>
        <td class="nump">$ 255,054,375<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_CapitalStockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_CapitalStockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValueOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleLongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepositsAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeRelatedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e7018-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SeniorNotesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_DescriptionOfBusinessDisclosureAbstract', window );"><strong>DESCRIPTION OF BUSINESS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">1.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">DESCRIPTION OF BUSINESS</font></b></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">BioSante Pharmaceuticals,&#160;Inc.&#8217;s (the Company) corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and the Company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company&#8217;s products, either approved or in clinical development, include: (1)&#160;LibiGel, once daily transdermal testosterone gel in Phase III clinical development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD); (2)&#160;a once daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of hypogonadism, or testosterone deficiency in men, and licensed to Teva Pharmaceuticals USA,&#160;Inc. (Teva); (3)&#160;GVAX cancer vaccines, a portfolio of cancer vaccines, four of which have been granted FDA orphan drug designation, and which are currently in 17 Phase I and Phase II clinical trials for the treatment of various cancers; (4)&#160;The Pill-Plus (triple component contraceptive), once daily use of various combinations of estrogens, progestogens and androgens in Phase II development; and (5)&#160;Elestrin, once daily transdermal estradiol (estrogen) gel approved by the FDA indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S. by Meda Pharmaceuticals Inc. (Meda), the Company&#8217;s licensee.</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_DescriptionOfBusinessDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_DescriptionOfBusinessDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ERJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares that remained available for issuance under the plan</a></td>
        <td class="nump">981,272<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock options</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted under the plan (in shares)</a></td>
        <td class="nump">358,582<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of options granted (in dollars per share)</a></td>
        <td class="nump">$ 4.08<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options expired and cancelled (in shares)</a></td>
        <td class="nump">105,781<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) (Gel Packaging Machine, Aptar Pharma, USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Gel Packaging Machine | Aptar Pharma</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Commitment and contingencies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Amount of commitment to purchase machinery</a></td>
        <td class="nump">$ 844,740<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_PurchaseCommitmentCumulativePaymentsToAcquireMachinery', window );">Amount paid</a></td>
        <td class="nump">804,132<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Remaining obligation</a></td>
        <td class="nump">$ 40,608<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_PurchaseCommitmentCumulativePaymentsToAcquireMachinery">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the cumulative amount paid by the entity for purchase of machinery.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_PurchaseCommitmentCumulativePaymentsToAcquireMachinery</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermPurchaseCommitmentAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermPurchaseCommitmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PurchaseObligation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">BASIS OF PRESENTATION</font></b></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In the opinion of management, the accompanying unaudited condensed financial statements contain all necessary adjustments, which are of a normal recurring nature, to present fairly the financial position of the Company as of September&#160;30, 2012 and December&#160;31, 2011, the results of operations for the three and nine months ended September&#160;30, 2012 and 2011, and the cash flows for the nine months ended September&#160;30, 2012 and 2011, in conformity with accounting principles generally accepted in the United States of America (GAAP).&#160; Operating results for the three and nine month periods ended September&#160;30, 2012 are not necessarily indicative of the results that may be expected for the full year ending December&#160;31, 2012.&#160; The Company does not have items of other comprehensive income for either of the three or nine month periods ended September&#160;30, 2012 or 2011; and therefore, has not presented comprehensive income.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">These unaudited interim condensed financial statements should be read in conjunction with the financial statements and related notes contained in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2011.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On June&#160;1, 2012, the Company effected a one-for-six reverse split of its outstanding common stock and class C special stock.&#160; These unaudited interim condensed financial statements give retroactive effect to the reverse stock split.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccounting</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EYNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Class C special stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Capital stock, issued shares</a></td>
        <td class="nump">65,211<span></span></td>
        <td class="nump">65,214<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Capital stock, outstanding shares</a></td>
        <td class="nump">65,211<span></span></td>
        <td class="nump">65,214<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Capital stock, issued shares</a></td>
        <td class="nump">24,422,240<span></span></td>
        <td class="nump">18,269,755<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Capital stock, outstanding shares</a></td>
        <td class="nump">24,422,240<span></span></td>
        <td class="nump">18,269,755<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities recorded at fair value on a recurring basis</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt">&#160;</p>
<table style="MARGIN-LEFT: 0.5in; WIDTH: 788px; BORDER-COLLAPSE: collapse; HEIGHT: 149px" cellspacing="0" cellpadding="0" width="788" border="0">
<tr style="HEIGHT: 0px">
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="32%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Description</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">September&#160;30,<br />
2012&#160;Balance</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Quoted&#160;Prices&#160;in<br />
Active&#160;Markets<br />
for&#160;Identical<br />
Assets&#160;(Level&#160;1)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Significant<br />
Other<br />
Observable<br />
Inputs&#160;(Level&#160;2)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Significant<br />
Unobservable<br />
Inputs&#160;(Level&#160;3)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Assets:</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Money market fund</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">36,957,469</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">36,957,469</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total assets</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">36,957,469</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">36,957,469</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Liabilities:</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2013 Notes</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,593,216</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,593,216</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total liabilities</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,593,216</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,593,216</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.5in; WIDTH: 783px; BORDER-COLLAPSE: collapse; HEIGHT: 149px" cellspacing="0" cellpadding="0" width="783" border="0">
<tr style="HEIGHT: 0px">
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="32%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Description</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">December&#160;31,<br />
2011&#160;Balance</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Quoted&#160;Prices&#160;in<br />
Active&#160;Markets<br />
for&#160;Identical<br />
Assets&#160;(Level&#160;1)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Significant<br />
&#160;Other<br />
&#160;Observable<br />
&#160;Inputs&#160;(Level&#160;2)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Significant<br />
Unobservable<br />
Inputs&#160;(Level&#160;3)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Assets:</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Money market fund</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">55,465,507</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">55,465,507</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total assets</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">55,465,507</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">55,465,507</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Liabilities:</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2013 Notes</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,336,760</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,336,760</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total liabilities</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,336,760</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,336,760</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Nov. 07, 2012

</div>
          <div>Class C special stock</div>
        </th>
        <th class="th">
          <div>Nov. 07, 2012

</div>
          <div>Common stock</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">BIOSANTE PHARMACEUTICALS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001023024<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">65,211<span></span></td>
        <td class="nump">24,422,240<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EXG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>item

</div>
          <div>vaccine</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_DescriptionOfBusinessDisclosureAbstract', window );"><strong>DESCRIPTION OF BUSINESS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation', window );">Number of cancer vaccines that have been granted FDA orphan drug designation</a></td>
        <td class="nump">4<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfPhaseIAndPhaseIIClinicalTrials', window );">Number of Phase I and Phase II clinical trials</a></td>
        <td class="nump">17<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_DescriptionOfBusinessDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_DescriptionOfBusinessDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfPhaseIAndPhaseIIClinicalTrials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of Phase I and Phase II clinical trials for the treatment of various cancers in which the entity is participating.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfPhaseIAndPhaseIIClinicalTrials</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of cancer vaccines developed by the entity which have been granted FDA orphan drug designation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfVaccinesGrantedWithFDAOrphanDrugDesignation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESRAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUE</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
        <td class="nump">110,383<span></span></td>
        <td class="nump">82,784<span></span></td>
        <td class="nump">333,163<span></span></td>
        <td class="nump">220,787<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
        <td class="nump">110,383<span></span></td>
        <td class="nump">182,784<span></span></td>
        <td class="nump">333,163<span></span></td>
        <td class="nump">320,787<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>EXPENSES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">3,872,736<span></span></td>
        <td class="nump">11,500,053<span></span></td>
        <td class="nump">14,454,258<span></span></td>
        <td class="nump">37,480,873<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administration</a></td>
        <td class="nump">1,546,864<span></span></td>
        <td class="nump">1,675,268<span></span></td>
        <td class="nump">5,327,711<span></span></td>
        <td class="nump">5,257,853<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">25,749<span></span></td>
        <td class="nump">35,670<span></span></td>
        <td class="nump">87,548<span></span></td>
        <td class="nump">118,132<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
        <td class="nump">5,445,349<span></span></td>
        <td class="nump">13,210,991<span></span></td>
        <td class="nump">19,869,517<span></span></td>
        <td class="nump">42,856,858<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Convertible note fair value adjustment</a></td>
        <td class="num">(843,412)<span></span></td>
        <td class="nump">463,000<span></span></td>
        <td class="num">(4,037,797)<span></span></td>
        <td class="num">(1,929,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(67,105)<span></span></td>
        <td class="num">(172,000)<span></span></td>
        <td class="num">(283,348)<span></span></td>
        <td class="num">(516,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">1,877<span></span></td>
        <td class="nump">1,516<span></span></td>
        <td class="nump">5,300<span></span></td>
        <td class="nump">6,472<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAX BENEFIT</a></td>
        <td class="num">(6,243,606)<span></span></td>
        <td class="num">(12,733,691)<span></span></td>
        <td class="num">(23,852,199)<span></span></td>
        <td class="num">(44,959,599)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
        <td class="nump">121,791<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">121,791<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS</a></td>
        <td class="num">$ (6,121,815)<span></span></td>
        <td class="num">$ (12,733,691)<span></span></td>
        <td class="num">$ (23,730,408)<span></span></td>
        <td class="num">$ (44,959,599)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED NET LOSS PER SHARE (in dollars per share)</a></td>
        <td class="num">$ (0.27)<span></span></td>
        <td class="num">$ (0.73)<span></span></td>
        <td class="num">$ (1.14)<span></span></td>
        <td class="num">$ (2.86)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
        <td class="nump">22,921,176<span></span></td>
        <td class="nump">17,406,536<span></span></td>
        <td class="nump">20,841,417<span></span></td>
        <td class="nump">15,744,738<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
        <td class="nump">22,921,176<span></span></td>
        <td class="nump">17,406,536<span></span></td>
        <td class="nump">20,841,417<span></span></td>
        <td class="nump">15,744,738<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOptionChangesInFairValueGainLoss1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 10<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Chapter V<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Audit and Accounting Guide (AAG)<br><br> -Number AAG-BRD<br><br> -Paragraph 80<br><br> -Subparagraph Exhibit 4-4<br><br> -IssueDate 2006-05-01<br><br> -Chapter 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RoyaltyRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt">&#160;</p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">STOCKHOLDERS&#8217; EQUITY</font></b></p>
<p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">During the nine months ended September&#160;30, 2012, the Company issued an aggregate of 3,652,125 shares of its common stock to holders of the 2013 Notes in exchange for the cancellation of $12,504,150 in aggregate principal amount of such notes and accrued and unpaid interest of $99,710. See Note 5, &#8220;Convertible Senior Notes&#8221; for information regarding the 2013 Notes.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 36.7pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In August&#160;2012, the Company completed an offering of 2,359,932 shares of its common stock and warrants to purchase an aggregate of 1,179,966 shares of its common stock at a purchase price of $1.4725 per share to one institutional investor for gross proceeds of $3,475,000.&#160; The offering resulted in net proceeds to the Company of $3,268,798, after deducting placement agent fees and offering expenses. The warrants are exercisable immediately and continue for a period of 5 years, at an exercise price of $1.50 per share.&#160; The number of shares issuable upon exercise of the warrants and the exercise price of the warrants are adjustable in the event of stock splits, combinations and reclassifications, but not in the event of the issuance of additional securities.&#160; On September&#160;20, 2012, warrants from the August&#160;2012 offering to purchase an aggregate of 140,712 shares of common stock were exercised resulting in proceeds of $211,068 to the Company.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 36.7pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 36.7pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On May&#160;30, 2012, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Restated Certificate of Incorporation to effect a reverse split of the Company&#8217;s outstanding shares of common stock and class C special stock in the discretion of the Company&#8217;s Board of Directors at an exchange ratio of not less than one-for-two and not more than one-for-ten.&#160; On June&#160;1, 2012, the Board of Directors of the Company effected a one-for-six reverse split of the Company&#8217;s outstanding shares of common stock and class C special stock.&#160; No fractional shares were issued as a result of the reverse stock split, and stockholders who otherwise would have been entitled to a fractional share received, in lieu thereof, a cash payment based on the closing sale price of BioSante&#8217;s common stock on June 1, 2012.&#160; The total cash payment for fractional shares was $658.&#160; The reverse stock split did not change the number of authorized shares of the Company&#8217;s common stock or class C special stock or the par value of the Company&#8217;s common stock or class C special stock, but because the number of authorized shares of the Company&#8217;s common stock and class C special stock was not affected, the effect of the reverse stock split was to increase the number of authorized but unissued shares of the Company&#8217;s common stock and class C special stock.&#160; The primary purpose of the reverse stock split was to increase the Company&#8217;s ability to maintain the listing of its common stock on The NASDAQ Global Market.</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK-BASED COMPENSATION</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">6.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">STOCK-BASED COMPENSATION</font></b></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company typically grants options to purchase shares of the Company&#8217;s common stock to existing employees and non-employee directors on an annual basis during the first quarter of each year and to new employees and non-employee directors throughout the year on or around the date their employment or service with the Company commences.&#160; All options are granted under the BioSante Pharmaceuticals,&#160;Inc. Amended and Restated 2008 Stock Incentive Plan (the 2008 Plan).&#160; As of September&#160;30, 2012, approximately 981,272 shares of the Company&#8217;s common stock remain available for issuance under the 2008 Plan.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">During the nine months ended September&#160;30, 2012, the Company granted options under the 2008 Plan to purchase an aggregate of 358,582 shares of the Company&#8217;s common stock to certain employees of the Company and the Company&#8217;s non-employee directors with a weighted average exercise price of $4.08 per share.&#160; Options to purchase an aggregate of 105,781 shares of the Company&#8217;s common stock expired and were cancelled during the nine months ended September&#160;30, 2012.&#160; Options are granted at an exercise price equal to the closing price of the Company&#8217;s common stock on the date of the grant.&#160; No options were exercised during the nine months ended September&#160;30, 2012.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">No warrants were granted during the nine months ended September&#160;30, 2012, other than the warrants issued in conjunction with the Company&#8217;s August&#160;2012 offering described in Note 7, &#8220;Stockholders&#8217; Equity&#8221;.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EFQBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="6">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 20, 2012

</div>
          <div>Common stock</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2012

</div>
          <div>Common stock</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2012

</div>
          <div>Warrants issued to institutional investors

</div>
          <div>Common stock

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>May 31, 2012

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>May 31, 2012

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>2013 Notes</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>2013 Notes</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>2013 Notes</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_StockholdersEquityLineItems', window );"><strong>Stockholder's equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued in exchange for cancellation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,784,070<span></span></td>
        <td class="nump">1,868,055<span></span></td>
        <td class="nump">3,652,125<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount of debt cancelled</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,504,150<span></span></td>
        <td class="nump">$ 9,000,000<span></span></td>
        <td class="nump">$ 12,504,150<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued and unpaid interest payable on cancellation of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,686<span></span></td>
        <td class="nump">79,024<span></span></td>
        <td class="nump">99,710<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">140,712<span></span></td>
        <td class="nump">2,359,932<span></span></td>
        <td class="nump">1,179,966<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.4725<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfInstitutionalInvestorsToWhomOfferingMade', window );">Number of institutional investors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_ProceedsFromIssuanceOfCommonStockGross', window );">Gross proceeds from issuance of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">211,068<span></span></td>
        <td class="nump">3,475,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of shares and warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,268,798<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_ClassOfWarrantOrRightTermOfWarrants', window );">Term of warrants (in years)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_StockholdersEquityReverseStockSplitConversionRatio', window );">Reverse stock split conversion ratio</a></td>
        <td class="nump">0.1667<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.5<span></span></td>
        <td class="nump">0.1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_PaymentsToFractionalSharePayout', window );">Fractional share payout</a></td>
        <td class="nump">$ 658<span></span></td>
        <td class="nump">$ 658<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_ClassOfWarrantOrRightTermOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the term over which the warrants expire.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_ClassOfWarrantOrRightTermOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfInstitutionalInvestorsToWhomOfferingMade">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of institutional investors to whom offerings were made to raise funds.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfInstitutionalInvestorsToWhomOfferingMade</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_PaymentsToFractionalSharePayout">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents payments of fractional shares as a result of reverse stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_PaymentsToFractionalSharePayout</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_ProceedsFromIssuanceOfCommonStockGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the gross amount of cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_ProceedsFromIssuanceOfCommonStockGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_StockholdersEquityLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_StockholdersEquityLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_StockholdersEquityReverseStockSplitConversionRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the conversion ratio used in the calculation of reverse stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_StockholdersEquityReverseStockSplitConversionRatio</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionOriginalDebtAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_StockholdersEquityReverseStockSplitConversionRatio', window );">Reverse stock split conversion ratio</a></td>
        <td class="nump">0.1667<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_StockholdersEquityReverseStockSplitConversionRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the conversion ratio used in the calculation of reverse stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_StockholdersEquityReverseStockSplitConversionRatio</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">10.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">SUBSEQUENT EVENTS</font></b></p>
<p style="MARGIN: 0in 0in 0pt 0.5in; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Agreement and Plan of Merger</font></i></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On October&#160;3, 2012, the Company entered into an agreement and plan of merger (the Merger Agreement) with ANIP Acquisition Company d/b/a ANI Pharmaceuticals,&#160;Inc.&#160; The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, ANI will merge with and into the Company, with the Company continuing as the surviving company (the Merger).&#160; At the effective time of the Merger, each outstanding share of capital stock of ANI will be converted into the right to receive a number of shares of the Company&#8217;s common stock, if any, as determined pursuant to the exchange ratios described in the Merger Agreement and the provisions of ANI&#8217;s certificate of incorporation.&#160; All options, warrants or other rights to purchase shares of capital stock of ANI, will be canceled at the effective time of the Merger without any consideration in exchange, except for certain warrants which although not cancelled will not represent the right to acquire any equity or other interest in the combined company after the Merger.&#160; No fractional shares of the Company&#8217;s common stock will be issued in connection with the Merger, and holders of ANI capital stock will be entitled to receive cash in lieu thereof.&#160; Following the consummation of the transactions contemplated by the Merger Agreement, the current stockholders of ANI are expected to own approximately 53 percent of the outstanding shares of common stock of the combined company, and current stockholders of the Company are expected to own approximately 47 percent of the outstanding shares of common stock of the combined company.&#160; The exchange ratios are subject to potential adjustment as described in the Merger Agreement depending upon the amount of the Company&#8217;s &#8220;net cash&#8221;, as defined in the Merger Agreement and generally consisting of the Company&#8217;s cash and cash equivalents less certain expenses and liabilities, as of a determination date prior to the closing date of the Merger, but in no event will the current ANI stockholders own less than 50.1 percent (or the current Company stockholders own more than 49.9 percent) of the outstanding shares of common stock of the combined company.&#160; The Merger is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Merger Agreement provides that, immediately following the effective time of the Merger, the board of directors of the combined company will consist of five former directors of ANI and two former directors of the Company, and ANI&#8217;s current executive officers are expected to serve as executive officers of the combined company.&#160; In connection with the Merger, the Company will seek to amend its certificate of incorporation to: (i)&#160;effect a reverse split of its common stock at a ratio between the range of one-for-two and one-for-five, as determined by the Company and ANI, which is intended to ensure that the listing requirements of The NASDAQ Global Market or The NASDAQ Capital Market are satisfied; and (ii)&#160;change the name of the Company to &#8220;ANI Pharmaceuticals,&#160;Inc.&#8221; or another name as designated by ANI (together, the Charter Amendments).&#160; No fractional shares of the Company&#8217;s common stock will be issued in connection with the reverse split and holders of the Company&#8217;s common stock will be entitled to receive cash in lieu thereof.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Consummation of the Merger is subject to a number of conditions, including, but not limited to (i)&#160;the adoption and approval of the Merger Agreement and the transactions contemplated thereby by both the Company&#8217;s and ANI&#8217;s stockholders and the approval of the Charter Amendments by the Company&#8217;s stockholders; (ii)&#160;the effectiveness of a Form&#160;S-4 registration statement to be filed by the Company with the Securities and Exchange Commission to register the shares of the Company&#8217;s common stock to be issued in connection with the Merger, which will contain a joint proxy statement/prospectus; (iii)&#160;approval for the listing of shares of the Company&#8217;s common stock to be issued in the Merger on The NASDAQ Global Market or The NASDAQ Capital Market; (iv)&#160;written opinions of counsel that the Merger will qualify as a reorganization within the meaning of Section&#160;368(a)&#160;of the Code; and (v)&#160;other customary closing conditions.&#160; In addition, the obligation of ANI to effect the Merger is subject to a condition that the Company&#8217;s net cash, as calculated pursuant to the terms of the Merger Agreement, be no less than $17.0 million immediately prior to the effective time of the Merger.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Each of the Company and ANI have made customary representations, warranties and covenants in the Merger Agreement, including among others, covenants that (i)&#160;each party will conduct its business in the ordinary course consistent with past practice during the interim period between the execution of the Merger Agreement and the consummation of the Merger; (ii)&#160;each party will not engage in certain kinds of transactions or take certain actions during such period; (iii)&#160;ANI will convene and hold a meeting of its stockholders for the purpose of considering the adoption and approval of the Merger Agreement and the transactions contemplated thereby and the board of directors of ANI will recommend that its stockholders adopt and approve the Merger Agreement, subject to certain exceptions; and (iv)&#160;the Company will convene and hold a meeting of its stockholders for the purpose of considering the adoption and approval of the Merger Agreement and the transactions contemplated thereby and the approval of the Charter Amendments and the Company&#8217;s board of directors will recommend that the Company&#8217;s stockholders adopt and approve the Merger Agreement and approve the charter amendments, subject to certain exceptions.&#160; Each of the Company and ANI also has agreed not to solicit proposals relating to alternative business combination transactions or enter into discussions or an agreement concerning any proposals for alternative business combination transactions, subject to exceptions for the Company in the event of the Company&#8217;s receipt of a &#8220;superior proposal.&#8221;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Merger Agreement contains certain termination rights in favor of each of ANI and the Company in certain circumstances. If the Merger Agreement is terminated due to certain triggering events specified in the Merger Agreement, the Company will be required to pay ANI a termination fee of up to $1.0 million or ANI will be required to pay the Company a termination fee of up to $750,000. The Merger Agreement also provides that under specified circumstances, the Company may be required to reimburse ANI up to $500,000 for ANI&#8217;s expenses in connection with the transaction. Any expenses paid by the Company will be credited against the $1.0 million termination fee if the termination fee subsequently becomes payable by the Company.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Voting Agreements</font></i></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Concurrently and in connection with the execution of the Merger Agreement, certain of ANI&#8217;s stockholders, who collectively hold approximately 90 percent of the outstanding shares of ANI capital stock as of the close of business on October&#160;3, 2012,&#160; entered into voting agreements with the Company, pursuant to which each stockholder agreed to vote its shares of ANI capital stock in favor of the Merger, the Merger Agreement and the transactions contemplated by the Merger Agreement and against certain transactions or certain actions that would delay, prevent or nullify the Merger or the transaction contemplated by the Merger Agreement.&#160; In addition, one of the stockholders of ANI, who holds approximately 57 percent of the outstanding shares of ANI capital stock as of the close of business on October&#160;3, 2012, has agreed to vote in favor of the election of the two directors designated by the Company at the first annual meeting of stockholders following the completion of the Merger.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In addition, certain of the Company&#8217;s stockholders, directors and officers, who collectively hold approximately two percent of the outstanding shares of the Company&#8217;s capital stock as of the close of business on October&#160;3, 2012, entered into voting agreements with ANI, pursuant to which each stockholder agreed to vote its shares of the Company&#8217;s capital stock in favor of the Merger, the Merger Agreement and the transactions contemplated by the Merger Agreement and the charter amendments, and against certain transactions or certain actions that would delay, prevent or nullify the Merger or the transaction contemplated by the Merger Agreement.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Lock-Up Agreements</font></i></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Concurrently and in connection with the execution of the Merger Agreement, ANI&#8217;s chief executive officer and chief financial officer and certain stockholders of ANI, who collectively hold approximately 85 percent of the outstanding shares of ANI capital stock as of the close of business on October&#160;3, 2012, entered into lock-up agreements with the Company, pursuant to which each stockholder will be subject to a six-month lock-up on the sale of shares of the Company&#8217;s common stock received in the Merger.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Contingent Value Rights Agreement</font></i></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company has the right in its sole discretion to issue contingent value rights (each, a CVR and collectively, the CVRs) to its existing stockholders immediately prior to the completion of the Merger.&#160; The Company expects that one CVR will be issued for each share of the Company&#8217;s common stock outstanding as of the record date to be set at a date prior to the completion of the Merger.&#160; However, the CVRs will not be certificated and will not be attached to the shares of the Company&#8217;s common stock.&#160; Each CVR will be a non-transferable (subject to certain limited exceptions) right to potentially receive certain cash payments in the event the Company receives net cash payments during the ten-year period after the distribution of the rights as a result of the sale, transfer, license or similar transaction relating to the Company&#8217;s LibiGel program,&#160; upon the terms and subject to the conditions set forth in a contingent value rights agreement to be entered into between the Company and an as of yet unidentified third party, as rights agent.&#160; The aggregate cash payments to be distributed to the holders of the CVRs, if any, will be equal to 66 percent of the net cash payments received by the combined company as a result of the sale, transfer, license or similar transaction relating to the Company&#8217;s LibiGel program, as determined pursuant to the CVR agreement, and will not exceed $40 million in the aggregate.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Employee Reduction Implications</font></i></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">As a result of the conclusion of the Company&#8217;s LibiGel Phase III cardiovascular events and breast cancer safety study, as announced by the Company in September&#160;2012, and considering the Company&#8217;s October&#160;4, 2012 announcement of its potential merger with ANI, the Company plans to reduce its workforce during the fourth quarter of 2012.&#160; In connection with the announced reduction, the Company will pay approximately $300,000 in aggregate severance costs during the remainder of 2012. The termination of employment of these employees will result in the cessation of any further vesting in certain stock options held by these employees and a reversal of previously recognized non-cash stock-based compensation expense related to such options in a similar amount, thereby offsetting the employee reduction severance costs.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Third Amendment To License Agreement with Teva</font></i></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In October&#160;2012, the Company entered into an amendment to its development and license agreement with Teva pursuant to which Teva made a $1.0 million payment to the Company upon the signing of the amendment and agreed to make the following milestone-based payments to the Company:&#160; (1)&#160;$500,000 if the FDA authorizes marketing of the licensed </font><font style="FONT-SIZE: 10pt" size="2">male testosterone gel as an &#8220;AB-rated&#8221; equivalent to AndroGel</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1">&#174;</font><font style="FONT-SIZE: 10pt" size="2">; (2)&#160;$750,000 upon the earlier to occur of (a)&#160;December&#160;31, 2012 and (b)&#160;five business days after Teva&#8217;s submission to the FDA of a final report regarding a &#8220;washing&#8221; clinical study required by the FDA; and (3)&#160;$500,000 upon the earlier to occur of (a)&#160;December&#160;31, 2013 and (b)&#160;five business days after Teva&#8217;s commencement of commercial manufacture of the licensed product for sale in the United States.&#160; In addition, Teva has agreed to pay the Company $4.0 million in the event Teva is the sole marketer in the United States of a generic 1% testosterone gel AB-rated to AndroGel</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1">&#174;</font><font style="FONT-SIZE: 10pt" size="2">&#160;for at least 180 days immediately following the launch date of the licensed product in the United States.&#160; The royalty rate to be paid by Teva to the Company under the agreement is five percent of net sales; provided, however, that during the period of time that Teva markets the licensed product and is the sole marketer of a generic 1% testosterone gel that is AB-rated to AndroGel</font><font style="FONT-SIZE: 6.5pt; POSITION: relative; TOP: -3pt" size="1">&#174;</font><font style="FONT-SIZE: 10pt" size="2">&#160;in the United States, the royalty rate will be seven and one half percent of net sales.&#160; Additionally, pursuant to the terms of the October&#160;2012 amendment, the parties agreed to release each other from certain liabilities.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt">&#160;</p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">8.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">COMMITMENTS AND CONTINGENCIES</font></b></p>
<p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Aptar Pharma &#8212; Gel Packaging Machine</font></i></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company has a commitment with Aptar Pharma to purchase a gel packaging machine for $844,740. As of September&#160;30, 2012, the Company had paid Aptar $804,132.&#160; The remaining obligation of $40,608 is due upon the shipment, assembly and calibration of the machine at a location designated by the Company.&#160; In light of the Company&#8217;s pending merger with ANI (see Note 10, &#8220;Subsequent Events&#8221;), the Company is evaluating the future plans for this gel packaging machine.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><i><font style="FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman" size="2">Pending Litigation</font></i></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On February&#160;3, 2012, a purported class action lawsuit was filed in the United States District Court for the Northern District of Illinois under the caption <i>Thomas Lauria, on behalf of himself and all others similarly situated v. BioSante Pharmaceuticals,&#160;Inc. and Stephen M. Simes</i> naming the Company and the Company&#8217;s President and Chief Executive Officer, Stephen M. Simes, as defendants.&#160; The complaint alleges that certain of the Company&#8217;s disclosures relating to the efficacy of LibiGel and its commercial potential were false and/or misleading and that such false and/or misleading statements had the effect of artificially inflating the price of the Company&#8217;s securities resulting in violations of Section&#160;10(b)&#160;of the Securities Exchange Act of 1934, as amended (Exchange Act), Rule&#160;10b-5 and Section&#160;20(a)&#160;of the Exchange Act.&#160; Although a substantially similar complaint was filed in the same court on February&#160;21, 2012, such complaint was voluntarily dismissed by the plaintiff in April&#160;2012.&#160; The plaintiff seeks to represent a class of persons who purchased the Company&#8217;s securities between February&#160;10, 2010 and December&#160;15, 2011, and seeks unspecified compensatory damages, equitable and/or injunctive relief, and reasonable costs, expert fees and attorneys&#8217; fees on behalf of such purchasers.&#160; The Company believes the action is without merit and intends to defend the action vigorously.&#160; On October&#160;10, 2012, the District Court entered an order setting the dates on which the plaintiff&#8217;s consolidated amended complaint is due and establishing a briefing schedule on the defendants&#8217; anticipated motion to dismiss.&#160; On November&#160;6, 2012, plaintiff filed a consolidated amended complaint; the Company and Mr. Simes intend to file motions to dismiss the consolidated amended complaint on or before December&#160;21, 2012.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">On May&#160;7, 2012, Jerome W. Weinstein, a purported stockholder of the Company filed a shareholder derivative action in the United States District Court for the Northern District of Illinois under the caption <i>Weinstein v. BioSante Pharmaceuticals,&#160;Inc. et al.</i>, naming the Company&#8217;s directors as defendants and the Company as a nominal defendant.&#160; A substantially similar complaint was filed in the same court on May&#160;22, 2012 and another substantially similar complaint was filed in the Circuit Court for Cook County, Illinois, County Department, Chancery Division, on June&#160;27, 2012.&#160; The suits generally related to the same events that are the subject of the class action litigation described above.&#160; The complaints allege breaches of fiduciary duty, abuse of control, gross mismanagement and unjust enrichment as causes of action occurring from at least February&#160;2010 through December&#160;2011.&#160; The complaints seek unspecified damages, punitive damages, costs and disbursements and unspecified reform and improvements in the Company&#8217;s corporate governance and internal control procedures.&#160; On September&#160;24, 2012, the District Court consolidated the two cases before it and entered a stipulation and order setting the dates on which the plaintiff&#8217;s consolidated amended complaint is due and establishing a briefing schedule on defendants&#8217; anticipated motions to dismiss. The Company expects a similar scheduling order to be entered in the action pending in Illinois state court.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The lawsuits are in their early stages; and, therefore, the Company is unable to predict the outcome of the lawsuits and the possible loss or range of loss, if any, associated with their resolution or any potential effect the lawsuits may have on the Company&#8217;s operations.&#160; Depending on the outcome or resolution of these lawsuits, they could have a material effect on the Company&#8217;s operations, including its financial condition, results of operations, or cash flows.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company is not involved in any other legal actions, however, from time to time may be subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business.&#160; Such matters are subject to many uncertainties and to outcomes that are not predictable with reasonable assurance and that may not be known for extended periods of time.</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a)(19))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">9.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">FAIR VALUE MEASUREMENTS</font></b></p>
<p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company accounts for its convertible debt and U.S. Treasury money market fund at fair value.&#160; Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Level 1:&#160; Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.&#160; The fair value hierarchy gives the highest priority to Level 1 inputs.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Level 2:&#160; Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Level 3:&#160; Unobservable inputs are used when little or no market data is available.&#160; The fair value hierarchy gives the lowest priority to Level 3 inputs.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Financial assets and liabilities recorded at fair value on a recurring basis as of September&#160;30, 2012 and December&#160;31, 2011 are classified in the tables below in one of the three categories described above:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0">
<tr style="HEIGHT: 0px">
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="32%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Description</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">September&#160;30,<br />
2012&#160;Balance</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Quoted&#160;Prices&#160;in<br />
Active&#160;Markets<br />
for&#160;Identical<br />
Assets&#160;(Level&#160;1)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Significant<br />
Other<br />
Observable<br />
Inputs&#160;(Level&#160;2)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Significant<br />
Unobservable<br />
Inputs&#160;(Level&#160;3)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Assets:</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Money market fund</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">36,957,469</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">36,957,469</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total assets</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">36,957,469</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">36,957,469</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Liabilities:</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2013 Notes</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,593,216</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,593,216</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total liabilities</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,593,216</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">7,593,216</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 0.5in; WIDTH: 93.34%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="93%" border="0">
<tr style="HEIGHT: 0px">
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="32%">
<p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Description</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">December&#160;31,<br />
2011&#160;Balance</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Quoted&#160;Prices&#160;in<br />
Active&#160;Markets<br />
for&#160;Identical<br />
Assets&#160;(Level&#160;1)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Significant<br />
&#160;Other<br />
&#160;Observable<br />
&#160;Inputs&#160;(Level&#160;2)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman" size="1">Significant<br />
Unobservable<br />
Inputs&#160;(Level&#160;3)</font></b></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="1">&#160;</font></b></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 32.5%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Assets:</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Money market fund</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">55,465,507</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">55,465,507</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total assets</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">55,465,507</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">55,465,507</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Liabilities:</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: medium none" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">2013 Notes</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.94%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,336,760</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF" colspan="2">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,336,760</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 1pt solid" valign="bottom" width="13%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 32.5%; PADDING-TOP: 0in" valign="top" width="32%">
<p style="MARGIN: 0in 0in 0pt 20pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Total liabilities</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.64%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,336,760</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 1.3%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">$</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 12.62%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="12%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">17,336,760</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 2.68%; PADDING-TOP: 0in" valign="bottom" width="2%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="BORDER-RIGHT: medium none; PADDING-RIGHT: 0in; BORDER-TOP: medium none; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; BORDER-LEFT: medium none; WIDTH: 13.92%; PADDING-TOP: 0in; BORDER-BOTTOM: windowtext 2.25pt double" valign="bottom" width="13%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#8212;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.08%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company made an election to record the values of the 2013 Notes at fair value with gains and losses related to fluctuations in the value of these financial liabilities recorded in earnings immediately.&#160; The fair values of the 2013 Notes are estimated based on the risk-free borrowing rate, the volatility of the Company&#8217;s stock, and the current borrowing rates for similar companies. &#160;See Note 6, &#8220;Convertible Senior Notes&#8221; for more information and disclosures regarding key assumptions used in this fair value determination.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13504-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15C, 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44A, 44B<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -Subparagraph a-d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 3, 10, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13433-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 17-22, 27, 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7491637&amp;loc=d3e13537-108611<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15B<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32, 33, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE SENIOR NOTES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock', window );">Schedule of key assumptions used to establish the value of the 2013 Notes</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in">&#160;</p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The assumptions as of September&#160;30, 2012 were:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="60%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Average risk-free rate</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.14</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Volatility of BioSante common stock</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">90.0</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Discount rate for principal payments in cash</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">19.6</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The assumptions as of December&#160;31, 2011 were:</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="60%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="bottom" width="74%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Average&#160;risk-free&#160;rate</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.19</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Volatility of BioSante common stock</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">77.4</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Discount rate for principal payments in cash</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">18.5</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the period to estimate the fair value of debt instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_ScheduleOfFairValueAssumptionsUsedForDebtInstrumentsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EYZAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>2013 Notes

</div>
          <div>holder</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>2013 Notes

</div>
          <div>holder</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>2013 Notes</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>2013 Notes</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>2013 Notes</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>2013 Notes</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>2013 Notes</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible senior notes</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.125%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.125%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 8,277,850<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 8,277,850<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20,782,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares issued in exchange for cancellation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,784,070<span></span></td>
        <td class="nump">1,868,055<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,652,125<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued', window );">Number of holders of debt instrument to whom shares are issued by the entity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Principal amount of debt cancelled</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,504,150<span></span></td>
        <td class="nump">9,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,504,150<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued and unpaid interest payable on cancellation of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,686<span></span></td>
        <td class="nump">79,024<span></span></td>
        <td class="nump">99,710<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99,710<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_FairValueOptionChangesInFairValueNonCashAdjustment', window );">Additional non-cash fair value adjustment attributable to conversion of debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(611,621)<span></span></td>
        <td class="num">(2,545,530)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Number of shares of common stock receivable upon conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">370,871<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 22.32<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 22.32<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Recorded fair value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,593,216<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,593,216<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,336,760<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionAggregateDifferencesLongTermDebtInstruments', window );">Amount of difference between aggregate recorded fair value of the notes and their total stated principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">684,634<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">684,634<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,445,240<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Fair value adjustment</a></td>
        <td class="num">(843,412)<span></span></td>
        <td class="nump">463,000<span></span></td>
        <td class="num">(4,037,797)<span></span></td>
        <td class="num">(1,929,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionCreditRiskGainsLossesOnLiabilities', window );">Fair value adjustment attributable to the change in instrument specific credit risk</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (41,000)<span></span></td>
        <td class="nump">$ 230,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract', window );"><strong>Assumptions to establish the value of the Notes</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Average risk-free rate (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.14%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.19%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility of BioSante common stock (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">90.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">77.40%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_FairValueAssumptionsDiscountRate', window );">Discount rate for principal payments in cash (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19.60%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18.50%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_FairValueAssumptionsDiscountRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents discount rate for principal payments in cash, an assumption used in valuation of an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_FairValueAssumptionsDiscountRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_FairValueOptionChangesInFairValueNonCashAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For each line item in the statement of financial position, the non-cash increase (decrease) in fair value resulting from transactions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_FairValueOptionChangesInFairValueNonCashAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of holders of debt instrument to whom shares are issued by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfDebtInstrumentHoldersToWhomSharesAreIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionOriginalDebtAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number APB14-1<br><br> -Paragraph 32<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number APB14-1<br><br> -Paragraph 32<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or discount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 21<br><br> -Paragraph 16, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest rate stated in the contractual debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsAndMethodologyForAssetsAndLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionAggregateDifferencesLongTermDebtInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the difference between the aggregate fair value and the aggregate unpaid principal balance of long-term debt instruments that have contractual principal amounts and for which the fair value option has been elected.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 18<br><br> -Subparagraph d(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOptionAggregateDifferencesLongTermDebtInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOptionChangesInFairValueGainLoss1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionCreditRiskGainsLossesOnLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the estimated amount of gains and losses from fair value changes included in earnings that are attributable to changes in the instrument-specific credit risk of liabilities with fair values that have been significantly affected during the reporting period by changes in the instrument-specific credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 159<br><br> -Paragraph 19<br><br> -Subparagraph d(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOptionCreditRiskGainsLossesOnLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EEMAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) (Recurring basis, USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Total</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="nump">$ 36,957,469<span></span></td>
        <td class="nump">$ 55,465,507<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
        <td class="nump">7,593,216<span></span></td>
        <td class="nump">17,336,760<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Total | 2013 Notes</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
        <td class="nump">7,593,216<span></span></td>
        <td class="nump">17,336,760<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Total | Money market fund</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="nump">36,957,469<span></span></td>
        <td class="nump">55,465,507<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Other Observable Inputs (Level 2)</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="nump">36,957,469<span></span></td>
        <td class="nump">55,465,507<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
        <td class="nump">7,593,216<span></span></td>
        <td class="nump">17,336,760<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Other Observable Inputs (Level 2) | 2013 Notes</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
        <td class="nump">7,593,216<span></span></td>
        <td class="nump">17,336,760<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Other Observable Inputs (Level 2) | Money market fund</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
        <td class="nump">$ 36,957,469<span></span></td>
        <td class="nump">$ 55,465,507<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. Fair value of convertible debt at the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Convertible Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509036<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebtFairValueDisclosures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the aggregate of the liabilities reported on the balance sheet at period end measured at fair value by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E5MAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS (USED IN) OPERATING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
        <td class="num">$ (23,730,408)<span></span></td>
        <td class="num">$ (44,959,599)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) operations</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">87,548<span></span></td>
        <td class="nump">118,132<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
        <td class="nump">117,794<span></span></td>
        <td class="nump">367,274<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Employee &amp; director stock-based compensation</a></td>
        <td class="nump">852,468<span></span></td>
        <td class="nump">886,564<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock warrant expense - noncash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">180,759<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Convertible note fair value adjustment</a></td>
        <td class="nump">4,037,797<span></span></td>
        <td class="nump">1,929,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in other assets and liabilities affecting cash flows from operations</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, deposits and other assets</a></td>
        <td class="nump">323,225<span></span></td>
        <td class="nump">1,539,903<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="num">(3,807,074)<span></span></td>
        <td class="nump">2,993,059<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash (used in) operating activities</a></td>
        <td class="num">(22,118,650)<span></span></td>
        <td class="num">(36,944,908)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS (USED IN) INVESTING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investment</a></td>
        <td class="num">(7,955)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
        <td class="num">(528,742)<span></span></td>
        <td class="num">(645,603)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash (used in) investing activities</a></td>
        <td class="num">(536,697)<span></span></td>
        <td class="num">(645,603)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS PROVIDED BY FINANCING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_PaymentsToFractionalSharePayout', window );">Fractional share payout</a></td>
        <td class="num">(658)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from common stock option exercises</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">32,442<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised</a></td>
        <td class="nump">211,068<span></span></td>
        <td class="nump">24,063<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering', window );">Proceeds from issuance of common stock by underwritten public offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,102,584<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock by registered direct offerings</a></td>
        <td class="nump">3,268,798<span></span></td>
        <td class="nump">23,876,370<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump">3,479,208<span></span></td>
        <td class="nump">69,035,459<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInContinuingOperations', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="num">(19,176,139)<span></span></td>
        <td class="nump">31,444,948<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
        <td class="nump">57,225,234<span></span></td>
        <td class="nump">38,155,251<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
        <td class="nump">38,049,095<span></span></td>
        <td class="nump">69,600,199<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
        <td class="nump">184,094<span></span></td>
        <td class="nump">344,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued for convertible senior notes and accrued interest</a></td>
        <td class="nump">13,881,052<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_UnpaidCostsAssociatedWithRegisteredDirectOffering', window );">Unpaid costs associated with registered direct offering</a></td>
        <td class="nump">7,933<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_UnpaidCostsAssociatedWithUnderWrittenPublicOffering', window );">Unpaid costs associated with underwritten public offering</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">141,447<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of fixed assets on account, non-cash investing activity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 59,016<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_PaymentsToFractionalSharePayout">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents payments of fractional shares as a result of reverse stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_PaymentsToFractionalSharePayout</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the proceeds, net of underwriters' discounts, commissions and offering expenses, from the issuance of stock through an underwritten public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_ProceedsFromIssuanceOfCommonStockByUnderwrittenPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_UnpaidCostsAssociatedWithRegisteredDirectOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of unpaid costs associated with registered direct offering in a noncash or partial noncash transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_UnpaidCostsAssociatedWithRegisteredDirectOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_UnpaidCostsAssociatedWithUnderWrittenPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of unpaid costs associated with underwritten public offering in a noncash or partial noncash transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_UnpaidCostsAssociatedWithUnderWrittenPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalExpendituresIncurredButNotYetPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOptionChangesInFairValueGainLoss1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) in cash associated with the entity's continuing operating, investing, and financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of net cash from (used in) the entity's financing activities, excluding cash flows derived by the entity from its discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of net cash from (used in) the entity's investing activities, excluding cash flows derived by the entity from its discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -Footnote 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of net cash from (used in) the entity's continuing operations, excluding cash flows derived by the entity from its discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -Footnote 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of stock issued in noncash financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE SENIOR NOTES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE SENIOR NOTES</a></td>
        <td class="text"><table style="font-size:10pt; font-family:'Times New Roman',times,serif;">
<tr>
<td>
<p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">5.</font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 3pt" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt" size="2">CONVERTIBLE SENIOR NOTES</font></b></p>
<p style="MARGIN: 0in 0in 0pt 37.05pt; TEXT-INDENT: -0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company has outstanding 3.125% convertible senior notes due May&#160;1, 2013 (the 2013 Notes).&#160; The aggregate principal amount of the 2013 Notes outstanding at September&#160;30, 2012 and December&#160;31, 2011 was $8,277,850 and $20,782,000, respectively.&#160; In February&#160;2012, the Company issued 1,868,055 shares of its common stock to one of the holders of the 2013 Notes in exchange for the cancellation of $9,000,000 in aggregate principal amount of such notes and the related accrued and unpaid interest of $79,024.&#160; In July&#160;2012, the Company issued an aggregate of 1,784,070 shares of its common stock to two of the holders of the 2013 Notes in exchange for the cancellation of $3,504,150 in aggregate principal amount of such notes and accrued and unpaid interest of $20,686. Non-cash fair value adjustments of $(2,545,530) and $(611,621) were recorded during the first and third quarters of 2012 as a result of the cancellation of such notes. The fair value adjustment recorded upon the cancellation of the 2013 Notes is primarily attributable to the time value effect of settling these obligations at a date prior to the stated maturity of the 2013 Notes.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The remaining $8,277,850 aggregate principal amount of the 2013 Notes are exchangeable at the option of the holder or upon certain specified events into an aggregate of approximately 370,871 shares of the Company&#8217;s common stock at a conversion price of $22.32 per share.&#160; The 2013 Notes are general, unsecured obligations of the Company and are described in Note 7 to the Company&#8217;s financial statements for the year ended December&#160;31, 2011.&#160; As of September&#160;30, 2012, the 2013 Notes were not eligible for redemption. The indenture governing the 2013 Notes, as supplemented by the supplemental indenture, does not contain any financial covenants and does not restrict the Company from paying dividends, incurring additional debt or issuing or repurchasing the Company&#8217;s other securities.&#160; In addition, the indenture, as supplemented by the supplemental indenture, does not protect the holders of the 2013 Notes in the event of a highly leveraged transaction or a fundamental change of the Company except in certain circumstances specified in the indenture.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.1pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">As described in Note 3, &#8220;Liquidity and Capital Resources,&#8221; from time to time, the Company may purchase, exchange or restructure its outstanding 2013 Notes through cash purchases and/or exchanges for other equity securities of the Company, in open market purchases, privately negotiated transactions and/or a tender offer.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.1pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.1pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company has elected to record the 2013 Notes at fair value in order to simplify the accounting for the convertible debt, inclusive of the redemption, repurchase and conversion adjustment features which otherwise would require specialized valuation, bifurcation and recognition.&#160; Accordingly, the Company has adjusted the carrying value of the 2013 Notes to their fair value as of September&#160;30, 2012, with changes in the fair value of the 2013 Notes occurring since December&#160;31, 2011, reflected in fair value adjustment in the unaudited condensed statements of operations.&#160; As described in Note 9, &#8220;Fair Value Measurements,&#8221; the fair value of the 2013 Notes is based on Level 2 inputs.&#160; The recorded fair value of the 2013 Notes of an aggregate of $7,593,216 as of September&#160;30, 2012 differs from their total stated aggregate principal amount of $8,277,850 as of such date by $684,634.&#160; The recorded fair value of the 2013 Notes of an aggregate of $17,336,760 as of December&#160;31, 2011 differed from their total stated aggregate principal amount of $20,782,000 as of such date by $3,445,240.&#160; During the three and nine months ended September&#160;30, 2012, the Company recorded a fair value adjustment of $(843,412) and $(4,037,797) related to the 2013 Notes that were converted to common stock during 2012 or that remained outstanding as of September&#160;30, 2012, that for the three months and nine months ended September&#160;30, 2012 increased the recorded liability and corresponding expense.&#160; For the three and nine months ended September&#160;30, 2011, the Company recorded a fair value adjustment of $463,000 and $(1,929,000) that decreased and increased the recorded liability and corresponding expense, respectively.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 35.1pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">For the nine months ended September&#160;30, 2012 and 2011, approximately $(41,000) and $230,000, respectively, of the fair value adjustment was attributable to the change in instrument specific credit risk.&#160; The change in the aggregate fair value of the 2013 Notes due to instrument specific credit risk for the nine months ended September&#160;30, 2012 was estimated by calculating the difference between the September&#160;30, 2012 fair value of the 2013 Notes as recorded and what the fair value of the 2013 Notes would have been on September&#160;30, 2012 if the December&#160;31, 2011 discount rate continued to be used in the calculation.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The instrument specific credit risk for both periods has increased the fair value of the 2013 Notes as market borrowing rates have decreased for similarly rated companies and are estimated to have decreased for the Company as well, indicating a lower credit spread assuming no significant changes in the risk-free borrowing rate.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company establishes the value of the 2013 Notes based upon contractual terms of the 2013 Notes, as well as certain key assumptions.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The assumptions as of September&#160;30, 2012 were:</font></p>
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="60%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Average risk-free rate</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.14</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Volatility of BioSante common stock</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">90.0</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Discount rate for principal payments in cash</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">19.6</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The assumptions as of December&#160;31, 2011 were:</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<table style="MARGIN-LEFT: 1in; WIDTH: 60%; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="60%" border="0">
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="bottom" width="74%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Average&#160;risk-free&#160;rate</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">0.19</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Volatility of BioSante common stock</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">77.4</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr>
<tr style="HEIGHT: 0px">
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 74.18%; PADDING-TOP: 0in" valign="top" width="74%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt 10pt; TEXT-INDENT: -10pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">Discount rate for principal payments in cash</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 4.16%; PADDING-TOP: 0in" valign="bottom" width="4%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 1pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 20%; PADDING-TOP: 0in" valign="bottom" width="20%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: right" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">18.5</font></p></td>
<td style="PADDING-RIGHT: 0in; PADDING-LEFT: 0in; BACKGROUND: #cceeff; PADDING-BOTTOM: 0in; WIDTH: 1.66%; PADDING-TOP: 0in" valign="bottom" width="1%" bgcolor="#CCEEFF">
<p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">%</font></p></td></tr></table>
<p style="MARGIN: 0in 0in 0pt; TEXT-ALIGN: center" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 34.55pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The discount rate is based on observed yields as of the measurement date for debt securities of entities having a Ca and Caa3 rating for long-term corporate obligations as assigned by Moody&#8217;s Investors Service.&#160; Volatility is based on the historical fluctuations in the Company&#8217;s stock price for a period of time equal to the remaining time until the debt maturity.&#160; The risk-free rate is based on observed yields as of the measurement date of six month and one-year U.S. Treasury Bonds.</font></p>
<p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 34.55pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">&#160;</font></p></td></tr></table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZDCK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="3"></th>
        <th class="th" colspan="3">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="4">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>Oct. 03, 2012

</div>
          <div>Subsequent Event

</div>
          <div>Agreement and Plan of Merger

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Oct. 03, 2012

</div>
          <div>Subsequent Event

</div>
          <div>Agreement and Plan of Merger

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>Oct. 03, 2012

</div>
          <div>Subsequent Event

</div>
          <div>Agreement and Plan of Merger

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Subsequent Event

</div>
          <div>ANI Pharmaceuticals, Inc

</div>
          <div>Employee Reduction</div>
        </th>
        <th class="th">
          <div>Oct. 03, 2012

</div>
          <div>Subsequent Event

</div>
          <div>ANI Pharmaceuticals, Inc

</div>
          <div>Agreement and Plan of Merger

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Oct. 03, 2012

</div>
          <div>Subsequent Event

</div>
          <div>ANI Pharmaceuticals, Inc

</div>
          <div>Agreement and Plan of Merger

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>Oct. 03, 2012

</div>
          <div>Subsequent Event

</div>
          <div>ANI Pharmaceuticals, Inc

</div>
          <div>Agreement and Plan of Merger

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Oct. 03, 2012

</div>
          <div>Subsequent Event

</div>
          <div>ANI Pharmaceuticals, Inc

</div>
          <div>Voting Agreements

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Oct. 03, 2012

</div>
          <div>Subsequent Event

</div>
          <div>ANI Pharmaceuticals, Inc

</div>
          <div>Lock-Up Agreements</div>
        </th>
        <th class="th">
          <div>Oct. 03, 2012

</div>
          <div>Subsequent Event

</div>
          <div>ANI Pharmaceuticals, Inc

</div>
          <div>Contingent Value Rights Agreement</div>
        </th>
        <th class="th">
          <div>Oct. 03, 2012

</div>
          <div>Subsequent Event

</div>
          <div>ANI Pharmaceuticals, Inc

</div>
          <div>Contingent Value Rights Agreement

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>Subsequent Event

</div>
          <div>Teva

</div>
          <div>Third Amendment To License Agreement</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>Subsequent Event

</div>
          <div>Teva

</div>
          <div>Third Amendment To License Agreement

</div>
          <div>Milestone payment upon FDA authorization of marketing of licensed male testosterone gel

</div>
          <div>Forecast</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>Subsequent Event

</div>
          <div>Teva

</div>
          <div>Third Amendment To License Agreement

</div>
          <div>Milestone payment upon earlier of December 31, 2012 and five business days after submission to FDA of final report on washing clinical study

</div>
          <div>Forecast

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>Subsequent Event

</div>
          <div>Teva

</div>
          <div>Third Amendment To License Agreement

</div>
          <div>Milestone payment upon earlier of December 31, 2013 and five business days after commencement of commercial manufacture of licensed product for sale in the United States

</div>
          <div>Forecast

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>Subsequent Event

</div>
          <div>Teva

</div>
          <div>Third Amendment To License Agreement

</div>
          <div>Payment for being the sole marketer in the United States of a generic 1% testosterone gel AB-rated to AndroGel for at least 180 days immediately following the launch date of the licensed product in the United States

</div>
          <div>Forecast</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>Subsequent Event

</div>
          <div>Teva

</div>
          <div>Third Amendment To License Agreement

</div>
          <div>Minimum

</div>
          <div>Payment for being the sole marketer in the United States of a generic 1% testosterone gel AB-rated to AndroGel for at least 180 days immediately following the launch date of the licensed product in the United States

</div>
          <div>Forecast

</div>
          <div>item</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders', window );">Percentage of outstanding shares of common stock of combined company owned by current stockholders</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">47.00%<span></span></td>
        <td class="nump">49.90%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">53.00%<span></span></td>
        <td class="nump">50.10%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany', window );">Number of directors of the entity in board of directors of the combined company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_ReverseStockSplitConversionRatio', window );">Reverse split ratio</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.2<span></span></td>
        <td class="nump">0.5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NetCashRequiredToObligateEntityToEffectMerger', window );">Net cash required to obligate the entity to effect merger</a></td>
        <td class="nump">$ 17,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 17,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_BusinessMergerTerminationFeePayable', window );">Termination fee payable under specified circumstances</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_BusinessMergerReimbursementOfExpenses', window );">Reimbursement of expenses in connection with merger</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders', window );">Percentage of outstanding shares of capital stock held by stockholders as of the close of business</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">90.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock', window );">Number of stockholders holding 57 percent of outstanding shares of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors', window );">Percentage of outstanding shares of common stock held by stockholders who agreed to vote in favor of election of directors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">57.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfDirectorsDesignatedByEntity', window );">Number of directors designated by the entity at the first annual meeting of stockholders following the completion of the Merger</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements', window );">Percentage of outstanding shares of common stock held collectively by specified personnel who entered into voting agreements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.00%<span></span></td>
        <td class="nump">85.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_LockingPeriodOnSaleOfSharesPostMerger', window );">Locking period on the sale of shares of the Company's common stock received in the Merger</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfContingentValueRightsIssuedInExchangeForOneShare', window );">Number of contingent value rights issued in exchange for one share of common stock (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights', window );">Period during which net cash payments can be received after distribution of rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived', window );">Net cash payments to be distributed to holders of the CVRs expressed as percentage of net cash payments received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">66.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_AggregateNetCashPaymentsToBeDistributedToHolders', window );">Aggregate net cash payments to be distributed to holders of CVRs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts', window );">Severance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received from agreements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_CollaborativeArrangementPotentialMilestonePaymentsReceivable', window );">Aggregate amount receivable, if regulatory milestones are successfully achieved</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfBusinessDaysConsideredInMilestonePayments', window );">Number of business days considered in milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight', window );">Payments receivable, if sole marketer rights are given</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment', window );">Number of days from the launch of the licensed product in the United States for which sole marketer right is given for additional payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">180<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales', window );">Royalty rate as a percentage of net sales</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_AggregateNetCashPaymentsToBeDistributedToHolders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the aggregate net cash payments to be distributed to holders of the contingent value rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_AggregateNetCashPaymentsToBeDistributedToHolders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_BusinessMergerReimbursementOfExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of reimbursement of expenses in connection with merger on meeting certain specified circumstances as specified in the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_BusinessMergerReimbursementOfExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_BusinessMergerTerminationFeePayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of a termination fee that may be payable on meeting of certain triggering events specified in the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_BusinessMergerTerminationFeePayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_CollaborativeArrangementPotentialMilestonePaymentsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the total amount that could be received based on certain regulatory or commercial events achieved by members to the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_CollaborativeArrangementPotentialMilestonePaymentsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the payments receivable, if sole marketer rights are given by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_CollaborativeArrangementPotentialPaymentsReceivableForGivingSoleMarketerRight</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the royalty rate as a percentage of net sales.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_LockingPeriodOnSaleOfSharesPostMerger">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the locking period on the sale of shares of the entity's common stock received in the merger.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_LockingPeriodOnSaleOfSharesPostMerger</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the net cash payments to be distributed to holders of the contingent value rights expressed as percentage of net cash payments received by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NetCashPaymentsToBeDistributedToHoldersExpressedAsPercentageOfNetCashPaymentsReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NetCashRequiredToObligateEntityToEffectMerger">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of net cash required to obligate the entity to effect merger</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NetCashRequiredToObligateEntityToEffectMerger</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfBusinessDaysConsideredInMilestonePayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of business days considered in milestone payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfBusinessDaysConsideredInMilestonePayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfContingentValueRightsIssuedInExchangeForOneShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of contingent value rights issued in exchange for one share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfContingentValueRightsIssuedInExchangeForOneShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of days from the launch of the licensed product in the United States for which sole marketer right is given for additional payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfDaysFromLaunchOfProductForWhichSoleMarketerRightIsGivenForAdditionalPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfDirectorsDesignatedByEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of directors designated by the entity at the first annual meeting of stockholders following the completion of the merger.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfDirectorsDesignatedByEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of directors of the entity in board of directors of the combined company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfDirectorsOfEntityInBoardOfDirectorsOfCombinedCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of stockholders holding specified percentage of outstanding shares of common stock as of the close of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfStockholdersHoldingSpecifiedPercentageOfOutstandingSharesOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the percentage of outstanding shares of common stock of combined company owned by current stockholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the percentage of outstanding shares of capital stock held by stockholders as of the close of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_PercentageOfOutstandingSharesOfCapitalStockHeldByStockholders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the percentage of outstanding shares of common stock held by specified personnel as of the close of business, who entered into agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_PercentageOfOutstandingSharesOfCommonStockHeldBySpecifiedPersonnelWhoEnteredIntoAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the percentage of outstanding shares of common stock held by stockholders as of the close of business, who agreed to vote in favor of election of directors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_PercentageOfOutstandingSharesOfCommonStockHeldByStockholdersWhoAgreedToVoteInFavorOfElectionOfDirectors</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the period during which net cash payments can be received after distribution of rights from contingent value rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_PeriodDuringWhichNetCashPaymentsCanBeReceivedAfterDistributionOfRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_ReverseStockSplitConversionRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the conversion ratio used in the calculation of a reverse stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_ReverseStockSplitConversionRatio</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a benefit arrangement associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination or a discontinued operation as defined by generally accepted accounting principles and costs associated with one-time termination benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)(10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e1928-114920<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 146<br><br> -Paragraph 8-13, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5-8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 112<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS146-1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SeveranceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>76</ContextCount>
  <ElementCount>142</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>30</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0010 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/BalanceSheet</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0015 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/BalanceSheetParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0020 - Statement - Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/StatementOfIncome</Role>
      <ShortName>Condensed Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0030 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/CashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1010 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1020 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1030 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureLiquidityAndCapitalResources</Role>
      <ShortName>LIQUIDITY AND CAPITAL RESOURCES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1040 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureBasicAndDilutedNetLossPerShare</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1050 - Disclosure - CONVERTIBLE SENIOR NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotes</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1060 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1070 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1080 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1090 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1100 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>3050 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesTables</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>3090 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>4010 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureDescriptionOfBusinessDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>4020 - Disclosure - BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureBasisOfPresentationDetails</Role>
      <ShortName>BASIS OF PRESENTATION (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>4030 - Disclosure - LIQUIDITY AND CAPITAL RESOURCES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureLiquidityAndCapitalResourcesDetails</Role>
      <ShortName>LIQUIDITY AND CAPITAL RESOURCES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>4050 - Disclosure - CONVERTIBLE SENIOR NOTES (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureConvertibleSeniorNotesDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>4060 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>4070 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>4080 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>4081 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureCommitmentsAndContingenciesDetails2</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>4090 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>4100 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biosantepharma.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element bpax_BusinessMergerTerminationFeePayable had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element bpax_CollaborativeArrangementRoyaltyRateAsPercentageOfNetSales had a mix of decimals attribute values: 2 4.</Log>
    <Log type="Info">Element bpax_NetCashRequiredToObligateEntityToEffectMerger had a mix of decimals attribute values: -6 -5.</Log>
    <Log type="Info">Element bpax_OwnershipPercentageOfOutstandingSharesOfCommonStockOfCombinedCompanyByCurrentStockholders had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element bpax_StockholdersEquityReverseStockSplitConversionRatio had a mix of decimals attribute values: 1 4.</Log>
    <Log type="Info">'Monetary' elements on report '4100 - Disclosure - SUBSEQUENT EVENTS (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 0010 - Statement - Condensed Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 0015 - Statement - Condensed Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0020 - Statement - Condensed Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 0030 - Statement - Condensed Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>bpax-20120930.xml</File>
    <File>bpax-20120930.xsd</File>
    <File>bpax-20120930_cal.xml</File>
    <File>bpax-20120930_def.xml</File>
    <File>bpax-20120930_lab.xml</File>
    <File>bpax-20120930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001104659-12-076010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-12-076010-xbrl.zip
M4$L#!!0````(`,>":$&:=>O%VVP``(_I!``1`!P`8G!A>"TR,#$R,#DS,"YX
M;6Q55`D``X4BG%"%(IQ0=7@+``$$)0X```0Y`0``[%WK4^,XMO^^5?L_>+E5
MN]U5!/S(DYZ>K4"@)W>!,"0]C_NE2]A*HAG'RD@V3?:OOT?R([;C/$D@`=76
M;`<_='[G?8YLR3_\^VGD:H^8<4*]ST?&B7ZD8<^F#O$&GX\"7D+<)N3HWS_^
M_6\__*-4TBX81CYVM(>)=H,9(ZZK75`VI@SY,(!6*L47?L$>9O&E5\$?Q.>!
MUO9\H.2C`=9^^Q5YCG:N&]7JMQO=F-Z9N;%]W^YJ=XSZ,/8O(4BM?**?F"=Z
M>,/3`W/)F?A_#1CQN/Q)/A\-?7]\=GKZ_?OW$W'DA++!J:GKUBGQ@+YGXZ/H
M^H<Q>LI<_D`H1X!S/$1LA$YL.H(;#5-O6'I\CTN\/Q>0$*<?$$](.'@*2%[)
ML7TRH(^G<$*.7=*-DF4<I3AP<G=$8U=/PY/)I3S+ZG<KOM(X_>WFNFL/\0B5
M\BP33LNF45LDI/"*^`8P@P%"X^2&/N(/\N+H1!$3,S**L!F-1N-4GCT"_6G:
M#^+G&9=([W%?DZ?._,D8?S[B9#1V!6QY;,AP__.1T%<I5LC)$W>.M--PH-`4
M;`JZ>_(UXGP^:L-U1D@F.8\]G_B3Z%ARE#CB>)]@IDDH.`,]UM=%^S]'/^H@
M7-VT=+/\PVG^YIC4:0&MB-(8,T*=&?I21?Z/`G`)9&D9R>#1F>S(J5'B0Q'C
MBV1A_FP=FC3`K!HE2]^%-(QO%W0THMZ%BSB_N,&C!\Q>03S)L!P/1CCA+3GA
M`(RGL4MLXH<8-8?`=6&\CASPK.M#Q!1W2V8Z_:Y/[3^;3X0?_1A?,LOL#Z>%
MXT]QG18!VU?CCM4I67\GVDSQ^K:4"9%*J?.%U;G#4#M5IPJV!Z_0EG#]`ZDD
M@&/FMT!=8;S2:U"E)I).SN5NPIZ3NB4MPOC,ED3X>Z]UD%(T]D>*AU+29D1H
MKF^(YDY%>)"&:*YOB#N2HDAQ^D$(,)4=]!V6X@?BE)E:=I?%3[>CJMD7+WYD
MOM]%\1,&3-"H]XB93QY<?$M]S._0!,'OP];N-?4&/F:C%G[P>Y,QSBMV`<LO
MI>0]3@)AGZ/,XC7,XN4F#95^7UF_.YIX:BG][DM8WZC)S!C%]CND;[*@Z8S%
M@TX>"N%;]_Q0+:+Y'3%GUA1F>51I7:;U&^KAR0UB?V+_*O"<V``NN4]&0*?3
MOT*$_8+<`"<_6H3;+N4!BSSI6W+F!B-Q6,B+WV,[8(QX@\..,`EOYY,FYSCL
M#K*V52S"9?:U(8CDYT_`*&+V<'*-'[&;1;2.]G:$,V4*5PS_%6#/GF1!KF(U
M;ZO(6N!OB3#:WCCPN=2IJ=QK/]UK@;*4-[VH-ZDTI3+$6[-IE0I4%#XLBUTK
M"B]LRI6![U>,OB;H@;@@WH*Z[%FS*\H#7RQG*(?;WXRB_&O__<M0<V1OL8G?
M@^QZL-ZVT]?=U0S9X3N7ZLWVPY=4BE+9X6U9M$H#*@(?DKVJN;&W&I]5[WX(
M_J=FQ@XSFRCOVF_O"M\?A&Y=-]6KI?OP:JE9TLWU7RTT2V9C-Z^6FF`:U8-8
M+I478W5],59WNIA6.=@^.-B^+1`6#E;Y=D,\,@I&AVT*]\@;Y/2?X>NU`FIE
M_4A0V=F[^I&^T=/;U'>:+Z7O9#$F&A,?N4W'(>GU&<TQH+N3.[D=MB6()-"#
M)'`70.>!.!9+;(DOACN?7(`L!Y1-.OVVCY,KG%R>*!30-IH`!Y.S:SQ`[J44
M9DA6;--V-B/]U[+7/5M+HHQ5&6M*@2^R8X]:FKPGY?'^;/X2AJ/RMQM#UZUO
MS=MV:/TV#GQB(Y>W/3N*3#>8#3!K#AB6LS71T6[PP.4,CW_YF!P]-#-:$!#F
M"V2;<V=M<'(6"-PIVH4"WR;5G.X*%H(6*?=50J*AEW1K%Y/>4]M_P_:MS&Q_
MS&S]$)OI[M^&0;[3@/O<J1OE==L-[F_0LY2!*P-/&7AZHE`9^&X,?)W)6&7@
M+U@WO3WC5W63\KH=>UU+I15EX*]GX+EI4F'BYGK3I!FO>/EITE^H3[S!FYQ&
MVL_L4RCP]^,P+YT1E.TKV]\7VS_X9'%-[3^_CI7#O)C#%`K\_3C,/B4+9?O*
M]E6R6"-97,!=D.V!8[ERYIX,ACY7_O-B_K.*_-^/.^U3*E&>H3QC?SSC?22:
M-S@'K)Q+S46_1HJSOMWH-?5B]N&^F%W;P;JF]M0T+/5!HCWXX%1.S]M]RT'N
M#6`VE)[W0L_IA?[;W@-":7@_POP&RP&MW2Y?5:O3]TO=.US]F7P+6&[8<W'8
M*E_Y8\!I9E^GAM_AUX`A@=>__8H8@S';G`?8Z5'1SQ$_$,M7D=N&(,A]RN*5
MOF_F8]"1VB/>.TQVJ*D&=@VA;+6WC,WR\J]`;(U%1V/JP9\S^V.]TG>J\Q&J
MOGZ$JN\N(4ES?C,FJFSAF3UH7?:@RAI>H1FI[ZSIC!6KLI;*6OMCF],$U##U
MMV-O^Z[8?`IJE(S&FBFH43)WLWW;PJ=5EZ.Q2R<8=_$C!H^UXRUIU2.IK3P-
MPN*1E.T'8E_6"\K]IN?`,<P><UW^'#6\GZ=%SY]QV.6WZV4X+7_K@LG@(74=
MS%HPU"/R"2C2%FGM,!TDF8$D/AD@P<<%XCCE)TLY?KT`:UKK!]CRMNTC*075
M[..NJJ0=;N<EYXW5+I?[%,5WN(NM?'GG6V](F-,$+AW!:8]>$QNDB?,OZ/3P
M(\I5"%^[S6G=]";JHX5OSJPFJ&U4*//+M"5:>+?ED7B=9MWR2-_9%-?N'0OR
MJROF##Q\AR9BL*_0_EVUFLW`'U)&_BM+ETX__#`=E-J=?D3=N4$N[HE;N8\9
MW/\%NS$AN``!PU>481MQY<+*A9^-X(*Z+GJ@+"R3Q138(/PX!_1]M]2SYYSN
MP2^.9%7-TPOGMV[T.YEKBQTI)^M"]WJ=!Y?ZSB:!7RGT72*`@UFG;QDM;,OK
M!!RPLBNPK/.`$P]SWD(3WNR#"<#`(\*%^GH4#*C3OR(><N_QF#*_X_V*^%!,
M3[A0ZP.FKA\X$Q4C58P\V!CY0MZA@NE;#J;6/',1SQBP9TLLG;[\B]D$N3?(
M"_I(S/7B:2:^8]0);%^%4Q5.WU@XW8%_J("ZB]6?^Q)0576JPJD*IZHZ55.C
MVXW`D6F!\,\QF$*7NCB<$L*L[7WM=OK&'21@03<[(P0W-'T7@[Z,NB[,K0V9
MVB'`NSNY`C.GWV&T:Q1X]E",HV*NBKD'$7-?U!_>391]ER6KF@-0`?3]!5`U
M!_".R]9T%,Y^X$45L7L:@U_RLS$JWK^]>*\*YG<:WU5$W].(KJ*LBK(JRAY8
ME`T\$H;8K]U6+O",0'W0\OQ(."V;1NT,KH@'BD^E!Q<C%8XL5^/P.8-'3,M+
M-AK]#JY<./88?FXT\B_(MJ%!G#.X=(_'\)*-AO])KD]:-'JX@FFCP=M@_(N&
M)G!^HX'!",#CI4ISXSOD$?)*WFK%C;>0%"#@T!E/7MG&TG9=/&**7`M[=$2\
MQ027V5V>XNR@\=D4W[/22Z(RXD,(P.(?L1;X$;DR)/L7B+$)A$*YS:<4<`\-
MC"/-P38909[Z?*0?:9';WN-^^(`&S@L*\F_IMI6::59,"_+[6O2R$.\8'B/B
M7#Z-98+VG(X_Q*S).?;Y1<`8#!`#--<%6(=CY=H4W@JTLN`*85AKRZFNFU6K
M;DR!+"!YQRB$4']RYR)/K(`5<AR+L'^+$P3EM051-:QJ.2V(^42R<,1V:SW,
M1N$^!#*CQR@JZZ*PRCJ((J6/@L&SU%MX3#D!"Y+R$G5$5A75]05ABJU5EXU?
M9`4QS=JZ-*NF56O4*I6\^G-$;)L&((!HQ[J<S=77EK51T:NUE*R+Q\]BB!=6
MWV,7$KMS3=`#<8E/<-X%&NO",2J-FB5V.ER95!99Z*BVS8)%L`Q]75QFN=:H
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M`%VP'5`^2%4J>J5LU78%<5GD%ELI+`<):;?2,&K&CD`N"^U3D*^BYK5#?JC4
M<EE_'J!P\B'<T2L!DXGW[=NK#:053VI4*^"_A1#3E->#5UT#7K'%Q>C,<MDT
MS3DRW!Q@;2G`)2$E+;WREL'55P:W6'9&W:QF\^IF\(J\H?%R&%=WD@*@EOYR
MGO(\H,9+F>3S8)HOZ=ISH=[3"7+]R3U^Q-YTVLE:E$+$$SACMGRIF[5Z2EK9
M@?-UICR8-"/6HI0PAYR1IQ>-N1)[BZK\B-[OO=9,'C+U6KVV(8N+BOGY)*T\
MR6(N\\065>>MXNK3,'2K;JU-:5'5/=VD:(8MRS*J*Q#C&#%;S%ZVX`*7RNFP
M:*8P0;"HTIYG.T9%U_5*!L`"4EE47["'&7+ARJ8S(A[A?O@$+8>KO*C4GH>K
M6JN8U51CNX36S,0<`X)R5P7X[6+Q0]PZHLR/=EM(T"VJM>>@LRK56BK&K$(N
M'Q:Y?/88H4^,J+RHJIXG*FB6]$8CDT6RHV]@2^45PEZ1-=?*=;U>VZTYK1`B
M"Z!5S$JMGC;TW5G49C'5,.J@RN=8U1=$O&O*><?K(A=W^IEY]&02/8&Y61PN
M6=6:64NEF]6HKFC_R\)U,::R6:]4ZY7ZJB[0AD&A%)@Q^F4AO,C[:B8$T"GA
MW-`%\\2WU!,"0F*?E[9GT]&4_@8!/$M]#H&5N*^L$*:+_,JH;DT`E15B<9'G
M5-87PBWVP\/"=)N/B+ABLKA'4_5B-,%TCCBQ$X0;!.B288I)ZW2$7I/Z=J!O
M%M)+Y7*C`O]K;`E]/+\9/S"7EXCL0-S`GW:LE4R4-U<0]/0)?$D_2:>@)10W
M@U=9#F]&F"F$YDF]NB'"7['8H!T[3;&]\`#?!J(7ZO1GNINL\E<(]D6M=*VL
M5RM6"NI:U%<"'C$YMSVLK)`3G@-]'OUM2'V%A)*UD@1]I58NUZSZJPI^A73T
M3/2KR3[V">R(S>(AJV3*K>IF>:M>KU;2+QT4$\EE3LX#L:-W_&DGSXD^CL"O
M*.MB]DAL8(-=N(B,DIJFNF%2J^NU2BKHKD4[G_!MAH&S%@[_;7O1JR8MW,>,
MX>)73A+\*Z2\HKQA5*Q&(_W,>#,8RUC)O3D@"N29Y^,)*YNE0+/1L/2,+C9"
M,9/%Q8M(4"V+-Z6<\\E7,+VVUXF+%K$S]V/X@%U^]S@0VP*&)ZDWY6BS9@B*
M^`;D=;V>2>K/P)-[2RA\09;W:-.&!H#AN6_T)'QLUC-5RY5JVL16)[R2,L(W
M?U97QH8=59Z+YZ'9"6<K3*,5<0;Y-_/^RC8Y@T%LC!U^Q>A(AL3.6%YU^206
M*/)IK59=.PM'$X[E<JH=7TIN/KIIZ$Y5R`FZM;-L&).L>JUJI6>AEE)<R3#$
MEB2>O;)AU#9+OE5(#)5RI;'4,E:$4]S@WD%N28!NEH6M<KFPNQ5#KT!T6>HL
M=ANC7M8;Y56(IG4>E0.Q/4Y5M&'2@_+9*K:N/*5GO-5;6_8(O.A=E;H.J:N1
M?KZW_HN]ZZ%<]BZ4/HO1J%3,BO&"&)>^(S4KR6JCJNM&NK7?`.66`LEF&<8J
MUQKF"F7,1G'D%H6KVPO0UN<"_/&?KO_)ER\Y<G_BXL]'?;BPQ,E_\9FAC_U/
MFOR[CT;$G9S]JT=&X*JW^+MV3T?(^]>Q+PX<<\Q(_]/1/P?^I[__38[(4K^=
MZ>]Q3.6F>?^E?7NFZ<0+_QO[FGY2(=XGK7?Y6Z_4OFU=WO;.M)(\*$<6]S_$
M/P2J>*RKSFVO].ME^\M/<,,#=9U/FCS4;?_?Y9D6<B$/7#5OVM>_GVDY+HXT
MP:Z8%Q&C&R=B_%-!("9V^O`,^M;8CPD8(1]H-/[T/T955[]V\$O;KO:$]63M
MHW79O;AOW_7:G5NM<Z6=?^VV;R^[W05D3\?;<X`9Y)L9>4IR,[A71)O#N1.8
MYX1V(75C+;?T\WB*'YK;D_"ONFG4/G'M`S3CFI@40=[D(X0]-A8K)45X$_\,
M)AKAFD\A>LO'>]J0#(;:HTQ-8G4CC.Y.2A[4#E"1CS-4M7&X70C7D.>((<AH
M[,KUB?'8Q-:0"\6/)Y_,<>T[\8<:E$)C;/OR!K@W.\@4ZK%&/-L-Y(R6&RZP
MY<?:0[2_B99:\RD"N[B9BEF']!6C![&X29ZG3/-3JT%#).$-.:;$2`^$^M@>
M>M2E(!];`H*44Q`(]\@V#L2$>U,59\PTMH-C#1.I%S2&0X]@=:`[@&='&RO&
MABKL++81?*9],#Y.!7!-'L@7[!YK%)HHS4&0JD/U.QA4[6I^:F&O-L"N&!\\
MBF.MW6X74H*LSZ1U^@PCN9A(HWVMCV$T\"3\%(C+)[P?>-+`M`]7W=;'8TU8
M.NF'3J0-)V,J[.]Q>@?FA`%`PBD#:-J'G[JMUL=/V@<SQ0Q:F8M$8@\3B?7K
M2?=$NZ+4D4;=8L%`2S\KES!;S8_`O?!S\7BDD$N!>T`]!#!'Q]*3TH0=^78[
M]NR)D"+<<RRI12XKXX)8JYZ/6-K7;C,7M;0/XD+!OI5B_\LOS=\T6W3#3(N6
MIH*-($WLNMFG+J$"XLSY/@V8./%]2.RA-D0@\P>,/6T@.A]`!7P#)^#ZGN8(
MN0A-#,)@$>(/;T2@G6C5EBOY,VJQH<BK8J.9VHS/B."N4)"/8G5VP".T'!@M
MIQ@5CG%'7+=TYP8B:C,"T50&'_E]55FP,A#@6%C0QXQM!P`B/7XF\O4U\>E+
M.@!U'`LO&PCMB;\D!_!?>"[M`VG+_R0O^U!)(;T4NU(QXLWU+W$:S(6ZVH>8
M]L=""Q5J6&)](^J(\AV7?%KBXIN<&/CD=$1]N)I/1F.?CD!<0PH^ZD+K@/E'
M#7%.Q:L7,*8,]#`6'2,A)<'+*%SL[PB.$S<!0#?8F373T##%*1"Y/R=V1<:.
M-T\0+YX,Y*^P$PE_LNE/T?V$L%.-V4PSE6VVQ',KWNE'$^FIQU"UANJU5E:;
MJ7JM0_ZU\U[KO-EM=T67=7=_V04;;8JN2W5:.X#9#G,#'4->AT)))"+DH7!?
MF3`10*T1I@(1[`(/0:LBD@K$.B>L?/KAI!7D0QYOW,)E*$3`!E2$FH=M:%00
MFVC(^2.(UJ@?ITH/H(HTC\J<RK`H1`0M3X;B8U%9C:&9DM4I(LP-4^J4JEQ]
M'H%/92[(CN)(%PH)^1[^5"&6?JR)Z!R6B]'FDJG3ACQMA.P#Y<#UY5!T.L&6
MI/`APV&V]:`@@R3N^4.N84]TD<LHAS3B=M"&G`Z9G7Z?#K[ID**+H!Z,,A(+
M'&5E@*;Y:@S"M47-Q:%4D>^6@D3AO!AZ6BMX4LER)Q[)>W,$Z<=&VH<OS>;=
MQY-4+$@>O2:B6B0<+=S:9B6&P#(\*'=B\R&R-)5%E.@M(FW'1/TA\L%V)U#_
M:OA)=-ZI2JL?@!E.,&*"K(`Z5^MFFK54#Z<Y%`0AX,@B6^S!$MJ$[.&$AS`\
M%!L9B9/AVX*">-3C15A#@<#AC>0!]PG]?HI-AF&@`/X!Q:P$%CF)],U9.*JI
MWTY3#\7U-`@2\<B+C)8%0SZD@>L(RX2*WXG\\X^XAY8.F@UIJ7N%LEFXOX/0
M,DY"Z]19BTKUIN>)SCO\:@/T+]`?L]%4RH9>^D_B';%CX$714-G/%F!V/.U_
M`P^G]!#Z=J;ETG"_'X8O,26"2Z`FZ!6>P`J@*P3SXV.7R)913"O2U`MQMGR(
M#C#%<WMA-[98+J==A-,STJS@3"[`;6+/`Q%6&(:.-YKG"1&+3!V&Y`BH!"+A
M'KCUK-M%SG2)81,IM^^Z)G\%Q!&['(H'F&/BBV^K<!HPR'(]Z![/W=1K%_7Y
MCQA55YE7HZ6ZRD/^M?.N\KK]\]=VJ]W[76O>MK2+YEV[]__M?6UOXSB2\/<#
M[C\(?;.X;L#)2/+[].X`>9W-7:>32=(SV$\#V:8=7<N25Y*3SO/KGZHB*9&R
M;,N.DR@)<7N[:5L6B\5Z9[T<?+'`P[SX=G5T8F[RG@),[)F*PSI\[F:`&:Y[
M:9K1$HNJ7[RFPZL[M&PIG#T"*87AU'$<3:WY#/X'O=.I'!O`C21>W&O-1'*E
M!58-&DF@$7G<$E6D=CF&OZ(W)O.!B#JGR1+[7X,SNWM3/,(<YCN,9L-R"6K4
M:91@2!TVG0/!33I><$C_4"]@O"SS8YDG`FJ?!>/,[`>=35=*W.X78P\0U_"H
MO&S27L4!U4T.?-D<]3UXAU/N:C'>'V<L4U*2AKS_]"S`.R@.\+-2"A/D6^.^
M1H,;$G`XTA?2O%QP\5E^G&C%N+;=MP#T";R4S.$C!I2"I8_)0_'2U_JH?OF)
MX@/C.;R?S*%P$B$<92>$,(`E'J=[`-L4@!9ZV,);7W/IN0LP#]:%7(I4-[)^
M:O8:=JO?L/MM?L.5<)Z@/UB>W*62\!;+J';R3[V&V^TV>FT;/2AO,HG9!%E7
M1$;P<GR*=INTL9O[CMO^&S*U[.!F@:/MHQ]/#MD(1-:Y]U"TZILJR&>A=3"?
MS),T_VP14/3;`[JR\3":-684!\/HF`HF_-MM--O]1K_I6KP+ZBJANN`5W(N"
M#`JL@=E)EV'%%9R&TX45.IT-5VB(@`P7!L!:&)?@.9GXBI^:#;?3:W3[/9`F
M.+<%9!]**`I,!1Z?WP*04+"/,37A(<,'$\6R^T`!S,(F>E:W84F(7/NS6MJG
M`&KQ'ER-[$GG,[G`WFA$\4.\J/:3X9Q&'UJ(BIC(!;===G;X"`KY&,YKY,?H
M`$D8C3#9A3`94,R7>Y2@,68I9X4']<2*J@>C9)G**KC5%!5,B*67BAEKX`5X
M;<U3A7C=#$:2=3:EE$Q&'(2WK?0230UE6D<76\E\*BFJ-#=$1"=537CP]>S2
MHC(1$>7.`I(_#W[V\.LU25+61WCF$V8_Y>)E-(\E'&,_!C7][[D7ISQ0B9++
M^IA(UG)LG;>R'O@6-<%/%&[ZM`V^UT?I`;%3QM(5M])2D<>,JFFX^9?>QM%\
M`JNF%C6S7_I[M$Y1[%/D-(@2(7/Q<7X0:HH6I\9L&0M.'-$VC^6A>7(Z`L)-
MQF`&P$].%VW60-Q5H&PD='P$'&!ZB1+2*[[LD^7)`F:P?R/^4"FP^Z6NU=ER
MZ;V$Z)!@T+S,B$8_W'N?+G9XX@L`B9ETJ#KPL,NSXN2%#\;H13H36)())A:)
M#0QE1AP_44^]U!'?(7MS=9`OHMCT58SWG%RRBR/:S`!S?!`9=*P2QZ5[`?4?
M4(3NLW4;W6.TJX&Y&`O,G5\:8%P>T[O0>@Y7;(#;V.7O8D-_)%X'KQF*@6?\
M8N$^@L.XQS@<B(#A@YJ>DR6)/05O2LPE\S%/CTJW95?2Q"JKACA`IKG7IO"T
M+D=S\9^)>NL^#['36T<RZKZ(PVW0MQ@UQ5*P*5V/(453O@_IH)A;`K&>Y!F"
MFPH?H./4H!\,;Z,H(5!BST<=4[8IQH?@&7-BMPF9A<L\SA`^E?99H/+A(*RQ
M-Y15N5S$<^&EFP%$<7#@T3VI_J1@\./#&-%(^>6D)C[IMX)4U;._C^+O!`:/
M#&=6Q7B.E^&*85'T'/!]H+2_DX/.JTJ!*P%D@BS7AOE2PL&/T`8?I`K5><KD
MF?V"ZN#4FFCD2@L,,,$ZF1/5\A<G>)-/*%R>498HICJQ!0JFV"?.'&'5?4&H
M'VN0@F(>YXJQ(53+7110"`8P3VY.3%E\W,=8!H<2)M`Y5[<4J$;Z@5*ZL<N]
MYCH`9`4A`2=`2I3D><RM2B0$1&..;47Z9^(T5_:HAE@\3<0-/7TFKEDRV<(E
MIQ<$!1\9?3I%:0E10R=<(FQT@M)%E)>"!IB1;!<Y@'@SA0M/(YZ_H:6X4^ZL
MR"OWN9GLP=O]>&3-P,X$\K^-:`6^.!-IKJ3N8S5(*"WM0H@L'/&3%UF6#27P
M)9M<T0M0G\C\7`%<`W5W8`W!D:?T%-Y#`%:-L?.#9/9E!)!)"8F%S$`K\K[$
M<(,'N?"RA<[-G[)%1$LOO`$+P!_`>P01TNV<1I>67/4MB45(/B==+M]+;O3/
MF(X@7L]5&[=#%KBUX.I3/@GP1R@22O.W8IHMV`HX%PK4YR1*>2IJ,<:*"\/Q
M,VXIHX>LXNH:993RRAQ$#04\`.F3_]?@?,*M->206<R08<B*Y3#B!::_*"=U
M;LZ8;*D%M"H5MLR*:<CLY71.J4Q"\.B5&SB.-M(MF@V0($0]"4=NO<SX%"\/
MJ>8^!$%ZZ\]6A6M4F2O#-=+O\$5%-OY>H0@4+Q0<H;`86GB"%&![C$M,D7U#
M"I7S$I('MLQ`84X;06KQ`X;;$C1+DBQ*V"IP,Y[3=(6@J\Q%7QJ;PA,5/KTF
M'BU,A*>:!=A1]IH5&17JFS#H/&%TFCR]*H1?*MIAA4EW?\M"B]<9"84%2_F5
M=(YTQ:2P!?\%;QATOPV)!PX.HW@%-T,K40+<@:E]QW2K!-X!4D:UYD7`?@K"
M$J$GL:$$-^IL\+U"NQ2(D3P)=%)*[(92K>V/,W):83Z,O;LHKFX]W-R"Y0+_
M077M#^>!1VF7,=9QC]'$PGLWY$*1HH?IAC28<A4#97<R7F[/PF:I2DY(6O$I
M+\LKIG,*%09K15,DYZS$09'VP,F8P4*5?TLU<@566\'`/@K_*:7+B.H.CF%A
M!.7Q'P1P%G@\J59G4DWV5XVT9>6.KE,([7@C>!"C+]P4EZ>BD$%<]F&H&96T
M"9).*M;I;@P_F2Z:+7GX!Z\?U<`G62A)6C2F97XF2)$A_VDFTE8)JP9W9#PL
M9^3FSP@472'0*JJQ1.!(-_4+E$!O&Y*]5<DOX1HW0#V5B!!S;J/ZL>`'//-7
M+A"KICE5SV-:W;5P,=W),>E.E8^S9=*=WMI?SU)8<T3I3\=G7[[=G!Q;7T]N
MK"\7U]?6Y<F5=?W/@ZL3DP?U1%;>@)IN4L*/:-.*5T"@5_`2)N87[?*>CKX>
M8)]'2]Q$W(O>E*#!J3FE%5)W2O+4LBOZ:BG`:BBA0;ILP$14(0$S#H/GH&QS
M/Y@*'2C-BM2TJDYY(]%U^WBP:-*J5,O9X\*`JK`U)?8AT]9CRFVGS`&JH=#B
MA"L1C-E)E.Y.QLLXH-QE]*0CS&?R*1&`QQZYX<T-@&B((3]?<XRS*$J6/T;!
M09PMHY_%/48#6=;S+8IE"(=G74?:TQJ"V9`J>HO96CX?LYEO$8,Z&&I23"(@
M;^:!K2,L:5EJDA6*++=_5'Q',Q%(R1)'B+"4"!3%CQ&W>)7*47?'/E/1$:50
M!`_"A%-#"H0/N@84B6#RFF^>9B&\%7R2%<&(&.O('XM8`Q!S>H]9@Y7XC:?Z
MO'97=M,$]:666'&>P"`]]A.\:)Z7F6LE':5K:*XUN_MV>^&@GM]@:QN#[:W]
M]>0&V]'%US].KF[.#K^<6-<G7\\NKJRO%S>[25:OQ!?OSTQ3M:RJ![=-`^6=
MJ>@OFOC[J9BELCH#5?^Q!A&8)MN7-X,Z3]146'SZ)]=N='MNP[;MAFQ@!:H\
M*$903MD@GGNQLM?%9%:?C_9S&KU.KV&WVXJ52EDGJG4$]@_=)_+=RKC+XN;1
MH)$W9-(,I"XS09#9##_U"7SX__79O624\-.3&>JRUM+CC;'I\WDXHW:I,JD=
M5^G",FZK@)?_F0=5<+*8;-OMM1IVUUZ#(\Q3V0V.FHVVW6HX53*@"SA:AQ>@
MH$ZOLP_`A'N\IAUO-WA$5RG_IV<_NHUVJ]UH-^U/G/P^=ARGT7&=3]Q>CAD:
MD&7YBORT\$)99"XF(G711<_%D[=:\AJYL/U\2_O$@*4@YJOG"7>%]Q0QGRCE
M$UZ:QOY@KMW8TRTP7T=43-(U6YH&8G=X$S8(_(D,:=*UFS@8>5W&>"4F!K_Q
M2C!]6(3DE1NS]0#SAH2!O/A2!>4FXEJX.<2.1`HB$8@[53HWHU=(M":S$T1;
M-3AK2B-*9`*A+CTH#>('Y:(!W36[=J/7=38N#$!2XZJ-TM_%S2XRM+O?='.'
MJ:B\"GL5+24:(!O(V4-?5Z'HQ3L=^M6()4/@%I[_RC/Z"_=4&N2E1<D;5K-K
MF3)5JDF4C9)PHK1.V!D9`F.ZIQ]AD@QF+!%F?$HEQ?NL201H#:4$RU^$6:,@
MC&:BG61^HY1_Y@7Y>QIYWEK67B5/)8(G\YPG<GKEPS(/04,]N=PSC[JZ4'`&
M4)8T1%BAD"-$_CVV)Q0)7K19D:ZP,JN*7^ID3O_*&SEEF]MB!?@@E;&<E0HR
MS\RCUC/8"Q18)V`\_*2EL-!M#UVL>6)EF:&CDS(P.5`0]780W#OTX^%\BL8:
MYC_DO"Q3+>0&WINT;K;WG=UW@CM(2J1(4[M1S6ZLB#W$G96575KIA4%/D;6E
M$.$KR=.J]9&_%M(L.I6B>(!'G]'&7#`:4M4DQ6.EMJGP?(*]A_TQEX=*4Z?,
MT"]$947I2J(U3))JJI%+<:;$=$G_*W;PF%$CKD2D0!,UWF-ZA)[$+&X88-\C
MBU>#T!(#?PQ+<).9%SX/HTGH%Q-[#]18<3'6S8%ALH28]_C7LT14UHK$O;QJ
MUJ_7\92;(=E.R&CE#26>^%"J2E""8"RMZB0F;AFX:"IW-\2291W6%"M':T-6
ML&(6Y5]?DW^GN"Z?QG#./(SH\J1%5>ZMW;6?Y-=27S`IUW)AN=E\L7(^\Y]6
M8W&QNO6G;J/=;S9<IU.A`H7'_9/L"@%3Z:)4FH:C-=:Z:M8GF6M(+A<8'3]U
MP"WO-%N[VYG3;32;G4:W(]=;$9\1-QJC;;>6QW)*]]9LM,#W=ENV=F^6.]I;
MMK;3N3?#E+>$ZBD,T&L!,(XK@P"MAMWL-KK][J<L&B.<`4V!@I0D0SR_2"M<
MH\FP@>R>1C_A+AW3*\(KB`?ZL=[93J!D\^Y_OAC,)B-.`D>!+S/0N#".,0(7
M<0A%T;-Z5J>/ZD'H;'%0K4Z3DQ,=D]/HNQ1K^\21(Y-H>6QH^ST6(X^UUNVO
M))@A:67K+I5:C`%8U.$'SX/&37LQ8MR0$K&<G##X7!8B$X:TCPG5:$CS,0NB
MO;PLSHK]I-C&3/EAJH745XKH$6\VLV:I+1MRXA9ED2#YL$,OP%3:+#NQY,H:
M/U[USI6[\1*%C:FWNP@VK?P5M^+RUO$@/5?*+OZ"E7I+U`G0^(V\A`<0/6"\
MRXPOXZD"(6@+UIE]7@F7\ZC3>EH>1$KC49%,H@CK=40F_$M>^4B-7ZD,ED@H
M5P*X$+@K/L\=CSW9F)1&C&21OYQ!9+F\_@8M6HB1MR!H9%U@47-;072/^3=\
MB\F,.FQF!=1AI-5Y%,Q[1,C>&+6GOA=#C#OV>N&40<C[.+6`$+^,N+AGP6/@
M2B%5EF!?$CY%BL#_E5&W[^R!'__,E*CL\B@5G%;I"P!Z[9>M]_1":-;2E3A8
M>U].3@&K#B:S_GEV?///7ZR._;?/UN'%U?')U=[1Q9<O!Y?7`!+-:9HE[(.%
M-X3)S,-:$3XA$/X]PU"W^/>]/TIO__$!7O,!Q<Z(Q?BQFN(D0?BG2!.Q9S_4
M[T?R^\N#X^.SK[_M78G'$$CY&8>;/CH\./K?WZXNOGT]_L7ZK^&0L?$X?^[P
MXN;FXEP\*7;8;>T[O;_ES]Q<7-(#'Y!O09K^XT,:S;*-=%NXD0D@((*=_-?1
MT<G)Z>F':@<M3E+//W&>@`+$0'=%XJ.<7Y],]UPH!XQW5F(<5'8:33.D/P+G
M:U'[=*F)SX5-U]X$EZZ]/3(%[1Y\.?L-OJ"ZUP^66(;_:\>$;.\[K?H@VMGO
M;$2VSA.2[8:(_-M&F;1/))IW*X5K)G/_B-"U"T2&2C;248W0/1DE[UC6OE7)
MNELA6E.1V;?W[1?!X!;2\1W+0F.FII^/M=#9F/?,$#<[65]K3"WQDMOZ6`'&
M>#7&:[41Z_W]3GT0_6Z,5_YG7@96AY#2JXY\K2JJ>%3@JT:8-\&PJE9&04R\
M"D-#Q,-R6L@"8\I')D)FC(S79V38^TZ_/HA^-T:&B9"9"-D;E*SO(D+6[>X_
MW:6"B9#5V'8U$3)CO+ZTB#7&JQ(AZ^VWZX/H=V.\;ADA$W0QI.DN&6&(?]8^
M8-9L[;?;3U/MIJ<`JR5#T2!A,<Y^?/!9,)(!-<SKF^8E2;Q(92PG4^@EC]BA
MC?Z^]>YX!NB1)PHZO:8ENL_B;X,HG/!1C\,HGE%+8+V[`OX'LT-Y=O9Y%(WT
M\N6SK,_Q-<#LZPW$%=M=W1^5'OOX*YS%98T#+`7-V[&M[#<KBNYI$HY(SR7D
M8!4J-O@-\@';LBT!?8<U@`'/*$=TR;X0"U5+6N[3MJ>"=43^#YX%SYO:AVR/
M:NZ_[5_O6S<Q_>#!.HS"'0[5?"):W7E?M24-TPI=U;('+L9(#"Q,B$*N>+'3
M$79.IJYLAW@^E\*J6>R^UGP5W=?JT2RW8WJOO;6_GKSWVO7-Q='_[AT>7)\<
M6T<7YY<G7Z\/;LXNOJY8US3(W46Y0/HP0^T9/%@3WG!4M"#5)M9NV.`&?II-
M$F'361`]R/&R813NR4_$(%?4^52O#O\)4?%B*]%DY=A,:K1*>E!,R::!<E46
M$JT@</!&UK]&]!V!+T1;,M*]O`:8OX(796)W%3)->/FZ6BTC)]SI5>+8MU[>
M96)G&L0OEEQD8X^R*.2:J:('4UX!AQN[8J(BV;7MGD7C=\%X0CL8^PY<X@P$
MT0,/OL9_?MJP_XY>?MCO.0VWN_'L8VXU*0,0QJ*E#4W8R#&006EJ1W81L,EY
MYA%UY)).)>V6G-;*<=;-=J_1[FU,,EA0+NJ*<E8NZ6&U[&5+.)[/#%IL>RW[
M0RO=MUK[L+W2YEL7)3)QH;&@W6YT>QLW`V,_9C1!DXI(J<2>-[[3._%M=)QE
MD*L"B,;B%1&@.3URVFV&FTI;$2Z9=%WP;UI2A>=KE-%5H4WW]KNM,TN^$LD!
MQY)U'*=SD;2R[:DT1">E]-83+?7EZT5?3I_*#O]O'LIIC+I*U:BL=")\-J.^
MI*'=!B/JE88LKYR2-O:?'^<:ZWZVBF2.6#R)5?W,6Z_!HR[#?+T+*U]%=_:N
MB1"\M;^>)T+PSXLOQR=7UYH8__W;V<V_=A$G,#W:G\BC6-**N]GHM-V&XZYK
M5_[(_ML`S5,UX.[W&UW'WL_G"K8UR^-(Z1!XS=O7$]R*S<$=XQ#^>\HA1N#B
M;'K/^^TSW>SL=W>O1,_"4F.R.."=#THDBLW,3.QYWFBV^XU^TUU%L.3(26-W
MI</8<+KPMDYGY=NP5W3VBMQ7=?9;76"<?+:.:.N/+6G\="Z:"<OIH41EDYBF
M\<31D.9,\M;TK6X;^TD5[Z^R7?/F[MRV#FD*L?BYWC):O,WM]!K=?J]A>6,,
MU8UP6"6?&A5X0S&I<\+[7`H.RQ82#<E$E_A\_%'N(Y)!Z$^G;.3SV)1HHTDM
MCQ9N\MH4W,.^)67>+D<A2(2EO;87QF)1]`I!H)8IV?N$4-+F-5'+XX4%T^*^
M>(LNOJU"GV1^^,DL\/F@Z^G`#Y79FS&C66/4:D<,C!K,4^K+7'P3M3]6)DTK
MK:;+FT5?E/:D<O/>G7(+V2"IU>[92A9HV2!`W65#U0H1`DZ+-!<VU.G8=9R&
MW>D5B')W-Z)/(HM>B\P$@M!&K93J^,4;]FQZ.,:3[X3ZQT`VB8$5'>>S"/<1
MZDXB<2*6LU#F%M"PN$C.=<`)%-A*EW%^616N4OM0;CS(3W`6YEO$3)TH4+;2
M801:G.J7LDBD%$3"7J%]X!/(M0'.:J98"5[Q@RS;P_DC_"(C!:LK9H5O65C@
MV?^9ATH]B:,>40DLQ8;JA$GJ2"E7P,2#9\%K(3HXCGF;;/R:O^F>#Y[C)N3B
MP)$,R%QD-F@UC0KO;Z.%;LIY'S[*<PEX8S1O`004M\R_PQE^0`.!S^:X<,RB
M<0,'.5!7<1X=T7-39!0U\0)%#<A+GY5Q5#Q-RUD,YZ)FXGUIM651^94@#H<.
M==J]Q9:Z"Q@#JN:D)H@SU32@-T]OHYBZ36\8W<;9B^53,;FQ/O,*W>^V?B/7
M@`-E@N,NX%\N#1"YB#!/L`YGM7S4S!+2I-]1&TS>>6\YI+B=>2CH?E=@%TF!
MS]"A_OJS*&&;`KYFLCO>`=*%#CX;B`OA,BL7_D!HOAY<'Q_\;OT61`,`^)Q:
M'VZOQ&L?@*T<,]5#K=A:G#J+YT^6)"RU7T-XM38!R;X)2+ZUOYX\('EZ<'9E
M_7'PY=N)=7YR</WMZN0<J-=,BWSZG"4QC(-/;.'*I#@@&12@GB,+RH8]R':Z
M.&)(G_RA-7M7YH$4THVY%<?[X9,-.<BM0YH90AU20TQV9I0R1#%#='9P``QX
MQ-A$-VO+[E/:$Y7B!P_:("39HUJ.E_%@<QBKI-!!6IHMO(]CGK+A)9F:ICGC
M"?@+0QDP`1S&"@1*!^*I.JE"[TY_Z[/8`R^>#PGA1G/6:';$,4*#\_P4#BT1
M6<Y\"AL%3Y4/^`@+WIT:K02^JCZ&A?Q#ZA8<1]Z(QD4%.!:;QJ+H8\P&+(CN
MWT0?B)<&D\\8<7Y1>.'W>81^(=%]8GV<AW(^S">B7FI`+ZA4S(F@R-80GDY\
M909?:<4!<0D-=I<\48A%W>@=LG,BG,"RB2@`F-QB.%X0']F=8A_9K)0ZX_Q5
MD8:KDL9%SM&"/++SSV2F8'5TE/[-*2DJ4@UWW'`Z132(8MF_7P@^(!7/G-_.
MSJ^IGM^W$IF,AT=R^?Z68:@C30.:M!9&ZHF@6LQ2.S?D5VPA7\JN3<.N.[WG
M&C&LQ^*E2_F9Z#==<ZRJ0G6=#1&S4C:\#?U_SR4[3[T?_A2>X0.S>(B@A&Y`
MQ^-:Q2?+]+X(_8)GBLI@%DE%H?271YN%PG9DY[$8[9\'?2))G;'_2HCD-!MF
M*A0QGJ*BB94))]J0/!3A^)V8R,;S]=?WJ5\S(AU%C[S5RL>64)PBX38>3>?+
M1Y=S^Q!O!R8@2I@ZD\T;1'=OJ2>^J&`1I<+]YGZSM9->8/WFHWN!"2!$.31>
MSLZGF(O-\EIFM51:/$[ES:4/K^MF(5[`']/>(+#3=/?;)874V2_EV^[]<!3=
M8X`,Z_2M)`K\T=)JZZ:[<3>,+6(,O:IDQ6-*QT3OE$V]-NB@Q":?HCO+?F>C
MOFV5L;E)\?<V09W-$+Z*CZOCNW8<XS3W^ZV=LXR#L@4D$HBA4`K"%S_P#3FL
M7)W1VK'U,]\1ZK;\ZT,OP$P+PX^&'Q_%C^Z3\&,M#GE#'N01J/RH+RG6D/_;
M#W5^/*#H0OX]OT9,](?&D<+29S@<'@LO"R\BHSA_["/YJ4J.Q2?#Y8;+:\CE
MKU[KYE,$=8Z\P+2;PD=9>$'__(QB#<N9US7,:YBWCLQ;BT/>%<.J(>;-^+/Y
MTOSI[-L;\6?E=IEO@3_YGUOUWWQ"5J[><V]G023EM^6-/C%P5/M&G]S2718O
M?3R?;=YU<G/E^`9Z>+X.UJ@<+2KEC3)S=>'D'FO`;M,\]`VT:C5,4VNFJ60O
M;L\TAE$,HQA&,=K%,(UA&J-=7K*1^\:!@U?(*(^(`.P@.+/$/5_N@M?,X3XO
M%B,\&?F^2`BZ1EQ>O\CQ?G/W<>.7&M7STULX$&"#)\A^V?*^YAGFGC0[C7Z[
MVVAUGFYTGY$Z=2/R6MU7/0.19R7I[M.9AH;*ZT;E1K?6[$"`#9Y`[!C=:J1.
MC8C<Z-;GGF3Z1*D9;SJ>LG$@:^,@R]9Y#NXSA5UNJ',6+W:K3\#01-9K'%G?
MV*)T]]TVD/0HF@^"%4'V^DSOK)>=N<NSVR*P4_'T'L&";]$D-2+O+;'-%N9L
M1;9YT9O%&AJYAF_>$M\84^'UGMT6<2IC*AB1]]Y%GC$5:FLJF#0DDX:TMBE<
MWNOIZ8I_S'U%#>\K=EO`8Q*J#9G7DLQWFA1M2-N0]ALE;2/!#9F_`S(WI&VR
M*=Y^-L5S>8_Y;-KZ1#U,M+#>T<(G:C-:BQK?#=FGVVCWFPW7Z1CN,=SSHNT"
M39S=\(SA&:-Q#/<8[C$:I_8:Q]SLOMZ;W>>M=%!F^9BHZ>N3Y;7+0]S1X=0Z
MZ[!,F>WR=)ZT**&F:O3I#4\CA>HFA9XT-;"F=/[2A;&&THV^-?KV&3/[:RJ'
MC+Y]?U+(Z%N3.K'CN`O_DV:WO(@B,F-SGU&`F+&Y](_!<\H/,P/LM<\`,V-S
MRSFL9,H[+:U.S77,U%S#CB]K`;_=D7QF:J[A<L/E[TGI+AW"F5-"R?Q<Y<LE
MDSH5CC<S=0UKOT;6KL4AFYFZ9J:NF:F[;37?JZN.,C-UW_I%C9FI6Y]C-DSS
M/IG&3#TTC&(8Y>49Q6@7PS2&:8QV,25/IN3)S-0UR8]U3\$V<__,3-U='EJ[
MW6AUVHVVW352Y]U(G5K=5[V#=&M#Y4:W&MWZ[F;J&MWZ#J6.T:VFE*G^\90:
M=X$U,W5-9+VFD74S*._UGIV9J?M,)JD1>6^);<R@O.<R<@W?O"6^,:;"ZST[
M,U/7F`I&Y!E3X>V8"B8-R:0AF9FZ;UN4;R^US4Q=0^;O@,S-1$9#VH:TC00W
M9&[(W$APDTWQ+K(IS$Q=$RVL:[30S-3-#MSI-IK-3J/;L0W[&/8Q(PY?:Z#=
M\(SA&:-R#/L8]C$JQ]SMOBHG_B7N=LU471,WK5T9K)GRIQR*F:K[*BU/(X;J
M)H;,F#]#Z>^#THW"K;G"?7=C=8W"?8=BR"A<DS[QPG-U"Z$-FFK[-$>^=M;N
M2X-Y<\NLHV@Z\T)L]3EBEA=:+&!#'.9JI9$5LV$4CZP4'@-:F<.+HC']*T^L
ML+S4&GM^S!\`$DIOK8GGA_!%.+*"*$G@F9@%7LI&^,IQ,!^F<P]72"S8:?9N
M\>J$66,_],*AK\>&!"SP$O@1\^+0#R?P@BE*&7AW\+"?X]S"?>5`E4(=,XLE
MJ3\EN`9>`O\=<6AB/_F^-XX9PYG$<022:&+%\%B#PQK!5A"F!_E6@<",R[N?
M$SB::/B]02C`1X;S.&9P8OH+$VL<Q7`>4S_P8FM(KX&=[EOY3JX!"@38ZC0L
MN8!K?SZ*PCL6ISY.:KYFH0^OX5DN\A'G,[U[&L$V_1#^G!+&":"1GPSA7.8Q
M(77BQ3B/V?K.'K#MR'PZXT<S3SBJTUL_40]XQ%(63^&$\+']6E/WCN3)WW^>
M)WL3SYO]<@IH^`.Q<)RC\`94U&$`I_WK?_Z'9?U]Q/Q?3L(4R..*3?PDC;TP
M_>I-X11&__APXTUZ';R%"U&Q7;'Q/SX<`TVZOS?_=7/\X=?#LXOK@Z\W)];E
M/P^NS@^.3K[=G!T=?+FVSKX>_?WG96\NKGL$A!9[P5DX8C_^%PY5+MQ=OK!M
MVX[M-FVWI2Y3>%&^SG$TG$_ARYN'6;ZOWO+7._;>[_S%ZB\7WW?)8C\:G82C
M8V".[,7]Y2_&/_?L_E[3UE^OO2A?YP"^&^'WIX$WD>_OV\O?/_:"A/%7:[_-
M7WG$&?L4Z,$+_@5BJ0!]WUG^]KT]@+[I\/<O>]'"Z?+GKM@L`OX/)]>IE\Z3
M;#EW^7+_8HEVNJ4O*BYWZ@<L/@(X)E&<D5*_N7R5@^$0%$A,4I5^K*ZIO6WQ
M_//-G\(G^:9:JRE`/_O"2Y:MPDE$7Z>]?)W?FV6K*"]9.*=H.HW":U0#U[>@
M;)*+>9JD('Y1ULH%01:,V!!T4)#\X\/9UU-]_3.^_O7%7\K+SFD2]`=K'OK\
M*?YVP$2KY;INR];.>`40'&`IV90R.T$8&9!=%4B[%$0%G&_7Q/!]T%*=3BXY
M%]^OKY])U@M2/T>W7CAAR5F8??X;F!1?P)AP,KAZ*^#"HW,6X6IUFB#J2N3Y
MVE4?#6U_/;1(:`6`]YR^V]\)R$=1DB8'X>CDQXR%:)()P!S;7@-9R?FV6ZUV
ML]7/H2J^O>K:SOJU2[#B]'N=?MOI5EW_*TN/O.3V,H[N?#`@#Q^^@6US%H(1
M!8)O#KQP,4.)Q2U2"9J[U8$UG5:KU6_U<M`V6)Q#/9AY/W[Y.D<VOQC_X0V'
M?LB2WU#;L]&?8%V?'A]<Q#,X]^-X/CEF"7APW+;+0&^N%"NE>!7K`(O\_>=M
M`="13E+G#`Q*-CJ>Q[!/+BRY'.+V:P(_NA@KMNPU`T.96_O99EH5-_.7\AZR
MA2^]![3AE@K,9J<-'GD[/ZG'0:SO_I@-TK,0C#32%F<X,1.\C2M0?:AGV0A>
MC7,TO0G+=]JNH@TJ;_,2C%.P[/;MIK;)ZH`IU`C$.V1LE)S&T101!-X90S1D
MV@6H&JS$^!Y0D;+P<CX(_.'%>,QB1=LY=F<KEFJU@1G;/4F8CX)%V=/U\):-
MY@'\-A.=![G[@TQZ&L4ZMI(;Q'1F\.<;6V%:4S`'?R;]&?1"]M!+^86[,_3O
ML0<^X,,O_UUP9_Z[D>('C02`'W]6TTC4E)/18STNW4VJD0.';KSJDWKDR5^S
M64K4KHSBM1OHW+O6/9#SLCX!SW]'43$*I-$'!TN$]APEBM>Q_Y9%28\NOGPY
MN+P&D(91$'BSA`$%L@"3.T%:3SAWP;]GWF@D_RV">_":#QB'`!;!CY\P=6GC
MG+%N:]]9':A4$YJZK5=0@'0`LAJ%?!Y30M>H/FEZ@/'.)J'A1^"\1M<B3Y8H
M;&]TH62_HB13>]]IU0?1SGYG([*M48.ZOVT4BWR!K-+-I7#-9.X?6H3^T(^N
MT77!^#J8B#PR_R+7<%O(VK<J67<K1&LJ,OO@?+W0?>_&TO$=RT)CIJ:?\3XK
MFL.KT#JEF\,9N,M#?^8%ULQ[(.<7+P.'7G);'RO`&*_&>*V6:=;?[]0'T>_&
M>#6).3N.?!VS83'PY5#@RWEDX*M&F#?!L*I61D%,O`I#0\3#<EK(`F/*1R9"
M9HR,UV=DV/M.OSZ(?C=&AHF0F0C9&Y2L[R)"UNWN/]VE@HF0U=AV-1$R8[R^
MM(@UQJL2(>OMM^N#Z'=CO&X9(1-T@8EZF/,GD"+^^=QAFVH[$]E[C\^Z6Y5G
MJ>1&YOF:E[$_9$Z>K*?EC;N/2[+\=GU\R6+*$/WPJ^ON-]UEF98K0"MDXD?A
MY(;%4_QYAJ,<^E5YY%M`_^'7;KO?=!TU5;\,@%58/_6&[&!*RE&"Z:Q**M\*
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M4)7101QCR1N*L<.'_)%+[H,?W'OQ2-8N\<J=@SO/#Q!`L"RIBBG?:P7-7E(X
MU.\Y;E<Q])X*SAUA@RL'7L"5G(6\J.FW.$IR3>6Z58NLJ,)&O)$?^%_7AV7%
M5>U>N[<+'"V'?D/T)!NM\"=#+YN-Q'WER0\6#_V$D<&>HZVYPI78`&F:%]':
MMWL;X&UWV]HMN0$1CYF?8H<$7I?IBR)'"4J.Q<H5?E6)S[';W9ZS.^);NY<"
MZDI]7$8%JDH=]#GSL('$Z"*\PB)"+$\#`/QE16;NBNKTA;R)%RLR6U-0MCRY
M@U).\@!RKS?[L2+!X[,E0]M.JS_[43G?HXMM*AZ7[U&[EEI+ND`_K@%Z]6[1
M6;QIL#3P]*=`Z2`*1B+TQ&-1O:JA*(?'X%DRC'WBR<58U&#74<L7Z1VW28!O
M"X17#L([:V-_U?%=.XYYPBE/CQRPL?,#WY##RDMK:>W8^IGO"/5._O6A%V`%
MMN%'PX_/VA2R&C_6XI`WY,'?Y^!4C_*C)N,\R?_MASH_'@Q3_TY)GSSWXN]@
M;.H/C2.%I<]&L"=_Z`6%%Y&1FC_V\0N[8T'^;^>3X7+#Y37D\E>O=6%9?PP,
M"0>M<>1%>@NJ6/]H`'[:'=VK:I^?A;/Y*N9U#?,:YJTC\];BD'?%L-_":$O^
M;+XT?SY9D^BWP)]*8DN-XD4['*-7-8A4.L;^U8T%YY;NLG*YE\@L-!,F:\L:
ME:-%I;Q1V[FL;R`=US!-K9FFDKVX/=,81C&,8AC%:!?#-(9IC'8QD[[-I._-
M)WT_E\-]#@R($Z;P9LH:S\/1DY'OBX2@:\3E]8L<;SQXM$+<^'T,'7VB`]EB
MN'>%(ZGOG-%FI]%O=QNMSM.U9S%2IVY$7JO[JG<P8]10N=&M1K=N,\?;Z%8C
M=5X7D1O=:N9WUS^>LG$@:^,@R]9Y#NXSA5UNHM0+L(^PR`>N1\#01-9K'%G?
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MO[8Q$W;K<\R&:=XGTY@9B(91#*.\/*,8[6*8QC"-T2ZF`,H40)D)NR85LNX)
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M0S$S=E^EY6G$4-W$D!GZ9RC]?5"Z4;@U5[CO;LBN4;CO4`P9A6O2)UYXRFXA
MM$$S;I_FR!^]E;__/$_V)IXW^^5Z>,M&\X!=C$\]/_[#"^:,C\0X"$=*COPY
M\Y)YS$87X14;SN/8#R>'7N(G-_C.&^"FPR`:?O_U/__#LOXN7\W?D[WVV$^&
M081OL?S1/S[<>!/'[7RP1FSH3[T@X8-\83_PLBLV_L>',]=VW-^;?U'#4#[G
M[G0>C@`4G%GYUTF2PN]2%?"2I<3#V3=B'U,6IDFV$_[0!VL>^GSI;]?''WYM
M=OKM;JO3SW&U=$,;[[N[_;ZS]_(Q0C0[R*WI-GL5MOFJS[%?88.U.;"C*+QC
M<>H#QQZS05KR?)+MK&GO^NB4U2EQZM)[0-GQ"$1TV_VFZW1R/%38X",PXCSR
MK.N(`$7"KZ+SIEL'1E[8[FKHM]MI\P4X^E$;6R^EFJTU>W)>3,>VVZU.NVUW
MGT`V-]O;[GK7Q_N4FUQG0#FO^PS7V4E.?0YK(UVRSC#:\-AVKUJ<;K/9Z7;L
MYU*NZPRIU0==R_U7U#BM=9;6,[#PXFZ?0+6VUAE0NV?FQ^T+C_DL3-)XCFNI
M-#;'Q2[&)_^>^^E#_DA.SRW-8#K[>JKO]I@;$O^Z.5Y-NLI^KF\]H#"P_KMV
MK^OD&]H<2'V39_"#),4OSL)A-`7,IPP62O.MK+*(<"/.[\T%O+=5:V;9$IL"
MLLJ,$8``1HNP=%I==U-8KM-H^/TL2>9LY.3KKS(H\A-=P$6SUW/LM@*#^O:"
MR/1F?NH%)S]F+!SY*<H4`!,HG(T.YRG0Q[]8>NGYHQRF5?I_.4[:?5MS&RHN
M6Y3OTZE/J$QR#LI"03F(W:68^I4BDDCN,C*&\:P]C'?]P@-C].^Q-_6#AU_^
MNQ`8^^]&BA\T$A;[X\]J+I2:-S7:).*H!]=F+W,!M3;$5R'3JMG=M]N+R59Z
M2'*P%/#E$Y8WW$MO?W$/@T>LWP1T+YOA;/YZEK^LW9XHY?]I-'-T<7Y^=G,.
M%'MM'7P]MH[@X;.OOYU\/3H[N5ZQ^&Z9HS[,O/):P:\.[_7-O[[`)RCI_>%&
M([)GJ1=;EV"`3#U+N7.R?F.!=>D-OWL3L,"L<V]XZX=L<9_^3G?\2@YF5ZFL
MM\P"13OSP@?KUDLL#W2I5+O6O9_>6MKII)$UF\=#>)+!HQ,XGUEV/E-^/J!3
M8^NG7JO5Z+;L?>L@L:*Q=<UF*5F<.5J:=L-"5=VP4@V&$;P2+!"^[$\]N]5P
MFNZ^(A\09##//3_$5:-!X$^\U(]"7.>GEMWHV#W+3ZS1G%GS&7R,KT]N_1EN
MJ4$=RJ>#X,'RPI$U!%(=Q-FO\4FY"R^%#8*AP;\<L<2?A.`BC:S!@PJP"MA9
M:`5X#2M?)1[)*+K[.;'(`D)DL7C"8H'AKV?6QX0Q*OB%$VQD3.#:GZ_G@X3]
M>X['<7*'ME#VG?/YDXX[V#2[`X<#0(85\)OQ'(TM:Q9X84+GDM["0Z7'5J)(
M:T2F;T',78JC_P+>(:=8(\IV">9%:)VR03SWX@=%RD@AXZ'@FD4QLO`P`"E@
M>4-B[<"[3\"#M>Y!^HW]`+[VN<SX!BX-_.LZ!;9/+'!!TM@?IL!M\S@5S(0L
M&\/_Q&'^/3#_61#X802<-@]'C#\W]&:T6D9L-[>P@\3ZXLUCWVM8\-6`W7K!
M&']_ZT\3!G^BB/*"P(IPB00V"WZ*%X/L2L")(F%TMV\=^M&U!^Z/$-%#-D]]
MD&M)(T<".%O[]++KE,UN66B=[UO7B,J<YJP0G"`A-:0\P5\LDV.7X,/Y(Y1*
M^-31K<_&ULD/-H3%[YAU,1[[0Q8W%A9$^0O"=`RL`#`G1;$.N@=DE8]O#0(V
M`;2GMR"(X54I?+I*KHZ4H%_,`B$"(WJ>(33>\`%__\4?^&A6(-1^FI"V8_'0
M]T`D@O0-4_SK'EQV:PPX9/C<SW#44S\)F$?LR[$"4"7SX>W2IQ*D&AZS094F
MP&"</KPX]0$D6`K.T@_'02ZQ9T!#;-5&$XQ(47P)]IG,`_HEX.;.CP(2*D+?
M$G'GZ'7LCX-/^3_%`M?YRTY^@%8/)\PZX#`Z_6:+3LN#78R`U#ZJ3X#FN9H'
M3'W_8*_-::RXM&M_]!:75M^FDL%!D-Y&\\DM,&P"JB_UZ$B(YHGZ%1I9X-@$
M8(7OD3^C,F'@.E(:T-GI;[J+@GD(-H</:P$UP5DFN;;GS_GC,2YU`(<4J/MS
M%NR3_'G0Z]\3I,28S>#`B&.$``),S("O\<CN;W/#:CG3*6<_8.D]8V6;=+A=
M9=-A'+-AP>QRVO0U8`*_Y]#-PV3&AD"2*!MA718F7AK%@`=OZDV0:QD&^2B0
M(DC=#_]O'@Z)V8'=@/OY^V+FP7[HP6&4I/C+'[!'D)<,@"9YEL*;0_:0*#OC
MWVHBD`Y(8B1>$!121`UP[3N2$TP*=)"[:%9%\Q2M+)]+*#@-(&,Z""Y^U%_<
M^9,HCN9)H)ESH$\NAFFD8T\S6@LZ@5&L#[8(DBI&P9^P-&/L$6D16.S^UH>M
M:42E'?(0Z`&S=$F^2^;+2558MK@GEN"1^&#;HEBR!C$<`\D>D7)E">,WE[<J
MSI&QAOZ,EIE&A`=$#J?\`AZ^1G<%,NI(/.24SEG16[.!SPLJYCP6RD$<$H*!
M[Q)0)0I87)6N1A":\C$0!FAH5D+_4@:\;WMW=R;7N:?(GJZDBO]A<02R^,]]
MZT_FATD*_Z6;8`G&J&^C`-E$UW89'25X(R$>@?_W[SP2-Y++G\-(RX#?Q-!B
M:+WLYZ95H\2V*M@N,>C,""P\S3@JVE^DC*TP@G>!C9(]IRG/Q^I,[31=EQ\G
ME]LA6:&;+W#DQT.TK_,C.8JB[_C/,'UH9,?0$)\`R\[`/N+.^A&8"&#\P8?^
MG9_`T9"A_#_S4+$\W*YD:%U%H%&/OF[(8@*5K$(VDD8A[9N11\W-.2`V_L5\
M\'_"3B.:T'R%S'7#B,`P]@=(J0.0CDLMV428LB">&7C:C-3^V!_-P?Q##3M'
M)'B#>4)6'UYDQ%'0L"9Q!,N"S`.>`Q4\E9;V'/1N@JH&R/B6?PHJPX.?TXL%
MG-%07%M:8^!#C&6`70H_*S&)T%)(;V,RN4JD)5@**[:&YH-F/60&PPPOA)!=
MLT_('J`]@#`?S.-$F,=\5_DK8I3<4ZZTI[,8-0^_^@R7,M`P0K$"IVM-X/$X
M1*+)M'Z,W"+P"N9U-`3="(980<.5!*C<U@I=KRDA_#Z]C^`<$C+-2/4(PR,S
M"D#D^;,YM]'IF]K8"%7M`U43[VMF&!IY0SS+3""(]U.$CO8)/QVP#!OB,`6Y
MRJ`8?)I)97*@N&`RJGI'@5X1ZDA(UO$C\&.+\9!"BFR*QSXB@B<V9`L!QCDW
M[C$.#.>(_(`/@*V-E]U29N;K"`TV`V&&.0-6@%(-5$!,KA\\CA\T+!]C'0\4
MG(U`+B+)4624`PC<"KX9%VPQ/JBXZL*IUE:=>AA'OLOLWS*1$8%7PMUE51"`
M[A&D*'Z:;4R'@K:9Y$L2FAZ06H,17]JS,*$F5D"L!`R@(AP&<\X-*6I2%&8^
MEV`C/R45R/U^DO?J+P%&$$"WUCB([A/#,SN^'`':!PL(CN<N"NZX!,./N5$$
M"AZ'GP[%2=Q&]V!9Q`VN?3&+@*P._%^DS4%N9,#'=U[L@^^9"4&R6<%6``J'
M9;0W$S^1"F/XJ$8MX/`F3%HR?B+Y&Z4OT%!,Q!ES(P,)"PP./V2ZHW>-/C>0
M;8K!1A01"I13W.P\%)$X"D%XW%43+*)848@G(1U(6!`K*Y$!X/)YG.EH^AFB
M!7\&J/D>1O<AV8GL1\HU&Q"Y'XV(X!&)V]-V[:NE5N>\Z/DQX)Q,;D%4'@"I
M@>R6^5@\D>MBGJ*9/A)U5,,\7695:JC(G2E)"W/=ONLX726I9Z/E*T%^[(-\
M9:.%-^2PK\KBW`'LRP#8!=[;J](P2[.[,O#M7LMI.=T717U[57+E;L"OAOTL
MJ_*"?/4C"B(G9V'V^6\@G[Z`59$GUK5759<LD@UEL.WU6LV6HR3555_W\?"N
MRX@L3P3<:]G-;K???3S,)UZ,=^O))8OI-(B.#L*1.*$<4"UCTJV`6/E&@-;>
M=Q50URRY)7SM]?`M(%(!T=EW6EN">!FC:98^7`;@1\%#F"5+&0A?69YQVJY0
MGKJ0[NGT6MV.`M:JE<KJ(?+5*Q2)%E=O-5&2MCK%ZH5">BL+_2BF=.,CS/(,
ME2U7*-E<6[ZT^/ZE">/YPA5**1=P;?==U^Z4%TXM)JM&(67><HXKD:&="C6/
M11#<;M-M]]UF1[<1EBQ5H$'O@2R)F^A@"$01LSPY.<=+9V/!SL^DWVXK-+AB
M)0[38.;]4!X[C;E)ZP7$2O`%7M=D,%40V&69V.W>WW^NLI".)N"3(_";@(_N
M?+`V#Q^^)6QT%A[!FGXX!ZQ>9$Y6#N&6(MKI@QWB-)7:V@U67YI#?CS'6-\E
M6<E<??(\?8R87HR5G'WEOC?;2:M")8'SU[GM;EQ*X/0Z/5LED\>!K!#2=7Y[
MD/#Z@RMTN!)&7US/@$/SUUTA]O+]:CJA5;9;%W;;4?9S.4=M8.\[G4Y7$-CF
M`*RV"M!;2J_\Y#MJY`15,IA`89D<ZZS+R-^P[D.8#HYMV\L-A[7@[6QWJW12
M7F^PV>[<IKV+W3V:\C35YRRCO/9?YW[H3^?3A<U(.FP_D@@?O9%^U8UX/U9N
MQ-D1-WV)PLD-BZ>7(E\@]Z(/IGBIE$'>K>:$_24*5@Y&/.0F"W<I)Y7?_I53
M6J_5ZK;4:K`U@*FZ<>&1H_F4K@ONV()Z%:G0\4.^LRK=`[;>EMURFJ[4K5L!
M6K!,Q#LN\N3=;"-56@%LNY&6W;%[BMFR`(9R(-]"S$,^PENK@RPL_:>?WG[#
M^^(_02>E++R<PT^'%^,QBU5+KUNAIJVLE`L<Y994,5NLKT"?.=5:^=X_.8_=
M1'_>1E.N=@_`6".-G`._>XN`KPL;%'O;'+J2K5WBT9V!Q\/_.#L*0&X.O>`&
MH^ZY2NFV*Y9**O">I6R*U9T%<%>ON%C<J9@TL3_!:WO\E+-^[NYWUVOTS;!-
MM-2W;5WKK05H:_C7Z>QM+!+';8/0:6\./QW8VL#'5_@0K.Z#$=ZF3U4'M5LA
M/KJA<=5QP*.1I+\Y:`6S/ZL'X.4`BP61W?YK*(CD-S8O7D#HV*:"L#Y_/7GM
MW_6WP^N3W[\!L5DG?V`%X"[J_2I0\BNY-WV6:K])S/)\)HQ:XKW>.=5#F8*8
M'6=G+B0P-\N*[O*LG#3"[&5/.Z*9.")1LO81?\F/R\K.\E-6R79ID>F?D&&>
MK3#Z>?"S1X5NJY,G"ZEFQ67P\AO#9/RRN9'7]P'\4WXCK=Q9BV1AX2-@IA5>
M*P.8XFJ\^/8&`7CO!P'?*]^3R".+5(PULO24;(?#+&"'&7D\D3"^\^_P@Z%X
M1D'=)RUM,U4*1#!ICE(%1#(-?[YA8?8@7K9G867*CZ6D0>X-\9Q:_"#;QH`0
M@*8*4S9!O6)Y2<*044JM%9*%2XGW9'>OJD`94OR9KZ:F[H#9A,?@8]K";!XG
M<R_,CH'):@\*929*]N22L\A3A_#$$UG7`CO386&\E`9SQ3"S(92I@/`#O:HD
ML**92,^X]^*8$FRC6.1O$$82K;HUQT,9>ALY?C&1@1*6UQ]B5I<@"`8KJ$3U
M*:!!X@AK)H9LQG-E9>E3!C-/#?1DE0PF37`0`DJ:`J#PH[S81#MPCWOEM#Z5
M=#SD./"S?BBAX)SI@,Y24J\W3D6>--^-BM^OD37.(NT;TE"&2E_XH2'B)N1E
M1#FC23Y`PA"Q(DGK^@G)UV&&6!KPC%])Z90@Y6,B+YOS++=HK.[C-`J"Z%[F
M8^(1S:=3K3XXA6-(9#X.F=F8=:D4!B]*%7J5N`=3\MXS\)&->08E!Q;S7[P9
M$/X/ZLH4/%CM)N;`#/$%`HP%0<!)546K3&`NG"/'X#)XM'SSM7"UNKN#JRC[
MBR*CD)"4IP!ZN1/G59$LHRS)+U,?'@\3KB!8I2([9"G1D5*(+<L::3^K)%J>
MCD[LGU#J[RH^07KEE>KP![+LG1?0_5W`DB23#GA*82)RLI2Y5`07IH5GLEDD
MKZ.\G,5^%&=Z,H@2A&4D)*G*<8,Y"84PXOGRG,%4HD8BU@D)*(4`!#4=6FU[
MW\GHY*.HR9"_E<2V\/MI1`GY\/M6?[\O?_]I]X0F#LJ7]4><V/\]!\-V+(HN
ME-,'B1%/O-#_?UY>Y4@T0))*G/V4>:$XV85RR&:G5U8/>293U3'T'<Z1'$:,
M%V+V.FHAILGLW%%FYSKCTI_B(``NZ,::7EAMJ.'?@\B+1_A%7MNSA!HY-PEI
MP&M#[JB'QA3+GM1?DZI`J^@^*OU>LT_QP05C2;`<R^JT(UZGG2R(^H3%:!<F
M9<]68*NSU2I<53*T?:HC0?L$29S79:\P[.#)7ZR/OL)#(L7:`SU/]T96@G=&
M,M=5$PK4UX/>D]70DHDD$]*CD.T!=O<0RU2E(?Z-QU*T<O56(!+G#6&C%00*
M".AY+#)T*5U=2/^8D4W&LS(``"3-KP?7QP>_6[\%T0`D`N\@BY::\IVX`I%?
MDG:$72580T-9_(`A%45"F>+*H3<MEI@C@(J0J^JH<<%'2?G<B*17<RVL]$NA
M!B=I-&'XC#A^>#N:DP=XXK3W3\]L3^JD4K`J-UJGNJ%99Y'X2B3W48E-GFMP
MQ4!4G=H\"J"DS'/#!KVEP)_Z0O!I8H5,PQ'W&WD1)%J_8($5%E[T6I=["40+
MP!/XGTB/(6B45B;`-1M)+E6$:9&S"G)JZ2L_%T2&INJP6(";DJ>@>_*'KO=:
M0/03K([C9Y)UOA`E7[P8M"`J,RY4,I)P0UE7"+I=3A)1E<X7$-[GAM*`0U'-
MM^2"6VID,JT]Z_\BGQL'/Q[RS?T,_\::Q73.T:;B+3L167\<Y(;^(X%7B`Z>
MV4I5(+AW"K3W_";9BF9^*,,L0W"'$A;DRBJ+7P!F-,M8-X<?:0.CR2MTEPHA
M5RU#</)`'&`EB_!5<JXNV![>2)9*D:>@=0A#783:.*\;6R(]LK?G6"@[+ND-
M-G@A;C"<<SXO1L!XA'*)W&C@*8-_E?M,/SG=?=N:`KXI.J28HIK;MLH2->IF
M!V">4-2U$!?AHID7^DV]$5-H,PN\>7JP40JX802BU%/JF1=)(:_I\D`03$3W
MIX;R4R)(W0!&,+%N/O<G1G.@9+74:UE%F/`]LH9_,ZP4GY'U-636B!(UZ8<4
M(?2GHAQ+,Y^%F["@DA<U8UE,C3]<5#_%/:&F9N'$FU!MFPQ]?/=#41FFJESD
M$.\[RYZ2GXO=\.XRM(T%Z9T%SRER'K+,-,2:3L:D($?,:OI8"GOJ<9%5\U.(
M5R+PJ6P)^62YUYEM"#[#;E>RYFYA!P2>`AM;0J"*F,P#4!BQ1@BE[W%7,"2.
M"N[N*T-M!2MK5;NTDI,I.Y(J5EK%8UIX8"@@]C*(UYRDJE17B4%P#B/>.Q37
M'A&?8@@A"ORA3X83'!IF9*E]V;R`PEVDNC(!Q4,*PL<OL#/=4?([+.SU-D\2
M^8UV80F'"#L)>:.V!V5QI*&-%M6PDV,E(\:L,%A(P#NV.H),GN&,]W]3?>UD
M3H(HSF!5?>M:Z\97HL)+8WW"O,]#Z&IX7%P'PJ=C[RXB#Y()!LB"<#H%R+<,
ML=G-%`/30Y;L6V=+Y`_8FG(];)HR9RH'IK#\A$LVT9\F;XZRU&A8$+$#)B-+
MY-?./!Z&\;2-CAD)T_D,'_G)42Q.V+5ZBUQ\E28'5KRRV[8;MFWOE]_FD^30
MHJZB&9/2CDY%J+Y-44JO@A8S?TJM90AX`4/;)AB(<8L>=79QLL0Q5`3"OG4@
M.IW0#ZA)\8)7*^Z$J:(`[X0G2&-<KFOH+6+,'V=.@OIQDB7[!;A77F<_X\F&
M"XV('\F#8JSLD`1M-E=6_/.528[GR&/Z(R)=EE%S8I*7=ASG$_<5HE?W$@Y=
MZWDTU/:QJR)J#>K".8R"@+O4L"ZW3;4K[[Y=[<I[,2_!RZ].`F'%9D9(M")5
M2S'#M$2M.TZ`F>V3+"0E-;0H!`]ND2)3N^\)JXV_D''C>\4N5*58O-/9PLY>
MDC3!K5<A/7/%J)N$1>>.%,@]]>`9@:F)VX^%619;X3R@J)4:08N+P%6";6FP
M*0JS"$Q)F@<G+_PL*69W5,RBV!U)J>9Z=O"%@V6!8#69^'(?*=[+TH;X,@]J
M[,<)'F,X]P+5N2LX=GJZ#6">+?*R"63M`$R-4BLTU-8EH]*B$N]$Q55P-8F)
MA%.)OI=&Q'=#\U6$)_'I8X5FM7T\HR!=YO[76LC6F9G>@OWZ!8AP[]O,&+#U
M-V`7$GEHW,)":@Z_8*#O\KZ!VG>"EY=:)^M$>:_][):*)K6QSFT/W/K'VKS2
M4=<N_!+_Q]X4SOXV6T8.#_("ML7=K4@%*01MC&![:L'&6Z=,D$BIH-*ZXN&\
MC*&,G'O*"6*46T4%!P`#&481L`_&[&,FIPQ00H,HF:&#NJ.#$G'7C\BOV"[^
MZ(\K<6F:BR41`_SC*OE$;THQB"?R*S2YMO3.?+F;H><%%YL;D^6#/AZ"5<@Q
MHW:5)&5D44XE$:%*SUQ"XJ50/.*IV#P!!$N7*'&Q)'&[PF[^*?N12M3E%ZH#
MIJ9:C@C=ZI=>FF+7\KQM^D8R<.$*244=]K(/]\@P'+.80IH?2RZD9')6?@7S
M*2]HR:H`J,&[2+V3L7A,P9N)CA3Z-8WJKXJ?Y9D<^6^4NV]89N^!>;&\_,Z+
M84;4&'R@J7!!R")#!KOU9H$!T"4-2VZZ`;L;8CP9S639.ELUE8NCC,H0+D<:
M@:*>Q-Y4C1=M7Q_G+>7._*ZMV-([U5-JU7M"O*,CJGE@&..GR5$\P)_>^O&(
M7_-3"DVV2B'2@ASI36#M"?4%U\Z)`Y(=1$ZMQ8Q.(/V\8BU+W\2$)OQ%IU.T
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M*7KMWH"&R&6#W!`B<6VM#L&A'#@)`6E\J8QX-60CRX&*QF-U2HF$+S^F(K*-
MOGAJ?7%#5E.6?&;=1""<N%61AWZ)LV[8G6?4QXYO4A8$;(6>&ME9":]U!#P3
M1+,L2"^M0F_Q_$I"6O0QY1Y[>F:)L%0+QJ,R"=N?R+1\$KH96/PR0%YK3#%[
MEHMS>44'*X`@PWHX+F!4\UM9ZA=%TG]TE"S0+!%')+N<'A]8WCR]C6)`+DYM
MP>H$!32!D-%B4Z`5!ZD?U10C=RE"C=4CZ+OC[&M2OUJYV^$>3H\:J45M>:TU
M[N\@',41J/ZJH'3VVTA4EQ?79S=G%T"CW*B_8T"@%Y>_6'O+VD1U6XO$7WF[
M@'!71;C(OLH/'T?]^'P8$XT(0U1KA1B+$\":CC($3ILA.];2*$?>0R*\8A(Y
MVEWB?*`4\\BSIT3(,0VSBQF.!<0R'[2G:%*5<CSW'HVO4D]G*#KO<8LJSP$3
MQA2\7N0A-\L(<`?X:#X&'SSG-S?#AOD08I`V\S$X@O,\BI3Q`1@]E-2/P2:*
M2?LE,Q"79B>0Q-#O_8N9?#^U]A><0!XPH1_[HJ\-QO,XMU)&[B(,_&BIUX$_
MM)R_+;*@Y+C7PUO*.6,FL9RHY_1L?M3+J\4##ZS:6ZVSPL*1KCM)M$_CZ,$+
MP(F(\[B@3$*DXRE*_&RLI:?FG1*5*F$.#'$@,26?92;F2!E@1#%/Q706T:]H
M+*8:X=="%2$]).6[H]NO,N)92R>\4"%YU?12=K;<5M!.-+N30HZ3I><6S4,N
M.RZMNY%@<@R#-E97GI5:+KD5P.'":!P5+&62`E#&T.?E:=#DU=!LJSQ(F_4<
M>5N)J/37!@.<EK;GU+MXGHEF2Z)QJ)AB`93]-;LUSOIY]BJ,C=BP-VR_ZRB=
M52L`4YRO00R>R%8E&:3K9DDX93,V]#:UA7=77'C=P(@E_9:KK$U=6R_N04:!
M%3*[Y*SH3=C%6!F\(886C979'/0/B@T+B7SX(#![K5U3R2TT5\RJX:?<^NL<
M(&[^A5WV].8,9^%0M,#FES^9#R@^+5#E\L[R3=&E]LGV^[PX736?2,?IX_"6
M->U^(WC36F8W=TN+VG2#ZI1I.V\+Q9W**-XE&EO]_C.B,9_L)K)'+\8GV"OE
MX2P\Q()([9O"NW-,=5?V;W]JT<A;P;>+C>NWV-'.$=/;`#&/V;R[V\U7GC/2
M6S5GI!*/J/-'JHL:L=T-AJF((4Y7(@QQ$XF)$HSCYR8ZH3X-LM.$V%]?,^SV
MVD\M!+C-TY6#`3:'7-GQH8AS\"]N\JN34\:$'9GOTWGT/C<Z2,6VD]NL`.ZV
MFUL_K^01NG+S?7?;.]KVE:RE1'B`T[-*2;GQ]2/0=GZH[>5GN@1<=<+.&D7'
M\U6)W?_)@M'A0ZGB[E>W*5>=-Z\>W-;>[$L</&I/)0I)_1K'L>"[9"UN=4,A
M1];JV2M/C2XQQJ6@OG:SQPT(*__1XAG\>1O1KD#RPAX9S@&YBP#($U%]I>C4
M'*N=&I!@NUN1!'>T^U76TW%6C';XP/56CJO5UN/QLU#@4@-J$?#'D)5"Q`GF
M5P2`WA-^#7D6IE%>Z)%CIU<#2K+=;2FI\H:?&:O]G6`5"W2^S;;%:J_]G%A%
M6+-YGA?AM1<P.8_\,DH*AJ]KK[06=H637R\[YP('E<`KD3!Y*0%5$O!"`CZ0
M["R4O0I/06*%C-Z6[]#9D>(KA6!3FL@&LA;DT*;;T]D(4,FGN/Z)&0ERCJU(
M"CCRPD-V)9)E#_`:]%C)D[X8BYJ,#%^EP[F?&$&_7CKVOW(NV<%^%EW"?"+B
M(3O.$Y1O(C'L#NQ4.)H$WIFHC%KX]5562B3QM9MH\4ZH2TH<G)/]=%M74'L@
MD_PJ+I1C3;/=]SI/BK8MW)N6K3FMF^YSBQB+:[<?&V/9*@[I;A1CV>W(:]?N
M5)D(^=>YW=U\Y'6WU[*[]FY'7F]Q:>C:JX8RGN4[;#H;SE*V.[W.(ZX.-]K#
MJE&,9_E@3+>_V1ZZ?=MM;;&'1PY6=>W^SNE.#E9=\#`V'*RZ\=1/UZDP2GFC
MK=#1-%]FZJ?KK+NY1E+;;.JGVVZUVTW[D6,_]?FS/)\FN8AOV/`VC()H`D)"
MW%IG+N1!<I#W.;R)KCP?NR7G.2*GO#8\'U?L.FX5PL09KLM&DY='6G8,+\?(
MB/F_\!\JKHOP9I1RRFQOS0J6>//ZXB_^MJ/`2Y*CI?*]TP92^?O/U6#80'E]
M9??T5:ZDG%8E_NK]]2=O,,S??!,AU_OIG*/N+,3:@RA.,L,E@W:Y"G.Z_7ZG
M4U&%98`_;K/MBINML@&WV>[W<5SY8S8`I(ME<<EI'$WQ>RQNN(BYX\A'U.?`
MKY_?O!YX+OW<3J_;5P>4KX6B@';<TF6,?9LSZ#1#H+7,$.B1(;`2/L`:O1](
M9+_5==L*@K-E50^Q#'8UW/!;'"4*"529NUP-BRVZ`Y&.724P2H1M.2-Q'2H'
MKI]C`GZV@WXEDPLQO2N>+1>[52%7-DUB[V(LX+J(R:7!^Z+LL_RDW"<31K]>
MMJ4_7@$@G?1+?W#R`].J$TZ;^2_%M\J6G+7N]*Z/KL!0JLVSS5:*THMA:K"X
M!`-3]@)3-@_`V4Z3HX*5[:Z_P%Q(VFLW6W:SJ\JIM>OI`"X!9=65XA)0FKTV
M'(LJ[E<L^R4*)TA$_*"TJ*WKKE*XRQ9O.<UN1UF[9(&B@3V+$C]-.)`E3H^[
M2A4N`\.V>SW59BY?HW`$0YSRD2:ZVY/#L4JK+8'#M>U6SU%<J_(U=#ADZ?,5
M+TW\DF<2+X!4P:=="*ETFOV6<D!K5].!XW0\',;SU9"M]U07(.MU;+NOX&KU
M4CI85SQQO)`&"X[P>AVZD"?AV,U>,P=#?W6E99L57,&2[-MFL^ET*JY\C&,U
MAC[E+L#?O.$)R!EP`L$A$\-G,GC6.W.+I-ONMOH:"ZU=3X?P-S[9$Y\93<%+
MXO.0[IB0B3EPZU*5R\ZHW>KT.@JMK%FL<&HL85X\O(6GC_.:PP6XUJ=SE,C>
MKMMM*J["RJ6V@JJ"%U26V-UJM5MNN[<59)5/LH+34@);N^EVN^A$;G68FS%"
M!<^D!,)>M]WJ/8879$1M`6.K!/@2&NMT';N]&*PK14ZN=<]"[)4N'\X!V$9`
M]KI==?WR):HAH+6=I'1[S:9Z(H]#0JN"!"JE6]O>%`]?F?CZ"_A8!W>>'Z`9
M<!,IAK'(!#GT$G^8@[B%,-KK..!$.@JM;+CZCD#?3F+M`7,T[9;=VQ'XOWE^
MB+^3E]W@!L]8G#Y<!N`U8.A@IL4_6]O)LCW'Z795(Z;:LB5!BT,L*3]26U9D
MH&TIQ-KPRUXA1K&P2I%UAMBUA1TS_K]GH7!LCAEXS3$K=W!R2"N(MS(D-L$H
M<#49MPT8Z[92L,51@"\8F_E6*D1C2K?2L[MVM[5J+U7@6&!%NOX4Y:F'#]\2
M3%"X`,JB1ED'V!J0&\MT,3N'S\27U-M$[JF"\"_E3-=Q>AW507\<0`57/;O4
M/1A2#K;&,H"=169M;Z=%VFZOJ[I"U5=>'AH580@9G,B1W:Y@@Y=I.G!'.DL"
MH,6U*@1LRY)2W?9V^J]:<'8Q173+D'B[@@K\Z]SNNW:UJ'[+[CI;QL2W">>V
MJUU?K`-?(XJ-X[G99F5[HB-J!97!N%;IK<P"D:&$[.V;I'HT"Z6G.H@*WK^%
M*/GI4Y#S$=KA;/2GG]Y>B9FX<("43BHCN_GVME.<W7Y35H%NO'99"AT(?12#
M.`YN1"7\&7Q54G,YD;3^(L+DYLXQ+'5''M(!)0E73+I=`.2Q]3O@7ZY/)VHN
MO3+=934.9][3**;4-;I'#D?X/R=9%YOD3S\(SAE+O_CPV<C'0(LR>#[;4[_B
MW>^OETT]=^X1JS_)3CI+*5Y/S5)O'7:TDS(-<10%8+]'8`,HJ?QN9V5IE)(%
M^1=U_,H:?MU$XA:]F(Z%S3@*$NO;]4$NM#:KG5J[$?4**?L<.1-5]80`NY3]
M!<]E_R@]M4^MIG([%:NIGA0=?Q4A_3:+PM/C@P/1K,KC*9_GLF'5Q5BF-)P#
MB=PH/4Q^8X%<"![P@+B`MMC02ZK4-ST&H3L_E_4W,R]T+B>\A=/%N.G(9DT(
M#O#M*>Q7UH@=>P\)9>U>9ZVH;B(XTHLQ9I<$5]1_ZB+\DW>:.A+=I:ZQN=1&
M!ZA5W]7J`-??;M7J`)O+#O!(Z9W%[3[>.>L\;YR5\Z-(0'IQ'I0VB+J;(]'(
M%3W'A;?DY[:Z@NZY-$2]6:^\1K\RLC?AM<5C!JA^`V\_G%Q'`3L7G:VN^``$
M>8B=55K^V;A/P`X`'[("O&?AM^N+L2/R\`LJ#'YPD%*[,Z=G(S;/\EYGI[+5
MV1?J<H;OV8C;6O9&[+8)^G?#?Y7K!^O"?R\B.7?'@5D&,_P&S4U.5UDNJ;3-
M%T[[+`$R8"'2:I8Y*EZ?'^;JCAGJ8>IE#>^)+45.6<\NII3O[D`J"%R9#`"[
M62@/PJL%A4-755N^@`>5E;6VUPBUM5O<*9JZ6M"X]4)BK&:TGIU5M[U.!54\
M+>7>0]S<<9]Y\1K@D(T!+/[<C?>#)2<_TMB+L/^M%S\@%U+J%OPR!I#@I]E%
M[N8WHVZKV;&ULITG@ZXF:"CI-+CGN-UFL]-WWA,>EMXV]]JNT^^_)U24]X#<
M:[7Z;?B_ET,%O$!<Z!ZRD(W]+1C<<9WN(ETOO'@WJY?F`6P"``^U9K>/IS$?
M?`1.']41>`_1?"T4[E_G6,99R!5J9[=$J]_^*[9L_3$`\_D7_&_XY_\'4$L#
M!!0````(`,>":$$<[@M-&0H``"!_```5`!P`8G!A>"TR,#$R,#DS,%]C86PN
M>&UL550)``.%(IQ0A2*<4'5X"P`!!"4.```$.0$``.U=67/CN!%^3U7^`Z-]
MEF79R20S-<Z6SRU5>48NV9N=/&U!5,M"E@*T`&A+^?4!*%+B`9`@=1"C[(L/
MLKO1QX>K&R0__[B<!]X;,(XIN>KTS\X['A"?3C!YO>J$O(NXCW'GQW_^^4^?
M_]+M>K<,D(")-UYY7X`Q'`3>+64+RI"0`KQN-R'\"0BPA/0A_`\6//0&1,B6
M!'H%[]LOB$R\F_/^AP^_?CGO;SDSC(/1X-G[=C-Z3.2I1N[)*R:P9@@P^>V3
M^C%&'+PEQY^X/X,Y>J1^1'S5F0FQ^-3KO;^_GRW'+#BC[+5W<7Y^V=MP&2G4
M?]V$K*LN=?L7W<O^V9)/.IYT'.%1VQ:-).12PPSU^V5"V^]]^_+X'"G?Q40Z
MB?A;+BD3E[12H"]H%;?3__CQ8R^ZVY'>\[RU_Q@-8`133_W^>33(,(XQY4B&
M;3%#;([.?#KO*;+>LY`QF@,1P^E`XF6NVHZ$B=4"KCH<SQ?!YMJ,P?2J,UZ@
MI?1B_^+\X^6Y\N$/&B&]'?6Z17SV$-!WWD2?%/.N>MR@0$7D>08@FJB2Y=]5
MFSO,_8#RD,$M);*W"SP.X!D(INPK%<#O0"`<-/*9M>BT#3X*_#"(>NBC_#_3
M+"P%D`E,DH:5`0TA&;68M!E0/]-.H(8(RK+VQ<U$W6N*^#CJ-7(8?$5HT5-V
M]R`0/+D2>:)[WH_'A!_BR[]^!;'6X)%R?OTF[4?2*2_TEL[GE#P+ZO\VH\%$
MCH4WB&,_44%207#5:<@ML%".JLW=:\M+6S4?&)U+]`A,0CGO#!?Q2,]O8$H9
MK.E>T!+X_5(P1)F<G1!;#62T^5<J[Q(A`2#U>XTF&.`BY]$CM!1[_Z`M92.5
MZD/7+!LTQ#:HD'\6.E!V\H@I>CR<SR-I72R52/BGTHSFD*3']'W*(9^\FAI[
M@GH'U502`5,+K(N.]P[X=2;D/RUVOA&\`0F!YWI*_G+LVNWE]C!X#"!1HP<R
MX#J@*@J(6Q5"+INF"R42!2D0G;L!HD?L`^'`8X5S6#+<C1U:N-L>L@HAIU7*
M9]"0L*O0%=@<C^"(KE`@5OH`ZF\F0T+NIEOA*U7=&+T\ESYX%ZX$[Y9RP:_)
MY'ZYB$"7"Y_I=NR%XNV3']LK/'+,,;ZHB@78NNVN&#C(6,ZDTG>R@P1TH?9:
ML?Z%980%[69M44K;'BB-:*'U#,S`*B]T/=^7"G-\"EEGY@*I_/5DC@GF0O6/
M-]`CPY(Z=ETEM9OHJ&=D)3XJQ3D^3]W!@H&/(POEWP%$`9+6S"D3^+_1]1Q,
MZK#$;K1C<1,P#<RM1(V=3#UT+EV!S@/"[%\H"&$8J7@[0^05^(!LKO^$,%&3
M=#\'H/J,L5_K,)[\@JFQ%X^YE*JCI.-P3\S2SYV&NYO48^[NR:.SW!_'A&!!
M$SW._NK,8GXH9L"D/71MO[(F7<2+`5=!%3O:2'7R`+3SSS&!:-1(#\B_N3/P
MO4D+U+9GK;"QD%-.MAD*360G#TE+#QUW<#2I%*/P@SLHC`V,Q_$;N?&:8GTU
MT4B5J01JJ+[C*EZ5S?NIP&E:T>4\MO/GYU[>E8_R_T,?-]@>%FGQF(%2XHG1
M-RPMN%G]S&$R(+H.7#QB4)=S>[S`GK.UCFS0<IC,BM>^P&]88.#-G5536+G_
MK(6U.GK4Q@S=L_?R`XRM0FIPV541Q].PW_&9(P=07!>.=%>7V2#94JD8W/64
M<1S-?Z2,]PO671/,NR-TEW2T,Y6,)),X),\H@.%4^D,:*59/@5PAWO\>XJAR
MER]YU6)**E^63*<`SD8.VC,\;76P2""WFMA[EKL4D&,\3.30KS91NJ&RG"AV
ML(GH%!!GY8`](\S4ID6JN-6<".>A>A)A.(U6$7+$_@4Q)CL%?Z#L&=@;]H$/
MV6V`\#R_<VK$F^1/ZO&>`BIW<=>>P5I3%<>SRW]4D0\-W?T4BG?'[>ZUX`_.
M3.5R0\=`SA=WL/X]($\,%@A/[F`*C$%RVD-VSJCL<\TYB,(0O).0;2Z[D9!3
M0/9>'+COT;FA3GK$_]UAQ%_[/@WEK/.$5BJAH?:+OL]"F#QB-,9!Y*5*Q-<1
M8D2\G9#31'P#!QX<\78ZZ1'_#U<6)@;'K"NF>ZI3U!167J>P%N9<1VA8IVCF
MO0/4*:P5<3R%)ONKRJ3P%WKM_QYB=:H@.1Z0![0-:>SP<E+GP%@75;26,VS0
M9ZF!`F1YRQ:%A%;7%`7M,YD]=6;:D+:MSVC"8@GC22+3UE&'QFF)'JX_;&7P
MQ@,FB/A[6AC4%%:^,+`6YASB&RX,FGGO``L#:T4.=O:]^%(8=24U\CXPY*^;
MC9+@\@8-S<-M*75AC#50.P>SNGBA=5UB`RU+);*CJ:%QYR=^1GV`272F-4IB
MKU."_'X)S,=\>^(O`:`M?0+!:OJ3`&%-M^P;AM7-N[[A25D0%U$2Y0L;'@M2
M#?J*I*<&O`IG'!!SQ9://HVFM-F6Y5('NZ2%1.KPSK`00)["<8#]X70*3!I6
M`K#&LC0(;"#KU""ZJSL/B.$&JCE^**'2NKJXKXOM_Q/\MHS1>@<+VGD,)/.B
MSK;Z@[;TJZU$ZDNS1U?U-F2LF'+3WLLHOKG77O?+N966JYWI,FM"!?T<BVO'
MKU7'OB83]4LES=Y0H+:"U[+#,[:2_3@Z2I$+7BV>Y!U4=CQM!SL?6MK,6@T6
M8LG1&Z'L)+H&E?CD@?;$@;Z7U^#83,<6'`Z"I+ZEY1"QDN?@_E>?A?\*1614
MDVY7:"6D;6,AM\BR-<HP691+<"W>CY2\O@";F^NZ)13)RT%U%"X%M=H$0RRU
MC*Z]AN8.%I1C.?E$:JLG^[4#>179]BDK`YE+$;4TQA!6,[=K6^?4\2@YE*2?
M#%3#BECE^ZHE^>:MOE7D+AANMM%L3IMHM0X"+3,F`]TJD>N7&:=$N;;N3"FG
M7V::"8K!=6`1J8L;M;#"%-5<`)W=:N;.<1H2`Z5$28;`0.1$3#6[`RNC3.%-
M[0I,<ER+]/U\$=`5P`@"]7VGR@YL31^[RH+>52C4-=4"%18B7=LYK'>SA5/<
M>G38$:=?45="["HN:AEI`8HJ>:YM1%+?D=*CP$R0/,6L(7`UVI7&6$18)\/Q
M8E[JNV')[CC2/Y[/\FEF.^K-1PXJJ)W`0B:Q7,N^LM5?I237QO_*S6CE]K-Z
MP^GJMJW2M-J[-YU$UR*>JO6NG]H-A?J2Y:1X<L6"<M/E2RC;`T-Y^.W-R^!`
M'_E288Z_^&FD/A=)8'*/&)'Z<KE8">=AM(2]@RGV"V_CM&?8?&^DFL%5F-0V
MU@(M-C+K'+%LYQB&[6=(VZZ*W,&XD*C2W,K50=:W6B_I*#6^(!&R:.89P2(^
M(ZY>EX2)CQ<H&,%<HDG"8SA]D"%!P;\!L1*#=Q&G<5(S<2TN$72QIWMW47;Q
MD)*=+DDU;\OQ.:6&@0.B+'IYI\TA6Q!1'Z8I$=\U-$VNV!<<4_+W,D/%-]0/
M]=%V>>5_4$L#!!0````(`,>":$$*1]F0)3L``+6O`P`5`!P`8G!A>"TR,#$R
M,#DS,%]D968N>&UL550)``.%(IQ0A2*<4'5X"P`!!"4.```$.0$``.U]6W/<
M.)+N^XG8_^#C?;9EV:=GMCNF=Z-T\RA6<BDDN3WSU$&1*!6F640U+[)J?OT!
M>*GB!9<$"1*H<KUT6\5$(A/Y`4@D@,3?_N=U%;YY07&"2?3KV]/W']Z^09%/
M`AP]__HV2]YYB8_QV__Y[__X/W_[O^_>O3F/D9>BX,W3YLTMBF,<AF_.2;PF
ML9=2!F_>O:L(/Z,(Q17I5?8OG";9F^LHI36EWC-Z\X]O7A2\.?MP^I>__'[[
MX717LE'P^O[ZX<T_SNYO*GZLDLOH&4>H*!#BZ(]?V'^>O`2]>4WP+XF_1"OO
MAO@Y\:]OEVFZ_N7DY/OW[^]?G^+P/8F?3SY^^/#I9%M*2,'^>E>1O6,_O3O]
M^.[3Z?O7)'C[AC9<E.1U`RJIR*F$#>KOGRK:TY-_W-X\Y,*_PQ%MI,C?E:(\
M@W1;L%[%3R?%QSHIE@C48=U1H!3I].>??S[)O[ZE#?WF3='4,0G1/5J\8?__
M>G_=*/B$2>)1"Z^77KSRWOMD=<+(3BYPXH<DR6+TD#TEZ,\,1>GE"_U/<H%2
M#X<)E25GGF[6Z->W"5ZM0U3]MHS1XM>W3VOOE1K@]..'GS]]8,W_GP"F)\;D
M/B<1[2(I?@K1`XHPB;^0%)F17L':G`XW^,\,!SC=S*+@W%OCU`OO44*RV#>D
M":@"<_H\I,3_8TG"@(XHE[3F=&,&36*VAF4_H\-"<$Y6:Q0E^5AE3GXQ:W,Z
M7'DX_LT+,W2+//;WREB'EG,VV:M7*YSFW!ED293228].?MA8UU;SGU*;CV.K
M\]&`/L3/6!6TADM:0;JYCA:$4C`0]Q)?RF^HM.=>LKP*R?=>0*D5'BK'0TH=
M)J;F?'%-G;<5ZB,/A\E0N<Z\D/D:#TN$TCXB-<N;E.;.BZFF2Y1BWPN'BM9B
M9M":W=EHH&5Y#,V-073>P3[M:A<XS*@'_P6E-R1)[E#\0(L@(X,JL(JZ3E[L
M5VJ5_ZQKMG6/<92>!'AU4M*<>"$`&`(_N_+*V:+AIUR#G)L!J>B_Z:1.1Z]W
M`5EY&#`H@D7LLC8A;\[JW0JMGE!L4M@F7P.2+JE0L9\]H7?;AC`H+Y>[63R@
MA9>%@'&V#R`JWG6)Z8\XPFPFO:%_-JI%KRF*`A14%3-1#:T5<P$J$4+B-^H-
MV;*?Q%Q]<UT77O*4*YPE[YX];WW"AID3%*9)]4L^\+S[<%JN\_^S_/GWECQ4
M971-1]7M<!9Z3RC\]:V*C/H@K"G$9">.*/CH/>V`PU>N0<)7K"1I*K4#SBQN
MJD=17?$K`:XU3B]BL@*8@(`TV4GYRQL1RS<I:7\K664)94'6K#CS"4A,9]PR
MOE9TLU\8SE'PZ]LTSM#N1^I6T\YS&>;S->V_Z)G]PR%8T/IFKU@!^S:5`!Q;
MJC'Q(1G7N7AI8H&#%;YN$KCD''E0V7*2H,4EPU\T7`ZQZ9MT8N-?-/R,<<PO
M<ICXMF_;EF]^KGXR`)1L!1BHV!TD"G[_Z!P.FH[2<"!T5!P+"A]=@L)MPZ7G
MPZ!)PP?`;<.%'\GXO%6(T/"M[MTU/5<MA=$+IARS5\S&Z_T)\M\_DY>3`.'"
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M[3L,"Z;86Q0_HWCV'*,\VLFUF)2F5%!`8VD2E?8X`M.(;[(=/V8X`9])G*/?
M"#O\(;><E*;44T#CJ.4@&D$L)^`S29^[(?X?7]=RRTEIJO4^G\91RT$T@EA.
MP,>LHR.PW/;$59H?CKO'S\LTD1M2ITC9"K`BCIJYA[X0J\/8\D'P_PRO2I<X
M#F:TVB`7D]Q@GWH.2`X#O4+5&A58R%$H]-(9`@8H8SX<?K+J(=\CII.?9C&%
M\SE)V+%(^AN*7WA[ND#JLNV4U$ZO??5TA2R&E1S-CA=F`,*@/E\T1.?&DY5T
MU2`BIK.W6(;:FL#UK`-"P3X?0\1L75Q8#T9%9TEJ'Q>\=;8)8$A7WV-`PVYH
M]'*U#LD&H0?T@F)V()KK@"BHJITH$94E%T/=^0E4M3H(A&SS#2L1.Q?'A7N/
M.L4\QZ']>^4B['YWVQD0R`^:]G=EG?0`F7C</LKY4C>;_1AWURI$)G5CW*V*
M;BWD<K>ZI7*OLA4_',K[5H5!F]\LC9H\BQ"YX!U3U8*<S6).FLM[%9N+]ZTR
M5_.;8^:2""XS5[.8BQ[+.0FI<?*$!=3KBF.F0'6I\0N)?,'G1_JOQ/.9*@EG
MRC/,=1N,,\35Z>EVG+:#3-;&:N8#_2_[#G1!4-DP7W-@M^^DF,:RF>ZA',8-
MB6VH3[D\VSO?JSH!B/WK5[S8C,L=2QKSV:>N9?I\!PY1DI((W7D;)LC7-8FN
M+F:S+%V2&/\[3\(P7]QZ\1^([:_-%^5>2G#KA>B1%4U2%-/RGU$H6`V-5<%V
M266^`DN.OOEIA$Q@`,,]J;ZP-"_Y)$=O>()?>G&(43Q??#J]0'XN#2M(V^6*
MML59EN`()<F%MTEF"RHU=8=7.&%C[2.A.L\75SABR9K6)$[GT3<O6;+P-!6%
MG<]]2+-@`^Y]$TLBZ::327+H_=F.22?M^).I:&W:Y6OX2:0AR_6$(K],&I/_
M%?O8"V^]*%MX;-<"[4;$NY@$F2\XONF"+-JCQ"BR_)CCQ/AF=6"D&$7)20X5
MEJI=D?@,T4'K@8*I\'E0?!U]?9@O3N^HQ*R)FBX/+3"CK>\EZ>E_?6#J7E/5
M`NRE*-Q<T58FWRFW&R^+_"7CPQT;K-1=@F;BN@^I[]LTVVA]?6*E7#S[M<T2
M]T#U]&),>&E>9#35]7X^C=-;$!"]0`E>^'SXYOZK77.7$GZ-DC7R\0*C@)_8
M0T57F5U,9S&]B]2N!*Y=P_@\IKGUQ<Q<#&57XM(Q#/ET!.-.TG*BENW;1+92
M>BB-2H"*-<PNXEHW?9O;)"&A^?<(Q731N2[G*.^9>I7S+&69WEDB_SPU9E+X
MGR3*4X#F?SQ19S5/$^U%F[/->1:S-*;U#*$M+(Q>3]GJ(];C1I*9&UY*NJE:
M%YK7;D1Y)@F#?,F8'>:+"TR[)"U$1;TL4T"?$2\.&E]:<K>`;X)5V?K#6#D,
M7X-M!$7HL"HG65_?LW.\29&5_V$=XK1X[X$Y+/=LCZ%]"!-(OKUSHR)W&#":
MND)!H68[R46]+RAE"=[OJ9@4@\$CF3^%^)DZC@5"'\GE8H%8L(==XFX/-WW*
M5N.+7EF'\3&D%<`CB%X=9D]T"Y!3!1&+2A]1O,)1OAUYA5@DDI.65Z-$V3Z@
M$@YC0U]C*")`G,T>]P/AX![AU5-&![8BE'SYRMYV06T/7:L,%PO",GN#!IC6
M_?`@Y&TVPB,*UBL<\>+1I7SF^SL*@[.-9"UGA%<53!_&RV%DF6PE*.(&ULE'
MXG^-L[:J5_UW^C\F9Q4<@2\;!:LML\Q;ZR]3S!T&[ZCMJ+M&,R4$']X_3SO0
M[@3J]L!O2Y+G@J#.Y&\D1=?1E?=":`-<AL@O#I5M%Z6:0[+A6H&#M[%:'>XI
M=EK>U(1@3#I!L/K#R'&Y"Y3@YX@]^7JV*=9=JO";N(0HRL8KX3`@]37N'3/C
M<18`P?"VA3:N:_-%0J((A13=E^Q)811<1RG9IN`9/+!J5]1W+-6HR&&T3M:^
MHXV8&@()^L8(:?JHQ%0>3()Y]."%5)5"_CN2\,.&6F5J:?P`91P&7Q^MH3@"
M\A9`PO!60C5R<[/172=)QK!Z^>HOV4FG*SK)1R@753"9]F73FF'UV3B,)4-M
MHSL7ZU<G0)SA/8P"]Q=YBIIO2^PORW!Y>5@N.?>B,W2/?(1?4)"?=[W`21KC
MIZQP+0M%NI.Q0::[B=<(4X>Q.4J[:4RH1BH7X-;P#DI+N$=RAK;BL)70W\OW
M;U_7="!/J,!)W6%HE:ZTXN_1C5-'<R_/=!T.@WR*5M7<&S0MBZ`+&-X\FCU3
MEY5M9`*U:*&[;_'JO1KMX@YC<F!;0.&F7XT`29:/%5>)ZUAZP\[Q<>['ZA!I
MZZ/#D)#J`7XWML5$8,Z^.S=FS'D7$Q^A(+FB;;.[<,&)7:OH*D=-3.>PO:':
M@=TI,3\!"@QO<(CNSMR1E/Z775!KW7TK)S#.X1,3K!292F"L',:/P3:"0FQ8
ME8(#NB/M!-2O3=*U<(*#(O#6$5$0RM`NWXIA:)1W&&1#6T,W:J%1CP!.AO<3
ME)#O(OV*Q)_Q2^O"7[Y8U1WE^O"&#GMZO!V&Z)BM:&Q@U)-!`.VQ[C+0OL:<
MAN)&Z7Q17AFG`N91F8Y\UPD5'$7LEFH0X$+(4C_1'JOY&MI[LB9K<!CLX[>H
M]IZO24D$P#?^Z!&_M]Z3C1>FFWNZ7N[$7=@V#30_*YB/8JP&\'$8JJ9:9^@8
M#*A/`+O:SL??3EH-3*O^H_C"^=!H>O1*YX!@%S%L-/[W[]_?/V&2>%&*UOD3
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M+H^%@N,X^2OX/M.G]Z<??RJ=P(L,T6*G*D/KE.Z:'E9Z'\#0HQVTX0&K0W`;
MZ<,'PZ%DJ&"?!D'HTR`(?3H8"/';P2R$/BDA9'<N:GI/U_EAX21E2]<\/U3M
M4I-T+0(IR%VBR`M:@ICV&D9#_5Y+&SE_%]\G:LI_Y?EHMB)9)UZK(N-BIDZV
M+P@1JM8+#W5N9A/`F$K"2/P_BJ._Q6G+XN1E<>9\E\DD/S.\&T9]2IKB3M#3
M#+-M6L=AS-S%F]%F`J)R:)W3Y+"I]@T:>I3GSQ[)MR59%0+/8E3H(MI4TF;0
MWC/28.`NT`8W!Q!<?>IQ\;%2)G^M+\3XF>799[\60_@I9TX$T=<F1P6]NV#2
M559CNE2P=?&QN\K/*^,59=;!,A-T\4<++!HERA8$E7`7,/H*`R$#8CQ)@IPK
M#\?Y%:IY7M%Y?G$J89?>R]^I1.QL]2SX5Y:DG%,0_1F43=:'@;N0&=P<0`3U
MJ<=LGILQUF[U6&HY(U_^F>7I*2L2^0ZL#@/N>@_&P%W\#6Z.7FM$6#UF$]&,
MC+_=C'X78Q_Q'">M<BJT=<OM(<@4R@_%5I>]X?PKYC99'\M([G8\YNRQ"FEJ
M6ZP<&G=Q`5$*B`$!*\-I5LS8NS47;Z^E7>#%@KIYD8^2NCKBN6PX([Y/I<7(
M77@9:YY^/I96?89SGHP"U*[3^)E:YX8D27NVTR\(=>YK!?<&>'#U33GS-?Z&
M,Z>,`ZP8!3B]Q\D?3/"$28Z2>72#O2<<\L+NO<L+8`8HOS]HTVV,GJ`#5&,X
MAXIA[,V2)%OEPK'WS&Y1NB0!"<GSAIW&I]KDSYS5])D]T7;Q?&%`8RB_-C;[
M\]L#K!IJ+%WL]J_6<%Z5\;#,NN15C%!]7QX`65DQ"3+YQ2P!T!RZ!%`%-%(=
MD8/E$6&7+X>+YTEYTK.<[GZ*@M](Z*5,XPT0H_*"$I2*"AXJ3D$--0E219),
M\CX53R!VCXCML@$AQR.7`*U)?JCPDC3*)*!JUC_)*U/;).LHQD6"T^8I[EPZ
MX>D,8*EV`GU5*7?]O'Z*:QZ^4#*?ZFAT/:ISCP)4P#2/.3<O6=*?(A^OO;#8
MZ2]64E6^*4G$=SA33HAX"%-WD3=*L_4(0@^IV_AY;,.X-8140]@\1#1.BS\)
MX@Q[9+RMNOP45/$H'(LK[3*'GX<D82E!V+5TCA*MW3W`AJOAFB1;M,9J<A?:
MTS7P@&U@8P().XAA/W.8$I5G]!A[+!L_RT9BM%M(^!OI#%S^A]H%U(TY"?"Y
M8@CA;OC\NUKT6@;W!/D92V<R!-TP=F`PJ]CM,W:UFLH85%6U"I%I-Q)?=[W.
M-K=>RNZ1;`1;1C!BCEO,(W878EIJ]G!Q>3R%\+![>+XN=BDT1LD]6I>9\&HN
M^3UB;1ZP/G"%$]\+_XD\66Q@"#L.Q/JQLWC?&H`P8KS%VA>QQ4*T0=NO<N.1
MK,EA?1TQ31Z_D_Y0[K#0AV^-Q2%!5M0RH\&T5J&CR0/JRD@@)X'2GD'$F.EA
MT2"[.0!O\)\9#I@245`^UWR/$I+1%;SU3(#W[#0>)R%:Y_?24K7?K?667`9N
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M5,[):DTB%KCGK&5!M-N\E%+:?02'COH#`*.HQL7TJ"U)N0M(*4W9:@(:>_$"
MF,D)3+L&)F2,&0H$#%V,']0.B@D6%8+OVV5#Y[NEA8'<BD2M2MW$7&:%X]]A
MXJ190R])YHMO'GL(+)T7;\]Q9@4E765F,=T^S@90M0?,!)(JS"8:'A$PW+D`
M0"D#C?UY06U\$4*4,X.0M1`1%<MQ`DIE745"XD?"CMCA-"N`=QV]L#>%XX0[
M[O<H6;:'5DE+<P7$NF1((RA!L9M1M"J9!"9WH>?G_LWLF7DU$'Q(B_"!(2BR
M5XB`J-T?"@+N3BP]\]2Q;/I+ELQ7>O'"W`%.SZD*&QP]\U(::I6IYA!8&5O!
M:-TP7)\FZ!6``U;D8E2C>1C\X%YKT<8,4-%>,!'S=C%4T93V^#Z4"3SU?"VJ
M)\+ZO!UE=V$D?57F"_J>?])Z):A3"/(:4*W0ON"L5R/TVVT"UN3B@RQW,?$1
M"I(KVLA,3B_RT3QFMS6K%.DM;,$+E$T**;`OF-)6OA>>(+68?;%%E(0(I<R#
MNT>TTI@M"<IKD^@RHOIM'LGE8H'\]!;%SYT56J^R54(BO;+[@IXA3=(+2)H5
M3O*@2S$V7I'XVQ+[2_XZX1L.PUN$TJVBI0:\G.3&^%7#U7!^^X)'TTW7;[`;
M+H39=V,4"=GHX!QD?IK,XT?D+R.65@XSE:@7F:#@;%-TK5DR"ZFK&7GY?7)R
M[V&6!&$6!+B0\@I'=%2G/[5'S7%K:25\,U[+OB!_FF;N-V:/)9K9UVT4O81Z
MO3?X"7]&X=W22]#U]36=:K#O^9O'&'MA>Q#7+=;"L;K8O@%3LR$&(4U=UU2G
M1[L2::)&$RV'@Y(IT`%&A>'MH<$>PO7B#D4LHTOAZ%XG7TC*SE:$*.UD4)VF
M,E.^IJ*R?<'SI(UNQTM52`A)]V;W!GP>Y%H6#PX708CCO??CO??CO?>=QL=[
M[\=[[\=[[\=[[\=[[X=_[_UX`]KR#6@70>'$?:CCU9WCU9V)AL#CU9WCU1US
M5W=LZWB\;3+9;1-'L\L:@44G^8\+P.#E-AJ*#&F6HQ&P<;R;Y/!-%`?N)DVU
M27F\K;1/MY6F&DZZVR,W@G1'`,KZB6P1Y1BIC;H5RA,:*>@[:8R$]),F+X(8
M@.BKV5SG":MHIB<2LC[0I$2JIAR2BDC`>Y\3$`&:2R_MD*2-^B0;<KEAAB59
MD#24=FH%SJTUEQMN>*XB2>/URE#D\!6LVI-2BT961K]\SH(W^P]F!KFR!6!F
MR7V$3L`FFTIG=AY8KXN[KFSBJXD>XV=,A6._%A=N3ULP!=/7+JHJZ-T&FZ["
M&G@"L';QMG-U5[;<>#O/XIBMKJ+@"XG\XH\6:#1*E*T(*N$V</25UH`.B/G>
MS9D_TK5E$W,=Y++RD#G-\2O*N9"\)[>['RI,U#XX;G>1"CJVK?&8YEIP>36`
M'X]])-^69#5?+!##V:T7M,W6MWCK&@>\N-L0&-@<&D#1KVF:&\&\Z^Z+VG;Y
MYY@DG6N_6H5DJ0@XA=P&3"_5-6`"Y6_VVNTQG855_$"36/3!#BAUA>&+J-P@
M'7MQ<OL;Z$`+OX1L9[]=PFTLZ"NM`080<T$0WL&3()>O*/9Q4KA:.Q7*KR`X
M`5G(\*5DL8>`TVN6H0A4UB:`Y.@[QO>(Q8B*FW8/ZQ#7HD;W'I5&N9$,92#<
M7U8S<!M=@YM$=TFM69<`699SJ?(Z2;56V`6VS[TP9(DG^HQ[^MQD0Z`.-[?Q
M:K:QA@Z,.A5/==KJKGP+_I%<L;?#\^J*@(>W(5D[`@VDKEQY%;7;X-%35L>)
M5S$6#&-NW54_\Q(4L/UE%"5L](ULWU?/F[`CU8SUK.=\2_QLLR,I;3#[[L5!
MQ_KU^*<1AO6XZ4"&]L+$N^,'*C42D1Z*XVYF^':/Q0WE.^WQ.7.H(^.U;F.X
M&RQQZ]#>4$D-G^:;L),56O"O;7._E>9H?7/E,)0AR!&Y\H)#4L,J9Y!L5>KB
M=;+^6NZ4BX*[T(N^>"O^O?HQJX!.C+VJL'<KC(]6,DE;UGM#0X[M7J;Q^H\=
MPU@5G5M?>]TU>/?B)NT;TDMT5GN'[:=EZ0INGLO$OU(E)J@'-UL$MM;S8PZJ
M!-`66LYP#V&VX="6$"Z.NV4H2W9/3W8A[\"A)&N!*5#4JM_1B^*]%Y1E__B<
M!U.OH^(0'N]XRX@U#(WUR&IPM5?HA21&;_L1@A-CR.RD8]![X.%J^@VQ_0P4
MS%Y0[#VCQM:P,6^Z=\V#7>P>-?\877@T6UGHVB9U<?$BRM"Q[8K$"X33+$8)
M]3DN7]<XSCELF\3PW`NNS]!,#*COQ^C4ANWBWBP-T&#O+@/5UXW58-3ID;T9
M0"X)"1@<1I\9VG(C=((>(NWK.E`U-5<J6O%'>U5NRB75K/PP.J--BSGHF&JJ
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MB7CNPE9L[K%,C1)M>,I*V#M-K`,CTD=_+NK$E37P)*ODA\%3YYBI2XCB'<(U
M#RGI2=OQ067WU`QW3;,=F+EG(76*2$#5+6(I(J`SZ@@0I5"?"RAQ;2)`=6MQ
M>I@ZVVS_^7=,5_RQO]S<H!<4RATS0*&N;R8M=-#N&;RYIO#0I-+LS?C7U0(\
MO2K+RD9$<5DG7#@(U$0#)+!9!%.OI&;A8"FNT>E1<VP<@AP^^TA4N'YC0!'J
M!TX!1KN#XF62XI67HOEB*_?V'[MP.-<Y[%.T>NQ5JZA#SJ)Z<".#&D;E/@KK
MS]^-U:K7Z:'Q.EIG:9)WMH_RE8F8LCWH\2CW#5IPM0<A25J-B\,83^!3,'!.
MP<`Y/23@\-4V#IQ3QR_R\63^!,;.)S!V/AT2=OAJ&\?.)R5V')FPSC;Y\CI/
MJ2</>O#ING&.-MU!AS:DC3)%-*,M@(MWH%JZ<[3-U?L:D:<$Q2],R[PKT<\D
M\FD;Y8=[ZKK*UY@C5<,_G6"P&B<B*`)$=T\AC-6^@B5M4R[.`0.#\CB]Q-C/
M3B2.Z>QK-U*$?Z;O1]#@D/V>9'?-=4LBM+GUXC]0>I5%`3]%CYRH;&`1D6U'
M>:P!F@#;1>+X&!.*X58DC-/C]]FF\OPV`*];3-OUO'FT!^U]*QMG"@^<)X2+
M%YFW(LO5AO7&IM)R3V+L^MH=8;SZG'#0):`GT[>ZP,?H"MGH->,)Y_30?R@]
M3^S,[WW?4WCUECL?U,5WK/M9?B)F]]+Y%Y*BI'R/F.OV@VBKYUWDM+87`:-/
M`$2ON;A0'4O(_)D8N7!.3`V%+\K9[9X])2E[OZ2%3S!]E;I>36\;IZ8O2^DV
MT:B7H`#"N#AD"L6&PA$*0VOP@Z-$!BD)E)052.'AIB-;ZPSP(4NO4-F2T$*'
M-GCU:JQ11S"H1"YN/-8\@`OTE'+D[SP`""_1]0+%)2S!5!--I(_^=?#!ZFOY
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M/JDKRETM507[FYQ'K-K9YMQ+T3.)-_,%:XF*(N!Y2<.X*$&HX&+U@`<4?5*@
MZC03#,#;8QJ]*]VO64"@"M<!&\A%"5<%%XN>]T``2C&LTW8P#$N%DF-;(<P1
MVRTN'3?>=71SERS6X"U?!3D#<,N'$+PU3KUP%@1YP_`/'<N)JH"S@,A6?'#@
MF$B`:L-`):TS#SP+Z@(/B@Y[6-)PG:[GU&;F8J<2ZS%;D2SJ[$0"R96S0$7N
M7)?37")RU3:Z1JQJF"36Q1D.LE46>BE^064.\.21S/P_,QRC6\]?4AWB30LD
MPYB4;=B7R7X`RD@3]8!9WWI=W)JN=)D_A?@Y/\@FP&&7H(6Q.L%^X4>HV@!L
MU'DJ;V&XO@OXT5K*_AN2)`V)Q(%F%>%V-A436G0@6D+QH\DR(I%Z=F+'2F,0
MH#[-+BAB6TS^?'82CWK/PL2T&8HAY9P.,+P(L)!@>[2C2V!Y52&%``'H)`7(
M;AG!8>-D_*DAYR.MCA]@4I!Q[5TGLQC^%!NT8VZA8LW3.FV&78/7&1V@V;N!
M0]N&YT8&>UE>'M4S8OLQ7DI;DI#ROD`Q?LG7!3.?5<J-MH'IZV^0R>FMG=%3
M]%ZBKZW8W#O^VY>XY'S-]GR!];]DK++Y@DG()J.$A#CPTLYSS$JZ4G\)G;55
M%L2[@^H'=_`D'!TY6$G\_.%&]JQX'K&\CA:$4N2K0'OOAM,FDAW1$1-LW_WN
M$EA\!KT4AK="XG]LJV%C121I9**0N_%H88=-\1AXL[A@G/NP?TN>K6;YE<KY
M(G_9G+/R4=*U,="EL[H.$@"`P#7CHF2[_)%PD8'%WBYE34RN)RPFJ'8G.03V
M%CUJ*Q*`3EP;MSGFFXL<3F[:F:Q6U)ECXIX+[L&+"+;7GKH$EOPBB?T(0).Z
M=;NLBLM*718.FS677F)5SO>&41O?';:I6`^H21L<!&M4$Q;5NS=QCYXQN^H4
MI5^\5=O5DI$T;E&T26R]92UUP`#:J-TP/A-GS'E.Y8V]\)HN;5[_%[6WFZ4T
M#8-V:!RVJ%P?J$D[7`0;N5/:M%IKLB!(RY2\3Z7&S4].&DXBO=I>S<*"?5<;
M9BI>=;^,@@LJML!>7)J6X5HT3EM0I@_<E"TN?)O^-*5-9U2L@(EV%7K/+5MR
MOU57V)K?G+2=3'ZUS5JE^;;ZBQ5;7:#$C_&:<\!%1M*V7(/$;0.*M=&P8X,)
MWYQ_G=*<YUD<,WCAQ/?"?R(OYH^H*K)JF2$D<]*T0*W4YA4S$KT2,KFS^@V%
MX?]&Y'OT@+R$1"BX3I*L^X(:A+;AO`IIG;2XCGY09U;(C6_[GZ>W_6\DS*+4
MBS=7.$1Q.]0KI6G8ND/CL(WE^D!MV^$BB@Y96'T68\X]6I.8[>\Q-3*^;>6D
MS;6H@-1A2X.T`Z],!<P$=C<2%M2S>X[$ZC8,U]Q<BH:56Q0.&U>F"]2F+1X"
M4UH((-UE3R'VKT+BM2^T"+\WS-CX[K`1Q7I`3=C@(##@I-&B<K38!9OSTS+)
M/$N3U(L".G+P1V)`@>9X+"W@L,TU-`6/S5*6`E18"4[M%@)7])?VI*R@:@6H
M.E1.&AVF$SQ(U>$C,.^D<:JF<$4<36U@#AW7Q`VZ/3"R6"]=,S<X"0Q=#W+9
M.(IV[B5+.O]\'YK`S\#1G0<?11YM,=FQ'1Y-^\A.D\;>D:12C*]1LD8^7F!!
M#@@E7:6?F,Z!\RI<PQ"X=MR^56>:GTX2,W/R>,/Q2.7Q2*79(Y7N'3>4C,C`
MHX9-#DYVY"\H91/E74Q>,)UESS9?J06OHSEM/H^%4]CU@9<\NV]Q*CVCOY4?
M290(\LR;95K=`C#$U$E';9064_=Q4]6.>,)G$+2O(^H.(G:G8O;BX9!UT$=2
M6Y46EV42EFK?[V*X3^D=6/5*6T*E8=R1H>U6AZP9V4J8Z\GDY%`]"_Z5)462
M@B\D\FG3Y/WXD52O,*&&GE0]6.N)WC>:J+KJ@,'HU1U,%YO8,N/TR?&5<')2
MND#KF"[P\O:@_PY1CL`HF*W8]M6_>>EG=(I4<2I0$5OO/4T%7]*K[1HO1XTL
M:AY9`XGHY(STF9J8Z3V/'KP0S1=4<ZIKNKD+O2B]_#/#ZV*EUX"S7J'2*-!"
M/P"D>[7?U*"&"NGD&)WO59VQ9)7405RC*.&-RG*B>IX"#M$/`%-0^TP-2Y%0
M(]YFZ`]#=BK-BWQ4W6R,@F]>S&[5)%<D?D#Q"_91,H_/0P]WPJ^]RI9&T2S[
M`V!Y2&M.#7%-64>\(&+@E?9Y+MCYTHN>47(=;7^OII?3%NSU"Z:M5],!!7\`
MP/=NQZG1KB/HB/=F^D/]+$MPA%C.E]43CO+I*,^:FN2->(]"EMWEG"1I>X37
M+UB:2*?@#P#UWNTX-=1U!!5=8C!RZKD_V.]1@JCYEW12ND`O*"3Y*N`ZHBU!
M)Z4VPH'4I3F4U#\`EO5:;&H`*Z43H;9WE$.0G^SRU<_[4910Z8O0Y)V'@_D+
MBK?S1OLPJ$:1ZC@HJ,@/@,H>;3<U-&$BBO!I.5PQ3Y<H?J2>SR-:K4GLQ9OK
MU9I*G>_VTA9A_M`+*IOPC@45V73AD^<(_YNUS:471[1E$MJ,+=2/P+DTL%'.
M/T`?&L\24W<UHYJ(>J3ER$VN8]6">7-=OK)H4WM64=+5>PN?[D?!/J"5K""9
M+Y<(EY;C*E3*&'D)ND#%_VLJ5H\Q\<\"Z!>L8HD:!0]F?[YW:XVSTZXCCIN!
M\(X"=S&B<P9=1BQ0'*.@['=T89'WR1F=13KQDF%,A'"&,;$$[1Y`Y,*W1TO5
MH0P7@P]76/5.[I!WE9GY/GN'*[GS-NP0&MOH]_TX0\$-]IYPF/=H)71UF`BA
M"V.RY]#MT5(FH0NKWLE=\*XR]V3CA4SB4ALE3$4%A)#L%MAS^"E:P"34NE4Y
M&@46]Q+JG"/\`H*6N(ARO*L7V7-X*5MAC+&L7IGQD*T+MUJ,WF8Q>HOE@!9)
M1EMUM&L#@T1T\FR%0*DBZ&;XPE=/IO*NHLUTGRY\#6NQWA>^M*MU,D[0>7BV
M%DEN`19"6C:JG-2M\;@O?(A6BP!&6TU!\F=CI0(XN;KOB-PXYLS>0!*<@=<O
M*`*CI.#A0A/:6A,!52*.DRO[84UA=.HW.N4?$.2-MNHXW6"HB/OA0CPL29RR
M1\\U?`E9&=$XSB]S,'CNTT83C=Y\21R-G?'FGB#S\X<^>;M>8'J)?]&B/UQ,
M*MIF.F^B)86C0;;\W"8*DBMJG^*6'V2PU"I4H1)8Z'"@V:>51L(G4!1'#T=V
MQ5>-F.`"0G`>\IBIVSI3@1(^:EKV,`6-<(4C+_(-QU][,I4OQK29[E/\=5B+
M]8Z_:E=K>&M!<%%BYYM<L6KSRO(KU/0#R<1!+2EUQ],44+LU9O8%!M%M%\"`
MJ2E+T\L4R.!F?+4^S+/;S,4MS^3R%<4^3G9)@7ESMXR>-W7SZ0\'A9IM,Q(.
MU5(X&3*MRUW>IZ]$ECF0(E(._KJD!PD]18N,C[JN`(8#D:*YM";#+D=#+0,A
MU2^B-7^/<9JBJ'@_8[Y8H!AWGJ8PPHN#P1Z\#A*D0]MT?!3WD-#)TRA*G721
MKXON'PG!;J#4T40<PUK`Z'K<Z#K\@`!NM%7'0?]0$?E=P\A[P68&Z6HA>47B
M_/8-1S/)D*U1FC.`@TH?#-J'M=OX@SM()D>W45ESE-MM`=.EEDBGA5X`9?64
MLHSR8%`);X]Q$"BM?ZH$,O=H78*_MAM&)7]!<8J?0G2!GMK!49TBVXQ&D"('
M@ZP>+30.Q&"".+K?*6B&_CYK?P?5*6^TUVZ0IANIM>6CX_]97AKE8VX4L/^Q
MHZTO7L@ZQXRJ%<<;J@`O8996F?H,JB[C)(+ZZ*O&#I"KDZN&AVR]+M[\\D*F
M`'N+\3I:D'A5Y"[D[V1KEJKR;$-+.8F=?CH#7G"#\N7CYZ^VKPFG*$9)RA*Q
MM4#"^[2]]EO_9,O<F@8E4I4:AH9Q+B[PUCDZN;_;S*!4G0**@JW3ED-9,%+T
M*\S-J*4NO#]`&M0L/:&F6Z>36[QY<)I%K%'03BO.^[1]_[/^R1),>MJ<2#6K
M8T&O@N(-S#ICPZ./8%G^-6)I@O(4R+,D(>Q-'11\P^GR'CWCA(V&P06.D9\*
MME5[ER];K$?YO0/,T#8:AJH>M1L>:W2AE^_(?@/LZ0_@H(*?C,/A`!#<3B-!
M4%:_DW?=RJ0O>3JU`*=9S%*O^AE+L7:6I5](^D_$<[YUBVT7]]!B>P?)GBTR
M#(?P2IT\^%'J.H_OO#@M_ZC%\O/VJ.5(HUTM6W4=LX%<JOAE7RY[AU0S[34,
MN+UE,+Z7*)C+&]IPDC<(OS?A5/^^KT`1ZF@$`G7NCMYQ5("U>'IH,7B@4O.!
M#54R/ON*P<%M-NIP)9/"U2U"N4:U6YW51KLFFF4<8#CF<S@T!`/::53L\NMW
M]=XDP&THKG[V1*V,@X:CV.%P:*@%M-/X#F*G?LB+"W\[:9G@AOY9?.%\:!@'
MO=)5?;"[)-4PS_?OW]\_89)X48K62R]>>>]]LCK)+;3=F9LOBC<BWMJ+;Y>2
M//@H\F),9J^X?09$2K.->'-I[,7M2S&^1LD:^7B!47"1=XNV;BJZ2C\QW:A=
M&=,V32BS=T%#JM8&,M<P!*X==]>XSC0/WHN9N;%Q.-CFOW]TSNIHX65A:LKL
M'04-&=[Z)IWH($5[!.L0M(>O&H%]=1XY2<_Y']MJ/(Z?R-P+0ZWC+#*Y`:=6
M6L4;(PZ3,4A_\4.2H.#7MVF<'ZHJ?R1T_GU-+XM-ZU_?)NAY_.C+DI:,_>P)
MO=MV94%;-5N#P"9;;G/EG!I-U>3@QAA]CUY0E'6?]-H>B.9_WAY^;G]V\NB6
M0@LUVKL,G#P<<8-]]N9.4HK;LJ7@:]D(G:^6+"FT%5%I4#=CFPLS8J>TDZ>M
MB@="-GP3\C]6G;'UT4$#2N57V:]=V,DN6`DN&$<%XZ>;QN++K#33MIB3^^EY
M8()E(ZO&`<&#N@*2^LG$#HF#1@3HHC(HGX6C=P9+$=FEL\\L@XB@(W:_-WMD
M_;N#5E5I`>RC]?*.;NT51WBBZCE!D9^J(JN.MPC)G/1;@5H!;J@(&3DY1M^C
M!-'&8Y=J+BA20Y+GZ>>_S@RBW79N*:TE#"BM3/2TK,-!Q+L8!*0\G?2./Z,(
MQ5[(7F@,5E1+I@U+)\K'!I"Z;#<EM</XT-,4BA`E5R==\`NTCA$[\4FEHO\.
M46XCJL.*O5/_;Z]^"[X$BDZ1L@UA11R&3`^=H;B!L79RZFFKI?`S%/Z%TP!0
MZ`(U=I>-DT=9S[*$>D1)<DY63S@J+D?MMJOO4<A.B.>ZM$RN7[!L0)V"#L.D
MM_Y0`.E4X,XRD^<[L4?0B4]5`?FH'6JIEUJC=A@L>IH.\U1K7$?+(7/YZN?(
MC!(<E/D?V'']^0N*KSP<\W(JZ!0IVP%6Q&&S]]`9:GL8:T</<99;#KQIA?>I
MN17C_M0@T0%JWB8+=T\UDNHYX>)\6*F*Z*$'*/WNQ***WLGXE*Z>@#0\:HY.
M>I?;H:C(E'Z^]*)G=M5K^_MGVL(W)$G:QUWU"Y9MJ5/05O8Q,#S(@(9HI!=3
MU<@PIE.3DT&P*F<(/^@E^-K*O&([J*6%#;E*V@#HL',RC%4=R6[IP]NK%%.U
M$JETJ/;!^C`5M5$@9.MD7&IW"Z00L\)PI_/+R;:C@(AL'P`!5++'N"#BZX:3
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M-XHT$*B:`G5ET`&G='JT')(2Z%".W1U58-A4E9:C4USZ</`);*&1$"JNW<F`
M6MO!$$S)*C*!T^;X%`O42M]-VS%R94G(=20A#CK$+;=F7J4!12ZYQ,(BGD)W
MW-DP0%M:V+(,MARSO0SK8WGU(DS']HHEF/5+(KOX`KO1PGNSY0PM2(P*ND?O
M%267KU1;*C^.6%B,#6XLAPTM2:T1YD$U07Q]])JV(?H1:W)RBIJN;=6SW*BR
M5.\%G3K0::CH9>3X#$6T6?B`%U(UP,JA<AAH*IV@(.'PJ0S\T6Y6JS,O9._Z
M/BP12NTGM.J8XI@+YI@+!I0+QH9YST,O82\+LNT)60HV$5W;Z%TZU_/=*#0#
MYKSI<G$C8%67BYN43$Q0W?7A$#B0>DYH-@+0B6O4-L?\T@^'T]X:MI.%S:)I
MI?GE]&P+2RZG:5W+,;QBTSB7[_RVX?AM+^B)"+97]+H$MH[8B[LC`6C2.&+?
M855<S>NR<*27[C;_)6;D?&]8L?'=82.*]8#:L,'!C:Y8)O?E!]'Y'TNEVQ^=
M7"1*-5#[Q.WB3NZ(%$*>L^=HHE1J20%-PZ`=&DMV%5B.P'2IF[;):6?6#@='
M!M7C"]`KE9$-/`+-K4#C'6@WP'(7(_9$6G5L-`IJ&=M+W5I0T2A1MAJHA*LP
MT5<7!!(06P>G!]FT()L.W#7P8%/RC>9"?L-[Y",Z_CR%*/D<DT1@0PAI_1B_
MD-15"VLH"#*XG)\K>^%W,;L:D&[N0H^*'P5L+LH3)G3O?4!(MV.YC-0Y5T]#
M,[G')V?DQD!=FT+8GJ/4GP?1UGN]F-8YH^OH)K>Z@I,;0_T-B9X?4;RJW>)I
M&5M"4>6:X%'8?`Q):3X"4:OSMI&(;9Z#@L?.#2_]`JU)@M.D+7[+SBJR7<XZ
M`9GK%@<JJ&5V,4\W1O5"+J[?S76X'1R0N=)"(BRN7+FMOQ@9!?7+:LP/2#>"
M25:WV#;Q#[28DR'3GEJK@ZEPQD[>W:^)+X^UJ@F[0'$EZJIM?**A;QTBT(I:
MP'$T9COS?9*QZ]?>ABTI!<$6*5$U"0B([.-!%H.!:":P/B\B(V#GAJTO5^N0
M;!`J4UIV56F9'4Q?'5Q7TSL-!EU]X;@`<';#YRN<5M^/,P`^8,2-M;R8V&ED
M:&D*AX6*K1ONPP.*,(F_D%2$`S%!=0J10^"TO94:P6W,8^7<VH)O5R72]ZX?
M&^R[DO[ZDW67C@THQ7-E0N,JJ'9.'9_*:3/#=--RZ_C\7-ER.2?1"XI33'W.
M?*21>O,PXNU!-SFQTSC0TA0.!Q5;5ZXEUN2L0LQU><6PD%%W<<&GM@\,<!A`
M3_.^L0!E+6ZL`&HJB=T!L1^P5X87:V0@X..,^PX-&H,#I@X&AOM8OU>`6`<,
ML@J&+@$$[T6<>VN<>F%QFT+P5*&$9'O`DD=B+>8/&L/56C7C_-*AFLO,R<1'
MM>/Y14YQ89(C`&7W<D.7TM8U!YE]B8YVC2L/'*ZM2P]=;FX8_AZEM*U04.7*
MH&N4;)7EX<4+JJ'?N4D/+[!]!TA=P.DQ05MC^`@!8>WDE8NN6DHO0#G[.PX#
MI49PL_-8N>'EJ?P2S0,"F@<#]LKOT]3=P%)`4`TG7&@[3<>=QT(82Y1BGXY9
MUK,@W!QS=AQS=AQS=AQS=CCA<A]S=AQJSHYC5@?^\OB8U<%A(QYD5H>:8$5>
MY^LDR3J)5!5477,VJ9P\O0S32>U9"?DX&8_H2`L*8*H2CLM)]\/\L`@F$`.`
M[.B?+"]#MYJ4@U5SL6S=N2_DH`V[)A&[H25S\&6T;2>?3VOOC'!3'*Z;*Z6I
MS@+S:1QP=J7&(3#MN#V0QS@__,MGZ.1V4F_S=Y*]V06`-(U=+P3`LMD9P8#E
M*;F]M\%UI>5$@ATDRTZUO&=S-HR4SC67(V]_J.+D9*<_AEN/X=9CN/48;MUR
M<7*4.D9?C4=?W;3S,1@[,!CKL%F/L=E>L5GX.L&]20H0#`%.5'Q.3JZAKB,_
M1EZ"+E#Q_^NH&].Z)V%X1>+O7MP.;_<LO7L,1Z^TD_'086T`>CQ'C_]08`E.
M;+/H/#M^,U^4_3Z/UPK.;L.(*QPHB"V9O:]AB:;Z=0AHUIGC0U&7DY-LKE6Q
MWW.1Q3AZOD,Q)D%^ACG_-L\%3BY?Z;".D\Z^6N_R];.A>N5MH1`&)3*\31HX
ME-:Z/6&J5YMA)`K&*9E@W[PX]NB$W`=6PK(`2''*[C6<5&UA#DJ<F@S[47HP
M*J3OB2-%83F0A(5MGFG7QH<86+#&Z1R!ATH@`9JP9B>GSEGPKZQ,OOE(9D&`
M"_'N/!Q<1]4]H?(A8A2P10A=#^5/<=:'Y7M$?8D$I^@!Q2_81T5+W".?/!?-
MVT+TQ+5661VFJG7_7$P[!AGHJTXFM)-K;8CVY2C$/4S6N[Q&;VJ5/\Q^(6ND
M"1#>JM[)5)RRN?4+^IY_Z6YD:90!>,VU,ON'PSZ-,1![P"KY>#-]P5\F3&,A
M$`65YZ4!)P4'`+B$'`X+:K"&&A%X0@'X,.R=DDP/AH,0.`A\KN%N"'C$V-.'
M70\Y)-#31)W#T="97SB[S/'5&"!YQ0"C8K/880V%DB89<?QKULJ'WU^<A%_9
M>[3Q)RX'"7`Y@4!M&*G"6D#L0>M5!K,@J#,=>(<L?<YC1'\O.M$5CKS(IX)?
M>3[+/]!._6",G\;R5\%O_P9$TXTXP?)8(0X?S']U8`AM*%[TQG83\490C6+"
MS#:B8OL'V)Y-8F(&!]4J&$O=]""+R0`.Q7X<(-.Z8P#51IEJ@M<&*50"Y52O
M"53+ER<O<,*.[V=YB!_[=&UV@<,L1<$7E-Z0A&F3JW7![J6$B;7KE/=>](PX
MA_4[OU<WB':_V[L/Q63@7X+J?JG+/<DY5>D9\VZS$IG4]8ZT+9I?9ZH7X?<`
MZSG006;JW.*S82C>Y425I:37#WO8ZM2JK6ZIZ*MLQ;46]UNI=.N;I5F.UX&(
M7/".M0HJ9J]6,4=[UZWW*K88[UMEL>8WQRPF$5QFL68Q1_O8+$IQP)P`_((>
MD$\='):*\/+5#S/J85S1=F$'`;(T/P<P7U0W52M/X49P%]0TVRJ*8(RMO<6"
MOT1!%J+Y8J`RW'NKHS"OEAB&F4]Z;]8X(,G(K=UX?]:0\/ERQK#0K:EGOVX)
M#VR"LPV?`6?I,D%-9L9(>4UVKY&-T]_(E-9I1"&,ZI-'>,?4PU&?DR_R%V^%
MN/>_H>32WE0GM[=NGP*UPLXA;#&#$Y=,0C'<ZY+]&)CM+/N=02TOB.$(;*6Q
M$G>!:W>Y6#\)SEWEBPGJ&Q4M`DOK??#`1@!ZJ=&S8[S=5F@Q='2T*@]P<>W-
M_58V2>O;'EA9IHVN@5N\'.W0M?<&+]!3NE-&D'X#1-U]_9%/O0>(T--8%R-*
M[D+4?+2?U&.TU9AHFV_<M5.M5D?[ZD!-9RN2=1]X-LG33`2BXNG4Z#`L4CA&
M*X\5(#0DJ_$^)#KX.$S<ZL+Q78S9+?D=![/]1%F-F:XCJ>;8FW1MX6@'DX@/
M\19$YX[*W]E_GKP$T5_^/U!+`P04````"`#'@FA!!1QRW*BA``!@H@D`%0`<
M`&)P87@M,C`Q,C`Y,S!?;&%B+GAM;%54"0`#A2*<4(4BG%!U>`L``00E#@``
M!#D!``#MO6USXSB6+OA](_8_8/O&;E=%.+LZ*_O>W9Z]HPVE+6<IQFFY;675
M5&3<F*`IR.:43*I)RIF>7[\`^$[BC<0!"<F.F.E*BP?G@,3SG'/P_C__O^]/
M._2,XR2(PG_]T_N__/5/"(=^M`G"AW_]TR%YYR5^$/SI_YO][__;__P_WKU#
MYS'V4KQ!]R_H,X[C8+=#YU&\CV(O)0K0NW>%X"<<XK@0O3S\9Y`F![0,4V(I
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MO-I>!#'V2:%DM5V$:9"^+,./D1=O&D_.HZ=[@N`-^>_>"U\*`^S=_O5/$*J(
M./T"9JI^:GX=6KO&]XEQ$AUB'[?JS_X#\D&TFK&!PNRU06KPM",O1)T@#M]]
MN?L3"C8@BF=9:11M42E%_\@TH"!$3$?G>:$'Y8K^YT_5-^^VTSQN0MF+_>(;
MD7\JOFLN\9,?$9>R3]\U/O$VCIZ`,!I!8J7>]/^"3#2B-$(0]3HDI#[1GD8A
M;S<AF_[CYSY\H@$:7QT7J<@;UFBUJ=,F?<0DGRFH=5]0JR/C%_3RW^C%!\\;
MP83?Z$,?@FTB__!$(,G2TR/BV(<_S6[QGGQ$4O>$<2:$I=Q?WCC7QM.Q<<X@
M@;[!<1!M+@XQZ7C^]ACXC]<X/?>2QQOOA;(E.??"CZ23XN/@&6_F6Q*F+H(D
MC8/[`ZW+:GL;/#RF28O;L$KSUH!2:N2O8-_,+-$&JXO8<P&9F&5Z4*8(?:.:
M$%&%J"Y4*$.^1_P61H4^Y%&%J*Z1^K!,Y[1."QC@D1UX-=T8C.[*H4'5%3*=
M@*D3:.9^-"REV7S.TTV=IR'AJ4]YNF_Q-&[R=-/B:?S&4VV<O3%UX!<$[@(<
M#UF[W8(].'<1)1'I)I`T-7P@I=&SMSO@_.'$W0;'F2WH2APGLTW&YYOU64<?
M<5D#O%E'OT2[#8F?B^\4R@FI8T)>R:<<?<"K;:MT\2+M@7N;-HH1?3LVS,9.
M;+ZWX1R`I:I)QEBL6)QU.RF$>\1_UG337W+MJ%2/O`15!JA+[6HJK$P\_F*5
M/=$H8&V-U]@P51O(L?,FH*.J-JH(.Y]Q&@Z"S8!T<JS,16R:+N(Q=Q'Y*.SY
MK[<)PG5WL6^XBV[F%K^Y"S`$OSF,,1P&]/S,B?@,SHS.(!<BZ)@-\RITU5<U
M@S3UG-`Q.QG1+-().AF#CN'\X2%FJ\TT*]YR6T.+YVW2O[B1>QU:6[-.V`"K
M8E?86]FL+,'I^L@Z4=.ZGL'`BDP;N^DN^FJI/$%_^Y"91%_KH+V*21%/^P(5
MYON'=-HC>&W8%V7DKP;]P"GRM`3H)K:>`1\D*>[$Z>D$/!$DE>[PQ'R.X!;_
M\Q#$U.3J?A?0JBU87V0=+;9;[*>?<?R`XQ;M!I5MCNGKEH7H8/>K)\@8O+9)
M93=84U,U9EX4H*@KBA0+[LE/62F4%7.BP]D31NV.Y"`4-KN'>BHZW3Y=RQ;&
MC/1,VQ@\'AO9C<'>N(;MJ,!V;0DN^1EG^'YZ9?A6C+*>+,+MC':.#G).$O<4
M'4@"5A\^?$._&@;NH=\@1_L2[KU@<QXE:3)/DL@/Z#[1WX*4U.R!9(N8U"U;
MOKXB]:&K45J$&EP^_XH#RAM1?W!]S7*V(6;%Q.^O;9850:P,J@HA6@I5Q?(]
MDJ@H."V_AX,K,F[O)LM[JZF8/J`&D+&NMWG0C&YBW-/,+D>^SY#O5<C_1I$?
M5\C/]E.1:/A:D2_*[UX3]H%SO:GA+\OY#L-X0?<@>B@DT*7Y8A2CO1>G@;<K
M?TIC+TP\GWZ3B8?S)B&1($UTB40ZZ6+^W=DWWWK)/?OPA^3=@^?M?Z)IY$]X
MER;%+RRQ?/?7]_E9+O\M__D_YM^\>+,F5N;?@\Y,+^]9,8W;?&8V=,^S8S@!
MVU(I&6IO2,[8GXC^C;[27_[7Q./=W":(I%^N-4Y=%ZD-0C=+6M[D>AG%;(T\
M[5#-PPW]SX)TJYZ]'75[OP6[W6>,TZN`_+8A?:N\S\5&Q9?;&QS2LYFRCM8R
MN8Y2NC=WA]/.<O1QC#4VQ=HS!K#'Q_:7@-A$:[&.JIU`UDP7F_FV)/@R"]F@
M/#W^B_VC9@51,XC:0:4A5+>$@BW*;:'"&"+64&G.A=U`UCD7C8MLWMXA6S;;
M>XKLO1O\+D);=;6P#_@$'4UMWS!U-=G&0[]P->P?N.9JOE%7\T1=S:YT-7'-
MUAGU-=E^QLS?9"/(B.0-(7$X_IO#L0GT-Y<SL<NQLJ'Y%+V.<`,TJ!/*YK/^
MG*B\D1.[H4_&'4EW3Y^Z.S+HY]X]>C'.EM!=D'=X)G[A&<_9&-MG3(^?:GDT
M;?F\'33DC7RK=GT`\C$=6V+GIBX]JXF@32F#LB'/:=V%?KM'O9NF25EEL8IU
M&A8@X[C27+_L7QV*+0..IN&U@!B$)`X^90=WD\"8>D&8CQ;3L);(L(FVP8YN
M'GOPZ/G6[NP*LX%:4>9[S+CME4**1\9LX_5#TT564B@30U\SP8D'OZV@3I#@
MC(DZ@$/724J$D_,H3*)=L/&Z(^%*N=9QZ1PYD,-EA?9A#CKGJ5<?!MLM53M+
MF3U$]:=N'-(J;LG.":RJ1L\A+Q3OGIS*T6CC*.*.&2L'>0.!IGD$M\]@XY\4
M;%0G8;L,'$L'5$-A1W:T=`:E]-%+T3<<XP:HICX=``)5BK.>;:#*(.+>8GI5
M$+Y+(_^/N_TN2(G=_/*@6XJ7%BYUQ?-W5XL;\4.W-F;16,.*F"/*PK-<`C$1
MQ&10)828U+2TT&[TJ&_#-"FB*E4Q1:T?T@VKK(&&<:MHR[KR&=X2AK3X%.$E
MBNQ'"S#@<&\78]W@[U?NC.&-?KP-7<?)'GH[_[#SB@-B/107`&4.D<%TXKS`
M`D(%6<)X".V[!C/!_E\>HN>?-CC(EE^2?[1779*?_F-.H+>A\+O`B1\'^SH(
M<]#+1(KUEUP1LV68$JN&JS'YFB6+,GD%9N6OJ/;SQ.LS92T5Z7S9UFI-CF1M
MT297C[74]^,A"4*<)-E4VAK'3T'(W-`EQC?>BW>_:P.I1XG\O;5*&,&Z1YW,
M4*YG2`QZG?*S0BA?"XAJ8HC(H5QP6E;T@4$TH)V:G-$H6%%(RPIDZJ)A$#0]
M'@&%-$FNXVY+<+?//_0AI#,*R1[[P3:@-UT%,4FVLKM:)SYCR18J1<GT\>,2
M.*L>`YJR_50>2ENH98-L3]X+/0ZI0#!Y1)<GT2E;.AB73>"B-`X>'K)M/R2O
MI+HKC.=YNO<08[8(9>)DW!K.!2GYV#BWGIA?[KSV)GKNLW8JGCV#R<'K=H"2
M[URE1M;-)&OI-OW;D3R[\?V["3:G>=J9-17AI-19R9%RZ5L</-T?2!RGEE?;
MQ?<]#A/<WG_7JPPWGQ:6`0P=BGI!YM1B4[I!0Z2ADU<W!-EMU;FH2[Y=!0F!
M=]=#$M>["XJ*_+O0DKU,1F#28HYM#9798'0+A[CXY"3K($`)<;9BA^T)=^'$
M'YL(U<NTCQ>C5O-M>S"5Y=QQ?_S6,_`B_19T*.DQ^T>2AP,S02L7'X<)9KO#
MRX/P5X>4MBI=N\]6V-&[F+U]D'H[-H3_"]YM/KZP?SYRSZ4'T57M[3;19;K+
MR?P]C'=F&U5!NC/)0/.L>:]734&V?C,[S#O3D2\7H%KH!1MU/9-O&`+`:00*
ME\YFG^$J&WMY3&H&O'-P>%6@]R*[2*U\)W&-7%&-7$E)+C\G5S;U_)B3*ZFW
MOU<=(;Z+$J;K/@\S;\3K8NJ->K+/!+\GUTGV<7?46B;C]/MFW6&C>->K\VP$
MV$Q2-T?O'*!U*SI5JKI'3T]1R!2TV&]'>6O;"I1RD$7HL&\*LT$&K$[J1>Y`
MIFI[*AILRE6B4B?2Z@PPS9DF-Y;.`_.AL][>"M]R?PAKH[NN'ZKN-K:8P-3-
MRH:FHR-Y<^M4(V%YS&G^W__O(@62Y#\9N9,W<@\%X1N]@;^LI6UGQ\=PV08W
M+N&K87RMKD^-^@YW<H[,+RAVYAVW7[`X35%5HMM_^^TQFM,)J<TZ^C5*\3*\
M])XC\M*+73;SM=IF1T-'O2<T@*UJ3GV`6;4ZJ@3\;>Q.I\!5=OCX%%0=]*9H
M:KTR[@P-(B919I.Z"VJ5SNXRNVPQ3FZ9_KNT[?9X%C1;M4>^[+@)S1$R(./Z
M8VE@;SOF&#A0I4>=J#HAIZ4]^55/.KG#[=^(V_)*M_6<NZUMX;9PS6UMWMS6
MN)QX<USN.JZ1I_E.R7<-G#I4NC))I_ILD)]S?+[QZ!W=P#G,4W5T`/.BI:T+
MG`0/(3UHZ./+@IW'*9CLU"C1FL&4E@`9V=2H$\Q<H]R0>N115KXV75!!KI*C
MWBN3=&.\3P<'G4$\??"TQN4D!;N#;5(K-D;6)0:MS(99A&%SWJJ,;&C3`&+M
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M](#S+@9R$H#C9)1S`0T/5+F>8QOR=]/W0`WL'Y7O,>B47I'JD$K>L*L$5^&=
MMR.USZI\$R5I-H[6<F&]RN3MH%G&R*GVJI=9!T[7E-C!Z6F8Y6+YG9+TM`\J
MR3;\9*Z)"CLQW-D/%=&@1FN26JMHQ4]-2Y!A7LLD:(]@)&#2/+V`YKZ$)KNR
M+X=G%3GIK_1642^D%]0VXFB,?4PR]O(TFE/'L2@U/A4D`^>>8X&YFQ'N>F`;
M%W<O2Z'MQ.B\56P+4J\IL`UQ:6`4TK$!TKB_>KL#O@T>'M-DF20'FIPMOON/
M!'#X,HI7(6:U$RQR&*JF?>5@;S4P5X4-K#WP/6+]:Z%QS5A?I9([R$I5Z)GJ
M0C%3A@*FC3H`G.MCE[Y'87ZQ;;M;Z<C4W6#(=J\S,P-_:XJOKS;.56B]ZV/E
M_KV>M>B7'ZJ7'CE!I^;JD*HT8L515AXM2P8MZ@PB2K+NSVLGC/+2R==*F5Z)
MJ.Y5J$[PYD/C(E6@R(-^H,>&LB3KQU?/*=65F\YQRB#;K1^G-+]/TMCSTQ83
M92+Y%^*+&#%?9M4L#`HTBZG*+3!KGISYM7@P\2WPTL:*=#YN$_0\R0K0?#V0
M`8!G`72\#`0--)DYKY\O=ZP@$.43\#``Z*'_ZOD^G5;[%'MABC>_!>GCY<5\
M%>^)_[R(#P_%XK[NE8$&&EK]\EX:0%*A`76&[8WWJX`Z`^JC3W8/.*%#3+*@
M3!G:X&>\B_:=!;??'@/_$3UZSQC=8QRBA\PJ(B91Q&RB#3%:KM@E5AWIE@\!
M:R<9&H[X5A;40U$W`>I5"QO]B1X5@.Y]3TB?9I^[*(CRDMFM`I0'66%$2Z-:
M\==)`U47^_40P4:?>DHV-'O2K?C!+KOK%29>*3T4O657Z`&0;]X\>@E>SL--
M]H_E.2D:^-YN'0?>KKT'HU^A5E:I*@1"?;V:P00]I2TULQ4J:E1F`FB)O'!3
M_'N)"G&4R;M!5DUP=/C9"U0M0LK+=CFHLF4C*LEM6MD(:QVAS>2+BU&_P&AZ
M\AA5954G@%)+FUGM`U6VI54'MVRJ@19+8^REQ55FSUX<1(<D3[38C6997[S6
M.0\2M/?B-/"#O4='R!WI>5NB@")S&I<"$">`X/MT&29IS)#\2[9K>1W]]A@]
M9>MWYC'.9CD$N5)_!>WS07HH@-G,WKO&0*>']+&KL<%=7UW];!%2"E7%SM`O
MU5T>M&BQ0IG.@66EW:#S`)AU=ZH/A6J+Y/IZ.+O8>]3!RDD.VO;M'%TR%0>:
MF5QQ.@,][X$2(BAUT!;[1GF05#S()^8;8]*OD17*,TQ>!R]L'7@R&35DN:,Y
M4QS)!T>FBNKD$R>H`I`_7N-O5\%]\`GO\@QVN=AN20;KOTA'V'2+M7)%=3$0
M9Z!;.YB\4,.:FNY*);7H1V11+ESV!Y>HD'=JL$T;)QVN]D18BY^JTEU6JNW9
M"%LJJU:2N%$`VTS80BYD<0%9E\;>[$%6E7^=#&@M95CCX%:636G!V)&$R2*.
M%<G1^#@V2(380N#5=L%RW754'D[W&=.J):OP8^3%F]5V&3[C),6XJ'+^O$44
M(&WY=S769D1WH'<Q2[+,*R%V"::Z9TP!N^VE//.P5()R*;J-E>FA<H4F5$7&
M7&Q:GP$%VP@8.TW_8JBT<CO&M8.,JH:5`<T0'69;,Y]\*IKT,3_,-9_,\ND:
MH9*"A'KW!?6J<V'IUC<<XP<<XC/"2'_B>.T:]T19ZAO[>!\+.-5UF8"RQ+C!
M1TK">UP_?UE(1*HE*(+B_0MZ#N+T@/,G09QOE(N^A43Y8[#/SG4@)IP8FG2.
MN8*\_%B8"S"<>8?C(#OWBU0A3H/[';Z.4IS,DX0P3S0'KEFJ-9BI+`5S[:]>
MW0"'A]06->[H5>BH7Z[-1/.-M84P"JDT\C)Q2OLG!TXIZHN7[BVXO8#6ZE8K
M"G-NK559LW)-M=QHOW2UQ_W3]D%+,U#QC=$:*'9Q6LT6E)4WN)\$F'ME?^J9
MI#%`W-B`<5>BMB:.F#S*"YPX3%47BH\,4X,4B&1C?ASLLTO(/N:'WUX$"3T0
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MJ^4_OBPOENO?T?SZ`IW/;Y;K^16Z7=RMOMR>+R:.2`-1$YFU9>LDU5XZ:D>J
M]K0]"6^O2/!<IOBI/8W=JXP&2VMEK)&S4R][G*R;&D;%2L.L%&/[NXH3C4I)
M])7*(B8\\3E7_5"AQ4(1F#3(5Q;5XUS-$N@1W3HF80^;'P>8[+#Y!C3]')K%
M]YAXS8)--`J/C)\`CT:NW\=A@JL[333R-.T2I=O7*&%(,>TZF;I\'4,R7JG+
MDX3K?'%]MT#S3[>+Q>?%]7KR'$N_Q:,!3=(FD+)@G3X:5J8@SQI_3S_2VPKT
MV=,IHJ9/K8@M_G1J!1*?M,P-HE&EX)AXU&U['2*)$*-F4EE2BTHU.[")D=HB
MU#%OHT`N2XB87.UF7%1)HJ]4%C'AR3-U6V`49T8G`$?HFW1&@>6'/\W6^:PR
MP>"F@B,]$<3;[1#Y#SW@HUIN11X\98=_Q7C'UF?1ALFA[<S=B!8Q++HT9W0,
M&Z0G7\*]%VS.HR2E<XN1'WCY86U?P@V.?XN#-,7AS>&>M.MJN\5Q$#ZTB&&@
M(?]N@S08T=B@SF8A9IAA,;6'Z)MEA1`KA:IBV2&BK"#*2Z*L*"K*3DME$Z1%
M`$W?I/D`117K!]4",I`-J`#H\),#1*"96$X%GU'!:U'A0(M^RYFPSY@0O6HF
MB-*VU\<%X!S/!3IT%^9[3]$A.P'N,)0G=,VMAT("92]Y+'+(P-N5/Z6Q%R:>
M[\!A[9.12I!'ND8JDT5E.0'FX29;];^L>@^B%64]BA3+R;2*F*TEZU$KPX5D
M>I8DJ\AT%,P**38UD^\_K0E.O)2L#P:B(6W46D2F4;*V@DS+CC5.W<21C_$F
MN22?BI[S0\_F;-Q4__'E2\TQ2_MP(+KR;VFHRXB>(.]AQEO3*H@);:9Y5A1'
ME%NH4)`MVF:WR66W8=V_H+H6MWJ`,#B-0.'2="%&*BO?8E@SR.S8J"K0^W0<
M91=G3\\^UW>&0IRGT'EITC'^,QM@I<DU>4XO<PR2A+QRPJ)PF3KC[WLZ-$A$
M&&79J&N-MMFFUO0QC@X/CZ2D-`^?.+=VB;BB3NP;=0VZN(KA'E=Y2[<Q$7KN
M&[&Q0;+L5$M-EKV13-6I?2-9\S/]K0_)GG%\'QTCS?[63C_K%&M<9DS2SS>"
M]4/.\1',H->[^.[C)#DGN5)`K+-$\<8+-BM"C4LOB-FES"V:]BF2?TN](D9N
MHT^MS'JDFI;$W-=2,,ND4$,,43D4$4%$)1$3G9;#O=`0#6FM)A]U2E:TT[,#
M&;YT+(+._(T"1]HARP'I-P"Y+P&YI8!\/F5`BCHZ)P%)X`FX<5!)NAOS<DZM
MZ-XCG_0Q'O`&>0\>/5<?82\.211-T.:0!64ZG$`":[2IK[2ZS_<LT_SI/LAN
M4CS+[V4*LC$(G#$@7[%%)^^*?WO^/P]!3!3E!]XQ1M`'%2OH-%_P$&;&R+\Q
MG?DKBM%QBEW@W0>[(`VJLTDF'F6P2"5!=V9\*AGD3IT\+KLF@#__IB><?PV5
ML)$[T*N)68ZDM"$FOJ+HC#?2G@TJ?"V$)E[FJ]G44;\&:1)%7J:BB$HW9)R1
MVP)->JSABR8Z2TYGF@F=$JQ$R<PXP#+PNJRWG%W$<L'B^0T+Y<S9-ZH2;G[S
M8GI;<GL;M8&&_%L-TF#$+8,ZFWGR88;%]!NB;Y9-I>8W]V3%4%8NZP*?M2(!
M3:>*TM.2U@1K$4#C-\D]0%'%^$&U@(PO`RH`&G0<H$(V,?H0)*2JA`K9H;WE
M:&[2B5B,"=_RPFSJ]'72013M7A\A@/OY+G#BPY]F6<>P/?E1!W]QB5YM#"#&
M^RBF=ROGHP$3][8GXX:@+^X:-PQRQOGF/P\)NWX[64?SS2;(3-#!@F68'P%Q
M3AQJD"[^>0C2E\L@)+DMJ?6EY],AF9<6_<#TY5\<0)^1(P%['[-<$Z(:8M=B
MKGU64T&A7BG))F:"L#PH*%.$,DVH5(4*7=.Z&CC\1N`0:CHA8[652P*H(63P
M-JX.:&[K./5HWIM3"F>4VI:4VKY12HF0-U+I?C+@_-AU7I'<>1GZ,::7)I+P
MU8IH[X+P71'1]H>8COBQ(4!?0<5LS5$^>5;<`14==AMT'\5Q]`UMB4#R%W1Y
MB$DB'I_Q3N>/,4H.]_^)LT%'DJN31F=W.]Z_%"KIC3,>L9#=IOUGTOW=.[#O
MS4E/(,CQC\D3V#H:NMAWE/50^.="2V5:V^5:,B#[X[AV83;$M56K=\`U2U1;
MWO(163<.@9:W6&=SFZQA<ZYP1;O;UUJ:QIX',9H",9K]&'7B8XHY#\#QK`$S
M'4<WQV$Z9@4QLS%TG&K*X=L)IS+L(]Q\`@/]$!0/?WQ-N.\YA7%*R!]GSF($
M\#=N>1+C_&CG*FQ!O]\,Q<C0M[26I3"_^(YC/T@ZMV0.*JNQ?H53UMHDI;">
M]M:L\$P.FX[L:M)8IU*"L2SE))$5*-*:;E2!4&.:L:-";X*18WFL:?>.Z=%6
MH%@$-DW:\A\1SG],T#OT[)$R!S=['U80/&09R2E@>,1%(S9A7"X4R9:'=+.L
M?%>(1](Q>I_&85=N\"A@3_\NTC0W<S`[P!^P1F0LX)N<^93/*=#,+V!CU^>'
MI\..(/<9WW@OQ6!VMDOGL^<_!B&.VXM!S)04ISP-5&*VU=ZHYH;G.@VU+=E3
M/TSEK"B'JH*H*HF*HFS%1U88E:4GWD!O!KT(!@BM#?.#=-5VR@^L"^@9%(/J
M`)KJ.<,/FOSEFRSI9M_7#'CA24>O%_+`F:$[J.^>WNM7(<&K^$"7(Z3Y10]T
M+00]DK>()R17?"H43GU@V+3$$9U>Y"1QX`?TLC'%@2-ZBL+R(3UA81N]1T5-
MK0SJB6WV[C6*5,F&];(R1S.NI\*2JG>HAT5YYU"@0]D[%-H>85Q$8'N,P3W[
M`%<,[SD_X6H)U#T'^TX)UN.,]XV`[,:$:S[36A[U>IKC?[;8T&\$<&0V&*1L
MU]G%&<OP&6?+5UL$$C[/OP/GN1%5A?;,TB>>6C'-NM*S_"=4_38M_,7M$BD_
M91/"';$*I1P-D&ZYHQXTH3!L<G842O5-WM$K9MY1D>-K=U$H=ZGE@6.N:>/G
M]U<^%QNK@_)10C>*%-<-93_3^!G%M8T@]`*B9W:4V<1!<A!:!*$.$BT&`8N>
M=Q;M@@UK^X]>$B2K[4TV4)7=E1)NYCX[#)]&52+I!\)3R4!TY5_)4)<1G4#>
MPRS`FE9!3$XSS;.[+Y\_SV]_1ZM+=+?\=+V\7)[/K]=H?GZ^^G*]7EY_0C>K
MJ^7Y<G$W,5=AP!B!8J+I`8Q45M["L&9N>9;.K;\FKD5TN[JILO&=2^=-`!(Z
MXXH`^YA*=0\G<X0^1G*Q-2C*3;P,YRILT[I!YKMF=>G7+0*.T6,0B)UO4->`
MF`J:>->5L%T"E1I4Z$%?J2;$5$U\^*E;!!-U_-XHUOE2P/U/=ZF6]VSIA'V,
MV<5ANR@YD'_2N7N_KOL,W1<LW+=9Z%4LW.<FCC%]ML<\02?Z.)AGD$3?XGV^
M\F"UO7N,XG2-XZ?SZGR+"WS?[H7W*9)_3;TB1OZD3ZW,PK*F);%'T%(PJZ0H
MHYD<HH*H)HFHZ+0\[H6&:$AK-1FI4[+BG9X=R+BF8U$S0?Q[AL00/]!;'\0=
MK5$`R7(^.H;*EI'EP:=Q"@[=]9FI.55$BO*SD\`D<$8U#BCS[(@-[D>'=+NC
MIS45UZ5F`$U8#I2B)R\]Q.RVDRWR4$(UODNI/]W0UJ%7K\39P3#9.5#?O(3>
MH/)(*H<SO)-">^P'VX#>@%+>X^(1Z#_B&"789^K/$&F0P/=VN_I*RS\GC;->
MSVB%Z-.L@8MI>S;%'].Y"?I7=D[4Q&F:13()4J[QR620/ET%_SP$&]+`)('+
M3XVZS9DH'&KL52;_-IIEC+Q$KWJ9I5"ZIL3>04_#K!1CO:#B<+A2TJ&1B'ZH
MB`8U6I-H6D4KIFE:@HQ;6B9!%R&,!$R:3%TM__%E>;%<_X[FUQ?H?'ZS7,^O
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M'R5!-?_W3&2S"WO9`%@G*:-EJ^&JJ?>*C,0!X9ZIB5E@MBBN&/JZPV$0Q=?T
M?/H/?WG_\W^_P:0"87IQP*38A\^8;C3JKH(;4KI:]M:OM.D"@B%U-5Z2T].H
M=&%`+UVS^L1?5@*Q(HB507DA1$HA6@Q]S0I.O\1F$*8BPX;N3.3W4=*8N>]G
M'7B13!_CH$-A$T*=1CJ&8";VNN`K60/V"@`,OZQK,@PWCV2I3Y8GF>_.;HZY
MQQ[;T.N%*`CI,>,)FU;,7/H^=^G9@!F;P607WU`STZ_?&I<7XA5:3O#"Y+Y'
MDG-O@MV!G@-SETTC!SA9?&?#HYM+\KG/HZ?](</Y:KOP8IKM)Z26;/]QL>WX
M)@[H!>>5AA8C;9LI;H>T9L;LKBW+;V^65UJLG>0^+EM&9W7-J'J`"MW9&HV:
M=NKR"OTTD<U.JCDKSZ=!S`A;"%=JF_C>+-MLBL9";NN.+4O6:E=O67L?T+OY
M+-42]A[,4W(;-.LO^;XO^)Y4"*(G^VRBW<Z+V:A7=D+*Q(?\'+\;$%Z[^>8(
M['YWZ+L[3\H7=`^TQ`K74"P&2!^C)%M*R<9G&Q>!1FQ_!>U196<J>0\Q9JL=
MDA]).2_-K_W<DYX`D61K.-G;8;:UQD>X2%%*]X-^6-S<_4B7;#:>'<(@I8^^
M_$B[:[3ZVP/MO)UE9KZ1?A[M_Q5K(#:%E-],B3+C&T1L4!-$'SWMB:C^QNH9
M%'>AUI^SE:D)_7.#\\>[**E7.<KK5X@6JSOR\Z3RKXZGOK7G!%RKZ![3DW6M
M(+/MEUX0L\/UYX3$3\Q4\B4AU8YBNIQW62[5SF931.MLX11VYN:'*P2:[S1]
M(^A)4(/ZZ,R-#E8_(W\?2,)87[*6+[9/@H<PV`8^C0U>I39;\-8]98\N<$O2
MX(G=HDK].:E2==Y0:P_!U)LK`:'/F5<%HE-GLG6H7MX<[/`ZVEF@,+0^4&<)
M.$]5VONK+]:A>K)KR%!-$_I2+$=EVT!JVO+5.\B9!?UN<E"]Y.&-A9ROUJNO
MICHYV7DJ?FA2\0_\THV063PDY8+DD07$,A;2/UR9O764A*+3:8^*A".L4GIO
MM$KIO=$JI?>CKE)Z/\4JI?>`T][OAZU2>G]DJY3:F.H]G<T'9<_)[/=#)[/?
M3[G(X_V$JY0L0#U?I?3>A3@W-GQ-5RD=-X`G6J5D`\.65RF]/Y)52F"\,%RE
M9)L7)D<=1.$#/5R!YHRW>(.S3)*-$,^3O"[>`Z;G6@6A'^R]778/WXK)K:-?
MV/[-%O]@E1:')0`I-=LK#/IFAL<M0-5%LL<8QL2,ZLF.N:*:SE"E*U\"Y"6H
M4I>=.)DK1)G&,Y3II!S*M$Z\LQ<6XI$=@+5V!H/HKFT=!JHKZ&9^D#K!GCYQ
M+#REJ6^3A?N2A?G12%Z1#U1'&;$C!6*<W4E<NX62P"3&Y364X?39M-N4%9Z?
M\49:W2\(?43'T?"VNZQF+Z<Q&^OE+TZA/\55>,Z6Y7!HG^CQGCYH3Z,B:BE&
MWC:EBU?*T]<V'NV3D%KYM*"'MH=PX[$FVJ'LQ#;T@T=WR&Z#L*I^$&Z(".F;
M_(@BWS_$4T_2.NYE1(>&'*67F:#?`]33`>K;3.1W'4B.K+C5?NE/[N\R-[C!
M^"D?52&.Z1OQD6Q%'OGWWHLG/CK5&*3&3@C6Z9B[&3?2%^C3*YSB4NM<"]M)
M29>,2?3$*.CM=H6*/HG(D:81<)R%[I"<#&M[=3/@A^_LL/4#Q"#=JZ<,<'9M
MGS(&&31O`<I%D+#K+FZ)!VV13E<\_W)J<2/RZ]8&)C!K6!-36EFX<7Q4_@#%
M=$4S75%9A=GRXHFLB_U(3]&LK0`KXR]=\E5&7C8U6`3,B6.B-H2BOLW<I*NJ
M5$5+M7[(B*6R!K6JV"I<:5XH6`5<B"$J=VI0$Z531PLVR,6S=A%'<IN+'GZ1
MC3)Z16]EXIW(%H`H2%+&`Z)!TM%<VGI>7@6RNM\%#RQHG;,+.>[H1M#S790$
MX<.=M\,))U6J2K.'+1:,8"G__E8M&?F`$;Z!6:2R6T&QR[%I=];:`X,J`53I
M1YD!Q"R@W`1B-D2]M9H>)C&M8QN#7]&(0&XZ4XL&*S]L]:T@<PF+%05=J7&"
M[J2[IH,-K^;^(F'^8E\<O2"\V2H[WZ!U^U96[.F0I/1*+9QU'J.8S@,69P]D
M$R($L/>XO@KUS?/`0O_-]TSC>X`7G)RB^U$M31GDC=B]?2G:88_XGI__BC;>
M2X*^!>DC<4`?_LKN3\9^=DQ=&GOL_!@F4GFQOA;K7H[K!CNNKS/7U/&"$X^F
MG8P;%/1G3]T-3M:+OC[0/0FK[3JCU@5A%FC?6:(?I,?,U3]AC)&\[Y2]8WZU
M;$41GC6HGG"FFSKX7#NBZH_9^\HH`N1SU2P$\;,<,U#>E?L&[J26G.HYU)F=
MG/VTXUH15S?#8VOOBC5!198'D=_Q>K390B/OR#NTT_@2.YW7-V]2_\1.=4^G
M=RC=KFA8^I>&$\G]C%<<$D>W1$M\3GZJ'(C?\?;[7>"S(Z]>?1=S(L=DI3OI
MEF.RVG4LZG->\<6DIZBG3KMCJ%)GV87KO8WM;I^R%B9N6:%<LU-7I7XU/4?5
M?],$;@]/UHL*VFY+KK6/EU+5;]QL25Z;D;M:$S*NV9$:)8OA]IXZ`_;2V<+C
MZ5N-S?/A/:=7RO31NT%3DEW6R9F\!Z/G!DZ@6S.Z3QC<:7'%)YA<,4#O-OCH
M)7A#;S_`8<*J,X]C>F0`K>W'ETKD)EOL.__FQ9NBQNQI,C^DCU$<_!?>?,0$
MBGA.Y#94MN65QC)77$]@W9S9*<PC?0W#<]+MUU)R=+-MXS,F@%AY5+>!:D;0
M_0NJR^6&$+-T5NMO9=9098XX7VH/E08G/OQY+/Y%8V.\=6RT9:NU0Z6MOQ_H
MN>^6:PO:,SQIQ]/L62:9WY`FBU[E5&BVQZ[S(D1'AY"='D-7AY%W*1R.]^9P
M;$/\S>4XX7*`NZBG[75(%W=-/,63]SUX.CS5^K>Y!_J!>):(^!+B4$C3T@?T
MD++TA=[G%SP$(;L`D'13X^B9^*$?#L0'T5](?L04%,>;>2')?")2K^S*OAC[
MI$.2_'C6\4Z9J+?Y3](39G^?91U=^DY)S;5EM7AWS](OOYZF4:?W%S1/<B]9
MW.07Y?MBJ?JL<//PDNP='XG#+"5IO:C=["H/>O100#<YLDJQZ[%R)YU92%",
MGSPZU5GY9?;:V*>'I]!1A/B9[ZNC0YJD1)8='YV]Z0_TZL,0^SA)O#@@7_09
M)RG>_#CUK5FGY[Y%%XV\&O<]Q6C!@C&P=J_*BO)O3>B7'5J7++[O@YAI2Y;A
M#5LZ`#5T8&+;=!QAF.UIXJW)=YIHA&%@E2W$WT$U@1A[R`PWKGU;5;$M-T[$
M*O-TT#BKP)'&%B-"FP<:`']B&G.&5`$@``U[<R<Z$T.J[L9@QG'[.#K,\9M'
M=1/'A.ESVFT@'BA+IB<^(.0UN2#P<8LW)S1*L[DRO''D?J@[M[_!?HSI:>GY
ML:F=L1"VX]6/#CO:J6=]>$P2+B]-X^#^D+)9>@)G6G3G[1,V6!('#X_9I#O.
M[XM'Q.9S$!T2TJ?/5!1=_MH01#YTD0]$5*,>)*8\E:/"K!CR'F*,LSRO-?!;
MNZ`[QOLH3MDB!/;VQSJ*<(QN%GI\X83<[!0C#]QJXTU1Y=\P92S>S)]Q[#W@
M1<Y:WJ%64U;!=!S"J`K3!$N`KS;1J(19S2T$3),*F8]1<,8C4%Z#:BCB#!6U
M0'DU4%$/%P[<FI3[YH$,S@.91C.#F@`$-:/OX$07PN`-W!C.."7GR`8W"K?E
MY6ZKEOCGZW^_\<8_-M%NY\4)3="S_L:Q#H4<O8<#'QAY\W'3M:4KHR4GY>:Z
M8R??VEYOW[Q5YH$Z/(R3?/CDD8B5CG%3C6;D8RS?<)R-=02A1Y5*1C+(,T:2
MD'@R\@%V`5M603>=9X,@V8C)"0Z%'+^;A1X8.5DW:S),XC_BS6&'5UNVWSU?
MCI6-Y:SIB&5[3$-7OAB`4,N;Q0S=^AAV[37,2'RPLO2L$&%[`FI"Q73]5R;W
MOR;V1=J-'_5NGQ;'5<5JA%1;`$U25.:@[YFS#+W6S7%!N(WBIWRA)(Y3+PA9
M8(SR2V'98I"D4O7G)%\L.768M`!-89X_(C@-7'L^B[YD<TCKB([,!^DAL[,,
MZ7+1*$X^8SJ'U4+Z@)+Y%^I5THB'`^H(P\=^AL7,[*.G<>D4)J3<)2UV%D,&
M9WD^38=6\]E#\C2H*R=_Y=HGYNP0F$4&[=]D<0\%%9][684,.ST,0UU,-0'0
M:XM_T+)$;Z,$*HN@KUFAB9.BL5`LBD:GBV/(.Z^F`/.'VDHVI2]^)2`6].FG
M!K%)#[J3V%T%(5ZF^*E]_)J&9-%KEDF:=5_4=8"8[)%:D?16).5F=YQ>Q\2=
M#HT&C7I\^58W0UR@UL&0:07M]XH-@?=XX=%#$POZ!PK8YXN+=!IM@]`+_8!X
MXKR=:0?7WQTVV5H##[%E>W]!ZT<B7\G0])K=X$H:@MX"NXN28N28=0#KW6@O
M22)B@8Y3LV'G3<1V`3XQQT3S>5*'_#J?D-VA_N2%+\C[GIW.Q5;U>=,?PP.%
M=6&G^FC0#G0CN0V4?VAXR6KPD$&?B4P]@@B%(M'<@&44P0W'W.P\G\T7S!]H
MMUYG'$9:A#\`(R@"F<)+:P7:`Q59TL[6^0HX/<Y2$&62;G8UY7@0I><Z*.)G
MY=R2PG1<8,=B9Y)K$701TRB`9)<(E@#TZ)-R>.]4\:<YN'&<"`1>8C(."#\8
M#SKOFQAV;+09$KQZ@QHC@-<@/;F)(WJJ:'))/M8R/WV$'B]9'H7_*8Z2]HA&
MOT+YU]$M9$3,?C4S2U.T;8DIJ:EB5L@ABFE42&8'MU?W<ITA)CXMWWIB(QK6
M<DW&Z96M.*=K"S)DZ-D$35M&`RA-7;)/O&\`-:@!-=LK><K8%"4S)X1.X)1F
M/(!V5Z8^L(_N/44'DJG0<[N]Y)&.W^VB;QEXV>+3S2;(9VQ\;Q^DV7AAMJ^7
MCO'E`W68G<,X<:)C&=R"9&<:<!LD/.<[+TE6VSSM6L6W=/WE&L=/Y6_M;*='
MB?S;:)4PXFN/.IDE.7J&Q/S4*3]C0I2$Q9!,%",FB*AD[<'$\:,/$J(!3=6D
MED;!BE=:5B`CAH9!T&1F!"#2-*8`7+D7B^[!>L%>//41-+:P)\I:CA]]P,G*
M&`#LIBDIP^,SCFL7A[3V"4Z<=U@#IB#C&!N8)H,KV3Z09!U=QIZ?Z6>[1,B#
MZ-"^\T)3NAA.44F;]0?TZF(X@*(T(LG[%65GA0#%0B62GSZ0"4V<KVLV=]2S
M35KYN;Q0+3%7:0?M;LJ-:28.?\\`%N('NLI",@YB#V<T9:BABPURH/T)HDLX
MN'&4^((>Q[`(L&9*L"^\&DE1MRW<)<@C_T</%#_LV)!&C.G]43@_-2S9[X)T
MZC$*:%2*1B6.$I5_@QS[M0C)O[T6G_<WV^BRN1SY-F,_>W!'N5_=)W=+75D+
MHL,5"!<OJQ4`+];3K3'T"CX-NWT6]BG5<5?[Y:7.LKE`Q`K6[WUF15U;!JB-
M,<GJP)XXS4G<7X]L):&Z#G:7J:KLPY[I-#4!LLW+G>2F?A=J_%K1KK_0^J3Q
M#GV^S^20[PX-MM&>[4S(#RGVO9U_V&4[$9SL"DS$#NT%Y%.RPR`/+.[^N8FC
MS<%/DU6\QOYC&.VBAP`G5X&/0X*2CR\+-F4]3^8[XNQ#CUTD'-UZ`;V1>E[.
M>E]FVV3"AQ8M+5O)V\::%2-G9/G=S7)3>Y43.S-;-FO77A:JZ<1P73DJM-.#
M93/]=!"D9H'2-+>!*B.HM#*M$[3-HV@DT#:=J25CE<>U]C:028NE2H)F\B?D
M+IKWY.YK#B.M.XQ=S6%42[?8R&F(O*;?B'._45L%MGWS&[`@?O,<XWD.X#[1
M*3F/;N\J',^73-P3.WIG(NC3G:HS,>@=SO>I%]\\>O&3Q]UY+'R>?UG.<R-/
M)[1GU@OBJ17[E*[TC/V$LM\<V00L;II(^36;O.B(58CF:(`,;!WUH,FL8:O3
M!++>[L?7W**LRJ4&!\Y!3-N<=]L;;\MK'1@3A^M!R!"$2$AD&(2E2R^(?_5V
M!YR=D7V>'3F[#,O?K\F/7O(XW_SG(4DI(EIH&ZX@_QY#%!@Q8WB-S4+C(+MB
M1@U0-Z//$'N87_.$SJLSAFL/K^D3NBNK*CPM\PQ0%IFW>Y.Y_?54U!Y2!\BH
MT-\^:)XP.058IE'U`\,H?,=V'VXI]I\9]KVJV=KWB-:F_4CG=(/O7R4K1+G.
M*^,%<#HU/35(0G89Q0A[_B/:%2?W%9/:":EZ=K0(7?Y:'N&WCQ+&I;-LX*:@
M4Q#F]_;^4-S@^R-55&-9ME26IGC9CM_8"Y-LG5[C:A@G+H29B&:"Q-$MF@',
MEU_C;U?!??`)[Q;;;>![_LLZ)MAJ[P76%6_-8(O%00:*5;6!F5.66%$/V`H+
MUR9MB`S*A5`AA3(Q-T9(E:W>&>K4Q$EKQ%)4JCOT*-9O8T)"9,W*G*05N#5G
M"<,:X'`!N/0D`:>:<3LZR%F:S+*#.MGTD@2$CDP,`:)0,55C'X4FNWE9&DBR
MT]_H3FR6H80;^A^ZZ(\DE+1M?PMVN\\8IU<!^6W#E@*2?\0L:>V<H@:EK]@1
M;*[/;'L3U/L8[BH&J(9D;Y2Q]EFF`FVC8D\_&^3RPDWVCYHB](UH0E05*G6A
MNK*)]UN!`3@"QU!KQY:IVMJ>+O,:@NXI-*T.[(ES;G./';';9I]?L(_]`[?9
M]T39MRO9%[^Q3PM,;_S3_630>]$=IV`W%=[#,9+FT^X<R.<B044;YH^(H`"C
M??P[H];1;X_1TVJ[Q73H][.W:5-^:/'6:*!^<9`N=-_:PHP6]K"J[EAK*ZL-
M[HBN#R1`I<5040[1@FYTM'OCJM/Q'HC,5C=<5TNW6ZYOW\9@D:YU*^.5DP"^
M.9[IY!V#XX-;-=9Y\O"V-#8Z#<)E8Z<"P+-+*JB/CW)%)'/$,49/>:/2Q?@8
M;0_AQI4AUA')H1B"G9X<)NO;KY?9DD4?DWKXWBY9ACY_I;M:LECS+I,T6QVK
MKH/A.GBI`<DZ64FY&7F(6D])=N6[LDQ>HUVC'@W06B\K+E!;.2O3"KJZ6FP(
M=F$]/(S8$K@ND,XHDDX#0,+%^$<#(>BE^A90I+U\7P"UJ9?R0V%-M+S?,M8,
M(O5G'#_@>/X08S;HPXW14IG\304R1J20VC6+R"+58OCS2\RRGU'YNR/A5]YD
MD=87;F*8*UJA5Z`)TD=R38`&6"!4L*!:`H(.H-^0XK2?E(D?+S1$P=15<`"'
M3BA\Z(;+I\RY>$7QB<.D$7($H=$&<@S"X:\1788N#X=2F?SM!#)&$)?:-0N'
M(M5B8/-+S+*?G0N'\B:+M+YP$[=<T0JW`DV0'H]K`C0<`J&"AL,V+B8>"S?!
M@R@&NHH(X!@(!0K=&/B<(:>,@5./%!M!1Q`$;4#'(`A>1?X?7_;R("B5R=].
M(&.$<:E=LR`H4BU&-K_$C/Z,ONR=BX+R-HNT/G$3N%S1"K@"39`^CVL"-`H"
MP8)&0?K@71T8$X=!$T"(PJ"KD``.@U"HT`V#.PJ=P]Z=.&B$'4$<M($=DRMJ
MHY`&7F**;8=E=]8E\K#8ITC^[GI%S&YI[%$K`(^I:4YR1:..@EDEE1]4DLE5
MWG7B^QC[0"$:TE1-\NB4K%W(J&4']*I0#8O]`K<XE1L%@32B*S'H2.IG#XS"
M>VM/`8[05]>.`DO=E,*OL)L?PY%AUYD4PR)H17?:C@Y:@_1D]2TD<?@QV-]@
M`G*"NP>\VJX.:9)ZX8;4B]UPEJRVY]'34Q2R2S#8'_=!B#?DOWLO?/GX<GZ(
M8U*X?GE&BR_6[>1M8-&.D:>P_OYFL<YF]<2>R)[56:D:5;KIY&E->W9],-MF
ME!G(+UO+_F8V4&Z$'@J=FVG<+C.M:[//J6@T^#9=J#5SE=^U^$:0&8:U:H(.
M;YV8^\BW%M?<1E1S&TGI-OS,;22%V_`+M^'G;B/Z%F8GRONY\TC>G(<5#+^Y
MC['=!W"OYM0\"'=GM&6',G%/ZR0\BJ!/=\H>Q:#WN,;/7FN]\9>[N6B;CJ9T
M_N65TD:.4;,N9KTJM1&Q:U*5G5&!SMX=(N+0_AW=!H]ZMDJ3FXI"%<,F111H
MOFT16#3WI2*GA1Q1IG@DV`%.MFS"1W?@6.2^7-C*`XX^059A#7TF(?TQB#=S
M@I\-Q=`ZRF^^DL]8]RM4!'C-0F;,ZE4SPW"O:TO"+CT5,R:'2D&*E%S4N5G#
MGMB(AK5<BUA:96O\<@>*L'G"6(AD64,+DVL.)D\9BL(<XXC!")UXC(;'9AH2
MA-N(!$]V/U$S#:$)2LJ`Z]6=:7X;J#.[IBPC5Y2?C(-<DYW'P8Z>3!+B&^^%
M6OBRC\++B_G\D#Y&<?!?K,57V\]>_`>FL^RK;7&1YV=OA]>T:$)<*"G_">^X
MF8T]`\6>9PL&S#9!6GMCP]W6-NHEV70);VY6ZD2Y4D2U(J(6-?2R7;Z%9OI'
MH1M1Y:BN'=&3YMU(]"Q2);(/SM:.4G`[M>VHI\]XV`WUQTY\FAQ7U-_GU#\4
MU/?:U'^J4[^\E_R)4C^M4_\![]X8;P+.-\Y#?E;H<Q*.GO;=H=`G.UY@ZB,=
MCM,-B`Z3.&XW`-R96GCQ+J`'0GYX?X%]9I(6G(>;R^`9?SPD08B3Y,)[2>9;
M4K6[P_U3D-#[3-<1>;'5]C((O1UA012GJ_`W+WDDKW5.JD+'L._2P^9%N]<U
M<DTDW;/1:@+NX4?^AO`=OO%>H%^D&*M>HBYD;I^&B@_O45$%1.O`SHZBM4!%
M-1"M!V(5055-J)>B@8BH8+5!6740>9)7"!4U0JQ*#G<[Q_85TC`UC>.21+.1
M*B0/>V].5%%SZWWH5^Y+);UR7'G3TI5^>']6N=,M=:?WA3O=4'?J,7>:\-SI
MEKG3N'2GWW)WZA?N-*&U>O.B+GC1/H,#;W[T*/SH".,2K]V5:H]T3.)9'1P>
M>96NM<>`RZMVK:,,X7P0O0;=7X`)F&GQ;+<!COW`VWWVPL/6\]-#C*MQJ9LX
MVAQ\_J)`)^K2>QC'2EU&BIT6O^-80SEV7@$B:MJH6?_AG`_RX9QZ78J-[5EM
M4*TZC24%>8V.;C3'IM,8$"[M^[#>X=)"E88$S#>/VJC[1.,ZK\JQ#AO;^2#O
M@?@MW^I7OO6IZ5O+V=I][EOI=<@)G;D-0M8[^A(&*7E\1[J9>.)S`*9&D$L.
MUWSPY\WE.NER)QL">EU>%V(8:"(G?#1C1*_`"QN/$[TB+VPP5I37_S**/V)Z
MO@2!:+;R",?+\,O=:OL^/XFBM?"(%)B3=O&2]/W_\U?Z3DM2_TU`6+1[N8QV
MN^@;T7;E'4+_D>KAC@U-8CN'T\BVC<+F)-_);*QG["J+@^&X-9D5(S@TSC"#
MB%I$A4D:=K[<T<CTOCB3L+N3@Y;-;2-B/!O:J9E'I7V452#7ZL;@S32LCB8E
M2S-&C5J%*B:]N31!74$'6UZI9V.G(=9\VSWS;32#3JA_>ZKYMTY:3=V=AQYP
MB./`1^__S\[2=33_^"[V:`%ZLV^XB:/"#7HIJOP@ZP$$-3^X+?T@M;G+?.&&
M/*,6V4_M]-^]H9?7Y"Y%0RMO#M,QAPD\5/):?2;G_$<8%UJ<(^F8)YUX_.15
MN5+!^,BK=*5&-S/MR!M$A#/!,Y[',7$;;$3F)DK)_]+AF-9(3W*+?1P\>_>[
MMJ.&4%7>Y&2BRO`V$_.W,+URQZ@&LCM/#!3/&J51K3@JRZ/.2HX$52JFO@(%
M`)T1)$K:%Z8,UUB_2.4HB0/:0W62/[3_.']XB/$#32J\I^A`B!.7C\]0L"5_
M/AQVU'._5%-&"?)BDB`=?!\GR?:P([F*YS\&^!EOWOC4!L\;HZJ/`G[AEHND
MZG8PTB@E<2CG5_I(LGX_.NPVI+.1LXV>'._11#X*D9^=@E8G7A379U,)S:CB
M@G'TS/DGEH(EQ;%IKIR-YA`=A3>".4='@[SY^D!AL-K6IS7/HS`)-CC&FV78
MJ4:+X8/+YQ]U0'DC7S2XOF:Y\!"S8E_37]LL*T)'`9HKC:MB="2@F_=.ZPV&
MHRLR;O`FZWNKJ:CN/,1!L]:)D4[STPKKS45'?@/KG=5,KQ#KHI3SI-$.G%%.
M#?AN[A@.Q/_$J=\D!!`D>9,2`""=HT8OR5?-AEQ7VWS=V644__88^(_U<5UV
M2>TR^43RT)`.XVXV07:W4%X_0<)GP4(K)02U`.)C++PS3%H)6S&U=X*T5PO7
M+".ESJ!8#T5^NZDM^&7*6PNQF'X4)(A9R-9<E3:*--8-QV:#,AW79X^7+=<(
M:*CK/$^:^U;R[2-V`<V<?5,Z@=H4=I_9:^8#OC%7T9R0CPM7\5"Z"J]R%?LW
M5P$!Z3=G`?QE+757CME?R+H\$[L/1_I01^<_%/VPH_4?%I:TW$8OWBY]N25@
MG2?U^V6O<7KGD<ZEYGH6;3V*Q2P:>JQ,'VK7W^)<O$X=^L\9JK7.<A$4LVGX
M!'FM*ZE#G++]D1,/:IIC3SF7UQ?&BFD\I3KU')ZSA.C7\1@^F3X1*V@_HI47
MQ+HT<73:>TR>]%U_<M),Z95UBP?H7&/(!]GZQR*FW.9DN6E0A>A`=V\1I8D.
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MQ2^7P8YDFUR2"&0:Y.C(`)!"8!>"#%W5*A*T2Q3@+W]'V0,7("]JL$CK^_(@
MWA)M0[NC:4I(GQ_BF(XKLQMM:#PB^=B!CVRY:`/@(E$`G,MK`0%WH045Z@4%
M"_#GCU'Y'&4"+I!`T;91GS;@48)?HLT,D=XI"<)(>NZE^"&*7[B\X$HTZ-"2
M`&`!UR8$^-N*59AORA=09[^BXF<7`,YOI$CCJ_+@W!!LH[BE94KPWASN=X%_
MN8N\]JR"\'D#N(WG`+#EV(,`;5.M"K)UZ0*PV6^(_>@"7'D-$RF_)0^J-;$V
M4!L:IH3I+7X(Z!Q=F%Y[3VW\R$0:8&V+`."5;Q4"LAW-*M2V"A3`K7Y&]'<7
ML"MHJDCGT_(0W)1L@[BM9])DFB0OL;=;AAO\_=\P/UL0R#33Y[8,1-[,MPN2
M,'=4*S/E5HDR1<Y^1^P!(D]<P+.HQ=I)L;1AF]EP4[23!K<U38KIZ.DI"N_2
MR/_C[M$C0%L=TB3UP@W)S_D`URC01+NT``3T-6H$P@.Y'24I9,5+AC`AQ*3.
M4":':H).$$8'`6WVZ*.F225)N0ZOI#:F(=E%/@MV&22^M_L=>_$E^:4]`*.0
MRC^,4,J(0PK;9L01*Q>S151F5CQ`V1-$'R'V;%I6J%HOTOS43?P+A"O0"[6Y
M@/0;'`?11HUUCAP7[0TY0+QS[$,BOJE>%_/U4AW49P_=PSVO)07(%S<Z%_LU
M<1'Z&QJGP?\5?O!V62":?P_:J!<\S5^[\]0(X0);9KCN*A6CN2T[8S_D$1U]
MI;]-?.N1J#DBQ3=LPK0E5(&S4WI:E[PF:@5>N/ZHY7BS1R"^MFX%QKWF&M4>
ME0E63I3^Z8;7;'SYCJ/DM$O+-U*)KCO,RL'"S7C+2'+CO=!5,?G\3PLJ<J&T
ML56D(P2Q341@&62+2%>W<GM(N\BL^!WE#\Z*J48G=H*(VJV]"T3>OCFX^;*=
MW1\=77+`0Z`"=+$R&#C8.>T%//;9HV-&A6BIKAU<C.H(XP/>9-O[`IP(/:%,
MJG*%?"E3U,ML&SM#@7(IX+EE9OD#5#YQQQ]*6R_2_-0=Y/.$&]#G:P/VB3PC
MT$X1"B34+5X<LO2('084Q>@=FM-565-O;#9%B<1#6L')B#YR\Y^')&4+J==1
M_<B=8+,,S[U]D'H[-J[[D5Z(<!X][4G#LMT%;,AWQ=X@N<7_/`1)D.(['#^3
MML]&!FZQ'SV$07TK0N%SQ[5:^/"QK)JQ?MQO8QAC1JNLQ!V-5(=9S1"[.K!^
M%&K`SGW.K>5S2.^R2T3J%L^R22:4&SU#I5F4VRV&&FN6)_:=(W,UFH@(+<\^
MCO%:I!CK;4$SE'$J#9OQO!Z713.RS-]D[8WP=ZIHZL[JB3L48;+X2EW*),GL
M-<&?ESPN4_Q$7I[6-O2#';[&Z3+THR=\%27D]W,B<A-'S\$&;SZ^?$GH'0*K
M/::;#L.'N9\&ST$J.7)G)'/=]-62.:A88/5K@"6LMFJIY?;M&*^GJ&<HMX&8
MD3/J%TH[[,2QS!+Z@=KZD3ZFYE!ACVZ4_H&:)(GMCZBTBBJSZ&MA>.*)Q=&(
MR`LE8U"_&T&L6.6&#DOO9RD-M5);6_GGZ7D@-C72[";'I<^A!X+NB%;Z*_TW
M<TX_'`H7$V5J2<KQYDULX?>U^A.W!E1_\^AY%BG;?;\9,#3*+=]CD+-5WOH0
M`+>^]@<>VV;-^N--;7T&`_.2V8D4$U_)/1Q>O;K1,H3VZ`XWU/3KV+9J,/:H
M5\/\Z.-7%I%?C2E]RV%]-(-*T+@V&>@9"]DC!KXP#3;![D#/:[K#_B%F`7KQ
MW=\=2`RG=X#0$:9#=C39:KOPXI"$<GK>,AN#FK/KV-O!$%)G$2!A=)IY$,CW
M,@RD0%61N!@0"[.Z&E3I086B[&*BFBIZL'JAC,ZJ99-R9RA3.+&[`@5V9`57
M+:<&H;KFZ&!J"AK6(:H$&^J/@YO-.P:3;/LD;M#2;]'R9NH#U1WFGS"M.$(&
M'DWZ<16$F`U)P&8@';4P24A-[90NK_-VDZ8B]=I8\WB5$:B$!'VE.K-)FJGG
M4:#!#N48132"\8RE=C#G6*NO0QE*62N7DI1Q6<M&+RJJ2I,47%!U3ZC*LIHW
M=NKBZE3X.77^0H]?NHB>O*"S@EI37)IOU,4M.*9N;6SD!PTK?3U(K;`HGI^Q
M,\#0UTS,R0C-:78%MX5`D3*V*J5B8EV_VPS3]AD?7_@*..<.C&`)IA\AMS1E
MKJ+S#2;M;2@J:"V5D=H5]DE<./YA#%9`I30]*`B3X\@,@J4]\K=RQD\G"4Z3
M2R^(?_5V!WP1)/XN2@YQV\\HY0H?*98S\W`J^X;^2:)>XEV$I6;9HS-$'R+V
M%%6/)W8-RJ:,M+]ZBY8B\1JIQ!I!.^\B,["]<5C4T/[R.DJ]7?XACQ\FPCZJ
M1:",[3OS7<:B;0LRF8;/[,@`$$!@%\)7=E6K$-\N4?K(8B.W,RO<I6T6:7UB
M'MY;HFVL=S3!.\26"0O.T!@6U`F>?[F]7="KH>_N%NNI)R\-P"!W?[!P&-OM
M2?V=U-&!>C@;KJT'>-O.S#$?IL*KCM<2X=.FG[+HH`8T+MMGX8PKTFU3N?,Q
M;=6)LBQ9=B7+JB"CIX4L2C],=K(F%R`I/N%'TCZ\6"B(@193H9X>AO;.-%,@
M_39E_;[5>GZ%G$U\%$VKE>@,;-RQ/0W7Q7!]"P@.(;V)!N0*_^$"MD2@DF&I
M#2(;KL&"3]!HF<H+N,-^40O)^=ZWC1P8[9;V9C3D5:/?H'T>C?I8&@WOD3S+
M2LM'QQWK0^FTOGHD5*>G)2FF,2YJLS\F,3?.@#H,\%A'C@G]R^DAJ_=8NP5L
MC>?)/WI)D*RV^:G(W9N\A,_SC\-Y;L03H3TS3\Q3*R9`5WK&?J(++*L?T=<U
M_IZBCZ1U_IC8PXI;*5)^V";*.V(5JCD:(#UD1SVH1S0$`/5X'^=WRSNTND0W
MMXL[TKN<KY>KZ^-K=Y%_@VSY$?W7(0E"G"1S/SOPC=2'L[9-(57X,I&4&:[E
MM@W]FE"Y!-R",K/B`:H]<6(1EJKY(LUOW0(\7[@&>Y$VE\%/_QEC_OIK;7D)
M(5KRX-3@U@>>)&TS_>C2+,TESADJI!Q9A:W?^%(ZR?`B(5:CF)QB+0NND>T\
M>KH/PNS,+\%PAXYHBV)\41!VR6H!0RR!!36GN`5G\_-_?%G>+6EZ1=.MZT4Q
MD$__.E]<7:%/B^O%W>\3#^UIM7*'2QJ8:-&(5Z++(+Y>A\E3]8II-XKUHM0T
MDA02$XI;")I:DIJ!DXQOJQ?=>"JJ.%83;`PHNM/A[0<-&0O5D!+SD5-6RDRN
M+=!.M)9-V)[U6/ADHXY'&QH`X2GLP4\"T$F#2"UOO,4[+Z4GPB>=N>?^!<7!
M1%@0FK>*&H('%;&]7L05J>$&E[/&4$,NCU@!YPBL0HR,Q'IH$]-84%Y*9:%-
MR_%&8-=VS+$+W^SV3-8QI<>DOMO'D4^Q3#X.)G!Z1%ZX01O\C'?1_FGRU63C
MH+='&!H1O^.%H_QDR^+`R^0SIJ>)M6@B%\H_G$C(B)IRRV;A0ZA;S#5!D5G^
M>WD6,;HA;_3H)9C&B:<@/ZSX:R8^<:]#T9B1WJ=OLH4O6S%#I`O2B_-M@'IL
M,,103_P)TP.K_3^\!SI-]=GS'XGS.&9HB%RI'7",[B(7]+!E4D72K4B6H4_7
MJVX^'M+K*/T=I_288+[3U"[6=*,:Q2#8HET[$%>K8TU));62TAW715$AB^X/
M*2+2Z`6G[,1X)SBG#Y,V"_L"K,E*9>D.3S7L67#K2JLV'/TX>*7!H,P7HBW:
M!M\)2KUL]2S));QLQ<(9"J/P';NY)0B?<<)6-WC9?1POIXYA16R9`,5CQI_D
M<1YNZ'\6I#?Q[.UH-CE/S[TX?B$@8,OS.L&G1YDR\FB5,61SCWJ9QAP]4S("
MZVB8L;O;:->9_:,F>8:\%!7"V<KFJ7G:!Q71H$9K\U.C:)V<6I9@XXN&2>#@
M,@HPV=[Y`IHL;.!*]G1Q*(X4IX'$#WV0N&<WQMZE7IQ.C\</!(_SNU_0_/H"
ML7\L_O%E^>O\:G&]OD/S-?JX^+2\OEY>?V++4Q>WR]7%"</TPVG#]&_]8;H(
M-].#]&\*D"[([Z\!GG]S!YXC9]KY!`D]TJ\V>L_+K^62]:Q:)&E.1'D=H+(5
MH14%W03ELKPDQCX.GME4%$IC+TQH9S8*'2"5HF&C'BW`H0^_0(LT(JW@GIQO
MJ%_"J^B$P:*GS&O+J4QVA'Q-XC00)$UD+6)H1'>[\Y)DM<UOU5O%M\'#8\I=
M\Z\A6;A;F:096]1U,.2*U("$*Y)R,_:0CBH65Z%&,6("CBSHUVG9J$<3M+@B
M+E#CBDRKTUSA;!)3RLEX`K!13&G?`D>4F\7$I63\<&#/F+HUY=P0[QL3BBMX
MX=;>,6X5%]]Q[`<)OHD#'Y</D_RI%F$T5<BXI%0!3S/-6EM@H-IR3W*J%(IY
M>X:*LH@5KLDDI=#4XY\FF),SOA]R9<Y`H4GA)Y3U`.W(#*@![)"^"Z2@':,2
M^WN&_1](GK.)=CLOKMVE]>-K!;^P1^4<_$>/H.Q>>5G7BR/0C'X-`0@V<RR"
M1*ZF7B4%Z^)5U&&_NM6%XK50FR[B5FQ2H2;7`7I#AV,P;I(PNQF9U+B\;N7<
MV^WPYN/+D)RPOS99>MA'&WQL[/\N%I+&7I7H&2I[Z):EDM7=VK4;G3)-Z/[E
M./+*`;B51]G!1)"%6WVEBLC;IW;6<U#]RMA/1]V@&TU22]H$27(@3*)9:G9W
MO8NIZ83\Z96P.LB@$>,_[>3<1[%'KU>;TUH^8+;I9AYNKDF#"QZOJVE'P<XG
M:+U%3@"GU\QK0;^?89X`6!V)"P.S,FNH0G5=;-G=-5VQ+1)!=86N]"7`\1Y9
M@UK+)T*IKWE':R0]*L?(FV6"U0KG%"%FL&#?;7*'J)X=`[)AY`S=N"@7&M>0
MSD\REP>C'-3Q<8DXIMLKMUVKC^C2$RZ=E%S8T/?HU`2BAZ@R)',7TJ*S\]7G
MS\OUYVS!+%U%N[I>+Z\_+:[/EXN)3S32;.BH7W.TR2@K4^>87#?HV(34%MA:
M/UN88BO^:N<H.'F8&RRVA#W_4=`UB9^FZ\0C=C`W#OT`U^HM.*!T4-FN%]<I
M"\4^_7J"45'+I!8S-30=B?/O`1<>7WNCK4M>M0HNEW4LNT3M*&2SA8*A-<'S
M&D5;SXUIR+4'E$ZU=<LYU92>93^AA/XV/4WXS1(IOV07[@VQ)J1;&J#SG89Z
MR!3'H)V+1(:T=+Z`P(T3H08TN2Q!<:71>VV5?<;Q?621XVS[:ZWMC[#)15M6
M`9M\DO!TQ^8>5X<T2;UPT[T^2D>T&[0XHE#X%M8"S+OQ+&B!O5NP@?HSE`F<
MH9J(,U00MRZ/%2HL=.G1*<%E"D>O)3_9L02["L$&G++=?]GQ7DF&J*CV/;-E
M!*<"*(T@:PE2$_KA)5L4HG+!32F1]RVD8`G3M`WL<TOE/?B1EQ%XVNRI8YQH
MM9^8#MR&%O$@$Y90H-!FU:%F1NSZTN$PX7C0?!V6D\ZS)U"T72805"9QE.S8
M#*U\5239=9A=22A2B.H`YC@Y!K18T2G7<J#LN9N9JK!=>?Q0@*#+D'8!+DNZ
M6BTYU;8A6XX5"D8=!WL:J-'PK%9P,[:'96MBSR5#UCR!AC]M"@#0@&<1#/LM
MY2K(-\3SO1/G*-EC/W`)[]Q&BM2?E8?MNEP;TDT=\!ZPKA]V%-N@W6OCV`4`
M7!K)[MOV<L\&U?JC^K$]#I/L`I)P<XO3(&8+M'2FU/N6K#R??DE37O2MHS%=
M>AB4\DA;S^QVL5[>+NA$.KJYFD]\0_L06$0&[=6AH:Z"!C_UK;I#W/`9QVEP
MO\,7^#ZM-N`(LA$MZ9*@"FE#4FK5Q92(*B,R\LG+SFH"B$K4=WRZ$MSTVCOJ
MV2AMMDD+U1FFT`Z;#$F-`7<)K<$L2YPJH&V(S&F!2IQ+C0.K29SU=93BY,9[
M\<B_S^E5$F$WL=(1[KIJKC`4DR0U`7/4?!M:!.(5;;"'":!<X@SE,L[P2=;0
M/#JI@='E$J<,ETI<W98<-,>6+?\,BR[FG?./N(]B=J)JM*U_;I(4A$$49\@[
M):!IN&V+4)O$:5]%X<,:QT_U^HJ]MDRZZ[;YTE`$D]4%S'$+C&AQBUM6YKKI
MIC+'O+>TP7FLTD!(EU2\0EQ6\;5;\N`\8[9<.#3.J!.GO[\C57A"?@US2>:[
M0Z=\-PC,-+RW5:!-GG2KQD?$LO*4&WIL1%P/*PEWOPXKIZ389[LW)B)I8U42
MI#D>TBVB3(`LCX5T38V1:9O"BKIHPN\/#J?1@P#4,XD&A=!D@]277A"S*?UJ
M8+U[6HAV"?Y@-;\$Y("BK$Z@@]8"0]HCBMSRG<'K,T3EL@5,M>W2[G!-B0/1
M>*,&>/@CCKR"PE%'OA6+`]H\@S8'M6W`D+IU!KMG!KMHV\B^G1OJ!H.?YI"W
M=0".&0*2=!YNZ)5NZ<MGG#Y&FR6[DEK[P)6!Y<OPT+N\(5D'UM<T=/0W*V-P
M7VTS6H0=W9050EDI5"OFZED<0_$5&3=YVP?T5%/W"+UK`!N@>IH'#E>30I^&
MLN7UKXN[["B+UX=F<4QS!\_CQCMZ]L;B.UU3A!/AZCFY6"UZ\<6,"2NS;AZ+
M!-KEO.,68I$E.Q6P>(:^%D\="![25HQTOWB7.CSI)D/X^J`=.\\*N/\&@PN[
MV.;?;Q;7=].?(62*#9ECM8..Z=RDPCTJW"(PS.VXP5YXYKD]M_"LQK$>>L6H
MM>O+>OJP*/5V^CZL5UM3G[6F^A$^TI;6]53#VWH\ST2'5)8A\9<'FFQ>!2%>
MIOBI[:`44OEG$$H9(5EAV\QKB96+`2TJ,V.+HZLGZ"M]AMC#B3,W5?M%FA^[
MB7>!<`5[H39(3R<P`IJT`<*DO=#9G;47IB`1N45;,)G*2:XYZ^$D$ESGN`98
M]R:Q">D4U\IU1SSYV9W_B#>''9OMJ%8=M5PDZ=LR<:?<XYJ_TDC=Q%R\KYOK
MB;A:7,)YYIL24I55'#P$I$+TU_E3=`C3]QS4:\G7.*"0-V:$5GW,^:$R(V>+
MO'262%0R9ZB0RJ>P,\'I.:/7]E'OYNGR25JLR2Z%!>C40VH./`FQ"#N:F-S$
M0>@'>P(TC_U(G3>=GD:^1X!`KSH[/=#)TI:Q8#>NBU=/0RND:NX<?DI98=O<
M=?>=(Q.5R=RTD].\JO:+-#]VEQ'2B2RA-FBG:WN2%1`FK+^WNOYU<;M>?KQ:
MH+O%]7)UBZY7ZZF'[$U!(G.<-F`RE9,4S&G*A;@N$F@^4VX9TD%J34X)BAP%
MZL735%K-RT5\=X)*I,LEO%>=TMKH5)74D,S0Q[S^7Z]RW+$0:3G`$1*-^D&.
MF\C-Z8ZFR+2T!YS/Z@LKSVH=2,0*3,^[?E@1C+SHPXP['B,I+AJED5JT-Y0M
M,6MQ<-LZ;*L!<`;-/?V1772^H9<GQ@G:XS@[<'?B.\_'0*S>F/FXF'4@[A07
MK6=+XFKCQ;H!2*E`%8DD"NQ07%EC2[%)9G<`V\7J%-$J*T@'G/(EU;6RCOH!
M-<C4#D$7J"J_(-2CX2`D=1@EN@GMCQ/FQF(`#7P5RK,CY;.]0-4-9RC&/@Z>
MV9S184]^]4OG_1I)T#L\3D*#J0+FI>?C;(!9&A:[8MS@5Q<#Y'G7.F0@:VC7
M)6NM4#<HT8?.3+!)&U'`*V%S<[E328L84M=G+QQ45BPZ?4.T\&;(CATC>AX6
M$B53><ME2+""D_362_%=2OYG<X,)-L/4>Y"OYM$IR/6H\H*`Y-&I(:375=C3
M99943=<S%^*(RI^AK`2JBKA$12W,",C9`V]<LLK*B^@KMVG/[<OL6@P$(P"8
M;90L$!N39^@'+T$>'=VB$DZ-;=E"JUYP&1NO8P:@?90$:3)/$IPFU5%^G7`C
M%RN#BTC,D)!RZZ:!0ZA=QC)!H5GQ!&6/W#D?4=F&D>[W;E.%+UTGAD@?K-OF
M6P%VTH!@H0ZX>';LV!`[4EOH&-5)QO2*)%H1\N\=SB^F(+V).`W^B_W>=9C:
M12KGJ5'$E"+:M3)VJCJ6I)Q1*YC5I<Y0*<=V:=8E)V>7/ABB(8W5X9RR9(-_
M&G:`/;72(K37MH_&W)N7<@R$WBL`H<3UCPS#,4-"XL<!J\=J>XV_S7V?CBP%
MX<--'(7DGSZ[L(B$L_1WG,XWI,J=>[&-=)1!8Y`.0_H:U-LTK`PS+6/V$(VS
M6C$Z048*HJHD:A:E1Z6B%YRBO+13J[!-(!B!(*+M-`:HJGN1036!C6X#J@`<
M[IQ@"0V(MXOSQ?7ZZG>TO+O[LKA`\_/SU9?K]?+Z$[JY75V3?Y\O'#BF:TH>
MB,.G>TP8,<"6BY%7V_I]@+=X1\?2V'$5[*[WCUZ"-S?>"WL9X6XA&&U%T#75
M9N9?8-[%,!`;5T+B;`QUSVH;GM@50)4*E.O(#D(Y0TS-NWNJ!Q6*7`K/0+"-
M@+'3<E1F2FLNR[1VH&'<K#*P`=U=MM$@?[=>G?_;NX_S.Q+@SU>?Z6%O\_5R
M-?'%MZZ11QCGCX0^#L;^^_J+B#;!@2CK&_D%RL;Q2-(W&2GNB^H`X(CXJH_=
M"\GAU]\)Z<"YKP?BZAS@@`1U<\7_++PX)/VDY`;'K+H7P>[0';Y32.6?6"AE
MY`H4MLTX+E8N)J^HS*QX0%=!9>GV&<H?3DM,5?-%FM^Z226!<,41H3;(W%5@
M!#0G!40)FSG)/Y2+V^Q,H2+*_&R!93I/23++P%?XR8:,P$OF,J`D:-B%]9"%
M:GWD9R6XWI$]<@OPS283PIW7L@*H,U$QT'---GTB,V'5(PY$!?6&V><Y!E_8
M!QJZ?A`"'!/[P'FXT<L:!=(ROUB7AJ=$MRZVJ-&PU),DM;(STN5;GJ/Y]06Z
M6%Y]69/NW_5BC:Y6=W?H9G&+[GZ9WRZ.ATL<+,A9)02/C%U5(07/ZMJMN^/*
M6#_'W#-2PP"/W6PABM]L\8^3_1Q3D/5RXA9@-IUC%TTN*N4$SAQJ0E!I'Y9"
M>M,*XE(<TC@TY:9N3"%1%--D0G$Q-2Q-;0G-6$V'#7'#TF*-2'_\\-'UL)``
MFLZK"J9M5&("GPHTU:*R#NM1M:9'A(6.D!7BZ0W-9A<PHCLE(=9GTZ%:N98-
M%#7LI)>30XFNYX3#R8A^\VF_BUXPSB?3K@+O/M@%:8"3<^Z636WYPI.JY<TX
MHEL?0]^J849"%V7I62'R+LZ7DM6$SM"Y"SL]]9L^ZMTZ+6*IBM48IK8`ZI)5
MYF!]LUW446\]]_WX0.#FUR;63P]F0@\^(M#&]^EW^!G']/Z*SY@>\"7PY`*I
MEO_N2('02&`;QE=WE:NYTBY3^F54/D%?LV=3CR@HFJ]##GD[MPC1$N[2H*/-
MAI=M&;'B6P%0PH9L"YS<XLW!=\>+#H6'RF-"`V1$[\A..:0+R:*0N.V+Z,D+
MVOOLI3*%9^3+F`%?9M?0*PI42]#.+3'+3ZDM?T=?LR=3^T-IDT5:7[@%=9YH
M#>A\3<[`/$F#)Y*IK+:77A#_ZNT.N/Q'M:*2GQD,*%J0HE=1,ZX,J*4AA?I9
ME#"KCZ)9(4UW'5$QQ.3.:O]NW,7D1G8R!$*12=.VN-M#0XW2O>R"9CP]+,.F
M05-@NKP)_;6`5)A-30[3\0)26<6/+Y^Q1VO(CD^-\3\/./1?YM^#]B4'/4KD
MGU6KA!%1>]3)+-CH&1+S4:?\K/8$E8_05_IPX@#2I^VC`8W3Y*%&P8I^6E:<
M8UUV#EI>X<TJO,7T0+0@?*`+99(O872?X)B=O[\,]X>4/":-$^RRDW,^OK#B
MYSLO2;@=)MMFVOP&-P/C%"R]/9`G@:^=AON!-CJKI;WW+]EQF(@).-(1M4Z%
MKKNS2[JVCP2VQG&LX._CHC<^/+'Z)(OO>^RG>/-KM"/UWP7I"SW;5^)?]0IR
M/*:J()@/U*LAG%=3VM/S4PHU=<]3DSY#A3RJ"K"CVMWQ0YJ0X7J67G#C^`IY
M>3[[538AN][Z=D$[WJ/CEW:Z:P"-MNAC$-UY(6F#QD5,+IW6/@Z&1;WS:5$\
M051:L;J</Q*HX609EK]_(D'T*DJ2]C6X_0NVHY)&01AR:]<0DMHZ1C6HK58S
MJ]WFA<*(`')+8]4SBU7>YC\/2?HT^?JA`6CIDKDOTMI45I;G4%G#II6`I+0+
MM9UI=,#26%2?RL@*G*&\""*]@OIC6@[]0$NZ$H^L0E@9CTX+Q!^T0/SW#,0A
M?F#+KQS"\H<W]\MKS5>!W;_U<<`$(O>14XD#J7_FAU\E5/_F(E0GF9`K__E+
M@&/20(\O5_B9M+-T3DZC4'=:3EH(:F9.HV9@DW-R6UKS<S(5C32I?.[:%)T.
M%'BS=/H0ZD[42<IRY^JDMASD9+'"_(6-9,NI*);M,I`G"T4\<3W`^,8UH44S
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MH($PR5(`7FGY0@"^/=N+67A6K2]EL098=F@!W5KZ@%%,GK_;4HC&]-N[OG(%
M%JA]5JV,`]7)5K7/P_IY#)QUHT3@.@KCQC+2-5T_*@E#('KYZ]9-]$(N5#=_
M/]"5Z4;5T5Z*;F"E'BM%XQGTA-9Z<?25E74EO04#MF@5.AAG..[,2+UPG;E)
MC9USB/75[_(Y`[Y<=[Z@+0<U5\"W#S9/T%&O-4?0*C5K;"]Q:VY`T'Z\>0%I
M4W?G!)KBW/F`MD;G>"!GM-X^DN:DAWP`R;:]-B_MV8/AM^WO`>0G+%93P]]8
ML][:)->9Y71KR,TZ=[H^<22ZMGVK+;,<'VWO#9WS]?54O+O*0WO@7UE6-A,L
M+@L_#Z>JIX6Y88G)GE-R0DV2V>*:-ZLM@7++B?4"DGPJ3Q.'LAD]D0K%U)[8
MLG.DKXU5D?[99YP^1IMH%SV\7$8QKU\G.!`>3)]D1J*G/O`!X$'O`S^'T;<:
M_<:*^VD7S'JPT9N:&K2-XNR(@>Q1317I#N;*7/%`Q@B6#D&;D$(R,MU+K7S(
MNF<-;4^[]*J.]?D8A\C'9G!JG".-BI.4)*%!\HC21YQO1HBV[(_K*,6NK-)Q
MB&%]9G]<Y=AQS1==!2%>IOA).*0*J1MPWJBF>_*YH\Y[3C]_5*^2W3FDRE*C
MJR-(+PJE*`IELTM,,_I*=2.FW*%L!(X-H)--(K(!3CB5)F`GG6HUMY6]&%?-
M6B9S1`0OM[>7F8Q7D7Q7Z7VC:G]4G1Y9)TB#JE-BE>,B$M%VDL(5A?%,DEH`
MI1!\"QH.@U=P=CE?WJ)?YU=?%NCS8G[WY7;Q>7&]OG.$\+(V[?)7C8`V&3DE
M.-SBZG69*J*;>K5D)62!NK%7JQ[P=-&[@55>LCX>5Q-PZ`9?O4:6LD=QDZ^T
MB)P_EF[TE9JRD^C!XHHE8L?BBH>B29D;6<33!`Z9S50G;._^!_GF7K%DVQGS
M)&&8(ZX#D"/F&M"@"Z=<8U@B>WZ&F`3ZX-H^74G;=EFC!$*;,=T"'+[PM%KQ
MOEU#=GPO')2HW[T+'L)@&_A>F*)5^D@^87V]28XO]$..+U>V:QCB2NF++2%K
M6C_\7ML/O]?VP^^M^>'WMOWP^X'D>:_VP^\=]L/MMI7RA0\$"5O>Z[#E_5A^
M^/U(?M@02M0/_^,0T;/);^+`ST[6G/MI\(S19R_^@XY)TB4.RPT.4^*J=\5L
M1.Z6WSOHEH?`K(];A@3:M&[Y9VVW_+.V6_[9FEO^V;9;_GD@EWY6N^6?'7;+
M[;:5\H4/!`E;?M9AR\]CN>6?1W++AE#BI\<K47+\LX->>`BJ^GAA2%Q-=I+^
M_.$A9N<57P3;+8XQ^<+)510^K''\=('OTV68I/&!K;P5.>G!BO@G[?=2!'F(
M[H`W`#W3O)]][;-U^ZCEGGA>*D`U#22L$!WOB&-Z0E0+JJEQQ!4,QZ7HI-[A
M&&^[D=[ZA.?X]JJ3Q2.H>]3#3NQSA41L[>A3="!!,]JB32F/[G'Z#>,0>26?
M8NQ'\8;T?+:-E1AT32D]HCU;C$'^"FB024G7)TGIR?)H'P>A'^S)#QXS]$:X
M5+W\PDG*37>#3HPW04J/4*''?B?TW&^<K,+:&A)YN-<O+[A/1Z,\Z`GYVO6%
MO:=$QZS^,?EJ;?P[2U@Y=EQ6=E-)DEU5@I,?Z=K-*^>6>_7&F/!L_;XPY7L-
MM1KQ.?L:-;!Y,X32O,UH/#;\6ZL:J\LBD)>F<7!_2(MC5FB,]=D5"'2\,2@]
M-DKVV*>=7N1GI*$'>+T^5NC>[S,E+\:+G<7-&*OPSMOAU?8FCO8X3E]N"&[3
MQ3\/P9Y"IT7'?H7RSZQ;R,A%]*N963S4MB7V`IHJ9K4KN&A4H\(TFR[$$9-'
M98%I2=T3'=&PMFN25Z]LQ5A=6Y#A2\^F9LS2O9!K-)#2^$2E*#XW0;*/$M*'
M(QC=!M])MRY;@7_*N!2%E6F0.6(`P2&.O=T\W,PW3T$8T*7$=(:37KL:)FTF
M:$H7(4,E;<9'O;H8!@FE$0GQ%&5GN0`;2VF*H%QF8L9IMG;4LTE:#),7JE%+
MI1W4V\N-@79-+(*,NO4ZS+R:4!2>%KR$+GPD@(WGM*MAO#4QQ5VH(!/)/P]?
MQ(@U,JMFCEB@64P,;H%9]2NB/SMR#I*TL2*=C]M$/$^R@CE?CWO8YIS`RG_8
MP3/`6:M\2U`85IZJVA*MX]:%DU0%[<"!JOC,U*8,#YYNG8ZZ#/WH"=_1>2Y6
M.?[63X54"56!E"%FI;9-P2M2+D,QOPR]\GE#0^H&E0\3VMM<D;X2RTPF[FNJ
M6C'2_.1MQ'.%Z]`7:'.+`VOO>[7=2;2O4T>TP0:1*``EY+6`X(70@HH<@H*S
M["DBCVM;.AW:T:G5O%&?9N!QA5^B31B17LC^H,P2:&?0"IYH-W!Y?;[ZO$#K
M^;\O)MZ_"8<=49?//GHF];G2W$,J*?:XH#F(M`[@_K9'+L(OYS8W5-F'3H.+
M>2'*0@1:'6)%C+T$7^#LO\MP[OMTQ1F]81,'SYS[B?H4J7BB4<24,-JU,F:.
MCB4IA=0*9H44^J&0^S';.)6)HDIV<J;IPR$:TEP=[BE+-DBH80<XPU%:!)[=
M'`61;-5K`;[XY,$G28E&AI\+P>#&>Z%5I4/ZOA\?\$:\C-1,B3)@R)588JY.
MS6T%%87M(:26JE0&GKQT-MV:E7=G@:DA^C1<1`\4*UV&3)>.$Y'799RH)JL#
M=(_>#8HT(N&^Q@8O9X,SIVM.RX;^(71*/DP99O/Q^O#AW-L'J;<3#TST+"@,
MI^*"P&Y"54/HL"FQU\</"-6(PF-9`.4EG+F;8P!J),371)R0ZJ+R,GJ+;=H-
M<2*[EL.:90C3\'7.-D:PDU@BMN^??S8T\K9;[#-4^U[RB+:[Z%N"**Q0Y,X4
MXPCHU@]E8^)[TI!%85-U8M6]0%$!<8CJ%("FMZ!&X"&I:Z<7C]O%A2&(,;DF
MZ1PS11"0,5(.&S$/6^6D_.O8<)=W-S'>>\'F`F]Q'.--OJ:29+SL);*3LY1<
M[*-$R$\])<"<[5-S:!YKVN[#;2V5(K[GA8M%[BQX9SY@[L`^$T/425S"`/0*
MW82.+IGKT*N+W315IP[69QPF(@=-9@L>X$P@.4,;O(^2(,]GZPGN:Z:$?@[K
M`BFFC+&WT8NWH_V??#Q)&4]%!82QLUL`V">(:@0=$SEV^E"\4UP4ZTK!8OK!
M-28+(2!AK0(V0GZVR\FXV+5A-QBU[5D>*P'&'PTG%X?L@P8^\5I1C-ZA>9AZ
ML7O=*0C(Z0<%FZ";TMG?I9'_QV.TVQ#HT8W%Z<MMM-M=1O$W+]XH/;]6:6$8
M4)0&IJ967:$#A,IH'[;*=8E"1[W4GU%6#GVE)5%>U+D!>CU426C>!Y9"QDN5
MR.BOL&XW`$F-6XY&HX&=+437A_OKPK=^3)L&X6-&.P)AG*1Y&#X_D.Y8F&87
M1?K9'YT(IUVBC&H:)0PYKETG$%;K6),Q65U^5JR;HN,3AY"-7@1YN7)%210B
MWR.DVNW8/!L[:Q3?3WRJ41]\1`,:L,U89<$Z2S6LP,8>I<%^\4:65UD'9192
M<@PZTLFV@S5Q?!@7;>/'`?YI1(*G+?\.<]J0P!8,.W0.>FG+5IAWXJP@45MT
M\"T]"Z@EU$6ME;-^6LK!IQP&-W+#M>%C;&:5RS)MZ"E2TJ`[NM)]U$DR`_-Q
MD:X5J.`<J#IY-<%ZL`TV;L"Q\>4Y(;73+IW(&6QX(3(`[_57FH&[]`.:LN%>
M]D?4F.I$:&ASCNE/GG%V`G2VW[:H9<>WR,5*/R,2,\2KW#H(<H4F9"@6%*KP
M'+`'4R-:T7B1[H=NXYPO7<>\2!^L.^-;@>L]`F(C\W;%LWPK_%GI,XX=*6*?
M:`LKT_G*:ZQRDS4)@8=D$J#HK]F$A7VF6!_Q5)X'=?*[6RBOMY(0X-VF%"";
M"(I!S;38]'W$`'!&9PR"1G[G8CS4;7]=WV:*@"D\6D+O99J'FVPVY@[[AYAM
M81%NI>M;L./_U`6!B*%;0RAOJ6%/AS]*-;/E]:^+N_7GQ?5Z\M.">J.!P[.>
M2.J03U6>QTFU36>HFB0'.IVUVK+)4U+GW[PX]L@K7$;Q'8Z?Z=7@J_A\YP5/
MG1T,0\H6A.U7UHRS0^II2-N>)B7,[:5I5HC3>4E6@$UF%D78C>Y%(43^G16;
MF.:#8!09M6Z+['U4U/C>SS)H?M;'-&SF-@VRV;W8#,_?,J%BQ@"]0R'!EI<\
MOAX4"S-&!W`\7NBB5W^F^=6?]*SW[+#[%EWD0OGG$PD9451NV2R\"'6+V28H
M,FM>)WWFTL4!BK:+]+YTDR)\V8H+(EVN@IYSC8!,1`!X@"L%9%9AP:Z\7H!;
M0`!T!ZX;D+:7$.3BJP=XDF*`NW4-P15=R"D:'>`_+"#=>F@&9JXE0QBW=4H`
MW!2=72WF=PLTO[V=7W]:.-`Q%S1$)/]\+90V9&KX;)5U"YFK[15.$HS5-P1H
MRS?P*Y4'@+1&?2!0+C>C`KZL]"P3H=W;3,C-"P3T6S_JW4`\'DF*M:DEM0#9
M1U6:`^V76@8>NT'423<,"S)1UW),F(WHU*M#M<ZY&R_$`H7;Y@B8L49HT=`Q
M\_1*"-$5G]5^.T/YKQ,S0-P\D?J#MA#>D:M!FJ,#U%5V]/?TC5'J[22^T;3M
MJ?=;K];S*W3^Y?:6>#YTM9Q_7%XMU\NIKY08!@&AFP,%P22.[-(+XE^]W:'F
M><5.32+<=7!<82C<2VH"YOCX-K2(P"O:=(A4`C&16DKJ##=D#<WCB1H87<9P
MRG#9P]5MR9UR;,&FG;;0Q5PN=>ONG%L-"R<-%VP14%/FF*+A+:6@,.>$&O92
MU@`Z!]4;#A,7X^:DSISQK-&BDAQ%,7XFE)=E+';.:!;;L>5K8>##SEQV/Z$=
M`AK]!!<2-I-X5;$;%?M-.,"#>T9=+#=\GS.0E6)4"4DN!JWY*EM];-T6K'K5
M+CH?:4MJN)=!;3F)`YF'F^[),>HD3:M8U_4HBD&!6ZMV8$Y+94V+#W(E=7?'
M%C469X:YE^SI(8/'JSZ8ZE).6IK+1X4]2XY7:M56RF@?HFR.J/+D:'Y]@>[6
MJ_-_^V5U=;&XO?LS6OSCRW+]^ZGC5",XC(Q45P9BU4%%HY#6P"Q\0-&HF<V!
MVKY,E:G0&+AU,:SH8$-S\$T[I$C*Z@[%60\G$ILCCO4"`I0%DDKR7TX9@<.&
M@6UAT)W^1\]^1\_^AN5<;IS^A5'2)NI/.,,U>3-K)V7#4C']%&S<3H*M(1MX
M?'$'=XZT2]`?=4.[`'"X&].3TRL)\'F4=.[XXCTJ/73]D2%INE9,/6]#HXP%
M-<%9_A=B?TX-:<Z7CV1?K`W42J(.RGHY6,=7:09.6@<T99:`TK_I):-.G,VH
MWZ!BWV/:I*/[E.06/^/PT%W`Q7W:]"S54PA@MFV!^)>:4B4N2]G"RR0H_\4)
M7';:H@U-06,UL5D(=>!9E;;@=`KE-OS.D"9N>I_X&%M9X8.,VWE,3Y0&#^RH
M^W,OP>)]U@JQTC>)Q`R!++=NZJV$VF68%A2:54\0?>34CFM5*T:Z7[P->[YT
M'?\B?6X2@;?O6BC`!3_$GFNA14C`J_=;=\4[('=BH[6X@02XEFRR[LB)L.S8
M!NLH?%CGV[_;^.4\JIT74#TR/B>@;<7\?(":1OFY`*5@ZSR`Z8\`Z'SZ2/;)
MNEO^"XGF5O^J'&CB6-,,.R0WI"W+I?+'THC"[-"X&:=Q).6$B\2C=&0XKJ4F
M`P;/CETX9U-7K8?4JD3G.))J%MH=%'?;C`MG4=-R4%V*\N%=TV3+794F8'N[
M,+"@GNP6^U&\P1NTI8AX/FY$Z'@Z*$Q,X_L^>VE^N.<MWGLO[/3/U?8F#D(_
MV'N[6TQ[,1L<K[:70>)[N]^Q%TO<I(DZCD<=I@Z,;"9O`^>G!]9"C[N#E'>\
M?Z7E#%5ZZ"DGI2;Z(-=%?\^T(:K.'?=@A%ZN)P'@`\?E#-'*]T[#ZF<KN`VI
MC;4XZ!SM:'2E'OV-+R($'"MCI@G]'U_R=Q%N%M$2YH1MGC"8DQ#7!"[D<FWH
M,9M3M-M9JH)?$3H=V@BBU^I<^BI1PJ%FMPR?>#S=M@)1UY:U,`,*-1HB*@=%
M\ZP8__,0Q*0[MB\\%"K3L_L7].)4_F4.-YU88`]PX_OQ&P+G1X^N_WAZ"MC=
M#6MZ<;#`D2ND6YY<*`U",T5=8'RYV(B:8:*R-6]>B*!*!GUE4H[X<%6#=UBE
MAY`6J02%NJP2:G>?5E=!B)<I[EPBTJ.$DEZU$I8HUJF3+9K5#0VA6E5>13<J
MB9BHLYSK(D&#=R+X*+E7%M3A7\V*C5Q*8M!*0F41B.RPE0IW=,<%`4,:A`^8
MY%63'V%A"7RJ?&HL^#DY.+X,:0]N_2T:/B#>4=%_$+RF8JR!N$ZM1QOLKEL&
M&6FK%`X9U$9!F/7BB0(W',`@S`T9BA,AM__@6ZEIT(!;K1X3#4N7-9AJ*-H>
M*?(AYP^O%=L`0\LCH7O\`%F[+E(0_S@2K?#6D`#A*\<F3'!J*E;3K"Y?"RVU
MG]T@%:^1.IP1MV2+$#7!+MX;6FPXZYH!*[[8``/-"^Z/M.U5[M"=UO_0I_6?
M<7P?V6[_#XU;WTG>>(YC3/J.^(Q>`?\7Y/E^=`A3O$$'MD;"CY(4/>'T,=H<
M*5@^C`,6%T8'/[Z<>RE^B.*7U9;V9PN)C>!^.P,MRE%$A19+XSI:=;<UVJ@R
M/F3@1ZYS5CRDW4'ZN!R<W+BQ5\009!IC1'W0JAPUDBK3&4E2U,9]%R*HOO!6
M6`,M2A>BT&+)A6C5W98+41D?XD+D.N43&V=(YF'<V&UIB$(-'],'SDH?(U6F
MXV,4M7'?Q\R?:(JI[4R:XDJO48A;<@_-VMCR`Z65(83/"ZN8G8FY2MY6JVNP
ME(L3)1VS4CJ\*_2/,T.961MI>A(`;G1D(?^6)%+XU10E^;+[`GY/GO\8A#B>
M^GPX<-3UGZ"$QMV8CCU)SNMSSORU7C*ATHGSA0PI);-LZK`%NF6\X1:9T=]1
MXX$K:[:D#1?I?>8V"WBR=>SS=3F+^"OA,BR5H`CY5V"+KE0U``DD$B,]J%`5
MFYVO/G]>KMEUP.QXQ_/5]7IY_6EQ?3[];1[J1A6S0@0`$3.N>.M6Q#IA<Q&1
MG7Y92`_W:8H;=L85QY%>N;,:#P([XNS")GK&\Z^?O>_!T^'I,WZZQ^UMO=QG
M^6=H/3-"/]>.&=S;*L4(;TK.\C_1U^R'B3',;X%(^N&:.&V(5-!LE83T90W5
MH)VH@8U*/=4OP<,CPN&&;8@A928^D:!/NXH\T-0M"SO!.K1M/Y24/:(6%<R+
M0K3HB)$C",61@_>LB!S-9V:(Y-DQC!PME1(@-B1G^9^N1`YN"T32#]="8UVD
MAL9F25#_4E<-&SF&-6J6XWYS*7#T:%9AX)BX88$#Q\"F_5`R]HA:5!0X`%IT
MQ,`1A?CELQ?_@=/+0[A)^!%$*E2$$H&0&5BEE@V#BTBW!+7\(C/V.\H>(/;$
ME<@C;[E([SNW`,Z5K2%=H`O4B7%MP(8I*'BP4P`80)XR@&S)LV.&A3"660'&
M>+[PFB[^QZOM:H]C=N!N>UA;+)!_")Z`$<[%%LU\'U>O&-@<\5GV&TW%JE_1
MUS7^GJ*/I)'^F-CS2=HJ4G_=)K"[<A6H>3H@/5U7/ZB7,P8"]6X7B[OSV^7-
M>KFZ1JM+]/'+W?)Z<3?Q=,4P`(A\&RP$1O1I.#WWDL>;.'H.-GCS\>5+@C?+
M\#((O=`/PH>YGP;/;,-3-CA^(+]5[R$XB0I6:>$[@92:L0WTS0Q]-%1=)'2&
M,3$C>NC!_(^HT$0/,_J!*D-!^",J]:%*X1FJ5#8BB"/G;@%C/+*#L):3`M%=
M<VQ`=06-AR!U@HVAQT)4=FC&_.X7='FU^NT.W=RN?EU>+"[0Q]_1Y?)Z?GV^
MO/Z$YN?KY:_L?LDW`NH`Z!0H.'D^DE=9]3YZ>4A/9?+\0UN9#:_6\TVLY!OZ
M=>CMOG15J_*+4H\ZOW#2I_4%K,J7#2.`W(-IZE1Z+NVZC9`T:-8%]$X:9UE&
MDP/*,Y_R[(=#P:VHY)97%G\CD<:`P5'0Z%@"?[^!B(%*01(!NP,1`]]LRL3`
MI'_3UP1@HN#Z0,10C`.YO4$#$3UU0SG!40<B>M9IC($(]XC:&HCXX<O=X@(M
MKPE!;Q:W\_41#$,X0C\[V<=4!)P\&QD^YC!\@&&\T831APZ@>C"#!@6.I_MO
MU$TQ[M@/ZGY,UF6?JG]N$\JLY[U8HQ\N%N>WB_G=XD<2"[-_D7\@%BC97D#Z
MC\4_OBQ_G5_1#8*O`\P]0]QH<)X\6&6'L@&-F?=4)@]IVLIL>(B>;V(E\.G7
MH;<#T56M"H^EGB,=,^\+6)7K&48`N2_2U*ET3]IU&R$`:]9EC)@\/<L$8^9!
MR2W'Q\PG(E'/D.X8C48-_,O0CYXPW;P^?_:"'3T/9!W1,W&B\"Z-_#\>H]T&
MQ\E'+PG\;J0?4KH*[?U*FSJ;(74U#MX]C4K]2"]=S&UD)=`/M,R/J"Q%@9R5
M0_6"9X@5G=R1#`)59-C2'4?11TG#,_2S#AQ1^QB'#J%38;WHWEZM)E\2/C)X
M)7'N%<"WU]92]<S&9/#]D#GK'9%^9?`5['!U!;Z3C\!HKL($W3T!NFMBTK78
M+NR2L+CH&G)7Q.1^!P*P0"NP;:R[AEIO[=)6AS%&8*9G66,$9E_CV;9DE^-C
M,!/1R,X&AK&(-'GHUQQ+ZK=N<:!2D,D8N^L6![[9E),S)LNA^IH`G*QQ?=WB
M4(P##3T/6K?84S?40/2HZQ9[UFF,=8ON$56X;G%Y_>OB[AC6+3I"/SLS0%,1
M<,QLY-L\NYF05)2\54C^Z6-V,=\\W)P_TD/QDF58EV%7U^ZP.!4!TUCF(0`:
M#5T<V#N99B`0%9%Y-7/]L]O%^>)Z??4[6M[=?2'^;'Y^OOK"3IVG.\2OR;_/
M%Y]=6&\&!]3(`E+:CLQ8<=V+`=32&1=&FIBXY%5\X\5I_L?<_^<A2`):MU7Z
MB.-YDF#R;O37&&_>MUW6<`V%BQJBP<PE#:\S1((UR+K$[PS0-V._(H_]C+S\
M]^SJW=T.?<(A3EX21-`:)G3()@HG]C<&*(L`FKWE3_HKJOF/(;4`[7/TKP#4
M71L.0)^-46:2*(H1+5BT)ZH5/4,90[+2J"C^.ED@["`XQ@-GXF;MBNZ!<5.F
M02]N\C78]!RR.MN/FP+K@YT'5U_]GOHR:J:/<71X>#S.T"D%FJ[3T$"KGLO@
M*=)V&?Q:C!@Z>148*72.@7[MT%DK?!R1TQH)!D;.T6G@3.1D8?\J\.Z#'1L)
M)!G`X6E8KU.BI4?/DZO%>OXMJ;O]#)QOW"P+Y^GLDX?7RJ-<@=,>18G`7OFX
M&LH],G*.LGY9.;<V8_=0.96`G09SARCL%FO?CP\DU]S5>+`EO-G@+8YI$NI5
M>I`?)6ERAL+,PNOFB4G?=0JF.!.)?_5V![S:&L=BM1Z]:"S38]/;J.MOW]M(
MZS#8WTBTSNKQ]C0ZNAHXU/4UVI#6\S5B==K>1E:C$2.SN!HC=8/')HIVEYBI
MH/>S'%LB.PIM!@;I28DS:J`N#W[-MNPLON]QF&#1*A)=^2KPJN1-G89>?8Q=
M@]*,U`4H2L_J(N5VX5SJ1W>6>FJW?M2[@3KLE!=KL%!E`3A,R<U!=Q5M`H_&
MF-7ZE\7MZ>%*XO='0]9X?GP5/WAA\%]L.>-Y%";1+MBP/^;AYH;@&8<I^W.U
MS3=F>+L[\DN^MHCOZT%UYHT`I-.(P:#O9197H*HB=@$P%F8?YW?+.WKGV\WM
MXFYQO9[3.^"F=1JP\(RLH*/I>D!45^X)J*;.NS"Z1SQ9;>NO]/&0!"%.D@N<
M^'&PSU^ZMBZ2%/9)PDUOJ6275.JZ-DA;*I<'8\N.*X3\#I9<)%`5![A.$,NS
MNGJVQZLRD)T`E-`^?=T(^3DW@VIVD!=N4&4)%:8<NJ-U'+JI7;@%=JM<.X1)
M#9</\V;.A`(ZP9$/J#02[[8;5\D5+E@L9^8^5?8-79]$O<1M"4OE*[.+0<3V
M,,/$/D+9EI'V9V]Q4R1>XY58(^38@=",YIC!WS/$A/B!I'$;\:@!,'#8*`&#
M3AB%[QAV`I)&3GS,`@1@1(,$-B$SLAN]Q3X.GNGY2\FG.$J2\T,<DQ#!\Z0*
MT;HS%8J:\T-1"P"7*K:@((>H8,Z.VN,SQ`1(7I>).$`55>M&?5J!0Q=!B19C
MA'K!_:S`$NCPK!4XY6MR:)J6H+B4.14(27VN51"-['G7CUZXQD_[*/;BE^73
MW@MB.O1"S\2CNSC+E;0W44PK3%XJ>B#)/=VWOO#BD*3HR37F.FI8S76_#J79
MG+ZP[P@0-<`JI/`*0';RF)02;:A4ARI]*%/86%%_AG*EJ-)*-VX6>L_HN0T.
M^"%@_$<6@<?Q<3`&6BX1JM;@81BF8C8Z2,=%:)H5U':(!161_4<O?G`A/3@"
M6DJ3CS=B#OB@D*<_'R,M/[S1$A)%IT7+D7L<V9YV.BB5=8A$"SMT9.N]`K&L
MN1M2U0,@<Y>84/@(8<E9_0B',U1).+-63Z^1HUYMP2&GJ$B+;F+-X'%-9`I^
MX`<>5^5Z/#2_NUM,?1(7)(2DB9=E$(T_<=E:-BB8MA1(M28M.U(@4U`"VS`3
MEEWEZEFG=IEJLK*],-H!4D@:KS/I)&_EUH132[@[W=319F-^LF4$WG/"8*2:
MEPQ.`!BJN4AH:$RUG*,XD37<E&?$+^ELLBQ9[5V8N_!#71AP=E^WII!+1#1L
MZD[_*U5U%I.45V&&F]J5)ZR06TEQ?S`)%A+T!"-W;8%*AVC!@=JVO84K*MM6
MXL7H"*_OOPP:Z';ORI%Q<:VW:F8J9(\<U^Z\'4YN\3,.#U@P72L0J<>HCH@Y
M7056`>)-5[."<^T"Y7H9]HLKLXJB9HIT/BN'"2W)%MX[>L#]=<L"O%<VQ4&5
MO\?9;\<*`JE#!(7!V`/*V=%`M2WLDN6#2N'&D+)8&&`(4%43B$%EB0W5Z)^P
M:#&LG)_(5)-P:26ANJ&C?LW!&Q(4E6F/"8IUPX\LBVQ9&%JV@*[*W7HYOG"V
M8MF%Y!4,4_*!9MNH&L\_WW@O;()R'>4G<=[$=``H?;DAX$A)]KP@O^Z?NKZZ
M?\'\0_8I:$2V_C4$6134RZR8A#W4S&[(-WCT$G9ZSS;X3L_:8W,<TQ)R`$*B
MX6W7I*E^^8JR?6Q"!@5]NU!'5(T.41HS"FGZP7-Y5!0X0ZS(&1L7*4N]!OB*
MXLRT`)XP_M06S:@B#D=4%&,:HK!LY=0"F)U-"SWX6"_(Y5]-P#&R\=I63"\Q
M$D1TJA\`+R900Z]5GU^S!+Q(V0J<F$.O91U!^>A4<*3MF,&1-&WROSG0R0B<
M+9+1R/FY\I)4OR4/GCEQZP.?+K7-],N2FJ5%J5$NE2\/=(Q8PJ:7)D$RM$@R
MGT8Q><+3LF`[46^8L^VY87'7]N&^MP]2;^=LW]$4;GU2;5N`F]"WWSU&<;K&
M\5./#%M61N3C^65@B2>K%["O%YCJP3NN!J[/9Y+O4B+J<&8NQ828C1I0$O&1
M5U3"2;XEJX&`9])V,+`#S'902*@,8I`,7@,DM8/$"*`<,5C@,,D.]F+S%C=1
MDL8X)=6F]?R(0[P-TN0B2/Q=E!QB+#H/T51-$5(&JS%CM6'M#0//<.L2R@]5
M.LM+L@'9;+:O61@5I5%5W*&C`HV1&$&AHN5&!FJK>9;!]0&-@`-K`3K%[11E
M:."\7:R7MXO/B^LUNKF:3WRP\?04$,929TDP8L2-\=X+-L5)\/F+9)U(_N*H
M'B6*.*I3PLP-Z-?),#IJ&9*P6J/\+!="Q2%]5>PK-N@ZL7BJ#Q"B`2W5(JNZ
M8(V7.E9`XY#:(&S(L8]#U@/+D5BLK&)0C+)%5RZ,SEE"H#!@C(S!,<-`Y&.\
M22[)=_W-BV,O3!??<>P'I-$[_E\M6CI^F:@AX=2U,'7U4@LR;DD*SHJGB$(8
MY<]1*3`UH33:-NK3!FT"B4O4F2/3"^NVQ9:`_;4%,&4>N@ZG;YE$0AQV)C/Q
MC7EP>!*[9-N(FL8)%P-WEU',XD:Y>6Q>[M&3^.4>I3FN6JLT&.]ZU!7.H>L9
MU:.ECJX63W\H9UVV4?QCGMQ7NXSGCNS#'`HI+J/[8Y)#<0TE?-9K6;<56C2,
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M2(6)D]\$Q-^G1&B+8WKZ[^GA4L?KVT;FQ%&`'<>QVM+M=NF+3AC@%I#%@58!
M>&)R:V0A$K3M].1DL[@P%L2(RE%J9I(.LHX/`3GM9+"1L:Y13D&[E@WK$:%A
MSWY(@,0?.^H-IV@O#`S)HQ?GL[G%E,$I0K%7"+`&QFF"0%9#U48Z[0*<("`J
M`,9%>8W@@H#0CAX)!<5;0:!P_*[MI]-'`)=X6JCAT(Y?CD\[D0U;,8!OSUH,
ML`*_;L<@R0'HT,$L5K"GX_3MHV]*IZ^SPZY7(:'SM[''KE?-H(-`_\U,>BH$
MP<#)C7;]H"%A9H^M=EIE9?P<8;.=EDW+4<(2/MFF`;S!3^Q3.;O?SBHR]>/&
M&-B<*'[00:T5JU-2+)#:R$*'3)X7-?CR<+R4U0>:D`);FESDEFZ%B<;X;0:5
M<F6?2UR4HH!/0PW@\/C'*R:@'M^"M8C`,P=V3IY=V'7["MDX>"Y7+DYV:#$I
M%.2TG+YET(WJZOGG\`DNJ]&6KUR]2MZ4<'KU,::;THR4;HK2LYO;U<WB=OT[
MFE]?H,4_OBQOZ%[-R=FEV=91[^;H<$M>K,$ME07GN=6]14-'5,4H\ULU=&IA
MB4>JVQ6D!6<WS<-:FV>U.G#[AE;SJDDDO(U#5D*#.N"W<\@L07>'X?'$DA^N
M/R906KCJE'M#29+H6`:3`RY8X\28`455+MK"R3`#:FG)A?<^SJ*/(KF+=_2D
MER$(4E-7_T27'AHTB&W_Y)8>EL>)(C8A+8XRKP6UO0/0:+@=,4#E!]JM[G?!
M@T>KTPY#0H$BV'`$S&@HM&@8.'AZ)5SJBE?'_U4_3DP6<>M$ZN_9@GU'K@9N
MC@Y0U]O1#^M@39L^FXUZ\H*0;H:-CKKUA6X/M/W'<V'_.'@Q:?_=2[[%T-LM
MPVT4/[%JBK+K?H7R#Z5;R(@*_6IFYA*U;8FYHJEB5LJA4A#5)!U*FWM"(QK6
M<$WNZ96M^*AK"])'Z]D$]=NCX9/Z][O%U>)\O;A`__@ROUTO;J]^1Y?+Z_GU
M^7)^A2[FZSGZX<OU_,O%DLC\>,H0%06(:4#J2""ILGC!S-3`TCJAA5?:'I7%
M=;48;+A&![*:H^MDR"T!DA[+E4C4(7M7B2;K>=9=H?\M@1J>?P_:"U,[O^<?
MJO:[$1D[^LUH5E<G)E`E-6/_1%_I'Q-G7MTO'0D_4A.MY>,*A[423B'L,WZZ
MQS$/8\TG=9053\QQUK0!@+12H0)KN5R!MHN(=J9=P%OKJT>2S\7!7";00EU1
MRAG<X023S_$X#S<7^!GO(C8NF1\#VD:BCFR!3;FL&5IUZF&(7X4)":*E)6?%
M8S9)5!,HCD^>&/5:+1SU:H@6,V1%:ER1:X;LNTI-@799+8$J&X"LP6I3B9P.
MG$0]SS$`-;4[7H9LV6;223_UI*4NN29M@4:=NEBC4=U27R)596?YQ4,;%(3O
M]MF/*#XB<G4;7T$O$5JD]"H+J0A6TV[?9Y?&H%:R6T1:QVG7<X$@1+G8:4&L
MGP^'!]FH?CR-#WYZH,<5G4<)G?6GE8^?N<,(>M*5'Y=+FU)+IR[&Q%(8D1)+
M6G;6$$!K\LINC&!H-G+4LR4Z5)(5:E!)KMT=*J5>$.+-PHOI#'LR]_W#TX&=
MS'N!MX$?M$?;]0N4A%(7,.24;HU,::5A1\8L9?%9(8,*(?1#30SE<A,/D_=`
M0-2_C=J$4Y6K<TYM`S9-4MD#[M]:AA]-FNIHVV0_GR+8Q*G2F'";SLOSA\*E
M0@)O#C-`+K4,Z[5UALWY13C>^6OV:/+<1]IP0EY(Q]BYLF+TZXV\0\#"JE,=
MC(ZV\[QPT7GV`X:NDX2!QIC.\!F'!TSW:']BQQUV_*#@>>D".\\-82ZP9^KX
MNFIEJ&Y+S_*?LE,`/CEP,*2X82+EMVQ#N"561V]'`ZQ/:ZD'=F=&;4Z=&/L7
MBK-'Q]?>8J<%U^*CNRJ!AQ(X)B!_!.N&M)!8.1TW/(T8<'*_T@67'2_2UWE$
MJ;=3.@^]EJ*N8DWU.>4J)`VF<`P#FFQ\-R!8`"MZW'(+0$M81=9@W(36(M2.
M<.DVT-?BM\G[9((VZ0!3OAJT+=6%J>YZ3K-6MI&F#&ML-K>W^'5Q_65Q;$VL
M\D'FC3RB3XI>O%WZDE>P[9&X#PM_U'IHAE.N)4-?U-8I`6=3=);_7;3HQ`#E
MMT(D_W8M:#9D:L!LE07U/0W=L)YG:-,RKY,WKAL93Z_&%7H>D.8=S^O<^3CT
MXB#Z$B9[[`?;`&^R!<TM("GE\L\@D3."L-*^F8>2J1<C6EQJ5CPZ0[6'CBP6
M5[=EI/W9F^@7BE=$D&ATC1.748Q]+TFYDSMRH18;VD(@5.!;!O#I0@-J)K2*
MS(J_W0"\H*TZ:)>V:0OJ3=DNSMNZ(.,ZWP;4<D(P&+`MR:4_+)XY,M=GA@U1
M&C`4'1/ZO$>\.=`#U2^](/[5VQWRNSCFX>8J\.Z#';OH^C/VZ);'S2J\Q?XA
MIHNQ/GI)D*R]^YWP_#<KNDL/"ZK;D(X6WM.4P[!5DE$?TM*L4$>O2Z`*$=-X
MEE_KQ)8@U[2B0BV*0E0J1DPS^LIT(V=.Y;!#A\@J"MO>#=!$W2F"UAPVT@)6
M#;0#?J0,SW*"BN/;\B@=KV+XKL9P$B>C>$,OUTK1ECJ$9UH!RG>//LL9?T\M
MO=&[/Q)/C^!3Y$Z?/;I`G;[#:GL5A0_T7IH+?)]JID?]BG<R(-WB0)ZP7VVA
M\AAMJSJ.3%-9PU-59>A?M%1VQQ@MYW"NT1-;''\S")T=AZ*GA><S=.W;B?MZ
MUBV%]@E`WP[03PW8QSC?=[HGWMD/]B1N[[V7[+*N^Q?T@KV8R&0K-TE3IH\8
M$90^XS@-*#\2'`91C,(HG7IARO@$4<?<J2DR1>2<AVFP"78'>@GH'8WZ["T6
MW_W=@21]="G9>?2T/Z3L[*75ME@*>X/C.WK=-GM!85R%5-Z)NC#*@;P4Y)M"
M16R@.NFX-A!3#;=7UX@JE:C0F2WFK6FEA<KM#$0Q8IKSQ,"9;`"4$1Q7:(%Q
M'3<)88/G1&'J[IZ+9;4C'2F\H?7'8<)>8![']*`G%KH_OE0R-UDXGW_SXHW<
MNP+I[3A68[U`/A7H_:#<J7EU=#RIJ96&$V6"[^ZI)*JK0W5]-&^L"^8Z$5/J
MFO^$PCS'=<+2J>,U#=7S'*9QC9WQE:Q;4B3.U[1WTO9Z8HG"?_$DS#R1V"9$
M)Y.K7>(B./*S:A3$T5Z>I-DBC>_<(E-7L$8+GA;0(8FN`;`9?W,LL&&#K-W9
MWV?D/R$=Q)W\`*JA&!#VUX%1,+:;8Y4ZSUJ&Z^5X`@TGUQ0``#7/(@2B6WI5
M@&Z(M]!\[@Z4N>T3J;\H#\9UN3:*FSK@75E=/^SXJ6GC4V=6?)1]%!?=>Y=C
M7%]0R+T;%"S&]&VD:3SRD>@94=WLC?>P]&G-AX;(YED"P71+L0S/#=%9^3<!
M<#+UUG-!4T3R#]C&:%VFCL]F65B75=<-EW@-;-4LW2K:]?S8VE7L?2!:=D2O
MP^T!M[V/5*CP0@(A,]!*+1M"5Z1;`F%^D9EHF&AB1,N;+=+[R"U\<V5K.!?H
M`O5D7!NP"1@4-JB;6SSM=]$+QNC_\I[V_R_:!#'V"9U1DD;^'SEJ_!-!C=`O
M6L'-U'ZR-E(H&BA<L;HGV7$BR_`&QT&T^11'G3/&+5J0>FA#"Q:8#/+.-F*#
M:<7Z.@\S>\*H5)^\D,Y=G*%<_5E^Z!,[,)N9H+]$4Q^;;9,R"C\'R4NIBS0R
MI/*OAF]A/Z@;57"$C."H/`+-1?*GZ($^)GP_A!NZN^L1HSVI"/J!$#RA:I.)
M3Q8^5FKWRW^.E]Q'D'E=!2%>IO@)+-'J*#3-JVH*I_&=G3>:*&NJU\."2ZS4
MF^=$Z"O5AIBZJ1=UP`'9W"6*R&'J_TJ]`.ZN5D<G4I>R/FYD*F.QD`W]'M'8
MQ]2,`L\I)N'4R!G#31QTZ-I]4(_@^0-S5]"P`!!1"WT*3F9B681#[`\'R-3\
MVI'X.W&@S9ZW()J7`7??3"^\&^[3=-0MWI!:/A**T=U)Y-UI=VP3[79>G*`]
MZ:>QKID+/3-ELTI]UN"&=:C7(5P9RNU3_8:#AT?2WY[36<`'O/B.8S](Q$YJ
M7,NZ_1A(RW8S+OAO9+EG!%IA@^0-L!Y:?2WYXGGI`'1A'.7646'>F>`W,HOU
M4TYK+D0W,X6K0(\4%O*M1^T_PE5\W([FZ3DUFJ.5?L?+_0XN_$Z6M$5;%+5&
MV9W-XUZ!AQK<>SYQ'W5$N73Q7I.DTX.,0V74/8U/&X8&?:F)\^J^=;88A?I5
M!3:[+FV_G@1[&*_A(IB)7X$*8;WJ`!C%>KZ[4\EVK[J[E6\?J[/KF7473TXT
M[SXJQV4M^SX)U^50#BYZ[>L#/=\[/RHAF3][P8X>?7`9Q:PK`K6V1M.,Z8H;
MI9EI%@)HOOU$JW/4M;.P6D!E%&)U<V:C/.<E0:49M(WB;,C9\6!ARB?S90K]
MF&NZ=$%A#6!!@_)]G%@ZI*BE&PN*7'0<-)>L>)]DO$\?/7K1\1.[K)QDF'4O
M$"3)@>U1;2Z5?O,+4`A]+9[A^)*]0_H8Q<%_X8VE+*^C'SB]J^EWPDMWWM>-
MA*Y>+?L.N;)F)X4K]9^&A^YR!-PUBV@([)%+,_"NN/8&+F9G9?6<3,LFHC\W
M$2/_H@D6*1ND+W].Z-+P)^(/V$YYY%4(.OG$;$S:VT[%7"#^$21?^0`C22>W
M.$@/]/7"S>+[/HB9AG+`$2H9ZVL/Z!0!#7N3;B36_A[3GC"@4TU[NXO5UD%/
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M2G2"EU"@#>LKJ!.VA!:!`'VE=_9.5[SNC:^<.9E*W$!=.(L:L8WE*\ZI-1P=
MH`,Z'?VP(S"FK9^=I)3_>HQ-+APE`&WT"5S7:LM.N'J,=AN"@<4_#T'Z,K]/
MTMCS.VNF^Y1I.SAY&1CPZ]0+R`TJ3&EP0ZJA(@N;:JY+_AEELHZP2`L+76+U
M@%";:;*B'/+)+3G(QW,O>;S<1=\2-0V%HEWV<42A2">L!1C7>!:T*-8M.#N/
MP@WI_N,-:G*,BB(FZPRSQ,W+(Y0*#%T>=4IPZ</1ZQQK,EK3D9THI`TJZV7*
M9-N\X<O"$$=6#R#F"$QH4(=;<I;]BJJ?W>J62ENV2QD-(+0YPRO"(0U?LW.L
M66TO@]`+_<#;W41)P`9$E3%'6:0;>R1%H&*0LE9@L4AF22LFB1748M-';\>6
M#-X]8CSYA6-]&I\7F70ATXU0PI+<2"6QXQSWSG=>DN2YJ2Q:B>3:+.O*P5!+
M9!^(3QSU&B3JE)JQ7\JNDEMA2=B$7:XH6KM-D+8XAQ5=C>Y0@51IF20'O+DX
MQ$'XD*U5R!;,9O]>AGZ,O01?X.R_'9(,UE#29X`&0V(-KK,IY888EI&QO[[L
M-'64E4)9L?(4GZSD6?XW*@JC'XKB4R]^,D!;!-#\;1_06U'=.PRHQ5'XC;E/
M4N\L^'=#:L]R.CZB6<Z>9^#5SZ(_:)D;Z`4:6K2X7R_A,-NY:-'CN`1H.LRN
M%]?D<],B[*R3IEG@R:A1@4NGKI;%#BYV-7VVTRO;![8_Q/01ZX^<X]T.?<(A
M3EX(E(D#_0LBO8\P(1T0NIW`G56\(T!;/%\V';A'#E'YXMS/F&X$X\4BKD`]
MZ+0$S+G*M0@01MIZ%;1KBN>!H5@"_S7[>?+.F["!(O4GY6"^(=<"=TL'N(MN
MZ(?WQ2:M7UZQ5!R*=XS-+G5V8`T_>8;]J[<[X'J]BR/D.CL]AY:79]RR\C;R
M&'5]K63@4K.]$QJ)-FE&SLJ=H:9O+LLZP-)!^%(E,MH0E:<S8C7*M$96@Q%R
M=['Y,7+XL:#?CCKE2:RO#]<]$_5)D.U&Y.L_M"0LIA'G[`\L"6MG+ZJ9]LZ[
M2G1BF/.#2F*<:/%Z\)!2I[0>AT<?4.I8'2T6@0,6:C3IU'$\)"S91;(;0>@:
M?V-/^D2@3AF-\%,K8XW1G7K9"SQU4\-(7&G0"3E$.A-P..!T8:'%4A&:-`A:
M%M5C9\W26$&F-#E:A`%$)HTM7^@1<]_B($UQ2.++%C-TM@/-&0KQY-MP["%S
M2/"PA<U)PL9[<71X+PX"[^&(]1[<I;_7Y<?[IH-V!N7OI6!N-TL7L>^YP'QO
MS3>^M^4"]5N2#=-DF7&015MZG";YW,\X3@.Z_SW!84!^"J,T/W#-\_V8"@8A
MJ1!.W'%RBN;7<%D#`3!YWIJU8,_$55!(9TF.Y=154#.+BW&,4H2V"JUE.(ZG
MKR)PZ"U3&);`MLIJ+D\8-X5MV1QOU0TD0JNQ^=SG;S*,[K-EH<>QBL88FX/6
MSQP7.C_T02>)^/>1&_C\\*?9;U[,KC<N(/I:0/G!)5`ZDM@8+(C04*"3\(RX
M)$*CQA83(;"989DZT/.@.=<5.^P@S.:8]=&LXS:&S3%+ZS!:C)ML_<1X-&D>
M6ER_QM;].&@-YH.2MM&![DC</&?#.`FIXVI[7@WIW&&?B*9!OX$";64Z\51#
MF3W?H?TF%N.L3AT&.A.U:JT!BDH-.[JE-B)8:7+8`^G#5<\;]86_CE]2ZM3T
M41IU&RTP*^O2+TB;=4JG9!GW3JN\,QO0Y9#^(TUUL_'V[!X"S]EE)Q-Q:E"T
M=X95(V<!C>/7EJ&_.VSH&T4Q.Z8C3>/@_I#2HXO7T34!0!2F!`RD*@_+?")'
M>#"-#>7U+`%0N;EC`W]3@"P"LDX*?P=G:E;75QRIR);993I1KA35M5)N-O6B
M0C'Z6JAV8>,:/"$BNS#D>%`P&RV/"EAW\+P%K&[P@PW'R'(VE;1>G?_;+ZNK
MB\7M'>'Y/[XLU[^_,70(DDZ1H\>6!5G)?JQD/4ZX0Y>RG!'\'GA6<PJ.TI:#
MM.D6H=VABZE*SQ0E2KV=[11E!(K2E&2]6L^OT*DF)K;X9C<1&9MQ4R8>VD,I
MVL,BUH8X;`]7#.R4R(<1.M'UQHO9M3?.#A'TZ4ST[;KKI/AC=:E'ZAX;HNI8
MNJU#4*/OQ2%Q,Z6W57I9I7<%IX$M;]H3[[V\IVO@UP&]+M1E$+?M$BVGX3TA
M<5SIL0X&]!V>"0JF='#748JU4TJ>L-#Q-86!@<^K";1#;-GHPX1&T:-(![A-
M*V&&!`I"CM3+R/C2U.TV=RZ"Q-]%R2'&:_P]_4CL_Z%%(TDY*:.XY2R02U(_
M&SSCF^M+.9X6?II"I5$ECK[2`HB5<*Y_IX*+@J5JI$D)RRFNXB[7HMU$2&#6
M<E?1*G*/I2,)#T_]K&L\@$X99[*E8SK7J?0H)HPRHF+`C)77#CK&"*WU(:I`
MB6#>+I-V]":4/D"1$%@+8D+V\DO+R"NRYPQW#_<)_N>!7B+X3*\.%.:$*KF"
MG6(Y,SJJ[!OR3Z)>0CAAJ5GU"&7/7$K8E&T9:7_V%F-$XC6*B#6")EPB,[`)
M%BQL6`+UY>,=29L6UVNT^)7\[]WQ8T68'5E$RW0>5#0VI1`3^$^H\2B%=5CO
MJ3<&)2KD.@4D@TYZ;2R`/V>@2:C/4?"OB;V+Z,D+0CGZNW)\^-?E(/'?M0]*
M@(9Z;0;42G72!T0?HJ_98[?2!TY;B@@A;'8^(RIQ(27J&AWEQ%40XF6*GSH;
MC!5B?$;4Q"`)T;$.RH>Z=FTZ5(6Z;/A*'R+VU"TR=%M1Q`51>_.I4$H+F5#3
M9S&/+JW83*/-X.)^$CT`))HI-"!,)LTA>#>4RZ7$^0/$[>1RV^"Y@_IF<D$9
M4=[@PO7DBO:3Y0R2J\GYPM)\P;%KR5L5I,N0%-"OBPAPGXF`@KYN%1;QN69]
MN+,"G*R`/7`,YXW&$H*<TZ0"A!?+U&1Z',4V_VI2F0P?W3`7E,KL@N);YZ)*
M;@D.PMVXK%3:9"*,2Z\LY8D*46[EXE*>"9M)[E!4L/2VA8OCA8-F7@L"B#']
MWGZ_8P<W>KMS+WF\W$7?EN$VBI_8J3;"$>)>I4K?J%G*D!Z]ZF;J/W6-R;BC
MIV-6%T14$E%15)-U9R--3X!$`UNO346MPG5R:EJ#]=]:1H$]^F@XS08U;FZN
M%I\7UVR]^ODOBXLO5PNTND3G\[M?T.75ZC>TO+Y<W7Z>KY>KZ].&JCAN3`/6
M\6(+[<&NMK>8U.O@I^R@+NZ,BU(N_W`2.2-"*NV;Q0B9>C';Q*5F;*`DVJ+&
M0T=F7-1M&6E_]B9?A.(50R0:7>%$?CX^MW_)?99_A-8S([QS[9AAO*U2C.NF
M9'%?@"/=17X+1-(/UT1I0Z1"9JLD9#K14`V:-`QL5)H`%-=`'$]SBL(T1(..
MZ%YP\/"8XLW\&<?>`\X.,EUMLY,Q5X<T2;V0GM<@Z-<-+5XXJ=[%S9`_L+:&
MKJZ_50EQ^BJ;%2507@15A]7F%\+5BIVABV!WH-*N=`P'(RPR;?46K7MJJ3&_
MMWU0;]_3.FQ`F!+Z+*PLEI]^62\NT/S7Q>W\TP)=?_G\<7%+>Y9WO\QO%W=H
M]65]MYY?7RRO/[TVH`LCF#-0=R\.?O22P!\8!!ME>T;`O.PHKJ!1SW%B7V'2
MG/V9IKY1CY4Z#OXW4=2;_#P0]N0]4]&?]+GE*8(;,SU)9`,&-HUIV>=WYGZ@
M,7%K&K%L(G?R6)5G[IW:ZT4K56EYO!*7ML%O55VMQ"R)T=[D%NH:V%MST@,H
M$:7R`9J0E/L`D1*E%Q!;'R&"B8R/$</&`#J-8\5(@^N1S!J.>T:ST9$\7D1;
MAG[TA*^B)+DD+7$>A6D0'D@-5WOR(NQ*OH]X&\4XDUM[WW&R^$YZD%%,WL.+
M7]BJ;ZUCWD>PE#>F54M&/F>$;P#@G>S64NS);-J=7:WN[M#'Q>7J=H&6U^>K
MSPNTGO\[^>5Z<;E<3^O^QJ!&-"(&FT[5HL'*`;]*SO?+2<1Y]PD2GJ8Y63'T
M`S7P(Z(F4&4#54909B4'*F)V4,-0MBG0S0LF3L5YB'*RDW,?8R=WI+:+[_0"
M>/P1AW@;\!,SH50CJ>)(`3A'H6VP9(9G0>67NF5FJ_01QRA@CUU@O;C1(LTO
MS.-:1[C-DY%0`!O>0"!0"RNI]QWA["&ZSYX>-R3D#M@94'S0`L7?,U"$^,$C
M'?!1W`.I61T;IX&)#W8P4?\J5^1?Y,?B)_(_]UZ"R2__/U!+`P04````"`#'
M@FA!_Q4SN_A$``"B<00`%0`<`&)P87@M,C`Q,C`Y,S!?<')E+GAM;%54"0`#
MA2*<4(4BG%!U>`L``00E#@``!#D!``#M?5MSY#:2[ON)./^AC_?9[I9[QC.>
MF#D;I5N/8M4JK22[=YXF*!)5PIA%R"1+K9I?OP`O522(2X($"R!;+[:ZF$CD
MY4/BGOCK?[YNXG<O*,TP2?[VW<D/'[Y[AY*01#A9_^V[;?9]D(48?_>?____
M_I^__K_OOW]WEJ(@1]&[Q]V[SRA-<1R_.R/I,TF#G#)X]_WW->$GE*"T)KW<
M_@OGV?;=59+3FO)@C=[]SY<@B=Z=?CCYZ:=_?OYP<BC9*GAU=W7_[G].[ZYK
M?JR2BV2-$U06B''RVU_8?QZ##+U[S?!?LO`);8)K$A;$?_ON*<^?__+^_=>O
M7W]X?4SC'TBZ?O_CAP\?W^]+22G8O[ZOR;YG/WU_\N/W'T]^>,VB[]Y1PR59
M43>@DIJ<2MBB_OJQICUY_S^?K^\+X;_'"352$AY*49Y844N'OB-55<_)SS__
M_+[X^AVUWKMWI?U2$J,[M'K'_O_+W96THI_?,XKW"5HS_UP'CRBF-18L\MTS
M^MMW&=X\QZC^[2E%*S&O.$U;K)AM?V:V/?F)V?8_VC6\!XKZB$D64(0]/P7I
M)O@A))NRDG.<A3')MBFZQK]O<83SW2*)SH)GG`?Q'<K(-@U1=H[R`,>97J''
MY^"5"GSRXX>?/WXHQ#6LP)X^]]O'#/V^14E^\4+_8T<'*5-[<I^C+$SQ,VN@
MR]7I-J/-.;,CO)JS/0W.2$*#9HX?8W2/$DS2&Y*C["&@_QZH@9JS/0TN`YS^
M&L1;]!D%[-\;YFL;"B@9VY/_-,APMES=IBBC%13!W@J"5'SM27]%G9SE&VN-
M5L3/)MHW&UQR9X&-)#D='M!A`K84-B'\+4;-G(2_/9$XHF.1"QJO\YV=N"EG
M.W;<L>0$)6O+]J?-#%%/;YY1DMEKO!K6(T=/*RJH.1^S3?\X=J/^<?0QQ0B#
MB6.-1\<;B(X?C\8(1.-'H#%"S[C]ENT.:_0(.4)H/%),'"T66I"?A%O&FG*^
MH(SSW56R(I2B-Z:5_$8=P5L?NH\YV[8[S;9MV9"Z[QS'VQQ%-RB_)EEVB])[
M6@0--[**]U`M[JGCBI:]7%TE]-=>X@J8#)7K+,B>+F/RM9?;&X6'RG$:Q&RI
M[_X)H;R/*.WR-J6YI?Y/\B>4XS``+`RJ1>.86425G6Y4P]#F&#&D@PFT6*?(
M1A\J8&<S0FXV0;JC)L'K!*^HZV@O$H9D6_1WMR3&P[M2:!WVM+I-R3,=C[*A
M-'/O,S/;,!W$'&VN+K&8]Q"\#C5VBY$]^18AU3K#Y<2*]B"++$,Y[;G/4!RS
MC9YL-U!N4`7V]+FC8:H<CM[2"#9,=)Z7Q4A"1\UHD:8!'7K:B"1==A8C"8I1
M2(<7_[T-TARE\>X2)[1OP$%\'N3!P`BBX6T3%S38YO'N*LNV*&I$J90D],_0
MAAN@=8RR=FUMT?IXHU]KFP2`*IHZ/3=F)=?TAU;]Z#5'282B6@*FT0A[FX4X
MM4`Q"5LRQ&S+G*0Z([!?_JFL[!"%'[,\#<)]9QFS_=R_?=>O,)V(,IN8%GYO
M36>V-Q]M8[1<J60H-KHXA7N4K+0U*ME6M8FW1=I6.TC#NB+Z9P=L[<,%%<7[
MYV)$_GWXA.,]3E<IV?1V*!EBF:9Z?WEG)L&[G+PSJIFD=&Q?G8[I`:C*M(59
M5T'V6-AVFWV_#H+G]PQH[U&<9_4O!?2^_W!2'33YC^KG?UZ39$V[J\TY>LP?
M:&6+5YSQ+4M!4K<?(8DSZ/0!``$IV@:(03T,'6+^7L+@G&P"G&B`T":20*$F
M<A='5%X5>%VH%1<8!"Q%#JY9>>'BQ@9(L?5Q&^P8,#^CS2-*.4^#:"O3:&B]
M\3OG5V*FI1H`)6\&`0W/)A(HRQ5*T^I$FD+70E%VQA&USJ[9&'Z(=\4^_G#R
MXQ_IN)/-`<ZWB!;[J(.)2>DN<&"EIP&E'I;H`2Y8+17<_OSAPX>C(\Y.U+IC
M"P&"04GG]\J4C=^G-OR0J31HS-%@6H'A1Z>]4"&/,)@(OC1]ZCP(=-U#5$*W
MO;8OO/>)J$=PYI7/.,&;[4;H%^&W2DGNFUO?<!(2M>@"_Y1TS$-<P?Z]-@W7
MC\1]%/T<O,K]*_I6^[?]S3O_*D17^[==<)O1`J0XDL6V!9N!<I+NWF\CEAN'
M[.@028IC(MV.%$1;+QRI::?6X9JH/J@3UE0DAM]'IST")ZEP/4!)4]E-0N,.
M*B"?$YAR'"A4K!D,)"S%[G>]6+#9D*0X@R"9^4F^[^=VG>_.7*[V)-$KTW:S
MD%TY.^NP4;AV@G.QLSC(LN7J2\"V9_-E>H?73[F@2]'2U2"1TTVM*X&J/*@;
M450B!MH?W,80D;C"C@1`J8*,\TY%[WT91`#=BI2Y%!*6EITE2X957>7)@`=R
ME614[&V)O'+OG:29L-/H4;*RB%%)OV#0[6[ZFP$`C$-W9%2-;^O2G/"W<5`>
M.5FLV8`*@BYE$3&L)$4FAB>(XD.`).'??](\#H)4/>HU3M`5':MW=KI-R@".
MCC3*3&U`T\<4PS;'816*!SI_G.J(.LB>"GVS)S:M>`GB8KZ8G]$FM\/)NKB7
MQ`^63,K4PR98&2_/^G311OH9`7ZX9U]E,<2"536OJ1[;>V0CAK2XLW5)(_YB
MPXZ`<EC4D566EY--!W%`57N"3,[=VMJTA[@J,C?1@>A=D*-B]2RJMK&#-1_U
MS`L*L:<N.%4T&IC#"C[5]2F6LR>(V&(]KQS[GF]3=@0>I9A$Q9'L[`9]+3YU
M-U5,"NUW5V"%IH/27F;HB5!H78J5L@FB\S8E(4)1=DD=Q#1D-QV7Z7W`AMWM
M:X@5,N$%*G=`"DP'D<;J]T0CI!Y?IC*2"?0-RMF8]PY1<5,V\5\^QIAET+LH
MKN\_D(O5"H7Y9Y2N.VLQO<I6%C<L.QWL#3%*3Q@:5BE&Y$^^(+*,Z)<D_?*$
MPR?QO.P+CN//".5[$U6ZMRZ6U;'0%K\Z5`[G-QTTVS9>WT`[7`PQZO_D"^IO
MMFR!E24@(=$VS+-E^H#"IX3$9(V9,8J;]]'IKFS2BVP14SD2:L<7]$#N`IS1
ML=`BBG"I7W4K-5GS$7O<6NK8/E8MTVDWQS%TW_YB+.'$;>S/OK4Q.D^XQH_X
M$XIOGX(,75U=T0X2AT&X>TAQ$/,=B&DQKA7HBTT/UH:F&(A3?6T2X+FX$`'&
MGB'F#+$V)XP=!UM@3'FS?3YX5'2UND4)2]=?3@VNLAN2LR-O,<H/^01L#:-!
ME=D:8VLJFTYK.*K978W.-3)*6Z*5U>:_ON^`@&KWVQ'3;\BRYD_^-M[;C3-W
M-\Y\/&_^=@%->0'-VN$"3RXHO=U'^[;NHW'=F"2%DXZLWB>5DOFBH#!=DX)$
MK)CK!$Q:=Q"05MRI0`G38@M7R,R+_HD739PI24,E<;,'^9)47A1X&90;2<!3
MY.0]+Q^')0)AA1=8M'1RUSN_O*)SKMC_D/N08L82$/A\&Y(35SAL4=*(W>]\
M&*/W:]?Y@,&-E*W`]3[?E,Q0^,.:O+R/$"ZQ0O_@(4)_^N<U6@=QM24B2)\G
M_EI?'^"_>@.&SHT`I1ZPX-_AH1CI'LEYI33B^^V"3_6U]M8G=XN&$I\0I?#<
M8EZ;1W%1O576;D26K%@O;JYNBV6P$&V+[/S951(*`RV`LM)32>GN.KK(,<1$
M+^X^>H,?<YZ2CR]A5H*"!_02<,+_<K^0(0%(75E-2^T=(LST4Z-"RVM>]PP.
M9]4%/;+X8V5&_J.W_;%2"UAWS+/P,1'-048VCA3&`15)QZM-$F>^E?B.@'1I
M^[;-JNW5)HNC].+E+MW^&1CQ^JZ*IE[G%=-XX"^!5PA,)YG;#AR+E6`Q)\_[
M[5\)>QQ"[7<E364C"8VW?H?H!/.[A),OO;+LDCT)?_OE6>UW)<T^:;B0QEN_
M0W2"^5W"R9<[=/*TT>5;DWEQ^[E(&)&I86!2Y)`@&E#$6Y#TT!B&&1AC7RZZ
MR:9Z3SB-%E3@J%"0\$_(B6=\1H7JB1^PD+=`ZJ4U#$I0UK[<5;-T)`@Q:X1Y
M<4_TC&3L45KZ&TI?A(>;8-3UT2$=M;<32C,]83-,+4\?$]>Q)K)<M407K@]K
MZ>H`)*=S=X(%Z&P"5Y,[X:*NH`@^<L9>;/M=;)YCLD/H'KV@E-W@%?9)&JIZ
MPT!&Y0P!>K<2J')MSTL9%UL+,H9C3&E]"JZPQQUD8?106M$3.\P6'-/&0-+B
M(ECS\4[:YF]($DH^/]"_LB!DJH@RDUOFNI]46.+J+=3&L1L,J-;J5EQ%GS+,
M)5-CRWSM0=UY+V4;S';:!R2IIAW!+36JX^X"X)AEETW0;;!C@OSR3)++\\5B
MFS^1%/^[,-!R]3E(?T-L'8,EB"PO%G\.8O3`BF:T3Z?E/Z%8<B-@K`KVUPKL
M5S#E)B2ZV3"R"ZRWIN;E"ONR>[Y!(U+Y(DACS&ZZ?CPY1V&A!RM(+7I)K7BZ
MS7""LNP\V&6+%96*=OD;G&54P0="K;5<L>O]\1UZ)FF^3+X$V1.;Z%%1V.&"
M^WP;[<!M]\B2*!KYT229?S1PX]0CAXVC*>GY1B#<-A]EMF'/IZ"D3"V^7!7_
M2D,<Q)^#9+L*V$(".D3B*D')P`@SHBS&,6846;[5*#.^8[V(,Z.HZ?G6<V64
M2Y*>(AHL[VE-Y4@-I5?)+_?+U4F5BY8;J-$""^JY(,M/_OR!&>J*&B7"08[B
MW27U#_E*N5T'VR1\8GR$D<5)W77BB^/6/:_(X=)Q(T:*(ZOERXD"RX]DWE,+
M!2DFJL<Q133\HYAM&F^7AR$Z`:]RBCDI\BFZ<W8EX2])]HQ"O,(H$E_DU-'5
M3I?3N7_:4NA8`E=.\JQEDVWA?CD[+R]Q5N+2X(="&OK$MSB51)SS>2*';_SH
M'$N`JO%/^$CX-MW/\_-E)6R4J[_7DI>C=&3B"\`-,G^["YAFO2[_-YAYGB!T
M^36A?)_P\^&AB^5JN<VS/"C2DY7/#)13K>H-V.(?CU3#B"4L"Y+=Z>YLFS(W
M%)^?2$Q5Y'$T>CV5NT:LQQ<D=Y%*CF=?97.X;J;(&U$B7R*Q)O'I.:8="'N,
M<KFZ*&XM7B6G)$BCUA=.8Z[9V&#%)4SMQ\IK\%NT$AS?PRKU?-G[CIUBRU#1
M[.Z?8YR?D83]0L6]8[;IG"2&D>^/$NO(O8:;H;9P2.D9>[Z&^?:TBH5@9NTU
M%67TLO&`BC=W;NI]@E+<!Y1N<%(8X1*QS09!UCJ#$I5M026\1I:YSG`\@7C[
M<MD&A*([A#>/6UI/N==T\?K,-I7X>8U1&2&2I&4FA"68WGW1).7N_[-.RHE/
MF6"\Z.W_CN+H=*>8/UOA=4@U/X27U[BT:2<X7@?6.I&'FII"_YW^CVE8+Y_"
M)_F2&:Y=YMR<UQ9SKZ$_JB7-Y\6VQ/!\`16N2K?E?WDBQ85D.OS^E>3H*KD,
M7@@UW46,PO*L[GX)P;`[L%PKL..P5JO7[<R-[>UU1M;D$[?,GWUIF9T%NG.4
MX77"7O6N'WK3K;;*2\@6544EO$:SN<X#EDA%O"6+^=X\8V;<G!J=7$:2!,6T
M45T4#\M'5TE.]BDH!L=TXXKZAG&#BKS&^M$L/&*P-A!)TK*\V2=C*:+V[]DO
MD_(1\5+S6Y*)5XF-RC22<`'*>`W=/GK#40CD+@&4-[M6=7\CS"/%7JMG;>3B
M-7QBIT\OZ;@F0862DF%`7S;<V,"<C==(M&0=\U&$>842O'JS75:VM_,BDTCQ
MD&"U*U,=?\[.@N04W:$0X1<4%?<?SG&6I_AQ6X[%2Q-TAQ$6F;9>IQS.U&MD
MCV(YHZ&`E>HEJ/=FLXY3ZX&<HKTB;.+Y]W(J>O'*3)=15;/F((DK7=M#O)D\
M3AWM36?;=7C=1(YA5^--;-O22!J0-_N4BS4=Y+.]>J#^7-OH6[Q^?,*XN->(
M'F@-.%C-*Y+@\/C[FY9.G->9T5C2O,XY<^''^G0Y]]%K0"DU@<.%9R,!P_$W
M">V`X38E(4)1=DGM>K@Z*-CHT-'5`U0YG==H@>IG,(R4<Y1@R)N]--D=TEN2
MT_^R:][<#?*JTQ:<[[+!2I-M#,;*:_19M!(<H,,JE6#8NUVG9NJ",Y)D."J7
M:#O*21:?C,MSJTX&Y;V&Z%![F*\S&=0D.<7OS=Z5MJEU6]@E23_A%^[2?;&T
M8!IA^_"&AEPSWEX#?$P[6@S*9E)(&H8W6T_[G6G:QME`J<P)L5Q5*6.H:L4*
M7$>SJXRJC!*69R**<*E>91G960+[-?!G#VS6X'53&=^F/<XVV)1%TFR\V6"3
M18D[L@OB?'<7Y*BSQL8V$Z$9L,%\-/T$@(_70+=EG^'Q'U"C!+16=MG^^K[C
M'BKV;^4WX:>6Z]`K[;VBPPISQWF/F&1!DJ/GX@71'T*R*24YQUD8DVR;HG.4
MA2E^+K=8]D-#E`<XSKZSUK#$M>R%6#QF>1J$?!]C6*H"!;B4_>[VUR`,676?
M4F;TZ`O.GUBVR)2:/SE/M^OZ?!@53=*=]N#`=9=&')Q%"5/7$ALF:H<+H`C-
MSM"H:E^O[=\^!1FZ6B11^<=5G;;T(:7#8-ET'5:(@Z*NT!319V2(P8#3U6;S
M7KW[OJB\#IYC.OFZ1PDFZ0V=G65%$IH^?9&=E?QS])@#>BH5T;YC$A/9:^+W
MX1.*MNQPVV6`T^(8T2++MIL"<]DO&8KHN)R)<7A6KC3O`_7>:=R]O62/X3X%
MUW"&#L.&TLMD!'OQ$40D0)G4:WC%4\_XM3?!YX"]7I5C=L+XFB1K=EV;Z0Z$
MNEGQ#K"AQ2<!XUZV,`<MM)KZ=MR'#U;6H-UW>?O6^AD%[-^'ANFNQ]O+=!`S
MD_1[$-(*%&I2#Z)&,W"B(J_O-0X><5S`LG)/M$SN4+A-V1G&TR##?7K/@;R5
M'6EOWLZ"$0A!TI[5CBW;\4HED;RK[2V)S5[7?3PK5&2KQ(=J^B\FV6GARW0=
M)-7K0&R_D\0X*I%-IU4-.<M'/1*6;G^?.E<6]ZSRK%,[VN%I<3;1N#A[\?L6
MYSO#M&G]&>Q3=)LS<!;)[&*"6#!?.ZY9D:],'VXNU[RBW!75+LL+P[B.;BU1
M'MECS:5+[EFG4W1$DA!F7K!"E4E!BQD;V>9BG8+R@>QO6I?9J[-EG92RE`ZA
M>@6M^LXI;XE;G>]Q*#=G,:L'"(AMZ[6C%%RB(J/D4$GF%9?8=6J<U\^2["\4
MAM1J=N)4AL(?UN3E?81P&:+H'WQDHC_]\QJM@[CTBN!U#LG7^CHS_W7@W!`J
M<UFE\'4)T:?Z??C6)V<-6692HA2^W?0X'L6K[ZVRX[PZNWC.@_2VP+3P:0?I
M]_K"3O>[,S<(;4WT.K0=T>127*WIEI[X6JTJ4.GV6GJ5W1^H,2KKS#[U&NCM
M-@W9SM]![@?!90`@]3Y=A(;:X1-B?3Q+3`W0;FQ&E9;))#25>?%JCES*T]T9
M'2&M2;JCXR(ZO:LI(E%//8R+%G$:+NZZ4R"@E-@S,1'7$ZNK5Z-04ZWGZ)3(
M+AR6#>2B1:>&BX?HA$%.B5H3TT%1JQ1+C6:-.%Z@N<I_6Q]XSH3#6#51/3Z1
M$'D(-1A."%!Q*)*4M18'?26UC3%@]L(/W0Y).;LV[VAX=HJG73SL3ZXE#[\9
ME-#V$XT2DP"(L>H61R>-*IR][C(VYA8;LNU<F(*2:]%6DWL(M2Y^E'`3*@[%
MVG7S>H>^#M].8PNZMNUF&Q?W4PZI4Q9A\7[-YX"Z(4$IG]!W&),ZM41/)E/!
MGQ4C]4)EWYI]>3S-4BJ4R@K5"TS=NR]R`@ZA38*IH4^JW"!D-;G:[$[=;V5U
M#QFXWFEGKLGK<ZFT,LERF8RDT:]W29P.8IKB2-=9Y$02Q;Q8)9$Z@P"UZK9.
MGF4]_!"Q\O$Y]<8EF^)Z3?5ZF7C-`D*[WUI1TGH#`\$"A8&6:CPTEB'4/'UY
MX=<.I.[8;6I!..S\7I^7.?SN5F8AZ`5?FG([!W37JD0E=!NQ^\+%Z9EF(1]C
MU6><X,UV(W23\%NE,_?-K:LX"8E:=(&[2CKF,*Z@M2A"0]4C<1]'/@>O<G>+
MOM7N;G_SSMT*T=7N;A?L/P_TQ+_[X\3E@)X]%DZ28N.]VW>`:/?'Q)6TSO3E
MQ!$?+5/1U&?,Q#3N4KR`?$-@RG$Y7%2LBQ-I8I8^]EZ-QVTDHVO)]\9A)>Z[
MNX-M2D\2O3+<"3<1NW+<W&$SK['R61QDV7+U)6`YB/)EF31+$/^T=#5(Y'1^
MZ2B,?@!*E9[.(Z'>2\1$2>YDFHQYT5!43+EKTO9V+:KJRE=I'@A+)H#S;=DT
MRS/V)!4??^A1LC**44F_D-`-D_W-`,#&(8P:56/Y4OT(.+N-@[`8%2S8\T@@
M@"F+B)$E*3(Q2$$4'X(E"?\#B*;:,W=W'-C*G>00.HQ8>HVU33Q&`J!NG:*3
MXV#Z3M8!*;W#60G()<1<:WZ*HJJGG2%`RE\^03FFQ<!V$&R7:,^6:;F+=DY4
M1\PF9"S9RG</"S58@4_>^6H6Z*2FAYD4K,5F^S@=LYFLA?4PG8:]V'Q_L#NQ
MZ(IW+3FX":"4=KO7'AS4-/0\5-E>?E<PK]Q\_$?A+`[FRB%K^>)D^?ID^>;O
M(3M%\>KJ(>=D?<5<!+G!S)JH',#,H_%5%XO$LK%T(Z_KYJ&HH37/;3N-C:D:
M:J=XC:EB15:%XE#L"0=S,'TCGZF&WG>PFJILA$<`\WF=]+Q*J!@HRZO#+F?;
ME+EGD40W)`G+?W"0,RBQSSX#*.$[[,S5-@(>B+UB5#Q!Z"EC_PWZ6GPRZM<[
MA2#]=Z.0[QCLI;R]_KA1@V*",44D,O5N4QQVUMHZ'VI$-3YXCQJ9$F;(:'`1
M>]^;QZCKC%'B+90'\N6);)8K*B;%]^<@XIW>MSCWD@*\N.\`&F@0(YB9UR4&
MX_%?I)9=&FN\?<NB)WL_F4UG]F<F/J4D4STQK"\D>&]85<AWN/52W@ADT!K$
MT)K#^]9[K5/V8M9R51H)@D)A`14"N0*31)]*Z>'(X[B+4>?/B]BB57MV_VW_
M&^A<E+B$ZN007\)W))FK;00E$'LQEH[_,O6(A]0N7E$:XJP<FQYTK[Z"L`AD
MH0*GEL4DT6IFF.'PU=8G6>_UYA#46_[UT=8][&55AZR!&-8FP>54SU4)&V<]
M-3OLOYP%<8RBTUV?F&O.315^3;CYCG:[YAH>E$VJEHQ=/3JF>DCB<<G.?A6"
MEFM;P8YL^<T.('4]_]%1^PX],W7-9CXZUI(0.NMW,M_R8QQ!J;?\&*IF:YH?
MPY-K>F\),9PGQ/`M/9LXQ'[\X>3'/][2:26[L[A%M-A''4Q,2G>!`RL]#2CU
ML$0/<,%JD0XM)P?`DT$`/!D$P),9`5!L"=L`/-$"\/AS&WN'#;U[)MV>:H=G
MLT77J!04#:4Z%!Z_`*W7J-TTY(\\"SEY<:-'I6.?"T\"?A:N.#D#>F=2+P1[
M=^HO`ORU!Q<O-.Z&J07RN)35Q,_WMO6J3YG>!3DJKA!%55<7K-7Q$5)0B")U
M04^`)5P+ZVT`%=ZN^</FT!KFE5&EK?EE$")A_G4=F1!Q3;+IX$NJ7$\T-?G-
MZ\;"VS4Q%V@=\8J8`M/C7`_K<6%B\/4PS5'EM@W^7NZBE*==2V47*2KMP`&X
M/P/NN+()`Y^!.M@@8'#VJ6E>]R:^Y=N*P!Z^_TU%35??ZY;B5*^&O]U2!,!M
MZ`U%!>`&W$[TYB+&98#37X-XBY:%B&=/+$E+=I7L?Z>ZG`79TR+ZU[9\S9Z#
M5'\&E;G[,/`9<(,-`L9?GYKF=7FC;9SFSFPU"BF/W!Q(U$N`)@R$LVP8`Y_1
M.]@@/6?FL)I\N00R,GH/HYCBR+=HP&A43H?5;KE)0E2C_G!D=BN8UTV2^LTN
M9H!])R(X(B:EX9Y\Y&A\!A5$+3"`),R\N:9A!RW<\&.Q7J=H'>3H'+.;R"@)
M4=8TA+P3'LY(/)0T8N0S.*T9J._0TJC&F=WZT(ZR/P4XN299QG?3Y@6A,Z)&
MP0G!%FX`>S.@1@WV3M)[DA6-5YZ*C_,[G/W&E,Z8UBA;)M<X>,2Q:)>G=WD)
M3`'EIX164W/T!BV@(@EVIYKC:F^!199M-X5:V2*)/J/\B40D)NO=)4GI-Y2S
MGQN6D)S&L\:/1W9_?I-`NB5SF2._?\62EC#5O2*115@HN$P1:AY]`0!>54R!
M:W$Q9_"UATT)T`%F:N-YL$0RY(LEF=>1)I'>%Z_/*,Q1]"MA#\C'["8Y#.'J
M@@J,RPK.%^4@4QT)YS)9G)VXTFV%-61G)\'9WC$0H2)R!2[;Y/-%H\(L1\)@
M6P)G*6(UYYWN44IU:9W;*J[?%(I(#SD!2W$GF[2E?![!]E/=^`R3EKV'F1R:
MRW)W*$)E`RCV*Q;9X>ST<D5_2D+\',3EZ9AR,OI`RI-:BD7_X4P%NP1#F/H,
MU%$,UVL?8DCM'MXJ[:N:)6!;@O(\P7MLN#8!ZLUH4K2)7)Q+?(SQNK!%([/J
M64PRG*Q9QLM,H"^W[PPX#F"Y)L4!`FLU^=P2CF?B08<4K(ET:$_>C)&'Z5N/
MZ![2(*(?SH,=Y"28%?Y6VHZ0_WQ;C-Z<1VHG0D$.K>/XR\Z]6T>M"?V6H7";
MXQ<TI#'`V(&QKV,W;:@;&<LBLG7U'H`\U2L0S2'CZ>YSD+-+;CO)-B&,6#"D
M%Q'[C$@C17L-ST5<#V@Z_NT&^VBJ],,HNT//59;&QLSC#K&,.1%K79<X"X/X
M'RA0K9H,82=`9#]V3K,;`0!)K-NLF_9(+@:/\7[53S\!DH$-KA*F],-7/E_W
M$!;F:&^PF!?"9;89$=6-*EVN^ME'L@*A"N1-#E$6D3)T68WD0>Q9ON%BDG<:
M9"AB;X.C)"MJ<IUO^"!?\=S27JX[%+.$-V<DR[/BSOPCD[Q.&2W+3&>%63UQ
M&\C,[=N%'4<O6&+V=?%"_.GN0%+)O?@:I-%^ZZ_,4?!"@<'N]EZ2]!-+ZLX9
M>^QJFN\JCE*-NUF,'9B2H_F`FR8-$G__<N0H8L_K!-E]^(2B+7L)3&NQ3&8R
M4:9+ZWSKMFJ/[QP:YTA6MMX:[<FIR"OFK!&5\HF?,A!^J\S,?7/W4(=U&!&U
MXMPC'K:J9U#CJO4B7VI_M0[:)-%M'"0WP4;\M,2854"'2;VJ<`9Z,3XA(Y[A
MIFSCOR4):/#22P(_F@*;(I8'H#)A1GHY03/A(4?@+G*.B14"L`8724<09Y\2
MD1-CX@/?ZADQ(0:%WRJ#<]]FBSR5#8X#.DZ"V;V$T'N*VMF4'+I<TMWE'+@P
MTF`XKT&M=1./.!*V(>O4TS;W-4'5UQ5+/ME54F8`_I22S%J;T]<PM!&J:O"W
MVX(WH"'-$6Q]PZY.*_V@AJF2>N+#L?[Q3FB4+XB]#8NBQ0M*@S5J/?%M;>;<
MN^;!$^H>-7\K+7XT;SF)!#:U^<;[\DN2KA#.MVQ7)XDN7I]Q6G#86\]RSPZN
MSU(_#ZCO6XD!ECWCXQ@`H(.S:]A'>'*EN2!5A[E.`^[-`/*TBH3!7)K84-N-
MTF9Z"/4-+!/IQ@BU-9P,CGM5;FM\;%CY7-JN2Y]Y.4HV5,C#^_B]#=G)\K[,
MGU#Z\!0D>]N,-A`>4O?007&_NK^5"#"BQ[P:+/?31[K3Y$WV@_ZS!Y'^*!IC
M9#"B"(-GS$-$^-9CA#W_>14J!JDEC1C>Y'?H;1?N//0V?R(I_C>*3M&*I&A!
MZ2)&.]+)?5UUED_PRZN;PV'AX_K$UQ/]<O'?3ICH3#9V*Q^[6;^U8X#5O6^X
MBI9J9<+N_B+E/L?J9Q2P?Q<V=7V/<B_404[MBP$*4CYQKY#4B\S:G72XE5>B
M)6T%["52G*S+9TG3^I\4RS@3W8NRSE>0_W@@7_>)DE6H(>/94)(L62`-GP=Y
MH!1>G,S?ZW.Z:T2=RQ3]OD5)N!-<;3(HP:-45<(]_JSABO0QDCQG]R"A6IA5
M">,7&D5R"F]`&93@T:@JX1Z-`."0/NI+<":OKH4@537>(BC;-Q/AO0^3(@H,
M=8NX!Q$`%1(0:0P@09&\/AF*NO5,_$AKHT7M__P[1BGUVM/N&KV@6-VG`@IU
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M^W17]V`[P-A!3ML=/XAH?4&N]3&$UC#'&4>(Q*B0^@<_QA)J/6'MM*VE>E`Q
M=GT\[L>KSWW;4<*<'-_HTC%'5\Q6.QE//"\&(/SCW[?!CJDA'(>`:"MS:VC=
MXW-TV!$S@TGP.9:8#.,:\>:5:=]&+WHMR?PX"F^+)TNO/<@'.>Z@:@3#'V,0
M9D?LJF5.]97+T@B"34O)Z78P?9WF7T\_Z5;1!3`Q-Y)]M%\W[X4"Q)EX_R+5
M$(I>*&I=YNP'@TJ%0"7RM%4HT31Y%#6:&3P@FA6JWP$$%II?:.QEKI'C(U2F
MB9^K:,PXV!N,`E7YH;5!B>[,4U["W;N79N`C?2S`/8L)JI&;#\IKFG6`-0JL
M1@%U4I`STKLOVG25V`QU[J\4GY'-!N?EY>PDHBTMI_T`2D*J?76Q^$=G-XM5
MLNG&'KW*[B.U45F'#RUG64LZT<UB-='^\64QD;/8T,]]!*AN.S08U54^URRN
M0[$PZ;!?R?&Z4/0LR$0/$<H)]OU'E\#A\]Q*]Q*`/OSCW"*&93_09>2_A]FS
M2<+-1!V9T-M-,H?C!*E'._Z6ZL6/!GB678\W6=GUNRH7UQ.)*>]SE.(7*LD+
M6H2L4O&3>%#Z9MH<-;TG/A9XD9CKJW+YH89]*AHUYWEM.G6B7F=!0C9ZD.U*
MJ`A][BV@^H%[#05#Q1O%/N0"K/,JL?;!=,A(C".6S(G#A):N,IF"SA]$"%?B
MH!IJ0-%:25/PM!E,W,\HSU$6IKA`^7)UNLVH$;(^V:DD*!6RUTX'#4M5_@67
M<A;(;P+VUL=RM7Q&5;YBOK%*">I6*B!PEPW/T$T$H""7MPY60]%B!9PEPP`K
ME[S<-]UK_/L61SC?L7EP\(SS(+Y#&=FF(;+8@E6U`/:4^A3>3V[,"MOK6U4U
M/U#/G5)FOQFHVBD#T+!1QN$XOY?[2#]K\#,`D[K+"2&HSGD'A<;NRSU*,$F+
M,WG.%H79#A"@NU<1[7MW,9&SSKPMD"PL:*B$ROG0]#4^(5#-^/Y<Q)4U7BFW
M>3?7XL&K3EI==\W52G[C&OIVDB57+60@,W=A`BIX,W.R=)1AB9NI467<9I"(
MVZY%;:?='BS=-Q`^RZ7@K'PFR%GH[(K"1EZ2T`@C;KY@J2!V^[AG1S#]F,BX
MG-(0?HV;@)XE_:W`/;BCK&__X":LGGD'"V$BE[=$_*Z4E44'$*U"71^B`,AC
MQ$S7GHGMQ9SGW=(59X3>CL=Y>CRN(:=^!`$C[EK`K[%"[V-S1NH//#ZGJVL>
MH8.$Q=.BU"07U"+LM=$5H10]%V-DFZ&*6F1K*`9%ZDD]J(C#20.=N#+Y1,=?
MQ1_WP__V1W>+#R9.(1JMN!4#`.MR4-]FJ>K/W;NZR!BP7!4S$<&A5BT=#X`N
MG</YGM"W!*X5/Y]K\FNYNLO'2Z\WQ12>;943U!VV@,"]@Z5N)`"5)$[F>18=
MKH"7GXZF(P.2%.*>23*]R`@:(S.>P-UH3.Y#`M"%&V9UF-5C*9[)F#,Q9Z`H
M]%9@0O"]!8G6=Z\1(=<$#H@6#\FQTZGB81_JKB5GEN4$?*]_[<$994!W+],#
MW,]?:\\@NP5#AL(?UN3E?81PB0/Z!^]^^M,_RP'L'5IC-FY-\IM@PX_W523U
MFQ]"$O<`Z+J9@/21P."Z>?I8S&;$08"92\^HO&D07]&I]NM_H9W0IQ*:EE,[
M-%Y[5:T1W*T=/JI&?B2_UM-.=M%&L@+1_,2M-)2?/'6>0GZ(S]K%Q:[ZZ,)5
MMRC%)+I(HG,JML1G0AK.>1R-YUY4:63B3HZ/V*]_.*9?%U2LJ'AI,0[6G#^%
MW^H,3^UOGOI/I0'$;UQYL;_^Z,1?C3L*,K<)2'COM4A\=Z)<'R-?MMB(7?K3
M,5UZMDV982YQ%@;Q/U"0BJ.KCJR>R4K)/'4O4"^(B^6LQ&[^T_$'L5]0'/]7
M0KXF]RC(2(*BJRS;=A\KA-"V!K526D^];J(A?)`KY2?V_Y^/[_]?2;REJJ2[
M2QS3N;'0[Q*:EK\[-%[[6:T1W+\=/F*__NQ@<EJ&GCOT3%*VM\VTV(K=JR9M
M3U4EI%X[&Z2?P<15PDZV+G%\WQ=@/*,:K$DJ7I804K0\S5%X[6"5-G"_<EPD
M[G2PSG2[?8QQ>!F3@#\6(?W><F7KN]>.E&L"=V.+A\2)1UU4JJ+&88NCN*B0
M+;=YE@=)1".(."H#"K1CL[*`UWXWT-4@3BN92I#A9`WK,#^XI+_PG;2&BEO'
MZE!YZGB85B9K61U.$A<?=3FK+5RYW*9WLH!.Z.86W20<+=?,W-4M7A)G-]?"
MW!_(+E)5+U>WC6J<'<1>INL@P?\NDXOM,_LPM"114\#EZA(G01+B(-X[179#
MPRK/"A>6>#K;^:]\O@A#LBU.&7,VDWZO]!=\=];2[?J7Z)5O!P4KU;,X(JAV
MWC=![K>/&?I]2ZNX>$$NKWOQ@L@NAFK(ZC,Q4C)W!WTXD:27/W5T$A5]N+"A
M]0Z!Z\=U^Q+.Q<$@.<=Y-UX6K4(:XLYQO,U1=(-REK2/CGZ*:8VSIGP1I`D-
MG7M!)$U91U;/8:5DSIHR+Y*L*6OI)"KZT)2UWB%P_=I-6<:YF*#+.<ZQ*>\'
M(<O554)_===F]Y+<AR@)Z/1)=0U%1,,?1FW3N.MU*S%^2;)G%.(51I'PSH66
MKM9/3N=^FBWT"X$K)YEI-]D6_:V<G9?W,,:Z4?=V2OSME+@+,-PA.LS=2K-A
MR#Y7!NQ^=@\#X?J@1@_(LF"7Q<QN$UUC&HLSE%6*<DB0?-TG5^6^.L.!U--$
MIT,;!#R?,NDI5WYF"+@CNR!F=R%$`!!_K`,!]]%+]RLUT'N?+S[3GD#2`T@B
MOZ^N%DL-</*^H.KZ@:%[21[$KMV[S)_H/#B(]]'K!G4V5A0D]3Z)D,1+"`"T
MT<-!S$1VKO+#Q-O^)37J)W8'3A($NM_;T:#YW4M,Z/0`QX<F!QD:)CL,*!*=
MLJ0HK\_%<$>:*$M-MK]D+B/S=*X`U`MT-%_*:G:#APQ1NS^Q#03:0F+RS&Q1
MJ=T))@#:?6!1TCK,)J;!"#'3D\\;)N9>!B`EUYG-2#ZA!*5!3)5=1!N<%%>T
MV0MT8F0!J2N;:ZF]1I>9KG!\:?G.+'*=(RITB`O+T+]C5!WU6&S8P?OR&`A_
MC,Z@2'VB#E3$:\#UT!J..AASBU,R'Z#'&T0SOM*,JSR'CT8;.%2ZC%07RB<X
M4Z^?7CLCFT><E/X+?]_B#+,_FX\1\(?\C`O6I_\,"GH-LMX6@,//I(HY+`R(
M1IM7R6U*0O9V)61DWZ%6CNT;U%Y#S4S7H>/[!E^7ZPN27+L7KV'1(I(,1]6#
MD+<!CI8O*-VG1N>/,QD4J4\V@8IX#9H>6L.1`V,N6ZV:[`"^VI03=8BB3^T-
MRRET:@HMX.!H,Y&!8+)#Z1N2D/(MVF1=GGZKC"!9NP335X8&T'NZFFFJ*619
M$\!S9E.U?0!=%BJ=/07)&F57R?[W3P%.V('I$PYHY@5S[K450$%GT(.#BPPP
M11N2VCI;+[(`ZIKZ&NE50L5`F62U7?*U,FWGZS2@I%:J!UXZ#"VL<OY<8B1!
M:S8E=(V28B>[:PO1$0`Y5?,4@(AJ&NB!*=D#15+&,^L-KY(7VE;*>2E3L&X]
MG="C)MO'(!G9-.`$5+-75))Q'K+&Z0."BI;R0'OE![1Y)FF0[JXVS[1O+H::
MM%MF?76M>W;+]@#8VEI(U@G^-XJNDOINC^00DUW.S:AGB_,TH#V>,?M&5UO"
M6#G"Y5</3_4J;<>,L7@)<,SN,3R01HJ:ZF72XJXG/R/N5[J>'YN6]G6V/,@*
MH+FS:0UUOMT?)[J=Q5_#Y"X:\^O",&K)9=<.M:<P,],2E(U*Q[&5XW>"(X8O
M"*^?J":+%]I/K-'-EKW@LEQUDFY)%OSZ%J]<8%[<4^0-M`,$BN95M!(3SQB;
MHGZW5UE#5+KN<WN#S@"P^O[85`H3+%>US^STI43[JD_199CL65J-;7GI.:$;
M:*/1\"VO?^K'/=WDD_&F^P?JU6?$V>G.)WSL23B:ALQ4(/.3B27BT7>L)DEX
ME!WEC!`#F]W"9K7N9[-]<`.9RYH@9\]O=O?M#NM![%KA&6')(K=4]>5S=8PK
M.T4KDJ*2[B%X1=G%*[43U1PG;!F4A>0;0K\F.=4J+A91)3LRH]>TW]09L29/
M.]?C61?2/X\J3;W_=#+I)D>5KO893E&"5EC<7*14+:@+J+R&J4XK.,0$G.HU
M:Q-X`#93_,HJI<A<!TXLU>;A9<:STLE[B243)@U5JZD(J)SY62<WT61U:WM:
MPJWE\HJ+WM>N$DF>!=G394R^.LS?_)9`\BV!Y%L"21F:WQ)(OB60]&8D?8-R
MUF'<IN0%T][F=/=+Q@[;+.OC/(LPQR\XQR@334%DUS.L,CV<4;'"U#U0A</Z
M46P&/-%BI>*I[Y:]G;\"G3^T"U/+9[;L2-?KG-?,]HX7T;^VU5E,MHA$C5H$
MC`?"CF0F(8Y1RT+4,#"[2WJ,8U57H6;\ZF;40(_LF[%:]/AJ3'TL^)9+:7-$
MM-O(R32VL$-S.TVV^ZOOERX3ECV6O<;(+CCDN]LX2/*+W[>X2.O!-0:S0G4:
M.V"A;Z)!]++@\9L$5,S9W4*MSX"P%$D;MF<DZA/41/42DH3HFX`YR$+'A[5,
MK+E=?\VR;9"$M-T6TSC:E7T)TB(9]"5)[U'Z@D.4+=.S.,"=I=%>9>O=,[.R
MWT1+&&+/XS<00VDM)C;TH=V\)5%QWEPLY6`Y1ELQ$57<4/XXW7'26PY0YTW%
M4B[18S05$U%G=_+ZVTQ1>LR6,"35Z3'@KY7/HQ/C;QE4_<#TX$RLQP#V-YK1
M]2TYT+?0`H^56^@8#?4HJ8DFNUY6I\4K;-_,[B1JG2HZ+OV@@.[;:3D`.SEJ
M!V+)9*@V6LWR:Y).-4Q1D*%S5/Z_89ZSX!GG02R_+&%8\'!_`EQP1@=(>MMK
MK*,@)@+-;?.CH_IMBFA?1Z=>I2IUYKXD*J+!@O9^G56J84RDC0'&Q.5=(U,8
M"\'?PU:=:TI`0<1@APE@X42'[_%^$89DRX9TP8Z=[F2'6L(PW5)1<?"(XR*6
M:*%OPD0*?1B3R4._AZWL0A\FP,SN>'3-<$=V0<QTK>R@!;FL@!30W0*3!Z_&
M!G:!VJUL=BO_\M9)IS0(OX"`*2^BC;7-(I,'I]8.X\319G7]UN7]&B,,FV-8
MO09G]?K;K.:35NTZX@6B04)._1E4B?[E0JKEBZ4]F:I;EC'3:5TL'6:S`1=+
MC2N>^O";CN"*9=L'4ISJ8"F;]IL)'+XAI)4'U*2^1?N^:"-&-@'%<D-1&)+5
M(DQ_9:2C7^M"`WN24G+CQ;R@#+V*@G/&,M1>1T.V0J#9W6899D:K0Q.K0Y)9
M-1FK=AVK&0T5<LBND@^#_4X8N7\B:?Z`THW!6$=51M9MB,O,"/Y]K'2TSD(L
MRPS?YA)UD]&6&0X)-TC!](KA$$<_9TQKK'/,P0\GAY6CQYYAF1VK1E&15KB\
MO@P)UD:%:E0#"\T)VGWL-!J^@<+,[@1R5W%=O`87D$)[WA';U#['@S0\9D_V
MS);$?)<X"9+0\E)Z3Z;J>:LQTVDMI0^SV8"E=..*W9U>E%R<.@S!+IF$19,M
MTE#0#V0K7VY44G<&U1)JWP)T7QP14\N`HK.A-.T!M42*V9TI;/5'+"=$>=L]
MNWA%:8BSS@M"8'K1.$-,/R<4&UIG-!SKY9C9$<&FQE5.DUI9U5A91BI`;Y=T
MIL#5V.08F.V*X,TM!MDXH"'](<M.(]DNM4Q"9?Z:XCQ'R>WV,<;A<D7EQIV'
M2ZWP$B"X!Z^90GRH58_1!GK(:"]?TPM*'XE?45UH#].68]HZOJT6X`O*K214
M\FET,LQV5A<^K"YXS*IY6+7K6&UGJ)#BAO739/?M&Z&DGKQ?DK2X!RBPB:*[
M,"@MZ#Q`I6?45H99[A@="TBJV5U)8H:L]H(C9H5&&C8.^P#*REM*RAEA&FZ1
ML?"KE,#_)&)WZ+EJ=(V-6JHSG4SD^#%&Y^B17Q`W*;+/B0<I,B-<]K#16`"%
MB6)E.]ZO97*)"?N/UOL/S3T;A_?:<#0>0!OM*L[S/EK1.201^Q\[T_X2Q*P=
M+J@%TG1'=17E:#0JT^SN]64\!5P?C2%0`_*UMVY!D8M)1(5)\]DB[Y\_?GO8
MZ^@\.OKZ3.Y+]%TDSCO>^^WS<UP8)(B9^NQA\*MD1=)-Z6_QV2##4O63+M!2
MGN*OG]80_($YBQ'XIZE.IZ\2*@;*<I;UEH.8Z-,^8T?SDSNP&,*!*)7B8`+C
M7>;>:/*<V3-K[823]6G0)-K/K8HF)(E2_0H+DY#J"T\)AH,,TQNHIK7.[`1-
ML?/&MN-0Q+]_(_I4]YFM3\Y`UA,Q1*E;&TEF512]9HNU-Y%/LGKW2\)R*A:O
M="RRC+`',U'T!>=/=VB-,Q;#HW.<HC"7G%KI7;ZR=H_R$X3;4"L-Q62/^KV)
M<Z;`+8[*?`$<N!K`00=>%8<YP1=LJ=$`K)+`F].#MA9DB@QW1=[;".?;E.7W
M#[=,B=-M?D/R?R#1E,6TV'Y1!EIL@H#N:9.A*(97.[,W&"LK+=/;(,VK?S2V
M.0M+-E+9TB:^W70'I`.YU!LL?;E,$.=V+#84]KVE\.B@AF04TK*#(-.4]'L;
MC,WOTX695$M+`&KR]^A<Q%%"9/DFZ6IPD-3S@85)%9_I(GBPU48.E2HY9I<.
M06.+1BZ(^O2485M0<8"U`C&'^>$?8*F1D2^68'XY$P!#I3)A1$_,JS@8#)`[
M'.:'>8"ECC$P[DA@Y4DS+>9=;&\_M/+_D\:7^Q`E08K)XA4#3XP5O,KE>"$/
MU;J\P\V82M;EJMZUDNTB0DCWFS4J4O=N5VE`I/!0>E_`LH6%!]7;)$T0_/5]
MQRS7](?RF_!3RV3H-4=)=$@`T#':(R99D.3H^2E(-\$/(=F4#?,TB-G]N/LG
MA/+OG,/Q0?"FB=(M_$?W+>HL#C)V?)EMSC6C"*^-C(Y7K$OGOB')XZ=&*W`,
M[?+Q,HXVQ3PGFP!WKL%(">K5;P&!>P=+W4@`*DF<S/,LUJD%O/QT='%[N!#W
M[#/:/**4=[24H':T@,"9HQ4^)`!=VA[N,BM<*V#BS1D%FZ`H]%9@0O"]!8G6
M=Z\1(=<$#H@6#V^V_BV/`:[YX[-\Y]\AX'O]!H'[WD#>W<OT`/?S#08S`T,U
MG19/JL0?*^/Q']T#H.MFHM$!<NJ;9S"SWJ%4[XQMNB>Y$@<2FA8<.C3.4"'Q
M.X%ITP9&F]<!%!T>,\/&VV6[)I9DB+%RWTY8Q>!+3Y-%WFWYMKGP3?/*2!SN
M#$KL,Y<`2OB+.7.%@8@#,9[E,$B,+)5))X,6"[@`(6"R;Q\5(#^\@YQ]2DDF
M`02$M'D_24KJ+UP,5`2B1\W1HY-MUE)RB1_@NT'=GDM/>DBVI2#U<*QMH)MN
MR*UF-;/^J-'ELGUPY>P,1-N,1W):#Q%DHIT.0AI>,[L?<4V2M?HY*`5%95$A
MA=NS+5HL$(AB@J,J,L8,.4*&,YMSG:-GDN'B0E'+#AQH=&25@>5D_L,'J*(A
MAN1<9]9Y"=_F$KXOY?R-+=TJ8:]E0:O7E7R8&S7/5R=1L3?V1&*J4\8&8?E.
M,C`Q+5;W.>!BGFXY]-0;LAD!9SVSF-)07+U7H2?LPLR?70MCZ!`#C=L`@U;%
MP6[N>QZ+,"1;.KR[#79LG4*R)*@DJCLW"9$/X%*M%$)TDT))M&XH83@SX%QL
MGF.R0^@.Q46NUHY-.`R!Z2N3`^@]1Y:IQB8@`_">68]8SC?",-T"P`8C;BT2
MR8D]AYF1KB88TS&>V?K1/4HP26](+@.5G*`^)R8@\!P\6IU,`"-B-K-,%MK(
MHVV!$XPP5J,*/)+T>OC)A_6#*F;>D5T0RY&BH3J,JL54GF,&IIWAN%K,<7:;
MJ8VW%8I@JIR;P8CW9]O5Q)Z#RDA7$VSI&,\NW4A#X7JOIZFX'&,JZB[(Q-0^
MH`R\W&2F>_\U)VT],YO/-6PC'T+)QTX30Y%<)RNKE+,[G@;>=`%O-WBYL=('
M2CTW6$R0I:K"W0Q.DH.MRJI8WF`5@T1%TLYWR9$XW'$#]4UZO?A=-F47)&0W
MLW7KQH7',IW6-L_R((FZ"8(!E-TKHUU*=Y='5>@@)OIQ%TD%?+FKI%U^,T/1
M'<H#G*#H(D@3JE]&)Z?;S;98BS]'*QQB/@3!"^Q?/-07\#P\&>ML$JP@S&<V
M9.X:1#L8T@Z"O`>15B<3T(B837VHK!O8&9Y2,CR=-+'!LZ'V5B9GDHIFMNC=
M2+Y59;P+XEM29K+3)S'3%NDF,U,4<7]0#J)1[^1F4M;337)V6YCT">4XI%(Z
MQ_!;QK.WC&=O&<_<._@MX]E;QK.WC&=O&<\$2U9O&<_>,IZ]93PS"@[W=`".
MLO)M2GF($%%U`T6;RCTVN@@@4*T@%Y&DG.;;E91Z@K9'I*0RW/BQ06(('NC^
M"!!!@.V1R0:=M\6@M\4@L\6@AD:"Q5+G."[EH&WXF22():13K*BH:'GDBFG=
M7>IJBR-<2E#2U)>WQ#3NFZ+2-P2FG*0IBE@75[7$+/U83^!W487S1S619+_:
M^4Q2[4K!]C1@1BGD*=J-KGE-?3SXMB+^MB+^MB+^MB+^MB+NT?KGVXKXVXKX
MVXKXVXKXL5;$IWZS_RH)4Q1DZ!R5_[]*NDL,=R2.+TGZ-4CYI?&>I2M[&Y=V
M#RKA:N@P*T`62(UK<-=)26ZBL#T!=J)IN:HB:K'.*UGOA!'7*-(0.P--7U@0
M0P.T`618:X$N36U3CW&%`<I-J?-MBI/U+4HQB8J+&,6W9=&99Q>O*`UQUMD`
M[%V^>;+<K+P[T,*01X9;A8.MLM[]^72S^KR+@BH=O@1I&B1Y+Q1*RP(0*"@[
M<?3IK&$3>8*ZW$T(S%!7*MH3=IK":MQ)"[N];V,,)SD.8>817,^!RJ#`I;3N
MJ:]<+*)_;:N,ZP]D$46XG(+?!CBZ2NJ;ETSY4SKNB=A.!$JRPKC-_N$.T3%0
MAG-TC](7'*+2:'<H).NDX,@U@"/76N<V.E:M4QP>NW')X''VT<2>>B8YB*&J
M^"8\L=>[O$'CX\K/M1FIS'24!L$),.0JH`_05G7R-^AK\:6[`&M0!C#B;Y29
M(FS[F&,P5(&55O#\R?>Q?R%W:[Z31/6(T0!]&@X`+$HYS`V9,%.-BE.I"!5J
M_^0[:@<!=A!6_8/I$*S)H=H'I3TD42!5!]+)SEY59EJ$Y9B>C>\-PJ^H&"#F
MMHO-+=`JC#)J=&W7NT^#.B^T5NW2&*[R<I"50D\`:XPZW?H@&*K0FK6K@D*0
M^K,_`ID0GE$1<76BO+K@D:PO@Y!EE.$3^ECC9[`PH.$WQ7!KVXQ'63C0"%1A
M_^=)!^B6C<IVSEM3%)\-BDF3H\F*31'?/8UB9S@!JK>.U!_='BA6]BUP_/7C
M`!DI>(=*8VCIQ@P]D`F503MZT*%3`$Z_3GX"KA^"#X&*>;4V_]V?Z17=&-5?
M,M:7Z=XR5I5Q#PF03KWO&<MYBRX:>W2S^!QG84RR;8JN<8B2#"W6*4+EF^;6
M!O4=UH=:I0^W@DOL4W$"2MB;IRBJ>Z#..*6\?H/KU"FB5ZI1Q&&.4;B72"\#
M\"E&M?65V44A]8S[,)+[]GR_W6R"=$=C$UXG>(5#2EZ]OLHZ=1+CD+V-8>^E
M`9)DE&E4*'0:9#A;KFZ;6$RB;O6R)PEL\#H\N#.$E\6G&/H((@LF=I@-,9$/
M`<@.3HAE<W*WRH;(6+U]-$BVV46VVY0\HY0.L9*(C;6>68QWE@2E%N8V9O&U
M(9$DM('I*S`!Z)U-,J2RZ0=#?8KJ+.+7X`CN:#+('.UHHZV5112SVF87/ZX2
M^B-Z"%Y[#7^LW;HL9=!.A0"4A]N4<DJ7]TMYJ61!`4(JU]6'1@]Q%C%2M+/$
M+.-?W1)5\)U=0V[L92Y7-RA?9!G*Z>CH#,7Q)Y2@;.>N@9]N,TPER,[(YA$G
MA0EDLQT(:84&-:FS-BX02]_:S0K)#>!7!``YD_34OAT,5%6Q:`"M8G9QX0[E
M."V6?M@(QUD(:-[?H*.L@U3:/K]'R4-N%GA)=Q,'*F(IX#)_0NDMH1+M)3VE
MD7N%(2NJ0]G4$XK>;!PN?)@#A%@S&+_``9:EF'STEF%V<>J:;9XNV/'6=>\M
M%TO/I#%)9.,3\<=ZBX+[Z.ZEMT*0Y>J:]G@(`;9CH/0M197T[C9BQ!XBYEIR
M&RXMOL7>BI[?[)KI/8I1F*/HO[=!2N6+=_NLTN=!'CAKLUUQKI(5H3JT!WJ2
M1MVS=`43X]+.PH)24EEL,"L$L8D/4:*ORTE/@[1CB6'M+-A`:YU=Q+E#(64?
M[\IC6(W=G90D],_0\6CA!GV5R42'=6=/;#R3725-&DS=]QQ+AQ@6.5;@L\+1
M6=0Z1UF8XN=Z94NJR@W)_X'R142>\\X=^$$\*BOVY.$LQ-G$$;%CPG84M"`@
MBXP]!9O[F9>KY`55MP(<[NSL93A'C_7V6KZ[1^$V+9\\EFWTF!;<[X7`"SI,
M.IP=)/N,\B=VC/@@MW:ZUKO\?F',N+S#721C))#A%N)WFJ`RE&=4C.N>>RQB
M)W5":I-S'&]I\+U!^37)V`'ZXB3].7L2(W87I>Y81R-XYZ'S>_V`R>%W=\^Q
M,!G$;[!TOS3E=IZEO&M5HA*ZW1+WA8NG5)J%N#;CS#&?<8(WVXW0-<)OE9[<
M-[?NX20D:M$%+BKIF).X@I9#FPL'!Z]R!XN^U0YN?_/.P0K1U0YN%SPX^&2B
M#JY?9JJ[)\D054=6/W`F)7-W'RI\0M$V1LO5@DZ3(M8GXQ=T&,Q<O(;QEG;X
MEQ0O;$-K6WI^N>)U$3[U-`KS^H:59>;NGAS3@8>,;,EVDY:)4US8LBR&+QWU
M0&U.=V(&@G'D$6JJ,S*,69.[>XOC-`1R3,]PMR6M:E3D@!A3$[^;[$VP0<*'
MVZ#DRL;3)'?6`HZ!4VESD!JLC>D1990#O"F;+RAMIB<6SA+D!,VD#AR!9]@3
M@((`-(-`YL!ZGX*!8SG]2625R$\(#^&WRG[<MTF`0J6/.1XX;M.?;IZ1Y`6E
M.:8=.5M</N@M>8\01'VXS*JFG@2`S'0VAY26_P%D/]H$V2R&T+)%\K$'O(UZ
MN1C@V?`4K-JUY,5)VVSMS!6O?7C=TM>)H<SFGL\"KSLO>=H.>=-IC8L-.T1B
MMRFV>=IIAS5/SWKR`4UE>/,3VMGJ;/6Z^1ZI)6E=SFID&6B':5:_MG6;8O:B
MW(&#W6:EK<9.2U-4\];XS+WA;7M4*&!YMBD_F%-]8?]Y##)$?_E?4$L#!!0`
M```(`,>":$&9INHRIA(``%6N```1`!P`8G!A>"TR,#$R,#DS,"YX<V155`D`
M`X4BG%"%(IQ0=7@+``$$)0X```0Y`0``[5U/<]NXDK]OU7X'KB\[[^`XBB>S
MD]1D7E$2[6&M+&I$*LF<IB`2DO"&(C0`:%O[Z;<!D!(E_I4LQ4P]Y9"RR6X`
MW3]TH[L)P+_\\WD9&H^8<4*C3U>=-V^O#!SY-"#1_--5S*\1]PFY^N>O__D?
MO_S7];718Q@)'!C3M?&`&2-A:/0H6U&&!#1@7%^GA/<XPBPEO8O_102/#3L2
MT)-`<VQ\_8*BP.B^[?STTY\/;SM;SAU&>VR[QM?N>)"V)SNQHCF)L&9XYL%'
M[B_P$AD"L3D60[3$?(5\_.EJ(<3JX\W-T]/3FRFA'$'GJP5B2_3&I\N;=V\[
M[]Y^N`5YD1",3&.![RA;]O$,Q:$`V:._8Q22&<$!J"3$2QR)'8+,:]!AQ#_"
M6'8Z?;I]0]D<.GK;N?GZ,'#5,%/BZ0H]-Q^BY@$XQ'J%^89OAOA4]9&^42S7
M;SO7MYV4*2317SL=/4]9F`[L]D:^GB*.4_(H7A93!X+=R#YN@`(SXF\8:-2`
MAT;7>WR2*!`;ONRHWM_HERDIP[-2"7Z\@;>;L>"YG#FEQ!]N&`UA-)HLY0HP
MV1T&Q_Z;.7V\@1<%"GT.*]3Y=0#ZW$X(4C\AKDD$%A'Y.*L84M'%/GV#Z;N9
M/G.$5H6S1[XHE'5_]B0R=#Y\^'"CWEZ!&1J&,D04150H&U7/TJ>K%8EF-'D$
M#R77QW3>C?',4.U\E!/ETQ4GRU4H95//%@IZ:2O7J3'\N6+X#8PN)9&(5FA+
M`0XL',Q7#6VP[3AM`C$_UTI.3FB$KC`3!*QL:S0W)Q/+1^&A8@&+'X>MEBK`
MLT.E`A82D38+%:+IH4(!"P[/*X]LQP,)#/G#9&S7K2YJ7'WJQW)E,Z/`B@01
M:QM,%2BD^J\,`JZTDF(SA'006_!^?0O_C&LCY<_^*)=^W9B1:>V7F_TF]EN/
M.0Z<Z%?U\[Y-)]P)217GGMDT9]R=F<5\R=,4C%-@U$6A]/?N`F.A,=EY4HU!
M1V+@@IIP`D*/1@&.8-!&THJAFN$7[==K?X08"+W`@H`4>2AV7]?@\KXA+L8/
M.\W^XX)3,4X;73HS&Q*8)=;XY!]7X_*NW%XV3[E!9X:S2O*1B^64(-)#?'$7
MTB>ND=C^6HW`;5,$9(.&:O&"0,GJ3K@?4AXSW,?<9V0E1^#,NC&'!)HGN-01
M5:'5T>O+M@GYB^7VQO;(LYVAX=P9W8EK#RW7O6!4AU$7<<*=V2@C^CY"1235
M^+S+X=,U7=N5R(S&EFL-/5,B=4&G#IT!^3LF`82L$`CWT(H(%(XQIS'S<<Z0
M*FFK\;K-X36P?Y_8?=O[PS"'?:-GCFS/'!B`G3,9]ZR+736R*Q^0Z),P%C@8
M8C&@G(\P<X$%%YE8!74U>C\66EM/(=>W!Q//ZAM#RS,&CNL:(VMLN+^98^L"
M81V$$`(\R@1X&F(71X2R(15YLRNAJH;L?0ZRGC/\;(T]NSNP#'"0MC,VAHYW
ML;1ZF%Q!_;_`@'#0H\L5Q&R%BU@)535,/^5@<CVG][_78%]@4SWG860-W<M2
MUARF!0T#S+@%*Y58%T*T2U$-S_\4P_.;,^A;8_>_#0O6,.^/"S3UCFZY)$*E
M.#)VH)$@T1Q'/BGR=N6DU6#]7.#R'AYL[P&B05='&<[0LX?WUK!G7_Q>/6IW
MB+#/*(SQ`T;R=P7*/E[%1-5(?<@A=6?:8^.S.9A8QH-ENI.QI5"[8%3K].(I
MQW_'(+;U6`1/[GTE,IVW>8<WZ;K@Y@`-P_I\P>3XL,Y#\'O#X"ZAK<+J]H`0
MS_A!-WBILA[G\XJAJR*M1JZQ_[L`][)28!\+1,)F%<&4M@JZ'YL7!HT?D@8O
MV!U3(BQ!KH*R&K>&!<,+:J<I'9;`UX2E&L>#"XD71%\:N)1@64U<C>(AH<L%
MOI?5J4K@JR:NAJ]YU>H"WTOJ5U70%1)6P]:LFG6!["1UK5*O6<M1#>*!5:YC
MT3PK)L=/GU=&\]WA<+ZKP[-S')[&NXM]'I?-EUAF)6TUA@?D\Q??>FQELVPQ
M+"&K1*Q)G?."U0%[$\N^O5635&'TL]YGG=TQM[M/+ML>Q"ZJQ0M2]5:U7"*V
M!CC(/"(SX@.YZ?LT5BO7B(:DZ*-<0ZYJ//.E,W?R\&"._Y!%&->^']IW=L\$
M^S-[/6>BUCQCY`SLR\>Z)L":/E@`)[JF.<3"Y!P+[LQZ.`SE*4.^SJ':A*4:
MTGQ5S>Q!$N'::354[@HR7=?R5*6M9PT&!@0REOO'!=$&]35?[@\VYPP7?WK-
M$U2C550[ZT&F;AGF_=BZ?'%M!LM(GUJ2)4RYZ*RDYO>1*:2I!B>_QVXT=D;6
M.*EKRMQ\)!&Z`%0'D#X0X:'G_#J6?54-1[Y":0\A,;,,S_QZ68[J01AC070.
M-0I1;J_<WMMJ*/+5QK'EV3JC,D8#\[(UKGXI@906FXRA:%ZRE.0(JC')EQ('
MD.;"0C(>F\/[RU+2U$A@`1?AVN8\QD$FH&8T@A_]8JP:<E4#F"\CCBV(!;S!
M'X;MNA.KOQ.%CYTA_-R[X-HPR<(A]@4.?H\1$YB%ZSL2H<@G*.PC@7+)535U
M-8[YTI-K#:R>W)'_^\0<>]88$+VSA^:P9YL#HV]ZIO'#9&A.^C;0'%C:.&]M
M]^@Y<.9HXA%S46B(V5>5*!64F^SA9\OUCK"G?W,,2JJ`!135B.2+$1E$+J6_
M4QU#JMC&4\]4C6#QCIZZ0TG_%M#^<K-_0TWR9/<F&W6/#5FN*!-&5'C!5,V5
M1_J*J@'U59OUG$/->"WO++KNO+ON_/0&AI#>^7'`<`HN/6HREI"Q':ZC!E)Y
MOU#)*-0("AEO<"AX^N1ZVU3S\53>[50UGGT>^<-1(ZBY4.NP6?*"*5)];]CQ
MT*BV7JZ9O6NNFJA%L<C?-M=I2<7<2L4</$5RMY`U'$#*('M^G^LSN4).=?KI
MREL0%ICP()`//;I?H7S`RREF>C60EP_]V91!WV&D+V7[&-`E(I$M\%+Z/!`D
MGG)!1"S%N&<T7GVZ4K>-?21`<F4@>,N0+SY="18#>43"4.ZJ3G_7M"N8=C3P
M5#]!S)(C?J62/I`0`@X:X1%:R\>3%8WN^J89BP5EY/^0+JH_(/87EKF9,TLD
M"QX0N&K)RB'6!_Y['.:T<H[&OPL-6@@:PLR9W7;ZD.7*D4NS@TCACCSBS4YM
MM.;F#"1TX^F2<'G'HT=!/\Y,9D[A&$LS<*(OB"]`.SU8(>45,ZZ(@W4C57^S
M47S'F-R6:4/NB,%)$<*9J=^8S&4?4!3/8+P0JFWGZXC1(/;S;N&5Q]$Z7!(U
MW%'6Q3"97(AAM/5C9D<3UYEU(':65:$]XP<&4X08<='Y^:U4C0UJ"`C$/N'Z
MCH8A?8+6!BB._(5L)X?#-^ZW=7KO4=F(N@;V,5L>'5$!_\O9M#=1N2S.D4?9
M<4:-+VM&:T6/?PDT`K'U$6J9H9"7ZF6J+^<"I>`I$47:T@&(J%`61/=3:9]9
M4^S1B),`,QS844[(C(:.X,VJA4"*.H<Y>6*M'#A;4B'DX.\87>H)+D^K*.\"
M1O%E0?Q%UHK&9+X0-K^'>1%)HPD"E?"A,)&S0$4G;;U]2BRSE3%=HU"LQ^!#
M3)YX'33':N."BS;'\RKMK4$;B0L"_[/2[]LRIPC#OJ",.S,KN:^R2Q$+=M[`
M*C<%\U$[^E&T+IH\1S7SC6=)O:L9*>I^S&`94;,>`)3WIJ7>H8>B+M8^%`<J
M'.@3KN\35J&S,HSLC#E5@UE-I>B^]@S:E<2C7;P9.PX\^ENR)>]9EK@@%LI9
M1I8[54%V:IVG_6]JB/4SSIQ#2BJ+1@W%S2CH<-9ONN+[L,`>O>1KB<;X[QC<
M!XC@3$,B1=7.Q:/6;(9E7,WF.W'E@7S?2P0TB5:(@-OD@IN<4U\&O,$7(D#0
M.9'1,0ZTFW5`/.EJ,BHY@K<=:FF2OBCR-$*1R*OSGWPA-T<]PL(+UO`%NG_`
M6&R.B":30YF*/1OA2/[Q!CTC;#ZD0JY.(18[ONC<';70O:LO)GH;=!\X'W7,
MXTNN7#K7@+9U*5@:N0"*6*4$-"0!VH6]@N8EH<M)QC_&\L^0Z#-[[BHD0I^;
ME>6BL>3-B%%/FI5F)3][ONJ:F"9KVE8\S)8D4NJXPS)/VTN"&U%_-RO?KC1C
M3);3&+#3U2:(=619B9=*7TK_/;GT30SGQ$*J2[I-Y6%D"J$/]ZNI_!L.@^XZ
M>UQCUV._I)V618FI(\H.4D9U4J(5]M7?+:F3F"X!>-5`@8<[5<-MS.@:#CX_
M#;XLJ/I@!''D9RJP'=VA1PK*LN2^*I6>;9+;`V;>R7ILZ1S=C+"/.9E'<KGL
MKG7\754X**)N7Q7I8'`S1L0A^,$A0&Q%0E<?!=T_A''<##J@DY9-F@$((;>8
M*B8GDL4R<$9*T!&D++D$KR%]"^/I32R9GN46ZE"P+O#H+;=V9#W["UE4A$S#
MB7#FPN7=</3@)K+ZX$I;KPM[=ODUDPZR==;"USM"")FJMB.#^(Q\7\9@]TSN
M:%.YM?Q<RU:`0Y_%\]2SD?1NWQTP#^)^]:PC'?5H`2F1#4FP_L%./T-[C*"P
MZ`-,'4-K).OCJ;!A`C/UMY>2TIE'P:,NM9\Q(3U2ME:TFAW`W!J)A_AI0*;D
M'H<)-K8UDT=Q_74IFO4LKRZ=\HKIUPB/;L(+79#@3OI]0N_PQ3@5+7F?39]?
MVM*KZV(3Y0.;CB`V5VRIR[5,F)++P@E=R_'JLA7?N;@]BYQ?71ISM&W!J;SE
MKDKB0QF_)\$'`)\<'6\H;X:^?6+NG;NN`;4!]7<DHH>?13?<+4\T(]^I+8OT
M^;=U0Z6?6281Q`!?&!$"1Z-X&A+_D(\T5=POJNF=L817]2<PB]QQ(_*V3>01
MHS[&@=HQ(R,ZJ;:=U+R[5M@]U2#_PG;:.@<@"X5%-=UII:A',,,=""(V]V%E
MM-",O*W"YG#3H7Y^JM<1MFV2JPFH\Q6]A477710<.Q)$P1<DMT/ME+&.XCXG
MQN7?91KHP@S^%2<G`3V:W?%&`CM*@HR>ZD!?&94<MHWF=\@GX6[Q\P1MM59/
M):@?/5T:S90#:UIG-XYTE-:SW!S.=U*K`_E:"_0(PFF9_&^OJNS%2W4@\1%O
MMR*INZ`8?D#^`@)OEK6"8QMX'8W4%S5+@-53]X@94<KXVC-_2",?\<7V;'2V
M<)!_U]9E>[NA`^@*_@``>)O\771%U>J7M=.V1?\H<8J2MY<VU(:T;HQ7B2>2
MGYDH$W)_2:88)@N^.SMMFI"WUJ57U4V*T_-&]"\$\DS[V_P%#N)0'=:JD&)O
ML]%!7$=8=B`^+M;RRVP\556J\]EXP=]8N'W3>?<^^?C<C[$\!9?;ZG<P9^LV
M_IG@;P)Y/P2$&2[V8<$5X'<@`PWC``<R#Y<;,V.1G(:U$(L`N<TE$NDZ/&)$
M)G+;%K+Q_=FZV/E\KXB_<="[F?^;O%Q]"E#5=#Z!\.2.LMVO8-H:BMS'*1IK
MPR+1U"8Z1UM3I[76-*#17"YR$J8Q#K`&3\W<W0,9\`A2V!4*S:5<\AU%EYY-
MV-GA<9H&C]_H\JIZ.8$F7EWV(FN6A7LY.'E&+B-C/>DKR[+K?K8;IY.#)?!3
MIE;;"RF7&[7DD;\"G+;<ZN7.)\DS]O)=:S#]$.TQ)/?`R4.J)]-;8=LOVCKV
MC126V0C&(3B08<:Q^JEKZO75H:*<W!^4RIR^[:ZW)$G=R'Q"+-CL8="UP^22
M$QQT\8PRO+D<9O\<RUF[.FOIID&)ZE@!=1TZ$X<Y8H&9MT"17G?E,4RBH>1V
MI.M7IU#L<?V^=H'L:'$+I9.[.K5D7[#<BH0#$\P8?/U.GG`*;;^H^_:D)OF_
M"%*>QI?2MC=Y3RK"NF#L46D<R5A0J.NNE/%<JG$05^O2C#Q,1?M^*JG:5F?=
M`V04(GVID"DW=M?B5T+>.N!J]S?`0#@_9$-$PM#:KPHAXMR9)7`Y^JX4F<9M
MGNW<*-*$^O5CL.WGN#LY0Y334"X>7M`X&T+54K:V^)UW'@<<L3V&.:N)@P[=
MGG8GO[[FASO,P_XBHB&=$[E+4E]@EI[%,KD9"LPB]7'6HV-$9"JUW;JPV:%0
MM/7_U#UD%?<J>X[-%<S:D;JZ..>G"]ZUSBEOJBXZSNNI`T-<GC9,G@_AH;SD
M8+-/I:AD<P!S:XT^?Z#A@+,/ISSS<+;CBB^[M^*4=V"T^EA><3RLC^ZDVRT?
M4(`+)D1SUF\\01K</C2TM:OR,?3K0\-VY.==6A55ZYR;/@-:?C5PR?O6R?&9
MRGT1Y7*4O&^='/+([F15+D?)^];)47CJMERL9N2MD])YBB!(79!5\T/HN8O]
MNNM>S!@PE]S-<<8^CO_6<1;_ZN%'M.<Z)ZY9Y&-K*5LW4VHOG\W?.0O!PSUY
MW+OP5UG&(9?:'M;NBT+/\]SQIO]HAKXF'W[]?U!+`0(>`Q0````(`,>":$&:
M=>O%VVP``(_I!``1`!@```````$```"D@0````!B<&%X+3(P,3(P.3,P+GAM
M;%54!0`#A2*<4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`,>":$$<[@M-
M&0H``"!_```5`!@```````$```"D@29M``!B<&%X+3(P,3(P.3,P7V-A;"YX
M;6Q55`4``X4BG%!U>`L``00E#@``!#D!``!02P$"'@,4````"`#'@FA!"D?9
MD"4[``"UKP,`%0`8```````!````I(&.=P``8G!A>"TR,#$R,#DS,%]D968N
M>&UL550%``.%(IQ0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`QX)H004<
M<MRHH0``8*()`!4`&````````0```*2!`K,``&)P87@M,C`Q,C`Y,S!?;&%B
M+GAM;%54!0`#A2*<4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`,>":$'_
M%3.[^$0``*)Q!``5`!@```````$```"D@?E4`0!B<&%X+3(P,3(P.3,P7W!R
M92YX;6Q55`4``X4BG%!U>`L``00E#@``!#D!``!02P$"'@,4````"`#'@FA!
MF:;J,J82``!5K@``$0`8```````!````I(%`F@$`8G!A>"TR,#$R,#DS,"YX
M<V155`4``X4BG%!U>`L``00E#@``!#D!``!02P4&``````8`!@`:`@``,:T!
#````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ERZAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LIQUIDITY AND CAPITAL RESOURCES (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Sep. 20, 2012

</div>
          <div>Common stock</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2012

</div>
          <div>Common stock</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2012

</div>
          <div>Common stock

</div>
          <div>Warrants issued to institutional investors</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Minimum

</div>
          <div>item</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>2013 Notes</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>2013 Notes</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_LiquidityAndCapitalResourcesLineItems', window );"><strong>Liquidity and capital resources</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 38,049,095<span></span></td>
        <td class="nump">$ 57,225,234<span></span></td>
        <td class="nump">$ 69,600,199<span></span></td>
        <td class="nump">$ 38,155,251<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,277,850<span></span></td>
        <td class="nump">20,782,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.125%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">140,712<span></span></td>
        <td class="nump">2,359,932<span></span></td>
        <td class="nump">1,179,966<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of shares and warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,268,798<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NetCashRequiredToObligateEntityToEffectMerger', window );">Net cash required to obligate the entity to effect merger</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 17,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements', window );">Period for which cash and cash equivalents will meet liquidity requirements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bpax_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing', window );">Number of products or technologies licensed by the entity as an alternative to raising additional financing</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_LiquidityAndCapitalResourcesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_LiquidityAndCapitalResourcesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NetCashRequiredToObligateEntityToEffectMerger">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of net cash required to obligate the entity to effect merger</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NetCashRequiredToObligateEntityToEffectMerger</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of products or technologies licensed by the entity as an alternative to raising additional financing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_NumberOfProductsOrTechnologiesLicensedByEntityAsAlternativeToRaisingAdditionalFinancing</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the period for which cash and cash equivalents will meet liquidity requirements of the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>bpax_PeriodForWhichCashAndCashEquivalentsWillMeetLiquidityRequirements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>bpax_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The stated principal amount of the debt instrument at time of issuance, which may vary from the carrying amount because of unamortized premium or discount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 21<br><br> -Paragraph 16, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest rate stated in the contractual debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
